



You have complex
questions which
require precise
answers.

**myPHARMA thinktank
is here to help.**

**Get the insight you
need to stay ahead.**

www.mypharmathinktank.com

ABOUT US

We are a biotech and pharmaceutical intelligence platform developed to meet the research, insight, and analysis needs of the pharma industry. We provide an integrated platform linking companies, news, deals, products, patents, and regulatory information in an easy-to-use format for fast and effective decision making.

myPharmaThinktank is specially designed to help executives in pharma and biotech domains grow their business. We help you make the right decisions at the right time. An offering of Eli Global, our powerful platform is backed by hundreds of researchers working around the clock and across the globe to provide real-time insights and information solutions about companies, products, clinical trials, partnerships, M&A deals, regulatory approvals and patents.

info@mypharmathinktank.com | 800.544.7074

COMPANY REPORT



Pfizer Inc

235 East 42nd Street, New York (NY), United States

Telephone: 1-212-733-2323

myPharma thinktank

Table of Contents

Company Overview	3
Stock Quote	15
Key Ratios	16
People & Contacts	17
Facilities/Subsidiaries	19
Partnering Opportunities	49
Products	72
Regulatory	225
Patents	273
Deals	351
Sales	704
Financial Statements	739
News	745

Company Overview

Company Key Information

Company Type	Listed	Subsidiaries	653
Company Status	Active	Primary Industry	Pharmaceuticals and Biotech
Reason for Inactive		Service Provider	No
Other Names		Service Area Focus	
Incorporated Date	6/2/1942	Category	Company
IPO Date	6/22/1942	Partnering Opportunity	Yes
Fiscal Year End	Dec 31st	Total Employees	97900

Company Description

Pfizer Inc is a biopharmaceutical company, focuses on the discovery, development, manufacture and marketing of healthcare products such as medicines, vaccines, medical devices and consumer health care products. Pfizer work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of time. The company collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer manage commercial operations through two distinct businesses, an innovative products business and an established products business. The Innovative products business is composed of two operating segments, the Global Innovative Pharmaceutical segment and the global vaccines, oncology and consumer healthcare segment. Each operating segment has responsibility for its commercial activities and for certain IPR and D projects for new investigational products and additional indications for in-line products that generally have achieved proof of concept. Each business has a geographic footprint across developed and emerging markets.

Pfizer Global innovative pharmaceutical segment focuses on development and commercializing novel, value creating medicines that significantly improve patients lives. The company key therapeutic areas include inflammation or immunology, cardiovascular or metabolic, neuroscience or pain and rare diseases and include leading brands such as Xeljanz, Eliquis, Lyrica (U.S. and Japan), Enbrel (outside the U.S. and Canada) and Viagra (U.S. and Canada). The company global vaccines, oncology and consumer healthcare segment focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. consumer healthcare manufactures and markets several well known, over the counter (OTC) products. Each of the three businesses in VOC operates as a separate, global business, with distinct specialization in terms of the science and market approach necessary to deliver value to consumers and patients.

Pfizer established pharmaceutical segment includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. The company major categories and product lines in the consumer healthcare business include dietary supplements, centrum brands (including centrum, centrum silver, centrum mens and womens, centrum vitamints, centrum specialist, centrum flavor burst and centrum kids), caltrate and

emergen-C. Pfizer pain management include Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Childrens Advil, Infants Advil and Advil Migraine) and Thermacare. The product categories in the global established products segment include legacy established products. Peri-LOE products primarily include Celebrex, Zyvox and Revatio in most developed markets, Lyrica in the EU, Pristiq in the U.S. and Inspira in the EU. Sterile injectable pharmaceuticals includes generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). Pfizer infusion systems portfolio includes medication management products composed of infusion pumps and I.V. infusion products. Biosimilars portfolio includes Inflectra (biosimilar infliximab) in Canada, Mexico, Australia and certain European markets. Nivestim (biosimilar filgrastim) in Australia, certain European and Asian markets.

Company History

1849:

USD 2500 borrowed from Charles Pfizers father, cousins Charles Pfizer and Charles Erhart, young entrepreneurs from Germany, open Charles Pfizer and Company as a fine-chemicals business. A modest red-brick building in the Williamsburg section of Brooklyn, New York, serves as office, laboratory, factory, and warehouse. Their first product is a palatable form of santonin an antiparasitic used to treat intestinal worms, a common affliction in mid-19th century America. Combining their skills, Pfizer, a chemist and Erhart, a confectioner, blend santonin with almond toffee flavoring and shape it into a candy cone. The new santonin is an immediate success and the company was launched.

1862:

The first domestic production of tartaric acid and cream of tartar, products vital to the food and chemical industries, was launched by Pfizer. As demand for painkillers, preservatives, and disinfectants soars during the Civil War, Pfizer expands production of tartaric acid (used as a laxative and skin coolant) and cream of tartar (effective as both a diuretic and cleansing agent) as well as other vital drugs to help meet the needs of the Union Army. Among these were iodine, morphine, chloroform, camphor and mercurials, which, in addition to medicinal applications, were used in the emerging field of photography, the new medium photographer Mathew Brady employs to chronicle the Civil War.

1868:

The expansion propelled by the Civil War continued and Pfizers revenues doubled. The company had a substantially increased product line and 150 new employees. To accommodate this growth, it bought and renovated a post Revolutionary era building at 81 Maiden Lane in Manhattan and moves its headquarters there. The site carries the Pfizer name for nearly a century.

1880:

Using imported concentrates of lemon and lime, Pfizer begins manufacturing citric acid. As new drinks like Coca-Cola, Dr. Pepper, and Pepsi-Cola gain popularity, demand for citric acid soars. It became Pfizers main product and the launching pad of its growth in the decades to follow.

1882:

Spurred by Americas westward expansion and its own growing number of clients west of the Mississippi, Pfizer opened offices and a warehouse in Chicago, Illinois, its first location outside of New York.

1899:

A leader in the American chemical business, Pfizer marked its 50th anniversary. Its portfolio included a wide array of industrial and pharmacological products, anchored by citric acid, camphor, cream of tartar, borax, and iodine. The company had offices in New York and Chicago, and its contacts in the import export business crisscross the world. A statement made by Charles Pfizer at the companys 50th anniversary celebration revealed where the company stands as it moves into the 20th century and into an increasingly competitive marketplace. Pfizer goal has been and continues to be the same to find a way to produce the highest quality products and to perfect the most efficient way to accomplish this, in order to serve the customers. This company has built itself on its reputation and its dedication to these standards and if the company is to celebrate another 50 years, it must always be aware that quality is the keystone.

1900:

Pfizer filed an official certificate of incorporation in the state of New Jersey, with authorized capital of USD2 million divided into 20000 shares of USD100 each. Pfizer would remain a privately held company until June 22, 1942 when 240000 shares of new common stock were offered to the public.

1905:

Emile Pfizer, Charles Pfizers youngest son, was appointed President at a special board meeting. He served as President from 1906 to 1941 and briefly as Chairman in 1941. He was the last member of the Pfizer or Erhart family to be actively involved with the company.

1914:

The Board of Directors created the position of Chairman and elects John Anderson to that post. Anderson, who had joined Pfizer in 1873 as a 16 year old office boy, has remained Chairman until 1929.

1919:

Pfizer chemist James Currie and his assistant, Jasper Kane, successfully pioneered the mass production of citric acid from sugar through mold fermentation an achievement that eventually frees Pfizer from dependency on European citrus growers. Spurred by this invention, Kane goes on to develop a new deep-tank fermentation method using molasses rather than refined sugar as raw material-the process that ultimately unlocked the secret for large scale production of penicillin.

1924:

Charles Pfizer and Co turns 75 years old. A celebration at the Brooklyn plant, which has 306 employees, marked the milestone.

1928:

Alexander Fleming discovered the antibiotic properties of the penicillin mold an event destined to make medical history and to change the course of Pfizers future.

1929:

On January 10, 1929 John Anderson stepped down as chairman of the board. William Erhart (right) named as the new chairman, Emile Pfizer continued to serve as president and John Andersons son, George became senior vice president.

1936:

Doctor Richard Pasternack has developed a fermentation-free method for producing ascorbic acid, vitamin C. After building a new plant and initiating a 24-hour-a-day, seven-day-a-week production schedule, Pfizer became the worlds leading producer of vitamin C. Encouraged by this success, Pfizer pushed ahead in 1938 with production of vitamin B-2, or riboflavin, and eventually developed a vitamin mix that included riboflavin, thiamin, niacin, and iron. From vitamin B-12, the company moved on to vitamin A.

1939:

Pfizer succeeded so well in the production of citric acid by fermenting sugar that a pound of citric acid, which had cost USD1.25 in 1919, tumbled to 20Cent and Pfizer has widely recognized as a leader in fermentation technology.

1941:

Pfizer responded to an appeal from the United States Government to expedite the manufacture of penicillin to treat Allied soldiers fighting in world war II. Of the companies pursuing mass production of penicillin, Pfizer alone used fermentation technology. In a risky maneuver, Pfizers senior management invests millions of dollars, putting their own assets as Pfizer stockholders at stake, to buy the equipment and facilities needed for this novel process of deep tank fermentation. Pfizer purchased a nearby vacant ice plant, and employees work around the clock to convert it and perfect the complex production process. In just four months, Pfizer has produced five times more penicillin than originally anticipated. Penicillin was a turning point in human history-the first real defense against bacterial infection.

1944:

Using deep tank fermentation, Pfizer was successful in its efforts to mass-produce penicillin and became the worlds largest producer of the miracle drug. Most of the penicillin that goes ashore with Allied forces on D-Day is made by Pfizer. The companys contribution to the war effort is heralded nationwide and earns Pfizer the coveted Army Navy E Award on April 17, 1943.

1945:

George A Anderson (right) became Pfizers chairman of the board. John L Smith fills the office of President.

1949:

As the mid point of the 20th century nears, Pfizer celebrates its 100th anniversary and a new generation of leaders takes the helm. John McKeen became president, George Anderson retired and John L Smith has taken his place as chairman of the board. Pfizer scientists began an intensive quest to find new organisms to fight disease.

1950:

John E McKeen became the chairman of the board. Terramycin (oxytetracycline), a broad spectrum antibiotic, the result of the companys first discovery program, became the first pharmaceutical sold in the United States under the Pfizer label. Pfizer began expansion into overseas markets and the International Division has been created. Terramycin also marked the beginning of the Pfizer Pharmaceutical sales force. Upon its approval by the United States Food and Drug Administration on March 15, 1950, eight specially trained Pfizer pharmaceutical salesmen waiting for word at pay phones across the nation moved into action to get inventory to wholesalers and to educate physicians about Pfizers first proprietary pharmaceutical product. These men were

the vanguard of a sales and marketing organization.

1951:

In a major international expansion, Pfizer operations were established in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama and Puerto Rico. John Jack Powers Jr then assistant to Pfizer President John McKeen, directed his international teams to study the economy, establish proper contacts with government officials, learn the language, history and customs and hire local employees wherever possible. While other companies keep their international employees on a short leash, Pfizer gave its international people tremendous autonomy, enabling them to make critical decisions immediately, rather than waiting weeks or even months, for the home office to respond. This formula proved to be remarkably successful in the years ahead.

1952:

Pfizer has established an Agricultural Division dedicated to offering cutting edge solutions to animal health problems. The division opened its 700 acre farm and research facility in Terre Haute, Indiana.

1953:

After its acquisition, J B Roerig and Company, specialists in nutritional supplements, became a division of Pfizer. Roerig remains an integral part of Pfizers outstanding marketing division.

1955:

A fermentation plant opens in England, laying the foundation for Pfizers research and development operations in Great Britain. Pfizer partners with Japans Taito to manufacture and distribute antibiotics. Pfizer acquired full ownership of Taito in 1983.

1958:

New Pfizer pharmaceutical plants began production in Mexico, Italy, and Turkey. International personnel increases from 4300 in 1957 to over 7000.

1960:

The company signals its increasing commitment to research by consolidating its medical research laboratory operations in Groton, Connecticut.

1961:

Pfizer began a decade of substantial growth and established new world headquarters in midtown Manhattan.

1965:

John J Powers Jr. (right) was named president and CEO. John McKeen, whom he succeeded, remained chairman of the board, a position he holds until 1968, when Powers assumes full leadership of the company.

1967:

Vibramycin(doxycycline hydiate), the companys first once-a-day broad-spectrum antibiotic was introduced and quickly became a top seller.

1971:

Pfizer acquires Mack Illertissen, a prosperous manufacturer of pharmaceutical, chemical and consumer

products oriented to the needs of the German marketplace. The Central Research Division was established, combining pharmaceutical, agricultural and chemical R&D worldwide. It eventually grows to include research centers on three continents. In an era of unprecedented advances in medical discovery, Pfizer makes a long-term investment in research that will pay off years later.

1972:

Pfizer crossed the billion-dollar sales threshold. John Powers, Jr. (center), stepped down; Edmund T. Pratt, Jr. (right), became CEO; and Gerald D Laubauch (left) became President. Recognizing that the key to Pfizer's future growth lies in its ability to discover and develop innovative pharmaceuticals, Chairman Ed Pratt increased the company's Research and Development budget from about 5 percent to 15 to 20 percent of sales. He also lead the ongoing battle for intellectual property protection worldwide to encourage and safeguard innovation. As a result of his pioneering efforts, Pratt was named as chairman of the presidents advisory committee for trade negotiations during both the carter and reagan administrations. Pfizer established a microbiology laboratory for soil screening in Nagano, Japan. The site is expanded in 1985 into a major discovery laboratory complex where researchers are part of worldwide teams seeking novel ways to circumvent the inflammation process in diseases like arthritis and asthma, and new non-addictive analgesics to manage pain.

1976:

As America celebrated its 200th birthday, Pfizer has celebrated over 125 years of explosive growth. Pfizer introduced Minipress (prazosin HCl) in the United States, for the control of high blood pressure.

1980:

Feldene (piroxicam) became one of the largest selling prescription anti inflammatory medications in the world and, ultimately, Pfizer's first product to reach a total of a billion United States dollars in sales.

1984:

Glucotrol (glipizide), for diabetes, was launched.

1986:

Pfizer introduced Unasyn (ampicillin sulbactam) an injectable antibiotic.

1988:

The agricultural division was renamed the animal health division. During the next few years, the division introduces several breakthrough products, including Dectomax (doramectin).

1989:

Pfizer launched Procardia XL (nifedipine) extended-release tablets, an innovative once a day medication for angina and hypertension.

1990:

William C Steere Jr was appointed President. A year later, he was also named Chief Executive Officer. Diflucan (fluconazole), a powerful antifungal, launched in the United States and 15 additional countries. Originally approved for systemic fungal infections, in 1994 it received a new indication in the U.S. for vaginal candidiasis. The single dose Diflucan tablet has been a welcome alternative to the existing treatments that required topical applications of cream for a week or more.

1992:

William C Steere Jr becomes Chairman of the Board. His goal was to refocus the Company on its core competencies. Pfizer has a triple rollout of major new medicines Zoloft (sertraline hydrochloride) for treatment of depression, Norvasc (amlodipine besylate) for control of angina and hypertension and Zithromax (azithromycin) for respiratory and skin infections.

1993:

Pfizers Sharing the Care, the industrys premier drug-donation program was launched. Sharing the Care provides medicines to more than one million eligible low income and uninsured patients throughout the United States.

1995:

The Animal Health Division purchased SmithKline Beechams animal health business, making Pfizer a world leader in the development and production of pharmaceuticals for livestock and companion animals. Pfizer increased its presence in the Far East by building a pharmaceutical plant in Dalian, China and expanding throughout growing markets in the Pacific Rim. Cardura (doxazosin mesylate) was introduced in the United States for the treatment of benign prostate hyperplasia (BPH).

1997:

Fortune magazine has named Pfizer the worlds most admired pharmaceutical company. Pfizer continued its reign as most admired in 1998.

1998:

Pfizers roster of outstanding drugs has grown with the launch of Viagra (sildenafil citrate), a breakthrough treatment for erectile dysfunction. Pfizer has invested more than USD3.3 billion in research and development. Pfizer and the Edna McConnell Clark Foundation partnered to establish the International Trachoma Initiative (ITI) to help eliminate blinding trachoma.

1999:

Pfizer celebrated its 150th anniversary as one of the world's premier pharmaceutical companies. Recognized for its success in discovering and developing innovative drugs for human discovery, Forbes magazine named Pfizer company of the Year. Pfizer takes the drug discovery process to a new level of efficiency with the opening of the discovery technology center in Cambridge, Massachusetts. Utilizing the emerging knowledge of gene families, the Centers mission is to evolve new, more efficient models for discovering drug candidates. These candidates have an increased potential to survive the rigors of drug development. Pfizer investment in research and development exceeds 4 billion for the first time.

2000:

The Best Get Better Pfizer and Warner Lambert merged to form the new Pfizer, creating the worlds fastest growing major pharmaceutical company. Pfizer and the Ministry of Health of South Africa signed a Memorandum of Understanding to establish the Diflucan Partnership Program. Pfizer has opened the largest building in the world dedicated to the discovery of new medicines for human and animal health on its Groton Connecticut research campus.

2001:

William C Steere, Jr announced his retirement as CEO on January 1, 2001 and stepped down as Chairman of the Board in April, following the companys annual meeting. Henry A McKinnell, Jr Ph.D succeeded William C Steere Jr as chairman and chief executive officer. In June 2001, Hank McKinnell announced a new mission for Pfizer to become the worlds most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. In July, he announced a commitment to fund the building of a regional treatment and training center on the campus of Makerere University in Kampala, Uganda as part of the Academic Alliance for AIDS Care and Prevention. Pfizer launched Geodon (ziprasidone hydrochloride), a new antipsychotic for the treatment of schizophrenia.

2002:

In a major expansion of its commitment to improving health care for low-income Americans, Pfizer introduced The Pfizer For Living Share Card Program. The program provides qualified low-income Medicare beneficiaries with access to up to a 30-day supply of any prescription medicine for a flat rate of 15 per prescription. By April 2004, over half a million seniors enrolled in the program and nearly five million prescriptions were filled. Pfizer became the first U.S. pharmaceutical company and first top-ten company on the New York Stock Exchange to join the U.N. Global Compact, an international network that promotes good corporate citizenship by fostering partnerships between companies, U.N. agencies, non-governmental organizations (NGOs), trade unions and academic institutions. Pfizer invested an industry leading 5.1 billion in research and development and launched Vfend (voriconazole), an orally and intravenously administered antifungal indicated for treatment of serious fungal infections. The Pfizer Foundation announced the launch of a three-year initiative to provide grants to support training and capacity building for HIV, AIDS in developing countries. Twelve organizations received grants through the International HIV, AIDS Health Literacy Grants Program. Hank McKinnell, CEO and Chairman of Pfizer, announced the Global Health Fellows program at the World AIDS Conference in Barcelona - a call to action for Pfizer colleagues to volunteer in developing countries for up to six months on HIV/AIDS projects. In 2003, the first eighteen Global Health Fellows are sent into the field.

2003:

Pfizer invested more than USD7.1 billion in research and development. On April 16, 2003 Pfizer Inc and Pharmacia Corporation combined operations, bringing together two of the world's fastest-growing and most innovative companies. Pfizer launched Relpax (eletriptan HBr), a medication developed specifically for the treatment of migraines. Pfizer's Sharing the Care drug-donation program celebrated its 10th anniversary.

2004:

Pfizer Inc was selected by Dow Jones and Co. to be included in the Dow Jones Industrial Average, which is the best-known stock market barometer in the world. Caduet (amlodipine besylate and atorvastatin calcium), the first single pill that treats both high blood pressure and high cholesterol, was launched. Pfizer Helpful Answers, the pharmaceutical industry's most comprehensive prescription medicines access initiative was launched, enabling America's 45 million uninsured to obtain Pfizer medicines free or at significant savings. The Infectious Diseases Institute, a new medical facility providing state of the art training and treatment of HIV/ADS and other infectious diseases, opens its doors on the grounds of Makerere University in Kampala, Uganda. Pfizer Inc and the Pfizer Foundation, as part of a unique public-private partnership with a number of organizations, contribute more than 15 million to support construction of the building.

2005:

Pfizer launched Lyrica (pregabalin), the first treatment approved by the U.S. Food and Drug Administration to treat two distinct forms of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and adjunctive treatment of partial onset seizures in adults with epilepsy.

2006:

Pfizers roster of outstanding drugs grows with the launch of Sutent (sunitinib malate), a new, oral, multikinase inhibitor to treat patients with metastatic renal cell carcinoma (mRCC) or advanced kidney cancer and gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to, imatinib mesylate. Pfizer launched Eraxis (anidulafungin), a new medicine to treat certain infections caused by Candida, a yeast-like fungus that can cause serious infections in hospitalized patients or patients with compromised immune systems. Chantix (varenicline), a prescription medicine to help adults stop smoking, was launched by Pfizer. In July 2006, the Pfizer Board of Directors named Jeffrey B Kindler Chief Executive Officer. Kindler succeeded Hank McKinnell, who remained Chairman of the Board until his retirement in February, 2007.

2007:

Pfizer launched Selzentry (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. Pfizer launched an online site to provide up-to-date, user-friendly information on the status of its U.S. post marketing commitments studies conducted after a medicine received regulatory approval and designed to provide additional information about the medicine's safety, efficacy or optimal use. This initiative is the first of its kind for a pharmaceutical company. To help address critical gaps in malaria treatment and education, Pfizer announced the launch of Mobilize Against Malaria.

2008:

Jeff Kindler, Chairman and CEO of Pfizer, announced the next step in the companys evolution and outlines the companys plan to establish smaller operating units designed to enhance innovation and accountability, while drawing upon the advantages of Pfizers scale and resources. These customer-focused business units allow Pfizer to better anticipate and respond to customers' and patients needs, as well responds to changes in the marketplace. Pfizer launched a new Medicine Safety Website to help healthcare professionals and patients make better informed decisions about treatment options. Grameen Health an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize in 2006 for its work to alleviate poverty, partners with Pfizer to identify sustainable models for healthcare delivery in the developing world. Pfizer launched its Global Regenerative Medicine Unit. The unit is dedicated to understanding the biology of stem cells and the opportunity these cells provide, to discover and develop a new generation of regenerative medicines that may prevent disability, repair failing organs and treat degenerative diseases. Pfizer enters into an agreement with Medivation to develop and commercialize an investigational medicine, Dimebon, for treating Alzheimers disease and Huntingtons disease.

2009:

On October 15, 2009, Pfizer acquired Wyeth, creating a company with a broad range of products and therapies that touch the lives of patients and consumers every day and at every stage of life. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. Pfizer takes a new and unique approach to biomedical research, a move intended bring more innovative medicines to more patients more quickly. Specifically, Pfizer created two distinct research

organizations: The PharmaTherapeutics Research and Development Group, which focused on discovery of small molecules and related modalities; and The BioTherapeutics Research and Development Group, which focuses on large molecule research, including vaccines. Pfizer launched Toviaz (fesoterodine fumarate), a prescription medicine used in adults to treat symptoms of a condition called overactive bladder. Pfizer entered into major licensing agreements with two Indian based pharmaceutical companies Claris Lifesciences Ltd. and Aurobindo Pharma Ltd to enhance medicinal availability to underserved populations around the world and add new non Pfizer medicines to the companys existing portfolio of established products. Because patient participation in clinical trials is the key to progress in medical research, Pfizer enters into a collaboration with Private Access, an innovator in privacy enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation.

2010:

Pfizer announced a diversified R and D platform named Pfizer Worldwide Research and Development, supporting excellence in small molecules, large molecules and vaccine research and development. As a part of the acquisition of Wyeth in 2009, Pfizer initially implemented a two division structure for research and development (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations. Due to the speed and effectiveness of that integration, Pfizer progresses to this new model while maintaining the same breadth and research programs.

Company Highlights

Financial Year	2015
Business Operations	<p>Pfizer Inc is a biopharmaceutical company, which focuses on the discovery, development, manufacture and marketing of healthcare products such as medicines, vaccines, medical devices and consumer health care products. Pfizer work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of time. The Company's commercial operations consist of two businesses, innovative products business and established products business. The innovative products business consists of two segments the global innovative pharmaceutical segment and the global vaccines, oncology and consumer healthcare segment. The established products business consists of the global established pharmaceutical segment.</p> <p>Pfizer research and development focuses on major therapeutic areas, include oncology, inflammation, cardiovascular, immunology, metabolic diseases, vaccines, neuroscience and rare diseases.</p>
Geographic Reach	
Research and Development Spending	Research and development expenses of the company in the fiscal year end December 31, 2015 is USD7,690 million.

Sales and Marketing	<p>The total sales of Innovative products is USD26,758 million. Out of which, Global Innovative Pharmaceuticals sales is USD13,954 million and Global Vaccines, Oncology and Consumer Healthcare segment is USD12,803 million.</p> <p>Out of Global Innovative Pharmaceuticals, sales of Lyrica GIP is USD3,655 million, Viagra GIP is USD1,297 million, BeneFIX is USD752 million, Chantix or Champix is USD671 million, Genotropin is USD617 million, Refacto AF or Xyntha is USD533 million, Xeljanz is USD523 million, Toviaz is USD267 million, BMP2 is USD232 million, Somavert is USD218 million, Rapamune is USD197 million, Alliance revenue GIP is USD1,254 million and All other GIP is USD405 million.</p> <p>Out of Global Vaccines, Oncology and Consumer Healthcare segment sales Prevnar family sales is USD6,245 million, Sutent USD1,120 million, Ibrance USD723 million, Xalkori USD488 million, Inlyta USD430 million, FSME-IMMUN or TicoVac USD104 million, All other V/O USD298 million, Consumer Healthcare USD3,395 million.</p> <p>The total sales of Established products business is USD21,587 million. Legacy Established Products sales is USD11,745 million, out of which Lipitor sales is USD1,860 million, Premarin family USD1,018 million, Norvasc USD991 million, Xalatan or Xalacom USD399 million, Zoloft USD374 million, Relpax USD352 million, EpiPen USD339 million, Effexor USD288 million, Zithromax or Zmax USD275 million, Xanax or Xanax XR USD224 million, Cardura USD210 million, Neurontin USD196 million, Diflucan USD181 million, Tikosyn USD179 million, Depo-Provera USD170 million, Unasyn USD118 million and All other Legacy Established Products USD4,571 million.</p> <p>Sales of Peri-LOE Products is USD5,326 million. Out of which Lyrica GEP sales is USD1,183 million, Zyvox USD883 million, Celebrex USD830 million, Pristiq USD715 million, Vfend USD682 million, Viagra USD411 million, Revatio USD260 million and All other Peri-LOE Products sales is USD362 million.</p> <p>Sales of Sterile Injectable Pharmaceuticals is USD3,944. Out of which Medrol sales is USD402 million, Sulperazon USD339 million, Fragmin USD335 million, Tygacil USD304 million and All other Sterile Injectable Pharmaceuticals USD2,563 million.</p> <p>Sales of Infusion Systems is USD403 million, Biosimilars USD63 million, Other Established Products USD106 million.</p> <p>Revenues by geographic area include USD21,704 million in United States, USD9,714 million in Developed Europe, USD6,298 million in Developed Rest of World, USD11,136 in Emerging Markets and the total revenue is USD48,851 million.</p>
Partnering and Alliances	On November 23, 2015 Pfizer entered into a definitive merger agreement with Allergan, a global pharmaceutical company incorporated in Ireland, under which the company have agreed to combine with Allergan in a stock transaction valued at USD363.63 per Allergan share, for a total enterprise value of approximately USD160 billion.

Patents and Other Intellectual Property Rights	<p>Pfizer own or license a number of U.S. and foreign patents. These patents cover pharmaceutical and other products and their uses, pharmaceutical formulations, product manufacturing processes and intermediate chemical compounds used in manufacturing.</p> <p>The patent family include products Viagra whose expiry is Japan(2019), EU(2016), Japan(2019), Lyrica US(2018), Japan(2022), Chantix US(2020), EU(2021), Japan(2022), Inlyta US(2020), EU(2025), Japan(2025), Xeljanz US(2020), Japan(2025), Sutent US(2021), EU(2021), Japan(2024), Eliquis US(2023), EU(2026), Japan(2026), Ibrance US(2023), Prevnar 13/Prevenar 13 US(2026), EU(2026), Japan(2029) and Xalkori US(2029), EU(2027), Japan(2028).</p> <p>In addition to the basic product patent covering Viagra, which expired in 2012, Viagra is covered by a U.S. method-of-treatment patent which, including the six-month pediatric exclusivity period associated with Revatio (which has the same active ingredient as Viagra), expires in 2020.</p>
--	---

Financials

Stock Quote : Pfizer Inc (New York Stock Exchange:PFE)

Price : 31.93 Change : -0.55 Change(%) : (-1.69%)

Date	10/28/2016	52 Week High	37.39
Prev Close	32.48	52 Week Low	28.25
Open	32.52	Volume	28508651
High	32.56	P/E Ratio	28.31
Low	31.88	EPS	1.13
Shares Outstanding(mn)	6175	Market Cap(mn)	193680
EBITDA	20706	EBIT	15549
EBITA		Enterprise value(mn)	0
Trailing 12M EBITDA Margin	42	Currency	US Dollar

Key Ratios

Profitability Ratio	Value	Operational Ratio	Value	Financial Ratio	Value
Gross Margin %	80.69	Inventory Turnover	1.43	Current Ratio	1.49
EBITDA Margin %	42.39	Fixed Asset Turnover	3.55	Quick Ratio	1.07
EBITA Margin %	0.00	Total Asset Turnover	0.29	Debt/Equity	1.58
EBIT Margin %	31.83	Accounts Receivable Turnover	5.89	Debt/Capital	0.74
Net Income Margin %	24.79	Avg. Days Sales Outstanding	61.09	Total Liabilities/Total Assets	0.61
Return on Assets %	0.04	Avg. Days Inventory Outstanding	290.71	Interest Coverage Ratio	12.97
Return on Equity %	0.11	Avg. Days Payable Outstanding	140.07	Net Debt to Equity	24.14
Return on Capital %	5.04	Cash Conversion Cycle	211.73		

Growth Ratio	Value	Valuation Ratio	Value	PerShare Ratio	Value
Total Revenues, 1 Yr Growth %	-1.13	Price to Free Cash Flow	15.20	Revenue Per Share	7.91
Gross Profit, 1 Yr Growth %	-2.37	Cash Flow to Net Income	2.09	Dividends Per Share	1.16
EBITDA, 1 Yr Growth %	-1.41	Free Cash Flow to Equity	14416.00	Free Cash Flow Per Share	2.12
EBITA, 1 Yr Growth %	0.54	Free Cash Flow to Firm	14047.85	Working Capital Per Share	2.33
EBIT, 1 Yr Growth %	0.54	Price/Earnings Ratio	24.79	Long-Term Debt Per Share	11.83
Net Income, 1 Yr Growth %	-23.81	Price/Book Ratio	0.04	Total Assets Per Share	27.12
Diluted EPS, 1 Yr Growth %	-21.83	Price/Sales Ratio	0.11		
Accounts Receivable, 1 Yr Growth %	-2.68				
Inventory, 1 Yr Growth %	32.67				
Total Assets, 1 Yr Growth %	-0.06				

People & Contacts

Name	Designation	Email	Phone Number
Dr.Mikael Dolsten	Executive Vice President, President		
Dr.Dennis A Ausiello	Committee member, Director		
Mr.Ian C Read	Chairman, Chief Executive Officer (CEO), President		
Dr.Albert Bourla	President, Team Member		
Mr.Frank D'Amelio	Chief Financial Officer (CFO), Executive Vice President		
Mr.Chuck Hill	Executive Vice President		
Mr.Rady Johnson	Chief Compliance Officer, Executive Vice President, Officer		
Mr.Doug Lankler	Counsel, Executive Vice President, Team Member		
Dr.Freda C Lewis Hall	Chief Medical Officer, Executive Vice President		
Mr.Anthony J Maddaluna	Executive Vice President, President		
Ms.Laurie J Olson	Executive Vice President		
Ms.Sally Susman	Executive Vice President		
Mr.John Young	President		
Mr.W Don Cornwell	Committee member, Director		
Mr.Joseph J Echevarria	Committee member, Director		
Dr.Frances D Fergusson	Chairperson, Committee member, Director		
Ms.Helen H Hobbs	Chairperson, Committee member, Director		
Mr.James M Kilts	Committee member, Director		
Mr.Shantanu Narayen	Committee member, Director		

Name	Designation	Email	Phone Number
Ms.Suzanne Nora Johnson	Chairperson, Committee member, Director		
Mr.Stephen W Sanger	Chairperson, Committee member, Director		
Mr.James C Smith	Committee member, Director		
Dr.Rod MacKenzie	Chief Development Officer, Executive Vice President		
Mr.Margaret M Madden	Counsel, Secretary, Vice President		
Mr.Gen Germano	President		
Mr.Bill Meury	President		
Dr.Rory O Connor	Chief Medical Officer		
Mr.Bob Smith	Senior Vice President	bob.smith@pfizer.com	
Mr.Uwe Schoenbeck	Chief Scientific Officer, Senior Vice President		
Dr.Ole Isacson	Chief Scientific Officer, Vice President		
Dr.Greg LaRosa	Chief Scientific Officer, Senior Vice President		
Dr.Michael Vincent	Chief Scientific Officer, Senior Vice President		
Mr.James Rusnak	Chief Development Officer		

Facilities/Subsidiaries

Facilities

Facility	Region	Country	Address
Corporate Headquarter	North America	United States	235 East 42nd Street ,,,New York (NY)

Subsidiaries

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Asia-Pacific	Australia	Hospira Adelaide Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Hospira Holdings SA Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Hospira Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Mayne Pharma IP Holdings Euro Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Hospira Australia Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Pfizer Perth Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Pfizer ESP Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Pfizer PFE Australia Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	US Oral Pharmaceuticals Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Wyeth Australia Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Pfizer Australia Holdings Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Pfizer Australia Investments Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	Australia	Pfizer Australia Pty Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Pfizer China Research and Development Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Pfizer Pharmaceuticals Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Wyeth Pharmaceutical Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Pfizer International Trading Shanghai Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Pfizer Pharmaceutical Wuxi Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Pfizer Wuhan Research and Development Co Ltd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Asia-Pacific	China	Pfizer Finance Share Service Dalian Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	China	Hospira China Enterprise Management Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Hospira Ltd Hong Kong (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Pfizer PFE Corp Hong Kong Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Pfizer HK Service Company Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Pfizer HK Holding Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Parke Davis Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Pfizer Corp Hong Kong Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Korea Pharma Holding Company Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Pfizer Far East Ltd (Active)
Direct Subsidiary	Asia-Pacific	Hong Kong	Fort Dodge Hong Kong Ltd (Active)
Direct Subsidiary	Asia-Pacific	India	Pfizer Products India Private Ltd (Active)
Direct Subsidiary	Asia-Pacific	India	Pfizer Ltd India (Active)
Direct Subsidiary	Asia-Pacific	India	Wyeth Pharmaceuticals India Private Ltd (Active)
Direct Subsidiary	Asia-Pacific	India	IP Pharmaceuticals India Private Ltd (Active)
Direct Subsidiary	Asia-Pacific	India	Zydus Hospira Oncology Pvt Ltd (Active)
Direct Subsidiary	Asia-Pacific	India	Hospira Healthcare India Pvt Ltd (Active)
Direct Subsidiary	Asia-Pacific	Indonesia	PT Pfizer Indonesia (Active)
Direct Subsidiary	Asia-Pacific	Indonesia	PT Pfizer Parke Davis (Active)
Direct Subsidiary	Asia-Pacific	Japan	Pfizer Seiyaku KK (Active)
Direct Subsidiary	Asia-Pacific	Japan	Pfizer Japan Inc (Active)
Direct Subsidiary	Asia-Pacific	Japan	Hospira Japan Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	Japan	PFE Holdings GK (Active)
Direct Subsidiary	Asia-Pacific	Japan	Pfizer Holdings GK (Active)
Direct Subsidiary	Asia-Pacific	Japan	Pfizer Global Supply Japan Inc (Active)
Direct Subsidiary	Asia-Pacific	Malaysia	Pfizer Malaysia Sdn Bhd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Asia-Pacific	Malaysia	Hospira Malaysia Sdn Bhd (Active)
Direct Subsidiary	Asia-Pacific	Malaysia	Pfizer PFE Malaysia SDN BHD (Active)
Direct Subsidiary	Asia-Pacific	Malaysia	Pfizer Parke Davis Sdn Bhd (Active)
Direct Subsidiary	Asia-Pacific	New Zealand	Pfizer New Zealand Ltd (Active) Level 1, Suite 1.4, Building B , 8 Nugent Street,Grafton, Auckland 1023, New Zealand
Direct Subsidiary	Asia-Pacific	New Zealand	Pfizer PFE New Zealand (Active)
Direct Subsidiary	Asia-Pacific	New Zealand	Hospira NZ Ltd (Active)
Direct Subsidiary	Asia-Pacific	Pakistan	Wyeth Pakistan Ltd (Active) S-33, Hawkes Bay Road, S.I.T.E., , Karachi,Pakistan
Direct Subsidiary	Asia-Pacific	Pakistan	Pfizer Pakistan Ltd (Active) 12- Dockyard Road, , West Wharf,Karachi- 74000
Direct Subsidiary	Asia-Pacific	Philippines	Pfizer Parke Davis (Active)
Direct Subsidiary	Asia-Pacific	Philippines	Hospira Philippines Inc (Active)
Direct Subsidiary	Asia-Pacific	Philippines	Pfizer PFE Inc (Active)
Direct Subsidiary	Asia-Pacific	Philippines	Pfizer Philippines Inc (Active)
Direct Subsidiary	Asia-Pacific	Philippines	A H Robins Philippines Company Inc (Active)
Direct Subsidiary	Asia-Pacific	Russia	Pfizer Innovations LLC (Active)
Direct Subsidiary	Asia-Pacific	Russia	Pfizer LLC (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer Singapore Trading Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer Asia Manufacturing Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer Private Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer Asia Pacific Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer PFE Private Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer PFE Singapore Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Hospira Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Hospira Singapore Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	Singapore	Pfizer CentreSource Asia Pacific Pte Ltd (Active)
Direct Subsidiary	Asia-Pacific	South Korea	Pfizer Pharmaceuticals Korea Ltd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Asia-Pacific	South Korea	Hospira Korea Co Ltd (Active)
Direct Subsidiary	Asia-Pacific	Taiwan	Pfizer Biotech Corp (Active)
Direct Subsidiary	Asia-Pacific	Taiwan	Pfizer Taiwan Ltd (Active)
Direct Subsidiary	Asia-Pacific	Taiwan	Pfizer Ltd Taiwan (Active)
Direct Subsidiary	Asia-Pacific	Thailand	OCT Thailand Ltd (Active)
Direct Subsidiary	Asia-Pacific	Thailand	Pfizer Parke Davis Thailand Ltd (Active)
Direct Subsidiary	Asia-Pacific	Thailand	Pfizer PFE Thailand Ltd (Active)
Direct Subsidiary	Asia-Pacific	Thailand	Wyeth Thailand Ltd (Active)
Direct Subsidiary	Asia-Pacific	Thailand	Warner Lambert Thailand Ltd (Active)
Direct Subsidiary	Asia-Pacific	Thailand	Pfizer Thailand Ltd (Active)
Direct Subsidiary	Asia-Pacific	Ukraine	Pfizer Ukraine LLC (Active)
Direct Subsidiary	Europe	Austria	Wyeth Whitehall Export GmbH (Active) 1 Storcheng, Vienna 1150,Austria
Direct Subsidiary	Europe	Austria	Hospira Austria GmbH (Active)
Direct Subsidiary	Europe	Belgium	Hospira Benelux BVBA (Active)
Direct Subsidiary	Europe	Belgium	Pfizer PFE Sweden Holding 2 Sarl (Active) ,Luxembourg
Direct Subsidiary	Europe	Belgium	Pfizer PFE Sweden Holding Sarl (Active) ,Luxembourg
Direct Subsidiary	Europe	Belgium	Pfizer PFE Norway Holding Sarl (Active) ,Luxembourg
Direct Subsidiary	Europe	Belgium	Pfizer PFE Germany Holding 2 Sarl (Active) ,Luxembourg
Direct Subsidiary	Europe	Belgium	Pfizer PFE Germany Holding Sarl (Active) ,Luxembourg
Direct Subsidiary	Europe	Belgium	Pfizer Innovative Supply Point International SPRL (Active)
Direct Subsidiary	Europe	Belgium	Pfizer International Luxembourg Sarl (Active) ,Luxembourg
Direct Subsidiary	Europe	Belgium	Pfizer Financial Services NV SA (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Belgium	Pfizer Overseas Distribution (Active)
Direct Subsidiary	Europe	Belgium	Continental Pharma Inc (Active)
Direct Subsidiary	Europe	Belgium	Pfizer Financial Services NVSA (Active)
Direct Subsidiary	Europe	Belgium	Wyeth Lederle Vaccines SA (Active)
Direct Subsidiary	Europe	Belgium	Pfizer Service Company BVBA (Active)
Direct Subsidiary	Europe	Belgium	Pfizer SA Belgium (Active)
Direct Subsidiary	Europe	Belgium	Pfizer PFE Belgium SPRL (Active)
Direct Subsidiary	Europe	Belgium	Pfizer Manufacturing Belgium NV (Active)
Direct Subsidiary	Europe	Belgium	Lothian Developments V SPRL (Active)
Direct Subsidiary	Europe	Bosnia and Herzegovina	Pfizer BH Doo (Active)
Direct Subsidiary	Europe	Croatia	Pfizer Croatia doo (Active)
Direct Subsidiary	Europe	Croatia	Hospira Zagreb doo (Active)
Direct Subsidiary	Europe	Czech Republic	Hospira Czech Republic sro (Active)
Direct Subsidiary	Europe	Czech Republic	Pfizer PFE spol sro (Active)
Direct Subsidiary	Europe	Czech Republic	Pfizer Spol SRO (Active) Stroupežnického 3191/17 , 150 00 Prague 5 - Smíchov
Direct Subsidiary	Europe	Denmark	Pfizer PFE ApS (Active)
Direct Subsidiary	Europe	Denmark	Ferrosan AS (Active)
Direct Subsidiary	Europe	Denmark	Ferrosan Holding AS (Active)
Direct Subsidiary	Europe	Denmark	Ferrosan International AS (Active)
Direct Subsidiary	Europe	Denmark	Vesteralens Naturprodukter AS Denmark (Active)
Direct Subsidiary	Europe	Finland	Hospira Finland Oy (Active)
Direct Subsidiary	Europe	Finland	Kiinteisto oy Espoon Pellavaniementie 14 (Active)
Direct Subsidiary	Europe	Finland	Pfizer Oy (Active)
Direct Subsidiary	Europe	Finland	Pfizer PFE Finland Oy (Active)
Direct Subsidiary	Europe	Finland	Vesteralens Naturprodukter OY (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	France	Pfizer PGRD SAS (Active)
Direct Subsidiary	Europe	France	Pfizer Holding France SCA (Active)
Direct Subsidiary	Europe	France	Pfizer Services 1 SNC (Active)
Direct Subsidiary	Europe	France	Pfizer International Operations SAS (Active)
Direct Subsidiary	Europe	France	Hospira France SAS (Active)
Direct Subsidiary	Europe	France	Pfizer (Active)
Direct Subsidiary	Europe	France	Pfizer PGM (Active)
Direct Subsidiary	Europe	France	Pfizer PGRD (Active)
Direct Subsidiary	Europe	France	Pfizer Sante Familiale (Active)
Direct Subsidiary	Europe	France	Pfizer Services 1 (Active)
Direct Subsidiary	Europe	France	Rivepar (Active)
Direct Subsidiary	Europe	France	Pfizer France International Investments (Active)
Direct Subsidiary	Europe	France	Pfizer Holding France (Active)
Direct Subsidiary	Europe	France	Pfizer International Operations (Active)
Direct Subsidiary	Europe	France	Pfizer PFE France (Active)
Direct Subsidiary	Europe	France	Rivepar SAS (Active) France
Direct Subsidiary	Europe	France	Pfizer Services 4 SNC (Active)
Direct Subsidiary	Europe	France	Pfizer SAnte Familiale SAS (Active)
Direct Subsidiary	Europe	France	Pfizer France International Investments SAS (Active)
Direct Subsidiary	Europe	France	Pfizer PGM SAS (Active)
Direct Subsidiary	Europe	Germany	FPZ Deutschland den Ricken Starken GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Deutschland PFE Holding GmbH (Active)
Direct Subsidiary	Europe	Germany	Pharmacia GmbH (Active)
Direct Subsidiary	Europe	Germany	Hospira Deutschland GmbH (Active)
Direct Subsidiary	Europe	Germany	FPZ Deutschland den Rucken Starken GmbH (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Germany	Coley Pharmaceutical GmbH (Active)
Direct Subsidiary	Europe	Germany	Fpz AG (Active)
Direct Subsidiary	Europe	Germany	Pfizer Deutschland GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Germany BV and Co KG (Active)
Direct Subsidiary	Europe	Germany	Pfizer Finance Verwaltungs GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Finance GmbH and Co KG (Active)
Direct Subsidiary	Europe	Germany	Pfizer Consumer Healthcare GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Manufacturing Deutschland GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Manufacturing Deutschland Grundbesitz GmbH and Co KG (Active)
Direct Subsidiary	Europe	Germany	Pfizer Manufacturing Deutschland PFE GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Pharma GmbH (Active)
Direct Subsidiary	Europe	Germany	Pfizer Pharma PFE GmbH (Active)
Direct Subsidiary	Europe	Greece	Pfizer PFE Hellas EPE (Active)
Direct Subsidiary	Europe	Greece	Pfizer Hellas AE (Active)
Direct Subsidiary	Europe	Hungary	Pfizer Pharmaceutical Trading Ltd Liability Company (Active)
Direct Subsidiary	Europe	Hungary	Pfizer PFE Korlatolt Felelossegu Tarsasag (Active)
Direct Subsidiary	Europe	Hungary	Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Active)
Direct Subsidiary	Europe	Hungary	Wyeth KFT (Active)
Direct Subsidiary	Europe	Hungary	CP Pharma Gyogyszerkereskedelmi Korlatolt Felelossegu Tarsasag (Active)
Direct Subsidiary	Europe	Ireland	Wyeth Pharmaceuticals Ltd (Active)
Direct Subsidiary	Europe	Ireland	Sherama Ltd (Active)
Direct Subsidiary	Europe	Ireland	Soumillon Ltd (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Manufacturing Ireland (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Ireland	Pfizer Biologics Ireland Holdings Ltd (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Global Supply (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Manufacturing Services (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Investment Capital (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Investment Co Ltd (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Ireland Investments Ltd (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Ireland Pharmaceuticals (Active) Grange Castle Business Park , Clondalkin,Dublin 22
Direct Subsidiary	Europe	Ireland	Pfizer Ireland Ventures (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Leasing Ireland Ltd (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Service Company Ireland (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Shared Services (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Transactions Ireland (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Worldwide Services (Active)
Direct Subsidiary	Europe	Ireland	Hospira (Active)
Direct Subsidiary	Europe	Ireland	Hospira Ireland Holdings (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Global Trading (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Export Company (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Healthcare Ireland (Active) The Pfizer Building , 9 Riverwalk National Digital Park,Citywest Business Campus, Dublin 24
Direct Subsidiary	Europe	Ireland	Pfizer Holdings Europe (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Holding Ventures (Active)
Direct Subsidiary	Europe	Ireland	Pfizer International Business Europe (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Cork Ltd (Active)
Direct Subsidiary	Europe	Ireland	Pfizer Biotechnology Ireland (Active)
Direct Subsidiary	Europe	Ireland	Furina Ltd (Active)
Direct Subsidiary	Europe	Ireland	Covx Technologies Ireland Ltd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Ireland	Minarik Ltd (Active)
Direct Subsidiary	Europe	Italy	Pfizer Consumer Manufacturing Italy Srl (Active)
Direct Subsidiary	Europe	Italy	Hospira Italia Srl (Active)
Direct Subsidiary	Europe	Italy	Pfizer Srl (Active)
Direct Subsidiary	Europe	Italy	Pfizer Italia Srl (Active)
Direct Subsidiary	Europe	Italy	Pfizer Italy Group Holding Srl (Active)
Direct Subsidiary	Europe	Italy	Pfizer Finance Italy Srl (Active)
Direct Subsidiary	Europe	Italy	Vicuron Pharmaceuticals Italy Srl (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Jersey Finance Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Jersey Company Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Strategic Investment Company Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Searle Investment Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Jersey Capital Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Domestic Ventures Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Holdings Turkey Ltd (Active)
Direct Subsidiary	Europe	Jersey	Pfizer Healthcare Holdings Company UnLtd (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Group Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Holdings International Luxembourg PHIL SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Holdings North America SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Enterprises SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Europe Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	PF PRISM Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	PF Prism Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Brazil Holding Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Atlantic Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Precision Holdings SARL (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Luxembourg	Pfizer Asset Management Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Luxembourg International SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Wyeth Whitehall SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Asia Pac Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Wyeth Ayerst SARL (Active)
Direct Subsidiary	Europe	Luxembourg	PHIVCO Holdco Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	PHIVCO Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Investment Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Luxco Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Luxembourg Global Holdings SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Ireland Holdco Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE France Holdco 2 Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Group Luxembourg Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Italy Group Holding Cooperatief UA (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Italy Holdco 2 Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Italy Holdco Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Luxembourg Holding 1 Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Luxembourg Holding 2 Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Luxembourg Holding 3 Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Luxembourg Holding 4 Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE Luxembourg Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Shareholdings Intermediate SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Shareholdings Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE PHIL Holdco Sarl (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE PILSA Holdco Sarl (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Transactions Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer Warner Lambert Luxembourg SARL (Active)
Direct Subsidiary	Europe	Luxembourg	Pfizer PFE France Holdco Sarl (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE UK Holding 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Pharmaceuticals Global Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Business Enterprises CV (Active)
Direct Subsidiary	Europe	Netherlands	Pharmacia International BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Poland Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Philippines Holding 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Philippines Holding 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE New Zealand Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Spain BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Spain Holdings Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Mexico Holding 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Mexico Holding 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Netherlands Holding 1 CV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Australia Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Ireland Pharmaceuticals Holding 2 Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Ireland 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Ireland 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Argentina Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer OTC BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Philippines Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Manufacturing Holdings Cooperatief UA (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Hong Kong Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Baltic Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Holland Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Pharmaceuticals BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Commercial Holdings Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Australia Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Sweden Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Finance Netherlands BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Investments Netherlands BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Ireland Pharmaceuticals Holding 1 Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Global Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Hong Kong Holding 3 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Korea Holding 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Korea Holding 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Pharmaceuticals Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE PHIL UAE Holding 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE PHIL UAE Holding 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE PHIL UAE Holding 3 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE PHIL UAE Holding 4 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Service Company Holding Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Eastern Investments BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Europe Finance BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Argentina Holding 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE AsiaPac Holding BV (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Netherlands	Pfizer PFE BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Baltic Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Singapore Holding Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE South Africa Holding BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Turkey Holding 1 BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer PFE Turkey Holding 2 BV (Active)
Direct Subsidiary	Europe	Netherlands	AHP Manufacturing BV (Active)
Direct Subsidiary	Europe	Netherlands	AHP Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	CE Commercial Holdings CV (Active)
Direct Subsidiary	Europe	Netherlands	CE Commercial Investments CV (Active)
Direct Subsidiary	Europe	Netherlands	CE Holdings Europe CV (Active)
Direct Subsidiary	Europe	Netherlands	CP Pharmaceuticals International CV (Active)
Direct Subsidiary	Europe	Netherlands	Hospira Enterprises BV (Active)
Direct Subsidiary	Europe	Netherlands	Hospira Healthcare BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer East India BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Eastern Investments BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Enterprise Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer International Markets Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Finance International Holdings CV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Himalaya Holdings Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Germany Partner BV (Active)
Direct Subsidiary	Europe	Netherlands	Pfizer Global Holdings BV (Active)
Direct Subsidiary	Europe	Netherlands	PF Americas Holding CV (Active)
Direct Subsidiary	Europe	Netherlands	PF Asia Manufacturing Cooperatief UA (Active)
Direct Subsidiary	Europe	Netherlands	PF PR Holdings CV (Active)
Direct Subsidiary	Europe	Netherlands	PF Prism CV (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Norway	Nordic Sales Group AS (Active)
Direct Subsidiary	Europe	Norway	Pfizer AS (Active)
Direct Subsidiary	Europe	Norway	Pfizer Norge AS (Active)
Direct Subsidiary	Europe	Norway	Vesteralens Naturprodukter AS (Active)
Direct Subsidiary	Europe	Norway	Pfizer A S (Active)
Direct Subsidiary	Europe	Poland	Pfizer PFE Trading Polska Spzoo (Active)
Direct Subsidiary	Europe	Poland	Pfizer Polska Spzoo (Active)
Direct Subsidiary	Europe	Poland	Pfizer PFE Polska spzoo (Active)
Direct Subsidiary	Europe	Poland	Pfizer Trading Polska Spzoo (Active)
Direct Subsidiary	Europe	Portugal	Hospira Portugal LDA (Active)
Direct Subsidiary	Europe	Portugal	Pfizer SGPS Lda (Active)
Direct Subsidiary	Europe	Portugal	Sinergis Farma Produtos Farmaceuticos Lda (Active)
Direct Subsidiary	Europe	Portugal	Searle Laboratorios Lda (Active)
Direct Subsidiary	Europe	Portugal	Roerig Produtos Farmaceuticos Lda (Active)
Direct Subsidiary	Europe	Portugal	Upjohn Laboratorios Lda (Active)
Direct Subsidiary	Europe	Portugal	Parke Davis Productos Farmaceuticos Lda (Active)
Direct Subsidiary	Europe	Portugal	Instituto Pasteur de Lisboa Virginio Leitao Vieira dos Santos and Filhos SA (Active)
Direct Subsidiary	Europe	Portugal	Farminova Produtos Farmaceuticos de Inovacao Lda (Active)
Direct Subsidiary	Europe	Portugal	Farmogene Productos Farmaceuticos Lda (Active)
Direct Subsidiary	Europe	Portugal	Carlerba Produtos Quimicos e Farmaceuticos Lda (Active)
Direct Subsidiary	Europe	Portugal	Pfizer Biofarmaceutica Sociedade Unipessoal Lda (Active)
Direct Subsidiary	Europe	Romania	Ferrosan SRL (Active)
Direct Subsidiary	Europe	Romania	Pfizer Romania SRL (Active)
Direct Subsidiary	Europe	Slovakia	Hospira Slovakia sro (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Spain	Hospira Productos Farmaceuticos y Hospitalarios SL (Active)
Direct Subsidiary	Europe	Spain	Binesa 2002 SL (Active)
Direct Subsidiary	Europe	Spain	Invicta Farma SA (InActive)
Direct Subsidiary	Europe	Spain	Laboratorios Parke Davis SL (Active)
Direct Subsidiary	Europe	Spain	Pfizer GEP SL (Active)
Direct Subsidiary	Europe	Spain	Pfizer PFE Spain Holding SL (Active)
Direct Subsidiary	Europe	Spain	Pharmacia Nostrum SA (Active)
Direct Subsidiary	Europe	Spain	Pfizer SL (Active)
Direct Subsidiary	Europe	Spain	Vinci Farma SA (Active)
Direct Subsidiary	Europe	Spain	Wyeth Farma SA (Active)
Direct Subsidiary	Europe	Spain	Wyeth Far East Ltd (Active)
Direct Subsidiary	Europe	Sweden	Pfizer AB (Active)
Direct Subsidiary	Europe	Sweden	Pfizer Export AB (Active)
Direct Subsidiary	Europe	Sweden	Kommanditbolaget Hus Gron (Active)
Direct Subsidiary	Europe	Sweden	Wyeth AB (Active)
Direct Subsidiary	Europe	Sweden	Vesteralens Naturprodukter AB (Active)
Direct Subsidiary	Europe	Sweden	Pfizer Consumer Healthcare AB (Active)
Direct Subsidiary	Europe	Sweden	Pfizer International Sweden KB (Active)
Direct Subsidiary	Europe	Sweden	Pharmacia Holding AB (Active)
Direct Subsidiary	Europe	Sweden	Pfizer Sweden Partnership KB (Active)
Direct Subsidiary	Europe	Sweden	Pfizer Innovations AB (Active)
Direct Subsidiary	Europe	Sweden	Pfizer Health AB (Active)
Direct Subsidiary	Europe	Sweden	Hospira Nordic AB (Active)
Direct Subsidiary	Europe	Switzerland	Hospira Schweiz GmbH (Active)
Direct Subsidiary	Europe	Switzerland	Pfizer PFE Switzerland Holding GmbH (Active)
Direct Subsidiary	Europe	Switzerland	Pfizer PFE Switzerland GmbH (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	Switzerland	RedVax GmbH (Active)
Direct Subsidiary	Europe	Switzerland	Warner Lambert Company AG (Active)
Direct Subsidiary	Europe	Switzerland	BlueVax GmbH (Active)
Direct Subsidiary	Europe	United Kingdom	MPP Trustee Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Animal Health MA EEIG (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Ltd UK (Active)
Direct Subsidiary	Europe	United Kingdom	Wyeth Europa Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	PZR Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	PZR Property Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	PowderJect Research Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	PowderMed Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Thiakis Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Specialty UK Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pharmacia Laboratories Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pharmacia Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Leasing UK Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer UK Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer PFE UK Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Hospira UK Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Hospira Aseptic Services Ltd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Europe	United Kingdom	Pfizer Europe MA EEIG (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Development LP (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Development Services UK Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Pfizer Consumer Healthcare Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	John Wyeth and Brother Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Neusentis Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Meridian Medical Technologies Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Farmitalia Carlo Erba Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	Haptogen Ltd (Active)
Direct Subsidiary	Europe	United Kingdom	G D Searle and Co Ltd (Active)
Direct Subsidiary	Middle East and Africa	Algeria	Pfizer Pharm Algerie (Active)
Direct Subsidiary	Middle East and Africa	Algeria	Pfizer Saidal Manufacturing (Active)
Direct Subsidiary	Middle East and Africa	Angola	Pfizer Limitada (Active)
Direct Subsidiary	Middle East and Africa	Egypt	Pfizer Middle East for Pharmaceuticals Animal Health and Chemicals SAE (Active)
Direct Subsidiary	Middle East and Africa	Egypt	Pfizer Egypt SAE (Active)
Direct Subsidiary	Middle East and Africa	Egypt	Pfizer Africa and Middle East for Pharmaceuticals Veterinarian Products and Chemicals SAE (Active)
Direct Subsidiary	Middle East and Africa	Ghana	Pfizer Specialities Ghana (Active)
Direct Subsidiary	Middle East and Africa	Israel	Pfizer PFE Pharmaceuticals Israel Ltd (Active)
Direct Subsidiary	Middle East and Africa	Israel	Pfizer Pharmaceuticals Israel Ltd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Middle East and Africa	Kenya	Pfizer Laboratories Ltd (Active)
Direct Subsidiary	Middle East and Africa	Morocco	Laboratoires Pfizer SA (Active)
Direct Subsidiary	Middle East and Africa	Mozambique	A S Ruffel Mozambique Limitada (Active)
Direct Subsidiary	Middle East and Africa	Namibia	Pfizer Namibia Proprietary Ltd (Active)
Direct Subsidiary	Middle East and Africa	Nigeria	Pfizer Specialties Ltd (Active)
Direct Subsidiary	Middle East and Africa	Saudi Arabia	Pfizer Saudi Ltd (Active)
Direct Subsidiary	Middle East and Africa	Senegal	Pfizer Afrique de L'Ouest (Active)
Direct Subsidiary	Middle East and Africa	South Africa	Pfizer Laboratories PFE Pty Ltd (Active)
Direct Subsidiary	Middle East and Africa	South Africa	Pfizer Laboratories Pty Ltd (Active)
Direct Subsidiary	Middle East and Africa	South Africa	Pharmacia South Africa Pty Ltd (Active)
Direct Subsidiary	Middle East and Africa	Swaziland	Pfizer AG (Active)
Direct Subsidiary	Middle East and Africa	Tanzania	Pfizer Tanzania Ltd (Active)
Direct Subsidiary	Middle East and Africa	Tanzania	Warner Lambert Tanzania Ltd (Active)
Direct Subsidiary	Middle East and Africa	Tanzania	Pfizer Ltd Tanzania (Active)
Direct Subsidiary	Middle East and Africa	Tunisia	Pfizer Pharmaceuticals Tunisie SARL (Active)
Direct Subsidiary	Middle East and Africa	Tunisia	Pfizer Tunisie SA (Active)
Direct Subsidiary	Middle East and Africa	Turkey	Warner Lambert Ilac SANAYI ve Ticaret Ltd Sirketi (Active)
Direct Subsidiary	Middle East and Africa	Turkey	Pfizer Ilaclari Ltd Sirketi (Active)
Direct Subsidiary	Middle East and Africa	Uganda	Fort Dodge Animal Health Ltd (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	Middle East and Africa	Uganda	Pfizer Ltd India (Active)
Direct Subsidiary	Middle East and Africa	Uganda	Pfizer Uganda Ltd (Active)
Direct Subsidiary	Middle East and Africa	Uganda	Pfizer Ltd Uganda (Active)
Direct Subsidiary	Middle East and Africa	United Arab Emirates	Wyeth Pharmaceuticals FZ LLC (Active)
Direct Subsidiary	Middle East and Africa	United Arab Emirates	Pfizer Gulf FZ LLC (Active)
Direct Subsidiary	North America	Canada	Hospira Healthcare Corp (Active)
Direct Subsidiary	North America	Canada	Wyeth Canada ULC (Active)
Direct Subsidiary	North America	Canada	Pfizer Canada Inc (Active)
Direct Subsidiary	North America	United States	Bioren Inc (Active) Delaware
Direct Subsidiary	North America	United States	Pharmacia International Inc (Active)
Direct Subsidiary	North America	United States	BioRexis Pharmaceutical Corp (Active) Delaware
Direct Subsidiary	North America	United States	Agouron Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	G D Searle LLC (Active)
Direct Subsidiary	North America	United States	Hospira Worldwide Inc (Active)
Direct Subsidiary	North America	United States	Hospira Fleet Services LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Hospira Boulder Inc (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer Venture Investments (Active) 235 East 42nd Street , NY, NY 10017,USA
Direct Subsidiary	North America	United States	InnoPharma LLC (Active) 10 Knightsbridge Rd, , Piscataway Township, NJ 08854,,United States
Direct Subsidiary	North America	United States	Bioren LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	BioRexis Pharmaceutical LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	PFE Pfizer Holdings 1 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	PFE PH 1 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	PFE PHAC Inc (Active) ,Delaware (DE)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	North America	United States	PFE PUC Mexico 1 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	PFE PUC Mexico 2 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	PFE Wyeth Holdings LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	PFE Wyeth Ayerst Asia LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Hospira Puerto Rico LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Innovative Drug Delivery Systems Inc (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer PFE Colombia Holding 2 Corp (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer PFE Commercial Holdings LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer PFE US Holdings 3 LLC (Active)
Direct Subsidiary	North America	United States	Pfizer PFE US Holdings 4 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer PFE US Holdings 5 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer PFE US Holdings 6 LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer PFE Spain Holdings LLC (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	Pfizer Research NC Inc (Active) ,Delaware (DE)
Direct Subsidiary	North America	United States	CICL Corp (Active)
Direct Subsidiary	North America	United States	COC I Corp (Active)
Direct Subsidiary	North America	United States	Alpharma Holdings Inc (Active)
Direct Subsidiary	North America	United States	Alpharma Pharmaceuticals LLC (Active)
Direct Subsidiary	North America	United States	Alpharma Specialty Pharma Inc (Active)
Direct Subsidiary	North America	United States	Alpharma USHP Inc (Active)
Direct Subsidiary	North America	United States	American Food Industries LLC (Active)
Direct Subsidiary	North America	United States	Ayerst Wyeth Pharmaceuticals LLC (Active)
Direct Subsidiary	North America	United States	Alacer Corp (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	North America	United States	AH Robins LLC (InActive)
Direct Subsidiary	North America	United States	Pfizer HCP Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Health Solutions Inc (Active)
Direct Subsidiary	North America	United States	Pfizer International LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Holdings Americas Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Holdings Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Holdings International Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Enterprises LLC (Active)
Direct Subsidiary	North America	United States	Laboratorios Wyeth LLC (Active)
Direct Subsidiary	North America	United States	International Affiliated Corp LLC (Active)
Direct Subsidiary	North America	United States	Javelin Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	JMI Daniels Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	King Pharmaceuticals Holdings LLC (Active)
Direct Subsidiary	North America	United States	King Pharmaceuticals LLC (Active)
Direct Subsidiary	North America	United States	King Pharmaceuticals Research and Development Inc (Active)
Direct Subsidiary	North America	United States	Meridian Medical Technologies Inc (Active) 6350 Stevens Forest Road , Suite #301,Columbia, MD 21046
Direct Subsidiary	North America	United States	Monarch Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	MTG Divestitures LLC (Active)
Direct Subsidiary	North America	United States	NextWave Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	PAH USA IN8 LLC (Active)
Direct Subsidiary	North America	United States	Parke Davis and Company LLC (Active)
Direct Subsidiary	North America	United States	Parkedale Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	ParkeDavis Manufacturing Corp (Active)
Direct Subsidiary	North America	United States	PD Co LLC (Active)
Direct Subsidiary	North America	United States	Peak Enterprises LLC (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	North America	United States	G D Searle International Capital LLC (Active)
Direct Subsidiary	North America	United States	Genetics Institute LLC (Active)
Direct Subsidiary	North America	United States	GenTrac Inc (Active)
Direct Subsidiary	North America	United States	GI Europe Inc (Active)
Direct Subsidiary	North America	United States	GI Japan Inc (Active)
Direct Subsidiary	North America	United States	Greenstone LLC (Active) 100 Route 206 North , Peapack,NJ 07977
Direct Subsidiary	North America	United States	InnoPharma Licensing LLC (Active)
Direct Subsidiary	North America	United States	FoldRx Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	CovX Research LLC (Active)
Direct Subsidiary	North America	United States	Blue Whale Re Ltd (Active)
Direct Subsidiary	North America	United States	Coley Pharmaceutical Group Inc (Active)
Direct Subsidiary	North America	United States	Cyanamid de Argentina SA (Active)
Direct Subsidiary	North America	United States	Cyanamid de Colombia SA (Active)
Direct Subsidiary	North America	United States	Cyanamid Inter American Corp (Active)
Direct Subsidiary	North America	United States	Distribuidora Mercantil Centro Americana SA (Active)
Direct Subsidiary	North America	United States	Encysive Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	Esperion LUV Development Inc (Active)
Direct Subsidiary	North America	United States	Excaliard Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	Wyeth Pharmaceuticals Inc (Active)
Direct Subsidiary	North America	United States	Pfizer Production LLC (Active) Delaware
Direct Subsidiary	North America	United States	Wyeth Ayerst ASia Ltd (Active)
Direct Subsidiary	North America	United States	Wyeth Ayerst International LLC (Active)
Direct Subsidiary	North America	United States	Wyeth Ayerst Promotions Ltd (Active)
Direct Subsidiary	North America	United States	Pfizer ApS (Active) Denmark
Direct Subsidiary	North America	United States	Pfizer Colombia Spinco I LLC (Active) Pennsylvania

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	North America	United States	Wyeth Subsidiary Illinois Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Pharmaceuticals LLC (Active) Delaware
Direct Subsidiary	North America	United States	Pfizer Products Inc (Active)
Direct Subsidiary	North America	United States	Pfizer Pigments Inc (Active)
Direct Subsidiary	North America	United States	Wyeth Advertising Inc (Active)
Direct Subsidiary	North America	United States	Wyeth Ayerst Inc (Active)
Direct Subsidiary	North America	United States	Warner Lambert Company LLC (Active)
Direct Subsidiary	North America	United States	Warner Lambert SA (Active)
Direct Subsidiary	North America	United States	Whitehall International Inc (Active)
Direct Subsidiary	North America	United States	Whitehall Laboratories Inc (Active)
Direct Subsidiary	North America	United States	WL LLC (Active)
Direct Subsidiary	North America	United States	Wyeth ASia Ltd (Active)
Direct Subsidiary	North America	United States	Wyeth Consumer Healthcare LLC (Active)
Direct Subsidiary	North America	United States	Wyeth Holdings LLC (Active)
Direct Subsidiary	North America	United States	Wyeth LLC (Active)
Direct Subsidiary	North America	United States	Site Realty Inc (Active)
Direct Subsidiary	North America	United States	Solinor LLC (Active)
Direct Subsidiary	North America	United States	Vicuron Holdings LLC (Active)
Direct Subsidiary	North America	United States	Sugen Inc (Active)
Direct Subsidiary	North America	United States	Tabor LLC (Active)
Direct Subsidiary	North America	United States	The Pfizer Incubator LLC (Active)
Direct Subsidiary	North America	United States	Shiley LLC (Active)
Direct Subsidiary	North America	United States	Pharmacia Hepar LLC (Active)
Direct Subsidiary	North America	United States	Purepac Pharmaceutical Holdings Inc (Active)
Direct Subsidiary	North America	United States	PowderJect Vaccines Inc (Active)
Direct Subsidiary	North America	United States	PN Mexico LLC (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	North America	United States	Renrall LLC (Active)
Direct Subsidiary	North America	United States	Rinat Neuroscience Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Ireland PFE Holding 1 LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Ireland PFE Holding 2 LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Manufacturing Holdings LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Manufacturing LLC (Active)
Direct Subsidiary	North America	United States	Pfizer North American Holdings Inc (Active)
Direct Subsidiary	North America	United States	Pfizer Overseas LLC (Active)
Direct Subsidiary	North America	United States	Pfizer PFE Colombia Holding Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Transport LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Transactions LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Vaccines LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Zona Franca PFE Holding LLC (Active)
Direct Subsidiary	North America	United States	Pharmacia LLC (Active)
Direct Subsidiary	North America	United States	Pharmacia Inter American LLC (Active)
Direct Subsidiary	North America	United States	PHIVCO Corp (Active)
Direct Subsidiary	North America	United States	Pfizer Ventures LLC (Active)
Direct Subsidiary	North America	United States	Pharmacia and Upjohn Company LLC (Active)
Direct Subsidiary	North America	United States	Pharmacia and Upjohn Company Inc (Active)
Direct Subsidiary	North America	United States	Pharmacia and Upjohn LLC (Active)
Direct Subsidiary	North America	United States	Pfizer Services LLC (Active)
Direct Subsidiary	North America	United States	Pfizer PFE Pharmaceuticals Israel Holding LLC (Active)
Direct Subsidiary	North America	United States	Pfizer PFE US Holdings 1 LLC (Active)
Direct Subsidiary	North America	United States	Pfizer PFE US Holdings 2 LLC (Active)
Direct Subsidiary	Others	--	Parke Davis Ltd (Active)
Direct Subsidiary	South and	Argentina	Hospira Argentina SRL (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
	Central America		
Direct Subsidiary	South and Central America	Argentina	Pfizer PFE Argentina SRL (Active)
Direct Subsidiary	South and Central America	Bahamas	HBAF Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Costa Rica Ltd Bahamas (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas Australia Holdings Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas Donegal Corp (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas Ireland Corp (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas Irish Manufacturing Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas Beck Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas Biologics Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Bahamas International Holdings Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Holding Ltd (Active)
Direct Subsidiary	South and Central America	Bahamas	Hospira Ltd Bahamas (Active)
Direct Subsidiary	South and Central	Bolivia	Productos Farmaceuticos PFE Bolivia SA (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
	America		
Direct Subsidiary	South and Central America	Bolivia	Pfizer Bolivia SA (Active)
Direct Subsidiary	South and Central America	Brazil	Pfizer Prev Sociedade de Previdencia Privada (Active)
Direct Subsidiary	South and Central America	Brazil	RMV Produtos Veterinarios Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Sao Cristovao Participacoes Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Wyeth Prev Sociedade de Previdencia Privada (Active)
Direct Subsidiary	South and Central America	Brazil	Wyeth Industria Farmaceutica Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Pfizer Medicamentos Genericos e Participacoes Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Pharmacia Brasil Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Hospira Produtos Hospitalares Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Fort Dodge Manufatura Ltda (Active)
Direct Subsidiary	South and Central America	Brazil	Laboratorios Pfizer Ltda (Active)
Direct Subsidiary	South and Central America	Cayman Islands	Pfizer Pharmaceutical Ltd Cayman Islands (Active)
Direct Subsidiary	South and Central America	Chile	Pfizer Chile SA (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	South and Central America	Chile	Hospira Chile Ltda (Active)
Direct Subsidiary	South and Central America	Chile	Roerig SA (Active)
Direct Subsidiary	South and Central America	Colombia	Pfizer SAS (Active)
Direct Subsidiary	South and Central America	Colombia	Pfizer PFE Colombia SAS (Active)
Direct Subsidiary	South and Central America	Colombia	Hospira Ltda (Active)
Direct Subsidiary	South and Central America	Costa Rica	Pfizer Costa Rica PFE Sociedad de Responsabilidad Limitada (Active)
Direct Subsidiary	South and Central America	Costa Rica	Pfizer Zona Franca SA (Active)
Direct Subsidiary	South and Central America	Costa Rica	Pfizer costa Rica SA (Active)
Direct Subsidiary	South and Central America	Dominican Republic	Pfizer Dominicana SRL (Active)
Direct Subsidiary	South and Central America	Dominican Republic	Pfizer Dominicana PFE SRL (Active)
Direct Subsidiary	South and Central America	Dominican Republic	Pfizer Dominicana SA (Active)
Direct Subsidiary	South and Central America	Ecuador	Pfizer PFE CIA Ltda (Active)
Direct Subsidiary	South and Central America	Ecuador	Pfizer Cia Ltda (Active)
Direct Subsidiary	South and Central America	Guatemala	Warner Lambert Guatemala Sociedad Anonima (

Subsidiary Type	Region	Country	Subsidiary Company name
	Central America		Active) ,Guatemala
Direct Subsidiary	South and Central America	Guatemala	Industrial Santa Agape SA (Active)
Direct Subsidiary	South and Central America	Guatemala	WarnerLambert Guatemala Sociedad Anonima (Active)
Direct Subsidiary	South and Central America	Jamaica	Wyeth Lederle Srl (Active)
Direct Subsidiary	South and Central America	Mexico	Pfizer Mexico Luxco SARL (Active)
Direct Subsidiary	South and Central America	Mexico	Pfizer Mexico SA de CV (Active)
Direct Subsidiary	South and Central America	Mexico	Pfizer SA de CV (Active)
Direct Subsidiary	South and Central America	Mexico	Pharmacia and Upjohn SA de CV (Active)
Direct Subsidiary	South and Central America	Mexico	Servicios P and U SdeRLdeCV (Active)
Direct Subsidiary	South and Central America	Mexico	Pfizer PFE Servicios Mexico S de RL CV (Active)
Direct Subsidiary	South and Central America	Mexico	Hospira S de RL de CV (Active)
Direct Subsidiary	South and Central America	Mexico	CP Pharma Services Corp S de RL de CV (Active)
Direct Subsidiary	South and Central America	Mexico	Blue Umbrella Services Sde RL de CV (Active)
Direct Subsidiary	South and Central	Mexico	Servicios P and U Sde RL de CV (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
	America		
Direct Subsidiary	South and Central America	Panama	Pfizer Corp (Active)
Direct Subsidiary	South and Central America	Panama	Pfizer International S de RL (Active)
Direct Subsidiary	South and Central America	Panama	Pfizer Free Zone Panama PFE S De RL (Active)
Direct Subsidiary	South and Central America	Panama	Pfizer Free Zone Panama S de RL (Active)
Direct Subsidiary	South and Central America	Peru	Laboratorios Wyeth Peru SA (Active)
Direct Subsidiary	South and Central America	Peru	Laboratorios Wyeth Peru SA (Active)
Direct Subsidiary	South and Central America	Peru	Hospira Peru SRL (Active)
Direct Subsidiary	South and Central America	Peru	Pfizer SA (Active)
Direct Subsidiary	South and Central America	Peru	Pfizer PFE Peru SRL (Active)
Direct Subsidiary	South and Central America	Puerto Rico	Wyeth Puerto Rico Inc (Active)
Direct Subsidiary	South and Central America	Puerto Rico	Wyeth Pharmaceuticals Company (Active)
Direct Subsidiary	South and Central America	Uruguay	Warner Lambert del Uruguay SA (Active)
Direct Subsidiary	South and Central America	Venezuela	Roerig Venezuela SA (Active)

Subsidiary Type	Region	Country	Subsidiary Company name
Direct Subsidiary	South and Central America	Venezuela	Pfizer Venezuela SA (Active)
Direct Subsidiary	South and Central America	Venezuela	Laboratorios Wyeth SA (Active)

myPharma Thinktank

Partnering Opportunities

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Miscellaneous
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, invests in private companies in traditional venture capital syndicates. PVI also uses equity to support novel business structures such as consortium-based technology development (e.g., Ablexis), product out-licensing (e.g., Clovis Oncology) and business spinouts (e.g., Ziarco). Further, PVI invests in funds that offer geographic reach to provide a view into the development of healthcare and life sciences businesses in developing countries such as Africa, Brazil and China. PVI has an interest in working with others to explore new business models that can create value for all players in the healthcare/lifesciences ecosystem and ensure the continued development of therapeutics, technologies and services for all those whose medical needs are not being met.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Barbara Dalton(barbara.dalton@pfizer.com)-Pfizer Venture Investments</p>
Contact Info	barbara.dalton@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Miscellaneous
Opportunity Sub Type	
Therapy Area	

Product Name	
Details	<p>Pfizer currently supports numerous collaborative partnerships with researchers at world-class research institutions such as the University of California, Colorado, the University of Virginia, and Peking University among many others, and is seeking additional opportunities to collaborate in areas of strategic interest to Pfizer Research. Pfizer is committed to exploratory research and have empowered the External R and D Innovation team to seek opportunities to identify seed-stage investment opportunities to support early-stage technologies as they transition from the academic environment into new start-up companies that align with the core research interests. These investments complement the Pfizer Venture Investments activities and include recent funding of Neoantigenics and Circle Pharma.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Dan Grant(daniel.grant@pfizer.com)-Open Innovation Portal</p>
Contact Info	Daniel.Grant@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Miscellaneous
Opportunity Sub-Type	
Therapy Area	
Product Name	
Details	<p>The Centers for Therapeutic Innovation (CTI) facilitates authentic collaboration between Pfizer scientists and select academic medical centers, disease foundations, the National Institutes of Health. Pfizer has CTI labs in San Francisco, New York, Boston and San Diego. These state of the art laboratories are populated with Pfizer scientists and post-docs who are creating and advancing novel therapeutics, with the goal of moving the therapeutics rapidly into first in human proof of mechanism studies. CTI's research collaborators work side by side with Pfizer scientists in the discovery and development of new therapies for unmet medical needs.</p>

	<p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Jeff Southerton(jeff.southerton@pfizer.com)-Academic Partnerships & Centers Jeff Southerton for Therapeutic Innovation Margi McLoughlin(margi.mcloughlin@pfizer.com)-Academic Partnerships & Centers Jeff Southerton for Therapeutic Innovation</p>
Contact Info	jeff.southerton@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer is focused on Precision Medicine as an approach to discovering and developing medicines and vaccines that deliver superior outcomes for patients, by integrating clinical and molecular information to understand the biological basis of disease. This effort leads to better selection of disease targets and identification of patient populations that demonstrate improved clinical outcomes.</p> <p>Pfizer is interested in establishing alliances to develop and/or access Patient cohorts with high quality longitudinal molecular and phenotypic data and/or DNA and appropriately consented, IRB-approved tissue samples in diseases of interest to Pfizer for clinical trials, data mining, biomarker studies, genetic and pharmacogenomic studies, Systems Biology/Pharmacology, Databases with high quality treatment and disease outcomes associated with genetic, as well as molecular (metabolomic, proteomic, transcriptomic, epigenetic, clinical chemistry markers) or functional measures in particular imaging data, Databases of searchable eQTLs, pQTLs across tissues.</p> <p>Pfizer is also interested in Disease biology guided combination therapy design platforms, Systems biology approaches and proven in silico tools to evaluate pharmacological perturbation and elucidate mechanisms of in vivo toxicity, Mining of data for correlation and understanding of causality, Breakthrough diagnostic technologies that also are highly quantitative,</p>

	<p>require minimal specimen tissue, offer quick turnaround time and can be multiplexed. This will include but not limited to Near-patient Point of Care technologies, Next Generation Sequencing technologies, Circulating cells, Circulating and urinary cell-free nucleic acids, Antigen receptor sequencing, Microbiome, including virome characterization, In vivo imaging technologies (including MRI, PET, CT, optical imaging technologies, imaging agents, genetically encoded tags, etc.,) with particular interest in Imaging agents for small and large molecule compound distribution studies, Imaging agents monitoring physiology mechanisms and disease, Analytical tools and technologies, Biospecimen Analysis, Circulating tumor cell and Nucleic Acid quantification and analysis, Multiplexed flow cytometry for leukocyte analysis, Automated IHC for tissue analysis (cancer, safety). Advanced ADME related genotyping, 3D cell models for safety and efficacy assessment that ideally incorporate genetic diversity, Physiological Biomarkers, Technologies adding precision to pain management and treatment in pre-clinical and clinical studies, EEG-based biomarker for assessment of central pharmacology, iPS cell resources and technologies to generate iPS cells that may be used to enable Precision Medicine strategies, Validated cell differentiation protocols, iPS cells derived from sub populations with specific genotypic/phenotypic data, Technology to create iPS cells in a rapid and reproducible fashion without insertional approaches.</p> <p>Contacts: Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Anne-Marie Mueller (marie.mueller@pfizer.com)-Precision Medicine anne-marie.mueller@pfizer.com </p>
Contact Info	

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	Pfizer's Clinical Innovation seeks partners from all sectors with a shared interest in improving study start-up, enriching high-quality data collection, enhancing patient engagement, and supporting robust relationships with investigators. With hundreds of clinical trials at thousands of institutions

	<p>around the world, Clinical Innovation links innovators with opportunities to impact the development of new medicines for patients.</p> <p>Pfizer Clinical Innovation is applying novel technologies, innovative partnerships, and new approaches to enhance and transform clinical trials and the development of new medicines. Clinical Innovation areas of focus include, Patient Engagement - Raising awareness and supporting patient recruitment and retention for clinical trials, enhancing patient participation, improving generation of patient insights into study design, sharing data and information with trial participants.</p> <p>Real World Data - Leveraging diverse data sources and analytics tools to enhance study design and protocol optimization, capture clinical trial data more efficiently.</p> <p>Mobile and Digital Tools - Supporting the informed and engaged patient during studies, improving study access and convenience, and enabling robust data capture whether reported by the patient or leveraging novel sensors.</p> <p>Biospecimen Management - Enabling robust acquisition, innovative consent approaches, and advanced tracking and storage capabilities to enable ready access to human clinical specimens to advance both traditional and precision medicine R&D.</p> <p>Innovative Partnerships - Partnerships spanning other biopharma companies, others in healthcare, technology partners and beyond to stimulate new approaches to rapidly understanding the efficacy and safety of medicines in development.</p>
Contact Info	bob.smith@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	Pfizer Pharmacokinetics, Dynamics and Metabolism (PDM) group is focused on development of innovative therapies through an improved

understanding of targets, pathways and modeling for preclinical efficacy, and discrete toxicity. The company will pursue collaborations to enhance physiological relevance of pharmacological endpoints, biomarkers, biomeasures and metabolomics, systems pharmacology, PKPD, quantitative bioanalytics, prediction of transporter-mediated disposition, tissue targeting.

Pfizer is interested in establishing alliances to develop and access Translational research large and small molecule efforts, Translational modeling and simulation approaches, systems pharmacology/PK-PD, integrated with quantitative biomeasures, deeper knowledge of targets and pathways and increased confidence in target and drug selection, Systems models of specific areas of toxicity, e.g., cardiovascular toxicity and application of PKPD to safety biomarker technologies increasing confidence in safety, Understanding and de-risking the influence of hepatic and renal uptake and clearance on toxicology in these organs focus on disorders of bile production and bile acid transport, Quantitative Bioanalytics, Biomarkers, Biomeasures, and Immunogenicity (ADA) Assays o Novel LC-MS/MS large molecule bioanalysis and automation techniques o Stable isotope labelled pulse chase studies with LC-MS/MS for measurement of target turnover o Flow cytometry, cellular imaging techniques (Amnis) for biomarkers and biomeasures , and highly multiparametric single cell analysis using mass cytometry (CyTOF).

Development of a universal platform for cell-based neutralizing antibody assays, Biocomparability identification of critical attributes influencing PK and disposition, Targeted and untargeted metabolomics and fluxomics, Biotherapeutics bioanalytical capabilities across various modalities, Next-generation of advanced intelligent high-throughput automation platforms for bioanalysis, Alternative methodologies to analytical reagent generation, characterization and modification, Methods and reagents for high specificity ligand binding and affinity capture LCMS, Disposition of Antibody-Drug Conjugates, Cellular and systemic fate of the conjugate and components, Quantification and prediction of pharmacokinetics.

Biodistribution of large molecules (drug and target) at whole organ and cellular level, Catabolism of large molecules (drug and target) at tissue level, Disposition and delivery of therapies large and small molecule efforts, Novel commercially viable delivery technologies (oral and non-oral), Predictive tools and technologies targeting oral absorption and disposition of peptides, Targeting, prediction and modeling of transporter-mediated disposition and DDIs small molecules, Quantitation and scaling of transporters for input into physiological PK models of tissue penetration and clearance, Determination of intracellular unbound concentrations of transported drugs, Prediction and quantification of human transport mediated (e.g., biliary) clearance,

Novel approaches to achieving selective tissue distribution, Immunogenicity prediction large molecules, In silico immune epitope prediction, In vitro

drug-specific immune response (e.g., PBL stimulation, whole protein and epitope mapping, DC-T cell assays, Bcell response assays), Ex vivo immune response and immune tolerance biomarkers, Models for predicting immunogenicity impact of product and treatment-related risk factors, ADA Clinical relevance predictors to include ADA affinity measures and prediction of adverse events, e.g., infusion reactions, Physiologically relevant in vitro assays, Methods for expanding cell numbers or stabilizing phenotypes of directly isolated primary cells (particularly from patients), Robust, reliable in vitro differentiation protocols from human pluripotent stem cells for difficult to obtain cell types, Non-natural amino acid substitutions in target proteins to create novel screening readouts, Advances in human genome editing technologies for greater speed and efficiency and reduction of off-target effects, Advances in High Content Analysis cell based assays.

Endogenous gene reporter and genetically encoded biosensor models in human primary cells and stem cells, Detection of tagged-protein at physiologically relevant concentrations in human cell based assays o Visualization of drug interaction with targeted protein within the cellular environment, Quantification of cellular environment changes by biosensors, Advances in 3D culture systems and high content analysis for metabolism, safety, distribution and pharmacology, Novel expression approaches for functional expression of difficult gene families e.g., solute transporters.

In vitro Phenotypic Screening, Novel deconvolution advances for in vitro phenotypic screening, Prediction of in vitro cellular phenotypic changes due to patient-derived single point mutation and genetic defects, Quantification of electro-physiologic measurement in plate cell based assays, Advances in single cell mass cytometry technology for phenotypic screening, Optimizing Human ADME Properties and PK Prediction Capabilities, Novel technologies to enhance SAR for ADME properties utilizing chemical library, high throughput in vitro assays coupled to LC-MS detection and computational models, Full complement of drug metabolism assays, including biotransformation and induction capabilities, Ability to conduct a suite of nonclinical studies to develop robust human PK prediction for routine and less common elimination pathways (AO, UGT, GST etc.,), Integration in vitro and in silico PK data and mechanisms into PB-PK models to predict human plasma-time profiles for small and large molecules, Selection and deselection of monoclonal antibody drug candidates based on PK properties that are predictive of human PK by using a characterized human FcRn transgenic mouse model and allometric scaling o Prediction of routine and complex DDI involving CYPs and transporters.

Contacts:

Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development
Erik Kuja(erik.w.kuja@pfizer.com)-Pharmacokinetics, Dynamics

	& Metabolism (PDM)
Contact Info	erik.w.kuja@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer's Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development. Pfizer seeks to enhance capabilities for target safety assessment, selection of safer compounds, toxicity risk management and translation of preclinical models.</p> <p>Pfizer is interested in establishing alliances to develop and access, Mechanisms, translatable and monitorable biomarkers, and screening approaches related to target organ toxicity, Cardiovascular safety including vascular injury and early detection of cardiotoxicity, CNS biomarkers including peripheral neuropathy, Liver injury in particular immune-mediated DILI and transporters, Immunostimulation, including hypersensitivity, autoimmunity, cytokine release Nephrotoxicity - glomerular and tubular, Skeletal and cardiac muscle toxicity, Pancreatic toxicity, Ocular safety, Screening for abuse potential, Animal models, biomarkers and screening approaches for preclinical immuno-oncology investigation, supporting mono- and combination-therapy approaches (interpretation and translatability), Immune system components and responses comparability between preclinical species and human.</p> <p>Pfizer also interested in Biotherapeutics-related analytical technologies, Immunogenicity and other safety-relevant assays, Assays related to aggregation, subvisible particles, 3D and complex models including stem cell approaches and microfluidics, Deeper knowledge of targets and pathways, Knock-in, knock-out technologies, Novel technologies and increased throughput for target localization studies, Safety biomarker technologies and enablers, Emerging platforms, including miRNA-based multiplex, analytical approaches, Academic collaborations to leverage</p>

	<p>annotated biofluid collections to understand target organ toxicities and enable clinical translation, Advancing Regulatory Science, Systems pharmacology approaches for prediction of adverse events, Novel in silico modelling approaches for pro-arrhythmia detection.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Erik Kuja (erik.w.kuja@pfizer.com)-Drug Safety</p>
Contact Info	erik.w.kuja@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer's Small Molecule Product and Process Development Sciences group envisions a network of partners to enhance active pharmaceutical ingredients (API) and drug product development and manufacturing of small molecules. Pfizer is interested in establishing alliances to develop and access in various areas include</p> <p>Computational Product and Process Design (CPPD) Complement and advance the experimentation and manufacturing processes with computational tools, including translating drug molecular structures to material properties in silico. Pfizer specific areas of interest include Computational models for process operations, Prediction of oral absorption in humans, Computational Chromatography, Multi-scale integrated modeling platform technologies for systems-based pharmaceutics predictions and simulations, In silico design and screening of API synthetic pathways, Predictive science of stability, including structure-based stability prediction.</p> <p>Materials Sciences and Particle Engineering, Development of molecular structure-based particle design and engineering tools that allow for the prediction and manipulation of crystal form, solid-state stability and material properties. Specific areas of interest include Computational Materials Science for particle engineering, including predicting crystallizability, Solid State Chemical Stability Prediction and Control, Delivery of API ensuring</p>

	<p>physical integrity during ensuing process operations, Particle engineering through directed assembly.</p> <p>Portable, Continuous, Miniature and Modular Development and Manufacturing Equipment, Design and development of fit for purpose, small footprint, plug and play (modular) processing platforms, for drug product and or API that allow the same equipment to be used for development and commercial manufacturing. Continuous, semi-continuous operation, rapid deployment, and rapid changeovers between products are cornerstone concepts that are being pursued. Desired state is for processing modules to be capable of manufacturing multiple products at a wide range of manufacturing scales and enable significant reduction in scale-up, tech transfer efforts.</p> <p>Innovative and Chemical Synthesis, Development of new platform syntheses that include sustainable, green chemical technologies and innovative chemical transformations. Specific areas of interest include Replacement of endangered metal catalysts, General methods for catalytic preparation of chiral amines, General methods for direct amide formation.</p> <p>Drug Delivery Technologies, Advanced drug delivery technologies to enable differentiated therapies and the next generation of precision medicine. Specific areas of interest include Tissue targeting of drugs to improve therapeutic index (e.g., brain delivery, tumor targeting, etc.), Technologies to improve monitor patient adherence, compliance, Abuse-deterrent technologies, Differentiated pediatric dosage forms that Neutralize or improve taste without affecting the pharmacokinetics for oral immediate-release products, use a solids-based platform (versus conventional liquids), and or are enabled by use innovative dosing, administration aids.</p> <p>Rapid Analytics, Innovative analytical platforms to enable real-time process understanding and or control via on line or at line technology for Drug Product and Active Pharmaceutical Ingredients (API). Specific areas of interest include Rapid, precise, robust, and integrated in-situ Process Analytical Technologies (PAT) for routine process monitoring and control, 3-D mapping, imaging of drug products o Real-time data integration from disparate sources.</p> <p>Contacts: Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Michael Flakus(michael.l.flakus@pfizer.com)-Small Molecule Product & Process Development</p>
Contact Info	michael.l.flakus@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer's Worldwide Medicinal Chemistry core capabilities include small molecule design and associated functions including structural biology and computational chemistry, synthetic innovation and compound safety prediction. Pfizer partnering strategy is designed to maintain and enhance these areas as well as generate new synergistic capabilities.</p> <p>Pfizer is interested in establishing alliances to develop and access Computational methods to integrate, manage, visualize, and mine large-scale compound-centric datasets from published literature and patents, Technology to expand NCE target space orally bioavailable and cell penetrable peptides, and non-Ro5 compounds, Natural product synthetic biology and screening technologies, Ion channel modulator design and screening technologies, Membrane protein structural biology technologies and capabilities, including ion channels, GPCRs and solute carrier proteins, Computational methods for quantitative affinity prediction and molecular dynamics simulation, New high efficiency synthetic transformations and novel flow chemistry approaches, Systems chemical biology technologies enabling mechanism determination for phenotypic screening hits, Bioinformatic approaches to define target selectivity, CH activation chemistry, Novel synthetic methodology to access small conformationally constrained multifunctional templates.</p> <p>Novel strategies for enhancing permeability of poorly absorbed molecules, Novel fragment or compound collections validated for protein-protein interaction targets, Identification of and access to novel sub-nanomolar cytotoxic agents, New chemistry to develop disease imaging agents (e.g., plaques, AD, beta cells, T2D, angiogenesis, cancer, Novel methodology and capabilities to enable 18F chemistry, Biophysical techniques to enable rapid state dependent ion channel screening, Novel receptor mediated and transporter mediated tissue targeting strategies, High content and in silico approaches to predict small molecule toxicity.</p> <p>Contacts: Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development</p>

	Mike Clark (michael.t.clark@pfizer.com)-Medicinal Chemistry
Contact Info	michael.t.clark@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Technology
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer's Biologics Product and Process Development include biopharmaceutical and vaccine development and manufacturing and prokaryotic expression to augment core competencies. Pfizer is interested in establishing alliances to develop and access, Next generation of microbial and mammalian cell protein production systems, Next generation process and manufacturing technologies.</p> <p>Pfizer's specific areas of interest include Systems and Synthetic Biology Technologies to design and influence host cell performance and product quality Novel expression systems with alternative posttranslational modifications (e.g., glycosylation), Automated methods for mammalian cell line screening, selection and scale up, Next generation cell culture process technologies, Next generation purification process technologies, Harvesting technologies (e.g., smart polymer, automation), High throughput analytics for product quality attributes, Advanced analytics for glycoconjugates and antibody drug conjugates, Flexible and adaptive manufacturing technologies for biotherapeutics.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Beth Stark (elizabeth.t.stark@pfizer.com)-Biologics Product & Process Development</p>
Contact Info	elizabeth.t.stark@pfizer.com

Licensing Information	Licensing-In
-----------------------	--------------

Region	North America
Country	United States
Opportunity Type	Technology
Opportunity Sub Type	
Therapy Area	
Product Name	
Details	<p>Pfizer's Biotherapeutics Discovery focuses on establishing alliances to develop and access Transformational technologies to design, construct, and optimize biotherapeutics o Informed protein design optimizes molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentiations, Antibody drug conjugate technologies, Novel ADC platforms, novel payloads, linkers, conjugation sites, Bioconjugation technologies, Novel approaches that enhance antibody function or improve site-specific bioconjugation.</p> <p>Pfizer's combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties, Structure-based and computational design of therapeutics, Novel technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability), Technologies that enhance multi-transmembrane protein target expression and presentation for antibody generation and screening, Technologies and patient sample access for antibody discovery from human antibody responses, Targeted delivery technologies that address overcome cell membrane penetration, cross blood brain barrier, Technologies that can significantly enhance general protein expression, purification, stability for discovery, Integrated service providers to support early discovery activities for development of therapeutics, Broadly applicable platforms to enhance speed and quality of antibody generation, Novel biologics, combination therapies, and biobetters that fit Pfizer strategies.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Mike Clark (michael.t.clark@pfizer.com)-Biotherapeutics Discovery</p>
Contact Info	michael.t.clark@pfizer.com

Licensing Information	Licensing-In
Region	North America

Country	United States
Opportunity Type	Technology
Opportunity Sub Type	Drug Delivery Technology
Therapy Area	
Product Name	
Details	<p>Pfizer is interested in establishing alliances to develop and access, Next generation of microbial and mammalian cell protein production systems, Next generation process and manufacturing technologies. Pfizer is interested to ensure commercial and clinical differentiation of products by accessing leading drug delivery technologies. Specific areas of interest include, Tissue specific delivery, Alternative routes of delivery (transdermal, transmucosal), Analytics (biophysics) to predict stability and ease of development, advanced formulations (high dose delivery, convenient dose administration), Innovative injectors including large volume bolus injectors, and compliance and adherence supporting systems.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Beth Stark(elizabeth.t.stark@pfizer.com)-PBiologics Product & Process Development</p>
Contact Info	elizabeth.t.stark@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Cardiology
Product Name	
Details	Pfizer is interested in establishing alliances to develop therapeutics, expand understanding of disease biology, and identify biomarkers that can help to impact CVD (Heart failure, dislipidemia, and atherosclerosis), Diabetes and related co-morbidities, Non-alcoholic fatty liver disease (NAFLD),

	<p>Nonalcoholic steatohepatitis (NASH) and cirrhosis, Obesity and related comorbidities.</p> <p>Pfizer specific areas of interest include preventing cardiac remodeling that is associated with heart failure, Preventing heart failure via anti-inflammatory pathways, Improving cardiac performance via myocardial protection or repair or improved myocardial perfusion and energetics, Primary and secondary prevention of cardiovascular events in high-risk patients (T2D, end stage renal disease, and highest-risk subgroups post-acute coronary syndrome), Novel therapies that reduce hyperinsulinemia and hyperglycemia, Decreasing hepatic lipid content and inflammation and the development of liver fibrosis in patients with NASH/NAFLD, Addressing obesity and eating disorders to induce and sustain weight loss, Brain signals that regulate energy homeostasis and metabolism, Centrally-acting anorectics.</p> <p>Contacts: Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Erik Kuja (erik.w.kuja@pfizer.com)-Cardiovascular and Metabolic</p>
Contact Info	erik.w.kuja@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Endocrine, Metabolic and Genetic
Product Name	
Details	Pfizer is partnering in metabolic and endocrinology areas with a number of groups in the healthcare space, including biotech and academic, to access emerging science and technology. Pfizer has led in the creation of new collaboration models, partnering with disease foundations and creating pre-competitive collaborations across the industry. Pfizer believes collaborations across the healthcare ecosystem are key to accelerating the pace of innovation. Pfizer has several key areas of interest where they are looking to partner with others. Pfizer key areas include Biopharmaceuticals, consumer healthcare, core therapeutic areas research and development and venture Investments.

Contact Info	erik.w.kuja@pfizer.com
--------------	------------------------

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Endocrine, Metabolic and Genetic
Product Name	
Details	<p>Pfizer is interested in the application of gene therapy to select central nervous system (CNS) and heart diseases. Beyond expansion of the development portfolio, they seek to build their technical capabilities by partnering in the gene therapy space on novel vectors that can target the liver, brain, and heart. The company is also seeking promoter technologies, as well as industry leading vector analytics and immune surveillance approaches.</p> <p>Pfizer is also interested in partnering to develop and access Novel targets in key areas of interest, Parkinson's Disease, Friedrich's Ataxia, Spinal Muscular Atrophy, Duchene's Muscular Dystrophy, Heart Failure. Novel AAV vectors with strong tissue-specific tropism (CNS, liver, and heart) with favorable transduction, expression. Promoter technology to ensure regulated and sustained tissue-specific gene expression, Vector analytics to identify viruses with superior bioactivity, AV immunology expertise to test, challenge existing hypotheses and develop more robust gene therapy products.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Leslie Coney (leslie.coney@pfizer.com)-Gene Therapy</p>
Contact Info	leslie.coney@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States

Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Immunology and Inflammatory
Product Name	
Details	<p>Pfizer is developing medicines for patients suffering from chronic immune diseases. Pfizer's commitment to the discovery and development of novel therapeutics to help patients living with chronic autoimmune diseases is evidenced by products such as Xeljanz (tofacitinib citrate), Celebrex (celecoxib capsules), Rapamune (sirolimus), and Enbrel (etanercept) for patients suffering from conditions such as osteoarthritis, solid organ transplant rejection, rheumatoid arthritis, and psoriasis.</p> <p>The Inflammation and Immunology Research Unit is focused on discovering, evolving and developing the next generation of therapies for immune- mediated diseases. Pfizer is interested in entering into strategic relationships with innovative collaborators to develop increasingly novel and differentiated therapies for autoimmune diseases.</p> <p>Pfizer is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory GI disorders (i.e., Inflammatory Bowel Disease), Nonalcoholic steatohepatitis (NASH), Atopic Dermatitis and Other indications.</p> <p>Pfizer is also interested to collaborate in specific areas including cytokines and their signaling pathways, adaptive immunity, Lymphocyte biology including Th17 lymphocytes, Regulatory cells and Tolerance induction, Host-microbial interactions and microbiome with an interest in epithelial barrier, Innate Immunity and Innate Lymphoid Cell biology, Oxidative stress modulators, Anti-fibrotics, Technology platforms and products to help understand patient segmentation in the disease areas of interest and develop precision medicine strategies for innovative portfolio products, Technology platforms and products that allow for greater tissue and cell specific delivery.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Phil McGurk (philip.mcgurk@pfizer.com)-Inflammation & Immunology</p>
Contact Info	philip.mcgurk@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Infectious Diseases
Product Name	
Details	<p>Pfizer is involved in the discovery and development of innovative prophylactic and therapeutic vaccines for unmet medical needs throughout all stages of life and for all geographies and markets. Pfizer focus on Prevention of viral and bacterial infections in infants, children, adolescents and older adults; hospital acquired infections and active immune oncology (cancer vaccine) targets.</p> <p>Pfizer is interested in establishing alliances to pursue development of Vaccines for the prevention and/or treatment of infectious diseases Vaccines for the prevention and treatment of non-infectious diseases with special emphasis on cancer vaccines through the active elicitation of disease-modifying immune responses.</p> <p>Pfizer is also interested in Adjuvants, Novel immune system enhancers to bolster the immune system of an older population, Novel in vitro systems for assessment of vaccine immunogenicity, Novel animal models for assessment of vaccine effectiveness, Novel immunomodulators of the adaptive immune response, Novel vaccine target antigen identification systems, Novel vaccine delivery platforms.</p> <p>Contacts: Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Jan Reid (jan.reid@pfizer.com)-Vaccines</p>
Contact Info	

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product

Opportunity Sub Type	
Therapy Area	Neurology
Product Name	
Details	<p>Pfizer is interested to collaborate in Neuroscience area, in Neuroscience, Pfizer investigating new ways to attack Alzheimer's Disease, Parkinson's Disease, and Schizophrenia, as well as a wide range of disorders that manifest symptoms which are common to several diagnoses, such as impaired cognition. Pain is a symptom where the CNS can both be a source as well as a potential therapeutic target. As such, pfizers historical pain franchise developing a new generation of analgesics.</p> <p>Neuroscience primary areas of interest include Neurodegenerative Diseases, Alzheimer's Disease (AD) including strategic partnerships on Pfizer assets, Parkinson's Disease (PD), Trans diagnostic domains relevant to psychiatric disorders such as Cognition, Anxiety, and Motivation/Apathy. Other areas of focus include Huntington's Disease (HD) siRNA and knock down approaches, symptomatic and disease modifying treatments, Vascular Dementia (Cerebellar Amyloid Angiopathy), Multiple Sclerosis (MS), Remyelination approaches targeting Chronic Progressive disease only Cerebrovascular disease sensory disorders involving abnormal sensations of clinical relevance, e.g., visual, auditory, vestibular, or somatosensory systems, Adjunctive treatment of depression, Addiction (opiate and alcohol), Agents modulating (or biomarkers of) chronic neuroinflammation with evidence of impact on AD or PD neurodegeneration, Imaging agents (e.g., tau, synuclein, neurotransmitters, neuroinflammatory markers and gliosis), Conformational antibodies that have cross reactivity to all "amyloids" (e.g., tau, Aß, huntingtin, -synuclein).</p> <p>Pfizer Pain franchise Primary areas of interest include Chronic Pain, Nociceptive pain and neuropathic pain, Acute Pain Postoperative, moderate-severe pain associated with hospital and outpatient recovery, Novel targets where there is strong human genetic or pharmacological evidence for a role in pain initiation or treatment, Highly differentiated opiates which offer a significantly altered side effect potential and reduced abuse potential. Approaches to targeted delivery to pain circuits or pathways, Technology platforms for patient segmentation and precision medicine support.</p> <p>Pfizer Approaches to Trans Diagnostic Domains in Psychiatry/Behavioral Disorders include area Ketamine-like mechanisms without side effects, approaches such as oral Ketamine and GABA B, Standalone or adjunctive agents with superior efficacy for major depressive disorder as well as for subdomains such as anhedonia, motivation, cognition and anxiety,</p>

	<p>Adjunctive schizophrenia agents with efficacy in treating negative symptoms. Pfizer Enabling Technologies include Novel modes of delivery of growth factors and other biotherapeutics, Gene therapy and other oligonucleotide-based approaches with CNS application, Technologies and models, such as imaging, enabling characterization of circuits related to neurofunctional domains (e.g., cognition, arousal, attention), Tools for remote monitoring of motor function and cognitive state, In vitro blood brain barrier models derived from rodent, non-human primate or human sources, Plasma/CSF biomarkers coupled with phenotype, genotype and drug history, to predict responders, monitor disease, and to identify prodromal patients.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Kelly Longo (kelly.l.longo@pfizer.com)-Neuroscience & Pain James Eshelby (james.eshelby@pfizer.com)-Neuroscience & Pain</p>
Contact Info	kelly.l.longo@pfizer.com

Licensing Information	Licensing-In
Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Oncology
Product Name	
Details	<p>Pfizer is partnering in Oncology area with a number of groups in the healthcare space, including biotech and academia, to access emerging science and technology. The company has led in the creation of new collaboration models, partnering with disease foundations and creating pre-competitive collaborations across the industry.</p> <p>Pfizer core areas of interest include Tumor Cell Biology, Bioconjugates Discovery and Development, Precision Medicine, Integrative Biology and Biochemistry, and ImmunoOncology. In Tumor Cell Biology they are focused on oncogenic drivers, tumor metabolism, and epigenetic. Pfizer interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact Lung, colorectal, breast, ovarian, renal, and hematologic cancers, Cancers prevalent in Asia</p>

	<p>(e.g., gastric cancer, hepatocellular carcinoma).</p> <p>Pfizer specific areas of interest include Targets and technologies that enable antibody and ADC approaches Oncogenic signaling mechanisms Tumor metabolism, Epigenetics Small molecule immuno modulators, Directed tumor cell killing via immune-based mechanisms Precision medicine, Functional genomics, Liquid biopsy technologies, Technologies that deliver drugs asymmetrically to specific tissues, and Targeted nanoparticle technologies and assets.</p> <p>Pfizer also focuses on Immuno-Oncology area and plans to significantly advance its leadership in this area by partnering to develop cutting edge science beyond the current mainstream immune checkpoints, e.g. CAR-T, vaccinia, and small molecules. The IO programs at Pfizer uniquely leverage a combination of scientific and clinical strength in immuno-biology alongside historical expertise in developing first-in-class cancer and vaccine therapies. Pfizer's efforts in IO include external collaborative alliances with leading academic medical centers (e.g, MD Anderson) and visionary biotech firms (e.g., Cellectis).</p> <p>Pfizer interested in establishing alliances to develop and access, Novel Targets for Overcoming Tumor-induced Immune Resistance Targets that promote immune response whether alone or in combination with checkpoint inhibitors Targets that provide Innate immune support, activation, Targets that reduce immune suppression, Cell-based Therapies o CAR-T, TCR, and other hybrid targeting modalities with a focus on allogeneic approaches, platform technologies include Mechanisms, biomarkers, and screening approaches to identify and accelerate the most promising combination therapies, New modalities to induce immune responses Bi-specific mAbs, nanoparticles, oncolytic viruses, tumor vaccines, chimeric antigen receptors (CARs), or novel T cell receptors (TCRs) o Identification of new immune modulating targets o Monitoring of immune-supporting and immune-suppressing biomarkers within the tumor as well as of the anti-tumor immune responses, Novel animal models that accurately recapitulate human tumor-immune system interactions.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Stefanie Hansen (stefanie.a.hansen@pfizer.com)-Oncology Anne-Marie Mueller (anne-marie.mueller@pfizer.com)-Oncology</p>
Contact Info	stefanie.a.hansen@pfizer.com

Licensing Information	Licensing-In
-----------------------	--------------

Region	North America
Country	United States
Opportunity Type	Product
Opportunity Sub Type	
Therapy Area	Other Diseases
Product Name	
Details	<p>Pfizer is adopting an innovative and collaborative approach to the development of new medicines for patients with rare diseases. It has a track record of creating innovative strategic partnerships with academic institutions, patient advocacy groups, and commercial enterprises to accelerate the development of novel therapeutics across the entire spectrum of rare diseases. Pfizer looking to capitalize on recent scientific advances linking diseases to specific genetic defects. As 70% of rare diseases are monogenic in origin, it believe this is an area where scientific knowledge is enabling significant advances in drug development. Pfizer expertise in large molecule therapeutics, small molecule protein chaperones, and transcriptional modulators has resulted in a broad pipeline of potentially transformative medicines across multiple disease areas.</p> <p>Pfizer interested in partnering to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact Hematology (non-malignant), Hemophilia, Coagulation factors with extended duration of activity or improved delivery, Oral agents to treat haemophilia, Immune tolerance, Novel approaches (including gene therapy) to treat hemophilia patients, Other rare hematologic (non-malignant) indications, Sickle cell anemia, beta-Thalassemia follow on with focus on disease modifying and therapies that significantly change disease pathology, Hemostasis (systemic and topical), Opportunistic approaches in the field of hematology that promise well differentiated novel medicines.</p> <p>Neuromuscular Diseases Duchenne Becker muscular dystrophy and other muscular dystrophies, disease-modifying therapies preferred Spinal Muscular Atrophy Friedreich's ataxia Upregulate frataxin expression, inhibition of degradation or frataxin pathway bypass Amyotrophic lateral sclerosis Protein misfolding approaches and other disease-modifying approaches, Pulmonary Diseases Cystic Fibrosis (in conjunction with the CF Foundation) Pulmonary arterial hypertension and idiopathic pulmonary fibrosis, Disease modifying approaches for other diseases such as transthyretin amyloidosis, myasthenia gravis, Huntington's disease, General mechanisms of interest o Pharmacologic chaperones and other modifiers of protein trafficking, misfolding, or degradation that could apply to multiple</p>

	<p>diseases (e.g., a small molecule approach that could apply across multiple lysosomal storage disorders), Targeting technologies or platforms (e.g., muscle and CNS targeting) Modifiers of gene transcription via epigenetic approaches Nucleic acid gene therapy approaches to therapy Antibody-drug conjugates Oral small molecule and biologics approaches.</p> <p>Contacts:</p> <p>Bob Smith (bob.smith@pfizer.com)-SVP, WRD Business Development Leslie Coney (leslie.coney@pfizer.com)-Rare Disease</p>
Contact Info	leslie.coney@pfizer.com

myPharma Thinktank

Products

Products Summary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
AAT008	--	Allergic Contact Dermatitis(Pre clinical); Inflammatory Bowel Disease(Preclinical); Autoimmune Disorders(Prec clinical); Gastrointestinal Cancer(Preclinical); Breast Cancer(Preclinical); Osteoarthritis(Preclinical); Lung Cancer(Preclinical)	Preclinical	Active	Prostaglandin E2 (PGE2) Receptor Subtype EP4 Antagonist	RaQualia Pharma Inc (Primary Owner);Pfizer Inc (Originator);askAt Inc (Primary Owner)
AAT076	--	Nociceptive Pain(Phase II); Post-Operative Pain(Phase II); Lung Cancer(Resear ch)	Phase II	Completed	Cyclooxygenase-2 (COX-2) Inhibitor	RaQualia Pharma Inc (Primary Owner);Chinese Academy of Sciences (Co-developer);Pfizer Inc (Originator,Primary Owner);askAt Inc (Primary Owner)
Above V	rabeprazole	Gastroenterology(M)	M	Active	Proton Pump Inhibitor (PPI)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Accupril	quinapril hydrochloride	Cardiovascular Failure(M); Hypertension(M	Active	Angiotensin-Converting Enzyme (ACE)	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		M); Angioedema(M)			Inhibitor	Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Originator,Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Accuretic	hydrochlorotiazide; quinapril hydrochloride	Hypertension(M); Angioedema(M)	M	Active	Angiotensin-Converting Enzyme (ACE) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Parke Davis Ltd (Distributor,Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Originator);Pfizer Canada Inc (Sales/Marketing)
Acetylcysteine ALVOGEN	acetylcysteine	Pulmonology(M)	M	Active	Not Available	Alvogen (Sales/Marketing);Pfizer Inc (Primary Owner)
Activella	estradiol; norethisterone acetate	Menopausal Disorders(M); Postmenopausal Osteoporosis(M)	M	Active	Estrogen Receptor (ESR) Agonist; Progesterone Receptor (PR) Agonist	Novo Nordisk AS (Originator);Pfizer Inc (Sales/Marketing); Novo Nordisk Canada Inc (Sales/Marketing)
Activin-Like Kinase 5 Inhibitor program PFIZER	--	Scar(Research)	Research	Active	Not Available	Pfizer Inc (Originator)
Actos	pioglitazone hydrochloride	Non-Insulin-Dependent Diabetes	M	Active	Peroxisome Proliferator-Activated	Teva Pharmaceutical Industries Limited (Sales/Market

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Mellitus(M)			Receptor-Gamma (PPAR-Gamma) Agonist	ing);Sandoz Inc (Sales/Marketing); Mylan Inc (Sales/Marketing); Wockhardt Ltd (Sales/Marketing); Tianjin Takeda Pharmaceuticals Co Ltd (Sales/Marketing); Takeda Pharmaceuticals USA Inc (Sales/Marketing); Takeda Canada Inc (Sales/Marketing); Ranbaxy Laboratories Ltd (Sales/Marketing); Pfizer Inc (Sales/Marketing); Aurobindo Pharma Ltd (Sales/Marketing); Takeda France SA S (Sales/Marketing);Synthon Pharmaceuticals (Sales/Marketing);Breckenridge Pharmaceutical Inc (Sales/Marketing); Hikma Pharmaceuticals Plc (Sales/Marketing); Dr Reddys Laboratories Ltd (Sales/Marketing); Eli Lilly and Co (Sales/Marketing); Takeda Pharmaceutical Company Ltd (Originator);Torrent Pharmaceuticals

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Ltd (Sales/Marketing); Alphapharm Pty Ltd (Sales/Marketing); Watson Pharmaceuticals Asia Ltd (Sales/Marketing)
Acupil	quinapril	Cardiology(M)	M	Active	Angiotensin-Converting Enzyme (ACE) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
ADL5747	--	Osteoarthritis(Phase II); Post-Herpetic Neuralgia(Phase II)	Phase II	Terminated	Delta-Opioid Receptor Agonist	Cubist Pharmaceuticals Inc (Developer, Primary Owner);Adolor Corp (Originator);Pfizer Inc (Co-developer)
ADL5859	--	Rheumatoid Arthritis(Phase II); Osteoarthritis(Phase II); Pain(Phase II); Neuropathic Pain(Phase II)	Phase II	Completed	Delta-Opioid Receptor Agonist	Cubist Pharmaceuticals Inc (Primary Owner);Adolor Corp (Originator);Pfizer Inc (Co-developer)
Adriamycin	doxorubicin hydrochloride	Oncology(M); Bladder Cancer(M)	M	Active	Protein Synthesis Inhibitor; Topoisomerase II Inhibitor	Pfizer SL (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer China Research and Development Co Ltd (Sales/Marketing); Pfizer Pharmaceuticals Ltd (Sales/Marketing); Novamed Pharmaceuticals Inc (Sales/Marketing)
Advil	ibuprofen	Dysmenorrhea (M); Pain(M);	M	Active	Cyclooxygenase-2 (COX-2)	Pfizer Healthcare Ireland (Sales/Marketin

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Migraine(M); Fever(M)			Inhibitor	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Advil allergy and congestion relief	chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride	Allergic Respiratory Diseases(M); Common Cold(M); Fever(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor; Histamine H1 Receptor Antagonist	Pfizer Inc (Primary Owner);Pfizer Consumer Healthcare Ltd (Primary Owner)
Advil allergy sinus	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	Allergic Respiratory Diseases(M); Common Cold(M); Pain(M); Fever(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor; Histamine H1 Receptor Antagonist	Wyeth Consumer Healthcare LLC (Primary Owner);Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Primary Owner)
Advil cold sinus	ibuprofen; pseudoephedrine hydrochloride	Sinusitis(M); Pain(M); Headache(M); Nasal Congestion(M); Fever(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor; Histamine H1 Receptor Antagonist	Wyeth Consumer Healthcare LLC (Primary Owner);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					se-2 (COX-2) Inhibitor	
Advil congestion relief	ibuprofen; phenylephrine hydrochloride	Pain(M); Headache(M); Nasal Congestion(M); Sinusitis(M); Fever(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Inc (Primary Owner)
Advil PM	diphenhydramine hydrochloride; ibuprofen	Insomnia(M)	M	Active	Cyclooxygenase-2 (COX-2) Inhibitor; Histamine H1 Receptor Antagonist	Wyeth Consumer Healthcare LLC (Primary Owner);Pfizer Inc (Primary Owner)
Alavert	loratadine	Pharyngitis(M); Rhinitis(M); Ocular Infections(M); Perennial Allergic Rhinitis(M); Nasal Congestion(M)	M	Active	Histamine H1 Receptor Antagonist	Pfizer Inc (Primary Owner)
Aldactazide	hydrochlorothiazide; spironolactone	Liver Cirrhosis(M); Congestive Heart Failure(M); Essential Hypertension(M); Nephrotic Syndrome(M)	M	Active	Aldosterone Receptor Antagonist	G D Searle LLC (Distributor, Primary Owner);Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing)
Aldactide	spironolactone	Congestive Heart Failure(M)	M	Active	Aldosterone Receptor Antagonist; Sodium-	Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Glucose Cotransporter Type 1 (SGLT1) Inhibitor	
Aldactone	spironolactone	Liver Cirrhosis(M); Congestive Heart Failure(M); Essential Hypertension(M); Nephrotic Syndrome(M); Hyperaldosteronism(M); Hypokalemia(M)	M	Active	Aldosterone Receptor Antagonist	G D Searle LLC (Distributor, Primary Owner);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Alesse	ethinyl estradiol; levonorgestrel	Acne Vulgaris(M); Contraception(M)	M	Active	Estrogen Receptor (ESR) Agonist	Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Originator);Pfizer Canada Inc (Sales/Marketing)
Alsuma	sumatriptan succinate	Cluster Headache(M); Migraine with Aura(M); Migraine without Aura(M)	M	Active	5-Hydroxytryptamine-1B (5-HT1B) Receptor Agonist; 5-Hydroxytryptamine-1D (5-HT1D) Receptor Agonist	Meridian Medical Technologies Inc (Manufacturer);Pfizer Laboratories Ltd (Distributor);Pfizer Inc (Primary Owner);US WorldMeds LLC (Sales/Marketing)
Amisant	amisulpride	Psychiatric Disorders(M)	M	Active	Dopamine Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Owner)
Amlodin	amlodipine besylate	Angina Pectoris(M); Hypertension(M)	M	Active	Calcium Channel Blocker	Pfizer Inc (Originator);Sumitomo Dainippon Pharma Co Ltd (Primary Owner)
Amlogard	amlodipine	Cardiology(M)	M	Active	Calcium Channel Blocker	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Amlogard Met	amlodipine; metoprolol	Diabetes Mellitus(M)	M	Active	Beta-1 Adrenergic Receptor (ADRB1) Antagonist; Calcium Channel Blocker	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Amlogard TM	amlodipine; telmisartan	Cardiology(M)	M	Active	Angiotensin II AT1 Receptor Antagonist; Calcium Channel Blocker	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Anadin	aspirin; caffeine	Pain(M); Common Cold(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor; Phosphodiesterase (PDE) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner)
Anbesol	benzocaine	Mouth Sores(M); Dental Pain(M); Dental Plaque(M)	M	Active		Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Andexxa	--	Bleeding Disorders(PA)	PA	Active		Pfizer Inc (Co-developer,Developer);Janssen Pharmaceuticals Inc (Co-developer);Bayer HealthCare AG (Co-developer);Portola Pharmaceuticals Inc (Originator);Bristol Myers Squibb Company (Co-developer,Developer);Daiichi Sankyo Co Ltd (Co-developer)
Anti 5T4 antibody OXFORD	--	Oncology(Phase I)	Phase I	Active	5T4 Oncofoetal Antigen Inhibitor	Pfizer Inc (Primary Owner);Oxford BioMedica Plc (Originator,Primary Owner)
Antivert	meclizine hydrochloride	Nausea and Vomiting(M); Vertigo(M); Dizziness(M)	M	Active	Histamine H1 Receptor Antagonist	Roerig SA (Distributor);Pfizer Inc (Primary Owner)
Anugesic	benzyl benzoate; bismuth oxide; hydrocortisone acetate; pramocaine hydrochloride	Pain(M); Post-Operative Pain(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner,Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Apolipoprotein C III program WAVE	--	Metabolic Disorders(Research)	Research	Active	Not Available	Pfizer Inc (Technology Owner);WaVe Life Sciences Ltd (Originator)
Aricept	donepezil hydrochloride	Down Syndrome(Phase II);	PM	Active	Acetylcholinesterase (AChE) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Teikoku Seiyaku

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Alzheimers Disease(M); Vascular Dementia(M); Dementia with Lewy Bodies(PM)				Co Ltd (Co-developer);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Eisai Europe Ltd (Sales/Marketing); Pfizer Inc (Sales/Marketing); Eisai Inc (Originator);Pfizer Canada Inc (Sales/Marketing); Eisai Korea Inc (Sales/Marketing); Teikoku Pharma USA Inc (Co-developer);Eisai Pharmaceuticals India Pvt Ltd (Sales/Marketing); Eisai Co Ltd (Originator,Primary Owner,Sales/Marketing);PT Eisai Indonesia (Sales/Marketing)
Aromasin	exemestane	Metastatic Breast Cancer(PM); Estrogen Receptor Positive Breast Cancer(PM)	PM	Completed	Aromatase Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing);

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Originator);Pfizer UK Ltd (Sales/Marketing)
Arthrotec	diclofenac sodium; misoprostol	Rheumatoid Arthritis(M); Osteoarthritis(M)	M	Active	Prostaglandin E Synthase (PTGES) Inhibitor	G D Searle LLC (Primary Owner);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Asonep	sonepcizumab	Solid Tumors Unspecified(Phase I); Renal Cell Carcinoma(Phase II)	Phase II	Terminated	Sphingosine 1-Phosphate (S1P) Inhibitor	Pfizer Inc (Primary Owner);Lpath Inc (Originator)
Atgam	anti-thymocyte globulin (equine)	Aplastic Anemia(M); Transplant Rejection(M)	M	Active		Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor)
ATIR101	--	Stem Cell	Phase II	Completed		Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Transplantation(Phase II); Graft-Versus-Host Disease(Phase II)				Owner);Hospira Inc (Sales/Marketing); Kiadis Pharma (Originator)
Ativan	lorazepam	Status Epilepticus(M); Insomnia(M); Anxiety(M)	M	Active	Gamma-Aminobutyric Acid (GABA) Receptor Agonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
ATM AVI	avibactam; aztreonam	Intra-Abdominal Abscesses(Phase II); Bacterial Infections(Phase I)	Phase II	Active	Beta-Lactamase Inhibitor	Allergan Plc (Developer,Sales/Marketing);Allergan Inc (Co-developer);AstraZeneca Plc (Originator);Pfizer Inc (Co-developer)
ATN103	ozoralizumab	Rheumatoid Arthritis(Phase II)	Phase II	Active	Tumor Necrosis Factor (TNF) Inhibitor	Ablynx nv (Originator);Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Primary Owner);Eddingpharm (Developer);Taisho Pharmaceutical Co Ltd (Developer)
Atorvastatin calcium PFIZER	atorvastatin calcium	Cardiology(M); Hyperlipoproteinemia(M)	M	Active	3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitor	Watson Pharma Inc (Distributor,Sales/Marketing);Pfizer Pharmaceuticals LLC (Manufacturer);Pfizer Inc (Primary Owner)
Atpark	atenolol	Cardiology(M)	M	Active	Beta-1 Adrenergic Receptor (ADRB1)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Antagonist	
Autoimmune disease program KAROBIO	--	Ulcerative Colitis(Research); Psoriasis(Research); Rheumatoid Arthritis(Research); Multiple Sclerosis(Research)	Research	Active	Undisclosed Cytokine Inhibitor	Pfizer Inc (Originator);Karo Pharma (Originator)
Avinza	morphine sulfate	Pain(M)	M	Active	Delta-Opioid Receptor Agonist; Kappa-Opioid Receptor Antagonist; Mu-Opioid Receptor Antagonist	Pfizer Inc (Sales/Marketing); Ligand pharmaceuticals Inc (Primary Owner)
Azoren	amlodipine besylate; olmesartan medoxomil	Hypertension(M)	M	Active	Angiotensin II AT1 Receptor Antagonist; Calcium Channel Blocker	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Azulfidine	sulfasalazine	Crohns Disease(M); Ulcerative Colitis(M); Rheumatoid Arthritis(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Inc (Distributor, Primary Owner)
Bacitracin PFIZER	bacitracin	Pneumonia(M); Subdural Empyema(M)	M	Active		Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor)
Bactrim		Bacterial Infections(M)	M	Active	Dihydrofolate Reductase (DHFR) Inhibitor	Pfizer Inc (Unknown);F Hoffmann La Roche Ltd (Sales/Marketing); moksha8 Pharmaceuticals Inc (Sales/Marketing)
Bapineuzum ab JOHNSON	bapineuzum ab	Alzheimers Disease(Phase III)	Phase III	Discontinued		Pfizer Inc (Co-developer);Janssen Alzheimer Immunotherapy Holding Ltd (Co-developer);Johnson and Johnson (Primary Owner)
Basalog	insulin glargine	Diabetes Mellitus(M)	M	Active		Mylan Inc (Sales/Marketing); Pfizer Inc (Sales/Marketing); Biocon Ltd (Primary Owner);Fuji Pharma Co Ltd (Sales/Marketing); PiSA Farmaceutica (Sales/Marketing)
Becosule	vitamin B complex; vitamin C	Vitamin Deficiency(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Benefix	nonacog alfa	Bleeding Disorders(M); Hemophilia B(PM); Post-Operative Pain(M)	PM	Completed	Factor IX Activator	Pfizer Healthcare Ireland (Sales/Marketing);Takeda Pharmaceuticals Korea Co Ltd (Distributor);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Manufacturer,Primary Owner);Swedish Orphan Biovitrum AB (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Takeda Pharmaceutical Company Ltd (Distributor);Pfizer UK Ltd (Sales/Marketing)
Beta secretase inhibitors PFIZER	--	Alzheimers Disease(Research)	Research	No Development Reported		Pfizer Inc (Primary Owner);Pharmacia Corp (Originator);Perrigo Co plc (Primary Owner)
Bicillin CR	penicillin G benzathine; Penicillin G procaine	Upper Respiratory Tract Infections(M); Scarlet Fever(M); Skin Bacterial Infections(M);	M	Active	Bacterial Cell Wall Synthesis Inhibitor	Wyeth Ayerst Inc (Primary Owner);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Streptococcus Pneumonia(M); Otitis Media(M)				
Bicillin LA	penicillin G benzathine	Upper Respiratory Tract Infections(M); Bacterial Sexually Transmitted Infections(M); Rheumatic Fever(M); Huntingtons Disease(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor	Wyeth Ayerst Inc (Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing)
Bidiab	metformin	Diabetes Mellitus(M)	M	Active	Cyclic Adenosine monophosphate (cAMP) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Bilaxten	bilastine	Skin Rash(PA); Chronic Urticaria(M); Allergic Rhinitis(M)	M	Active	Histamine H1 Receptor Antagonist	Pfizer Inc (Sales/Marketing); Merck Serono (Sales/Marketing);Faes Farma SA (Originator);Taiho Pharmaceutical Co Ltd (Co-developer);Hikma Pharmaceuticals Plc (Sales/Marketing); Tribute Pharmaceuticals Canada Inc (Sales/Marketing); Aralez Pharmaceuticals Inc (Sales/Marketing)
Bone morphogene	--	Bone Disorders(Prec	Preclinical	Active	Not Available	Pfizer Inc (Primary Owner);Bioventus

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
tic protein program PFIZER		linical)				LLC (Primary Owner)
Bosulif	bosutinib	Solid Tumors Unspecified(P hase II); Chronic Myeloid Leukemia(M)	M	Active	Bcr-Abl Tyrosine Kinase Inhibitor; Src Tyrosine Kinase (STK) Inhibitor; SRC/ABL Tyrosine Kinase Inhibitor	Pfizer ApS (Sales/Marketing);Pfizer Croatia doo (Sales/Marketing) ;Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketi ng);Pfizer Luxembourg SARL (Sales/Marketi ng);Pfizer Pharma GmbH (Sales/Marketi ng);Pfizer SL (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner,Sales/Marketi ng);Pfizer Italia Srl (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Polska Spzoo (Sales/Marketi ng);Wyeth Pharmaceuticals Inc (Primary Owner);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing); Pfizer Canada

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Inc (Sales/Marketing); Pfizer Innovations AB (Sales/Marketing); Pfizer Romania SRL (Sales/Marketing);Pfizer Spol SRO (Sales/Marketin g);Avillion LLP (Co-developer);Pfizer UK Ltd (Sales/Marketing)
Brevinor	ethinylestradiol; norethisterone	Female Contraception(M)	M	Active		Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Brophylin	acebrophylline	Immunology and Inflammatory(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketin g);Pfizer Inc (Primary Owner)
brtxDISC Program	--	Lumbar Degenerative Disc Disease(Phase I)	Phase I	Completed	Not Available	Pfizer Inc (Developer);Biorestorative therapies Inc (Originator)
Cabaser	cabergoline	Hyperprolactinemia(M); Parkinsons Disease(M)	M	Active	Dopamine D2 Receptor Agonist	Pfizer Healthcare Ireland (Sales/Marketin g);Pharmacia LLC (Primary Owner);Pharmacia and Upjohn Company LLC (Primary Owner);Farmitalia Carlo Erba Ltd (Originator);Pfizer New Zealand Ltd (Sales/Marketing);

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Italia Srl (Manufacturer);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Kissei Pharmaceutical Co Ltd (Sales/Marketing); Pfizer Ltd UK (Sales/Marketing)
Cabotegravir GLAXOSMITHKLINE	cabotegravir	Human Immunodeficiency Virus Infection(Phase II)	Phase II	Active	HIV Integrase Inhibitor	Shionogi Ltd (Developer);Pfizer Inc (Primary Owner);GlaxoSmithKline Plc (Primary Owner);ViiV Healthcare UK Ltd (Co-developer)
Caduet	amlodipine besylate; atorvastatin calcium	Stable Angina(M); Variant angina(M); Myocardial Infarction(M); Hypertension(M); Hyperlipoproteinemia(M); Hypercholesterolemia(M); Heterozygous Familial Hypercholesterolemia(M); Homozygous Familial	M	Active	3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitor; Calcium Channel Blocker	Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner,Sales/Marketing);Pfizer Japan Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Astellas Pharma Inc (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Hypercholesterolemia(M); Mixed Dyslipidemia(M); Stroke(M)				
Calan	verapamil hydrochloride	Arrhythmia(M); Angina Pectoris(M); Essential Hypertension(M)	M	Active	Calcium Channel Blocker	G D Searle LLC (Distributor, Primary Owner);Pfizer Inc (Primary Owner)
Camptosar	irinotecan hydrochloride	Ovarian Cancer(M); Solid Tumors Unspecified(M); Metastatic Colorectal Cancer(M); Hepatocellular Carcinoma(Phase II); Pancreatic Cancer(M); Stomach Cancer(M); Breast Cancer(M); Cervical Cancer(M); Non-Hodgkins Lymphoma(M); Squamous Cell Lung Carcinoma(M); Medulloblastoma(Phase II); Metastatic Non-Small Cell Lung Cancer(M); Small Cell Lung	M	Withdrawn	Topoisomerase I Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Polska Spzoo (Sales/Marketing);Daiichi Pharmaceutical Co Ltd (Developer);Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor, Primary Owner);Pfizer Spol SRO (Sales/Marketing);Daiichi Sankyo Co Ltd (Developer);Aventis Pharma Ltd (Primary Owner);Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Carcinoma(M)				
Cardiovascular Antibody Therapeutics Program PFIZER	--	Congestive Heart Failure(Research)	Research	Active	Not Available	Pfizer Inc (Originator);California Institute for Biomedical Research (Originator)
Cardura	doxazosin mesylate	Hypertension(M); Benign Prostatic Hyperplasia(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Antagonist	Pfizer Healthcare Ireland (Sales/Marketing);Roerig SA (Distributor);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Cardura XL	doxazosin mesylate	Benign Prostatic Hyperplasia(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Antagonist	Roerig SA (Distributor,Primary Owner);Pfizer Inc (Primary Owner)
Caverject	alprostadil	Erectile Dysfunction(M)	M	Active	Prostaglandin E1 (PGE1) Receptor Agonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner);Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
CB813d	coagulation factor VIIa (recombinant, human)	Hemophilia A(Phase I); Hemophilia B(Phase I)	Phase I	Completed		Pfizer Inc (Co-developer);Catalyst Biosciences Inc (Developer, Originator)
CD RAP	--	Osteoarthritis(Clinical Phase Unknown)	Clinical Phase Unknown	No Development Reported	Not Available	Pfizer Inc (Primary Owner);Scil Technology GmbH (Originator)
Cefobid	cefoperazone sodium	Abdominal Diseases(M); Peritonitis(M); Endometritis(M); Pelvic Inflammatory Disease(M); Respiratory Tract Infections(M); Skin Infections(M); Urinary Tract Infections(M); Enterococcal Infections(M); Septicaemia(M); Female Urinogenital Infection(M)	M	Discontinued	Bacterial Cell Wall Synthesis Inhibitor	Roerig SA (Distributor);Pfizer Inc (Primary Owner)
Celebrex	celecoxib	Dysmenorrhea (M); Rheumatoid Arthritis(M); Ankylosing Spondylitis(M); Juvenile Idiopathic Arthritis(M); Osteoarthritis(M); Nociceptive Pain(M)	M	Active	Cyclooxygenase-2 (COX-2) Inhibitor	G D Searle LLC (Distributor, Primary Owner);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Celontin	methylsuximide	Absence Seizures(M)	M	Active	T-Type Calcium Channel (CaV3.1d) Blocker	Parke Davis Ltd (Distributor, Primary Owner); Pfizer Inc (Primary Owner)
Cenilos	losartan potassium	Cardiology(M)	M	Active	Angiotensin II AT1 Receptor Antagonist	Pfizer Ltd India (Sales/Marketing); Pfizer Inc (Primary Owner)
Cerebyx	fosphenytoin sodium	Epilepsy(M); Status Epilepticus(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing); Parke Davis Ltd (Primary Owner); Pfizer Inc (Distributor, Manufacturer, Primary Owner); Eisai Inc (Sales/Marketing); Nobelpharma Co Ltd (Developer, Primary Owner); Eisai Co Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Cesavess	cefuroxime axetil	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing); Pfizer Inc (Primary Owner)
Champix	varenicline tartrate	Pulmonology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing); Pfizer Inc (Primary Owner)
Chantix	varenicline tartrate	Nicotine Abuse(PM)	PM	Active	Alpha4Beta2 Neuronal Nicotinic Receptor	Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Ltd India (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					(NNR) Partial Agonist	g);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Chloromycetin	chloramphenicol	Bacterial Infections(M); Otitis Externa(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Inc (Primary Owner)
Cholesterol-Acyltransferase Inhibitor program PFIZER	--	Acne(Phase II)	Phase II	No Development Reported	Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitor	Pfizer Inc (Originator)
Citicoline PFIZER	--	Parkinsons Disease(M)	M	Active	Dopamine Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Citrosoda PFIZER	--	Urology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Claribid	clarithromycin	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Cleocin	clindamycin	Acne	M	Active	Bacterial	Pfizer Healthcare

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	clindamycin phosphate	Vulgaris(M); Pneumococcal Infections(M); Staphylococcal Infections(M); Streptococcal Infections(M); Bacterial Vaginosis(M)			Protein Synthesis Inhibitor	Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Primary Owner,Sales/Marketing);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Clindamycin phosphate ALVOGEN	clindamycin phosphate	Bacterial Infections(M); Pneumococcal Infections(M); Pseudomonas Infections(M); Staphylococcal Infections(M); Streptococcal Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Alvogen (Primary Owner);Pfizer Inc (Primary Owner)
Clopichek	clopidogrel	Cardiology(M)	M	Active	P2Y12 Purinergic Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
CMV vaccine REDBIOC	--	Cytomegalovirus Infection(Preclinical)	Preclinical	Active		Pfizer Inc (Primary Owner);Redbiotec AG (Originator)
CO338	rucaparib	Solid Tumors Unspecified(Phase II); Pancreatic Cancer(Phase	Phase III	Active	Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor;	Clovis Oncology Inc (Developer,Primary Owner);Warner Lambert Company LLC (Developer,Prim

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		II); Gynecological Cancer(Phase II); HER2-Negative Breast Cancer(Phase II); Endometrial Cancer(Phase III); Ovarian Cancer(Phase II); Epithelial Ovarian Tumor(Phase II); Metastatic Ovarian Cancer(Phase II)			Poly(ADP-ribose) polymerase-2 (PARP-2) inhibitor	ary Owner);Pfizer Inc (Developer,Primary Owner);Agouron Pharmaceuticals Inc (Originator)
Coforin	pentostatin	Hairy Cell Leukemia(M); T-Cell Lymphoma(M)	M	Active	Adenosine Deaminase (ADA) Inhibitor	Parke Davis Ltd (Originator);Warner Lambert Company LLC (Primary Owner);Pfizer Inc (Sales/Marketing);Kaketsukan KK (Sales/Marketing);Hospira Inc (Sales/Marketing);Mayne Pharma Group Ltd (Sales/Marketing);Nippon Kayaku Co Ltd (Unknown);Mayne Pharma International (Sales/Marketing)
Colestid	colestipol hydrochloride	Myocardial Infarction(M); Coronary Atherosclerosis(M);	M	Active		Pharmacia and Upjohn LLC (Primary Owner);Pharmacia and Upjohn Company LLC (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Hypercholesterolemia(M)				Owner);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Combantrin A	albendazole	Parasitic Infections(M)	M	Active	Microtubule Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Cordarone	amiodarone hydrochloride	Ventricular Fibrillation(M); Ventricular Tachycardia(M)	M	Active	Potassium Channel Blocker; Sodium Channel Blocker	Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Distributor,Primary Owner);Wyeth (Distributor,Primary Owner)
Corex DX	chlorpheniramine; dextromethorphan	Pulmonology(M)	M	Active	Histamine H1 Receptor Antagonist; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Corex Group	chlorpheniramine; codeine	Pulmonology(M)	M	Active	Histamine H1 Receptor Antagonist; Mu-Opioid Receptor Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Corgard	nadolol	Angina Pectoris(M); Hypertension(M)	M	Active	Beta Adrenergic Receptor (ADRB) Antagonist	Pfizer Inc (Primary Owner);Bristol Myers Squibb Company (Primary Owner);US

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						WorldMeds LLC (Primary Owner)
Cortef	hydrocortisone	Gastroenterology(M); Hematology(M); Dermatology(M); Nephrotic Syndrome(M); Endocrine Disorders(M); Allergy(M); Inflammatory Disorders(M); Neoplasia(M); Autoimmune Connective Tissue Disorders(M); Neurology(M); Pulmonology(M); Ophthalmology(M)	M	Active		Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)
Cortisporin	hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate	Dermatosis(M)	M	Active	Protein Synthesis Inhibitor	Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Distributor,Primary Owner)
Corvert	ibutilide fumarate	Atrial Fibrillation(M); Atrial Flutter(M)	M	Active	Calcium Channel Blocker; Potassium Channel Blocker	Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Primary Owner)
Corzide	bendroflumethiazide; nadolol	Hypertension(M)	M	Active	Beta Adrenergic Receptor (ADRB)	Pfizer Inc (Sales/Marketing); Bristol Myers Squibb Company (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Antagonist	Owner)
Covera HS	verapamil hydrochloride	Angina Pectoris(M); Hypertension(M)	M	Active	Calcium Channel Blocker	G D Searle LLC (Distributor,Primary Owner);Pfizer Inc (Primary Owner)
CP868596	crenolanib besylate	Mastocytosis(Preclinical); Gastrointestinal Stromal Tumor(Phase III); Acute Myeloid Leukemia(Phase III); Glioma(Phase II); Non-Small Cell Lung Cancer(Phase II); Lung Adenocarcinoma(Phase II)	Phase III	Active	FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitor; Platelet-Derived Growth Factor Receptor-Alpha (PDGFRA) Tyrosine Kinase Inhibitor; Platelet-Derived Growth Factor Receptor-Beta (PDGFRB) Tyrosine Kinase Inhibitor	Pfizer Inc (Developer,Originator);Arog Pharmaceuticals Inc (Developer)
CP870	--	Oncology(Preliminary)	Preclinical	Completed	Cluster of Differentiation 40 (CD40) Receptor Agonist	Pfizer Inc (Originator);VLST Corp (Primary Owner)
CXL	avibactam; ceftaroline fosamil	Bacterial Infections(Preliminary); Staphylococcal Infections(Phase II)	Phase II	Active	Beta-Lactamase Inhibitor	Forest Laboratories Inc (Developer);Allergan Plc (Sales/Marketing); AstraZeneca Plc (Developer);Pfizer Inc (Co-developer);Novexel Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Cyklokapron	tranexamic acid	Hemophilia(M); Hereditary Angioedema(M)	M	Active	Carboxypeptidase B2 (CPB2) Inhibitor; Plasminogen (PLG) Activation Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Ltd India (Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Primary Owner)
Cyklokapron	tranexamic acid	Cardiology(M)	M	Active	Plasminogen (PLG) Activation Inhibitor	Pfizer Ltd India (Sales/Marketing); Pfizer Inc (Primary Owner)
Cytomel	liothyronine sodium	Goiter(M); Hypothyroidism(M)	M	Active	Thyroid Hormone Receptor (TR) Agonist	Pfizer Inc (Primary Owner); Pfizer Canada Inc (Sales/Marketing)
Cytotec	misoprostol	Duodenal Ulcer(M); Non Steroidal Anti Inflammatory Drugs Induced Gastric Ulcer(M); Upper Gastrointestinal Bleeding(M); Gastroduodenitis(M)	M	Active		G D Searle LLC (Distributor, Primary Owner); Pfizer Healthcare Ireland (Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner); Pfizer Corp Hong Kong Ltd (Sales/Marketing, Unknown); Pfizer UK Ltd (Sales/Marketing)
Dantrium	Dantrolene	Malignant	M	Active	Ryanodine	Pfizer Healthcare

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	sodium	Hyperthermia(M); Multiple Sclerosis(M); Spinal Cord Injuries(M); Stroke(M)			Receptor 1 (RYR1) Antagonist	Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner,Sales/Marketing)
Daunoblastin	daunorubicin hydrochloride	Acute Lymphoblastic Leukemia(M)	M	Active	Not Available	Pfizer Croatia doo (Sales/Marketing);Pfizer Europe MA EEIG (Sales/Marketing);Pfizer Enterprises SARL (Sales/Marketing);Pfizer SL (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Italia Srl (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Novamed Pharmaceuticals Inc (Sales/Marketing);Sciclone Pharmaceuticals Inc (Sales/Marketing);Pharmacia Corp (Originator)
Daxid	sertraline	Psychiatric Disorders(M)	M	Active	5-Hydroxytryptamine (5-HT) Reuptake Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Daypro	oxaprozin	Rheumatoid Arthritis(M); Juvenile Idiopathic	M	Active		G D Searle LLC (Distributor,Primary Owner);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Arthritis(M); Osteoarthritis(M)				
Daypro Alta	oxaprozin potassium	Rheumatoid Arthritis(M); Osteoarthritis(M)	M	Active		G D Searle LLC (Distributor,Primary Owner);Pfizer Inc (Primary Owner);Pharmacia Corp (Primary Owner)
Dekavil	--	Rheumatoid Arthritis(Phase II); Inflammatory Bowel Disease(Phase I)	Phase II	Active	Interleukin-10 (IL-10) Inducer	Pfizer Inc (Primary Owner);Philogen SpA (Originator)
Delestrogen	estradiol valerate	Atrophic Vaginitis(M)	M	Active	Not Available	Pfizer Inc (Sales/Marketing); Bristol Myers Squibb Company (Primary Owner)
Depo Estradiol	estradiol cypionate	Menopausal Disorders(M); Estrogen Hormone Deficiency(M)	M	Active	Estrogen Receptor (ESR) Agonist; Follicle Stimulating Hormone Receptor (FSHR) Negative Allosteric Modulator	Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)
Depo Medrol	methylprednisolone acetate	Thrombocytopenia(M); Pure Red Cell Aplasia(M); Acquired Hemolytic Anemia(M); Lichen Planus(M);	M	Active	Glucocorticoid Receptor (GR) Agonist	Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Congenital Adrenal Hyperplasia(M); Hypercalcemia (M); Allergy(M); Ulcerative Colitis(M); Alopecia Areata(M); Discoid Lupus Erythematosus (M); Pemphigus(M) ; Temporal Arteritis(M); Gastroenteritis (M); Dermatitis Herpetiformis(M); Exfoliative Dermatitis(M); Stevens-Johnson Syndrome(M); Trichinosis(M); Polymyositis(M); Dermatomyositis(M); Systemic Lupus Erythematosus (M); Rheumatoid Arthritis(M); Ankylosing Spondylitis(M); Psoriatic Arthritis(M); Gout(M); Osteoarthritis(

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		M); Tuberculous Meningitis(M); Multiple Sclerosis(M); Eosinophilic Pneumonia(M) ; Sarcoidosis(M) ; Uveitis(M); Sympathetic Ophthalmitis(M)				
Depo provera	medroxyprogesterone acetate	Endometriosis(M); Female Contraception(M); Metastatic Renal Cancer(M); Metastatic Breast Cancer(M); Metastatic Endometrial Cancer(M)	M	Active	Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist	Pharmacia and Upjohn Company LLC (Originator);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Manufacturing Belgium NV (Manufacturer);Pfizer Canada Inc (Sales/Marketing); BMP Sunstone Corp (Distributor);Pfizer UK Ltd (Sales/Marketing)
Depo subq provera 104	medroxyprogesterone acetate	Endometriosis(M); Contraception(M)	M	Active	Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist	Pfizer Australia Pty Ltd (Distributor,Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor,Primary Owner);Pfizer UK Ltd (Distributor,Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Depo Testosterone	testosterone cypionate	Male Hypogonadism (M); Gonadotropins Deficiency(M)	M	Active	Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist	Pfizer Inc (Primary Owner);Pfizer Canada Inc (Distributor);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)
Detrol	tolterodine tartrate	Overactive Bladder(M)	M	Active	Muscarinic Receptor Antagonist	Pfizer Healthcare Ireland (Sales/Marketing);Pharmacia and Upjohn Company LLC (Distributor,Primary Owner);Pfizer New Zealand Ltd (Distributor);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Almirall (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Didrex	benzphetamine hydrochloride	Obesity(M)	M	Active	Dopamine Reuptake Inhibitor; Norepinephrine Reuptake Inhibitor	Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer Inc (Primary Owner)
Diflucan	fluconazole	Peritonitis(M); Fungal Pneumonia(M); Oropharyngeal Candidiasis(M)	M	Active	Lanosterol 14 Alpha-Demethylase (CYP51) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		; Urinary Candidiasis(M); Candida Fungemia(M); Cryptococcal Meningitis(M); Vaginal Candidiasis(M); Esophageal Candidiasis(M); Hepatosplenic Candidiasis(M)				Ltd (Sales/Marketing); Roerig SA (Distributor);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Dilantin	phenytoin sodium	Partial Seizures(M); Tonic-Clonic Seizures(M); Trigeminal Neuralgia(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Parke Davis and Company LLC (Distributor,Primary Owner);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Manufacturing Deutschland GmbH (Manufacturer);Pfizer Canada Inc (Sales/Marketing)
Dilantin 125	phenytoin	Complex Partial Seizures(M); Tonic-Clonic Seizures(M)	M	Active		Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing)
Dimebon	latrepirdine	Huntingtons	Phase III	Completed	Acetylcholinest	Pfizer Inc (Co-

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Disease(Phase III); Alzheimers Disease(Phase III)			erase (AChE) Inhibitor; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	developer);Medivation Inc (Originator)
Dimetapp	chlorpheniramine maleate; dextromethorphan hydrobromide	Cough(M); Seasonal Allergic Rhinitis(M)	M	Active	Histamine H1 Receptor Antagonist; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Primary Owner)
Dimetapp cold and allergy	brompheniramine maleate; phenylephrine hydrochloride	Seasonal Allergic Rhinitis(M); Nasal Congestion(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Histamine H1 Receptor Antagonist	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Dimetapp cold and cough	brompheniramine maleate; dextromethorphan hydrobromide; phenylephrine hydrochloride	Cough(M); Seasonal Allergic Rhinitis(M); Nasal Congestion(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Histamine H1 Receptor Antagonist; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Primary Owner)
Dimetapp multi symptom cold and flu	acetaminophen; diphenhydramine hydrochloride	Influenza(M); Seasonal Allergic Rhinitis(M); Nasal	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist;	Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	e; phenylephrine hydrochloride	Congestion(M)			Histamine H1 Receptor Antagonist	
Dimetapp night time cold and congestion	diphenhydramine hydrochloride; phenylephrine hydrochloride	Common Cold(M); Seasonal Allergic Rhinitis(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Histamine H1 Receptor Antagonist	Pfizer Inc (Primary Owner)
DMPA7909	--	Bacterial Infections(Clinical Phase Unknown)	Clinical Phase Unknown	No Development Reported	Not Available	Pfizer Inc (Primary Owner);Emergent Biosolutions Inc (Primary Owner)
Docetaxel PFIZER	docetaxel	Gastric Adenocarcinoma(M); Metastatic Prostate Cancer(M); Breast Cancer(M); Head and Neck Cancer(M); Non-Small Cell Lung Cancer(M)	M	Active	Microtubule Inhibitor	Pfizer Laboratories Ltd (Distributor,Primary Owner);Pfizer Inc (Primary Owner);Hospira Inc (Sales/Marketing)
Dolonat	acetaminophen; tramadol hydrochloride	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor; Mu-Opioid Receptor Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Dolonex	piroxicam	Immunology	M	Active	Cyclooxygenase	Pfizer Ltd

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		and Inflammatory(M)			cse-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	India (Sales/Marketing);Pfizer Inc (Primary Owner)
Doxorubicin hydrochloride PFIZER	doxorubicin hydrochloride	Bone Sarcoma(M); Metastatic Soft Tissue Sarcomas(M); Metastatic Thyroid Cancer(M); Metastatic Gastric Cancer(M); Transitional Cell Carcinoma of the Bladder(M); Wilms Tumor(M); Breast Cancer(M); Metastatic Ovarian Cancer(M); Acute Myeloid Leukemia(M); Acute Lymphoblastic Leukemia(M); Hodgkins Lymphoma(M); Non-Hodgkins Lymphoma(M); Lung Cancer(M); Neuroblastoma(M)	M	Active	Protein Synthesis Inhibitor; Topoisomerase II Inhibitor	Pharmacia and Upjohn LLC (Primary Owner);Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Hospira Australia Pty Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Dristan 12 hour nasal spray	oxymetazoline hydrochloride	Nasal Congestion(M)	M	Active	Alpha-2 Adrenergic Receptor (ADRA2) Agonist	Pfizer Inc (Primary Owner)
Dristan cold	acetaminophen; chlorpheniramine maleate; phenylephrine hydrochloride	Pain(M); Fever(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; Histamine H1 Receptor Antagonist	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Duavee	bazedoxifene; conjugated estrogens	Menopausal Disorders(M); Postmenopausal Osteoporosis(M)	M	Active	Transforming Growth Factor, Beta (TGFB) Upregulator	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner);Ligand pharmaceuticals Inc (Originator);Wyeth (Originator)
Dynastat	parecoxib sodium	Post-Operative Pain(M)	M	Active	Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Edronax	reboxetine mesylate	Depression(M)	M	Active	Norepinephrine Reuptake Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Effexor XR	venlafaxine hydrochloride	Generalized Anxiety Disorder(M); Panic Disorder(M); Social Phobia(M); Major Depressive Disorder(M); Schizophrenia(Preclinical)	M	Active	5-Hydroxytryptamine (5-HT) Reuptake Inhibitor; Norepinephrine Reuptake Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Almirall (Sales/Marketing);Wyeth Pharmaceuticals Inc (Distributor,Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Eleyso	taliglucerase alfa	Gauchers Disease(M)	M	Active		Protalix Ltd (Developer,Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing)
Eliquis	apixaban	Atrial Fibrillation(PM); Pulmonary Embolism(M); Venous Thromboembolism(M); Deep Vein Thrombosis(M)	PM	Active	Factor Xa Inhibitor (Direct)	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Inc (Developer);Pfizer Corp Hong Kong Ltd (Sales/Marketing);

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
)				Pfizer Canada Inc (Sales/Marketing); Bristol Myers Squibb Company (Originator)
Ellence	epirubicin hydrochloride	Breast Cancer(M)	M	Active	Topoisomerase II Inhibitor	Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Embeda	morphine sulfate; naltrexone hydrochloride	Pain(M)	M	Active	Mu-Opioid Receptor Agonist; Mu-Opioid Receptor Antagonist	Pfizer Inc (Primary Owner);Alpharma Pharmaceuticals LLC (Primary Owner)
Emcyt	estramustine phosphate sodium	Metastatic Prostate Cancer(M)	M	Active	Microtubule Inhibitor	Pfizer Inc (Primary Owner);Pfizer China Research and Development Co Ltd (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Primary Owner);Novamed Pharmaceuticals Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Enablex	darifenacin	Overactive Bladder(M); Urinary Incontinence(M); Urge Urinary Incontinence(M)	M	Active	Muscarinic M2 Receptor Antagonist	Vivax Pharmaceuticals Srl (Sales/Marketing);POA Pharma Scandinavia AB (Distributor,Sales/Marketing);SPCare Lda (Sales/Marketing);Arriani Pharmaceuticals SA (Sales/Marketing);Merus Labs International Inc (Manufacturer,Primary Owner,Sales/Marketing);Eurocept Pharmaceuticals (Sales/Marketing);Pfizer Inc (Primary Owner);Novartis AG (Primary Owner,Sales/Marketing);Warner Chilcott plc (Sales/Marketing)
Enbrel	etanercept	Plaque Psoriasis(PM); Rheumatoid Arthritis(PM); Psoriatic Arthritis(PM); Ankylosing Spondylitis(M); Polyarticular Juvenile Idiopathic Arthritis(M)	PM	Completed	Tumor Necrosis Factor (TNF) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Immunex Corp (Originator,Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Sales/Marketing);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Ariad Pharmaceuticals Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Owner);Genentech Inc (Primary Owner);Amgen Inc (Co-developer,Originator, Primary Owner,Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Ensemblins Program ENSEMBLE	--	Un-Disclosed(Clinical Phase Unknown)	Clinical Phase Unknown	No Development Reported	Not Available	Pfizer Inc (Co-developer);Ensemble Therapeutics Corp (Originator)
Enzira	influenza virus split virions (inactivated)	Influenza(M)	M	Active		Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Epivir	lamivudine	Human Immunodeficiency Virus Infection(M)	M	Active	HIV Reverse Transcriptase Inhibitor	Glaxo Operations UK Ltd (Manufacturer);Viiv Healthcare Ltd (Primary Owner,Sales/Marketing);Pfizer Inc (Primary Owner);GlaxoSmithKline Plc (Primary Owner)
Epzicom	abacavir sulfate; lamivudine	Human Immunodeficiency Virus-1 Infection(M)	M	Active	HIV Reverse Transcriptase Inhibitor	GlaxoSmithKline Ireland Ltd (Sales/Marketing); GlaxoSmithKline Oy (Sales/Marketing); GSK Services Spz oo (Sales/Marketing); ViiV Healthcare SAS (Sales/Marketing);Pfizer Inc (Primary Owner);GlaxoSmithKline AEBE (Sales/Marketing);GlaxoSmithKline

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Plc (Primary Owner,Sales/Marketing);GlaxoSmithKline sro (Sales/Marketing);GlaxoSmithKline KK (Sales/Marketing);ViiV Healthcare UK Ltd (Primary Owner,Sales/Marketing);GlaxoSmithKline PharmAGmbH (Sales /Marketing);Glaxosmit hline Lietuva UAB (Sales/Marketin g);Glaxosmithkline Pharma AS (Sales/Marketing);Glaxosmithkline AS (Sales/Marketing);Glaxosmithkline Slovakia Sro (Sales/Marketing) ;Glaxosmithkline AB (Sales/Marketing);Glaxosmithkline DOO (Sales/Marketin g);Glaxo Wellcome SA (Manufacturer);Gl axoSmithKline GSK SRL (Sales/Marketing);GlaxoSmithKline Malta Ltd (Sales/Marketing);GlaxoSmithKline EOOD (Sales/Marketi ng);Laboratorios ViiV Healthcare SL (Sales/Marketing);ViiV Healthcare BV (Sales/Marketing);ViiV Healthcare GmbH (Sales/Marketi

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						ng);ViiV Healthcare Srl (Sales/Marketing); ViiV Healthcare sprl (Sales/Marketing) ;ViiV HIV Healthcare Unipessoal Lda (Sales/Marketing)
Equiflex	aceclofenac; thiocolchicoside	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Equio	aceclofenac; acetaminophen	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Equio PFIZER	terbutaline	Pulmonology(M)	M	Active	Beta-2 Adrenergic Receptor (ADRB2) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Eraxis	anidulafungin	Intra-Abdominal Abscesses(M); Peritonitis(M); Candida Fungemia(M); Esophageal Candidiasis(M)	M	Active	1,3-Beta-Glucan Synthase Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);RaQualia Pharma Inc (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Developer,Primary Owner);Vicuron Pharmaceuticals Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Eli Lilly and

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Co (Originator);Pfizer UK Ltd (Sales/Marketing)
Erythrocin	erythromycin estolate	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
ESP41091	--	Non-Insulin-Dependent Diabetes Mellitus(Preclinical); Obesity(Preclinical)	Preclinical	Completed		Pfizer Inc (Originator);Esperion Therapeutics Inc (Primary Owner)
Estring	estradiol	Postmenopausal Atrophic Vaginitis(M)	M	Active	Estrogen Receptor (ESR) Agonist	Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor,Primary Owner);Pfizer UK Ltd (Sales/Marketing)
ETC1002	bempedoic acid	Hypertension(Phase II); Dyslipidemia(Phase II); Hypercholesterolemia(Phase III); Non-Insulin-Dependent Diabetes Mellitus(Phase II)	Phase III	Active	Adenosine 5-Monophosphate-Activated Protein Kinase (AMPK) Activator	Pfizer Inc (Originator);Esperion Therapeutics Inc (Originator,Primary Owner)
Etuser	pantoprazole	Gastroenterology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Eurartesim	dihydroartemisinin;	Plasmodium Falciparum	M	Active	Not Available	Pfizer Inc (Distributor);Sigma

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	piperaquine	Malaria(M)				a Tau Pharmaceuticals Inc (Primary Owner)
Exubera	human insulin [rDNA origin]	Diabetes Mellitus(M)	M	Discontinued	Not Available	Pfizer Inc (Primary Owner)
Ezegalin SR	Pregabalin	Muscle Spasm(M); Partial Seizures(M); Neuropathic Pain(M)	M	Active	Calcium Channel Blocker	Pfizer Inc (Primary Owner);Eisai Pharmaceuticals India Pvt Ltd (Sales/Marketing); Eisai Co Ltd (Sales/Marketing)
Feldene	piroxicam	Rheumatoid Arthritis(M); Ankylosing Spondylitis(M); Osteoarthritis(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Fibercon	calcium polycarbophil	Irritable Bowel Syndrome(M)	M	Active	Factor Xa Inhibitor (Direct)	Pfizer Inc (Primary Owner)
Filgrastim PFIZER	filgrastim	Cancer Chemotherapy Induced Neutropenia(Phase I)	Phase I	Active	Granulocyte Colony-Stimulating Factor (G-CSF) Receptor Agonist	Pfizer Inc (Primary Owner);Hospira Inc (Co-developer)
Flagyl	metronidazole	Abdominal Diseases(M); Gynecology(M); Skin Bacterial Infections(M); Bacterial	M	Active	Deoxyribonucleic acid (DNA) synthesis inhibitor	G D Searle LLC (Distributor,Primary Owner);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Endocarditis(M); Septicaemia(M); Bacterial Vaginosis(M); Trichinosis(M); Amoebiasis(M); Musculoskeletal Bacterial Infections(M); Central Nervous System Bacterial Infections(M); Lower Respiratory Tract Bacterial Infections(M)				
Flector	diclofenac epolamine	Pain(PM)	PM	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Teikoku Seiyaku Co Ltd (Manufacturer);Pfizer Inc (Sales/Marketing); Alpharma Pharmaceuticals LLC (Sales/Marketing);IBSA Institut Biochimique SA (Primary Owner)
Florinef	fludrocortisone acetate	Adrenal Insufficiency(M)	M	Active	Glucocorticoid Receptor (GR) Agonist	Pfizer Inc (Sales/Marketing); Bristol Myers Squibb Company (Primary Owner)
Fragmin	dalteparin sodium	Unstable Angina(M); Non-Q-Wave Myocardial Infarction(M); Venous Thromboembolism	M	Active	Factor Xa Inhibitor (Direct)	Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		lism(M); Deep Vein Thrombosis(M)				Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Primary Owner);Kissei Pharmaceutical Co Ltd (Sales/Marketing); Eisai Co Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Fusilev	levoleucovorin	Cancer Chemotherapy Induced Mucositis(Phase I); Metastatic Colorectal Cancer(M); Osteosarcoma (M)	M	Active	Dihydrofolate Reductase (DHFR) Inhibitor; Fungal Thymidylate Synthase Inhibitor	Pfizer SA Belgium (Sales/Marketing);Pfizer Inc (Primary Owner,Sales/Marketing);Pfizer Japan Inc (Sales/Marketing); Takeda Pharmaceuticals Europe Ltd (Sales/Marketing); Sanofi (Sales/Marketing);Cyanamid Inter American Corp (Primary Owner);Spectrum Pharmaceuticals Inc (Co-developer,Sales/Marketing);Takeda Pharmaceutical Company Ltd (Sales/Marketing); Wyeth (Primary Owner,Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Gemcabene GEMPHIRE	gemcabene	Atherosclerosis(Phase II); Hypertriglyceridemia(Phase	Phase II	Active	Low Density Lipoprotein (LDL) Inhibitor	Pfizer Inc (Originator);Gempire Therapeutics Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		II); Heterozygous Familial Hypercholesterolemia(Phase II); Homozygous Familial Hypercholesterolemia(Phase II)				
Gemcitabine PFIZER	Gemcitabine	Pancreatic Cancer(M); Breast Cancer(M); Ovarian Cancer(M); Non-Small Cell Lung Cancer(M)	M	Active	Deoxyribonucleic acid (DNA) synthesis inhibitor	Pfizer Inc (Primary Owner)
Genotropin	somatropin (recombinant)	Dwarfism(M); Idiopathic Short Stature(M); Turner Syndrome(M); Prader-Willi Syndrome(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor, Primary Owner)
Geocillin	carbenicillin indanyl sodium	Urinary Tract Bacterial Infections(M); Bacterial Prostatitis(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor	Roerig SA (Distributor);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	Bipolar I(M); Schizophrenia(M)	M	Active	5-Hydroxytryptamine-1A (5-HT1A) Receptor Agonist; 5-Hydroxytryptamine-2A (5-HT2A) Receptor Antagonist; Dopamine D2 Receptor Antagonist	Pfizer Healthcare Ireland (Sales/Marketing); RaQualia Pharma Inc (Primary Owner, Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Roerig SA (Distributor); Pfizer Inc (Originator, Primary Owner); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing)
GL2045	--	Chronic Inflammatory Demyelinating Polyneuropathy(Preclinical); Idiopathic Thrombocytopenic Purpura(Preclinical); Oncology(Preliminary); Myasthenia Gravis(Preclinical)	Preclinical	Active	Not Available	Pfizer Inc (Developer, Primary Owner); Gliknik Inc (Originator)
Glucotrol	glipizide	Non-Insulin-Dependent Diabetes Mellitus(M)	M	Active		Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Roerig SA (Distributor); Pfizer Inc (Primary Owner); Pfizer Manufacturing

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Belgium NV (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Glynase	glyburide	Non-Insulin-Dependent Diabetes Mellitus(M)	M	Active	Sulfonylurea Receptor 1 (SUR1) Antagonist	Pharmacia and Upjohn LLC (Distributor);Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Primary Owner)
Glyset	miglitol	Non-Insulin-Dependent Diabetes Mellitus(M)	M	Active	Alpha-Glucosidase Inhibitor	Pharmacia and Upjohn Company LLC (Distributor,Sales /Marketing);Pfizer Inc (Sales/Marketing)
GMI1070	rivipansel	Sickle Cell Anemia(Phase III)	Phase III	Active	E-Selectin Inhibitor; L-Selectin Inhibitor; P-Selectin Inhibitor	Pfizer Inc (Developer,Primary Owner);Halozyme Therapeutics Inc (Technology Owner);Glycomimetics Inc (Originator)
Halcion	triazolam	Insomnia(M)	M	Active	Gamma-Aminobutyric Acid Type A (GABAA) Receptor Modulator	Pfizer Healthcare Ireland (Sales/Marketing);Pharmacia and Upjohn Company LLC (Distributor,Primary Owner);Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Hemabate	carboprost	Abortion(M);	M	Active	Prostaglandin	Pharmacia and

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	tromethamine	Postpartum Hemorrhage(M)			F2 alpha (PGF2 alpha) Receptor Agonist	Upjohn Company LLC (Distributor,Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Distributor);Pfizer UK Ltd (Sales/Marketing)
Heparin Sodium PFIZER	heparin sodium	Cardiology(M); Atrial Fibrillation(M); Embolism(M); Venous Thromboembolism(M); Cardiac Surgery(M)	M	Active		Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing)
Hetrazan	diethylcarbamazine citrate	Helminthic Infections(M)	M	Active	15-Lipoxygenase (15-LO) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
HibTiter	haemophilus influenzae type b	Haemophilus Influenzae Type B Infection(M)	M	Discontinued	Not Available	Pfizer Inc (Primary Owner);Wyeth LLC (Originator);Mitsubishi Tanabe Pharma Corp (Developer);Nuron Biotech Inc (Primary Owner)
Histizer	cetirizine	Allergy(M)	M	Active	Histamine H1 Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
HSP130	pegfilgrastim	Cancer Chemotherapy Induced	Phase II	Active	Granulocyte Colony-Stimulating	Pfizer Inc (Primary Owner);Hospira Inc (Originator,Primar

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Neutropenia(Phase I); Breast Cancer(Phase II)			Factor (G-CSF) Receptor Agonist	Primary Owner)
Humatin	paromomycin sulfate	Persistent Hepatic Encephalopathy(M); Acute Intestinal Amoebiasis(M); Chronic Intestinal Amoebiasis(M)	M	Discontinued		Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Monarch Pharmaceuticals Inc (Distributor)
Hysite	latanoprost	Intraocular Pressure(M)	M	Active	Prostaglandin F2 alpha (PGF2 alpha) Receptor Agonist	Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Inc (Primary Owner)
Ibrance	palbociclib	Oncology(Phase I); Metastatic Melanoma(Phase II); HER2-Positive Metastatic Breast Cancer(M); HER2-Negative Metastatic Breast Cancer(M); Head and Neck Squamous Cell Carcinoma(Phase II)	M	Active	Cyclin Dependent Kinases 6 (CDK 6) Inhibitor; Cyclin-Dependent Kinase 4 (CDK4) Inhibitor; MEK Inhibitor	Pfizer Inc (Developer, Primary Owner);GlaxoSmithKline Plc (Co-developer);Onyx Pharmaceuticals International GmbH (Originator);Pfizer Canada Inc (Sales/Marketing)
Idamycin	idarubicin hydrochloride	Acute Myeloid Leukemia(M)	M	Active	Topoisomerase II Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Distributor,Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Distributor,Sales/Marketing);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor,Primary Owner);Pfizer UK Ltd (Sales/Marketing)
INCB8696	--	Multiple Sclerosis(Phase I)	Phase I	No Development Reported	CC Chemokine Receptor 2 (CCR2) Antagonist	Pfizer Inc (Primary Owner);Incyte Corp (Co-developer,Originator)
Infinair	levocetirizine hydrochloride; montelukast sodium	Pulmonology(M)	M	Active	Histamine H1 Receptor Antagonist; Leukotriene (LT) Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Influenza VLP vaccine NOVAVAX	--	Influenza(Phase II)	Phase II	Completed		LG Life Sciences Ltd (Co-developer,Developer);Novavax Inc (Originator,Primary Owner);Pfizer Inc (Technology Owner);Cadila Pharmaceuticals (Co-developer)
Inlyta	axitinib	Solid Tumors Unspecified(P)	M	Active	Vascular Endothelial	Pfizer ApS (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		hase I); Liver Cancer(Phase II); Hepatocellular Carcinoma(Phase III); Pancreatic Cancer(Phase III); Renal Cell Carcinoma(M); Non-Small Cell Lung Cancer(Phase II)			Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor) Pfizer Croatia doo (Sales/Marketing); Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Luxembourg SARL (Sales/Marketing); Pfizer Pharma GmbH (Sales/Marketing); Pfizer SL (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Developer, Originator, Primary Owner); Pfizer Japan Inc (Developer, Primary Owner, Sales/Marketing); Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Manufacturing Deutschland GmbH (Manufacturer); Pfizer Polska Spzoo (Sales/Marketing); Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing); Merck Sharp and Dohme Corp (Co-

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						developer);Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer A S (Sales/Marketing);Pfizer Romania SRL (Sales/Marketing);Pfizer Spol SRO (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Inotuzumab Ozogamicin PFIZER	inotuzumab ozogamicin	Acute Lymphoblastic Leukemia(PA); Non-Hodgkins Lymphoma(Phase III)	PA	Active		Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner)
Inspira	eplerenone	Congestive Heart Failure(M); Hypertension(M)	M	Active	Aldosterone Receptor Antagonist	G D Searle LLC (Distributor);Pfizer Healthcare Ireland (Sales/Marketing);Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Distributor,Sales/Marketing);Pharmacia Corp (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Owner);Pfizer UK Ltd (Sales/Marketing)
Intal	cromolyn sodium	Asthma(M)	M	Active		Pfizer Inc (Primary Owner);Aventis Pharma SA (Primary Owner)
Intratect	immunoglobulin [human]	Immunodeficiency Disorders(M)	M	Active	Not Available	Pfizer Inc (Primary Owner,Sales/Marketing);Hospira Australia Pty Ltd (Sales/Marketing)
Ipravent	ipratropium bromide	Asthma(M); Chronic Bronchitis(M)	M	Active	Acetylcholine Receptor (AchR) Antagonist	Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner)
Isokin	isoniazid	Bacterial Infections(M)	M	Active	Fatty Acid Synthase (FAS) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Isonep	sonepcizumab	Wet Age-Related Macular Degeneration(Phase II)	Phase II	Completed	Sphingosine 1-Phosphate (S1P) Inhibitor	Patheon Inc (Manufacturer);Pfizer Inc (Primary Owner);Gallus Biopharmaceuticals LLC (Co-developer);Lpath Inc (Originator)
Jetex	cefixime; clavulanate potassium	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Jetflex	levofloxacin	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Juxtapid	lomitapide	Homozygous Familial Hypercholesterolemia	M	Active	Microsomal Triglyceride Transfer	Pfizer Inc (Developer);Aegerion Pharmaceuticals

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		rolemia(M)			Protein (MTP) Inhibitor	Inc (Primary Owner);Bristol Myers Squibb Company (Originator)
Kemadrin	procyclidine hydrochloride	Parkinsons Disease(M)	M	Discontinued		Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Distributor,Primary Owner);Aspen Pharmacare Holdings Ltd (Primary Owner)
Ketalar	ketamine hydrochloride	Sensory Loss(M)	M	Active	N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Keytruda	pembrolizumab	Oncology(Prec clinical); Hematological Malignancies Unspecified(Phase I); Solid Tumors Unspecified(Phase II); Metastatic Melanoma(M); Adrenal Cortical Carcinoma(Phase II); Thymic Lymphoma(Phase II); Metastatic Colorectal Cancer(Phase II); Metastatic	M	Active	Cyclin Dependent Kinases 6 (CDK 6) Inhibitor; Programmed Cell Death 1 (PD-1) Receptor Antagonist	Merck Sharp and Dohme Ltd (Sales/Marketing); Merck and Co Inc (Originator,Primary Owner);Pfizer Inc (Co-developer);NanoString Technologies Inc (Technology Owner);Merck Sharp and Dohme Corp (Co-developer,Sales/Marketing);Taiho Pharmaceutical Co Ltd (Sales/Marketing);Eli Lilly and Co (Co-developer)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Esophageal Cancer(Phase III); Hepatocellular Carcinoma(Phase III); Metastatic Gastric Cancer(Phase III); Bladder Cancer(Phase III); Transitional Cell Carcinoma of the Bladder(Phase III); Hormone Refractory Metastatic Prostate Cancer(Phase II); Renal Cancer(Phase II); HER2-Negative Metastatic Breast Cancer(Phase III); Germ Cell Ovarian Tumor(Phase II); Metastatic Ovarian Cancer(Phase II); Metastatic Nasopharyngeal Cancer(Phase II); Metastatic Head and Neck				

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Cancer(M); Hodgkins Lymphoma(Phase III); Non-Hodgkins Lymphoma(Phase II); Mediastinal Large B-cell Lymphoma(Phase II); Multiple Myeloma(Phase III); Metastatic Non-Small Cell Lung Cancer(M); Glioblastoma Multiforme(Phase II)				
Kinase inhibitor Program BIND THERAPUTICS	--	Solid Tumors Unspecified(Preclinical)	Preclinical	Active		Pfizer Inc (Primary Owner);DNIB Unwind Inc (Originator,Technology Owner)
KUX1151	--	Hyperuricemia (Phase II); Gout(Phase II)	Phase II	Suspended	Urate Transporter 1 (URAT1) Inhibitor; Xanthine Oxidase (XO) Inhibitor	Pfizer Inc (Developer);Kissei Pharmaceutical Co Ltd (Originator)
Lactulose PFIZER	lactulose	Gastroenterology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Lasofoxifene LIGAND PHARMA	lasofoxifene tartrate	Postmenopausal Osteoporosis(PA	Active	Estrogen Receptor (ESR) Agonist	Pfizer Inc (Developer,Originator);Ligand

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		PA)				pharmaceuticals Inc (Primary Owner)
Latanoprost PSIVIDA	latanoprost	Glaucoma(Phase II); Intraocular Pressure(Phase II)	Phase II	Active	Prostaglandin F2 alpha (PGF2 alpha) Receptor Agonist	Psivida Corp (Originator);Pfizer Inc (Primary Owner)
LC OD M	levocetirizine; montelukast	Allergy(M)	M	Active	Histamine H1 Receptor Antagonist; Leukotriene (LT) Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Ledermol	acetaminophen	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Ledgins Program KU LEUVEN	--	Human Immunodeficiency Virus Infection(Research)	Research	Active	HIV Integrase Inhibitor	Pfizer Inc (Primary Owner)
Levefree	levetiracetam	Neurology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Levocetirizine PFIZER	levocetirizine	Allergy(M)	M	Active		Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Levofloxacin PFIZER LTD	levofloxacin	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Levoxyl	levothyroxine sodium	Goiter(M); Hypothyroidism(M); Thyroid Cancer(M)	M	Active		Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Lincocin	lincomycin hydrochloride	Pneumococcal Infections(M); Staphylococcal Infections(M); Streptococcal Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pharmacia and Upjohn Company LLC (Distributor, Primary Owner); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Distributor); Pfizer Inc (Primary Owner); Pharmacia and Upjohn Company Inc (Distributor)
Lipitor	atorvastatin calcium	Angina Pectoris(M); Myocardial Infarction(M); Hyperlipoproteinemia(M); Hypertriglyceridemia(M); Hypercholesterolemia(M); Heterozygous Familial Hypercholesterolemia(M); Homozygous Familial Hypercholesterolemia(M); Mixed Dyslipidemia(M); Stroke(M)	M	Active	3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitor	Pfizer ApS (Sales/Marketing); Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Luxembourg SARL (Sales/Marketing); Pfizer Europe MA EEIG (Sales/Marketing); Laboratorios Parke Davis SL (Sales/Marketing); Pfizer SA Belgium (Sales/Marketing); Pfizer GmbH (Sales/Marketing); Pfizer Hellas AE (Sales/Marketing); Warner Lambert Company LLC (Primary Owner, Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Parke Davis and

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Company LLC (Originator);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BVI (Sales/Marketing); Pfizer Ireland Pharmaceuticals (Sales/Marketing);Pfizer Polska Spzoo (Sales/Marketing);Pfizer Holding France SCA (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing);Pfizer AB (Sales/Marketing);Pfizer A S (Sales/Marketing);Parke Davis Productos Farmaceuticos Lda (Sales/Marketing);Pfizer Spol SRO (Sales/Marketing);Pharmacia Nostrum SA (Sales/Marketing);

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Astellas Pharma Inc (Distributor,Manufacturer,Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Lo Ovral	ethinyl estradiol; norgestrel	Contraception(M)	M	Active	Estrogen Receptor (ESR) Antagonist; Progesterone Receptor (PR) Antagonist	Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Sales/Marketing);Akrimax Pharmaceuticals LLC (Distributor);Wyeth (Primary Owner)
Loette	ethinyl estradiol; levonorgestrel	Pregnancy Related Complications(M)	M	Active	Estrogen Receptor (ESR) Agonist; Progesterone Receptor (PR) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Loette	ethinylestradiol; levonorgestrel	Acne Vulgaris(M); Contraception(M)	M	Active	Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing)
Lomotil	atropine sulfate; diphenoxylate hydrochloride	Diarrhea(M)	M	Active	Mu-Opioid Receptor Agonist; Muscarinic Receptor Antagonist	G D Searle LLC (Distributor);Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Primary Owner)
Loniten	minoxidil	Hypertension(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pharmacia and

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Upjohn Company LLC (Distributor, Primary Owner);Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Primary Owner);Pfizer Canada Inc (Distributor);Pfizer UK Ltd (Sales/Marketing)
Lopid	gemfibrozil	Coronary Artery Diseases(M); Hyperlipoproteinemia(M); Mixed Dyslipidemia(M)	M	Active	Peroxisome Proliferator-Activated Receptor-Alpha (PPAR-Alpha) Agonist	Pfizer ApS (Sales/Marketing);Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing);Warner Lambert Company LLC (Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing); Parke Davis and Company LLC (Distributor, Primary Owner);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer SA (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Lopid	fenofibrate	Cardiology(M)	M	Active	Peroxisome Proliferator-Activated Receptor-Alpha (PPAR-Alpha) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Lotemax	loteprednol	Inflammatory	PM	No		Bausch and Lomb

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	etabonate	Disorders(M); Post-Operative Pain(M); Keratoconjunctivitis Sicca(PM); Cataract Surgery(M)		Development Reported		Inc (Primary Owner); Pfizer Inc (Sales/Marketing); Pharmos Corp (Originator); Valeant Pharmaceuticals International Inc (Co-developer)
Lyrel		Contraception(M)	M	Active	Estrogen Receptor (ESR) Antagonist; Luteinizing Hormone (LH) Inhibitor	Pfizer Inc (Primary Owner); Wyeth Pharmaceuticals Inc (Primary Owner)
Lyrica	Pregabalin	Partial Seizures(M); Fibromyalgia(M); Neuropathic Pain(M); Diabetic Neuropathic Pain(M); Post-Herpetic Neuralgia(M); Generalized Anxiety Disorder(M)	M	Active	Calcium Channel Blocker	Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Ltd India (Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Originator); Pfizer Japan Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Eisai Co Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Macugen	pegaptanib sodium	Diabetic Macular Edema(PA); Wet Age-Related	M	Active	Vascular Endothelial Growth Factor (VEGF) Inhibitor;	OSI Pharmaceuticals Inc (Sales/Marketing); Eyetech Inc (Primary Owner); Pfizer Inc (Co-

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Macular Degeneration(M)			Vascular Endothelial Growth Factor A (VEGFA) Inhibitor	developer,Sales/Marketing);NeXstar pharmaceuticals (Originator);Eyetech Pharmaceuticals (Primary Owner);Gilead Sciences Inc (Primary Owner,Technology Owner);Valeant Pharmaceuticals International Inc(Primary Owner)
Magnamycin	cefoperazone	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Magnex	cefoperazone; sulbactam	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Magnocef	cefpodoxime ; clavulanic acid	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
MDCO216	apolipoprotein A1 (recombinant)	Coronary Artery Diseases(Phase II)	Phase II	Active	ATP-Binding Cassette, Sub-Family A, Member 1 (ABCA1) Activator	The Medicines Company (Primary Owner);Pfizer Inc (Primary Owner)
MDR TB program PFIZER	--	Tuberculosis(Research)	Research	Active	Not Available	Pfizer Inc (Co-developer,Originator); MicuRx Pharmaceuticals Inc (Co-developer,Technology Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Medrol	methylprednisolone	Gastroenterology(M); Hematology(M); Endocarditis(M); Dermatology(M); Endocrine Disorders(M); Allergy(M); Polymyositis(M); Systemic Lupus Erythematosus (M); Neoplasia(M); Joint Disorders(M); Multiple Sclerosis(M); Pulmonology(M); Ophthalmology(M)	M	Active	Undisclosed Cytokine Inhibitor	Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor)
Melphalan ALVOGEN	melphalan	Epithelial Ovarian Tumor(PA); Multiple Myeloma(PA)	PA	Active	Deoxyribonucleic acid (DNA) synthesis inhibitor; Ribonucleic acid (RNA) synthesis inhibitor	Alvogen (Sales/Marketing);Pfizer Inc (Primary Owner)
Mencevax	--	Meningococcal Meningitis(M)	M	Active	Not Available	Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); GlaxoSmithKline Plc (Primary Owner);Pfizer Ireland Pharmaceuticals (Pri

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						mary Owner)
Menest	estrogens (esterified)	Menopausal Disorders(M); Atrophic Vaginitis(M); Female Hypogonadism (M); Ovarian Disorders(M); Prostate Cancer(M); Breast Cancer(M)	M	Active	Estrogen Receptor (ESR) Antagonist	Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Primary Owner);King Pharmaceuticals LLC (Manufacturer)
Merrem	meropenem	Intra-Abdominal Abscesses(M); Pregnancy Related Complications(M); Hospital-Acquired Pneumonia(M); Skin Bacterial Infections(M); Urinary Tract Infections(M); Bacterial Meningitis(M); Cystic Fibrosis(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor	AstraZeneca Pharmaceuticals LP (Sales/Marketing); AstraZeneca Plc (Sales/Marketing); AstraZeneca UK Ltd (Sales/Marketing); Pfizer Inc (Co-developer)
Metabolic Disease program WAVE	--	Metabolic Disorders(Research)	Research	Active	Not Available	Pfizer Inc (Technology Owner);WaVe Life Sciences Ltd (Originator)
Methoblastin	methotrexate	Psoriasis(M); Solid Tumors Unspecified(M); Soft Tissue Sarcomas(M); Breast	M	Active	Dihydrofolate Reductase (DHFR) Inhibitor	Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer UK

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Cancer(M); Choriocarcinoma(M); Acute Lymphoblastic Leukemia(M); Non-Hodgkins Lymphoma(M) ; T-Cell Lymphoma(M) ; Rheumatoid Arthritis(M)				Ltd (Sales/Marketing)
Microbiome Program SECOND GENOME	--	Metabolic Disorders(Clinical Phase Unknown); Obesity(Clinical Phase Unknown)	Clinical Phase Unknown	Active	Not Available	Pfizer Inc (Co-developer);Second Genome Inc (Originator)
Micronase	glyburide	Non-Insulin-Dependent Diabetes Mellitus(M)	M	Active	Sulfonylurea Receptor 1 (SUR1) Antagonist	Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor, Primary Owner)
Minipress	prazosin hydrochloride	Congestive Heart Failure(M); Hypertension(M); Raynauds Disease(M); Benign Prostatic Hyperplasia(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Australia Pty Ltd (Primary Owner,Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Minipress XL	prazosin	Cardiology(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Minulet	ethinylestradiol; gestodene	Contraception(M)	M	Active	Gonadotropin Releasing Hormone	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Receptor (GNRHR) Antagonist	Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
MK8835A	ertugliflozin; sitagliptin	Non-Insulin-Dependent Diabetes Mellitus(Phase III)	Phase III	Completed	Dipeptidyl Peptidase IV (DPP-IV) Inhibitor; Sodium-Glucose Cotransporter Type 2 (SGLT2) Inhibitor	Merck and Co Inc (Primary Owner);Pfizer Inc (Primary Owner)
MK8835B	ertugliflozin; metformin	Non-Insulin-Dependent Diabetes Mellitus(Phase III)	Phase III	Completed	Adenosine 5-Monophosphate-Activated Protein Kinase (AMPK) Activator; Sodium-Glucose Cotransporter Type 2 (SGLT2) Inhibitor	Merck and Co Inc (Primary Owner);Pfizer Inc (Primary Owner)
MLR1023	--	Non-Insulin-Dependent Diabetes Mellitus(Phase II)	Phase II	Active	V-Yes-1 Yamaguchi Sarcoma Viral Related Oncogene Homolog (LYN) Activator	Bukwang Pharmaceutical Co Ltd (Co-developer);Pfizer Ltd India (Developer);Pfizer Inc (Developer)
MOD4023	somatotropin	Dwarfism(Phase III)	Phase III	Active	Growth Hormone (GH) Receptor Agonist	Pfizer Inc (Co-developer);Opko Health Inc (Primary Owner)
Monoclonal	--	Infectious	Research	No	Not Available	Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Antibodies THERACLO NE		Diseases(Research); Oncology(Research)		Development Reported		Owner);Theraclone Sciences Inc (Originator,Technology Owner)
Monofeme	ethinylestradiol; levonorgestrel	Menstrual Disorders(M); Endometriosis(M); Female Contraception(M)	M	Active	Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Monofer	--	Iron Deficiency Anemia(M)	M	Active		Pfizer Inc (Sales/Marketing);Eddingpharm (Sales/Marketing);Pharmacosmos AS (Originator)
MS553	--	Diabetic Retinopathy(Phase I); Uveitis(Clinical Phase Unknown); Keratoconjunctivitis Sicca(Clinical Phase Unknown)	Phase I	No Development Reported	Not Available	Mingsight Pharmaceuticals (Primary Owner);Pfizer Inc (Originator)
MSB001071 8C	avelumab	Merkel Cell Carcinoma(PA); Ovarian Cancer(Phase III); Solid Tumors	PA	Active	Cluster of Differentiation 274 (CD274) Inhibitor	Pfizer Inc (Co-developer);Pfizer Japan Inc (Primary Owner);Merck KGaA (Originator);EMD Serono Inc (Co-

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Unspecified(Phase II); Stomach Cancer(Phase III); Transitional Cell Carcinoma of the Bladder(Phase III); Renal Cell Carcinoma(Phase III); Hodgkins Lymphoma(Phase I); Non-Small Cell Lung Cancer(Phase III)				developer);EMD Serono Research and Development Institute Inc (Co-developer)
Mucaine	--	Gastroenterology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Multistem	--	Congestive Heart Failure(Preliminary); Myocardial Infarction(Phase II); Peripheral Arterial Occlusive Disease(Preliminary); Peripheral Vascular Diseases(Preliminary); Critical Limb Ischemia(Preliminary)	Phase II	Completed		Pfizer Inc (Co-developer);Healios kk (Co-developer);Chugai Pharmaceutical Co Ltd (Co-developer);Athersys Inc (Originator);Angiot ech Pharmaceuticals (Co-developer)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		inical); Ulcerative Colitis(Phase II); Organ Transplantation(Phase I); Stem Cell Transplantation(Phase I); Graft-Versus-Host Disease(Phase I); Multiple Sclerosis(Precinical); Traumatic Brain Injury(Preclinical); Spinal Cord Injuries(Preclinical); Ischemic Stroke(Phase II); Acute Respiratory Distress Syndrome(Phase II)				
Mycobutin	rifabutin	Tuberculosis(M); Mycobacterium Avium Complex Infections(M)	M	Active	Bacterial DNA-Dependent RNA Polymerase Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor, Primary Owner); Pfizer UK Ltd (Sales/Marketing)
Mylotarg	gemtuzumab ozogamicin	Acute Myeloid Leukemia(M)	M	Withdrawn	Cluster of Differentiation 33 (CD33) Receptor Antagonist	Wyeth Ayerst Inc (Sales/Marketing); Pfizer Inc (Primary Owner); Wyeth Pharmaceuticals Inc (Primary Owner); Pfizer UK Ltd (Sales/Marketing)
Nardil	phenelzine sulfate	Depression(M)	M	Active	Monoamine Oxidase (MAO) Inhibitor	Parke Davis and Company LLC (Distributor, Primary Owner); Pfizer Inc (Primary Owner)
Nasalcrom	cromolyn sodium	Allergic Rhinitis(M)	M	Active	Histamine Release Inhibitor	Warner Lambert Company LLC (Primary Owner); Pfizer Inc (Primary Owner); Johnson and Johnson (Primary Owner); Prestige Brands Holdings Inc (Primary Owner); Pharmacia Corp (Primary Owner)
Navane	thiothixene	Schizophrenia(M)	M	Active	Dopamine Receptor Antagonist	Roerig SA (Distributor); Pfizer Inc (Primary Owner)
Navane Injection	thiothixene hydrochloride	Psychiatric Disorders(M)	M	Discontinued	Dopamine Receptor Antagonist	Roerig SA (Distributor); Pfizer Inc (Primary Owner)
NBI34060	indiplon	Insomnia(PA)	PA	Active	Gamma-Aminobutyric Acid Type A (GABAA)	Pfizer Inc (Primary Owner); Neurocrine Biosciences Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Receptor Agonist	
NCX422	nitric oxide	Diabetic Macular Edema(Preclinical)	Preclinical	Completed		Pfizer Inc (Co-developer);Nicox SA (Originator)
NCX434	triamcinolone acetonide	Diabetic Macular Edema(Preclinical)	Preclinical	Completed	Glucocorticoid Receptor (GR) Agonist	Pfizer Inc (Co-developer);Nicox SA (Originator)
Nebasulf	bacitracin; neomycin; sulfacetamide	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor; Dihydropteroate Synthase (DHPS) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Neisvac C	tetanus toxoid	Meningococcal M Meningitis(M)	M	Active	Not Available	Baxter International Inc (Sales/Marketing); Shire Pharmaceuticals Group (Sales/Marketing);ID Biomedical Corp of Quebec (Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);GlaxoSmithKline Plc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Neosporin	neomycin sulfate; polymyxin b sulfate	Urinary Tract Bacterial Infections(M); Septicaemia(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor; Bacterial	Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
)			Protein Synthesis Inhibitor; Protein Synthesis Inhibitor	
Neosporin Ophthalmic solution	gramicidin; neomycin sulfate; polymyxin b sulfate	Ocular Bacterial Infections(M)	M	Active	Bacterial Cell Membrane Permeability Inducer; Bacterial Protein Synthesis Inhibitor	DSM Pharmaceutical Products (Manufacturer);Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Distributor)
Neumega	oprelvekin	Thrombocytopenia(M); Cancer Chemotherapy Induced Thrombocytopenia(M)	M	Active		Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Manufacturer, Primary Owner)
Neurontin	Gabapentin	Partial Seizures(PM); Neuropathic Pain(M)	PM	Completed		Pfizer ApS (Sales/Marketing);Pfizer Oy (Sales/Marketing);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Europe MA EEIG (Sales/Marketing);Parke Davis Ltd (Distributor,Primary Owner);Pfizer Hellas AE (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer Spol SRO (Sales/Marketing);Pfizer AS (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Newsta	rosuvastatin calcium	Cardiology(M)	M	Active	3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Newsta F	fenofibrate; rosuvastatin	Cardiology(M)	M	Active	3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitor; Peroxisome Proliferator-Activated Receptor-Alpha (PPAR-Alpha) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Nexium	esomeprazole magnesium	Gastroesophageal Reflux Disease(M);	M	Active	Proton Pump Inhibitor (PPI)	AstraZeneca KK (Developer,Manufacturer,Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Duodenal Ulcer(M); Gastric Ulcer(M); Zollinger Ellison Syndrome(M); Heartburn(M)				Owner,Sales/Marketing);AstraZeneca Plc (Originator,Sales/Marketing);Pfizer Inc (Sales/Marketing);Pfizer Consumer Healthcare Ltd (Sales/Marketing);AstraZeneca Korea Ltd (Sales/Marketing);Daewoong Pharmaceutical Co Ltd (Sales/Marketing);Daiichi Sankyo Co Ltd (Distributor,Primary Owner,Sales/Marketing)
NGI	insulin	Insulin-Dependent Diabetes Mellitus(Phase I)	Phase I	No Development Reported	Not Available	Pfizer Inc (Primary Owner);Nektar Therapeutics (Co-developer)
Nicopress	nicorandil	Cardiology(M)	M	Active	Potassium Channel Opener	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Nicotrol	nicotine	Nicotine Abuse(M)	M	Active	Neuronal Nicotinic Acetylcholine Receptor (nAChR) Modulator	Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor)
Nimenrix	--	Meningococcal Meningitis(M)	M	Active	Not Available	Pfizer Healthcare Ireland (Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Ltd (Sales/Marketing); GlaxoSmithKline Plc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Nitrostat	nitroglycerin	Angina Pectoris(M)	M	Active	Guanylyl Cyclase (GC) Activator	Warner Lambert Company LLC (Primary Owner);Parke Davis and Company LLC (Primary Owner);Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing)
Norgestrel Ethinyl Estradiol PFIZER		Contraception(M)	M	Active	Estrogen Receptor (ESR) Antagonist	Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Manufacturer);Akrimax Pharmaceuticals LLC (Sales/Marketing)
Noriday	norethisterone	Female Contraception(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Norinyl	mestranol; norethisterone	Female Contraception(M)	M	Active	Gonadotropin Releasing Hormone Receptor	Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer UK

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					(GNRHR) Antagonist	Ltd (Sales/Marketing)
Normiflo	ardeparin sodium	Deep Vein Thrombosis(M)	M	Discontinued	Not Available	Pharmacia and Upjohn LLC (Primary Owner);Pfizer Inc (Primary Owner)
Norpace	disopyramide phosphate	Ventricular Arrhythmia(M)	M	Active		Pfizer Inc (Primary Owner)
Norvasc	amlodipine besylate	Coronary Artery Diseases(M); Stable Angina(M); Variant angina(M); Hypertension(M)	M	Active	Calcium Channel Blocker	Pfizer ApS (Sales/Marketing);Pfizer Oy (Sales/Marketing);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Pharma GmbH (Sales/Marketing);Pfizer Europe MA EEIG (Sales/Marketing);Pfizer Hellas AE (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing);Pfizer Italia Srl (Sales/Marketing);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer BV (Sales/Marketing);Pfizer Holding France SCA (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer A S (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Noxantor	pantoprazole	Gastroenterology(M)	M	Active	Proton Pump Inhibitor (PPI)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Noxantor D	domperidone; pantoprazole	Gastroenterology(M)	M	Active	Dopamine Receptor Antagonist; Proton Pump Inhibitor (PPI)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
NOXB11	--	Obesity(Preliminary)	Preclinical	No Development Reported	Ghrelin (GHRL) Inhibitor	Pfizer Inc (Co-developer,Primary Owner);NOXXON Pharma AG (Originator)
Nuthrax	--	Bacterial Infections(Phase III)	Phase III	Active	Toll-Like Receptor 9 (TLR9) Agonist	Pfizer Inc (Primary Owner);Emergent Biosolutions Inc (Originator)
Ogen	estropipate	Menopausal Disorders(M); Atrophic Vaginitis(M); Estrogen Hormone Deficiency(M); Osteoporosis(M)	M	Active	Estrogen Receptor 1 (ESR1) Agonist; Estrogen Receptor 2 (ESR2) Agonist	Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)
Olmify	olmesartan	Cardiology(M)	M	Active	Angiotensin II	Pfizer Ltd

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					AT1 Receptor Antagonist	India (Sales/Marketing);Pfizer Inc (Primary Owner)
Olmify H	hydrochlorothiazide; olmesartan	Cardiology(M)	M	Active	Angiotensin II AT1 Receptor Antagonist; Sodium-Chloride Cotransporter (NCC) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
ONC392	--	Oncology(Preliminary)	Preclinical	Active	Cytotoxic T Lymphocyte Associated Protein 4 (CTLA4) Inhibitor	Pfizer Inc (Primary Owner)
Oncology and Diabetes program FIVE PRIME	--	Diabetes Mellitus(Research); Oncology(Research)	Research	Completed	Not Available	Pfizer Inc (Primary Owner);Five Prime Therapeutics Inc (Originator)
Oncology program PFIZER	--	Oncology(Research)	Research	No Development Reported	Not Available	Pfizer Inc (Co-developer,Originator)
Oncology program PHILOGEN	--	Oncology(Research)	Research	Active	Not Available	Pfizer Inc (Primary Owner);Philogen SpA (Originator)
Opiodur	Fentanyl	Non Nociceptive Pain(M)	M	Active	Mu-Opioid Receptor Agonist	Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Ovral G	ethinylestradiol; norgestrel	Pregnancy Related Complications(M)	M	Active	Estrogen Receptor (ESR) Agonist; Progesterone Receptor (PR) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Oxileptin	oxcarbazepine	Neurology(M)	M	Active	Sodium Channel Blocker	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Pacitane	benzhexol; trihexyphenidyl	Neurology(M)	M	Active	Muscarinic M1 Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Pactiv	acetaminophen	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Panta D	pantoprazole	Gastroenterology(M)	M	Active	Proton Pump Inhibitor (PPI)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Pantoprazole PFIZER	pantoprazole	Gastroenterology(M)	M	Active	Proton Pump Inhibitor (PPI)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Paraextra	acetaminophen; caffeine	Pain(M); Fever(M)	M	Active	Cyclooxygenase-2 (COX-2) Inhibitor; Phosphodiesterase (PDE) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner)
PB272	neratinib	Solid Tumors Unspecified(Phase II); Metastatic Breast Cancer(Phase II); HER2-Positive Breast Cancer(PA); HER2-Negative Metastatic Breast Cancer(Phase II); Non-Small Cell Lung Cancer(Phase	PA	Active	Epidermal Growth Factor Receptor Family (ERBB) Tyrosine Kinase Inhibitor; ErbB2 Receptor Tyrosine Kinase Inhibitor; ErbB4 Receptor Tyrosine Kinase Inhibitor	Pfizer Inc (Primary Owner);Puma Biotechnology Inc (Primary Owner);Wyeth (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		II)				
PDCs 1 Program CYTOMX	--	Oncology(Research)	Research	Active		Pfizer Inc (Developer);Cytomx Therapeutics Inc (Co-developer,Technology Owner)
PDE10 inhibitor BIOCREA	--	Huntingtons Disease(Preclinical); Schizophrenia(Preclinical)	Preclinical	Active	Phosphodiesterase (PDE) Inhibitor	BioCrea (Primary Owner);Pfizer Inc (Co-developer,Developer);GlaxoSmithKline Plc (Co-developer,Developer);Boehringer Ingelheim (Developer, Primary Owner);Biotie Therapies Corp (Originator)
Pediotic	hydrocortisone; neomycin sulfate; polymyxin b sulfate	Ear Infections(M)	M	Active		Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Distributor,Primary Owner)
Penicillin G procaine PFIZER	Penicillin G procaine	Pulmonary Anthrax(M); Diphtheria(M); Pharyngitis(M); Syphilis(M); Pneumococcal Infections(M); Staphylococcal Infections(M); Streptococcal Infections(M); Fever(M); Gingivitis(M)	M	Discontinued	Bacterial Cell Wall Synthesis Inhibitor	Pfizer Inc (Originator,Primary Owner)
PF0029980 4	dacomitinib	Solid Tumors Unspecified(P)	Phase III	Active	Epidermal Growth Factor	SFJ Pharmaceuticals Inc (Co-

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		hase I); Head and Neck Cancer(Phase II); Non-Small Cell Lung Cancer(Phase III); Glioblastoma Multiforme(Phase II)			Receptor Family (ERBB) Tyrosine Kinase Inhibitor	developer);Pfizer Inc (Originator);Pfizer Japan Inc (Primary Owner)
PF0048979 1	--	Diabetic Nephropathy(Phase II)	Phase II	Completed	Phosphodiesterase-5 (PDE-5) Inhibitor	Pfizer Inc (Originator)
PF0054765 9	--	Crohns Disease(Phase II); Ulcerative Colitis(Phase II)	Phase II	Active	Mucosal Vascular Addressin Cell Adhesion Molecule 1 (MADCAM1) Inhibitor	Pfizer Inc (Originator);Pfizer Japan Inc (Primary Owner);Shire Plc (Developer,Primary Owner)
PF0254592 0	--	Huntingtons Disease(Phase II); Schizophrenia(Phase II)	Phase II	Terminated	Phosphodiesterase-10A (PDE-10A) Inhibitor	Pfizer Inc (Originator)
PF0371545 5	--	Asthma(Phase II); Chronic Obstructive Pulmonary Disease(Phase II)	Phase II	Terminated	p38 kinase inhibitor	Pfizer Inc (Originator)
PF0413630 9	--	Metastatic Pancreatic Cancer(Phase II)	Phase II	Active	CC Chemokine Receptor 2 (CCR2) Antagonist	Pfizer Inc (Originator)
PF0417132 7	fosdagrocorat	Rheumatoid Arthritis(Phase II)	Phase II	Discontinued	Glucocorticoid Receptor (GR) Agonist	Pfizer Inc (Originator)
PF0423692 1	--	Crohns Disease(Phase	Phase II	Discontinued	Interleukin-6 (IL-6) Inhibitor	Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		e II); Rheumatoid Arthritis(Phase I); Systemic Lupus Erythematosus (Phase II)				
PF0436036 5	ponezumab	Neurological Disorders(Phase II)	Phase II	Discontinued	Beta-Amyloid Aggregation Inhibitor	Pfizer Inc (Originator)
PF0441506 0	--	Non-Insulin-Dependent Diabetes Mellitus(Preliminary); Obesity(Preliminary)	Preclinical	No Development Reported	Acyl Coenzyme A: Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor	Pfizer Inc (Primary Owner);Bayer AG (Originator);Bristol Myers Squibb Company (Co-developer);Bayer Pharma AG (Originator)
PF0444794 3	--	Sickle Cell Anemia(Phase I); Alzheimers Disease(Phase II)	Phase II	Discontinued		Pfizer Inc (Originator)
PF0444991 3	glasdegib	Myelofibrosis(Phase III); Oncology(Phase I); Hematological Malignancies(Phase I); Acute Myeloid Leukemia(Phase II); Myelodysplastic Syndrome(Phase II)	Phase III	Active	Hedgehog Signaling Pathway Inhibitor	Pfizer Inc (Originator);Pfizer Japan Inc (Primary Owner)
PF0445784 5	--	Post Traumatic Stress Disorder(Phase	Phase II	Discontinued	Fatty Acid Amide Hydrolase (FAAH)	Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		e II)			Inhibitor	
PF0451860 0	--	Solid Tumors Unspecified(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0454804 3	erythromycin	Gastroesophageal Reflux Disease(Phase I)	Phase I	Discontinued	Motilin Receptor Agonist	Pfizer Inc (Primary Owner);Kosan Biosciences Inc (Originator)
PF0463481 7	--	Diabetic Nephropathy(Phase II); Diabetic Macular Edema(Phase II)	Phase II	Terminated	CC Chemokine Receptor 2 (CCR2) Antagonist; CC Chemokine Receptor 5 (CCR5) Antagonist	Pfizer Inc (Originator)
PF0493731 9	--	Non-Insulin-Dependent Diabetes Mellitus(Phase II)	Phase II	Discontinued	Glucokinase (GK) Activator	Pfizer Inc (Originator)
PF0495061 5	bococizumab	Cardiology(Phase III); Hyperlipoproteinemia(Phase III); Hypercholesterolemia(Phase II); Heterozygous Familial Hypercholesterolemia(Phase III)	Phase III	Discontinued	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor	Pfizer Inc (Primary Owner);Rinat Neuroscience Corp (Originator);Halozyme Therapeutics Inc (Co-developer)
PF0495824 2	--	Schizophrenia(Phase I); Hearing Impairment(Phase I)	Phase I	Completed	Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid	Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					(AMPA) Receptor Agonist	
PF0496584 2	--	Psoriasis(Phase II); Systemic Lupus Erythematosus (Phase I); Atopic Dermatitis(Phase II)	Phase II	Terminated	Janus Kinase 1 (JAK1) Inhibitor	Pfizer Inc (Originator)
PF0497172 9	ertugliflozin	Non-Insulin-Dependent Diabetes Mellitus(Phase III)	Phase III	Completed	Sodium-Glucose Cotransporter Type 2 (SGLT2) Inhibitor	Merck and Co Inc (Co-developer);Pfizer Inc (Originator);Merck Sharp and Dohme Corp (Co-developer)
PF0508256 6	utomilumab	Oncology(Phase I); Solid Tumors Unspecified(Phase I); Non-Hodgkins Lymphoma(Phase I)	Phase I	Active	Cluster of Differentiation 137 (CD137) Receptor Agonist	Merck and Co Inc (Co-developer);Pfizer Inc (Originator);MorphoSys AG (Co-developer);Kyowa Hakko Kirin Co Ltd (Co-developer)
PF0508977 1	--	Erythromelalgia(Phase II); Diabetic Neuropathic Pain(Phase II)	Phase II	Discontinued	Sodium Channel Blocker	Icagen Inc (Originator);Pfizer Inc (Primary Owner)
PF0520638 8	--	Wet Age-Related Macular Degeneration(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0521237 7	--	Alzheimers Disease(Phase II)	Phase II	Discontinued	5-Hydroxytryptamine-6 (5-HT6) Receptor Antagonist	Pfizer Inc (Primary Owner);Wyeth (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
PF0521238 4	gedatolisib	Oncology(Phase I); Solid Tumors Unspecified(Phase I); Metastatic Colorectal Cancer(Phase II); Endometrial Cancer(Phase II)	Phase II	Terminated	Mammalian Target of Rapamycin (mTOR) Inhibitor; Phosphoinositide-3-Kinase (PIK3) Inhibitor	Pfizer Inc (Originator)
PF0523090 7	--	Cerebral Hemorrhage(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0525174 9	--	Alzheimers Disease(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0528001 4	trastuzumab	HER2-Positive Breast Cancer(Phase III); HER2-Positive Metastatic Breast Cancer(Phase III)	Phase III	Completed	ERBB2 Receptor Antagonist	Pfizer Inc (Primary Owner)
PF0528058 6	rituximab	Follicular Lymphoma(Phase III); Rheumatoid Arthritis(Phase II)	Phase III	Active	Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1) Inhibitor	Pfizer Inc (Primary Owner)
PF0540253 6	--	Nicotine Abuse(Phase I)	Phase I	Completed		Pfizer Inc (Originator)
PF0625261 6	--	Duchenne Muscular Dystrophy(Phase II)	Phase II	Active	Myostatin Inhibitor	Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
PF06266047	--	Schizophrenia(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06282999	--	Coronary Artery Diseases(Phase I)	Phase I	Active	Myeloperoxidase (MPO) Inhibitor	Pfizer Inc (Originator)
PF06290510	--	Staphylococcal Infections(Phase II)	Phase II	Active		Pfizer Inc (Originator)
PF06291874	--	Non-Insulin-Dependent Diabetes Mellitus(Phase II)	Phase II	Active	Glucagon Receptor Antagonist	Pfizer Inc (Originator)
PF06293620	--	Non-Insulin-Dependent Diabetes Mellitus(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06342674	--	Insulin-Dependent Diabetes Mellitus(Phase I); Multiple Sclerosis(Phase I)	Phase I	Terminated	Interleukin 7 (IL7R) Receptor Antagonist	Pfizer Inc (Primary Owner); Rinat Neuroscience Corp (Originator)
PF06372865	--	Epilepsy(Phase II); Non Nociceptive Pain(Phase II); Generalized Anxiety Disorder(Phase II)	Phase II	Discontinued	Gamma-Aminobutyric Acid Type A (GABA A) Receptor Agonist	Pfizer Inc (Originator)
PF06410293	adalimumab	Rheumatoid Arthritis(Phase III)	Phase III	Active	Tumor Necrosis Factor (TNF) Inhibitor	Pfizer Inc (Primary Owner)
PF0641256	--	Mild Cognitive	Phase I	Completed		Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
2		Impairment(Phase I); Parkinsons Disease Dementia(Phase I); Schizophrenia(Phase I)				
PF0642326 4	--	Acne(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0642509 0	--	Clostridium Difficile Associated Colitis(Phase II)	Phase II	Active		Pfizer Inc (Originator)
PF0642787 8	--	Hyperlipoproteinemia(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0643817 9	infliximab	Rheumatoid Arthritis(Phase III)	Phase III	Active	Tumor Necrosis Factor (TNF) Inhibitor	Pfizer Inc (Primary Owner);Novartis AG (Primary Owner)
PF0643953 5	bevacizumab	Non-Small Cell Lung Cancer(Phase III)	Phase III	Active	Vascular Endothelial Growth Factor (VEGF) Inhibitor	Pfizer Inc (Primary Owner)
PF0644475 2	--	Allergic Rhinitis(Phase I); Asthma(Phase I)	Phase I	Discontinued		Cytos Biotechnology AG (Technology Owner);Pfizer Inc (Originator)
PF0646392 2	Iorlatinib	Non-Small Cell Lung Cancer(Phase II)	Phase II	Active	Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase Inhibitor; c-ros oncogene 1 (ROS1)	Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Inhibitor	
PF06473871	--	Scar(Phase II)	Phase II	Active	Connective Tissue Growth Factor (CTGF) Inhibitor	Excaliard Pharmaceuticals Inc (Primary Owner);Pfizer Inc (Primary Owner);Ionis Pharmaceuticals Inc (Originator)
PF06480605	--	Crohns Disease(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06647020	--	Solid Tumors Unspecified(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06647263	--	Solid Tumors Unspecified(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06648671	--	Alzheimers Disease(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06649751	--	Parkinsons Disease(Phase II); Idiopathic Parkinsons Disease(Phase I)	Phase II	Active	Dopamine Receptor Modulator	Pfizer Inc (Originator)
PF06650808	--	Solid Tumors Unspecified(Phase I)	Phase I	Active	Notch Signaling Pathway Inhibitor	Pfizer Inc (Originator)
PF06650833	--	Systemic Lupus Erythematosus (Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF06651600	--	Crohns Disease(Phase I)	Phase I	Completed		Pfizer Inc (Originator)
PF06664178	--	Solid Tumors Unspecified(Phase I)	Phase I	Discontinued		Pfizer Inc (Originator,Primary)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Phase I); Lung Cancer(Phase I)				Owner)
PF0666957 1	--	Mild Cognitive Impairment(Phase I); Idiopathic Parkinsons Disease(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0667100 8	--	Oncology(Phase I)	Phase I	Active	Cadherin 3, Type 1, P-Cadherin (CDH3) Inhibitor	Pfizer Inc (Primary Owner); Macrogenics Inc (Technology Owner)
PF0670084 1	--	Plaque Psoriasis(Phase I); Systemic Lupus Erythematosus (Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0674108 6	--	Hemophilia(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0674777 5	--	Non-Small Cell Lung Cancer(Phase II)	Phase II	Active	Epidermal Growth Factor Receptor (EGFR) Antagonist	Pfizer Inc (Originator)
PF0675197 9	--	Alzheimers Disease(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0675351 2	--	Prostate Cancer(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0680159 1	--	Sarcomas(Phase I); Metastatic Melanoma(Phase I); Ovarian Cancer(Phase	Phase I	Active	Programmed Cell Death 1 (PD-1) Receptor Antagonist	Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		I); Head and Neck Cancer(Phase I); Hodgkins Lymphoma(Phase I)				
PF0681534 5	--	Hyperlipoproteinemia(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0681702 4	--	Atopic Dermatitis(Phase I); Sinusitis(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0682385 9	--	Systemic Lupus Erythematosus (Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0683692 2	--	Dwarfism(Phase III)	Phase III	Active	Growth Hormone (GH) Receptor Agonist	Pfizer Inc (Co-developer)
PF0683843 5	coagulation factor IX	Hemophilia(Phase II)	Phase II	Active		Pfizer Inc (Originator)
PF0688354 1	--	Oncology(Phase I)	Phase I	Active		Pfizer Inc (Originator)
PF0693016 4	crisaborole	Psoriasis(Phase II); Atopic Dermatitis(PA)	PA	Active	Phosphodiesterase-4B (PDE-4B) Inhibitor	Anacor Pharmaceuticals Inc (Originator); Pfizer Inc (Primary Owner)
PF4929113	--	Hematological Malignancies(Phase I); Oncology(Phase I); Solid Tumors Unspecified(Phase I)	Phase I	No Development Reported	Heat-Shock Protein 90 (Hsp90) Inhibitor	Pfizer Inc (Primary Owner)
PF582	ranibizumab	Wet Age-Related	Phase II	Completed	Vascular Endothelial	Pfizer Inc (Co-developer); Hospira

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Macular Degeneration(Phase II)			Growth Factor A (VEGFA) Inhibitor	Inc (Co-developer);Pfenex Inc (Primary Owner)
PF655	--	Diabetic Macular Edema(Phase II); Wet Age-Related Macular Degeneration(Phase II)	Phase II	Completed	Mammalian Target of Rapamycin (mTOR) Inhibitor; Vascular Endothelial Growth Factor (VEGF) Inhibitor	Quark Pharmaceuticals Inc (Originator);Pfizer Inc (Primary Owner);Silence Therapeutics plc (Co-developer);Biocon Ltd (Developer)
Pfizerpen	penicillin G potassium	Bacterial Infections(M); Diphtheria(M); Syphilis(M); Gas Gangrene(M); Streptococcal Infections(M); Bacterial Endocarditis(M); Bacterial Meningitis(M); Meningococcal Meningitis(M); Botulism(M); Tetanus(M); Fever(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor	Roerig SA (Distributor);Pfizer Inc (Primary Owner)
Phospholine Iodide	echothiopate iodide	Ophthalmology(M); Glaucoma(M)	M	Active	Acetylcholinesterase (AChE) Inhibitor	Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Primary Owner);Cangene bioPharma Inc (Manufacturer)
Phylomer peptide program PHYLOGIC	--	Un-Disclosed(Research)	Research	No Development Reported	Protein Synthesis Inhibitor	Opsona Therapeutics Ltd (Co-developer);Pfizer Inc (Originator);Gene

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
A						ntech Inc (Originator); Janssen Biotech Inc (Co-developer); Phylogica Ltd (Originator); PharmaAust Ltd (Co-developer)
Pipracil	piperacillin sodium	Intra-Abdominal Abscesses(M); Gynecology(M); Gonococcal Urethritis(M); Lower Respiratory Tract Infections(M); Skin Bacterial Infections(M); Urinary Tract Bacterial Infections(M); Septicaemia(M); Osteomyelitis(M); Joint Disorders(M)	M	Discontinued	Bacterial Cell Wall Synthesis Inhibitor	Pfizer Inc (Primary Owner); Wyeth Pharmaceuticals Inc (Originator, Primary Owner)
Piroxicam and rabeprazole PFIZER	piroxicam; rabeprazole	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing); Pfizer Inc (Primary Owner)
Pitressin	vasopressin	Abdominal Diseases(M)	M	Active		Parke Davis and Company LLC (Primary Owner); Pfizer Inc (Primary Owner); Pfizer Corp Hong Kong Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
PoloCard	aspirin	Myocardial Infarction(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Inc (Primary Owner)
Ponstan	mefenamic acid	Menorrhagia(M); Dysmenorrhea (M); Pain(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Ponstel	mefenamic acid	Dysmenorrhea (M); Pain(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Parke Davis Ltd (Primary Owner);Warner Lambert Company LLC (Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Sciele Pharma (Sales/Marketing);Shionogi Inc (Sales/Marketing);Shionogi and Co Ltd (Sales/Marketing);Chemidex Pharma Ltd (Sales/Marketing)
Prelay	troglitazone	Non-Insulin-Dependent Diabetes Mellitus(M)	M	Withdrawn	Peroxisome Proliferator-Activator Receptor (PPAR) Modulator	Pfizer Inc (Distributor,Manufacturer,Sales/Marketing);Daiichi Sankyo Co Ltd (Originator,Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Premarin	conjugated estrogens	Menopausal Disorders(M); Postmenopausal Osteoporosis(M); Abnormal Uterine Bleeding(M); Postmenopausal Atrophic Vaginitis(M); Vulvitis(M); Estrogen Hormone Deficiency(M); Dyspareunia(M); Prostate Cancer(M); Metastatic Breast Cancer(M)	M	Active	Estrogen Receptor (ESR) Agonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Distributor,Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Distributor,Primary Owner);Pfizer Canada Inc (Sales/Marketing); Takeda Pharmaceutical Company Ltd (Distributor);Pfizer UK Ltd (Sales/Marketing)
Premphase	conjugated estrogens; medroxyprogesterone acetate	Menopausal Disorders(M); Postmenopausal Osteoporosis(M); Atrophic Vaginitis(M); Vulvitis(M)	M	Active	Estrogen Receptor (ESR) Agonist; Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist	Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Distributor,Primary Owner)
Preparation H anti itch cream	hydrocortisone	Skin Rash(M)	M	Active	Glucocorticoid Receptor (GR) Agonist	Pfizer Inc (Primary Owner)
Preparation	phenylephrine	Hemorrhoids(M	Active	Alpha-1	Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
H cream	ne hydrochloride; pramoxine hydrochloride	M)			Adrenergic Receptor (ADRA1) Agonist; Sodium Channel Blocker	Owner)
Preparation H ointment	phenylephrine hydrochloride	Hemorrhoids(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Prepidil	dinoprostone	Cervical Ripening(M)	M	Active		Pfizer Inc (Originator);Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Distributor, Primary Owner)
Prevnar 13	pneumococcal 13-valent Conjugate	Streptococcus Pneumonia(M) ; Otitis Media(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer China Research and Development Co Ltd (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Manufacturer,Pri

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						mary Owner);Pfizer Canada Inc (Sales/Marketing); Takeda Pharmaceutical Company Ltd (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Prevnar 7	--	Pneumococcal Infections(M); Otitis Media(M)	M	Active		Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Primary Owner)
Primatene	ephedrine hydrochloride; guaifenesin	Cough(M); Asthma(M)	M	Active	Alpha Adrenergic Receptor (ADRA) Agonist	Pfizer Inc (Primary Owner)
Pristiq	desvenlafaxine succinate	Major Depressive Disorder(M)	M	Active	5-Hydroxytryptamine (5-HT) Reuptake Inhibitor; Norepinephrine Reuptake Inhibitor	Wyeth Canada ULC (Primary Owner);Pfizer Australia Pty Ltd (Primary Owner);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Primary Owner);Wyeth Europa Ltd (Primary Owner)
Procardia	nifedipine	Stable Angina(M); Variant angina(M)	M	Active	Calcium Channel Blocker	Pfizer Inc (Originator)
Prostin E2	dinoproston	Abortion(M);	M	Active		Pfizer Healthcare

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	e	Miscarriage(M); Benign Hydatidiform Mole(M)				Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Prostin F2 alpha	dinoprost	Abortion(M)	M	Active		Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner)
Prostin VR	alprostadil	Patent Ductus Arteriosus(M)	M	Active		Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing)
Prostin VR Pediatric	alprostadil	Patent Ductus Arteriosus(M)	M	Active	Prostaglandin Receptor Agonist	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)
Protonix	pantoprazole sodium	Gastroesophageal Reflux Disease(M); Erosive	M	Active	Proton Pump Inhibitor (PPI)	Takeda Pharmaceuticals Korea Co Ltd (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Esophagitis(M); Zollinger Ellison Syndrome(M)				Owner);Wyeth Pharmaceuticals Company (Sales/Marketing);Pfizer Inc (Sales/Marketing);Prasco Laboratories (Primary Owner);Wyeth Ayerst Laboratories (Primary Owner)
Provera	medroxyprogesterone acetate	Abnormal Uterine Bleeding(M); Secondary Amenorrhea(M); Endometrial Hyperplasia(M); Metastatic Renal Cell Carcinoma(M); Metastatic Breast Cancer(M); Metastatic Endometrial Cancer(M)	M	Active	Progesterone Receptor (PR) Agonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Sales/Marketing);Pharmacia and Upjohn Company Inc (Distributor, Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Quillivant XR	methylphenidate hydrochloride	Autism(PM); Attention Deficit Hyperactivity Disorder(PM)	PM	Active	Dopamine Reuptake Inhibitor	Pfizer Inc (Primary Owner);NextWave Pharmaceuticals Inc (Originator);Tris Pharma Inc (Manufacturer, Technology Owner)
R343	--	Allergic Asthma(Phase II); Chronic Obstructive Pulmonary Disease(Phase II)	Phase II	No Development Reported	Immunoglobulin E (IgE) Inhibitor; Spleen Tyrosine Kinase (Syk) Inhibitor	Pfizer Inc (Co-developer);Rigel Pharmaceuticals Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
RA Morph	morphine hydrochloride	Pain(M)	M	Active	Opioid Receptor Antagonist	Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Inc (Primary Owner)
Rapamune	sirolimus	Stem Cell Transplantation(Phase II); Kidney Transplant Rejection(M); Lymphangioleiomyomatosis(M)	M	Active	Mammalian Target of Rapamycin (mTOR) Inhibitor	Wyeth Ayerst Inc (Primary Owner);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Service Company BVBA (Sales/Marketing);Pfizer New Zealand Ltd (Distributor);Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Manufacturing Deutschland GmbH (Manufacturer) ;Pfizer Canada Inc (Distributor);PF Prism CV (Primary Owner);Nobelpharma Co Ltd (Primary Owner,Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Rebif	interferon beta-1a	Multiple Sclerosis(PM)	PM	Completed		Columbia Laboratories UK Ltd (Primary Owner);Pfizer Inc (Sales/Marketing); Merck KGaA (Primary Owner);EMD Serono Inc (Primary Owner);Merck Serono Europe

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Ltd (Sales/Marketing); Merck India Ltd (Sales/Marketing)
Recombinant Human Insulin	insulin (human)	Insulin-Dependent Diabetes Mellitus(Phase III); Non-Insulin-Dependent Diabetes Mellitus(Phase III); Gestational Diabetes(Phase III)	Phase III	Active	Not Available	Pfizer Inc (Primary Owner);Biocon Ltd (Primary Owner)
ReFacto	moroctocog alfa	Hemophilia A(M)	M	Active		Sobi Inc (Sales/Marketing); Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Primary Owner);Swedish Orphan Biovitrum AB (Sales/Marketing)
Refolinon	calcium folinate	Megaloblastic Anemia(M); Methotrexate Poisoning(M)	M	Active		Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner,Sales/Marketing);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Relpax	eletriptan hydrobromide	Migraine(M)	M	Active	5-Hydroxytryptamine-1B (5-HT1B) Receptor Agonist; 5-Hydroxytryptamine-1D (5-	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing); Roerig SA (Distributor);Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					HT1D) Receptor Agonist	Pfizer Japan Inc (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Remoxy	oxycodone	Non Nociceptive Pain(PA)	PA	Active	Mu-Opioid Receptor Agonist	Pfizer Inc (Co-developer,Primary Owner);Durect Corp (Originator);Pain Therapeutics Inc (Primary Owner)
Remsima	infliximab	Crohns Disease(M); Ulcerative Colitis(M); Psoriasis(M); Rheumatoid Arthritis(M); Ankylosing Spondylitis(M); Psoriatic Arthritis(M)	M	Active	Tumor Necrosis Factor (TNF) Inhibitor	Alvogen (Sales/Marketing);Mundi Pharma international ltd (Primary Owner,Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Sales/Marketing); Orion Corp (Sales/Marketing);Hospira Inc (Sales/Marketing); Celltrion Inc (Primary Owner,Sales/Marketing);Nippon Kayaku Co Ltd (Sales/Marketing); Egis Pharmaceuticals (Sales/Marketing);Hospira UK Ltd (Sales/Marketing)
Retacrit	epoetin alfa	Anemia(M)	M	Active	Erythropoietin (EPO) Receptor Agonist	Pfizer GEP SL (Sales/Marketing); Pfizer Pharma PFE GmbH (Sales/Marketing);Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Owner);Hospira Inc (Primary Owner,Sales/Marketing);Pfizer SA (Sales/Marketing);Hospira Portugal LDA (Sales/Marketing);Hospira France SAS (Sales/Marketing);Hospira Italia Srl (Sales/Marketing);Hospira Nordic AB (Sales/Marketing);Hospira UK Ltd (Primary Owner,Sales/Marketing)
Revatio	sildenafil citrate	Pulmonary Arterial Hypertension(M)	M	Active	Phosphodiesterase-5 (PDE-5) Inhibitor	Pfizer ApS (Sales/Marketing);Pfizer Croatia doo (Sales/Marketing);Pfizer Oy (Sales/Marketing);Pfizer GEP SL (Sales/Marketing);Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Pharma GmbH (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer PFE France (Sales/Marketing);Pfizer Inc (Originator);Pfizer Japan Inc (Primary Owner,Sales/Marketing);Pfizer Italia

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Srl (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Polska Spzoo (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer A S (Sales/Marketing);Pfizer Romania SRL (Sales/Marketing);Pfizer Spol SRO (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
RG3039	--	Spinal Muscular Atrophy(Phase I)	Phase I	No Development Reported		Pfizer Inc (Primary Owner);Repligen Corp (Originator)
RGI3100	--	Insulin-Dependent Diabetes Mellitus(Preclinical)	Preclinical	Active		Pfizer Inc (Co-developer);Regimmune Corp (Originator)
Rintega	rindopepimut	Glioblastoma Multiforme(Phase III)	Phase III	Discontinued	Epidermal Growth Factor Receptor vIII (EGFRvIII) Antagonist	Pfizer Inc (Co-developer);Celldex Therapeutics INC (Developer,Primary Owner);Johns Hopkins University (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Robitussin	dextromethorphan; hydrobromide; guaifenesin	Common Cold(M); Cough(M)	M	Active		Pfizer Inc (Originator, Primary Owner)
Robitussin	dextromethorphan	Cough(M)	M	Active	N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Sales/Marketing); Tris Pharma Inc (Primary Owner)
Robitussin cold	dextromethorphan; hydrobromide; guaifenesin; phenylephrine hydrochloride	Common Cold(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Agonist; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Primary Owner)
Robitussin congestion	guaifenesin	Productive Cough(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Inc (Primary Owner)
Robitussin cough	chlorpheniramine maleate; dextromethorphan hydrobromide	Allergic Respiratory Diseases(M)	M	Active	Histamine H1 Receptor Antagonist; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Primary Owner)
Robitussin cough cold and flu	acetaminophen; dextromethorphan hydrobromide; guaifenesin; phenylephrine	Allergic Respiratory Diseases(M); Common Cold(M); Cough(M); Fever(M)	M	Active		Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	hydrochloride					
Robitussin cough relief	dextromethorphan hydrobromide; dextromethorphan polistirex	Cough(M)	M	Active	N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Primary Owner)
Robitussin maximum strength night time cough	dextromethorphan hydrobromide; doxylamine succinate	Allergic Respiratory Diseases(M)	M	Active	Histamine H1 Receptor Antagonist; N-Methyl-D-Aspartate (NMDA) Receptor Antagonist	Pfizer Inc (Primary Owner)
Robitussin Medi soothers	dextromethorphan hydrobromide; menthol	Cough(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner)
Robitussin cold and flu	acetaminophen; dextromethorphan hydrobromide; guaifenesin; phenylephrine hydrochloride	Infectious Diseases(M); Common Cold(M); Cough(M)	M	Active		Pfizer Inc (Primary Owner)
Roxify	roxithromycin	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
S1153	capravirine	Human Immunodeficiency Virus Infection(Phase II)	Phase II	Discontinued	Non-Nucleoside Reverse Transcriptase Inhibitor	Warner Lambert Company LLC (Primary Owner);Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					(NNRTI)	Owner);Agouron Pharmaceuticals Inc (Primary Owner);Shionogi and Co Ltd (Originator)
Saphris	asenapine	Bipolar I(M); Schizophrenia(M)	M	Active	5-Hydroxytryptamine-2A (5-HT2A) Receptor Antagonist; Dopamine D2 Receptor Antagonist	Forest Laboratories Holdings Ltd (Sales/Marketing); Allergan Inc (Sales/Marketing); Merck and Co Inc (Primary Owner);H Lundbeck A S (Sales/Marketing);Pfizer Inc (Unknown);Organon BioSciences Ltd (Originator)
SAS1B Targeted Program NEOANTIGENICS	--	Oncology(Research); Cervical Cancer(Clinical Phase Unknown)	Research	No Development Reported		Pfizer Inc (Co-developer);Neoantigenics Inc (Originator)
Satyor	gosogliptin	Non-Insulin-Dependent Diabetes Mellitus(PA)	PA	Active	Dipeptidyl Peptidase IV (DPP-IV) Inhibitor	Pfizer Inc (Originator);SatRx LLC (Developer,Sales/Marketing)
SBI087	--	Systemic Lupus Erythematosus (Phase II); Rheumatoid Arthritis(Phase II)	Phase II	Discontinued	Not Available	Pfizer Inc (Co-developer);Wyeth Pharmaceuticals Inc (Co-developer);Emergent Biosolutions Inc (Primary Owner);Trubion PharmaceuticalsLtd Inc (Originator)
Schizophrenia Program	--	Psychiatric Disorders(Clinical)	Clinical Phase	No Development		Pfizer Inc (Co-developer,Primary)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
PFIZER		Cancer Phase Unknown); Schizophrenia(Clinical Phase Unknown)	Unknown	Not Reported		Wyeth Pharmaceuticals Inc (Co-developer);Biotie Therapies Corp (Primary Owner,Unknown)
Selsun	selenium sulfide	Dermatology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Seltouch	felbinac	Inflammatory Disorders(M); Pain(M)	M	Active	Not Available	Teikoku Seiyaku Co Ltd (Developer-Originator);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner);Aska Pharmaceutical Co Ltd (Sales/Marketing);Takeda Pharmaceutical Company Ltd (Sales/Marketing);Wyeth (Primary Owner)
Selzentry	maraviroc	Human Immunodeficiency Virus-1 Infection(M)	M	Active	CC Chemokine Receptor 5 (CCR5) Antagonist	GlaxoSmithKline Ireland Ltd (Sales/Marketing);ViiV Healthcare SAS (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing);ViiV Healthcare Company (Sales/Marketing);Pfizer Manufacturing Deutschland GmbH (Manufacturer);GlaxoSmithKline Plc (Sales/Marketing);

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						GlaxoSmithKline sro (Sales/Marketing); ViiV Healthcare UK Ltd (Sales/Marketing); Glaxosmithkline Pharma AS (Sales/Marketing); Glaxosmithkline DOO (Sales/Marketing)
Septra	sulfamethoxazole; trimethoprim	Pneumocystis Pneumonia(M) ; Urinary Tract Infections(M); Otitis Media(M); Shigellosis(M); Travelers Diarrhea(M); Chronic Bronchitis(M)	M	Active	Dihydrofolate Reductase (DHFR) Inhibitor	Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Distributor);King Pharmaceuticals LLC (Manufacturer,Primary Owner)
Sermion	nicergoline	Cerebral Infarction(M)	M	Active	Alpha-1 Adrenergic Receptor (ADRA1) Antagonist	Pfizer Inc (Originator);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Mitsubishi Tanabe Pharma Corp (Co-developer)
SHP625	--	Cholestasis(Phase II); Primary Biliary Cirrhosis(Phase II); Genetic Gastrointestinal Disorders(Phase II)	Phase II	Completed	Bile Acid Reabsorption Inhibitor	Pfizer Inc (Originator);Lumenia Pharmaceuticals LLC (Co-developer,Primary Owner);Shire Plc (Co-developer,Primary Owner)
Silvadene	silver sulfadiazine	Wound(M)	M	Active	Deoxyribonucleic acid (DNA) synthesis inhibitor	Pfizer Inc (Primary Owner);King Pharmaceuticals LLC (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Sinequan	doxepin hydrochloride	Anxiety(M); Bipolar Disorders(M); Depression(M)	M	Active	5-Hydroxytryptamine (5-HT) Reuptake Inhibitor; Norepinephrine Reuptake Inhibitor	Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Originator,Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Skelaxin	metaxalone	Musculoskeletal(M)	M	Active		Pfizer Inc (Primary Owner);King Pharmaceuticals LLC (Primary Owner);Mutual Pharmaceutical Co Inc (Primary Owner)
Solu cortef	hydrocortisone sodium succinate	Gastroenterology(M); Other Hematological Diseases(M); Dermatology(M); Kidney Disorders(M); Endocrine Disorders(M); Allergy(M); Trichinosis(M); Leukemia(M); Lymphoma(M); Joint Disorders(M); Neurological Disorders(M); Pulmonology(M); Ophthalmology(M)	M	Active	Cytosolic Phospholipase A2 (cPLA2) Inhibitor	Pharmacia and Upjohn Company LLC (Originator,Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing)
Solu Medrol	methylprednisolone sodium succinate	Gastroenterology(M); Other Hematological Diseases(M); Dermatology(M);	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer New

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Proteinuria(M); Endocrine Disorders(M); Allergy(M); Trichinosis(M); Neoplasia(M); Joint Disorders(M); Multiple Sclerosis(M); Pulmonology(M); Ophthalmology(M)				Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Somavert	pegvisomant	Acromegaly(M)	M	Active	Growth Hormone (GH) Receptor Antagonist	Pfizer Healthcare Ireland (Sales/Marketing);Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Sonata	zaleplon	Insomnia(M)	M	Active	Gamma-Aminobutyric Acid (GABA) Receptor Agonist	Wyeth Ayerst Inc (Primary Owner);Wyeth Canada ULC (Sales/Marketing);Pfizer Inc (Primary Owner);Meda AB (Sales/Marketing); Wyeth Ayerst Laboratories (Primary Owner)
Spiriva	tiotropium bromide	Chronic Obstructive	M	Active	Muscarinic M3 Receptor	Boehringer Ingelheim GmbH (Originator);Pfi

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Pulmonary Disease(M)			Antagonist	zer Inc (Sales/Marketing); Boehringer Ingelheim Canada Ltd (Sales/Marketing); Boehringer Ingelheim Pharmaceuticals Inc (Sales/Marketing); Boehringer Ingelheim (Sales/Marketing);Boehringer Ingelheim Pty Ltd (Sales/Marketing)
Spiriva Respimat	tiotropium bromide	Asthma(M); Chronic Obstructive Pulmonary Disease(M)	M	Active	Muscarinic M3 Receptor Antagonist	Boehringer Ingelheim GmbH (Originator,Sales/Marketing);Pfizer Inc (Co-developer);Boehringer Ingelheim Canada Ltd (Sales/Marketing); Boehringer Ingelheim Pharmaceuticals Inc (Co-developer,Sales/Marketing);Boehringer Ingelheim Pty Ltd (Sales/Marketing); Boehringer Ingelheim Ireland Ltd (Sales/Marketing)
SPK9001	--	Hemophilia B(Phase II)	Phase II	Active		Pfizer Inc (Sales/Marketing); Spark Therapeutics Inc (Primary Owner)
Stearoyl CoA desaturase 1 inhibitor program PFIZER	--	Dermatology(Phase II)	Phase II	Active		Pfizer Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Stem cell therapies PFIZER INC	--	Ophthalmology(Research); Age-Related Macular Degeneration(Research)	Research	Active		Pfizer Inc (Developer)
Sulperazon	cefoperazone sodium; sulbactam sodium	Cholecystitis(M); Peritonitis(M); Pelvic Inflammatory Disease(M); Endometritis(M); Gonorrhea(M); Skin Bacterial Infections(M); Urinary Tract Infections(M); Septicaemia(M); Bone Disorders(M); Bacterial Meningitis(M); Respiratory Tract Infections(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing)
Sutent	sunitinib malate	Pancreatic Endocrine Tumors(M); Metastatic Colorectal Cancer(Phase III); Gastrointestinal Stromal Tumor(M); Hepatocellular Carcinoma(Phase III); Prostate Cancer(Phase	M	Active	C-Kit Receptor Tyrosine Kinase (CD117) Inhibitor; FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitor; Platelet-Derived Growth Factor Receptor (PDGFR) Tyrosine	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Manufacturer,Sales/Marketing);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing);

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		III); Renal Cell Carcinoma(M); Breast Cancer(Phase III); Non-Small Cell Lung Cancer(Phase III)			Kinase Inhibitor; Platelet-Derived Growth Factor Receptor-Beta (PDGFRB) Tyrosine Kinase Inhibitor; Ret Receptor Tyrosine Kinase Inhibitor; Vascular Endothelial Growth Factor (VEGF) Inhibitor; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor; Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Tyrosine Kinase Inhibitor	Pharmacia Corp (Originator); Pfizer UK Ltd (Sales/Marketing)
Sutezolid	--	Tuberculosis(Phase II)	Phase II	Completed	Bacterial Protein Synthesis Inhibitor	Pfizer Inc (Primary Owner); Sequella Inc (Developer, Primary Owner)
Synarel	nafarelin acetate	Endometriosis(M); Precocious Puberty(M)	M	Active	Gonadotrophin Releasing Hormone	G D Searle LLC (Distributor, Primary Owner); Pfizer

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					(GnRH) Agonist	Healthcare Ireland (Sales/Marketing);Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Synercid	dalfopristin ; quinupristin	Skin Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Aventis Inc (Primary Owner);Pfizer Inc (Primary Owner);King Pharmaceuticals LLC (Primary Owner)
T Cell Engaging Bispecifics Program CYTOMX	--	Colorectal Cancer(Preclinical)	Preclinical	Completed		Pfizer Inc (Co-developer);Cytomx Therapeutics Inc (Primary Owner)
Tadalafil	tadalafil	Erectile Dysfunction(M)	M	Active	Phosphodiesterase-5 (PDE-5) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Tanezumab PFIZER	tanezumab	Low Back Pain(Phase III); Osteoarthritis(Phase III); Cancer Pain(Phase III)	Phase III	Active	Nerve Growth Factor (NGF) Inhibitor	Pfizer Inc (Primary Owner);Rinat Neuroscience Corp (Primary Owner);Pfizer Japan Inc (Primary Owner);Genentech Inc (Originator);Eli Lilly and Co (Co-developer)
Tapazole	methimazole	Hyperthyroidism(M); Graves	M	Active	Thyroid Hormone	Pfizer Inc (Primary Owner);King

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Disease(M)			Receptor (TR) Antagonist	Pharmaceuticals LLC (Primary Owner)
Targit	telmisartan	Cardiology(M)	M	Active	Angiotensin II AT1 Receptor Antagonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Tedral	chloramphenicol	Respiratory Tract Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Teflaro	ceftaroline fosamil	Community-Acquired Pneumonia(M); Skin Infections(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor	Forest Laboratories Inc (Primary Owner);Allergan Inc (Primary Owner);Cerexa Inc (Primary Owner);AstraZeneca Plc (Sales/Marketing); Pfizer Inc (Co-developer,Sales/Marketing);Takeda Pharmaceutical Company Ltd (Originator,Sales/Marketing);Forest Laboratories Ltd (Primary Owner);AstraZeneca AG (Co-developer)
Teluron	terguride	Hyperprolactinemia(M); Pulmonary Arterial Hypertension(Phase II)	M	Active	5-Hydroxytryptamine-2A (5-HT2A) Receptor Antagonist; 5-Hydroxytryptamine-2B (5-HT2B) Receptor Antagonist; Dopamine	Pfizer Inc (Co-developer);Bayer Yakuhin Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Receptor Agonist	
Terbatuline	terbutaline	Pulmonology(M)	M	Active	Beta-2 Adrenergic Receptor (ADRB2) Agonist	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Terramycin	oxytetracycline hydrochloride; vitamin B complex	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Johnson and Johnson KK (Primary Owner);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Takeda Pharmaceutical Company Ltd (Sales/Marketing)
Tessalon	benzonatate	Cough(M)	M	Active		Pfizer Inc (Primary Owner)
TEV48125	--	Migraine(Phase III)	Phase III	Active	Calcitonin Gene Related Peptide (CGRP) Receptor Antagonist	Teva Pharmaceutical Industries Limited (Developer, Primary Owner);Pfizer Inc (Developer, Primary Owner);Rinat Neuroscience Corp (Originator)
TG4001	--	Head and Neck Squamous Cell Carcinoma(Phase II); Cervical Intraepithelial Neoplasia(Phase II)	Phase II	Completed	Human Papillomavirus (HPV) E1 Protein Inhibitor	Pfizer Inc (Co-developer);Merck KGaA (Co-developer);F Hoffmann La Roche Ltd (Primary Owner);Transgene SA (Originator)
Thalitone	chlorthalidone	Hypertension(M)	M	Active	Sodium-	Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
PFIZER	e	M); Edema(M)			Chloride Cotransporter (NCC) Inhibitor	Owner);Monarch Pharmaceuticals Inc (Distributor,Primary Owner);King Pharmaceuticals LLC (Primary Owner)
Thelin	sitaxsentan sodium	Pulmonary Arterial Hypertension(M)	M	Withdrawn	Endothelin ETA Receptor Antagonist	Encysive Pharmaceuticals Inc (Primary Owner);Pfizer Inc (Primary Owner)
Thermostem Program	--	Hyperlipoproteinemia(Preclinical); Non-Insulin-Dependent Diabetes Mellitus(Preclinical); Obesity(Preclinical); Pulmonary Hypertension(Preclinical)	Preclinical	Active	Not Available	Pfizer Inc (Co-developer);Rohto Pharmaceutical Co Ltd (Co-developer);Biorestorative therapies Inc (Originator)
Tigan	trimethobenzamide hydrochloride	Nausea and Vomiting(M); Postoperative Nausea and Vomiting(M)	M	Active		Pfizer Inc (Primary Owner);King Pharmaceuticals LLC (Distributor,Manufacturer,Primary Owner)
Tikosyn	dofetilide	Atrial Fibrillation(M); Atrial Flutter(M)	M	Active		Pfizer Inc (Primary Owner)
Tilade	nedocromil sodium	Asthma(M)	M	Active	Leukotriene C4 (LTC4) Receptor Antagonist; Prostaglandin D2 (PGD2) Receptor	Pfizer Inc (Primary Owner);Aventis Pharma Ltd (Manufacturer,Sales/Marketing);Sanofi Aventis Australia Pty Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Antagonist	
Tivicay	dolutegravir sodium	Human Immunodeficiency Virus-1 Infection(M)	M	Active	HIV-1 Integrase Inhibitor	GlaxoSmithKline LLC (Manufacturer);Pfizer Inc (Primary Owner,Sales/Marketing);ViiV Healthcare Company (Sales/Marketing);GlaxoSmithKline Plc (Originator);Glaxo SmithKline China Investment Co Ltd (Sales/Marketing); ViiV Healthcare UK Ltd (Sales/Marketing); Shionogi and Co Ltd (Originator,Sales/Marketing);GlaxoSmithKline NZ Ltd (Sales/Marketing)
Tolterodine tartrate PFIZER	tolterodine tartrate	Overactive Bladder(M)	M	Active	Acetylcholine Receptor (AchR) Antagonist	Teva Pharmaceuticals (Manufacturer);Pfizer Inc (Primary Owner)
Torisel	temsirolimus	Renal Cell Carcinoma(M); Mantle Cell Lymphoma(M)	M	Active	Mammalian Target of Rapamycin (mTOR) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Primary Owner);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Distributor,Primary Owner);Pfizer Canada Inc (Sales/Marketing); PF Prism CV (Primary Owner);Pfizer UK

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Ltd (Primary Owner,Sales/Marketing)
Toviaz	fesoterodine fumarate	Overactive Bladder(M); Urethral Disorders(Phase III)	M	Active	Muscarinic Receptor Antagonist	Pfizer Healthcare Ireland (Sales/Marketing);UCB SA (Primary Owner);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Developer);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Trecator	ethionamide	Tuberculosis(M)	M	Active		Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Distributor,Primary Owner)
Tremelimum ab MEDIMMUNE	tremelimum ab	Metastatic Melanoma(Phase III); Mesothelioma(Phase II)	Phase III	No Development Reported	Cytotoxic T Lymphocyte Associated Protein 4 (CTLA4) Inhibitor	AstraZeneca Plc (Co-developer);Pfizer Inc (Co-developer,Developer, Primary Owner);MedImmune LLC (Co-developer);Medarex Inc (Originator);BioAtla LLC (Co-developer);Amgen Inc (Technology Owner);Debiopharm (Co-developer)
Tricorex	ambroxol; guaifenesin; terbutaline	Pulmonology(M)	M	Active	Beta-1 Adrenergic Receptor (ADRB1) Agonist; Sodium	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Channel Blocker	
Tritace	ramipril	Cardiovascular Failure(M); Myocardial Infarction(M); Essential Hypertension(M); Kidney Disorders(M); Ischemic Stroke(M)	M	Active	Angiotensin-Converting Enzyme (ACE) Inhibitor	Sanofi Aventis Deutschland GmbH (Sales/Marketing);Sanofi Aventis France (Primary Owner,Sales/Marketing);AstraZeneca GmbH (Sales/Marketing);sanofi aventis Deutschland GmbH (Sales/Marketing);Valeant Canada LP (Sales/Marketing); Pfizer Inc (Sales/Marketing); Aventis Pharma SA (Sales/M arketing);Handok Inc (Sales/Marketing); Sanofi India Ltd (Sales/Marketing); Arrow Pharmaceuticals Ltd (Sales/Marketing); Skyepharma Plc (Sales/Marketing); Wyeth Ayerst Laboratories (Sales/M arketing);Aventis Pharma Ltd (Sales/Marketing); Sanofi Aventis Australia Pty Ltd (Sales/Marketing); Sanofi Aventis GmbH (Sales/Marketing)
Tritorvis	atorvastatin	Cardiology(M)	M	Active	3-Hydroxy-3-Methylglutaryl Coenzyme A	Pfizer Ltd India (Sales/Marketin g);Pfizer Inc (Primary

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					(HMG-CoA) Reductase Inhibitor	Owner)
Trobicin	spectinomycin hydrochloride	Proctitis(M); Cervicitis(M); Gonococcal Urethritis(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer Inc (Primary Owner)
Trosyl	tioconazole	Skin Bacterial Infections(M); Skin Fungal Infections(M)	M	Active	Lanosterol 14 Alpha-Demethylase (CYP51) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Troxycia ER	naltrexone hydrochloride; oxycodone hydrochloride	Pain(A)	A	Active	Mu-Opioid Receptor Agonist	Pfizer Inc (Originator,Primary Owner)
TRPV3 Antagonist HYDRA BIOSCIENCES	--	Pain(Clinical Phase Unknown)	Clinical Phase Unknown	Active	Transient Receptor Potential Cation Channel, Subfamily V, Member 3 (TRPV3) Antagonist	Pfizer Inc (Co-developer);Hydra Biosciences Inc (Co-developer,Originator)
TRPV3 HYDRA BIOSCIENCES	--	Dermatology(Preclinical); Psoriasis(Preliminary); Skin Rash(Preclinical); Nociceptive Pain(Research)	Preclinical	Active	Transient Receptor Potential Cation Channel, Subfamily V, Member 3 (TRPV3) Antagonist	Pfizer Inc (Developer);Hydra Biosciences Inc (Originator)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Trulimax	azithromycin	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Trumenba	--	Meningococcal Meningitis(M)	M	Active		Pfizer Inc (Developer,Originator,Primary Owner);Wyeth Pharmaceuticals Inc (Manufacturer,Primary Owner)
TT034	--	Hepatitis C(Phase II)	Phase II	Discontinued		Oncols Biopharma Inc (Primary Owner);Pfizer Inc (Co-developer);Tacere Therapeutics Inc (Co-developer,Originator); Benitec Biopharma Ltd (Primary Owner)
TTP4000	--	Alzheimers Disease(Phase I)	Phase I	Completed	Receptor for Advanced Glycation End Products (RAGE) Antagonist	Pfizer Inc (Primary Owner);vTv Therapeutics Inc (Originator)
TTP488	azeliragon	Diabetic Nephropathy(Phase II); Alzheimers Disease(Phase III)	Phase III	Active	Receptor for Advanced Glycation End Products (RAGE) Antagonist	Pfizer Inc (Co-developer);vTv Therapeutics Inc (Developer,Primary Owner)
Turvel	trovafloxacin mesylate	Gonococcal Urethritis(M); Cervicitis(M); Salpingitis(M); Chlamydial Cervicitis(M); Gastrointestinal Infections(M);	M	Active	Topoisomerase II Inhibitor	Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Mixed Connective Tissue Disease(M); Acute Bronchitis(M); Pneumonia(M) ; Sinusitis(M)				
Tussigon	homatropine methylbromide; Hydrocodone bitartrate	Cough(M)	M	Active	Mu-Opioid Receptor Agonist	Pfizer Inc (Primary Owner);King Pharmaceuticals LLC (Primary Owner)
Tuvace	aceclofenac; acetaminophen	Immunology and Inflammatory(M)	M	Active	Cyclooxygenase-1 (COX-1) Inhibitor; Cyclooxygenase-2 (COX-2) Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
TVX001	--	Influenza(Preliminary)	Preclinical	Active		Pfizer Inc (Co-developer);Wyeth (Technology Owner);TechnoVax Inc (Primary Owner)
Tygacil	tigecycline	Skin Bacterial Infections(M); Bacterial Infections(M); Bacterial Pneumonia(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Ltd India (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Wyeth Pharmaceuticals Inc (Distributor, Primary Owner);Pfizer

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Canada Inc (Sales/Marketing); PF Prism CV (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
UCART19	--	Acute Lymphoblastic Leukemia(Phase I); Chronic Lymphoid Leukemia(Pre clinical)	Phase I	Active	Cluster of Differentiation 19 (CD19) Receptor Antagonist	Pfizer Inc (Co-developer);Cellectis SA (Originator)
Unasyn	ampicillin sodium; sulbactam sodium	Intra-Abdominal Abscesses(M); Gynecology(M); Skin Bacterial Infections(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Pharma GmbH (Sales/Marketing);Pfizer Europe MA EEIG (Sales/Marketing);Pfizer Hellas AE (Sales/Marketing); Roerig SA (Distributor);Pfizer Inc (Originator,Primary Owner);Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Holding France (Sales/Marketing)
Utolan	norethisterone	Menstrual Disorders(M); Abnormal Uterine Bleeding(M); Menorrhagia(M); Endometriosis(M); Breast Cancer(M)	M	Active		Pfizer Inc (Primary Owner);Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Vantin	cefpodoxime proxetil	Anorectal Disorders(M); Community-Acquired Pneumonia(M); Sinusitis(M); Pharyngitis(M); Tonsillitis(M); Gonorrhea(M); Skin Bacterial Infections(M); Urinary Tract Bacterial Infections(M); Otitis Media(M); Chronic Bronchitis(M)	M	Discontinued	Bacterial Cell Wall Synthesis Inhibitor	Pfizer Inc (Primary Owner);Pharmacia and Upjohn Company Inc (Distributor,Primary Owner)
Venlafaxine hydrochloride PFIZER	venlafaxine hydrochloride	Generalized Anxiety Disorder(M); Panic Disorder(M); Social Phobia(M); Major Depressive Disorder(M)	M	Active	5-Hydroxytryptamine (5-HT) Reuptake Inhibitor; Norepinephrine Reuptake Inhibitor	Pfizer Inc (Primary Owner)
Vfend	voriconazole	Invasive Aspergillosis(M); Skin Fungal Infections(M); Bloodstream Fungal Infections(M); Candida Fungemia(M); Esophageal Candidiasis(M); Ocular Fungal	M	Active	Cytochrome P450 2C19 (CYP2C19) Inhibitor; Cytochrome P450 3A4 (CYP3A4) Inhibitor; Lanosterol 14 Alpha-Demethylase (CYP51) Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Originator);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Ligand

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Infections(M)				pharmaceuticals Inc (Technology Owner)
Viagra	sildenafil citrate	Erectile Dysfunction(M)	M	Active	Phosphodiesterase-5 (PDE-5) Inhibitor	Pfizer ApS (Sales/Marketing); Pfizer Croatia doo (Sales/Marketing); Pfizer Oy (Sales/Marketing); Pfizer GEP SL (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Luxembourg SARL (Sales/Marketing); Pfizer Pharma GmbH (Sales/Marketing); Pfizer Ltd India (Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer PFE France (Sales/Marketing); Pfizer Inc (Originator); Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Polska Spzoo (Sales/Marketing); Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer A S (Sales/Marketing);P fizer Romania SRL (Sales/Marketing);Pfizer Spol SRO (Sales/Marketin g);Pfizer UK Ltd (Sales/Marketing)
Vibazime DT	cefixime; clavulanate potassium	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Ltd India (Sales/Marketin g);Pfizer Inc (Primary Owner)
Vibramycin Calcium	doxycycline calcium	Acne(M); Respiratory Tract Infections(M); Klebsiella Pneumonia(M); ; Pulmonary Anthrax(M); Chancroid(M); Chlamydia Trachomatis Infections(M); Donovanosis(M); Gonorrhea(M); Lymphogranuloma Venereum(M); Non-Gonococcal	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Inc (Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Urethritis(M); Syphilis(M); Yaws(M); Tularemia(M); Urinary Tract Bacterial Infections(M); Chlamydial Urethritis(M); Escherichia Coli Infections(M); Hemophilus Influenzae Infections(M); Q Fever(M); Louse-Borne Relapsing Fever(M); Tick-Borne Relapsing Fever(M); Chlamydial Cervicitis(M); Cholera(M); Clostridium Difficile Infections(M); Gastrointestinal Parasitic Infections(M); Adult Inclusion Conjunctivitis(M)				
Vibramycin Hyclate	doxycycline hyclate	Acne(M); Infectious Diseases(M); Bacterial Infections(M); Respiratory Tract Infections(M);	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Inc (Originator,Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Klebsiella Pneumonia(M); Upper Respiratory Tract Infections(M); Pulmonary Anthrax(M); Chancroid(M); Chlamydia Trachomatis Infections(M); Donovanosis(M); Gonorrhea(M); Lymphogranuloma Venereum(M); Non-Gonococcal Urethritis(M); Syphilis(M); Yaws(M); Tularemia(M); Urinary Tract Bacterial Infections(M); Chlamydial Urethritis(M); Escherichia Coli Infections(M); Hemophilus Influenzae Infections(M); Q Fever(M); Louse-Borne Relapsing Fever(M); Tick-Borne Relapsing Fever(M);				

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Chlamydial Cervicitis(M); Cholera(M); Clostridium Difficile Infections(M); Paratyphoid(M); Gastrointestinal Parasitic Infections(M); Adult Inclusion Conjunctivitis(M)				
Vibramycin Monohydrate	doxycycline monohydrate	Acne(M); Respiratory Tract Infections(M); Klebsiella Pneumonia(M); Pulmonary Anthrax(M); Chancroid(M); Chlamydia Trachomatis Infections(M); Donovanosis(M); Gonorrhea(M); Lymphogranuloma Venereum(M); Non-Gonococcal Urethritis(M); Syphilis(M); Yaws(M); Tularemia(M); Urinary Tract Bacterial Infections(M); Chlamydial	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Inc (Originator,Primary Owner)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Urethritis(M); Escherichia Coli Infections(M); Hemophilus Influenzae Infections(M); Q Fever(M); Louse-Borne Relapsing Fever(M); Tick-Borne Relapsing Fever(M); Chlamydial Cervicitis(M); Cholera(M); Clostridium Difficile Infections(M); Gastrointestinal Parasitic Infections(M); Adult Inclusion Conjunctivitis(M)				
Viracept	nelfinavir mesylate	Human Immunodeficiency Virus-1 Infection(M)	M	Active	HIV-1 Protease Inhibitor	Warner Lambert Company LLC (Sales/Marketing);Pfizer Inc (Sales/Marketing);Agouron Pharmaceuticals Inc (Primary Owner,Sales/Marketing);Pfizer Canada Inc (Sales/Marketing)
Viroptic	trifluridine	Keratitis(M); Keratoconjunctivitis(M)	M	Active	Deoxyribonucleic acid (DNA) synthesis inhibitor	Pfizer Inc (Primary Owner);Monarch Pharmaceuticals Inc (Primary Owner);Glaxo

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Wellcome Manufacturing Pte Ltd (Originator)
VIS410	--	Influenza A(Phase II)	Phase II	Active		Pfizer Inc (Co-developer,Developer);Visterra Inc (Originator)
Vistaril	hydroxyzine pamoate	Skin Rash(M); Sensory Loss(M); Tension-Type Headache(M); Anxiety(M)	M	Active	Histamine H1 Receptor Antagonist	Pfizer Inc (Primary Owner)
Vistide	cidofovir	Cytomegalovirus Retinitis(M)	M	Discontinued	Viral DNA Polymerase Inhibitor	Gilead Sciences International Ltd (Sales/Marketing); Pfizer Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Sales/Marketing); Gilead Sciences Inc (Primary Owner,Sales/Marketing)
Viviant	bazedoxifene	Postmenopausal Osteoporosis(M)	M	Active	Estrogen Receptor (ESR) Agonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Inc (Developer,Primary Owner);Almirall (Sales/Marketing);Ligand pharmaceuticals Inc (Originator);Wyeth (Originator)
Voglibose	voglibose	Diabetes Mellitus(M)	M	Active	Alpha-Glucosidase Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Voriconazole AVOGEN	voriconazole	Fungal Infections(M)	M	Active	Lanosterol 14 Alpha-	Alvogen (Sales/Marketing);Pfizer

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
					Demethylase (CYP51) Inhibitor	Inc (Primary Owner)
Vraylar	cariprazine	Bipolar Disorders(M); Major Depressive Disorder(Phase III); Schizophrenia(M)	M	Active	Dopamine D2 Receptor Partial Agonist; Dopamine D3 Receptor Partial Agonist	Allergan Plc (Co-developer);Forest Research Institute Inc (Co-developer);Pfizer Inc (Co-developer);Recordati SpA (Sales/Marketing);Gedeon Richter Plc (Co-developer,Originator); Mitsubishi Tanabe Pharma Corp (Co-developer)
VS6063	defactinib	Pancreatic Cancer(Phase I); Ovarian Cancer(Phase I); Mesothelioma(Phase I); Non-Small Cell Lung Cancer(Phase II)	Phase II	Active	Protein Tyrosine Kinase 2 (PTK2) Inhibitor	Pfizer Inc (Co-developer);Merck KGaA (Co-developer);Verastem Inc (Primary Owner)
Vyndaqel	tafamidis meglumine	Cardiomyopathy(Phase III); Amyloidosis(M); Heredofamilial Amyloidosis(M)	M	Active	Transthyretin (TTR) Amyloid Fibril Formation Inhibitor	Pfizer ApS (Sales/Marketing);Pfizer Croatia doo (Sales/Marketing);Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing);FoldRx Pharmaceuticals Inc (Originator);Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Pharma

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						GmbH (Sales/Marketing);Pfizer SL (Sales/Marketing); Pfizer Hellas AE (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner,Sales/Marketing);Pfizer Srl (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Polska Spzoo (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer Romania SRL (Sales/Marketing);Pfizer Spol SRO (Sales/Marketing);Pfizer AS (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Waterburys	creosote; guaiacol	Pulmonology(M)	M	Active	Not Available	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Wymox	amoxicillin	Bacterial Infections(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Wysolone	prednisolon	Endocrine	M	Active	Glucocorticoid	Pfizer Ltd

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
	e	Disorders(M)			Receptor (GR) Agonist	India (Sales/Marketing);Pfizer Inc (Primary Owner)
Xalacom	latanoprost; timolol maleate	Intraocular Pressure(M)	M	Active	Beta-1 Adrenergic Receptor (ADRB1) Antagonist; Beta-2 Adrenergic Receptor (ADRB2) Antagonist; Prostaglandin F2 alpha (PGF2 alpha) Receptor Agonist	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)
Xalatan	latanoprost	Primary Open-Angle Glaucoma(M)	M	Active	Prostaglandin F2 alpha (PGF2 alpha) Receptor Agonist	Pfizer ApS (Sales/Marketing);Pfizer Croatia doo (Sales/Marketing) ;Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing);Bausch and Lomb Inc (Sales/Marketing); Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Europe MA EEIG (Sales/Marketing);Pharmacia and Upjohn Company LLC (Primary Owner);Pfizer Enterprises SARL (Sales/Marketing);Pfizer SL (Sales/Marketing); Pfizer Hellas

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						AE (Sales/Marketing); Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Primary Owner);Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Holding France SCA (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing);Pfizer AB (Sales/Marketing); Pfizer A S (Sales/Marketing);P harmacia and Upjohn Company Inc (Primary Owner);Pfizer Spol SRO (Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Xalkori	crizotinib	Oncology(Phase I); Lymphoma(Clinical Phase Unknown); Non-Small Cell Lung Cancer(M);	M	Active	Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase Inhibitor; c-MET Receptor	Pfizer ApS (Sales/Marketing);Pfizer Croatia doo (Sales/Marketing);Pfizer Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketi

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Metastatic Non-Small Cell Lung Cancer(M); Neuroblastoma(Clinical Phase Unknown)			Tyrosine Kinase Inhibitor; c-ros oncogene 1 (ROS1) Inhibitor	ng);Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Pharma GmbH (Sales/Marketing);Pfizer SL (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Japan Inc (Primary Owner,Sales/Marketing);Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer Manufacturing Deutschland GmbH (Manufacturer);Pfizer Polska Spzoo (Sales/Marketing);Pfizer Pharmaceutical Trading Ltd Liability Company aka Pfizer Kft or Pfizer LLC (Sales/Marketing);Merck KGaA (Sales/Marketing);Merck Sharp and Dohme Corp (Co-developer);Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); Pfizer A

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						S (Sales/Marketing);Pfizer Romania SRL (Sales/Marketing);EMD Serono Inc (Sales/Marketing);Pfizer Spol SRO (Sales/Marketing);OxOnc Development LP (Co-developer);Pfizer UK Ltd (Sales/Marketing)
Xanax	alprazolam	Anxiety(M); Panic Disorder(M); Depression(M)	M	Active	Gamma-Aminobutyric Acid Type A (GABAA) Receptor Modulator	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pharmacia and Upjohn Company Inc (Primary Owner)
Xeljanz	tofacitinib citrate	Crohns Disease(Phase II); Ulcerative Colitis(Phase III); Plaque Psoriasis(PA); Atopic Dermatitis(Phase II); Rheumatoid Arthritis(PM); Ankylosing Spondylitis(Phase II); Psoriatic Arthritis(Phase III); Transplant Rejection(Phase	PM	Active	Janus Kinase (JAK) Inhibitor	Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Developer, Originator, Primary Owner);Pfizer Canada Inc (Sales/Marketing);Takeda Pharmaceutical Company Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		se II); Juvenile Idiopathic Arthritis(Phase III); Keratoconjunctivitis Sicca(Phase II)				
Xtandi	enzalutamide	Hepatocellular Carcinoma(Phase II); Prostate Cancer(M); Breast Cancer(Phase III)	M	Active	Androgen Receptor Antagonist	Pfizer Inc (Primary Owner,Sales/Marketing);Medivation Inc (Co-developer,Primary Owner,Sales/Marketing);Astellas Pharma Inc (Co-developer,Primary Owner,Sales/Marketing)
Xyntha	Antihemophilic Factor [Recombinant]; moroctocog alfa	Hemophilia A(M)	M	Active	Coagulation Factor VIII, Procoagulant Component (F8) Upregulator	Sobi Inc (Sales/Marketing); Pfizer New Zealand Ltd (Distributor);Pfizer Australia Pty Ltd (Distributor);Pfizer Inc (Primary Owner);Wyeth Pharmaceuticals Inc (Primary Owner);Pfizer Canada Inc (Distributor);Dyax Corp (Technology Owner);Shire Plc (Technology Owner);Wyeth (Primary Owner)
Zantac	ranitidine hydrochloride	Gastroesophageal Reflux Disease(M); Erosive Esophagitis(A)	M	Active	Histamine H2 Receptor Antagonist	Covis Pharmaceuticals (Sales/Marketing);Pfizer Inc (Developer,Sales/Marketing);GlaxoSmithKline Inc (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		; Acidity Disorders(M); Duodenal Ulcer(M); Gastric Ulcer(M); Heartburn(M)				hKline Plc (Primary Owner);Boehringer Ingelheim Pharmaceuticals Inc (Unknown);Boehringer Ingelheim (Sales/Marketing);Johnson and Johnson Inc (Sales/Marketing);Concordia International Corp (Sales/Marketing)
Zarate	rabeprazole; sodium bicarbonate	Gastroenterology(M)	M	Active	Proton Pump Inhibitor (PPI)	Pfizer Ltd India (Sales/Marketing);Pfizer Inc (Primary Owner)
Zarontin	ethosuximide	Absence Seizures(M)	M	Active		Pfizer Healthcare Ireland (Sales/Marketing);Parke Davis Ltd (Distributor,Primary Owner);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Distributor);Parke Davis and Company LLC (Primary Owner);Pfizer Inc (Primary Owner);Warner Lambert SA (Primary Owner);Pfizer UK Ltd (Sales/Marketing)
Ziagen	abacavir sulfate	Human Immunodeficiency Virus-1 Infection(PM)	PM	Completed	HIV Reverse Transcriptase Inhibitor	GlaxoSmithKline Ireland Ltd (Sales/Marketing);GlaxoSmithKline Oy (Sales/Marketing);Glaxo Operations UK Ltd (Manufacturer);G

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						SK Services Spz oo (Sales/Marketing); ViiV Healthcare SAS (Sales/Marketing);Pfizer Inc (Primary Owner);GlaxoSmithKline AEBE (Sales/Marketing);GlaxoSmithKline Plc (Primary Owner);GlaxoSmithKline sro (Sales/Marketing); GlaxoSmithKline KK (Sales/Marketing); GlaxoSmithKline PharmAGmbH (Sales /Marketing);Glaxosmit hline Lietuva UAB (Sales/Marketin g);Glaxosmithkline Pharma AS (Sales/Marketing); Glaxosmithkline AS (Sales/Marketing); Glaxosmithkline Slovakia Sro (Sales/Marketing) ;Glaxosmithkline AB (Sales/Marketing); Glaxosmithkline DOO (Sales/Marketin g);GlaxoSmithKline GSK SRL (Sales/Marketing);GlaxoSmithKline Malta Ltd (Sales/Marketing); GlaxoSmithKline EOOD (Sales/Marketi ng);GlaxoSmithKline Pharmaceuticals SA

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
						Poland (Manufacturer);Laboratorios ViiV Healthcare SL (Sales/Marketing);ViiV Healthcare BV (Sales/Marketing);ViiV Healthcare GmbH (Sales/Marketing);ViiV Healthcare Srl (Sales/Marketing);ViiV Healthcare sprl (Sales/Marketing)
Zinecard	dexrazoxane	Cardiomyopathy(M)	M	Active		Pfizer Inc (Primary Owner);Pfizer Canada Inc (Sales/Marketing);Pharmacia and Upjohn Company Inc (Primary Owner)
Zithromax	azithromycin dihydrate	Cervicitis(M);Community-Acquired Pneumonia(M); Sinusitis(M); Pharyngitis(M); Tonsillitis(M); Non-Gonococcal Urethritis(M); Skin Bacterial Infections(M); Mycobacterium Avium Complex Infections(M); Otitis Media(M); Chronic Bronchitis(M)	M	Active	Bacterial Protein Synthesis Inhibitor	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer New Zealand Ltd (Sales/Marketing);Pfizer Australia Pty Ltd (Sales/Marketing);Pfizer Inc (Primary Owner,Sales/Marketing);Pfizer Japan Inc (Sales/Marketing);Pfizer Corp Hong Kong Ltd (Sales/Marketing);Pfizer Canada Inc (Distributor,Sales/Marketing);Pfizer UK Ltd (Sales/Marketing)
Zoloft	sertraline hydrochloride	Premenstrual Dysphoric Disorder(M);	M	Active	5-Hydroxytryptamine (5-HT)	Pfizer ApS (Sales/Marketing);Pfizer

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Obsessive-Compulsive Disorder(M); Panic Disorder(M); Social Phobia(M); Post Traumatic Stress Disorder(M); Major Depressive Disorder(M)			Reuptake Inhibitor	Oy (Sales/Marketing); Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Luxembourg SARL (Sales/Marketing);Pfizer Pharma GmbH (Sales/Marketing);Pfizer Europe MA EEIG (Sales/Marketing);Pfizer Hellas AE (Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Roerig SA (Distributor);Pfizer Inc (Primary Owner);Pfizer Japan Inc (Sales/Marketing); Pfizer Italia Srl (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer BV (Sales/Marketing); Pfizer SA (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pfizer AB (Sales/Marketing); moksha8 Pharmaceuticals Inc (Sales/Marketing); Pfizer AS (Sales/Marketing); Pfizer Holding France (Sales/Marketing);Pfizer UK

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
Zosyn	piperacillin sodium; tazobactam sodium	Pelvic Inflammatory Disease(M); Hospital-Acquired Pneumonia(M); Community-Acquired Pneumonia(M); Skin Bacterial Infections(M); Urinary Tract Infections(M); Septicaemia(M); Gastrointestinal Bacterial Infections(M)	M	Active	Bacterial Cell Wall Synthesis Inhibitor; Beta-Lactamase Inhibitor	Pfizer Ltd India (Sales/Marketing); Pfizer New Zealand Ltd (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Sales/Marketing); Pfizer Corp Hong Kong Ltd (Sales/Marketing); Wyeth Pharmaceuticals Inc (Distributor,Sales/Marketing); Taisho Toyama Pharmaceutical Co Ltd (Manufacturer, Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Taiho Pharmaceutical Co Ltd (Manufacturer, Primary Owner,Sales/Marketing); NAEJA Pharmaceutical Inc (Primary Owner); Pfizer UK Ltd (Sales/Marketing)
Zoton	Lansoprazole	Gastroesophageal Reflux Disease(M); Duodenal Ulcer(M); Gastric Ulcer(M); Non Steroidal Anti Inflammatory	M	Active	Proton Pump Inhibitor (PPI)	Pfizer Healthcare Ireland (Sales/Marketing); Pfizer Australia Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner,Sales/Marketing); Pfizer UK Ltd (Sales/Marketing)

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		Drugs Induced Gastric Ulcer(M); Zollinger Ellison Syndrome(M); Helicobacter Pylori Infections(M); Esophagitis(M)				
ZP1609	Danegaptide	Atrial Fibrillation(Phase I); Myocardial Reperfusion Injury(Phase II)	Phase II	Failed	Gap Junction Modulator	Zealand Pharma AS (Originator);Pfizer Inc (Co-developer);Wyeth Pharmaceuticals Inc (Co-developer);Wyeth (Co-developer)
Zyrtec	cetirizine hydrochloride	Idiopathic Urticaria(M); Seasonal Allergic Rhinitis(M); Perennial Allergic Rhinitis(M)	M	Active	Histamine H1 Receptor Antagonist	UCB SA (Primary Owner,Sales/Marketing);Pfizer Inc (Sales/Marketing);GlaxoSmithKline KK (Distributor);Daiichi Pharmaceutical Co Ltd (Distributor);McNEIL PPC Inc (Sales/Marketing);Johnson and Johnson Services Inc (Sales/Marketing);Dr Reddys Laboratories Ltd (Sales/Marketing);Daiichi Sankyo Co Ltd (Distributor);Johnson and Johnson Consumer Inc (Sales/Marketing)
Zyvox	linezolid	Hospital-Acquired Pneumonia(M)	M	Active	Bacterial Protein Synthesis	Pfizer Healthcare Ireland (Sales/Marketing);Pfizer Australia

Product Name	Active Ingredient	Therapeutic Indication	Highest Phase	Phase Status	Mechanism of Action	Companies (Role)
		; Community-Acquired Pneumonia(M); Skin Bacterial Infections(M); Diabetic Foot Infections(M); Enterococcal Infections(M); Bacteremia(M)			Inhibitor	Pty Ltd (Sales/Marketing); Pfizer Inc (Primary Owner);Pfizer Corp Hong Kong Ltd (Sales/Marketing); Pfizer Canada Inc (Sales/Marketing); Pharmacia and Upjohn Company Inc (Originator,Primary Owner);Pfizer UK Ltd (Sales/Marketing)

Regulatory

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Accuretic	hydrochlorothiazide;quinapril hydrochloride	03/01/1998	NDS	Essential hypertension in patients(for whom combination therapy is appropriate)	Canada
Accuretic	hydrochlorothiazide;quinapril hydrochloride	12/28/1999	NDA	Hypertension	United States
Advil	ibuprofen	06/12/2012	NDA	1. The temporary relief of minor aches and pains due to: headache, toothache, backache, menstrual cramps, the common cold, muscular aches, and minor pain of arthritis 2. The reduction of fever	United States
Advil	ibuprofen	11/07/1997	sNDA		United States
Advil	ibuprofen	06/27/1996	NDA	1. Temporarily reduces fever 2. Relieves minor aches and pains due to the common cold, flu, sore throat, headaches and tooth aches	United States
Advil allergy and congestion relief	chlorpheniramine maleate;ibuprofen	12/21/2011	NDA	Temporary relief of symptoms associated with	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
	phenylephrine hydrochloride			hay fever or other respiratory allergies; and the common cold	
Advil cold sinus	ibuprofen;pseudoephedrine hydrochloride	03/31/2011	NDS	Temporary effective relief of symptoms associated with the common cold including nasal congestion, headache, fever, sinus pain and minor body aches and pains	Canada
Advil congestion relief	ibuprofen;phenylephrine hydrochloride	05/27/2010	NDA	Temporary relief of the following symptoms associated with cold and flu: headache, fever, sinus pressure, nasal congestion, minor aches and pain, reduces swelling of the nasal passages, temporarily restores freer breathing through nose	United States
Advil PM	diphenhydramine hydrochloride;ibuprofen	12/21/2005	NDA	Liqui-Gels and Caplets for relief of occasional sleeplessness when associated with minor aches and pains.	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Alsuma	sumatriptan succinate	06/29/2010	NDA	Acute treatment of migraine headache	United States
Aromasin	exemestane	05/12/2006	SNDS	Postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy	Canada
Aromasin	exemestane	08/17/2000	NDS	Advanced breast cancer in women with natural or artificially induced postmenopausal status whose disease has progressed following antiestrogen therapy	Canada
Benefix	nonacog alfa	02/18/2013	Post-approvals	Prophylaxis of bleeding in patients with haemophilia B in children less than 6 years of age	Europe
Benefix	nonacog alfa	08/23/2012	Post-approvals		Europe
Benefix	nonacog alfa	07/30/2007	Post-approvals		Europe
Benefix	nonacog alfa	08/27/1997	MAA	Prophylaxis of bleeding in patients with haemophilia B (congenital	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				factor-IX deficiency)	
Bosulif	bosutinib	03/07/2014	NDS	Chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy(TYROSINE KINASE INHIBITOR)	Canada
Bosulif	bosutinib	03/27/2013	MAA	Adult patients with chronic-phase, accelerated-phase and blast-phase Philadelphia chromosome-positive chronic myelogenous leukaemia previously treated with one or more tyrosine-kinase inhibitors and for whom imatinib, nilotinib and dasatinib are not consi	Europe
Cabaser	cabergoline	06/30/2000	NDS	i. Treatment of hyperprolactinemic disorders ii. Inhibition of physiological	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				lactation	
Caduet	amlodipine besylate;atorvastatin calcium	07/29/2004	sNDA		United States
Caduet	amlodipine besylate;atorvastatin calcium	01/30/2004	NDA	Patients for whom treatment with both amlodipine and atorvastatin is appropriate	United States
Camptosar	irinotecan hydrochloride	02/28/2001	SNDS	IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN AS FIRST-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER	Canada
Camptosar	irinotecan hydrochloride	07/04/1997	NDS	As a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum	Canada
Cardura XL	doxazosin mesylate	02/22/2005	NDA	Signs and symptoms of benign prostatic hyperplasia (BPH)	United States
Chantix	varenicline tartrate	09/26/2006	MAA	For smoking cessation in adults	Europe
Chantix	varenicline tartrate	01/25/2008	NDA	As a smoking-cessation aid for nicotine-	Japan

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				dependent smokers	
Chantix	varenicline tartrate	10/15/2014	sNDA		United States
Chantix	varenicline tartrate	05/10/2006	NDA	Aid to smoking cessation treatment	United States
Convert	ibutilide fumarate	07/14/2000	NDS	Rapid conversion of atrial fibrillation or atrial flutter to sinus rhythm	Canada
Detrol	tolterodine tartrate	04/20/2006	NDA	Urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder	Japan
Detrol	tolterodine tartrate	12/22/2000	NDA	Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency	United States
Duavee	bazedoxifene; conjugated estrogens	12/16/2014	MAA	Oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				(experience treating women older than 65 years is limited)	
Dynastat	parecoxib sodium	03/22/2002	MAA	For the short-term treatment of postoperative pain in adults	Europe
Elelyso	taliglucerase alfa	05/21/2014	BLA	Long-term enzyme replacement therapy for adult and paediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following splenomegaly, hepatomegaly, anaemia, thrombocytopenia	Australia
Elelyso	taliglucerase alfa	05/29/2014	NDS	Long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease	Canada
Elelyso	taliglucerase alfa	05/01/2012	NDA	Long-term enzyme replacement therapy in patients with Type 1 Gaucher	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				disease	
Ellence	epirubicin hydrochloride	09/15/1999	NDA	Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer	United States
Enbrel	etanercept	07/28/2014	Post-approvals	Adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs)	Europe
Enbrel	etanercept	07/31/2012	Post-approvals	1. Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				<p>adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate</p> <p>2. Psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate</p> <p>3. Enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy</p>	
Enbrel	etanercept	08/24/2011	Post-approvals	Polyarticular juvenile idiopathic arthritis (JIA) "from the age of 4 years" to "from the age of 2	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				years"	
Enbrel	etanercept	06/29/2011	Post-approvals		Europe
Enbrel	etanercept	12/22/2008	Post-approvals	Chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies	Europe
Enbrel	etanercept	01/18/2007	Post-approvals	Psoriatic arthritis	Europe
Enbrel	etanercept	08/04/2006	Post-approvals		Europe
Enbrel	etanercept	04/28/2005	Post-approvals		Europe
Enbrel	etanercept	09/24/2004	Post-approvals	Adult patients with moderate to severe plaque psoriasis	Europe
Enbrel	etanercept	05/10/2004	Post-approvals	In combination with methotrexate for the treatment of active rheumatoid arthritis in adults, when the response to disease-modifying antirheumatic drugs has been inadequate, and, to inhibit the progression of disease-associated structural damage in	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				patients with rheumatoid arthritis, as measured by x-ray	
Enbrel	etanercept	02/03/2000	MAA	1. Adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy 2. Adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)	Europe
Enbrel	etanercept	03/21/2012	sBLA	Rheumatoid arthritis	Japan
Enbrel	etanercept	02/05/2010	BLA	Rheumatoid arthritis	Japan

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Enbrel	etanercept	02/05/2010	sBLA	Rheumatoid arthritis	Japan
Enbrel	etanercept	07/07/2009	sBLA	Polyarticular-course juvenile idiopathic arthritis	Japan
Enbrel	etanercept	01/19/2005	BLA	Humanized fusion protein having an inhibitory action on the binding of the tumor necrosis factor (TNF) to a TNF	Japan
Eraxis	anidulafungin	07/28/2009	SNDS		Canada
Eraxis	anidulafungin	11/14/2007	NDS	Invasive candidiasis/candidemia in adult non-neutropenic patients	Canada
Eraxis	anidulafungin	08/26/2014	Post-approvals	Invasive candidiasis in adult non-neutropenic patients	Europe
Erxaxis	anidulafungin	09/20/2007	MAA	Patients with candidaemia and only in a limited number of patients with deep tissue Candida infections or with abscess-forming disease	Europe
Exubera	human insulin [rDNA origin]	01/24/2006	MAA	1. Adult patients with type 2 diabetes mellitus not adequately controlled with	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				oral antidiabetic agents and requiring insulin therapy 2. Adult patients with type 1 diabetes mellitus, inaddition to long or intermediate acting subcutaneous insulin, for whom the potential benefits of adding inhaled insulin outweigh the potential safety concerns	
Exubera	human insulin [rDNA origin]	01/27/2006	NDA	Diabetes mellitus for the control of hyperglycemia in adult patients	United States
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	11/09/2009	sNDA	Acute control and short-term management of agitation and disturbed behaviours in patients with schizophrenia and related psychoses when oral therapy is not appropriate	Australia
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	10/29/2001	NDA	1. Treatment of schizophrenia, related psychoses,	Australia

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				prevention of relapse and for maintenance of clinical improvement during continuation therapy; and 2. As monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar I	
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	11/20/2009	sNDA	Maintenance treatment of bipolar disorder; as an adjunct to lithium or valproate	United States
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	03/29/2006	NDA	Schizophrenia and for the treatment of acute manic or mixed episodes associated with bipolar disorder; with or without psychotic features	United States
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	08/19/2004	sNDA	As monotherapy in the treatment of acute manic or mixed episodes in Bipolar I Disorder; with or without psychotic features	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	06/21/2002	NDA	Acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of the agitation	United States
Geodon	ziprasidone hydrochloride; ziprasidone mesylate	02/05/2001	NDA	Schizophrenia	United States
Heparin Sodium PFIZER	heparin sodium	07/21/2011	NDA	1. Prophylaxis and treatment of venous thrombosis and pulmonary embolism 2. Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation 3. Treatment of acute and chronic consumption coagulopathies (disseminated intravascular)	United States
Ibrance	palbociclib	03/16/2016	NDS	Postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease	
Ibrance	palbociclib	02/19/2016	sNDA	Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				for their metastatic disease	
Idamycin	idarubicin hydrochloride	07/06/2006	SNDS		Canada
Idamycin	idarubicin hydrochloride	05/02/1995	SNDS		Canada
Idamycin	idarubicin hydrochloride	01/14/1994	NDS	1.Acute non-lymphocytic leukemia (ANLL) in adults for remission induction as front-line therapy or for remission induction in relapsed or refractory patients 2.Acute lymphocytic leukemia (ALL) as second line treatment in adults and children	Canada
Inlyta	axitinib	03/24/2014	SNDS		Canada
Inlyta	axitinib	07/12/2012	NDS	Metastatic Renal Cell Carcinoma (RCC) of clear cell histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib	Canada
Inlyta	axitinib	08/26/2013	Post-approvals		Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Inlyta	axitinib	09/03/2012	MAA	Adult patients with advanced renal-cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine	Europe
Lipitor	atorvastatin calcium	03/02/2007	sNDA	In adult patients with clinically evident coronary heart disease to reduce the risk of non-fatal myocardial infarction, fatal and non-fatal stroke, angina, revascularization procedures, and hospitalization for congestive heart failure	United States
Lipitor	atorvastatin calcium	09/21/2005	sNDA	In adult patients with type 2 diabetes and without clinically evident coronary heart disease (but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension), to reduce the risk of	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				myocardial infarction and stroke. In addition, the use of atorvastatin is indicated to reduce the risk of stroke in adult patients without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease	
Lipitor	atorvastatin calcium	07/30/2004	sNDA	In adult patients without clinically evident coronary heart disease (but with multiple risk factors for coronary heart disease such as age >55 years, smoking hypertension, low HDL-C or a family history of early coronary heart disease), to reduce the risk of myocardial infarction, and to reduce the risk	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				for revascularization procedures and angina	
Lipitor	atorvastatin calcium	10/18/2002	sNDA	Heterozygous familial hypercholesterolemia in adolescent boys and postmenarchal girls, ages 10 to 17 years, with a recommended dosing range of 10 to 20 mg once daily	United States
Lipitor	atorvastatin calcium	04/07/2000	sNDA		United States
Lipitor	atorvastatin calcium	12/09/1999	sNDA	Increase the HDL-C in patients with primary hypercholesterolemia(heterozygous familial and non familial) and mixed dyslipidemia(Fredrickson Type-1ia and Type 1ib)	United States
Lipitor	atorvastatin calcium	07/10/1998	sNDA	Adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				Type IV)	
Lipitor	atorvastatin calcium	07/10/1998	sNDA	Primary disbetaipoproteinemia (Fredrickson Type III) who do not respond adequately to diet	United States
Lipitor	atorvastatin calcium	12/17/1996	NDA	1. Adjunct to diet to reduce elevated total cholesterol (total-C), LDL-C, TG, and Apo B levels, and TG levels in patients with primary hypercholesterolemia(heterozygous familial and non familial) and mixed dyslipidemia (Frederickson Type IIa and IIb) 2. Reduce total - C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid lowering treatments (LDL apheresis) or if such treatments are not available	United States
Lyrica	Pregabalin	03/04/2009	SNDS	Management of pain associated	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				with fibromyalgia	
Lyrica	Pregabalin	11/09/2007	SNDS	Management of neuropathic pain associated with spinal cord injury	Canada
Lyrica	Pregabalin	06/03/2005	NDS	Management of neuropathic pain associated with 1. Diabetic peripheral neuropathy 2. Postherpetic neuralgia	Canada
Lyrica	Pregabalin	09/07/2006	Post-approvals	Peripheral and central neuropathic pain in adults	Europe
Lyrica	Pregabalin	07/06/2004	MAA	1. As adjunctive therapy in adults with partial seizures with or without secondary generalisation 2. Generalised anxiety disorder (GAD) in adults	Europe
Lyrica	Pregabalin	02/28/2013	sNDA	Neuropathic pain	Japan
Lyrica	Pregabalin	06/22/2012	sNDA	Pain associated with fibromyalgia	Japan
Lyrica	Pregabalin	10/27/2010	sNDA	Peripheral neuropathic pain	Japan
Lyrica	Pregabalin	04/16/2010	NDA	Postherpetic neuralgia	Japan
Lyrica	Pregabalin	06/20/2012	sNDA	Neuropathic pain associated	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				with spinal cord injury	
Lyrica	Pregabalin	01/04/2010	NDA	Neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN); adjunctive therapy for patients with partial onset seizures; and fibromyalgia	United States
Lyrica	Pregabalin	06/21/2007	sNDA	Management of fibromyalgia	United States
Lyrica	Pregabalin	06/10/2005	NDA	Adjunctive therapy for adult patients with partial onset seizures	United States
Lyrica	Pregabalin	12/30/2004	NDA	Management of postherpetic neuralgia	United States
Lyrica	Pregabalin	12/30/2004	NDA	Management of neuropathic pain associated with diabetic peripheral neuropathy	United States
Macugen	pegaptanib sodium	07/13/2008	NDA	Age-related macular degeneration with concurrent choroidal neovascularization	Japan
Neurontin	Gabapentin	07/18/2000	SNDS		Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Neurontin	Gabapentin	02/25/1999	SNDS		Canada
Neurontin	Gabapentin	04/07/1994	NDS	Adjunctive therapy for the management of patients with epilepsy who are not satisfactorily controlled by conventional therapy	Canada
Nicotrol	nicotine	05/02/1997	NDA	Nicotine replacement product as an aid to smoking cessation	United States
Nicotrol	nicotine	07/03/1996	NDA	Smoking cessation for the relief of nicotine withdrawal symptoms	United States
Nicotrol	nicotine	03/22/1996	NDA	Aid to smoking cessation for the relief of nicotine withdrawal symptoms	United States
Nimenrix	--	03/05/2013	NDS	Active immunization of individuals from 12 months to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135 and Y	Canada
Nimenrix	--	04/20/2012	MAA	Active immunisation of	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135 and Y	
Nitrostat	nitroglycerin	05/01/2000	NDA	Acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease	United States
Norvasc	amlodipine besylate	09/28/2005	sNDA	Angiographically documented coronary artery disease	United States
Norvasc	amlodipine besylate	01/08/2004	sNDA		United States
Norvasc	amlodipine besylate	07/31/1992	NDA	1. Hypertension 2. Coronary Artery Disease (CAD) i. Chronic stable angina ii. Confirmed or suspected vasospastic angina iii. Angiographically Documented CAD (Reduce the risk of hospitalization)	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				for angina and to reduce the risk of a coronary revascularization procedure)	
Prelay	troglitazone	06/16/1999	sNDA	Combination with metformin and sulfonylurea in patients with type 2 diabetes	United States
Prelay	troglitazone	08/04/1997	sNDA		United States
Prelay	troglitazone	08/04/1997	sNDA	Combination with sulfonylureas in the treatment of type II diabetes	United States
Prelay	troglitazone	08/04/1997	sNDA	Monotherapy in type II diabetes	United States
Prelay	troglitazone	01/29/1997	NDA	Type 2 diabetes	United States
Prevnar 13	pneumococcal 13-valent Conjugate	06/28/2013	SNDS	Prevention of pneumonia and invasive pneumococcal disease (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23 in infants and	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				children from 6 years to 17 years of age	
Prevnar 13	pneumococcal 13-valent Conjugate	12/21/2009	NDS	Prevention of pneumonia and invasive pneumococcal disease (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia) caused by <i>Streptococcus pneumoniae</i> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adult patients	Canada
Pristiq	desvenlafaxine succinate	02/04/2009	NDS	Symptomatic relief of major depressive disorder	Canada
Quillivant XR	methylphenidate hydrochloride	12/04/2015	NDA	Attention Deficit Hyperactivity Disorder (ADHD)	United States
Rapamune	sirolimus	03/23/2007	SNDS	In combination with cyclosporine for the prophylaxis of organ rejection in high-risk renal transplant	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				recipients	
Rapamune	sirolimus	08/29/2005	SNDS		Canada
Rapamune	sirolimus	02/10/2003	SNDS		Canada
Rapamune	sirolimus	01/05/2001	NDS	Prophylaxis of organ rejection in patients receiving allogeneic renal transplants	Canada
Rapamune	sirolimus	03/13/2001	MAA	1. For the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant 2. Be used initially in combination with cyclosporine microemulsion and corticosteroids for two to three months 3. May be continu	Europe
Relpax	eletriptan hydrobromide	12/26/2002	NDA	Acute treatment of migraine	United States
Revatio	sildenafil citrate	03/21/2012	Post-approvals		Europe
Revatio	sildenafil citrate	05/02/2011	Post-approvals	Paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension	Europe
Revatio	sildenafil citrate	12/21/2009	Post-approvals		Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Revatio	sildenafil citrate	07/07/2009	Post-approvals	Patients with pulmonary arterial hypertension classified as WHO functional class III, to improve exercise capacity	Europe
Revatio	sildenafil citrate	10/28/2005	MAA	Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension	Europe
Revatio	sildenafil citrate	01/31/2014	sNDA		United States
Revatio	sildenafil citrate	08/30/2012	sNDA		United States
Revatio	sildenafil citrate	08/30/2012	NDA	Pulmonary arterial hypertension in adults	United States
Revatio	sildenafil citrate	11/18/2009	NDA	Pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening	United States
Revatio	sildenafil citrate	07/05/2009	sNDA	Pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Revatio	sildenafil citrate	06/03/2005	NDA	Pulmonary arterial hypertension (WHO Group I) to improve exercise ability. The enclosed labeling acknowledges that the efficacy of Revatio has not been evaluated in patients currently on bosentan therapy	United States
Somavert	pegvisomant	07/17/2015	Post-approvals		Europe
Somavert	pegvisomant	11/13/2002	MAA	Adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerate	Europe
Somavert	pegvisomant	01/26/2007	NDA	To treat excessive secretion of IGF-I (somatomedin	Japan

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				C) and other related symptoms in patients with acromegaly	
Sonata	zaleplon	07/18/2007	NDS	short-term treatment and symptomatic relief of insomnia	Canada
Sonata	zaleplon	08/13/1999	NDA	Short-term treatment of insomnia	United States
Sutent	sunitinib malate	06/30/2011	SNDS	Unresectable locally advanced or metastatic, well differentiated pancreatic neuroendocrine tumours (pancreatic NET), whose disease is progressive	Canada
Sutent	sunitinib malate	07/07/2009	SNDS		Canada
Sutent	sunitinib malate	05/01/2008	SNDS	Metastatic renal cell carcinoma (MRCC) of clear cell histology	Canada
Sutent	sunitinib malate	08/17/2006	SNDS	Metastatic renal cell carcinoma of clear cell histology after failure of cytokine-based therapy or in patients who are considered likely to be intolerant of such therapy	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Sutent	sunitinib malate	05/26/2006	NDS	1. Gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance 2. Metastatic renal cell carcinoma (MRCC) of clear cell histology 3. Unresectable locally advanced or metastatic, well differentiated pa	Canada
Sutent	sunitinib malate	05/29/2009	Post-approvals		Europe
Sutent	sunitinib malate	01/11/2007	Post-approvals	Advanced and/or metastatic renal cell carcinoma (MRCC) after failure of interferon alfa or interleukin-2 therapy	Europe
Sutent	sunitinib malate	07/19/2006	MAA	Malignant gastrointestinal stromal tumour (GIST) and renal cell carcinoma	Europe
Thelin	sitaxsentan sodium	05/30/2007	NDS	Primary pulmonary arterial hypertension or pulmonary	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				hypertension secondary to connective tissue disease	
Thelin	sitaxsentan sodium	08/10/2006	MAA	Pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease	Europe
Tikosyn	dofetilide	03/08/2016	sNDA		United States
Tikosyn	dofetilide	11/25/2015	sNDA		United States
Tikosyn	dofetilide	07/08/2015	sNDA		United States
Tikosyn	dofetilide	10/01/1999	NDA	Atrial fibrillation and atrial flutter to normal sinus rhythm	United States
Torisel	temsirolimus	12/21/2007	NDS	Metastatic renal cell carcinoma	Canada
Torisel	temsirolimus	10/14/2009	Post-approvals	Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and/or refractory	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				mantle-cell lymphoma (MCL)	
Torisel	temsirolimus	11/19/2007	MAA	For the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors	Europe
Torisel	temsirolimus	07/23/2010	NDA	Unresectable or metastatic renal cell carcinoma	Japan
Toviaz	fesoterodine fumarate	02/09/2012	NDS	Patients with overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, or any combination of these symptoms	Canada
Toviaz	fesoterodine fumarate	04/20/2007	MAA	Symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive-bladder syndrome	Europe
Toviaz	fesoterodine fumarate	10/31/2008	NDA	Overactive bladder	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Turvel	trovafloxacin mesylate	12/18/1998	NDA	Sexually transmitted diseases	United States
Turvel	trovafloxacin mesylate	12/18/1997	NDA	1. Nosocomial pneumonia 2) Community acquired pneumonia 3) Acute bacterial exacerbation of chronic bronchitis 4) Acute sinusitis 5) Uncomplicated skin and skin structure infections 6) Complicated skin and skin structure infections including diabetic foot infections 7) Complicated intra abdominal infections including post surgical infections 8) Complicated gynecologic and pelvic infections including post surgical infections 9) Surgical prophylaxis elevated	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				colorectal surgery 10) Surgical prophylaxis elevated abdominal and vaginal hysterectomy	
Tygacil	tigecycline	10/23/2008	SNDS	1. Complicated intra-abdominal infections (cIAI) in patients 18 years of age and older caused by <i>Citrobacter freundii</i> , <i>Enterobacter cloacae</i> , <i>Escherichia coli</i> , <i>Klebsiella oxytoca</i> , <i>Klebsiella pneumoniae</i> , <i>Enterococcus faecalis</i> (vancomycin-susceptible strain)	Canada
Tygacil	tigecycline	09/14/2006	NDS	Complicated skin and skin structure infections in patients 18 years of age and older (cSSSI) caused by <i>Escherichia coli</i> , <i>Enterococcus faecalis</i> (vancomycin-	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				susceptible strains only), <i>Staphylococcus aureus</i> (methicillin - susceptible and -resistant strains),	
Tygacil	tigecycline	05/28/2015	Post-approvals	Restricted use of Tygacil (tigecycline) in paediatric patients =8 years to <18 years of age The agreed indications for tigecycline in children are the same as those approved for adult patients	Europe
Tygacil	tigecycline	04/24/2006	MAA	1. Complicated skin and soft tissue infections 2. Complicated intra-abdominal infections	Europe
Tygacil	tigecycline	09/28/2012	NDA	Deep skin infections, chronic pyoderma, secondary infection, such as trauma, burns and surgical wounds, secondary infection of erosions, ulcers, peritonitis, intra-	Japan

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				abdominal abscess, cholecystitis	
Vfend	voriconazole	01/11/2012	sNDA	Prophylaxis against development of invasive fungal infections (IFI) in high risk patients such as haematopoietic stem cell transplant (HSCT) recipients	Australia
Vfend	voriconazole	09/13/2002	NDA	Fungal Infections: Invasive aspergillosis 1. Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia) 2. Serious fungal infections caused by	Australia
Vfend	voriconazole	05/15/2006	SNDS		Canada
Vfend	voriconazole	10/12/2005	SNDS	Candidemia in non-neutropenic patients and the	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds	
Vfend	voriconazole	08/20/2004	NDS	Invasive aspergillosis	Canada
Vfend	voriconazole	06/23/2014	Post-approvals	Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients	Europe
Vfend	voriconazole	02/23/2004	Post-approvals		Europe
Vfend	voriconazole	03/19/2002	MAA	1. Invasive aspergillosis 2. Candidaemia non-neutropenic patients 3. Serious fungal infections caused by Scedosporium spp and Fusarium spp in Adults and children aged 2 years and above	Europe
Vfend	voriconazole	12/21/2004	sNDA	Candidemia in nonneutropenic patients and the following Candida	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				infections: disseminated infections in skin and infections in abdomen; kidney; bladder wall; and wounds	
Vfend	voriconazole	12/19/2003	NDA	Invasive aspergillosis and serious fungal infections caused by <i>Scedosporium</i> <i>apiospermum</i> and <i>Fusarium</i> spp.; including <i>Fusarium solani</i> ; in patients intolerant of; or refractory to; other therapy	United States
Vfend	voriconazole	11/14/2003	NDA	Esophageal candidiasis	United States
Vfend	voriconazole	05/24/2002	NDA	Invasive aspergillosis and serious fungal infections caused by <i>Scedosporium</i> <i>apiospermum</i> and <i>Fusarium</i> spp.; including <i>Fusarium solani</i> ; in patients intolerant of; or refractory to; other therapy	United States
Vfend	voriconazole	05/22/2002	NDA	Invasive aspergillosis and serious	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp.; including <i>Fusarium solani</i> ; in patients intolerant of; or refractory to; other therapy	
Viagra	sildenafil citrate	03/08/1999	NDS	Erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance	Canada
Viagra	sildenafil citrate	04/17/2013	Post-approvals		Europe
Viagra	sildenafil citrate	09/14/1998	MAA	Men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance	Europe
Viagra	sildenafil citrate	01/25/1999	NDA	Erectile dysfunction	Japan
Viviant	bazedoxifene	04/17/2009	MAA	Postmenopausal osteoporosis in women at increased risk of	Europe

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				fracture A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established	
Viviant	bazedoxifene	07/23/2010	NDA	Postmenopausal osteoporosis	Japan
Vyndaqel	tafamidis meglumine	11/16/2011	MAA	Transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment	Europe
Xalkori	crizotinib	04/25/2012	NDS	Anaplastic lymphoma kinase (ALK) positive locally advanced (not amenable to curative therapy) or metastatic nonsmall cell lung cancer (NSCLC)	Canada
Xalkori	crizotinib	04/25/2012	NDS	Anaplastic lymphoma kinase (ALK)-positive locally advanced (not	Canada

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				amenable to curative therapy) or metastatic nonsmall cell lung cancer (NSCLC)	
Xalkori	crizotinib	11/23/2015	Post-approvals	For the first-line treatment of adults with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)	Europe
Xalkori	crizotinib	10/23/2012	MAA	Adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)	Europe
Xalkori	crizotinib	03/11/2016	sNDA	Metastatic NSCLC whose tumors are ROS1-positive	United States
Xalkori	crizotinib	08/26/2011	NDA	Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				detected by an FDA approved test	
Xeljanz	tofacitinib citrate	02/05/2015	NDA	Signs and symptoms of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate	Australia
Xeljanz	tofacitinib citrate	04/17/2014	NDS	Reducing the signs and symptoms of Rheumatoid Arthritis (RA), in adult patients with moderately to severely active RA who have had an inadequate response to MTX(in combination with methotrexate)	Canada
Xeljanz	tofacitinib citrate	03/25/2013	BLA	Rheumatoid arthritis in patients who have not sufficiently responded to conventional treatments	Japan
Xeljanz	tofacitinib citrate	02/23/2016	NDA	Adult patients with moderately to severely	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, to be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic d	
Xeljanz	tofacitinib citrate	02/08/2016	sNDA		United States
Xeljanz	tofacitinib citrate	11/08/2013	sNDA		United States
Xeljanz	tofacitinib citrate	11/06/2012	NDA	Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, to be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic d	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
Zithromax	azithromycin dihydrate	06/10/2005	NDA	Community Acquired Pneumonia (CAP) and Acute Bacterial Maxillary Sinusitis (ABS)	United States
Zithromax	azithromycin dihydrate	10/19/1995	NDA	Mild to moderate infections caused by designated, susceptible bacteria 1. Acute bacterial exacerbations of chronic bronchitis in adults 2. Acute bacterial sinusitis in adults 3. Uncomplicated skin and skin structure infections in adults 4. Urethritis and	United States
Zoloft	sertraline hydrochloride	03/20/2015	sNDA	Posttraumatic stress disorder	Japan
Zoloft	sertraline hydrochloride	04/20/2006	NDA	Depression and panic disorder	Japan
Zoloft	sertraline hydrochloride	09/16/2003	sNDA		United States
Zoloft	sertraline hydrochloride	02/07/2003	sNDA	Social anxiety disorder	United States
Zoloft	sertraline hydrochloride	09/20/2002	sNDA	Long-term treatment of	United States

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				obsessive compulsive disorder	
Zoloft	sertraline hydrochloride	09/20/2002	sNDA	Long-term treatment of panic disorder	United States
Zoloft	sertraline hydrochloride	05/16/2002	sNDA	Premenstrual Dysphoric Disorder (PMDD)	United States
Zoloft	sertraline hydrochloride	10/12/2001	sNDA	Pediatric obsessive compulsive disorder (OCD)	United States
Zoloft	sertraline hydrochloride	08/06/2001	sNDA	Long-term treatment of posttraumatic stress disorder	United States
Zoloft	sertraline hydrochloride	12/07/1999	NDA	Depression	United States
Zyvox	linezolid	11/21/2012	sNDA	1. Sepsis 2. Deep skin infection 3. Chronic pyoderma 4. Secondary infection of trauma 5. Burn 6. Surgical wounds 7. Pneumonia	Japan
Zyvox	linezolid	04/20/2006	sNDA	Methicillin-resistant Staphylococcus aureus (MRSA)	Japan
Zyvox	linezolid	05/04/2001	sNDA		Japan
Zyvox	linezolid	04/04/2001	NDA	Vancomycin-resistant Enterococcus faecium of	Japan

Product Name	Active Ingredient	Approval Date	Application Type	Regulatory Indication	Country
				sensitivity to this drug for Various infectious diseases	

myPharma Thinktank

Patents

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Caduet	amlodipine besylate,atorvastatin calcium	AL1491193	Formulation	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	AP1225A	Composition, Formula, Method of Use	Pfizer Inc	08/27/2018			
Caduet	amlodipine besylate,atorvastatin calcium	AR012269A1	Composition, Formula, Method of Use	Pfizer Inc	02/28/2011			
Caduet	amlodipine besylate,atorvastatin calcium	AT277615T	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018	SPC	07/07/2020	
Caduet	amlodipine besylate,atorvastatin calcium	AT332689T	Formulation	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	AU755636B2	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018	AU 70	07/20/2020	
Caduet	amlodipine besylate,atorvastatin calcium	BE1491193	Formulation	Pfizer Inc	08/31/2014			
Caduet	amlodipine besylate,atorvastatin calcium	BG104177A	Composition, Formula, Method of Use	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	BG64665B1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	BR9812030A	Composition, Formula, Method	Pfizer Inc	10/21/2008			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			of Use					
Caduet	amlodipine besylate,atorvastatin calcium	CA230173 2C	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	CH149119 3	Formula	Pfizer Inc	08/31/2014			
Caduet	amlodipine besylate,atorvastatin calcium	CN101062 035A	Composition, Formula, Method of Use	Pfizer Inc	11/04/2009			
Caduet	amlodipine besylate,atorvastatin calcium	CN126805 2A	Composition, Formula, Method of Use	Pfizer Inc	03/19/2008			
Caduet	amlodipine besylate,atorvastatin calcium	CO497069 4A1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	CY149119 3	Formula	Pfizer Inc	08/11/2013			
Caduet	amlodipine besylate,atorvastatin calcium	CZ301081 B6	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018	SPC	07/07/2020	
Caduet	amlodipine besylate,atorvastatin calcium	DE698266 83T2	Composition, Formula, Method of Use	Pfizer Inc	09/05/2013			
Caduet	amlodipine besylate,atorvastatin calcium	DE698352 45T2	Formula	Pfizer Inc	03/03/2015			
Caduet	amlodipine besylate,atorvastatin calcium	DK149119 3T3	Formula	Pfizer Inc	08/31/2014			
Caduet	amlodipine besylate,atorvastatin	DZ2596A1	Composition, Formula	Pfizer Inc	08/26/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	calcium		tion, Method of Use					
Caduet	amlodipine besylate,atorvastatin calcium	EA003549 B1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	EP100350 3B1	Composition, Method of Use	Pfizer Inc	04/08/2013			
Caduet	amlodipine besylate,atorvastatin calcium	EP146868 2A1	Composition	Pfizer Inc	05/06/2009			
Caduet	amlodipine besylate,atorvastatin calcium	EP149119 3B1	Formula	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	ES222786 5T3	Composition, Method of Use	Pfizer Inc	08/11/2014	SPC	07/07/2020	
Caduet	amlodipine besylate,atorvastatin calcium	ES226696 1T3	Formula	Pfizer Inc	09/25/2015			
Caduet	amlodipine besylate,atorvastatin calcium	FI1491193	Formula	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	FR149119 3	Formula	Pfizer Inc	04/30/2015			
Caduet	amlodipine besylate,atorvastatin calcium	GB149119 3	Formula	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	GEP2008 4338B	Composition, Formula, Method of Use	Pfizer Inc	08/10/2027			
Caduet	amlodipine besylate,atorvastatin calcium	GR149119 3	Formula	Pfizer Inc	03/04/2015			
Caduet	amlodipine besylate,atorvastatin calcium	GT199800 127A	Composition, Formula,	Pfizer Inc	08/11/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			Method of Use					
Caduet	amlodipine besylate,atorvastatin calcium	HN199800 0132A	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	HRP9804 73B1	Composition, Formula, Method of Use	Pfizer Inc	08/28/2018	SPC		
Caduet	amlodipine besylate,atorvastatin calcium	HU000365 6A3	Composition, Formula, Method of Use	Pfizer Inc	10/28/2015			
Caduet	amlodipine besylate,atorvastatin calcium	ID23670A	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	IE1491193	Formula	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	IL134303A	Composition, Formula, Method of Use	Pfizer Inc	10/31/2011			
Caduet	amlodipine besylate,atorvastatin calcium	IS2029B	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018	SPC	06/07/2020	
Caduet	amlodipine besylate,atorvastatin calcium	IT1491193	Formula	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	JP200151 4222A	Composition, Formula, Method of Use	Pfizer Inc	05/21/2004			
Caduet	amlodipine besylate,atorvastatin calcium	JP200421 0797A	Composition, Formula,	Pfizer Inc	09/07/2009			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			Method of Use					
Caduet	amlodipine besylate,atorvastatin calcium	JP2010111693A	Composition	Pfizer Inc	06/03/2013			
Caduet	amlodipine besylate,atorvastatin calcium	LI1491193	Formation	Pfizer Inc	08/31/2014			
Caduet	amlodipine besylate,atorvastatin calcium	LT1491193	Formation	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	LU1491193	Formation	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	LV1491193	Formation	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	MA26535A1	Composition, Formation, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	MK1491193	Formation	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	MY123993A	Composition, Formation, Method of Use	Pfizer Inc	06/30/2021			
Caduet	amlodipine besylate,atorvastatin calcium	NL1491193	Formation	Pfizer Inc	03/01/2015			
Caduet	amlodipine besylate,atorvastatin calcium	NO320267B1	Composition, Formation, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	NZ527158A	Composition	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin	NZ537880A	Formation	Pfizer Inc	08/11/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	calcium							
Caduet	amlodipine besylate,atorvastatin calcium	OA11290A	Composition, Formula, Method of Use	Pfizer Inc	02/18/2020			
Caduet	amlodipine besylate,atorvastatin calcium	PA8457101A1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	PE107199A1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	PL192360B1	Composition, Formula, Method of Use	Pfizer Inc	08/31/2015			
Caduet	amlodipine besylate,atorvastatin calcium	PT1003503E	Composition, Formula, Method of Use	Pfizer Inc	07/12/2013	SPC		
Caduet	amlodipine besylate,atorvastatin calcium	PT1491193E	Formula	Pfizer Inc	02/11/2015			
Caduet	amlodipine besylate,atorvastatin calcium	RO1491193	Formula	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	RS50485B	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	SE1491193	Formula	Pfizer Inc	08/11/2014			
Caduet	amlodipine besylate,atorvastatin calcium	SI1003503T1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2014	SPC	08/28/2021	
Caduet	amlodipine	SI1491193	Formula	Pfizer Inc	08/11/2014			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	besylate,atorvastatin calcium	T1	tion					
Caduet	amlodipine besylate,atorvastatin calcium	SK284958 B6	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	TNSN98156A1	Composition, Formula, Method of Use	Pfizer Inc	08/26/2018			
Caduet	amlodipine besylate,atorvastatin calcium	TR2000000561T2	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	TW592696B	Composition, Formula, Method of Use	Pfizer Inc	08/25/2018			
Caduet	amlodipine besylate,atorvastatin calcium	UA71897C2	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	US20030008904A1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate,atorvastatin calcium	US20040048906A1	Composition, Formula, Method of Use	Pfizer Inc	10/27/2008			
Caduet	amlodipine besylate,atorvastatin calcium	US20060223865A1	Method of Use	Pfizer Inc	05/09/2011			
Caduet	amlodipine besylate,atorvastatin calcium	US20060270717A1	Composition	Pfizer Inc	04/27/2009			
Caduet	amlodipine besylate,atorvastatin	US20090297598A1	Composition	Pfizer Inc	03/17/2010			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	calcium							
Caduet	amlodipine besylate, atorvastatin calcium	US20100168187A1	Composition	Pfizer Inc	03/11/2011			
Caduet	amlodipine besylate, atorvastatin calcium	US20110201654A1	Method of Use	Pfizer Inc	04/21/2012			
Caduet	amlodipine besylate, atorvastatin calcium	US20120208854A1	Method of Use	Pfizer Inc	02/01/2013			
Caduet	amlodipine besylate, atorvastatin calcium	US20130131125A1	Method of Use	Pfizer Inc	10/18/2013			
Caduet	amlodipine besylate, atorvastatin calcium	US20140039017A1	Method of Use	Pfizer Inc	01/26/2015			
Caduet	amlodipine besylate, atorvastatin calcium	US6455574B1	Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate, atorvastatin calcium	UY25157A1	Composition, Formula, Method of Use	Pfizer Inc	08/11/2018			
Caduet	amlodipine besylate, atorvastatin calcium	WO1999011259A1	Composition, Formula, Method of Use	Pfizer Inc	04/08/2013			
Caduet	amlodipine besylate, atorvastatin calcium	ZA9807844B	Composition, Formula, Method of Use	Pfizer Inc	08/28/2018			
Camptosar	irinotecan hydrochloride	AU4564200A	Method of Use	Pfizer Inc	03/21/2002			
Camptosar	irinotecan hydrochloride	US2004229841A1	Method of Use	Pfizer Inc	01/25/2008			
Camptosar	irinotecan hydrochloride	US6403569B1	Method of Use	Pfizer Inc	04/28/2020			10/28/2020
Camptosar	irinotecan hydrochloride	US6794370B2	Method of Use	Pfizer Inc	01/05/2020			01/11/2020

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Camptosar	irinotecan hydrochloride	WO0066125A1	Method of Use	Pfizer Inc	11/30/2001			
Chantix	varenicline tartrate	AL1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	AL1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	AL1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	AL1619192	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	AP1170A	Composition, Product	Pfizer Inc	12/17/2018			
Chantix	varenicline tartrate	AP1473A	Product Specific	Pfizer Inc	05/09/2022			
Chantix	varenicline tartrate	AP1860A	Product	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	AR017967A1	Product	Pfizer Inc	12/29/2018			
Chantix	varenicline tartrate	AR033635A1	Product Specific	Pfizer Inc	05/13/2022			
Chantix	varenicline tartrate	AT302607T	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	AT328872T	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	AT386024T	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	AT453643T	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	AU2002253482B2	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	AU2005234671B2	Product	Pfizer Inc	09/03/2009			
Chantix	varenicline tartrate	AU753389B2	Composition, Method of Use, Product	Pfizer Inc	02/15/2022			
Chantix	varenicline tartrate	AU784081B2	Composition, Method of Use, Product Derivative	Pfizer Inc	10/04/2007			
Chantix	varenicline	BE104418	Method	Pfizer Inc	11/13/2018	SPC	09/27/2021	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	tartrate	9	of Use, Product Generic					
Chantix	varenicline tartrate	BE1259489	Product Derivative	Pfizer Inc	02/28/2015			
Chantix	varenicline tartrate	BE1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	BE1619192	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	BG65058B1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	BG65891B1	Product Derivative	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	BG66408B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	BR0108610A	Product	Pfizer Inc	08/07/2012			
Chantix	varenicline tartrate	BR0209605A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	BR9814592B1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	BR9816186B1	Process	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	CA2316921C	Composition, Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	CA2401229C	Product Derivative	Pfizer Inc	02/08/2016			
Chantix	varenicline tartrate	CA2447405C	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	CH1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	12/20/2021	
Chantix	varenicline tartrate	CH1259489	Product Derivative	Pfizer Inc	02/28/2015			
Chantix	varenicline tartrate	CH1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	CH1619192	Product Derivative	Pfizer Inc	02/28/2010			
Chantix	varenicline tartrate	CN100370987C	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	CN1263745C	Product Derivative	Pfizer Inc	02/08/2021			
Chantix	varenicline	CN132401	Product	Pfizer Inc	11/13/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	tartrate	3C						
Chantix	varenicline tartrate	CN171528 0A	Process	Pfizer Inc	06/22/2012			
Chantix	varenicline tartrate	CO481037 3A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	CR6726A	Product	Pfizer Inc	08/09/2022			
Chantix	varenicline tartrate	CR7080A	Product Specific	Pfizer Inc	10/05/2009			
Chantix	varenicline tartrate	CU23148 A3	Product	Pfizer Inc	08/11/2015			
Chantix	varenicline tartrate	CY104418 9	Method of Use, Product Generic	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	CY125948 9	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	CY139230 7	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	CY161919 2	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	CZ301925 B6	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	CZ303203 B6	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	CZ304763 B6	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	DE161919 2	Product Derivative	Pfizer Inc	09/01/2015			
Chantix	varenicline tartrate	DE601203 66T2	Product Derivative	Pfizer Inc	09/01/2015			
Chantix	varenicline tartrate	DE602057 42T2	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	DE698391 31T2	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	DK104418 9T3	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	DK125948 9T3	Product Derivative	Pfizer Inc	02/28/2015			
Chantix	varenicline tartrate	DK139230 7T3	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline	DK161919	Product	Pfizer Inc	02/28/2015			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	tartrate	2T3	Derivative					
Chantix	varenicline tartrate	DOP2002 000392A	Product Specific	Pfizer Inc	06/05/2022			
Chantix	varenicline tartrate	DZ2697A1	Product	Pfizer Inc	12/30/2018			
Chantix	varenicline tartrate	EA003190 B1	Product Derivative	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	EA005316 B1	Product Derivative	Pfizer Inc	11/30/2015			
Chantix	varenicline tartrate	EA005528 B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	ECSP034 849A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	ECSP034 850A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	EE05441B 1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	EE200200 475A	Product	Pfizer Inc	12/15/2003			
Chantix	varenicline tartrate	EG23816 A	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	EG24228 A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	EP104418 9B1	Method of Use, Product Generic	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	EP125948 9B1	Product Derivative	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	EP139230 7B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	EP161919 2B1	Product Derivative	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	EP165911 4A2	Process	Pfizer Inc	09/23/2014			
Chantix	varenicline tartrate	ES224639 6T3	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	ES226364 0T3	Product Derivative	Pfizer Inc	03/29/2016			
Chantix	varenicline tartrate	ES230121 0T3	Product	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	ES233680 0T3	Product Derivative	Pfizer Inc	03/29/2016			
Chantix	varenicline tartrate	FI1044189	Method of Use,	Pfizer Inc	11/13/2018	SPC	09/26/2021	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			Product Generic					
Chantix	varenicline tartrate	FI1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	FI1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	FI1619192	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	FR1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	FR1259489	Product Derivative	Pfizer Inc	03/02/2015			
Chantix	varenicline tartrate	FR1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	FR1619192	Product Derivative	Pfizer Inc	03/02/2015			
Chantix	varenicline tartrate	GB1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/27/2021	
Chantix	varenicline tartrate	GB1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	GB1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	GB1619192	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	GEP20053454B	Product	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	GEP20053712B	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	GR1044189	Method of Use, Product Generic	Pfizer Inc	11/14/2018	SPC	09/27/2021	
Chantix	varenicline tartrate	GR1259489	Product Derivative	Pfizer Inc	09/02/2015			
Chantix	varenicline tartrate	GR1392307	Product Specific	Pfizer Inc	04/27/2022			
Chantix	varenicline tartrate	GR1619192	Product Derivative	Pfizer Inc	03/31/2010			
Chantix	varenicline tartrate	GT199800200A	Product	Pfizer Inc	02/08/2021			
Chantix	varenicline	GT200200	Product	Pfizer Inc	04/26/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	tartrate	084A	Specific					
Chantix	varenicline tartrate	HK103187 8A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	HK105089 4A1	Product	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	HK106264 5A1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	HN199800 0177A	Product	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	HRP2000 0445B1	Product	Pfizer Inc	11/13/2018	SPC	09/28/2021	
Chantix	varenicline tartrate	HRP2002 0700A2	Product	Pfizer Inc	12/31/2004			
Chantix	varenicline tartrate	HRP2003 0910B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	HRP2005 0506A2	Product	Pfizer Inc	03/31/2006			
Chantix	varenicline tartrate	HU229482 B1	Product Derivative	Pfizer Inc	09/28/2015			
Chantix	varenicline tartrate	HU229867 B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	HU230297 B1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	IE1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/27/2021	
Chantix	varenicline tartrate	IE1259489	Product Derivative	Pfizer Inc	10/30/2015			
Chantix	varenicline tartrate	IE1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	IE1619192	Product Derivative	Pfizer Inc	10/30/2015			
Chantix	varenicline tartrate	IL136727A	Product	Pfizer Inc	11/13/2018	Extension	05/10/2020	
Chantix	varenicline tartrate	IL150639A	Product	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	IL157933A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	IN-MUMNP-2006-00869A	Product Derivative	Pfizer Inc	06/08/2007			
Chantix	varenicline tartrate	IS2217B	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	IS2293B	Product Derivative	Pfizer Inc	08/29/2015			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Chantix	varenicline tartrate	IS5514A	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	IT1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/25/2021	
Chantix	varenicline tartrate	IT1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	IT1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	IT1619192	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	JP2003524002A	Product	Pfizer Inc	05/28/2008			
Chantix	varenicline tartrate	JP3550359B2	Product	Pfizer Inc	11/13/2018	Extension	08/07/2022	
Chantix	varenicline tartrate	JP3779682B2	Product Specific	Pfizer Inc	04/26/2022	Extension	03/11/2024	
Chantix	varenicline tartrate	KR100408138B1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	KR100537976B1	Product Derivative	Pfizer Inc	12/15/2014			
Chantix	varenicline tartrate	KR100551184B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	LI1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	12/20/2021	
Chantix	varenicline tartrate	LI1259489	Product Derivative	Pfizer Inc	02/28/2015			
Chantix	varenicline tartrate	LI1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	LI1619192	Product Derivative	Pfizer Inc	02/28/2010			
Chantix	varenicline tartrate	LT1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	LT1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	LT1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	LT1619192	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	LU1044189	Method of Use,	Pfizer Inc	11/13/2018	SPC	09/26/2021	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			Product Generic					
Chantix	varenicline tartrate	LU1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	LU1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	LU1619192	Product Derivative	Pfizer Inc	02/08/2010			
Chantix	varenicline tartrate	LV1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/24/2021	
Chantix	varenicline tartrate	LV1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	LV1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	LV1619192	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	MA26589A1	Product	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	MA26875A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	MA27020A1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	MC1044189	Method of Use, Product Generic	Pfizer Inc	11/30/2008			
Chantix	varenicline tartrate	MC1259489	Product Derivative	Pfizer Inc	02/28/2007			
Chantix	varenicline tartrate	MC1392307	Product Specific	Pfizer Inc	04/30/2006			
Chantix	varenicline tartrate	MC1619192	Product Derivative	Pfizer Inc	03/01/2010			
Chantix	varenicline tartrate	MK1044189	Method of Use, Product Generic	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	MK1259489	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	MK1392307	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	MK1619192	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline	MXPA020	Product	Pfizer Inc	02/08/2021			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	tartrate	08311A						
Chantix	varenicline tartrate	MXPA030 10364A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	MY118163 A	Product	Pfizer Inc	09/30/2019			
Chantix	varenicline tartrate	MY127807 A	Product Specific	Pfizer Inc	05/10/2022			
Chantix	varenicline tartrate	NL104418 9	Method of Use, Product Generic	Pfizer Inc	11/12/2018	SPC	09/27/2021	
Chantix	varenicline tartrate	NL125948 9	Product Derivative	Pfizer Inc	09/01/2015			
Chantix	varenicline tartrate	NL139230 7	Product Specific	Pfizer Inc	04/25/2022			
Chantix	varenicline tartrate	NL161919 2	Product Derivative	Pfizer Inc	09/01/2015			
Chantix	varenicline tartrate	NO319115 B1	Product	Pfizer Inc	11/13/2018	SPC	09/28/2021	
Chantix	varenicline tartrate	NO323608 B1	Product Derivative	Pfizer Inc	02/28/2015			
Chantix	varenicline tartrate	NO326148 B1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	NZ504482 A	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	NZ519973 A	Product Derivative	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	NZ528210 A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	OA11428 A	Product	Pfizer Inc	06/16/2020			
Chantix	varenicline tartrate	OA12181 A	Product Derivative	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	OA12599 A	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	PA846390 1A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	PA854510 1A1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	PE005320 00A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	PE106520 02A1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	PL209404 B1	Product	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline	PL214876	Product	Pfizer Inc	04/26/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	tartrate	B1	Specific					
Chantix	varenicline tartrate	PL365163 A1	Product	Pfizer Inc	04/30/2009			
Chantix	varenicline tartrate	PT104418 9E	Product	Pfizer Inc	11/13/2018	SPC	09/28/2021	
Chantix	varenicline tartrate	PT125948 9E	Product Derivative	Pfizer Inc	08/31/2006			
Chantix	varenicline tartrate	PT139230 7E	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	PT161919 2	Product Derivative	Pfizer Inc	04/30/2010			
Chantix	varenicline tartrate	RO104418 9	Method of Use, Product Generic	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	RO125948 9	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	RO139230 7	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	RO161919 2	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	RS50069B	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	RS50814B	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	RS51123B	Product Derivative	Pfizer Inc	09/03/2015			
Chantix	varenicline tartrate	SE104418 9	Method of Use, Product Generic	Pfizer Inc	11/13/2018	SPC	09/25/2021	
Chantix	varenicline tartrate	SE125948 9	Product Derivative	Pfizer Inc	09/10/2001			
Chantix	varenicline tartrate	SE139230 7	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	SE161919 2	Product Derivative	Pfizer Inc	09/10/2015			
Chantix	varenicline tartrate	SG102686 A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	SG91138	Product	Pfizer Inc	08/15/2015			
Chantix	varenicline tartrate	SG99582	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	SI0161919 2	Product Derivative	Pfizer Inc	12/30/2009			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			ve					
Chantix	varenicline tartrate	SI1044189 T1	Product	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	SI1259489 T1	Product Derivative	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	SI1392307 T1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	SK120420 02A3	Product	Pfizer Inc	02/08/2015			
Chantix	varenicline tartrate	SK286886 B6	Product Derivative	Pfizer Inc	11/13/2018	SPC	09/26/2021	
Chantix	varenicline tartrate	SK287170 B6	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	TNSN031 13A1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	TNSN982 37A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	TR125948	Product Derivative	Pfizer Inc	11/26/2015			
Chantix	varenicline tartrate	TR139230 7	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	TR161919 2	Product Derivative	Pfizer Inc	12/30/2009			
Chantix	varenicline tartrate	TR200001 840T2	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	TW51341 2B	Product	Pfizer Inc	12/28/2018	Extension	07/09/2023	
Chantix	varenicline tartrate	TWI26207 8B	Product Specific	Pfizer Inc	05/12/2022			
Chantix	varenicline tartrate	UA66825 C2	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	UA73422 C2	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	UA74813 C2	Product Derivative	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	US200207 2524A1	Method of Use, Product	Pfizer Inc	01/22/2008			
Chantix	varenicline tartrate	US200727 5973A1	Method of Use	Pfizer Inc	05/11/2009			
Chantix	varenicline tartrate	US641055 0B1	Product Generic	Pfizer Inc	11/13/2018	USC 156	05/10/2020	
Chantix	varenicline tartrate	US660561 0B1	Method of Use	Pfizer Inc	09/07/2015			
Chantix	varenicline tartrate	US688788 4B2	Product Derivative	Pfizer Inc	12/22/2019			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			ve					
Chantix	varenicline tartrate	US6890927B2	Product Specific	Pfizer Inc	05/06/2022			
Chantix	varenicline tartrate	US6897310B2	Intermediate, Process	Pfizer Inc	10/12/2019			
Chantix	varenicline tartrate	US6951938B2	Intermediate	Pfizer Inc	10/13/2019			
Chantix	varenicline tartrate	US7144882B2	Product Derivative	Pfizer Inc	01/05/2015			
Chantix	varenicline tartrate	US7205300B2	Product Derivative	Pfizer Inc	05/08/2015			
Chantix	varenicline tartrate	US7265119B2	Polymorph	Pfizer Inc	08/03/2022			
Chantix	varenicline tartrate	WO0162736A1	Product	Pfizer Inc	02/08/2021			
Chantix	varenicline tartrate	WO2002092089A1	Product Specific	Pfizer Inc	04/26/2022			
Chantix	varenicline tartrate	WO9935131A1	Product	Pfizer Inc	11/13/2018			
Chantix	varenicline tartrate	ZA200307235A	Product Specific	Pfizer Inc	04/26/2022			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AL0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AL0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AP796A	Composition	Pfizer Inc	04/30/2017			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AP838A	Product	Pfizer Inc	04/30/2017			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AR007002A1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AR007003A1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride, ziprasidone mesylate	AR045528A2	Composition	Pfizer Inc	10/31/2007			
Geodon	ziprasidone	AT231394	Method	Pfizer Inc	09/15/2010			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	hydrochloride,ziprasidone mesylate	T	of Use					
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	AT236902 T	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	AT257714 T	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	AU713711 B2	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	AU730856 B2	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	AU739472 B2	Method of Use, Product	Pfizer Inc	07/29/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BE090008 8	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BE090427 3	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BE093154 7	Method of Use	Pfizer Inc	12/31/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BG63601 B1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BG64474 B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BG64475 B2	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BR970893 2A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	BR970921 3A	Composition	Pfizer Inc	01/18/2011			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CA2251912C	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CA2252895C	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CA2256227C	Method of Use	Pfizer Inc	12/16/2018			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CH0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CH0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CH0931547	Method of Use	Pfizer Inc	12/31/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CN1092658C	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CN1216923A	Composition	Pfizer Inc	11/10/2006			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CO4600677A1	Composition	Pfizer Inc	08/27/2001			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CO4940465A1	Product	Pfizer Inc	04/28/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CY0931547	Method of Use	Pfizer Inc	12/15/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CZ289216B6	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	CZ297847B6	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DE69720719T2	Product	Pfizer Inc	03/26/2017			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	ziprasidone mesylate							
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DE697272 18T2	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DE698108 89T2	Method of Use	Pfizer Inc	07/01/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DK090008 8T3	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DK090427 3T3	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DK093154 7T3	Method of Use	Pfizer Inc	07/20/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DZ2220A1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	DZ2221A1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	EA001180 B1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	EA001731 B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	EG24135 A	Composition	Pfizer Inc	04/05/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	EG24401 A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	EP090008 8B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	EP090427 3B1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride	EP093154 7B1	Method of Use	Pfizer Inc	12/15/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	de,ziprasidone mesylate							
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ES2190570T3	Method of Use	Pfizer Inc	03/04/2011			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ES2192264T3	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ES2212809T3	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	FI0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	FI0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	FI0931547	Method of Use	Pfizer Inc	12/15/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	FR0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	FR0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	FR0931547	Method of Use	Pfizer Inc	12/31/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GB0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GB0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GB0931547	Method of Use	Pfizer Inc	12/15/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GEP20074185B	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone	GR090008	Composition	Pfizer Inc	04/02/2017			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	hydrochloride,ziprasidone mesylate	8	ition					
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GR0904273	Product	Pfizer Inc	03/27/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GR0931547	Method of Use	Pfizer Inc	12/15/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GT19970042A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	GT19970044A	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HK1017893A1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HN199700039A	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HN199700040A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HRP970235B1	Product	Pfizer Inc	05/07/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HRP970237B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HU222451B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HU229057B1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	HU9802958A1	Method of Use	Pfizer Inc	08/30/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ID16866A	Composition	Pfizer Inc	04/01/2017			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ID17504A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IE0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IE0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IE0931547	Method of Use	Pfizer Inc	09/10/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IL126546A	Composition	Pfizer Inc	01/10/2003			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IL126590A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IL127497A	Method of Use	Pfizer Inc	12/10/2004			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IS2301B	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IS2524B	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IT0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	IT0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	JP3102896B2	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	JP3579060B2	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	JPH11246409A	Method of Use	Pfizer Inc	12/10/2004			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	ziprasidone mesylate							
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	KR20000010822A	Product	Pfizer Inc	08/02/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	KR20000010823A	Composition	Pfizer Inc	03/09/2016			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LI09000088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LI0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LI0931547	Method of Use	Pfizer Inc	12/31/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LT0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LT0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LU0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LU0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LU0931547	Method of Use	Pfizer Inc	12/15/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LV0900088	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	LV0904273	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	MA24172A1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride	MA26427A1	Product	Pfizer Inc	03/26/2017			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	de,ziprasidone mesylate							
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	MY121036 A	Method of Use	Pfizer Inc	12/30/2020			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	MY121999 A	Composition	Pfizer Inc	03/31/2021			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	MY128051 A	Product	Pfizer Inc	01/31/2022			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NL090008 8	Composition	Pfizer Inc	03/31/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NL090427 3	Product	Pfizer Inc	03/25/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NL093154 7	Method of Use	Pfizer Inc	07/01/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NO312513 B1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NO324373 B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NZ332219 A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NZ332220 A	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NZ333436 A	Method of Use	Pfizer Inc	12/17/2011			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	NZ508303 A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	OA10907 A	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone	OA10908	Product	Pfizer Inc	03/26/2017			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	hydrochloride,ziprasidone mesylate	A						
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	PL188164 B1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	PL189324 B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	PT093154 7	Method of Use	Pfizer Inc	06/24/2011			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	PT900088 E	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	PT904273 E	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	RO090008 8	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	RO090427 3	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	RS49532B	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SE090008 8	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SE090427 3	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SE093154 7	Method of Use	Pfizer Inc	07/10/2010			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SG57071	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SG57111	Composition	Pfizer Inc	04/01/2017			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SI0900088 T1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SI0904273 T1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SK282032 B6	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	SK282674 B6	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TNSN970 73A1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TNSN970 75A1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TR980223 1T2	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TR980224 1T2	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TW42798 9B	Product	Pfizer Inc	03/31/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TW51452 9B	Composition	Pfizer Inc	03/24/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	TW52098 9B	Method of Use	Pfizer Inc	02/21/2009			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	US611091 8A	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	US623230 4B1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	US624576 6B1	Method of Use	Pfizer Inc	12/18/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	ziprasidone mesylate							
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	US6399777B2	Product	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	UY24543A1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	UY24544A1	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	WO1997042190A1	Product	Pfizer Inc	03/26/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	WO9741896A2	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	YU49398B	Product	Pfizer Inc	05/06/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ZA9703874A	Composition	Pfizer Inc	04/01/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ZA9703875A	Product	Pfizer Inc	05/06/2017			
Geodon	ziprasidone hydrochloride,ziprasidone mesylate	ZA9811573A	Method of Use	Pfizer Inc	03/13/2014			
Ibrance	palbociclib	AL1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	AP1767A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	AR038814A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	AR083686A2	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	AT314370T	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	AU2003237009B2	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	BE1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	BG1470124	Product Specific	Pfizer Inc	01/10/2023			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Ibrance	palbociclib	BR0307057A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CA2473026C	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CH1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CN101001857B	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CN101906104B	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CN102295643B	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CO5700765A2	Product Generic	Pfizer Inc	01/26/2009			
Ibrance	palbociclib	CR20120129A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CY1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	CZ1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	DE60303009T2	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	DK1470124T3	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	DOP2003000561A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	EA007395B1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	ECSP045201A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	ECSP105201A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	EE1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	EP1470124B1	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	ES2251677T3	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	FI1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	FR1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	GB1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	GEP20063909B	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	GR1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	GT200300005A	Product Generic	Pfizer Inc	01/10/2023			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Ibrance	palbociclib	HK1104296A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	HK1146048A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	HK1162026A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	HN2003000039A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	HRP20040660B1	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	HU1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	IE1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	IL162721A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	IL198243A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	IN218291A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	IS2423B	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	IT1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	JP4291696B2	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	KR100669578B1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	KR20060111716A	Product Generic	Pfizer Inc	01/05/2010			
Ibrance	palbociclib	LI1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	LT1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	LU1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	LV1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	MA27166A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	MC1470124	Product Specific	Pfizer Inc	01/31/2006			
Ibrance	palbociclib	MEP46108A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	MK1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	MXPA04005939A	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	MY134818A	Product Generic	Pfizer Inc	01/20/2023			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Ibrance	palbociclib	NI200300008A	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	NL1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	NO329350B1	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	NZ534069A	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	OA12755A	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	PA8563701A1	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	PE09752003A1	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	PL218692B1	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	PT1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	RO1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	RS51044B	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	SE1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	SG104840	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	SI1470124T1	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	SK1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	SV2004001459A	Product Generic	Pfizer Inc	01/16/2008			
Ibrance	palbociclib	TR1470124	Product Specific	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	TWI343920B	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	UA79444C2	Product Generic	Pfizer Inc	01/20/2023			
Ibrance	palbociclib	US6936612B2	Product Specific	Pfizer Inc	01/22/2023			
Ibrance	palbociclib	US7208489B2	Product Generic	Pfizer Inc	01/16/2023			
Ibrance	palbociclib	US7456168B2	Method of Use	Pfizer Inc	01/16/2023			
Ibrance	palbociclib	UY27617A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	WO03062236A1	Product Generic	Pfizer Inc	01/10/2023			
Ibrance	palbociclib	ZA200404840A	Product Generic	Pfizer Inc	01/10/2023			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Lipitor	atorvastatin calcium	AM AR003458 A1	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	AR003458 A1	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	AR003459 A1	Polymorph	Pfizer Inc	04/25/2011			
Lipitor	atorvastatin calcium	AS AR003458 A1	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	AT208375 T	Polymorph, Process	Pfizer Inc	10/15/2009			
Lipitor	atorvastatin calcium	AT284868 T	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	AZ AR003458 A1	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	BD AR003458 A1	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	BY AR003458 A1	Polymorph, Process	Pfizer Inc	07/08/2016			
Lipitor	atorvastatin calcium	EP084870 5B1	Polymorph	Pfizer Inc	02/25/2009			
Lipitor	atorvastatin calcium	EP114804 9B1	Polymorph	Pfizer Inc	05/24/2011			
Lipitor	atorvastatin calcium	US596915 6A	Polymorph	Pfizer Inc	07/08/2016			01/08/2017
Lyrica	Pregabalin	AT207052 T	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	03/15/2014	
Lyrica	Pregabalin	AU677008 B2	Composition, Method of Use, Process, Product	Pfizer Inc	12/18/2014			
Lyrica	Pregabalin	AU913709 1A	Composition, Method of Use, Product	Pfizer Inc	08/19/1993			
Lyrica	Pregabalin	BE064133 0	Formation, Method	Pfizer Inc	05/18/2013	SPC	11/30/2013	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			of Use, Process, Product					
Lyrica	Pregabalin	CA2134674C	Process, Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	CH0641330	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	12/18/2013	
Lyrica	Pregabalin	CZ286106B6	Product	Pfizer Inc	05/18/2013	SPC		
Lyrica	Pregabalin	DE69330949T2	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	12/03/2013	
Lyrica	Pregabalin	DK0641330T3	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	01/20/2014	
Lyrica	Pregabalin	EP0641330B1	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	ES2165857T3	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	12/10/2013	
Lyrica	Pregabalin	FI945426A	Formation, Method of Use, Process, Product	Pfizer Inc	08/12/1995			
Lyrica	Pregabalin	FI945426A0	Formation, Method of Use, Process, Product	Pfizer Inc	05/18/2013			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			Product					
Lyrica	Pregabalin	FR0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	01/30/2014	
Lyrica	Pregabalin	GB0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	05/18/2013	
Lyrica	Pregabalin	GR0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	05/19/2015	
Lyrica	Pregabalin	HK1011022A1	Product	Pfizer Inc	05/17/2013			
Lyrica	Pregabalin	HU222339B1	Product	Pfizer Inc	05/18/2013	SPC	12/10/2013	
Lyrica	Pregabalin	HU222776B1	Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	IE0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	07/02/2014	
Lyrica	Pregabalin	IT0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	05/20/2014	
Lyrica	Pregabalin	JP3856816B2	Method of Use, Product	Pfizer Inc	05/18/2013	Extension	10/20/2017	
Lyrica	Pregabalin	JP4297814B2	Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	LI0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	12/18/2013	
Lyrica	Pregabalin	LU064133	Formula	Pfizer Inc	05/18/2013	SPC	05/18/2013	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
		0	Composition, Method of Use, Process, Product					
Lyrica	Pregabalin	MC0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	MX9102241A	Composition, Method of Use, Product	Pfizer Inc	11/27/2011			
Lyrica	Pregabalin	MX9302970A	Composition, Method of Use, Product	Pfizer Inc	05/20/2013			
Lyrica	Pregabalin	NL0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	11/12/2013	
Lyrica	Pregabalin	NO944370A	Product	Pfizer Inc	12/21/1995			
Lyrica	Pregabalin	NZ253459A	Process, Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	PT641330E	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	11/27/2014	
Lyrica	Pregabalin	RU2140901C1	Method of Use, Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	RU94046105A	Process, Product	Pfizer Inc	11/18/2014			
Lyrica	Pregabalin	SE0641330	Formulation, Method of Use, Process, Product	Pfizer Inc	05/18/2013	SPC	01/02/2014	
Lyrica	Pregabalin	SG48288	Product	Pfizer Inc	05/18/2013			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
		A1						
Lyrica	Pregabalin	SK283281 B6	Product	Pfizer Inc	05/18/2013			
Lyrica	Pregabalin	US200322 5161A1	Method of Use, Product	Pfizer Inc	03/07/2011			
Lyrica	Pregabalin	US556317 5A	Method of Use	Pfizer Inc	10/08/2013			
Lyrica	Pregabalin	US559997 3A	Process	Pfizer Inc	02/04/2014			
Lyrica	Pregabalin	US560809 0A	Product	Pfizer Inc	03/04/2014			
Lyrica	Pregabalin	US568418 9A	Process	Pfizer Inc	11/04/2014			
Lyrica	Pregabalin	US571030 4A	Product	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US584715 1A	Product	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US602821 4A	Product	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US611790 6A	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US614036 6A	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US619781 9B1	Product	Pfizer Inc	03/06/2018	USC 156	12/30/2018	
Lyrica	Pregabalin	US625534 5B1	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US626212 0B1	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US629152 6B1	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US634252 9B1	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US635916 9B1	Product	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US641402 4B1	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	US641402 4B1	Method of Use	Pfizer Inc	11/27/2010			
Lyrica	Pregabalin	WO92095 60A1	Combination, Composition, Method of Use, Product	Pfizer Inc	08/28/1992			
Lyrica	Pregabalin	WO93233 83A1	Process	Pfizer Inc	05/18/2013			
Nitrostat	nitroglycerin	AL101903 9	Composition	Pfizer Inc	09/16/2009			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Nitrostat	nitroglycerin	AT209911T	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	AU759018B2	Composition	Pfizer Inc	05/06/2010			
Nitrostat	nitroglycerin	BE1019039	Composition	Pfizer Inc	09/30/2009			
Nitrostat	nitroglycerin	BR9812605B1	Composition	Pfizer Inc	04/22/2014			
Nitrostat	nitroglycerin	CA2299231C	Composition	Pfizer Inc	09/16/2010			
Nitrostat	nitroglycerin	CH1019039	Composition	Pfizer Inc	09/30/2009			
Nitrostat	nitroglycerin	CY1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	DE69802832T2	Composition	Pfizer Inc	04/01/2010			
Nitrostat	nitroglycerin	DK1019039T3	Composition	Pfizer Inc	09/30/2009			
Nitrostat	nitroglycerin	EP1019039B1	Composition	Pfizer Inc	09/16/2018			
Nitrostat	nitroglycerin	ES2169558T3	Composition	Pfizer Inc	09/17/2009			
Nitrostat	nitroglycerin	FI1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	FR1019039	Composition	Pfizer Inc	05/31/2010			
Nitrostat	nitroglycerin	GB1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	GR1019039	Composition	Pfizer Inc	04/06/2010			
Nitrostat	nitroglycerin	IE1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	IL134395A	Composition	Pfizer Inc	09/16/2012			
Nitrostat	nitroglycerin	IT1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	JP2001518500A	Composition	Pfizer Inc	06/12/2009			
Nitrostat	nitroglycerin	LI1019039	Composition	Pfizer Inc	09/30/2009			
Nitrostat	nitroglycerin	LT1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	LU1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	LV1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	MC1019039	Composition	Pfizer Inc	09/30/2009			
Nitrostat	nitroglycerin	MK1019039	Composition	Pfizer Inc	09/16/2009			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Nitrostat	nitroglycerin	NL1019039	Composition	Pfizer Inc	04/01/2010			
Nitrostat	nitroglycerin	NZ502878A	Composition	Pfizer Inc	09/16/2011			
Nitrostat	nitroglycerin	PT1019039E	Composition	Pfizer Inc	09/16/2010			
Nitrostat	nitroglycerin	RO1019039	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	SE1019039	Composition	Pfizer Inc	04/10/2010			
Nitrostat	nitroglycerin	SI1019039T1	Composition	Pfizer Inc	09/16/2009			
Nitrostat	nitroglycerin	TWI228989B	Composition	Pfizer Inc	03/11/2009			
Nitrostat	nitroglycerin	US6500456B1	Composition	Pfizer Inc	09/16/2018			
Nitrostat	nitroglycerin	WO1999017766A1	Composition	Pfizer Inc	09/16/2018			
Pristiq	desvenlafaxine succinate	AL1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	AR032671A1	Process, Product	Pfizer Inc	10/24/2014			
Pristiq	desvenlafaxine succinate	AR082076A2	Process, Product	Pfizer Inc	01/05/2015			
Pristiq	desvenlafaxine succinate	AT369330T	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	AU2002250058B2	Process, Product	Pfizer Inc	02/11/2022	AU 70	08/18/2023	
Pristiq	desvenlafaxine succinate	BE1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	BR0207157A	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	CA2436668C	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	CA2666611A1	Process, Product	Pfizer Inc	04/26/2012			
Pristiq	desvenlafaxine succinate	CH1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	CN100567253C	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafax	CN101671	Process	Pfizer Inc	07/10/2013			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	ine succinate	260A	, Product					
Pristiq	desvenlafaxine succinate	CY110695 2T1	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	CY136016 9	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	DE602216 42T2	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	DK136016 9T3	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	EA011451 B1	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	EP136016 9B1	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	EP186496 7A1	Process , Product	Pfizer Inc	02/15/2011			
Pristiq	desvenlafaxine succinate	EP231982 6A1	Process , Product	Pfizer Inc	10/07/2015			
Pristiq	desvenlafaxine succinate	ES229028 1T3	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	FI1360169	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	FR136016 9	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	GB136016 9	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	GR136016 9	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	GT200200 022A	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	HK105788 5A1	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	HN200200 0030A	Process , Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	HU030312 8A2	Process , Product	Pfizer Inc	02/11/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Pristiq	desvenlafaxine succinate	IE1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	IL157340A	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	IL200255A	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	IL209444A	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	IT1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	JP4220243B2	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	KR100875610B1	Process, Product	Pfizer Inc	03/02/2016			
Pristiq	desvenlafaxine succinate	LI1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	LT1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	LU1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	LV1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	MC1360169	Process, Product	Pfizer Inc	02/28/2008			
Pristiq	desvenlafaxine succinate	MK1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	MXPA0307043A	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	NL1360169	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	NO328807B1	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	NZ539791A	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine	PA8539901A1	Process, ,	Pfizer Inc	02/11/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	succinate		Product					
Pristiq	desvenlafaxine succinate	PE087720 02A1	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	PL211788 B1	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	PL212943 B1	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	PT136016 9E	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	RO136016 9	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	SE136016 9	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	SI1360169 T1	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	TR136016 9	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	TWI31820 1B	Process, Product	Pfizer Inc	02/14/2022			
Pristiq	desvenlafaxine succinate	US200400 44241A1	Formulation, Process	Pfizer Inc	11/23/2004			
Pristiq	desvenlafaxine succinate	US200900 18208A1	Composition	Pfizer Inc	07/22/2013			
Pristiq	desvenlafaxine succinate	US667383 8B2	Composition, Formulation, Method of Use, Product	Pfizer Inc	02/11/2022	USC 156	03/01/2022	
Pristiq	desvenlafaxine succinate	US702650 8B2	Process	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	US729134 7B2	Composition	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	UY27175A 1	Process, Product	Pfizer Inc	02/11/2022			
Pristiq	desvenlafaxine succinate	WO20020 64543A2	Process, Product	Pfizer Inc	02/11/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Relpax	eletriptan hydrobromide	AP576A	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	AT163182T	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	AU691005B2	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	BE0776323	Process , Product Specific	Pfizer Inc	05/16/2015			
Relpax	eletriptan hydrobromide	BG61840B1	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	BR9503812A	Process , Product Specific	Pfizer Inc	08/25/2015			
Relpax	eletriptan hydrobromide	CA2198599C	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	CH0776323	Process , Product Specific	Pfizer Inc	05/16/2015			
Relpax	eletriptan hydrobromide	CN1066727C	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	CO4410334A1	Process , Product Specific	Pfizer Inc	08/23/2015			
Relpax	eletriptan hydrobromide	CZ287693B6	Process , Product Specific	Pfizer Inc	05/17/2015	SPC	12/14/2015	
Relpax	eletriptan hydrobromide	DE69501620T2	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	DK0776323T3	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	DZ1923A1	Process , Product	Pfizer Inc	08/23/2015			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
			Specific					
Relpax	eletriptan hydrobromide	EG23822A	Process, Product Specific	Pfizer Inc	08/26/2015			
Relpax	eletriptan hydrobromide	EP0776323B1	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	ES2112650T3	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	FI113768B	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	FR0776323	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	GB0776323	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	GR3026475T3	Process, Product Specific	Pfizer Inc	05/18/2015			
Relpax	eletriptan hydrobromide	HRP950460B1	Process, Product Specific	Pfizer Inc	08/25/2015			
Relpax	eletriptan hydrobromide	HU227822B1	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	IE0776323	Process, Product Specific	Pfizer Inc	05/16/2015			
Relpax	eletriptan hydrobromide	IL115013A	Process, Product Specific	Pfizer Inc	08/21/2015			
Relpax	eletriptan hydrobromide	IS1850B	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	IT0776323	Process, Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	JP2904588B2	Process, ,	Pfizer Inc	05/17/2015	Extension	06/29/2018	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	de		Product Specific					
Relpax	eletriptan hydrobromide	KR100228952B1	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	LI0776323	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	LU0776323	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	LV11800B	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	MA23650A1	Process , Product Specific	Pfizer Inc	08/21/2015			
Relpax	eletriptan hydrobromide	MX9701538A	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	NL0776323	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	NO311297B1	Process , Product Specific	Pfizer Inc	05/26/2015			
Relpax	eletriptan hydrobromide	NZ288210A	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	OA10600A	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	PE41596A1	Process , Product Specific	Pfizer Inc	08/23/2015			
Relpax	eletriptan hydrobromide	PL180867B1	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	PT0776323	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan	RO116400	Process	Pfizer Inc	05/17/2015			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	hydrobromide	B1	, Product Specific					
Relpax	eletriptan hydrobromide	RU2159241C2	Polymorph, Process	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	SE0776323	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	SI9520091B	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	SK282922B6	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	TNSN95092A1	Process , Product Specific	Pfizer Inc	08/16/2015			
Relpax	eletriptan hydrobromide	TR9501061A2	Process , Product Specific	Pfizer Inc	08/25/2015			
Relpax	eletriptan hydrobromide	US6110940A	Polymorph, Process	Pfizer Inc	08/29/2017			
Relpax	eletriptan hydrobromide	US6380226B1	Polymorph, Process	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	WO1996006842A1	Process , Product Specific	Pfizer Inc	05/17/2015			
Relpax	eletriptan hydrobromide	YU49287B	Process , Product Specific	Pfizer Inc	08/25/2015			
Relpax	eletriptan hydrobromide	ZA9507142A	Process , Product Specific	Pfizer Inc	08/25/2015			
Toviaz	fesoterodine fumarate	AL1230209	Process , Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	AT286872T	Process , Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	AT337293T	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodin	AT395056	Formula	Pfizer Inc	11/15/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	e fumarate	T	tion, Method of Use					
Toviaz	fesoterodine fumarate	AU778132 B2	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	BE1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	BE1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	BE1690536	Formation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	BRPI0015610B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CA2389749C	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CH1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CH1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CH1690536	Formation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CN1215045C	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CY1110389T1	Formation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CY1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CY1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CZ302497B6	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	CZ302967B6	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	DE1230209	Process, Product	Pfizer Inc	11/15/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Toviaz	fesoterodine fumarate	DE1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	DE1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	DE19955190A1	Process, Product	Pfizer Inc	03/20/2012			
Toviaz	fesoterodine fumarate	DK1230209T3	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	DK1481964T3	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	DK1690536T3	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	EA005588B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	EP1230209B3	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	EP1481964B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	EP1690536B1	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	ES2236032T3	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	ES2270240T3	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	ES2303708T3	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	FI1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	FI1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	FI1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine	FR123020	Process	Pfizer Inc	11/15/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	fesoterodine fumarate	9	, Product					
Toviaz	fesoterodine fumarate	FR1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	FR1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	GB1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	GB1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	GB1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	GEP20084430B	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	GR1230209	Process, Product	Pfizer Inc	11/16/2020			
Toviaz	fesoterodine fumarate	GR1481964	Polymorph, Process	Pfizer Inc	11/14/2020			
Toviaz	fesoterodine fumarate	GR1690536	Formulation, Method of Use	Pfizer Inc	11/16/2020			
Toviaz	fesoterodine fumarate	HK1045148A1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	HK1067114A1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	HK1095736A1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	HU227608B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	HU228197B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IE1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IE1481964	Polymorph, Process	Pfizer Inc	11/15/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Toviaz	fesoterodine fumarate	IE1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IL149567A	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IS2124B	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IS2673B	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IT1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IT1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	IT1690536	Formulation, Method of Use	Pfizer Inc	11/15/2012			
Toviaz	fesoterodine fumarate	JP2007137895A	Formulation, Method of Use	Pfizer Inc	11/18/2011			
Toviaz	fesoterodine fumarate	JP4083431B2	Formulation, Method of Use	Pfizer Inc	11/15/2020	Extension	09/17/2025	
Toviaz	fesoterodine fumarate	JP5290351B2	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	JP5503393B2	Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	JP5650924B2	Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	JP5717824B2	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	KR100563149B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LI1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LI1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LI1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Toviaz	fesoterodine fumarate	LT1230209	Process, Product	Pfizer Inc	11/15/2020	SPC	04/20/2022	
Toviaz	fesoterodine fumarate	LT1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LT1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LU1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LU1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LU1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LV1230209	Process, Product	Pfizer Inc	11/15/2020	SPC	04/20/2022	
Toviaz	fesoterodine fumarate	LV1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	LV1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MC1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MC1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MC1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MK1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MK1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MK1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	MXPA0204603A	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine	NL123020	Process	Pfizer Inc	11/14/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	e fumarate	9	, Product					
Toviaz	fesoterodine fumarate	NL1481964	Polymorph, Process	Pfizer Inc	11/14/2020			
Toviaz	fesoterodine fumarate	NL1690536	Formulation, Method of Use	Pfizer Inc	11/14/2020			
Toviaz	fesoterodine fumarate	NO323920B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	NO332637B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	NZ519230A	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	PL201422B1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	PT1230209E	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	PT1481964E	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	PT1690536E	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	RO1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	RO1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	RO1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SE1230209	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SE1481964	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SE1690536	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SI1230209T1	Process, Product	Pfizer Inc	11/15/2020	SPC	04/20/2022	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Toviaz	fesoterodine fumarate	SI1481964 T1	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SI1690536 T1	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SK287430 B6	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	SK288185 B6	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	TR123020 9	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	TR148196 4	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	TR169053 6	Formulation, Method of Use	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	UA73324 C2	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	UA77322 C2	Polymorph, Process	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	US685865 0B1	Process, Product	Pfizer Inc	05/11/2019	USC 156	07/03/2022	
Toviaz	fesoterodine fumarate	WO20010 35957A1	Process, Product	Pfizer Inc	11/15/2020			
Toviaz	fesoterodine fumarate	ZA200203 315A	Process, Product	Pfizer Inc	11/15/2020			
Tritace	ramipril	AT303800 T	Method of Use	Pfizer Inc	12/05/2012			
Tritace	ramipril	AU200520 9687A1	Method of Use	Pfizer Inc	03/19/2009			
Tritace	ramipril	AU200920 0746B8	Method of Use	Pfizer Inc	08/30/2020			
Tritace	ramipril	AU764910 0A	Method of Use	Pfizer Inc	10/27/2005			
Tritace	ramipril	BG110003 A	Method of Use	Pfizer Inc	12/05/2012			
Tritace	ramipril	BG65474 B1	Method of Use	Pfizer Inc	08/30/2020			
Tritace	ramipril	BR001370 4A	Method of Use	Pfizer Inc	11/23/2010			
Tritace	ramipril	CA238254	Method	Pfizer Inc	08/30/2016			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
		9C	of Use					
Tritace	ramipril	CA2488370A1	Method of Use	Pfizer Inc	01/04/2010			
Tritace	ramipril	EP1216038B1	Method of Use	Pfizer Inc	05/12/2012			
Tritace	ramipril	US2004087645A1	Combination, Method of Use	Pfizer Inc	10/09/2006			
Tritace	ramipril	US2005101658A1	Method of Use	Pfizer Inc	07/02/2008			
Tritace	ramipril	US2008287403A1	Method of Use	Pfizer Inc	12/29/2009			
Tritace	ramipril	US7368469B2	Method of Use	Pfizer Inc	08/30/2020			
Tritace	ramipril	WO0115674A2	Method of Use	Pfizer Inc	12/05/2012			
Tritace	ramipril	ZA200201470B	Method of Use	Pfizer Inc	08/30/2020			
Vfend	voriconazole	AL1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	AP912A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	AR015900A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	AT238812T	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	AU724799B2	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	BE1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	BG64584B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	BR9809468B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	CA2295035C	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	CH1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	CN1125653C	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	CO4940450A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	CY1001813	Formulation	Pfizer Inc	06/02/2008			
Vfend	voriconazole	CZ289570B6	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	DE69814091T2	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	DK1001813T3	Formulation	Pfizer Inc	06/02/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Vfend	voriconazole	DZ2523A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	EA001924B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	EG23910A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	EP1001813B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	ES2195355T3	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	FI1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	FR1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	GB1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	GR1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	HK1027966A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	HRP980341B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	HU228338B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	ID22939A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	IE1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	IL132918A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	IN262988A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	IS2004B	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	IT1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	JP2000513029A	Formulation	Pfizer Inc	05/07/2004			
Vfend	voriconazole	JP5089004B2	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	KR100372988B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	LI1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	LT1001813	Formulation	Pfizer Inc	06/02/2018	SPC		
Vfend	voriconazole	LU1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	LV1001813	Formulation	Pfizer Inc	06/02/2018			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Vfend	voriconazole	MA26508A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	MK1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	MY118151A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	NL1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	NO313125B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	NZ501066A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	OA11232A	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	PA8453201A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	PE84899A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	PL191295B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	PT1001813E	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	RO1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	RS49633B	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	SE1001813	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	SG68935	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	SI1001813T1	Formulation	Pfizer Inc	06/02/2018	SPC		
Vfend	voriconazole	SK282946B6	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	TNSN98090A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	TR9903191T2	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	TW406023B	Formulation	Pfizer Inc	05/04/2018			
Vfend	voriconazole	US6632803B1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	UY25055A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	WO1998058677A1	Formulation	Pfizer Inc	06/02/2018			
Vfend	voriconazole	ZA9805364A	Formulation	Pfizer Inc	06/02/2018			
Viagra	sildenafil citrate	AT163852T	Method of Use	Pfizer Inc	02/01/2005			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Viagra	sildenafil citrate	AU676571 B2	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	CA216344 6C	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	CN107111 8C	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	CN174273 1B	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	CY2099B1	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	CZ284946 B6	Method of Use	Pfizer Inc	07/20/2010			
Viagra	sildenafil citrate	DE694089 81T2	Method of Use	Pfizer Inc	02/01/2005			
Viagra	sildenafil citrate	DK070255 5T3	Method of Use	Pfizer Inc	02/01/2005			
Viagra	sildenafil citrate	ECSP941 102A	Method of Use	Pfizer Inc	06/09/2014			
Viagra	sildenafil citrate	EP070255 5B1	Method of Use	Pfizer Inc	02/01/2005			
Viagra	sildenafil citrate	ES211365 6T3	Method of Use	Pfizer Inc	02/01/2005			
Viagra	sildenafil citrate	FI955911 A	Method of Use	Pfizer Inc	12/18/2009			
Viagra	sildenafil citrate	GR302652 0T3	Method of Use	Pfizer Inc	02/01/2005			
Viagra	sildenafil citrate	HU227877 B1	Method of Use	Pfizer Inc	05/14/2014			
Viagra	sildenafil citrate	IL109873A	Method of Use	Pfizer Inc	06/02/2014			
Viagra	sildenafil citrate	IL121836A	Method of Use	Pfizer Inc	06/02/2014			
Viagra	sildenafil citrate	JP200509 7304A	Method of Use	Pfizer Inc	10/15/2008			
Viagra	sildenafil citrate	JP292503 4B2	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	JPH11263 728A	Method of Use	Pfizer Inc	05/21/2004			
Viagra	sildenafil citrate	JPH11286 444A	Method of Use	Pfizer Inc	09/26/2002			
Viagra	sildenafil citrate	KR100262 926B1	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	LV12269B	Method of Use	Pfizer Inc	02/15/2019			
Viagra	sildenafil citrate	NO309227 B1	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	NO325558 B1	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	NZ266463 A	Method of Use	Pfizer Inc	11/30/2006			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Viagra	sildenafil citrate	NZ314110 A	Method of Use	Pfizer Inc	11/30/2006			
Viagra	sildenafil citrate	PL311948 A1	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	RU213077 6C1	Method of Use	Pfizer Inc	11/27/2009			
Viagra	sildenafil citrate	RU237393 8C2	Method of Use	Pfizer Inc	05/13/2014			
Viagra	sildenafil citrate	TW29297 1B	Method of Use	Pfizer Inc	05/14/2014	Extension	07/02/2016	
Viagra	sildenafil citrate	US200300 27824A1	Method of Use	Pfizer Inc	11/28/2005			
Viagra	sildenafil citrate	US646901 2B1	Method of Use	Pfizer Inc	10/22/2019			04/22/2020
Viagra	sildenafil citrate	WO19940 28902A1	Method of Use	Pfizer Inc	02/01/2005			
Viagra	sildenafil citrate	ZA940401 8B	Method of Use	Pfizer Inc	06/08/2011			
Xeljanz	tofacitinib citrate	AL123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AL123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AL138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AL138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AP1905A	Method of Use, Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AP1905A	Method of Use, Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AR026534 A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AR026534 A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AR037635 A1	Polymorph	Pfizer Inc	01/30/2015			
Xeljanz	tofacitinib citrate	AT257157 T	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AT257157 T	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AT380031 T	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AT380031 T	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	AT497962 T	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	AU200234 8857B2	Polymorph	Pfizer Inc	11/25/2022	Extension	11/25/2027	
Xeljanz	tofacitinib	AU777911	Product	Pfizer Inc	11/23/2020	AU 70	11/23/2025	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	citrate	B2						
Xeljanz	tofacitinib citrate	AU777911 B2	Product	Pfizer Inc	11/23/2020	AU 70	11/23/2025	
Xeljanz	tofacitinib citrate	BE123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BE123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BE138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BE138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BE145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	BG145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	BG65821 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BG65821 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BR001626 3A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BR001626 3A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	BR021476 1A	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CA239364 0C	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CA239364 0C	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CA246935 0C	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CH123583 0	Product	Pfizer Inc	11/23/2020	SPC	11/22/2025	
Xeljanz	tofacitinib citrate	CH123583 0	Product	Pfizer Inc	11/23/2020	SPC	11/22/2025	
Xeljanz	tofacitinib citrate	CH138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CH138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CH145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CN119575 5C	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CN119575 5C	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CN132549 8C	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CO527166 5A1	Product	Pfizer Inc	04/30/2009			
Xeljanz	tofacitinib	CO527166	Product	Pfizer Inc	04/30/2009			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	citrate	5A1						
Xeljanz	tofacitinib citrate	CO558078 0A2	Polymorph	Pfizer Inc	04/23/2008			
Xeljanz	tofacitinib citrate	CR6655A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CR6655A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CU23220 A3	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CU23220 A3	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY110885 0T1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY110885 0T1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY111131 1T1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CY123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CY145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CZ145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	CZ303875 B6	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	CZ303875 B6	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DE145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	DE600075 52T2	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DE600075 52T2	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DE600373 45T2	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DE600373 45T2	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DK123583 0T3	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DK123583 0T3	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	DK138233 9T3	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib	DK138233	Combination	Pfizer Inc	11/23/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	citrate	9T3	ation					
Xeljanz	tofacitinib citrate	DK145119 2T3	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	EA006227 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EA006227 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EE05351B 1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EE05351B 1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EE145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	EG24399 A	Product	Pfizer Inc	06/12/2020			
Xeljanz	tofacitinib citrate	EG24399 A	Product	Pfizer Inc	06/12/2020			
Xeljanz	tofacitinib citrate	EP123583 0B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EP123583 0B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EP138233 9B1	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EP138233 9B1	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	EP145119 2B1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	ES220843 3T3	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ES220843 3T3	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ES229549 5T3	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ES229549 5T3	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ES235794 2T3	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	FI1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	FI1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	FI1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	FI1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	FI1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	FR1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib	FR123583	Product	Pfizer Inc	11/23/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	citrate	0						
Xeljanz	tofacitinib citrate	FR1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	FR1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	FR1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	GB1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GB1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GB1382339	Combination	Pfizer Inc	11/24/2020			
Xeljanz	tofacitinib citrate	GB1382339	Combination	Pfizer Inc	11/24/2020			
Xeljanz	tofacitinib citrate	GB1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	GEP20053479B	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GEP20053479B	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GR1235830	Product	Pfizer Inc	11/24/2020			
Xeljanz	tofacitinib citrate	GR1235830	Product	Pfizer Inc	11/24/2020			
Xeljanz	tofacitinib citrate	GR1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GR1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GR1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	GT200000208A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GT200000208A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	GT200200234A	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	HK1051195A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	HK1051195A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	HK1070653A1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	HN2000000265A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	HN2000000265A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	HN2002000349A	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib	HRP2002	Product	Pfizer Inc	11/23/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	citrate	0509B1						
Xeljanz	tofacitinib citrate	HRP2002 0509B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	HU229671 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	HU229671 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IE1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IE1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IE1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IE1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IE1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	IL149616A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IL149616A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IN-PCT-DEL-2002-00588A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IN-PCT-DEL-2002-00588A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IN218212 A1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	IN251800 A1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	IS2173B	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IS2173B	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IT1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IT1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IT1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IT1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	IT1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	JP407807 4B2	Product	Pfizer Inc	11/23/2020	Extension	11/23/2025	
Xeljanz	tofacitinib citrate	JP407807 4B2	Product	Pfizer Inc	11/23/2020	Extension	11/23/2025	
Xeljanz	tofacitinib citrate	JP420113 5B2	Polymorph	Pfizer Inc	11/25/2022	Extension	02/05/2027	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Xeljanz	tofacitinib citrate	KR100691 590B1	Polymorph	Pfizer Inc	11/25/2022	Extension	11/24/2027	
Xeljanz	tofacitinib citrate	LI1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LI1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LI1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LI1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LI1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	LT1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LT1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LT1382339	Combination	Pfizer Inc	12/05/2007			
Xeljanz	tofacitinib citrate	LT1382339	Combination	Pfizer Inc	12/05/2007			
Xeljanz	tofacitinib citrate	LU1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LU1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LU1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LU1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LU1451192	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	LV1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LV1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LV1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	LV1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MA26851 A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MA26851 A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MC1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MC1235830	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MC1382339	Combination	Pfizer Inc	11/30/2008			
Xeljanz	tofacitinib citrate	MC1382339	Combination	Pfizer Inc	11/30/2008			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Xeljanz	tofacitinib citrate	MC14511 92	Polymorph	Pfizer Inc	11/30/2011			
Xeljanz	tofacitinib citrate	MK123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MK123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MK138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MK138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MXPA020 05675A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MXPA020 05675A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	MXPA040 05401A	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	NL123583 0	Product	Pfizer Inc	11/22/2020			
Xeljanz	tofacitinib citrate	NL123583 0	Product	Pfizer Inc	11/22/2020			
Xeljanz	tofacitinib citrate	NL138233 9	Combination	Pfizer Inc	11/22/2020			
Xeljanz	tofacitinib citrate	NL138233 9	Combination	Pfizer Inc	11/22/2020			
Xeljanz	tofacitinib citrate	NL145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	NO200427 21A	Polymorph	Pfizer Inc	06/29/2009			
Xeljanz	tofacitinib citrate	NO323378 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	NO323378 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	NZ518884 A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	NZ518884 A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	NZ528905 A	Method of Use	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	NZ528905 A	Method of Use	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	NZ532366 A	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	OA12118 A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	OA12118 A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PA850730 1A1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PA850730 1A1	Product	Pfizer Inc	11/23/2020			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Xeljanz	tofacitinib citrate	PA856020 1A1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	PE080720 03A1	Polymorph	Pfizer Inc	08/09/2006			
Xeljanz	tofacitinib citrate	PE109620 01A1	Product	Pfizer Inc	12/06/2020			
Xeljanz	tofacitinib citrate	PE109620 01A1	Product	Pfizer Inc	12/06/2020			
Xeljanz	tofacitinib citrate	PL218519 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PL218519 B1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PL221493 B1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	PT123583 0E	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PT123583 0E	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PT138233 9E	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PT138233 9E	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	PT145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	RO123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	RO123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	RO138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	RO138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	RS51574B	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	RS51574B	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	RU231505 2C2	Polymorph	Pfizer Inc	11/25/2022	Extension	11/25/2027	
Xeljanz	tofacitinib citrate	SE123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SE123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SE138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SE138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SE145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	SG104520	Polymorph	Pfizer Inc	11/25/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Xeljanz	tofacitinib citrate	SG89534	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SG89534	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SI1235830 T1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SI1235830 T1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SI1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SI1382339	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SK145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	SK287188 B6	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SK287188 B6	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SV200200 0236A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	SV200200 0236A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TNSN002 39A1	Product	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	TNSN002 39A1	Product	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	TR123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR123583 0	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR138233 9	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR145119 2	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	TR200201 498T2	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR200201 498T2	Combination	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR200400 105T4	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TR200400 105T4	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	TW20030 0690A	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	TWI24893 5B	Product	Pfizer Inc	12/05/2020	Extension	06/28/2025	
Xeljanz	tofacitinib citrate	TWI24893 5B	Product	Pfizer Inc	12/05/2020	Extension	06/28/2025	

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Xeljanz	tofacitinib citrate	TWI26430 5B	Product	Pfizer Inc	12/04/2020			
Xeljanz	tofacitinib citrate	TWI26430 5B	Product	Pfizer Inc	12/04/2020			
Xeljanz	tofacitinib citrate	UA72290 C2	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	UA72290 C2	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	US695604 1B2	Composition, Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US695604 1B2	Composition, Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US696502 7B2	Polymorph	Pfizer Inc	03/25/2023			
Xeljanz	tofacitinib citrate	US709120 8B2	Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US709120 8B2	Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US726522 1B2	Product	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US726522 1B2	Product	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US760172 7B2	Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US760172 7B2	Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US780380 5B2	Method of Use	Pfizer Inc	12/04/2022			
Xeljanz	tofacitinib citrate	US784269 9B2	Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	US784269 9B2	Method of Use	Pfizer Inc	12/08/2020			
Xeljanz	tofacitinib citrate	USRE417 83E1	Product	Pfizer Inc	12/08/2020	USC 156		
Xeljanz	tofacitinib citrate	USRE417 83E1	Product	Pfizer Inc	12/08/2020	USC 156		
Xeljanz	tofacitinib citrate	UY26477A 1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	UY26477A 1	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	UY27567A 1	Polymorph	Pfizer Inc	11/25/2022			
Xeljanz	tofacitinib citrate	WO01422 46A2	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	WO01422 46A2	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib	WO03048	Polymorph	Pfizer Inc	11/25/2022			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
	citrate	162A1	ph					
Xeljanz	tofacitinib citrate	YU41302A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	YU41302A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ZA200204535A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ZA200204535A	Product	Pfizer Inc	11/23/2020			
Xeljanz	tofacitinib citrate	ZA200404270A	Polymorph	Pfizer Inc	11/25/2022			
Zithromax	azithromycin dihydrate	AL1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	AP2218A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	AP44A	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	AR045630A1	Composition	Pfizer Inc	05/30/2014			
Zithromax	azithromycin dihydrate	AR243532A1	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	AT407663T	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	AT72446T	Polymorph	Pfizer Inc	09/15/2008			
Zithromax	azithromycin dihydrate	AU2004216676B2	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	AU604553B2	Polymorph	Pfizer Inc	04/08/2009			
Zithromax	azithromycin dihydrate	BA98213B1	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	BE0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	BE1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	BG1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	BG47348A3	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	BRPI0403935A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CA1314876C	Composition, Polymorph	Pfizer Inc	03/23/2010			
Zithromax	azithromycin dihydrate	CA2467611C	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CH0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	CH1537859	Composition	Pfizer Inc	05/06/2024			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zithromax	azithromycin dihydrate	CL2004001501A1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CN1016785B	Polymorph	Pfizer Inc	02/11/2009			
Zithromax	azithromycin dihydrate	CN1697648B	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CR7500A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CS272241B2	Polymorph	Pfizer Inc	06/07/2008			
Zithromax	azithromycin dihydrate	CY1108486T1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CY1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	CY1776A	Polymorph	Pfizer Inc	10/20/2015			
Zithromax	azithromycin dihydrate	CZ1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	DD271705A5	Polymorph	Pfizer Inc	07/08/2008			
Zithromax	azithromycin dihydrate	DE0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	DE1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	DK1537859T3	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	DK172573B1	Polymorph	Pfizer Inc	07/28/2008			
Zithromax	azithromycin dihydrate	DOP2004000994A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	EA010110B1	Composition	Pfizer Inc	02/28/2013			
Zithromax	azithromycin dihydrate	ECSP045351A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	EE1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	EG18527A	Polymorph	Pfizer Inc	07/07/2008			
Zithromax	azithromycin dihydrate	EP0298650B1	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	EP1537859B1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	ES2038756T3	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	ES2312929T3	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	FI1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	FI91263C	Polymorph	Pfizer Inc	08/15/2007			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zithromax	azithromycin dihydrate	FR0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	FR1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	GB0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	GB1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	GEP20074056B	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	GR1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	GR3003737T3	Polymorph	Pfizer Inc	06/29/2008			
Zithromax	azithromycin dihydrate	GT200400183A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	HK1080367A1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	HK127594A	Polymorph	Pfizer Inc	06/27/2008			
Zithromax	azithromycin dihydrate	HR1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	HRP20040865A2	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	HU1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	HU211862A9	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	IE1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	IE60354B1	Polymorph	Pfizer Inc	09/03/2008			
Zithromax	azithromycin dihydrate	IL164165A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	IL86979A	Polymorph	Pfizer Inc	12/29/2008			
Zithromax	azithromycin dihydrate	IN168879	Polymorph	Pfizer Inc	05/11/2008			
Zithromax	azithromycin dihydrate	IN247177	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	IS1540B	Polymorph	Pfizer Inc	07/07/2008			
Zithromax	azithromycin dihydrate	IS2672B	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	IT0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	IT1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	JP2010132700A	Composition	Pfizer Inc	07/12/2013			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zithromax	azithromycin dihydrate	JP4602711B2	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	JPH0631300B2	Polymorph	Pfizer Inc	07/06/2013			
Zithromax	azithromycin dihydrate	KR100906290B1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	KR900006218B1	Polymorph	Pfizer Inc	07/09/2008			
Zithromax	azithromycin dihydrate	LI0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	LI1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	LT1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	LU0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	LU1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	LV10624B	Polymorph	Pfizer Inc	07/09/2008			
Zithromax	azithromycin dihydrate	LV1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	MA21323A1	Polymorph	Pfizer Inc	07/09/2008			
Zithromax	azithromycin dihydrate	MA27848A1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	MC1537859	Composition	Pfizer Inc	05/31/2009			
Zithromax	azithromycin dihydrate	MK1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	MX12213A	Polymorph	Pfizer Inc	07/09/2008			
Zithromax	azithromycin dihydrate	MXPA0409424A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	NL0298650	Polymorph	Pfizer Inc	06/28/2008			
Zithromax	azithromycin dihydrate	NL1026315C2	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	NL1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	NO171556B	Polymorph	Pfizer Inc	08/27/2007			
Zithromax	azithromycin dihydrate	NO20043903A	Composition	Pfizer Inc	12/27/2012			
Zithromax	azithromycin dihydrate	NZ225338A	Polymorph	Pfizer Inc	07/08/2008			
Zithromax	azithromycin dihydrate	NZ535464A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	OA12858A	Composition	Pfizer Inc	05/06/2024			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zithromax	azithromycin dihydrate	OA8743A	Polymorph	Pfizer Inc	07/08/2008			
Zithromax	azithromycin dihydrate	PA8611501A1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	PE05732005A1	Composition	Pfizer Inc	04/22/2013			
Zithromax	azithromycin dihydrate	PH30953A	Polymorph	Pfizer Inc	07/07/2008			
Zithromax	azithromycin dihydrate	PL1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	PL157145B1	Polymorph	Pfizer Inc	07/07/2008			
Zithromax	azithromycin dihydrate	PL379984A1	Composition	Pfizer Inc	01/31/2012			
Zithromax	azithromycin dihydrate	PT1537859E	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	PT87933B	Polymorph	Pfizer Inc	03/16/2009			
Zithromax	azithromycin dihydrate	RO107257B1	Polymorph	Pfizer Inc	07/07/2008			
Zithromax	azithromycin dihydrate	RO1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	RSP84704A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	RU2066324C1	Polymorph	Pfizer Inc	07/09/2007			
Zithromax	azithromycin dihydrate	SE0298650	Polymorph	Pfizer Inc	07/10/2008			
Zithromax	azithromycin dihydrate	SE1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	SG112121	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	SG27794G	Polymorph	Pfizer Inc	02/27/2011			
Zithromax	azithromycin dihydrate	SI1537859T1	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	SI8811325A8	Polymorph	Pfizer Inc	07/08/2008	SPC		
Zithromax	azithromycin dihydrate	SK1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	TR1537859	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	TWI351969B	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	UA78793C2	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	US2006029677A1	Composition	Pfizer Inc	09/27/2007			
Zithromax	azithromycin dihydrate	US2006039988A1	Composition	Pfizer Inc	08/17/2007			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zithromax	azithromycin dihydrate	US2008015343A1	Composition	Pfizer Inc	04/11/2009			
Zithromax	azithromycin dihydrate	US6268489B1	Polymorph	Pfizer Inc	07/31/2018			
Zithromax	azithromycin dihydrate	US6984403B2	Composition	Pfizer Inc	02/14/2024			
Zithromax	azithromycin dihydrate	WO2005053650A1	Composition	Pfizer Inc	08/10/2006			
Zithromax	azithromycin dihydrate	WO8900576A1	Polymorph	Pfizer Inc	07/09/2007			
Zithromax	azithromycin dihydrate	YU45075B	Polymorph	Pfizer Inc	07/08/2008			
Zithromax	azithromycin dihydrate	ZA200408075A	Composition	Pfizer Inc	05/06/2024			
Zithromax	azithromycin dihydrate	ZA8804925A	Polymorph	Pfizer Inc	07/08/2008			
Zyvox	linezolid	AL1255754	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	AR027261A1	Polymorph	Pfizer Inc	05/18/2011			
Zyvox	linezolid	AT297920T	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	AU782138B2	Polymorph	Pfizer Inc	08/30/2012			
Zyvox	linezolid	BE1255754	Polymorph	Pfizer Inc	01/31/2012			
Zyvox	linezolid	BR0107667A	Polymorph	Pfizer Inc	06/14/2011			
Zyvox	linezolid	CA2395603C	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	CH1255754	Polymorph	Pfizer Inc	01/31/2012			
Zyvox	linezolid	CN1221547C	Polymorph	Pfizer Inc	03/27/2013			
Zyvox	linezolid	CO5261555A1	Polymorph	Pfizer Inc	06/25/2010			
Zyvox	linezolid	CY1255754	Polymorph	Pfizer Inc	01/29/2011			
Zyvox	linezolid	CZ302292B6	Polymorph	Pfizer Inc	05/03/2011			
Zyvox	linezolid	DE60111497T2	Polymorph	Pfizer Inc	08/01/2012			
Zyvox	linezolid	DK1255754T3	Polymorph	Pfizer Inc	09/06/2012			
Zyvox	linezolid	EA004434B1	Polymorph	Pfizer Inc	10/30/2012			
Zyvox	linezolid	EE05197B1	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	EP1255754B1	Polymorph	Pfizer Inc	01/29/2021			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zyvox	linezolid	ES224272 8T3	Polymorph	Pfizer Inc	01/30/2012			
Zyvox	linezolid	FI1255754	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	FR1255754	Polymorph	Pfizer Inc	09/28/2012			
Zyvox	linezolid	GB1255754	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	GR1255754	Polymorph	Pfizer Inc	08/02/2012			
Zyvox	linezolid	HK1051196A1	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	HU0301076A2	Polymorph	Pfizer Inc	10/28/2011			
Zyvox	linezolid	IE1255754	Polymorph	Pfizer Inc	10/24/2012			
Zyvox	linezolid	IN208875	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	IT1255754	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	JP5235256B2	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	KR100864745B1	Polymorph	Pfizer Inc	10/16/2011			
Zyvox	linezolid	KR20080044358A	Polymorph	Pfizer Inc	09/01/2008			
Zyvox	linezolid	LI1255754	Polymorph	Pfizer Inc	01/31/2012			
Zyvox	linezolid	LT1255754	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	LU1255754	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	LV1255754	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	MC1255754	Polymorph	Pfizer Inc	01/31/2012			
Zyvox	linezolid	MK1255754	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	MXPA02007471A	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	NL1255754	Polymorph	Pfizer Inc	08/01/2012			
Zyvox	linezolid	NO20065836A	Polymorph	Pfizer Inc	05/21/2012			
Zyvox	linezolid	NO323459B1	Polymorph	Pfizer Inc	08/27/2012			
Zyvox	linezolid	NZ520541A	Polymorph	Pfizer Inc	08/29/2014			
Zyvox	linezolid	PE10862001A1	Polymorph	Pfizer Inc	08/16/2012			

Product Name	Active Ingredient	Patent Number	Patent Type	Company Name	Estimated Expiry Date	Patent Term Extension	Extended Expiry Date	Pediatric Expiry Date
Zyvox	linezolid	PL356433 A1	Polymorph	Pfizer Inc	11/30/2012			
Zyvox	linezolid	PT125575 4E	Polymorph	Pfizer Inc	07/08/2013			
Zyvox	linezolid	RO125575 4	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	SE125575 4	Polymorph	Pfizer Inc	01/30/2012			
Zyvox	linezolid	SI1255754 T1	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	SK287025 B6	Polymorph	Pfizer Inc	01/29/2012			
Zyvox	linezolid	TR125575 4	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	TWI29768 7B	Polymorph	Pfizer Inc	03/11/2012			
Zyvox	linezolid	US644481 3B2	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	US655930 5B1	Polymorph	Pfizer Inc	01/29/2021			07/29/2021
Zyvox	linezolid	WO20010 57035A1	Polymorph	Pfizer Inc	01/29/2021			
Zyvox	linezolid	ZA200205 162A	Polymorph	Pfizer Inc	06/27/2012			

Deals

Deal Date	10/20/2016
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Debiopharm International enters into clinical collaboration with the Merck-Pfizer alliance in cancer immunotherapy
Deal Status	Completed
Acquirer/Partner	Merck KGaA; Pfizer Inc
Source/Target	Debiopharm International S A
Deal Value (USD mn)	
Region/Country	Switzerland
Deal Details	Debiopharm International SA has entered into a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate Debio 1143 in combination with avelumab in patients with advanced or metastatic Non-Small Cell Lung Cancer. Under the terms of the agreement, Debiopharm will be responsible for conducting the Phase I/Ib clinical trial in Non-Small Cell Lung Cancer.
Updates/Amendments	

Deal Date	10/19/2016
Deal Type	Partnership
Sub Category	Award or Grant
Deal Headline	Pfizer receives grant to evaluate vaccine to protect new-borns against group B Streptococcus Infection
Deal Status	Completed
Acquirer/Partner	Bill and Melinda Gates Foundation
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has been awarded a grant from Bill and Melinda Gates Foundation to conduct a Phase 1/2 clinical trial of Pfizer's vaccine candidate against group B Streptococcus (group B strep or GBS) infection.
Updates/Amendments	

Deal Date	10/11/2016
Deal Type	Partnership
Sub Category	Development
Deal Headline	Transgene enters into collaboration with Merck and Pfizer to evaluate the combination of TG4001 with Avelumab
Deal Status	Completed
Acquirer/Partner	Merck KGaA; Pfizer Inc
Source/Target	Transgene SA
Deal Value (USD mn)	
Region/Country	France
Deal Details	Transgene SA has entered into a collaboration agreement with Merck KGaA and Pfizer Inc. As per the agreement, Transgene will sponsor a Phase 1/2 study evaluating the potential of the therapeutic vaccine candidate TG4001 in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, for the treatment of human papilloma virus positive head and neck squamous cell carcinoma, after failure of standard therapy.
Updates/Amendments	

Deal Date	10/06/2016
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	ICU Medical to acquire the Hospira Infusion Systems business from Pfizer
Deal Status	Announced
Acquirer/Partner	ICU Medical Inc
Source/Target	Hospira Infusion Systems
Deal Value (USD mn)	1000
Region/Country	United States
Deal Details	<p>ICU Medical Inc. has entered into a definitive agreement to acquire Hospira Infusion Systems from Pfizer Inc., for USD1000 million in cash and stock. The Hospira Infusion Systems business includes IV pumps, solutions, and devices. Hospira Infusion Systems combined with ICU Medical's existing businesses, will create a leading pure-play infusion therapy company, with estimated pro forma combined revenues of approximately USD1.45 billion based on trailing twelve month results as of June 2016.</p> <p>Under the terms of the agreement, Pfizer will receive approximately USD400 million in newly issued shares of ICU Medical common stock and USD600 million in cash from ICU Medical subject to customary adjustment for net working capital. Upon completion of the transaction, which the companies expect to occur in the first quarter of 2017 subject to customary closing conditions including required regulatory approvals, Pfizer will own approximately 16.6 percent of ICU Medical.</p> <p>ICU Medical's financial advisors for the transaction were Barclays and Wells Fargo Securities, LLC, and Latham and Watkins acted as its legal advisor. Goldman, Sachs & Co. and Guggenheim Securities served as Pfizer's financial advisors for the transaction, while Skadden, Arps, Slate, Meagher & Flom LLP and Ropes & Gray LLP served as its legal advisors.</p>
Updates/Amendments	

Deal Date	09/15/2016
Deal Type	Partnership
Sub Category	License; Option
Deal Headline	Oncolimmune enters into option and license agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Oncolimmune Inc
Deal Value (USD mn)	250 (Max)
Region/Country	United States
Deal Details	<p>Oncolimmune Inc. has entered into an exclusive option and licensing agreement with Pfizer Inc. for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody. As per the terms, Oncolimmune will receive up to USD250 million in upfront and potential milestone payments.</p> <p>Under the terms of the agreement, Pfizer plans to evaluate ONC-392 up until a certain agreed-upon time to determine whether it will exercise its option to exclusively license ONC-392 as well as any other Oncolimmune anti-CTLA4 antibodies. If Pfizer exercises its option under the agreement, Pfizer would be responsible for all development and potential commercialization of the program, and Oncolimmune would be eligible to receive potential developmental and commercial milestone payments as well as royalties, tiered from mid-single up to low-double digits, on sales of any potential resulting products.</p>
Updates/Amendments	

Deal Date	09/12/2016
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides
Deal Status	Completed
Acquirer/Partner	Circle Pharma
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Circle Pharma Inc. has entered into an agreement with Pfizer Inc. under which Pfizer will provide support for the library build, and Circle has granted Pfizer non-exclusive rights to screen the library against certain targets. The rights granted to Pfizer exclude specified targets for which Circle has reserved exclusive rights to screen the library.
Updates/Amendments	

Deal Date	09/08/2016
Deal Type	Venture Financing
Sub Category	Seed/Start-up
Deal Headline	AnTolRx announces USD4 million Series A financing
Deal Status	Announced
Acquirer/Partner	JDRF; Orion Equity Partners LLC; Pfizer Inc
Source/Target	AnTolRx Inc
Deal Value (USD mn)	4
Region/Country	United States
Deal Details	AnTolRx Inc. has announced USD4 million Series A financing led by Pfizer Inc., and joined by Orion Equity Partners LLC and JDRF. Proceeds from this financing will be used to fund research and development of AnTolRx's antigen-specific Targeted Nanoparticle Tolerance Therapeutics to treat immune disorders including T1D.
Updates/Amendments	

Deal Date	08/24/2016
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; Development
Deal Headline	Pfizer to acquire rights to late stage small molecule anti-infective's from AstraZeneca
Deal Status	Announced
Acquirer/Partner	Pfizer Inc
Source/Target	AstraZeneca Plc
Deal Value (USD mn)	1575 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with AstraZeneca Plc to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States. The agreement includes the commercialization and development rights to Zavicefta, the marketed agents Merrem/Meronem and Zinforo, and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.</p> <p>Under the terms, Pfizer will make an upfront payment of USD550 million to AstraZeneca upon the close of the transaction and a deferred payment of USD175 million in January 2019. In addition, AstraZeneca is eligible to receive up to USD250 million in milestone payments, up to USD600 million in sales-related payments, as well as tiered royalties on sales of Zavicefta and ATM-AVI in certain markets. Pfizer's legal advisor for the transaction was Ropes and Gray LLP.</p>
Updates/Amendments	

Deal Date	08/22/2016
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer to acquire Medivation
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Medivation Inc
Deal Value (USD mn)	14000
Region/Country	United States
Deal Details	<p>Pfizer Inc. and Medivation, Inc. have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for USD81.50 a share in cash for a total enterprise value of approximately USD14000 million.</p> <p>Under the terms of the merger agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Medivation common stock for USD81.50 per share. The merger agreement contemplates that Pfizer will acquire any shares of Medivation that are not tendered into the offer through a second-step merger, which will be completed promptly following the closing of the tender offer. Pfizer expects to complete the acquisition in the Third- or Fourth-Quarter 2016.</p> <p>Pfizer's financial advisors for the transaction were Guggenheim Securities and Centerview Partners, with Ropes & Gray LLP acting as its legal advisor. J.P. Morgan Securities and Evercore served as Medivation's financial advisors, while Cooley LLP and Wachtell, Lipton, Rosen & Katz served as its legal advisors.</p>
Updates/Amendments	<p>Deal Updated date : 09/28/2016</p> <p>Pfizer has completed the acquisition of Medivation, Inc. as of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment. Under the terms of the tender offer for USD81.50 per share in cash. In addition, notices of guaranteed delivery have been delivered for 17,659,861 shares of Medivation common stock, representing approximately 10.6% of the shares outstanding. Following its acceptance of the tendered shares, Pfizer</p>

	completed its acquisition of Medivation through a second-step merger. Pfizer and its wholly-owned subsidiary accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.
--	--

Deal Date	08/01/2016
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Bamboo Therapeutics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Bamboo Therapeutics Inc
Deal Value (USD mn)	645
Region/Country	United States
Deal Details	<p>Pfizer Inc. has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.</p> <p>Pfizer previously acquired approximately 22 percent of Bamboo's fully diluted equity during the first quarter of 2016 for a payment of approximately USD43 million. Under the terms of this transaction, Pfizer acquired all of Bamboo's remaining equity for an upfront payment of USD150 million, and Bamboo's selling shareholders will be eligible for potential milestone payments of up to USD495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. Following the acquisition, Bamboo is now a wholly-owned subsidiary of Pfizer.</p> <p>Kaye Scholer LLP acted as Pfizer's legal advisor for the transaction and Ice Miller LLP served as Bamboo's legal advisor.</p>
Updates/Amendments	

Deal Date	07/28/2016
Deal Type	Partnership
Sub Category	Development; License; Option
Deal Headline	Pfizer enters immuno-oncology research collaboration with Western Oncolytics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Western Oncolytics
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and Western Oncolytics Ltd have entered into a development collaboration, license and option agreement to advance WO-12. Under the terms, Pfizer and Western Oncolytics will collaborate on preclinical and clinical development of WO-12 through Phase I trials. Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12. Financial terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	07/27/2016
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer places high bid for BIND Therapeutics
Deal Status	Announced
Acquirer/Partner	Pfizer Inc
Source/Target	DNIB Unwind Inc
Deal Value (USD mn)	40
Region/Country	United States
Deal Details	Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND's assets. The winning bid of USD40 million, subject to U.S. Bankruptcy Court approval for which a hearing is scheduled to take place on July 27, 2016, was selected as the highest and best bid. Additional terms will be disclosed upon Court approval.
Updates/Amendments	

Deal Date	06/14/2016
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into agreement with Shire for PF-00547659
Deal Status	Announced
Acquirer/Partner	Shire Plc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has licensed global rights to all indications for PF-00547659 to Shire plc. Terms of the deal were not disclosed.
Updates/Amendments	

Deal Date	06/03/2016
Deal Type	Public Offerings
Sub Category	Debt
Deal Headline	Pfizer prices Public Offering
Deal Status	Completed
Acquirer/Partner	
Source/Target	Pfizer Inc
Deal Value (USD mn)	5000
Region/Country	United States
Deal Details	<p>Pfizer Inc. has announced the pricing for public offering of USD5000 million in five tranches i.e. USD1250 million aggregate principal amount of 1.2 percent notes due 2018, USD850 million aggregate principal amount of 1.45 percent notes due 2019, USD1150 million aggregate principal amount of 1.95 percent notes due 2021, USD1250 million aggregate principal amount of 2.75 percent notes due 2026 and USD500 million aggregate principal amount of 4.4 percent notes due 2044.</p> <p>The offering of the Notes was made pursuant to the Company's shelf registration statement on Form S-3 (Registration No. 333-202430) filed with the Securities and Exchange Commission on March 2, 2015.</p> <p>Pfizer intends to use the net offering proceeds for general corporate purposes, including to repay a portion of its outstanding commercial paper. Barclays Capital Inc., Goldman Sachs and Co., JP Morgan Securities LLC and Morgan Stanley and Co LLC are acting as joint book-running managers for the offering.</p>
Updates/Amendments	<p>Deal Updated date : 06/03/2016</p> <p>Pfizer Inc. has completed a public offering of USD1250 million aggregate principal amount of 1.2 percent notes due 2018, USD850 million aggregate principal amount of 1.4 percent notes due 2019, USD1150 million aggregate principal amount of 1.95 percent notes due 2021 and USD1250 million aggregate principal amount of 2.75 percent notes due 2026 and USD500 million aggregate principal amount of 4.4 percent notes due 2044.</p> <p>In connection with the offering of the Notes, Pfizer entered into an underwriting agreement and related pricing agreement, each dated May 31, 2016, with Barclays Capital Inc, Goldman Sachs and Co, JP Morgan</p>

	Securities LLC and Morgan Stanley and Co LLC, as representatives of the several underwriters named therein.
--	---

Deal Date	05/31/2016
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into collaboration with BioRap Technologies to research and develop novel immunomodulators
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	BioRap Technologies Ltd
Deal Value (USD mn)	
Region/Country	Israel
Deal Details	<p>Pfizer Inc. and BioRap Technologies have entered into a research and option and licensing agreement to develop a certain monoclonal antibody into potential new treatment options for a number of chronic autoimmune diseases.</p> <p>BioRap Technologies is eligible to receive milestone-based financial support from Pfizer linked to reaching agreed upon milestones. Biorap will receive an undisclosed upfront payment and royalties on sales from any product that may be successfully commercialized as a result of the collaboration.</p>
Updates/Amendments	

Deal Date	05/16/2016
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer to acquire Anacor Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Anacor Pharmaceuticals Inc
Deal Value (USD mn)	5200
Region/Country	United States
Deal Details	<p>Pfizer Inc. and Anacor Pharmaceuticals, Inc. have entered into a definitive merger agreement under which Pfizer will acquire Anacor for USD99.25 per Anacor share, in cash, for a total transaction value, net cash of approximately USD5200 million, which assumes the conversion of Anacor's outstanding convertible notes.</p> <p>Under the terms of agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Anacor common stock for USD99.25 per share in cash. The closing of the tender offer is subject to customary closing conditions. Pfizer expects to complete the acquisition in the third-quarter 2016.</p> <p>Pfizer's financial advisors for the transaction were Center view Partners and Guggenheim Securities, and Wachtell, Lipton, Rosen & Katz acted as its legal advisor. Citi served as Anacor's financial advisor, and Davis Polk & Wardwell, LLP served as its legal advisor.</p>
Updates/Amendments	<p>Deal Updated date : 06/24/2016</p> <p>Pfizer has completed the acquisition of Anacor Pharmaceuticals, Inc. through cash tender offer. 39,306,909 shares of Anacor common stock were validly tendered and all of the conditions to the offer have been satisfied.</p>

	<p>Pfizer Inc. and Anacor Pharmaceuticals, Inc. have entered into a definitive merger agreement under which Pfizer will acquire Anacor for USD99.25 per Anacor share, in cash, for a total transaction value, net cash of approximately USD5200 million, which assumes the conversion of Anacor's outstanding convertible notes.</p> <p>Under the terms of agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Anacor common stock for USD99.25 per share in cash. The closing of the tender offer is subject to customary closing conditions. Pfizer expects to complete the acquisition in the third-quarter 2016.</p> <p>Pfizer's financial advisors for the transaction were Center view Partners and Guggenheim Securities, and Wachtell, Lipton, Rosen & Katz acted as its legal advisor. Citi served as Anacor's financial advisor, and Davis Polk & Wardwell, LLP served as its legal advisor.</p>
--	---

Deal Date	05/13/2016
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Piramal Enterprises to acquire four brands from Pfizer
Deal Status	Announced
Acquirer/Partner	Piramal Enterprises Ltd
Source/Target	Pfizer Inc; Pfizer Ltd India
Deal Value (USD mn)	16.48
Region/Country	Bangladesh; India; Sri Lanka; United States
Deal Details	Piramal Enterprises Consumer Products Division has entered into an agreement to acquire four brands from Pfizer Ltd for a consideration of INR1100 million. The acquisition includes brands namely: Ferradol, Neko, Sloan's and Waterbury's Compound. Additionally the agreement also includes the trademark rights for Ferradol and Waterbury's Compound in Bangladesh and Sri Lanka.
Updates/Amendments	

Deal Date	05/11/2016
Deal Type	Partnership
Sub Category	Award or Grant
Deal Headline	Pfizer awards USD1 million in metastatic breast cancer research funding
Deal Status	Completed
Acquirer/Partner	Undisclosed Partner Company
Source/Target	Pfizer Inc
Deal Value (USD mn)	1 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. has awarded more than USD1 million funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies.</p> <p>The five organizations have received supportive funding from Pfizer's Story Half Told initiative, i.e., Breast Cancer Research Foundation, Dr. Susan Love Research Foundation, Metastatic Breast Cancer Network, METAvivor-Metastatic Breast Cancer Awareness, Research and Support and Susan G. Komen- Young Investigators in MBC.</p>
Updates/Amendments	

Deal Date	05/05/2016
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into collaboration with WAVE Life Sciences to develop genetically targeted therapies for the treatment of metabolic diseases
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	WaVe Life Sciences Ltd
Deal Value (USD mn)	941 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. and WAVE Life Sciences Ltd. have entered into a research, licensing and option agreement for the development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The agreement will focus on genetically defined targets and bring together WAVE's proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer's hepatic targeting technology for enhanced delivery to the liver.</p> <p>Under the terms of the agreement, WAVE will advance up to five programs from discovery through to the selection of clinical candidates, at which point Pfizer may elect to exclusively license the programs and undertake further development and potential commercialization. Two targets have been declared upon initiation of the agreement, including WAVE's Apolipoprotein C-III program, with the remaining targets to be declared within eighteen months. In addition, WAVE has received rights to Pfizer's hepatic targeting technology, which WAVE may elect to use for hepatic programs beyond the collaboration.</p> <p>WAVE Life Sciences should use this technology, Pfizer is eligible to receive potential development and commercial milestone payments from WAVE. Pfizer is also eligible to receive tiered royalties on sales of any products that include Pfizer's hepatic targeting technology. Per the agreement, Pfizer agreed to pay USD40 million upfront, USD30 million of which is in the form of an equity investment in WAVE at a price of USD16 per share. In addition, assuming five potential products are successfully developed and commercialized, WAVE may earn up to USD871 million in research, development and commercial milestone payments from Pfizer, plus royalties, tiered up to low double-digits, on sales of any products that may result from</p>

	the collaboration.
Updates/Amendments	

Deal Date	04/04/2016
Deal Type	Venture Financing
Sub Category	Early Stage
Deal Headline	Metabomed completes USD18 million Series A financing
Deal Status	Completed
Acquirer/Partner	Arkin Holdings; Boehringer Ingelheim Venture Fund; MS Ventures; Pfizer Inc; Pontifax Fund; Technion R and D Foundation Ltd
Source/Target	Metabomed Ltd
Deal Value (USD mn)	18
Region/Country	United States
Deal Details	Metabomed Ltd. has completed USD18 million Series A financing from existing investors include MS Ventures, Boehringer Ingelheim Venture Fund (BIVF), Pontifax Fund, and the Technion Research and Development Foundation.
Updates/Amendments	

Deal Date	03/03/2016
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration; Screening/Evaluation
Deal Headline	Verastem enters into an agreement with Merck and Pfizer
Deal Status	Completed
Acquirer/Partner	Merck KGaA; Pfizer Inc
Source/Target	Verastem Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Merck KgaA, Pfizer Inc. and Verastem Inc. have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063, an investigational focal adhesion kinase or FAK inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
Updates/Amendments	

Deal Date	02/12/2016
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; Development
Deal Headline	Sandoz acquires PF-06438179 from Pfizer
Deal Status	Completed
Acquirer/Partner	Sandoz Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Albania; Andorra; Austria; Belgium; Bosnia and Herzegovina; Bulgaria; Channel Islands; Croatia; Czech Republic; Denmark; Estonia; Faroe Islands; Finland; France; Germany; Gibraltar; Greece; Guernsey; Hungary; Iceland; Ireland; Isle of Man; Italy; Jersey; Latvia; Liechtenstein; Lithuania; Luxembourg; Macedonia; Malta; Moldova; Monaco; Netherlands; Norway; Poland; Portugal; Romania; San Marino; Scotland; Seborga; Serbia; Slovakia; Slovenia; Spain; Sweden; Switzerland; United Kingdom
Deal Details	<p>Sandoz Inc., a company of Novartis AG has acquired from Pfizer Inc. the rights for the development and commercialization of PF-06438179 in the 28 countries that form the European Economic Area (EEA). Pfizer retains commercialization and manufacturing rights to infliximab in all countries outside of the EEA.</p> <p>Under the terms, Sandoz plans to complete the clinical study program and submit the PF-06438179 to the European Medicines Agency. Sandoz also plans to conduct global phase III trial to investigating the safety and efficacy of PF-06438179 and infliximab in combination with methotrexate.</p>
Updates/Amendments	

Deal Date	01/13/2016
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option
Deal Headline	Pfizer enters into worldwide strategic agreement with California Institute for Biomedical Research
Deal Status	Completed
Acquirer/Partner	California Institute for Biomedical Research
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a global strategic collaboration with The California Institute for Biomedical Research (Calibr) to develop novel antibody-based therapeutic agents for the treatment of heart failure. Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting bio-therapeutics based on peptide and protein agonists and antagonists.</p> <p>Under the terms, Pfizer has the option to obtain an exclusive license to certain anti-body based therapeutic agents following Phase I clinical studies to be performed by Calibr on one such agent. If the option is exercised, Pfizer would be responsible for further development and commercialization of such potential products. In addition, the agreement grants Pfizer a right of first negotiation for additional therapeutic agents in development based on innovative platform technologies from Calibr.</p> <p>Calibr will receive an upfront payment and be eligible for additional pre-exercise milestone payments leading up to the completion of Phase I clinical studies. Upon exercise of the exclusive licensing option by Pfizer, Calibr will receive an option exercise fee and be eligible for development and commercial milestones, as well as tiered royalties on net sales of any potential products.</p>
Updates/Amendments	

Deal Date	01/11/2016
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into research collaboration with Schrodinger
Deal Status	Completed
Acquirer/Partner	Schrodinger Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a research collaboration agreement with Schrodinger, Inc., in which the two companies will work together to develop a computational model for predicting key properties relevant to biotherapeutic candidates.</p> <p>Under the terms, each company will perform tasks in an attempt to develop a novel model for predictions of properties. Pfizer will generate and provide experimental data against which the computational model is to be developed by the Schrodinger team, while teams from both companies will work together to determine future systems of interest to which to apply, test, and further refine the developing technology.</p>
Updates/Amendments	

Deal Date	01/08/2016
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into translational research collaboration with Adaptive Biotechnologies to help advance novel immuno-oncology solutions
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Adaptive Biotechnologies Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into translational research collaboration with Adaptive Biotechnologies Corporation to leverage next generation sequencing of the adaptive immune system to advance Pfizer's growing immuno-oncology franchise.</p> <p>Under the terms, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit from immunotherapy.</p>
Updates/Amendments	

Deal Date	01/07/2016
Deal Type	Partnership
Sub Category	Development; License; Research and Discovery
Deal Headline	Pfizer enters into collaboration with 4D Molecular Therapeutics for cardiac gene therapy vector discovery and development
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	4D Molecular Therapeutics
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a collaboration and licensing agreement with 4D Molecular Therapeutics LLC to discover and develop targeted and proprietary next-generation AAV vectors for cardiac disease indications with high unmet medical need. 4D Molecular Therapeutics will deploy its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to potentially identify and optimize novel gene delivery vectors for use in potential cardiac gene therapy products.</p> <p>Under the terms, the agreement include an equity investment by Pfizer, an upfront license payment to 4D Molecular Therapeutics and potential development and commercial milestone payments plus tiered royalties to 4D Molecular Therapeutics on net sales of any potential products that result from this collaboration.</p>
Updates/Amendments	

Deal Date	01/06/2016
Deal Type	Venture Financing
Sub Category	Early Stage
Deal Headline	NextCure raises USD67 million Series A financing
Deal Status	Completed
Acquirer/Partner	Alexandria Venture Investments; Canaan Partners; Lilly Asia Ventures; OrbiMed Advisors LLC; Pfizer Inc; Sofinnova Ventures Inc
Source/Target	Nextcure Inc
Deal Value (USD mn)	67
Region/Country	United States
Deal Details	NextCure Inc. has raised USD67 million Series A financing led by The Backers Co and Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer, Sofinnova Ventures, and Alexandria Venture Investments.
Updates/Amendments	

Deal Date	01/06/2016
Deal Type	Venture Financing
Sub Category	Early Stage
Deal Headline	Cortexyme raises USD15 million Series A financing
Deal Status	Completed
Acquirer/Partner	Dolby Family Ventures; Pfizer Inc; Takeda Pharmaceutical Company Ltd
Source/Target	Cortexyme Inc
Deal Value (USD mn)	15
Region/Country	United States
Deal Details	Cortexyme Inc. has raised USD15 million Series A financing led by Pfizer Inc. along with the participation of Takeda Pharmaceutical Company Ltd., through its venture arm, and other private investors, existing investors such as Dolby Family Ventures also participated. The funding will be used for ongoing development of novel therapeutics and diagnostics for Alzheimer's disease and other degenerative disorders.
Updates/Amendments	

Deal Date	01/04/2016
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer, Merck KGaA and Syndax enters into collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer
Deal Status	Completed
Acquirer/Partner	Merck KGaA; Syndax pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc., Merck KGaA and Syndax Pharmaceuticals, Inc. have entered into a collaboration agreement to evaluate avelumab in combination with entinostat in patients with heavily pre-treated, recurrent ovarian cancer. This is an exclusive agreement between the alliance and Syndax to study the combination of these two investigational agents in ovarian cancer. Syndax will be responsible for conducting the Phase Ib/II clinical trial in ovarian cancer. Financial terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	01/04/2016
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Research and Discovery
Deal Headline	Pfizer enters into strategic proteomic biomarker discovery collaboration with KineMed
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	KineMed Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into strategic collaboration with KineMed Inc. to discover and develop proprietary biomarkers in various fields of unmet medical need. KineMed's platform technology provides a proprietary, rate-based approach for developing novel biomarkers.</p> <p>Under the terms, Pfizer has licensed access to the KineMed platform and rights to pursue discovery, development and potential commercialization of kinetic biomarkers. Both companies will work together on discovery research of novel biomarkers, and Pfizer will be responsible for the development and potential commercialization of any novel biomarkers or companion diagnostics for the Pfizer-selected targets. KineMed will receive an upfront payment, as well as funding for research and development costs associated with Pfizer-selected targets. In addition, KineMed is eligible to receive development and regulatory milestone payments.</p>
Updates/Amendments	

Deal Date	12/30/2015
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer enters into agreement with Heptares
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Heptares Therapeutics
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a strategic drug discovery collaboration with Heptares Therapeutics, subsidiary of Sosei Group Corporation for research and develop potential new medicines directed at up to 10 G protein-coupled receptor targets across multiple therapeutic areas. Heptares will use its proprietary GPCR structure-guided platform to help deliver stabilised GPCRs (StaR proteins), high-resolution crystal structures and other technologies to support the discovery of potential novel agents directed to the GPCR targets selected by Pfizer. Pfizer will be responsible for developing and commercialising any potential therapeutic agents for each target and will have exclusive global rights to any potential resulting agents.</p> <p>Under the terms, Heptares will receive an initial payment on signing the agreement in return for delivering certain StaR proteins and structures for targets selected by Pfizer that it has already generated. Heptares is eligible to receive potential research, development, regulatory and commercial milestone payments of up to USD189 million per target. In addition, Heptares is eligible to receive potential tiered royalties on the net sales of any products that are commercialised by Pfizer.</p>
Updates/Amendments	

Deal Date	12/08/2015
Deal Type	Partnership
Sub Category	Award or Grant
Deal Headline	Pfizer awards more than USD4 million in grants to further clinical research in advanced breast cancer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Dana Farber Cancer Institute; Lombardi Comprehensive Cancer Center; Northwestern University; The Ohio State University Comprehensive Cancer Center; University of Illinois College of Medicine at Chicago
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. through Pfizer Investigator Research Exchange Breast Cancer Research Awards has awarded five grants totalling more than USD4 million in funding to support clinical research projects investigating Ibrance. The awards were granted to Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center, and University of Illinois at Chicago, Northwestern University and Lombardi Comprehensive Cancer Center at Georgetown University Medical Center.
Updates/Amendments	

Deal Date	12/07/2015
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option
Deal Headline	Pfizer enters into strategic license and option agreement with BioAtla for a new class of antibody therapeutics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	BioAtla LLC
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a licensing and option agreement with BioAtla LLC to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's Conditionally Active Biologic platform and utilizing Pfizer's proprietary antibody drug conjugate payloads.</p> <p>Under the agreement, BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialization of several CAB-ADC antibodies. Pfizer also gains an exclusive option to develop and commercialize BioAtla CAB antibodies that target CTLA4. BioAtla and Pfizer are both eligible to receive milestone payments and royalties based on individual CAB-ADC antibody candidates developed and commercialized by the other party. Including the CTLA4 option and license, BioAtla is eligible to receive a potential total of more than USD1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales.</p>
Updates/Amendments	

Deal Date	12/07/2015
Deal Type	Partnership
Sub Category	Supply
Deal Headline	Catalent Pharma Solutions enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Catalent Pharma Solutions
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Catalent Pharma Solutions has entered into an exclusive long term supply agreement with Pfizer Inc. to produce leading over-the-counter (OTC) heartburn treatment, Nexium 24HR (esomeprazole), also marketed as Nexium Control outside the United States. Under the terms, Catalent Pharma facility will formulate and manufacture the 20mg esomeprazole drug into enteric coated, delayed release pellets using fluid bed technology. Catalent will also encapsulate these pellets into two-piece, hard-shell capsules, where the Catalent Pharma has invested extensively in capsule banding technology required for OTC products.
Updates/Amendments	

Deal Date	11/30/2015
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Heptares enters into strategic drug discovery collaboration with Pfizer on GPCR targets across multiple therapeutics areas
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Heptares Therapeutics ; Sosei Group Corp
Deal Value (USD mn)	189 (Max)
Region/Country	Worldwide
Deal Details	<p>Heptares Therapeutics Ltd has entered into a strategic drug discovery agreement with Pfizer Inc. to research and develop new medicines directed at up to 10 G protein-coupled receptor targets across multiple therapeutic areas. Heptares will use its proprietary GPCR structure-guided platform to help deliver stabilized GPCRs, high-resolution crystal structures and other technologies to support the discovery of novel agents directed to the GPCR targets selected by Pfizer. Pfizer will be responsible for developing and commercializing any therapeutic agents, small molecules or biologics derived from StaR antigens for each target and will have exclusive global rights to any resulting agents.</p> <p>Under the terms, Heptares will receive an initial payment on signing the agreement in return for delivering certain StaR proteins and structures for targets selected by Pfizer that it has already generated. Heptares is eligible to receive research, development, regulatory and commercial milestone payments of up to USD189 million per target. In addition, Heptares is eligible to receive potential tiered royalties on the net sales of any products that are commercialized by Pfizer.</p>
Updates/Amendments	

Deal Date	11/23/2015
Deal Type	Mergers & Acquisitions
Sub Category	Merger
Deal Headline	Pfizer to merge with Allergan
Deal Status	Terminated
Acquirer/Partner	
Source/Target	Allergan Plc; Pfizer Inc
Deal Value (USD mn)	160000 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. and Allergan plc have entered into a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at USD363.63 per Allergan share, for a total enterprise value of approximately USD160 billion, based on the closing price of Pfizer common stock of USD32.18 on November 20, 2015.</p> <p>Under the terms of the proposed transaction, the businesses of Pfizer and Allergan will be combined under Allergan plc, which will be renamed Pfizer plc. Immediately prior to the merger, Allergan will effect an 11.3-for-one share split so that each Allergan shareholder will receive 11.3 shares of the combined company for each of their Allergan shares, and the Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares. It is expected that Pfizer stockholders will hold approximately 56% of the combined company and Allergan shareholders will own approximately 44% of the combined company on a fully diluted basis.</p> <p>The combination of Pfizer and Allergan will significantly increase the scale of Pfizer's established business, and their complementary capabilities will maximize the combined established portfolio. The addition of Allergan's Women's Health and Anti-Infectives portfolio will add depth to Pfizer's established business, and Pfizer will expand the reach of Allergan's established portfolio using its existing commercial capabilities, infrastructure and global scale. In addition, Allergan brings topical formulation, manufacturing and its distribution capabilities to the combined company.</p> <p>Guggenheim Securities, Goldman, Sachs & Co., Centerview Partners and Moelis & Company are serving as Pfizer's financial advisors for the transaction, with Wachtell, Lipton, Rosen & Katz, Skadden, Arps, Slate,</p>

	<p>Meagher & Flom LLP and A & L Goodbody acting as its legal advisors. J.P. Morgan and Morgan Stanley are serving as Allergan's financial advisors for the transaction with Cleary Gottlieb Steen & Hamilton LLP, Latham & Watkins LLP and Arthur Cox acting as its legal advisors.</p> <p>The transaction is expected to close in the second half of 2016.</p>
Updates/Amendments	<p>Deal Updated date : 04/04/2016</p> <p>Pfizer Inc. announced that the merger agreement between Pfizer and Allergan plc has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an "Adverse Tax Law Change" under the merger agreement.</p>

Deal Date	11/19/2015
Deal Type	Partnership
Sub Category	Co-Development; Commercialization; Development; License; Marketing
Deal Headline	Pfizer enters into agreement with Servier
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Servier
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. and Servier have entered into an exclusive global licensing and collaboration agreement to co-develop and commercialize UCART19. Under the terms of the agreement, Pfizer and Servier will work together on a joint clinical development program for UCART19 and share development costs. Pfizer will be responsible for commercialization of UCART19 in the United States, and Servier will retain marketing rights in countries outside the United States.</p>
Updates/Amendments	

Deal Date	11/18/2015
Deal Type	Partnership
Sub Category	Development
Deal Headline	Thermo Fisher Scientific signs development agreement for sequencing based companion diagnostic with Novartis and Pfizer
Deal Status	Completed
Acquirer/Partner	Novartis AG; Pfizer Inc
Source/Target	Thermo Fisher Scientific Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Thermo Fisher Scientific, Inc. has entered into a long-term agreement with Novartis AG and Pfizer Inc. to develop and commercialize a multi-marker, universal next-generation sequencing oncology test that will serve as a companion diagnostic for non-small cell lung cancer across multiple drug development programs.</p> <p>The streamlined and personalized methodology defined in the development agreement between the companies has the potential to improve safety, effectiveness and health outcome of patients via targeted risk stratification and tailored treatment approaches. The collaboration, focused on a universal testing approach, could also accelerate the development and registration of several new non-small cell lung cancer drugs and drug indications, with the ultimate goal of providing patients greater access to more targeted treatments and appropriate clinical trials.</p>
Updates/Amendments	

Deal Date	10/29/2015
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into collaboration with GlaxoSmithKline
Deal Status	Completed
Acquirer/Partner	
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a multi-year collaboration with GlaxoSmithKline plc on the development of a next-generation equipment design, continuous, miniature and modular prototype for oral solid dose pharmaceutical development and manufacturing.
Updates/Amendments	

Deal Date	10/19/2015
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing
Deal Headline	Pfizer enters into agreement with Celltech
Deal Status	Completed
Acquirer/Partner	UCB Pharma
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with Celltech, now UCB. Pfizer has sole responsibility for all manufacturing, clinical development and commercialization activities for this molecule. Inotuzumab ozogamicin originates from this collaboration.
Updates/Amendments	

Deal Date	09/24/2015
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer and Merck enters into collaboration with Dako on development of companion diagnostic for Avelumab
Deal Status	Completed
Acquirer/Partner	Dako an Agilent Technologies Company
Source/Target	Merck and Co Inc; Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and Merck and Co Inc. have entered into a collaboration agreement with Dako AG for the development of a potential companion diagnostic test. The agreement enables Dako, Merck and Pfizer to work to develop the CDx to assess programmed death-ligand 1 protein expression levels in tumor tissue, and its microenvironment, including tumor-associated immune cells. The investigational CDx is part of the protocols in ongoing clinical trials of avelumab. The financial terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	09/09/2015
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Evotec enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Evotec AG
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Evotec AG has entered into a four-year research collaboration agreement with Pfizer Inc. in the field of tissue fibrosis. Under the terms, Evotec and Pfizer will explore potential mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug discovery platform whereas Pfizer will provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise. Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.
Updates/Amendments	

Deal Date	08/26/2015
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Alvogen to acquire product portfolio from Pfizer for the US market
Deal Status	Announced
Acquirer/Partner	Alvogen
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a definitive agreement with Alvogen Inc., under which Alvogen will acquire a portfolio of four pharmaceutical products, in the U.S. The products being acquired include three injectable products and one inhaled solution product. Two are on-market products, Clindamycin injection and Acetylcysteine inhalation solution. In addition, Alvogen will acquire two pending ANDAs, Voriconazole injection and Melphalan injection.
Updates/Amendments	

Deal Date	08/03/2015
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization
Deal Headline	Pfizer and Synthon enters into US commercialization agreement for potential generic treatment of multiple sclerosis
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Synthon Pharmaceuticals
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into an agreement with Synthon Pharmaceuticals Inc., whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate.</p> <p>Under the terms, Pfizer will have exclusive rights to commercialize both dosage formulations of Synthon's glatiramer acetate in the United States. Synthon is responsible for the clinical development, manufacture and supply of glatiramer acetate. Pfizer is solely responsible for the commercialization of glatiramer acetate in the United States. Financial terms of the agreement were not disclosed.</p>
Updates/Amendments	

Deal Date	07/08/2015
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into agreement with Jeffrey Modell Foundation to conduct research in the field of immunological diseases
Deal Status	Completed
Acquirer/Partner	Jeffrey Modell Foundation
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer's Centers for Therapeutic Innovation and the Jeffrey Modell Foundation have entered into a collaboration agreement to conduct research in the field of immunological diseases. Pfizer's Centers for Therapeutic Innovation and Jeffrey Modell Foundation will identify and co-fund translational research projects with leading academic medical centers within the CTI network. The goal of each research project will be to identify and validate a potential drug candidate for an immunological disease that can be moved into further clinical testing.
Updates/Amendments	

Deal Date	07/02/2015
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	XRPro Sciences acquires assets from Pfizer
Deal Status	Completed
Acquirer/Partner	Icagen Inc
Source/Target	ICAGEN-Ion Channel Biology Platform
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>XRpro Sciences, Inc., has completed the acquisition of assets related to the ion channel biology platform from Pfizer Inc. that had previously been obtained as part of Pfizer's 2011 acquisition of Icagen, Inc. XRPro Sciences also acquired all of Pfizer's rights to the "Icagen" name and trademark. The new Icagen will continue to operate out of the existing facility in Research Triangle Park, North Carolina in addition to the current XRpro Sciences Inc. site in Cambridge, Massachusetts.</p> <p>Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen, ensuring continuity of their extensive scientific expertise. The transaction's financial terms are not disclosed.</p> <p>Note : On 22 September, 2015 Xpro science changed its name to Icagen Inc.</p>
Updates/Amendments	

Deal Date	06/22/2015
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Pfizer to acquire Nimenrix and Mencevax from GlaxoSmithKline
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	
Deal Value (USD mn)	130 (Max)
Region/Country	United Kingdom
Deal Details	Pfizer Inc. has entered into an agreement with GlaxoSmithKline Plc to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately USD130 million.
Updates/Amendments	<p>Deal Updated date : 10/01/2015</p> <p>Pfizer Inc. has completed the acquisition of quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax from GlaxoSmithKline Plc.</p>

Deal Date	05/11/2015
Deal Type	Mergers & Acquisitions
Sub Category	Minority Acquisition
Deal Headline	Pfizer acquires minority stake in AMPharma
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	AM Pharma
Deal Value (USD mn)	600
Region/Country	Netherlands
Deal Details	<p>Pfizer Inc. has acquired a minority equity interest in AMPharma B.V. and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. Under the terms of the agreement, Pfizer has made an upfront payment of USD87.5 million for the minority equity interest and exclusive option, with additional potential payments of up to USD512.5 million upon option exercise and potential launch of any product that may result from this agreement.</p> <p>Ropes & Gray LLP and De Brauw Blackstone Westbroek N.V. acted as legal advisors to Pfizer, and Dechert LLP and Clifford Chance LLP acted as legal advisors to AM-Pharma.</p>
Updates/Amendments	

Deal Date	05/06/2015
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	EMD Serono enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	EMD Serono Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, has entered into an agreement with Pfizer for co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance.
Updates/Amendments	

Deal Date	05/01/2015
Deal Type	Venture Financing
Sub Category	Growth Capital/Expansion
Deal Headline	CytomX Therapeutics completes USD21.5 million Series C financing
Deal Status	Completed
Acquirer/Partner	Canaan IX LP; Cytomx Therapeutics Inc; Pfizer Inc; Roche Finance Ltd; Third Rock Ventures LP
Source/Target	Cytomx Therapeutics Inc
Deal Value (USD mn)	21.5
Region/Country	United States
Deal Details	CytomX Therapeutics Inc. has completed USD21.5 million Series C financing. CytomX Therapeutics has issued 4,049,543 Series C preferred stock at a purchase price of USD5.309387 per share to Third Rock Ventures LP, Canaan IX LP, CytomX Therapeutics Holdings LLC, Roche Finance Ltd and Pfizer Inc.
Updates/Amendments	

Deal Date	04/30/2015
Deal Type	Partnership
Sub Category	License
Deal Headline	Mylan enters into licensing agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Mylan Inc; Mylan Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Mylan Pharmaceuticals Inc. and Mylan Inc. have entered into a licensing agreement with Pfizer Inc. regarding sildenafil, generic version of Viagra in the United States.
Updates/Amendments	

Deal Date	04/15/2015
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	REGiMMUNE enters into collaboration with JDRF and Pfizer
Deal Status	Announced
Acquirer/Partner	JDRF; Pfizer Inc
Source/Target	Regimmune Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	REGiMMUNE Corporation and JDRF have entered into a research collaboration with Pfizer Inc. to develop an antigen-specific immunotherapy utilizing RGI's proprietary GalCer/liposome platform for immunological tolerance for the treatment of type 1 diabetes.
Updates/Amendments	

Deal Date	04/07/2015
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Merck enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Merck KGaA
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Germany
Deal Details	<p>Merck KGaA and Pfizer Inc AVE entered into co-promotion agreement allowing the companies to co-promote Pfizer's anaplastic lymphoma kinase inhibitor XALKORI (crizotinib).</p> <p>Under the terms of agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom). In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian</p>
Updates/Amendments	

Deal Date	02/18/2015
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization
Deal Headline	Pharmacosmos enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Pharmacosmos AS
Deal Value (USD mn)	
Region/Country	Canada
Deal Details	Pharmacosmos A/S announced that it has entered into an agreement with Pfizer Inc. under which Pfizer would acquire the exclusive commercialization rights to Monofer in Canada. Monofer, under development by Pharmacosmos in Canada, is an innovative intravenous iron replacement therapy for the treatment of iron deficiency anaemia (IDA). The structure of Monofer is different from other intravenous iron replacement therapies, allowing the possibility to administer high iron doses in less than one hour during one visit to the doctor for the potential benefit and convenience of patients and healthcare professionals. Terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	02/05/2015
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer completes the acquisition of Hospira
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Hospira Inc
Deal Value (USD mn)	16100 (Max)
Region/Country	United States
Deal Details	Pfizer Inc. has completed the acquisition of Hospira, Inc., a provider of injectable drugs and infusion technologies and biosimilars, is now part of Pfizer. Under the transaction, Hospira's common stock ceased trading on the New York Stock Exchange, and former Hospira shareholders became entitled to receive the per share merger consideration of USD90 in cash for each share of Hospira common stock they owned and for a total enterprise value of approximately USD16100 million.
Updates/Amendments	Pfizer has entered into a definitive merger agreement under which Pfizer agreed to acquire Hospira Inc., the global provider of injectable drugs, infusion technologies and biosimilars, for USD90 per share in cash, for a total enterprise value of approximately USD17000 million. Pfizer will finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt.

Deal Date	01/05/2015
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Redvax
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	RedVax GmbH
Deal Value (USD mn)	
Region/Country	Switzerland
Deal Details	Pfizer Inc. has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program. Financial terms are not disclosed.
Updates/Amendments	

Deal Date	12/22/2014
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option
Deal Headline	Philogen enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Philogen SpA
Deal Value (USD mn)	
Region/Country	Italy
Deal Details	<p>Philogen S.p.A has entered into an agreement with Pfizer Inc. for the development and commercialisation of multiple empowered antibodies.</p> <p>Under the terms of the agreement, Pfizer has exclusive rights to pursue development of certain ADCs and guided nanoparticles. Pfizer will be responsible for research and development and potential commercialization of candidate molecules.</p>
Updates/Amendments	

Deal Date	12/17/2014
Deal Type	Partnership
Sub Category	Co-Development; Commercialization
Deal Headline	Pfizer enters into global strategic alliance with Merck to jointly develop and commercialize anti-PD-L1
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Merck KGaA
Deal Value (USD mn)	2850 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with Merck KGaA to jointly develop and commercialize MSB0010718C. Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's broad portfolio of approved and investigational oncology therapies.</p> <p>Under the terms, Merck KGaA will receive an upfront payment of USD850 million and is eligible to receive regulatory and commercial milestone payments up to approximately USD2000 million. Both companies will jointly fund all development and commercialization costs and all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products generated from this collaboration will be shared equally.</p>
Updates/Amendments	

Deal Date	12/15/2014
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing
Deal Headline	OPKO enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Opko Health Inc
Deal Value (USD mn)	570
Region/Country	Worldwide
Deal Details	<p>OPKO Health, Inc. has entered into a worldwide agreement with Pfizer Inc. for the development and commercialization of long-acting hGH-CTP. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA. Pfizer will be responsible for all development costs for additional indications as well as all post-marketing studies.</p> <p>In addition, Pfizer will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan. Under the terms, OPKO will receive an upfront payment of USD295 million and is eligible to receive up to an additional USD275 million upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide. In addition, OPKO is eligible to receive initial royalty payments associated with the commercialization of hGH-CTP for Adult GHD which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to gross profit sharing for both hGH-CTP and Pfizer's Genotropin.</p>
Updates/Amendments	

Deal Date	12/08/2014
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into collaboration with Spark Therapeutics to advance phase 1/2 adeno-associated virus vector program in Hemophilia B
Deal Status	Completed
Acquirer/Partner	Spark Therapeutics Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into an agreement with Spark Therapeutics to develop SPK-FIX, a program incorporating a bio-engineered adeno-associated virus vector for the potential treatment of Hemophilia B.</p> <p>Under the terms, Spark will maintain responsibility for clinical development through Phase I/II studies. Pfizer will assume responsibility for pivotal studies, any regulatory approvals and potential global commercialization of the product.</p>
Updates/Amendments	

Deal Date	12/08/2014
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into licensing and collaboration agreement with iTeos for discovery and development of cancer immunosuppression targets
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	iTeos Therapeutics SA
Deal Value (USD mn)	
Region/Country	Belgium
Deal Details	<p>Pfizer Inc. has entered into a strategic collaboration with iTeos Therapeutics SA, where iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase and Tryptophan 2,3-dioxygenase. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.</p> <p>Under the terms, iTeos will receive from Pfizer an up-front payment of EUR24 million, plus an equity investment, licensing fees and collaborative funding. Further, iTeos will be eligible to earn potential milestone payments from Pfizer based on the achievement of specific development, regulatory and commercial milestones across the IDO1 and TDO2 programs, in addition to royalties on sales. iTeos also has the opportunity to earn additional milestone and royalty payments for any of the new target programs that are advanced by Pfizer.</p>
Updates/Amendments	

Deal Date	12/06/2014
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Spark Therapeutics enters into an agreement with Pfizer for SPK-FIX product candidates
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Spark Therapeutics Inc
Deal Value (USD mn)	160
Region/Country	United States
Deal Details	<p>Spark Therapeutics, Inc. has entered into a global collaboration agreement with Pfizer Inc. for the development and commercialization of SPK-FIX product candidates in gene therapy program for the treatment of hemophilia B. Spark have granted Pfizer an exclusive worldwide license under specified patent rights and know-how relating to any FIX gene therapy to develop, manufacture and commercialize such licensed FIX gene therapy products for the diagnosis, prevention, treatment and cure of hemophilia B.</p> <p>Under the terms, Spark received an USD20.0 million upfront payment. Spark also are eligible to receive up to USD260.0 million in aggregate milestone payments under the agreement, USD140.0 million of which relate to potential development, regulatory and commercial milestones for the first product candidate to achieve each milestone and USD120.0 million of which relate to potential regulatory milestones for additional product candidates. In addition, Spark are entitled to receive royalties, calculated as a low-teen percentage of net sales of licensed products. The royalties may be subject to certain reductions, including for a specified portion of royalty payments that Pfizer may become required to pay under any third-party license agreements, subject to a minimum royalty. Under the agreement, Spark remain solely responsible for the payment of license payments payable by us under specified license agreements.</p>
Updates/Amendments	

Deal Date	11/17/2014
Deal Type	Partnership
Sub Category	Co-Development; Commercialization
Deal Headline	Pfizer enters into an agreement with Merck to Jointly develop and commercialize Anti-PD-L1
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Merck KGaA
Deal Value (USD mn)	2850 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with Merck KGaA to jointly develop and commercialize MSB0010718C. Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's broad portfolio of investigational oncology therapies.</p> <p>Under the terms, Merck KGaA will receive an upfront payment of USD850 million and is eligible to receive regulatory and commercial milestone payments up to approximately USD2000 million. Both companies will jointly fund all development and commercialization costs and all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products generated from this collaboration will be shared equally.</p>
Updates/Amendments	

Deal Date	11/13/2014
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into agreement with Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation
Deal Status	Completed
Acquirer/Partner	Bill and Melinda Gates Foundation; Childrens Investment Fund Foundation
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc., the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation have entered into an agreement that will expand access to Pfizer's injectable contraceptive, Sayana Press for women most in need in 69 of the world's poorest countries.
Updates/Amendments	

Deal Date	09/29/2014
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Kyowa Hakko Kirin enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	
Source/Target	Kyowa Hakko Kirin Co Ltd; Pfizer Inc
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Pfizer Inc. and Kyowa Hakko Kirin have entered into a collaboration agreement on immuno-oncology combination of Kyowa Hakko Kirin's Mogamulizumab and Pfizer's PF-05082566 in a clinical study. Under the terms of agreement, Pfizer and Kyowa Hakko Kirin will co-fund the clinical study, which will be conducted by Pfizer.
Updates/Amendments	

Deal Date	09/25/2014
Deal Type	Partnership
Sub Category	Development
Deal Headline	Thermo Fisher Scientific enters into agreement with GlaxoSmithKline and Pfizer to develop oncology companion diagnostics using next-generation sequencing
Deal Status	Completed
Acquirer/Partner	GlaxoSmithKline Plc; Pfizer Inc
Source/Target	Thermo Fisher Scientific Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Thermo Fisher Scientific Inc. GlaxoSmithKline Plc. and Pfizer Inc. have entered into an agreement to develop a universal next-generation sequencing oncology test for solid tumors, the test will be developed using Thermo Fisher Scientific's Ion Personal Genome Machine Dx Platform, Ion AmpliSeq technology, and content from the Oncomine Cancer Research Panel.
Updates/Amendments	

Deal Date	09/22/2014
Deal Type	Venture Financing
Sub Category	Seed/Start-up
Deal Headline	Circle Pharma receives seed funding
Deal Status	Completed
Acquirer/Partner	Mission Bay Capital; Pfizer Inc; QB3
Source/Target	Circle Pharma
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Circle Pharma Inc. has received seed funding from Pfizer Inc. and QB3's seed stage venture fund, Mission Bay Capital LLC. Proceeds from the financing will be used to develop cell permeable macrocyclic peptide therapeutics.
Updates/Amendments	Circle Pharma Inc. has extended its seed funding round with an investment from ShangPharma Investment Group Limited.

Deal Date	09/16/2014
Deal Type	Partnership
Sub Category	License; Option
Deal Headline	Pfizer enters into agreement with MedGenesis for potential treatments for Parkinson's disease
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Medgenesis Therapeutix Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with MedGenesis Therapeutix Inc., granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor protein and convection enhanced delivery technology to be used in research for potential treatments for Parkinson's disease. Under the terms, MedGenesis will receive an upfront option fee and upon exercise of the option by Pfizer will be eligible for further milestone and royalty payments.
Updates/Amendments	

Deal Date	08/26/2014
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer and Merck enters into collaboration for evaluating novel anti-cancer combination regimen
Deal Status	Completed
Acquirer/Partner	Merck and Co Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and Merck & Co. Inc. have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib with Merck's pembrolizumab. The financial terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	07/30/2014
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Baxter to divests of commercial vaccines business to Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	
Deal Value (USD mn)	635
Region/Country	Worldwide
Deal Details	<p>Baxter International Inc. has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of USD635 million, subject to certain adjustments.</p> <p>The sale includes the company's commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis (MenC), and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. Both vaccines are currently available outside the United States, primarily in a number of European markets.</p>
Updates/Amendments	<p>Pfizer Inc. has completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.</p>

Deal Date	07/16/2014
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer to acquire InnoPharma
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	InnoPharma LLC
Deal Value (USD mn)	360 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. and InnoPharma, Inc., a privately held pharmaceutical development company, have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of USD225 million, with up to USD135 million of contingent milestone payments.</p> <p>Pfizer's legal advisor for the transaction was Kaye Scholer LLP. J.P. Morgan served as InnoPharma's financial advisor, while Morgan, Lewis & Bockius LLP served as its legal advisor.</p>
Updates/Amendments	<p>Deal Updated date : 09/25/2014</p> <p>Pfizer Inc., has completed the acquisition of the pharmaceutical development company, InnoPharma, Inc., for an upfront cash payment of USD225 million, with up to USD135 million of contingent milestone payments.</p> <p>Pfizer's legal advisor for the transaction was Kaye Scholer LLP. J.P. Morgan served as InnoPharma's financial advisor, while Morgan, Lewis & Bockius LLP served as its legal advisor.</p>

Deal Date	06/18/2014
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer enters into global strategic cancer immunotherapy collaboration with Cellectis
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Cellectis SA
Deal Value (USD mn)	265 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive global strategic collaboration with Cellectis SA to develop Chimeric Antigen Receptor T-cell immunotherapies in the field of oncology directed at select targets. Pfizer has exclusive rights to pursue development and commercialization of CAR-T therapies directed at a total of fifteen targets selected by Pfizer. Both companies will work together on preclinical research and Pfizer will be responsible for the development and potential commercialization of any CAR-T therapies for the Pfizer-selected targets.</p> <p>In addition, the agreement provides for a total of twelve targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets and Cellectis will work independently on eight additional targets. Cellectis will be responsible for clinical development and commercialization of CAR-T therapeutics for the Cellectis-selected targets. Pfizer has right of first refusal to the four Cellectis-selected targets.</p> <p>Under the terms, Cellectis will receive an upfront payment of USD80 million, as well as funding for research and development costs associated with Pfizer-selected targets and the four Cellectis-selected targets within the collaboration. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to USD185 million per Pfizer product. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer.</p>
Updates/Amendments	

Deal Date	06/13/2014
Deal Type	Partnership
Sub Category	Product Divestment; Sales
Deal Headline	Baxter International enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Baxter International Inc
Deal Value (USD mn)	635
Region/Country	United States
Deal Details	Baxter International Inc has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of USD635 million, subject to certain adjustments. The sale includes the Baxter International commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis, an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.
Updates/Amendments	Deal Updated date : 12/01/2014 Baxter International Inc. has completed the acquisition with Pfizer Inc. Pfizer acquired the portfolio of Baxter marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac.

Deal Date	06/11/2014
Deal Type	Partnership
Sub Category	Development; License; Option
Deal Headline	Pfizer enters into multi-target collaboration with X-Chem
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	X Chem Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a multi-target collaboration with X-Chem, Inc. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.</p> <p>Under the terms, X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel leads for the Pfizer programs. Pfizer has an exclusive option to license any compounds generated in the course of the collaboration.</p>
Updates/Amendments	

Deal Date	06/02/2014
Deal Type	Partnership
Sub Category	License
Deal Headline	Mylan enters into licensing agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Mylan Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Mylan Inc has entered into a licensing agreement with Pfizer Inc. relating to Mylan's Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg. This product is the generic version of Celebrex, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.</p> <p>Under the terms of the agreement, Mylan will begin selling product at the earliest market formation, however in any case not later than December 2014. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.</p>
Updates/Amendments	

Deal Date	05/15/2014
Deal Type	Public Offerings
Sub Category	Debt
Deal Headline	Pfizer prices for public offering
Deal Status	Completed
Acquirer/Partner	
Source/Target	Pfizer Inc
Deal Value (USD mn)	4500
Region/Country	United States
Deal Details	<p>Pfizer Inc. has announced the pricing for public offering of USD4500 million in five tranches of notes i.e. USD1000 million aggregate principal amount of 1.1 percent notes due 2017, USD500 million aggregate principal amount of floating rate notes due 201, USD1500 million aggregate principal amount of 2.1 percent notes due 2019, USD1000 million aggregate principal amount of 3.4 percent notes due 2024 and USD500 million aggregate principal amount of 4.4 percent notes due 2044.</p> <p>Pfizer intends to use the net offering proceeds for general corporate purposes, including (i) pre-funding the repayment at maturity of the EUR900 million outstanding of its 4.75% notes due December 2014 and (ii) pre-funding a portion of its outstanding 5.35% notes due March 2015. Pfizer may use funds that are not immediately needed for these purposes to temporarily invest in short-term marketable securities or repay a portion of its outstanding commercial paper.</p> <p>Merrill Lynch Pierce Fenner and Smith Incorporated, Barclays Capital Inc., Deutsche Bank Securities Inc. and JP Morgan Securities LLC are acting as joint book-running managers for the offering.</p>
Updates/Amendments	<p>Deal Updated date : 05/15/2014</p> <p>Pfizer Inc. has completed a public offering of USD4500 million aggregate principal amount of senior unsecured notes.</p>

Deal Date	05/14/2014
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer, American College of Physicians and CECity enters into collaboration to increase adult immunization rates
Deal Status	Completed
Acquirer/Partner	CECity; The American College of Physicians
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc., The American College of Physicians and CECity.com, Inc. have entered into collaboration for the initiative designe to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The goal of this public health initiative is to meet the National Vaccine Advisory Committee's standards for adult immunization. The standards call on all health care providers to assess vaccine status at each visit, strongly recommend vaccinations to patients, administer or refer for immunization, and document vaccination.</p> <p>The program will encourage health care providers and practice teams to engage in ACP's Adult Immunization Registry available through CECity's MedConcert portal, a cloud-based performance improvement platform. With funding from Pfizer and the experience and resources from the three organizations, the program will be piloted in two states with the goal to broaden the effort nationwide</p>
Updates/Amendments	

Deal Date	05/02/2014
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into agreement with Second Genome on microbiome research initiative in obesity
Deal Status	Completed
Acquirer/Partner	Second Genome Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with Second Genome inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease.
Updates/Amendments	

Deal Date	04/10/2014
Deal Type	Partnership
Sub Category	License
Deal Headline	Acura Pharmaceuticals enters into an agreement with Pfizer
Deal Status	Announced
Acquirer/Partner	Pfizer Inc
Source/Target	Acura Pharmaceuticals Inc
Deal Value (USD mn)	2
Region/Country	United States
Deal Details	Acura Pharmaceuticals, Inc. has entered into a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERTION Technology and the return to Acura of the FDA approved Oxecta (oxycodone HCl) product. The letter agreement provides that Acura will make a one-time payment of USD2.0 million to Pfizer. The AVERTION Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.
Updates/Amendments	

Deal Date	04/01/2014
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	EMD Serono enters into research agreement with Pfizer and Broad Institute
Deal Status	Completed
Acquirer/Partner	Broad Institute; EMD Serono Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>EMD Serono Inc. has entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus and Lupus Nephritis patients. The research project will be jointly funded by EMD Serono and Pfizer.</p> <p>Under the terms, the Broad Institute will investigate clinical samples obtained from Systemic Lupus Erythematosus and Lupus Nephritis patients, applying biochemical and next-generation sequencing technologies. They will also analyze immune cell subpopulations. In addition, through computational modeling approaches, the project aims to identify key molecular drivers of Systemic Lupus Erythematosus and Lupus Nephritis kidney flares, and thereby to discover potential novel drug targets as the basis for innovative therapies.</p> <p>EMD Serono and Pfizer, as sponsoring members, will receive real-time access to all data and analysis. In addition, both companies will have the ability to send a research scientist to the Broad Institute to foster exchange of technology expertise in the area of computational and experimental genomic profiling.</p>
Updates/Amendments	

Deal Date	02/26/2014
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing; Research and Discovery
Deal Headline	Pfizer enters into agreement with Saniona to research and develop small molecule treatments for neurological disorders
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Saniona
Deal Value (USD mn)	52 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide drug discovery and development collaboration with Saniona AB. The collaboration focuses on research of medicines to treat neurological disorders, using Saniona's expertise in ion channels and related technology platforms. Pfizer will receive exclusive worldwide rights to research, develop, manufacture and commercialize medicines identified through the collaboration.</p> <p>Under the terms, Saniona is eligible to receive milestone payments upon the achievement of certain research and development milestones as well as royalties on any potential products developed and commercialized by Pfizer as a result of this collaboration. The total potential value of the pre-commercial milestone payments is up to USD52 million.</p>
Updates/Amendments	<p>Deal Updated date : 09/16/2015</p> <p>Pfizer Inc. has terminated the research collaboration with Saniona for neurological disorders.</p>

Deal Date	02/05/2014
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer collaborates with Merck for MK-3475
Deal Status	Completed
Acquirer/Partner	Merck and Co Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Merck & Co., Inc., through two Merck subsidiaries has entered into collaboration with Pfizer Inc. to explore the therapeutic potential of Merck's MK-3475 in combination with two Pfizer oncology assets. A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer's INLYTA in renal cell carcinoma. A separate Phase I study will evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566) in regulation of immune cell proliferation and survival. Under the terms, Pfizer will conduct the clinical studies of MK-3475 plus axitinib and MK-3475 plus PF-2566.
Updates/Amendments	

Deal Date	02/05/2014
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Manufacturing
Deal Headline	Pfizer enters into agreement with Ichor
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ichor Medical Systems Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a collaboration and licensing agreement with Ichor Medical Systems Inc. to develop electroporation devices for use in therapeutic cancer vaccine regimens. Ichor's TriGrid intramuscular electroporation technology will be used to facilitate clinical administration of DNA-based vaccines as part of Pfizer's preclinical cancer vaccine-based immunotherapy research program.</p> <p>Under the terms, Ichor will receive an upfront payment and potential development milestone payments for products in the licensed field as well as royalty payments on potential future licensed product sales. Ichor and Pfizer will share development expenditures during the collaboration phase and Pfizer will assume full responsibility for manufacturing and commercialization of Pfizer vaccine based immunotherapies and Ichor devices for any licensed products.</p>
Updates/Amendments	

Deal Date	01/28/2014
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Neoantigenics enters into collaboration agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Neoantigenics Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Neoantigenics LLC has entered into an early-stage research and development collaboration with Pfizer Inc. The collaboration is focused on the development of antibody-based therapeutics and companion diagnostics targeting Neoantigenics' proprietary oocyte-associated biomarkers, which are selectively expressed on a wide array of human cancers.</p> <p>In addition to scientific engagement between Neoantigenics and Pfizer's scientific teams, Pfizer is making an equity investment in Neoantigenics through the Pfizer Seed Fund, which supports promising early-stage life science companies. The investment is part of a round that included an investment from the Center for Innovative Technology's GAP Fund and an award from the Commonwealth Research Commercialization Fund.</p>
Updates/Amendments	

Deal Date	01/09/2014
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer enters into agreement with Avillion to co-develop Bosulif
Deal Status	Completed
Acquirer/Partner	Avillion Group
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive collaborative development agreement with The Avillion Group to conduct a global Phase III clinical trial of Pfizer's Bosulif. The trial will be conducted across multiple sites in the United States, Asia and Europe.</p> <p>Under the terms, Avillion will provide the funding for and will conduct the trial to generate the clinical data necessary to potentially support a registration dossier for marketing authorization of BOSULIF by regulatory authorities for an indication as first-line treatment of patients with chronic phase Ph+ CML. If approved for this indication, Avillion will be eligible to receive milestone payments from Pfizer upon regulatory approval of the drug. Pfizer will retain all rights to commercialize Bosulif globally.</p>
Updates/Amendments	

Deal Date	01/09/2014
Deal Type	Partnership
Sub Category	Clinical Trial Service Agreement
Deal Headline	Akili Interactive Labs enters into partnership with Pfizer to test project EVO
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Akili Interactive Labs Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Akili Interactive Labs Inc. has entered into an agreement with Pfizer Inc. to test the ability of Akili's mobile video game platform ("Project EVO") to detect cognitive differences in healthy elderly people at risk of developing Alzheimer's disease.</p> <p>Under the agreement, Pfizer will conduct a clinical trial that will evaluate healthy elderly subjects with and without the presence of amyloid in their brains. The goal of the trial is to investigate the Akili game as a biomarker or clinical endpoint for potential use in future Alzheimer's trials.</p>
Updates/Amendments	

Deal Date	01/06/2014
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer collaborates with MD Anderson to advance cancer immunotherapy
Deal Status	Completed
Acquirer/Partner	The University of Texas MD Anderson Cancer Center
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaboration with The University of Texas MD Anderson Cancer Center for the development of immune-based approaches to cancer treatment. The three-year agreement is designed to accelerate the progress of immune-based treatments to cancer patients and to more efficiently identify and exploit new combination therapies, as well as biomarkers to guide and monitor treatment.
Updates/Amendments	

Deal Date	01/05/2014
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer to merge with AstraZeneca
Deal Status	Rejected
Acquirer/Partner	Pfizer Inc
Source/Target	AstraZeneca Plc
Deal Value (USD mn)	106000
Region/Country	United Kingdom
Deal Details	<p>Pfizer Inc. has announced merger transaction with AstraZeneca. Pfizer has submitted a preliminary, non-binding indication of interest to the Board of Directors of AstraZeneca regarding merger transaction with AstraZeneca and included a combination of cash and shares in the combined entity which represented an indicative value of GBP46.61 (USD76.62) per AstraZeneca share and a substantial premium of approximately 30% to AstraZeneca's closing share price of GBP35.86 on 3 January 2014. Under which AstraZeneca shareholders would receive, for each AstraZeneca share, 1.845 shares in the combined entity and 1,598 pence in cash. The revised proposal was rejected by AstraZeneca. Pfizer is considering its options with respect to AstraZeneca.</p> <p>Merrill Lynch, Pierce, Fenner and Smith Inc and Merrill Lynch International, subsidiaries of Bank of America Corporation, are acting exclusively for Pfizer in connection with the merger offer. Guggenheim Securities LLC is acting as a financial adviser to Pfizer in relation to the possible offer. JP Morgan Securities LLC is acting exclusively for Pfizer in connection with the possible offer.</p> <p>The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients. A potential combination with AstraZeneca aligns with Pfizer's current structure and fully supports its existing strategy to build world-class businesses. The transaction would further strengthen their ability to generate strong and consistent cash flow, targeted for both investment in their business and return to shareholders, while at the same time offering an efficient operating structure and the anticipated realization of attractive synergies.</p>
Updates/Amendments	

	<p>Deal Updated date : 01/14/2014 AstraZeneca has declined merger transaction with Pfizer to pursue negotiations and the discussions were discontinued.</p>
	<p>Deal Updated date : 04/26/2014 Pfizer Inc. has contacted AstraZeneca seeking to renew discussions, but AstraZeneca again declined to engage.</p>
	<p>Deal Updated date : 05/02/2014 AstraZeneca has rejected merger transaction with Pfizer for USD106000 million. AstraZeneca said the offer of GBP50.00 (USD84.47) per share substantially undervalued AstraZeneca and its board would not engage with Pfizer on that basis. The share price increased to GBP50 per share from as previously announced GBP35.86 per share.</p>

Deal Date	12/24/2013
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Kissei Pharmaceutical enters into licensing agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Kissei Pharmaceutical Co Ltd
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Kissei Pharmaceutical co Ltd enters into licensing agreement with Pfizer Inc. for granting exclusive rights to Pfizer to develop and commercialize the investigational therapy KUX-1151 for gout and hyperuricemia. KUX-1151 was discovered by Kissei.Under the terms of agreement Kissei grants Pfizer exclusive worldwide rights to KUX-1151 excluding Japan. Kissei will receive an upfront payment and will be eligible to receive milestone payments and royalties on any product sales in accordance with the terms of the agreement.
Updates/Amendments	

Deal Date	12/18/2013
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing
Deal Headline	Pfizer enters into agreement with Mylan
Deal Status	Completed
Acquirer/Partner	Mylan Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with Mylan Inc. for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications. Mylan will have exclusive commercialization rights for this compound in the U.S., Canada, Australia, New Zealand, the European Union and European Free Trade Association countries, India and Japan. In the rest of the world, Mylan and Pfizer will have co-promotion rights to the product.
Updates/Amendments	

Deal Date	12/16/2013
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer collaborates with Siemens
Deal Status	Completed
Acquirer/Partner	Siemens Healthcare Diagnostics
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaboration with Siemens Healthcare Diagnostics to develop and commercialize diagnostic tests for undisclosed therapeutic products across Pfizer's pipeline.
Updates/Amendments	

Deal Date	12/11/2013
Deal Type	Partnership
Sub Category	Commercialization; Marketing
Deal Headline	Pfizer enters into agreement with Octapharma for human prothrombin complex concentrate
Deal Status	Completed
Acquirer/Partner	Octapharma AG
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with Octapharma AG for the future marketing and commercialization of human prothrombin complex concentrate. Under the terms, Octapharma AG has exclusive rights to commercialize this product globally, with the exception of the U.S. where Pfizer will exclusively be responsible for marketing and commercialization.
Updates/Amendments	

Deal Date	12/02/2013
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Pfizer acquires Polocard from ZF Polpharma
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	ZF Polpharma SA
Deal Value (USD mn)	
Region/Country	Poland
Deal Details	Pfizer Inc., through its wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard from ZF Polpharma SA.
Updates/Amendments	

Deal Date	10/01/2013
Deal Type	Partnership
Sub Category	Co-Development; Commercialization
Deal Headline	Eli Lilly enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Eli Lilly and Co
Source/Target	Pfizer Inc
Deal Value (USD mn)	1780 (Max)
Region/Country	Worldwide
Deal Details	Eli Lilly and Co and Pfizer Inc have entered into collaboration agreement to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs. Lilly will pay an upfront fee of USD200.0 million. In addition to this fee, Lilly may pay up to USD350.0 million in success-based regulatory milestones and up to USD1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.
Updates/Amendments	

Deal Date	09/30/2013
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into licensing agreement with Gliknik for drug candidate targeting autoimmune diseases
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Gliknik Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an exclusive worldwide licensing agreement with Gliknik Inc. for GL-2045. Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Under the terms, Gliknik will receive an upfront payment of USD25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to this license agreement.
Updates/Amendments	

Deal Date	08/13/2013
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer collaborates with Sanford-Burnham Medical Research Institute
Deal Status	Completed
Acquirer/Partner	Sanford Burnham Medical Research Institute
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaboration with Sanford-Burnham Medical Research Institute to identify new therapeutic targets for preventing and treating complications of obesity and diabetes. Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. Investigators will utilize the Conrad Prebys Center for Chemical Genomics to screen for new relevant targets using investigational compounds from Pfizer as well as evaluate compounds previously identified from the NIH chemical library.
Updates/Amendments	

Deal Date	07/30/2013
Deal Type	Partnership
Sub Category	License
Deal Headline	Lonza and BioWa enters into license agreement with Pfizer for Potelligent CHOK1SV Cell Line
Deal Status	Completed
Acquirer/Partner	BioWa Inc; Pfizer Inc
Source/Target	Lonza Group Ltd
Deal Value (USD mn)	
Region/Country	Switzerland
Deal Details	Pfizer Inc. has entered into licensing agreement with BioWa, Inc. and Lonza Group Ltd allowing the use of the Potelligent CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer's pipeline.
Updates/Amendments	

Deal Date	07/24/2013
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into licensing agreement with Harbour Antibodies
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Harbour Antibodies BV
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a licensing agreement with Harbour Antibodies BV, under which Harbour Antibodies has licenced its H2L2 mice, which can generate human monoclonal antibodies to Pfizer.
Updates/Amendments	

Deal Date	07/22/2013
Deal Type	Partnership
Sub Category	Development; License
Deal Headline	Ligand enters into global license agreement with Azure for Lasofoxifene
Deal Status	Completed
Acquirer/Partner	Azure Biotech Inc
Source/Target	Ligand pharmaceuticals Inc
Deal Value (USD mn)	2.7
Region/Country	Worldwide
Deal Details	Ligand Pharmaceuticals Incorporated has entered into a global licensing agreement with Azure Biotech, Inc. for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health. Under the terms, Ligand is entitled to receive USD2.7 million in potential development and regulatory milestones and a 5% royalty on future net sales.
Updates/Amendments	

Deal Date	07/17/2013
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; Development; License
Deal Headline	Sequella acquires exclusive worldwide rights to Pfizer's Sutezolid
Deal Status	Completed
Acquirer/Partner	Sequella Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an exclusive worldwide licensing agreement with Sequella Inc., where Sequella has licensed Pfizer's exclusive worldwide rights to develop and commercialize sutezolid.
Updates/Amendments	

Deal Date	07/03/2013
Deal Type	Partnership
Sub Category	Commercialization; Infringement
Deal Headline	Impax enters into collaboration with Pfizer and UCB Pharma
Deal Status	Completed
Acquirer/Partner	Impax laboratories Inc
Source/Target	Pfizer Inc; UCB Pharma
Deal Value (USD mn)	
Region/Country	Bermuda; Canada; Greenland; North America; St Pierre and Miquelon; United States
Deal Details	Pfizer Inc. and UCB Pharma GmbH filed suit for patent infringement against Impax Laboratories, Inc. for TOVIAZ which is used to treat overactive bladder with symptoms of urinary frequency, urgency, and incontinence.
Updates/Amendments	

Deal Date	07/01/2013
Deal Type	Partnership
Sub Category	Acquisition of Rights; License; Manufacturing; Option; Supply
Deal Headline	Bioventus acquires exclusive rights to Pfizer's bone morphogenetic protein Portfolio
Deal Status	Completed
Acquirer/Partner	Bioventus LLC
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with Bioventus LLC for an exclusive, worldwide license to Pfizer's bone morphogenetic protein portfolio of development programs and associated intellectual property. The portfolio includes a bone morphogenetic protein in development, designed to offer additional options to market bone morphogenetic protein products, and the rights to rhBMP-2 in indications and fields previously reserved to Pfizer. Bioventus has also acquired an exclusive option to a bone morphogenetic protein program for soft tissue indications.</p> <p>Under the terms, Pfizer has agreed to transfer to Bioventus all existing development work for the bone morphogenetic protein assets and to undertake certain early-development activities relating to the next-generation bone morphogenetic protein. Pfizer will also manufacture rhBMP-2 and supply it to Bioventus. Pfizer received an upfront payment and will be eligible to receive milestone payments and royalties on any sales.</p>
Updates/Amendments	

Deal Date	07/01/2013
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Bioventus acquires exclusive rights to Pfizer's BMP portfolio
Deal Status	Completed
Acquirer/Partner	Bioventus LLC
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Bioventus LLC has entered into worldwide licensing agreement with Pfizer Inc. for Pfizer's bone morphogenetic protein portfolio of development programs and associated intellectual property. The portfolio includes a next-generation BMP in development and the rights to rhBMP-2 in indications and fields previously reserved to Pfizer. Pfizer has agreed to undertake certain early-development activities relating to the next-generation BMP. Pfizer will also manufacture rhBMP-2 and supply it to Bioventus. Under the terms, Pfizer received an upfront payment and will be eligible to receive milestone payments and royalties on any sales.
Updates/Amendments	

Deal Date	06/12/2013
Deal Type	Partnership
Sub Category	License; Supply
Deal Headline	Pfizer enters into licensing agreement with Abcam to supply compounds to researchers
Deal Status	Completed
Acquirer/Partner	Abcam Plc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a licensing agreement with Abcam Plc. The agreement covers a broad group of Pfizer compounds including atorvastatin, doxorubicin, nifedipine and bosutinib, all of which are widely used in pre-clinical research. The Pfizer research compounds and Abcam Biochemicals range will support pre-clinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.</p> <p>Under the terms of the agreement, Abcam's Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.</p>
Updates/Amendments	

Deal Date	06/06/2013
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer enters into development agreement with Cytomx for Probody Drug Conjugates
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Cytomx Therapeutics Inc
Deal Value (USD mn)	635 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a global strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize multiple Probody Drug Conjugates (PDC). CytomX's novel Probody Platform brings to the collaboration a proprietary, highly differentiated approach to developing safer and more effective antibody-drug conjugates.</p> <p>Under the terms, Pfizer has exclusive rights to pursue development and commercialization of select PDCs. The companies will work together on preclinical research and Pfizer will be responsible for development and potential commercialization of any selected PDCs. CytomX will be eligible to receive up-front, research reimbursement and preclinical milestone payments totaling approximately USD25 million and approximately USD610 million in regulatory and sales milestone payments, as well as tiered royalties reaching double digits on potential future sales.</p>
Updates/Amendments	

Deal Date	06/06/2013
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	CytomX enters into global strategic collaboration with Pfizer to develop and commercialize multiple probody drug conjugates in Oncology
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Cytomx Therapeutics Inc
Deal Value (USD mn)	635 (Max)
Region/Country	Worldwide
Deal Details	<p>CytomX Therapeutics, Inc. has entered into a global strategic collaboration with Pfizer Inc. to develop and commercialize multiple probody-drug conjugates. CytomX's novel Probody Platform brings to the collaboration a proprietary, highly differentiated approach to developing safer and more effective antibody-drug conjugates.</p> <p>Under the terms, Pfizer has exclusive rights to pursue development and commercialization of select probody-drug conjugates. The companies will work together on preclinical research and Pfizer will be responsible for development and potential commercialization of any selected probody-drug conjugates. CytomX will be eligible to receive up-front, research reimbursement and preclinical milestone payments totalling approximately USD25 million and approximately USD610 million in regulatory and sales milestone payments, as well as tiered royalties reaching double digits on potential future sales.</p>
Updates/Amendments	

Deal Date	04/28/2013
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer enters into agreement with Merck to develop and commercialize ertugliflozin
Deal Status	Completed
Acquirer/Partner	Merck and Co Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Merck & Co., Inc. through its subsidiary has entered into a worldwide collaboration agreement with Pfizer Inc. for the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and JANUVIA tablets. Under the terms, Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products.</p> <p>As per the terms, Pfizer received an upfront payment and milestones of USD60 million and will be eligible for additional payments associated with the achievement of pre-specified future clinical, regulatory and commercial milestones. Merck and Pfizer will share potential revenues and certain costs on a 60/40 percent basis</p>
Updates/Amendments	

Deal Date	04/16/2013
Deal Type	Mergers & Acquisitions
Sub Category	Merger
Deal Headline	Pfizer completes merging with Pharmacia
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Pharmacia Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and Pharmacia Corporation as a unified company on April 16, 2003. Research and development budget of USD7.1 billion in 2003, the new Pfizer is now the world's leading research-based pharmaceutical company.
Updates/Amendments	

Deal Date	04/03/2013
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer enters into agreement with BIND Therapeutics
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	DNIB Unwind Inc
Deal Value (USD mn)	214 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer, Inc. has entered into a worldwide collaboration agreement with BIND Therapeutics to develop and commercialize Accurins utilizing select small molecule targeted therapies. The collaboration aims to employ BIND's Medicinal Nanoengineering platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs. Under the terms, Pfizer will have the exclusive option to pursue development and commercialization of the Accurins selected by its team. Both companies will work together on preclinical research, and if Pfizer exercises its option, Pfizer will have responsibility for development and commercialization of the selected Accurins. BIND could receive up-front and development milestone payments totaling approximately USD50 million and approximately USD160 million in regulatory and sales milestone payments for each Accurin commercialized as well as tiered royalties on potential future sales.</p>
Updates/Amendments	<p>Deal Updated date : 04/02/2015</p> <p>Pfizer, Inc. has extended its worldwide collaboration agreement with BIND Therapeutics, Inc. for the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline. The collaboration was established in April 2013 and the timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016. Under the terms, BIND has the potential to receive payments up to USD88.5 million upon the achievement of additional specified development and regulatory events. BIND may also receive additional payments up to USD110 million for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of each Accurin commercialized, if any.</p>

	<p>Deal Updated date : 09/24/2015</p> <p>Pfizer Inc. has exercised its option under the agreement with BIND Therapeutics, Inc. to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement. Under the terms of the option exercise agreement, BIND will receive a USD2.5 million option exercise fee from Pfizer.</p>
	<p>Deal Updated date : 07/27/2016</p> <p>Pfizer Inc. has terminated its agreement with BIND Therapeutics. Because Pfizer has filed U.S. Bankruptcy Court approval for its acquisition of all of BIND Therapeutics assets for which the pharma giant placed the highest bid of USD40 million at a court-authorized auction.</p>

Deal Date	04/03/2013
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into exclusive licensing agreement with Tetragenetics for SionX technology
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Tetragenetics Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a collaboration agreement with Tetragenetics Inc. for an exclusive license of TetraGenetic's SionX Technology.
Updates/Amendments	

Deal Date	04/03/2013
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into collaboration with Children's Hospital of Philadelphia for therapeutic innovation to speed pediatric research and development
Deal Status	Completed
Acquirer/Partner	
Source/Target	Childrens Hospital of Philadelphia; Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. and The Children's Hospital of Philadelphia have entered into collaboration with the goal of translating biomedical discoveries into novel treatments. Children's Hospital of Philadelphia will participate in the Centers for Therapeutic Innovation network.</p> <p>Under the terms, Centers for Therapeutic Innovation will bring together scientists from Pfizer and Children's Hospital to identify preclinical research at Children's Hospital of Philadelphia with potential applications for innovative treatments. Pfizer will share with Children's Hospital of Philadelphia researchers an extensive collection of antibodies and other proteins, along with other proprietary research and drug- development tools.</p>
Updates/Amendments	

Deal Date	03/31/2013
Deal Type	Partnership
Sub Category	Infringement; Settlement
Deal Headline	Pfizer files patent infringement against with Mylan
Deal Status	Completed
Acquirer/Partner	Mylan Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Mylan Inc. has been sued by Pfizer Inc in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for celecoxib. This product is the generic version of Celebrex.
Updates/Amendments	<p>Deal Updated date : 06/02/2014</p> <p>Mylan Inc has entered into a settlement agreement with Pfizer Inc. relating to Mylan's Abbreviated New Drug Application filed with the U.S. Food and Drug Administration for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg. This product is the generic version of Celebrex, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.</p>

Deal Date	03/01/2013
Deal Type	Partnership
Sub Category	Development; License
Deal Headline	Repligen enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Repligen Corp
Deal Value (USD mn)	70
Region/Country	Worldwide
Deal Details	Repligen Corporation has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy program which includes RG3039. Under the terms, Repligen is will receive up to USD70 million from Pfizer, commencing with an upfront payment of USD5 million and total potential future milestone payments of up to USD65 million as well as royalties on any future sales of SMA compounds developed under the agreement. As per the terms, Repligen is responsible for completing the first two cohorts of an active Phase I trial evaluating RG3039. Repligen will also provide certain technology transfer services to Pfizer.
Updates/Amendments	

Deal Date	02/08/2013
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration; Co-Development
Deal Headline	Pfizer enters into agreement with OxOnc to develop Crizotinib
Deal Status	Completed
Acquirer/Partner	OxOnc Development LP
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China; Japan; South Korea; Taiwan
Deal Details	<p>Pfizer Inc. has entered into a co-development agreement with OxOnc Development LP to conduct a pivotal clinical trial of Pfizer's crizotinib. The trial will be conducted at multiple sites in Japan, China, Taiwan and South Korea to assess the safety and efficacy of crizotinib.</p> <p>Under the terms, OxOnc will provide funding and supervision for the trial, with the goal of generating the clinical data necessary for Pfizer to submit crizotinib for review by regulatory authorities for the treatment of advanced ROS1-positive non-small cell lung cancer in the Asian region. If approved for this indication, OxOnc will be eligible to receive milestone payments from Pfizer. Additional terms were not disclosed.</p>
Updates/Amendments	

Deal Date	01/03/2013
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Labrys acquires RN-307 from Pfizer
Deal Status	Completed
Acquirer/Partner	Labrys Biologics Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Labrys Biologics Inc. has acquired RN-307 from Pfizer Inc. for the treatment of chronic migraine. Under the terms, Labrys has acquired worldwide rights to RN-307. Pfizer received an upfront payment and will be eligible to receive milestone payments, royalties on any sales.
Updates/Amendments	

Deal Date	01/03/2013
Deal Type	Partnership
Sub Category	License; Marketing
Deal Headline	Pfizer enters into worldwide licensing agreement with Philogen for Dekavil
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Philogen SpA
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into a strategic worldwide licensing agreement with Philogen S.p.A. for Dekavil. Under the terms, Philogen will receive an upfront payment and will be eligible to receive milestone and royalty payments. Pfizer retains exclusive rights to market any products that may be developed as a result of the collaboration.
Updates/Amendments	

Deal Date	12/21/2012
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Halozyme Therapeutics enters into collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Halozyme Therapeutics Inc
Deal Value (USD mn)	8
Region/Country	Worldwide
Deal Details	Halozyme Therapeutics Inc. has entered into a worldwide collaboration and license agreement with Pfizer Inc. for developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze Technology. Under the terms of the agreement, Halozyme has granted to Pfizer a worldwide license to develop and commercialize products combining rHuPH20 with Pfizer proprietary biologics directed to up to six targets. Targets may be selected on an exclusive or non-exclusive basis. Halozyme will receive an initial payment of USD8 million, which includes the upfront fee for exclusive licenses to two specified therapeutic targets in primary care and specialty care indications and the right for Pfizer to elect up to four additional targets upon payment of additional fees.
Updates/Amendments	

Deal Date	12/10/2012
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Nuron Biotech acquires Meningitec from Pfizer
Deal Status	Completed
Acquirer/Partner	Nuron Biotech Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Nuron Biotech Inc. has acquired from Pfizer Inc. Meningitec.
Updates/Amendments	

Deal Date	12/01/2012
Deal Type	Partnership
Sub Category	Development
Deal Headline	Protalix enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Protalix BioTherapeutics Inc
Deal Value (USD mn)	10.6
Region/Country	Israel
Deal Details	Protalix Ltd has entered into a clinical development agreement with Pfizer Inc, pursuant to which Protalix will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. Protalix is currently sponsoring adult and pediatric extension studies of taliglucerase alfa. New clinical trials for taliglucerase alfa will be conducted and sponsored by Pfizer. Protalix Ltd. received a milestone payment of USD8.3 million, sublicense fee equal to USD2.3 million to the academic institution from who it licensed certain technology relating to taliglucerase alfa. Protalix is also required to pay a royalty ranging between 3.0% and 6.0% of the revenues of taliglucerase alfa Pfizer records under the Pfizer agreement.
Updates/Amendments	

Deal Date	11/05/2012
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer enters into global commercialization agreement with Ziarco
Deal Status	Completed
Acquirer/Partner	Ziarco Pharma Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer, Inc. has entered into an exclusive worldwide agreement with Ziarco Pharma Ltd for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research anti-inflammatory and anti-allergic assets. Under the terms, Pfizer will receive equity as well as certain product-based milestone and royalty payments.
Updates/Amendments	

Deal Date	11/01/2012
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Portola collaborates with Bristol and Pfizer
Deal Status	Completed
Acquirer/Partner	Bristol Myers Squibb Company; Pfizer Inc
Source/Target	Portola Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. have entered into a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban). Under the terms, Bristol and Pfizer will make an undisclosed cash payment to Portola upon initiation of the proof-of concept study with Eliquis and will provide development and regulatory guidance for the study. Portola retains 100% global development and commercialization rights for PRT4445.
Updates/Amendments	Deal Updated date : 01/13/2014 Portola Pharmaceuticals Inc. has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company and Pfizer Inc. to study andexanet alfa (PRT4445), with Eliquis (apixaban). Under the terms, Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestone payments. Bristol-Myers Squibb and Pfizer will continue to provide development and regulatory guidance for the program. Portola retains full, worldwide commercial rights to andexanet alfa.

Deal Date	11/01/2012
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Bristol-Myers Squibb enters into an agreement with Portola and Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Bristol Myers Squibb Company; Portola Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Bristol-Myers Squibb Company, Portola Pharmaceuticals Inc. and Pfizer Inc. have entered into a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and Eliquis(apixaban). The study is designed to demonstrate the safety of PRT4445 and its ability to reverse the anticoagulation activity of Eliquis and other Factor Xa inhibitors, including betrixaban, Portola's Phase III oral Factor Xa inhibitor. Under the terms, Bristol and Pfizer will make an undisclosed cash payment to Portola upon initiation of the proof-of-concept study with Eliquis and will provide development and regulatory guidance for the study. Portola retains 100% global development and commercialization rights for PRT4445.
Updates/Amendments	

Deal Date	10/30/2012
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into collaborative research agreement with Apredica
Deal Status	Completed
Acquirer/Partner	Apredica LLC
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaborative research agreement with Apredica LLC. The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved. The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology.
Updates/Amendments	

Deal Date	10/22/2012
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires NextWave Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	NextWave Pharmaceuticals Inc
Deal Value (USD mn)	680
Region/Country	United States
Deal Details	<p>Pfizer Inc., has completed the acquisition of privately held NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder or ADHD. Pfizer had previously entered into an option and merger agreement with NextWave during the second quarter 2012 and made an option payment of USD20 million. Now Pfizer is exercised its option to acquire NextWave. Under the terms of the agreement, Pfizer made a payment of USD255 million to NextWave's shareholders at the closing of the transaction, and NextWave's shareholders are eligible to receive additional payments of up to USD425 million based on certain sales milestones.</p> <p>Pfizer's financial advisor for the transaction was Jefferies & Company, Inc. Pfizer legal alliance firms Kaye Scholer LLP and Ropes & Gray LLP acted as legal counsel. NextWave's financial advisor for the transaction was Aquilo Partners, L.P., while Cooley LLP served as its legal advisor.</p>
Updates/Amendments	

Deal Date	09/18/2012
Deal Type	Partnership
Sub Category	Development; License; Research and Discovery
Deal Headline	Pfizer enters into agreement with Open Monoclonal Technology
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Open Monoclonal Technology Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with Open Monoclonal Technology, Inc., where Pfizer will use Open Monoclonal's OmniRat for antibody research and development.
Updates/Amendments	

Deal Date	09/12/2012
Deal Type	Partnership
Sub Category	Commercialization; Development; Joint Venture; Manufacturing
Deal Headline	Pfizer and Zhejiang Hisun forms a joint venture Hisun Pfizer Pharmaceuticals Co Ltd
Deal Status	Completed
Acquirer/Partner	Pfizer Inc; Zhejiang Hisun Pharmaceutical Co Ltd
Source/Target	
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with Zhejiang Hisun Pharmaceuticals to launch Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.
Updates/Amendments	

Deal Date	09/11/2012
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer enters into antibody discovery collaboration with Visterra
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Visterra Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and Visterra Inc. have entered into a collaboration agreement to discover novel antibodies using Visterra's proprietary platform. Under the terms, Visterra will receive an up-front fee as well as research funding, and is eligible to receive predetermined payments for meeting certain research and development milestones, plus royalties upon any product commercialization.
Updates/Amendments	

Deal Date	09/07/2012
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer enters into agreement with SFJ Pharma to co-develop Dacomitinib
Deal Status	Completed
Acquirer/Partner	SFJ Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Asia-Pacific; Europe
Deal Details	<p>Pfizer Inc. has entered into a collaborative development agreement with The SFJ Pharmaceuticals Group to conduct a Phase III clinical trial of Pfizer's dacomitinib. The trial will be conducted across multiple sites in Asia and Europe.</p> <p>Under the terms, SFJ Pharma will provide the funding and clinical development supervision to generate the clinical data necessary to support a registration dossier on dacomitinib for marketing authorization by regulatory authorities for the indication. If approved for this indication, SFJ Pharma will be eligible to receive milestone payments and earn-out payments.</p>
Updates/Amendments	

Deal Date	08/31/2012
Deal Type	Partnership
Sub Category	Development; License
Deal Headline	Pfizer enters into licensing agreement with VLST Corporation for anti-CD40 monoclonal antibody
Deal Status	Terminated
Acquirer/Partner	VLST Corp
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an in-licensing agreement with VLST Corporation for an anti-CD40 monoclonal antibody. VLST plans to advance this compound into efficacy studies in an oncology setting. Under the terms, Pfizer will retain co-exclusive rights to CP-870,893 in the oncology vaccine field.
Updates/Amendments	

Deal Date	08/22/2012
Deal Type	Partnership
Sub Category	Commercialization; Development; Distribution; Manufacturing; Marketing; Research and Discovery
Deal Headline	Pfizer enters into agreement with Mylan
Deal Status	Completed
Acquirer/Partner	Mylan Inc; Pfizer Inc
Source/Target	
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Pfizer Inc. has entered into definitive agreement with Mylan Inc. to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. Under the terms, Pfizer is responsible for the commercialization of the combined generics portfolio, managing a combined marketing and sales effort using its brand reputation. Mylan is responsible for managing operations, including research and development and manufacturing, building upon the company's global reputation for development of difficult to formulate products, quality manufacturing, supply chain reliability and service excellence. The collaboration between Pfizer and Mylan will include a portfolio of more than 350 marketed products across a broad range of therapeutic categories, as well as more than 125 additional products in development. Products included in the collaboration are expected to be sold under the Pfizer brand with joint labeling. Pfizer and Mylan will each continue to operate independent entities in Japan, but will collaborate on current and future generic products, sharing the costs and profits resulting from the collaboration.
Updates/Amendments	

Deal Date	08/13/2012
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Pfizer enters into an agreement with AstraZeneca for over-the-counter Nexium
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	AstraZeneca Plc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with AstraZeneca Plc for the over-the-counter rights for Nexium. Pfizer will acquire the exclusive global rights to market NEXIUM for the approved over-the-counter indications in the United States, Europe and the rest of the world.</p> <p>Under the agreement, Pfizer will make an upfront payment of USD250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.</p>
Updates/Amendments	

Deal Date	08/13/2012
Deal Type	Partnership
Sub Category	Commercialization
Deal Headline	Pfizer and AstraZeneca enter into agreement for Nexium
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	AstraZeneca Plc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with AstraZeneca Plc, for the over-the-counter rights for NEXIUM, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market NEXIUM for the approved over-the-counter indications in the United States, Europe and the rest of the world. Under the agreement, Pfizer will make an upfront payment of USD250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.
Updates/Amendments	

Deal Date	08/09/2012
Deal Type	Partnership
Sub Category	Development; Option
Deal Headline	Pfizer enters into a multi-year strategic collaboration with Nodality for Autoimmune Disease
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Nodality Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into strategic collaboration with Nodality, Inc. for the use of Nodality's proprietary single cell network profiling technology for the development of Pfizer compounds. The agreement will initially focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling. The agreement also provides Pfizer the option to engage Nodality in companion diagnostics development. Under the terms, Pfizer will pay an upfront payment, research and development funding, and success-based milestone payments.
Updates/Amendments	

Deal Date	08/07/2012
Deal Type	Partnership
Sub Category	License; Marketing; Sales
Deal Headline	Pfizer enters into license agreement with Mylan Specialty for EpiPen Injection
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Mylan Specialty LP
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	<p>Pfizer Inc. and Mylan Specialty LP., a subsidiary of Mylan Inc. have entered into a licensing agreement, under which Pfizer will obtain the exclusive rights to market and sell EpiPen Injection 0.3/0.15mg in Japan.</p> <p>Under the terms of the agreement, the exclusive rights to market and sell the next-generation EpiPen Injection in Japan will be transferred to Pfizer from Mylan Seiyaku. The next-generation EpiPen Injection and EpiPen Auto-Injector are currently available in Japan, the U.S., Canada, South Africa, Australia and certain European countries.</p>
Updates/Amendments	

Deal Date	07/11/2012
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; License
Deal Headline	Verastem acquires clinical-stage FAK inhibitor from Pfizer
Deal Status	Completed
Acquirer/Partner	Verastem Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. and Verastem, Inc. have entered into an agreement for the exclusive in-license of worldwide commercial rights for VS-6063. Under the terms, Verastem will assume sole responsibility for global product development of VS-6063. Pfizer will receive an upfront payment in cash and Verastem equity, development milestones and royalties and milestones on future sales of VS-6063.
Updates/Amendments	

Deal Date	06/28/2012
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	Pfizer files lawsuit against Alembic and US firm Breckenridge Pharma
Deal Status	Announced
Acquirer/Partner	Alembic Pharmaceuticals Ltd; Breckenridge Pharmaceutical Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has filed a lawsuit against Alembic Pharmaceuticals Ltd and US firm Breckenridge Pharmaceutical Inc., for their move to market generic tablets for treating depression. The tablets in the strengths of 50 mg and 100 mg are a generic version of Pfizer Inc's Pristiq tablets. Breckenridge and Alembic filed their Paragraph IV ANDA on the first-possible submission date and expects to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge.
Updates/Amendments	

Deal Date	06/13/2012
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into collaboration with Cold Spring Harbor Labs to speed development of new cancer therapies
Deal Status	Completed
Acquirer/Partner	Cold Spring Harbor Laboratory
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into research collaboration with Cold Spring Harbor Laboratory to develop a next-generation human short hairpin RNA library which could be used to silence gene expression via the process of RNA interference and identify new therapeutic targets in cancer.
Updates/Amendments	

Deal Date	04/23/2012
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Pfizer to divest nutrition business to Nestle
Deal Status	Completed
Acquirer/Partner	Nestle
Source/Target	Nutrition Business - Pfizer Inc
Deal Value (USD mn)	11850
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into an agreement to divest its Nutrition business to Nestle for USD11850 million in cash. Pfizer's Nutrition business recorded revenues of approximately USD2100 million in 2011.</p> <p>Pfizer's financial advisors for the transaction were Morgan Stanley & Co. LLC and Centerview Advisors LLC. Pfizer legal alliance firms Skadden, Arps, Slate, Meagher & Flom LLP, Clifford Chance LLP and DLA Piper LLP acted as legal counsel for Pfizer.</p>
Updates/Amendments	<p>Deal Updated date : 11/30/2012</p> <p>Pfizer Inc. has completed the sale of its nutrition business to Nestle for USD11850 million in cash, following the conclusion of the required regulatory process in most markets.</p>

Deal Date	02/26/2012
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Alacer Corp
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Alacer Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has completed the acquisition of privately-held Alacer Corp., a maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States. The transaction's financial terms are not disclosed.</p> <p>Lazard acted as financial advisor to Pfizer, and DLA Piper LLP (U.S.) acted as legal advisor to Pfizer, in connection with the acquisition. Houlihan Lokey acted as financial advisor to the owners of Alacer Corp., and Rutan & Tucker LLP acted as legal advisor to the owners of Alacer Corp., in connection with the transaction.</p>
Updates/Amendments	

Deal Date	01/30/2012
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into research collaboration with KineMed for the advancement of novel approaches in metabolic disease
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	KineMed Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and KineMed, Inc. have entered into a non-exclusive research collaboration for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed's Dynamic Proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
Updates/Amendments	Deal Updated date : 03/27/2013 KineMed Inc. has renewed its non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed's unique dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

Deal Date	01/09/2012
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer enters into agreement with SFJ Pharma to develop Axitinib for adjuvant treatment of Renal Cell Carcinoma
Deal Status	Completed
Acquirer/Partner	SFJ Pharma Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Asia-Pacific
Deal Details	<p>Pfizer Inc. has entered into a collaborative development agreement with SFJ Pharma Ltd. II to conduct Phase III clinical trial in Asia for Pfizer's investigational agent axitinib. SFJ Pharma will provide funding and clinical development supervision to generate the clinical data necessary to submit axitinib for review by regulatory authorities for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.</p> <p>Under the terms, SFJ Pharma is eligible to receive milestone payments under the agreement. In addition, if approved, Pfizer intends to commercialize axitinib for this indication and SFL will receive earn-out payments.</p>
Updates/Amendments	

Deal Date	12/25/2011
Deal Type	Partnership
Sub Category	Co-Development
Deal Headline	Pfizer enters into cooperation agreement with CollPlant to jointly develop an orthopaedic product
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Collplant Holdings Ltd
Deal Value (USD mn)	1.9
Region/Country	Israel
Deal Details	Pfizer Inc. has entered into cooperation agreement with CollPlant Holdings Ltd. to jointly develop an orthopaedic product for the repair of compound fractures. Pfizer will pay CollPlant USD1.9 million for its share of the three-year agreement. The product will combine Pfizer's proteins and CollPlant's rhCollagen human recombinant collagen product. Both companies will own the final product.
Updates/Amendments	

Deal Date	12/20/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Manufacturing
Deal Headline	Pfizer Consumer Healthcare enters into licensing agreement with Antares Pharma
Deal Status	Completed
Acquirer/Partner	Pfizer Consumer Healthcare GmbH
Source/Target	Antares Pharma Inc
Deal Value (USD mn)	
Region/Country	North America
Deal Details	<p>Pfizer Consumer Healthcare GmbH has entered into a licensing agreement with Antares Pharma, Inc. where, Antares has licensed its drug delivery technologies to Pfizer's Consumer Healthcare Business Unit to develop an undisclosed product on an exclusive basis for North America.</p> <p>Under the terms, Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares will receive undisclosed upfront payments, development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the United States.</p>
Updates/Amendments	

Deal Date	12/01/2011
Deal Type	Partnership
Sub Category	Development; Marketing; Research and Discovery
Deal Headline	Pfizer enters into collaboration with Karo Bio to discover and develop innovative drugs for autoimmune diseases
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Karo Pharma
Deal Value (USD mn)	217 (Max)
Region/Country	Sweden
Deal Details	Pfizer Inc. has entered into a research collaboration agreement with Karo Bio AB to discover and develop small molecule RORgamma modulators for the treatment of autoimmune diseases. Under the terms, Pfizer will provide full funding for the research costs and have the exclusive right to market any products that may be developed as a result of the collaboration. Karo Bio may receive up to USD217 million in upfront and milestone payments and added to that, royalty fees.
Updates/Amendments	<p>Deal Updated date : 06/26/2013</p> <p>Pfizer Inc. has extended its existing research collaboration with Karo Bio AB on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.</p>

Deal Date	11/30/2011
Deal Type	Partnership
Sub Category	Marketing
Deal Headline	Watson enters into an agreement with Pfizer for generic version of Lipitor
Deal Status	Terminated
Acquirer/Partner	Watson Laboratories Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Watson Pharmaceuticals, Inc. has an exclusive agreement with Pfizer, Inc. to market the Authorized Generic version of Lipitor. Under the terms of the agreement, Pfizer supplies Watson with the product for distribution. Pfizer will receive a share of the net sales from Watson sales of the product.
Updates/Amendments	<p>Deal Updated date : 01/01/2013</p> <p>Due to the significant decline in the market for this product, the Watson agreed to terminate this agreement effective January 1, 2013. In exchange, the Watson is entitled to receive a royalty on future sales of the product by Pfizer through 2015.</p>

Deal Date	11/21/2011
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Excaliard Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Excaliard Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has completed the acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. While specific financial terms are confidential, Pfizer provided Excaliard's shareholders, which include Isis Pharmaceuticals, Alta Partners, ProQuest Investments and RiverVest Venture Partners, an upfront payment and will make contingent payments if certain milestones are achieved in the future.
Updates/Amendments	

Deal Date	11/09/2011
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; Development; Manufacturing
Deal Headline	Mylan to acquire Pfizer respiratory delivery platform
Deal Status	Completed
Acquirer/Partner	Mylan Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Mylan Inc. has entered into an agreement with Pfizer Inc. for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to Advair Diskus and Seretide Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform. In addition, Pfizer will grant Mylan rights to its dry-powder delivery platform to develop and commercialize additional brand and generic pharmaceutical products, including rights of negotiation for certain existing Pfizer compounds in various stages of development.</p> <p>Under the terms, Mylan will pay for remaining development and capital expenditures to bring products to market. Pfizer will be due a payment of USD17.5 million at closing of the transaction and will be eligible for additional payments, contingent upon regulatory and commercial success, including profit sharing. Mylan will have exclusive commercialization rights for the generic equivalent to Advair Diskus and Seretide Diskus in the United States, Canada, Australia, and New Zealand and in the European Union and European Free Trade Association countries. In the rest of the world, Mylan and Pfizer will have co-promotion rights to the product. All other financial terms and product details remain confidential.</p>
Updates/Amendments	

Deal Date	10/26/2011
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer establishes precision medicine research collaboration with Medco Health Solutions and United BioSource
Deal Status	Completed
Acquirer/Partner	Medco Health Solutions Inc; United BioSource Corp
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation to pursue the potential of precision medicine to deliver medicines.</p> <p>Under the terms, Pfizer and Medco will collaborate to identify and evaluate patient subgroups in which investigational drugs and marketed drugs are shown to be most effective in improving patient care and health. As a part of this agreement, Medco and Pfizer will jointly plan and implement precision medicine studies and initiatives.</p>
Updates/Amendments	

Deal Date	10/13/2011
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer and Humana form research partnership to improve health care delivery for seniors
Deal Status	Completed
Acquirer/Partner	Humana Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a five-year research partnership with Humana Inc. to explore ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations.
Updates/Amendments	

Deal Date	10/12/2011
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into collaboration with deCODE genetics to search for variants in the human genome that confer risk of Systemic Lupus Erythematosis
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	deCODE genetics
Deal Value (USD mn)	
Region/Country	Iceland
Deal Details	<p>Pfizer Inc. has entered into a research collaboration with deCODE genetics, Inc. to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis by utilizing deCODE's expertise in gene discovery.</p> <p>The research collaboration will utilize the expertise and capabilities of both deCODE and Pfizer: deCODE's comprehensive population genetics resources and analytical expertise and Pfizer's dedication to the application of genomic analysis to the discovery and development of drugs.</p>
Updates/Amendments	

Deal Date	10/11/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into license agreement wih GlycoMimetics for GMI-1070
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Glycomimetics Inc
Deal Value (USD mn)	340 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. and GlycoMimetics, Inc. have entered into an exclusive worldwide licensing agreement for GMI-1070. Pfizer will receive an exclusive worldwide license to GMI-1070 for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. GlycoMimetics will remain responsible for completion of the ongoing Phase 2 trial under Pfizer's oversight, and Pfizer will then assume all further development and commercialization responsibilities.</p> <p>Under the terms, the potential value of the agreement for GlycoMimetics is approximately USD340 million, including an upfront payment as well as development, regulatory and commercial milestones. GlycoMimetics is also eligible for royalties on any sales.</p>
Updates/Amendments	

Deal Date	10/10/2011
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into research agreement with Exonhit to identify Alzheimer's disease biomarkers
Deal Status	Completed
Acquirer/Partner	ExonHit Therapeutics SA
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a research agreement with ExonHit Therapeutics S.A. for the identification of new Alzheimer's disease biomarkers using Exonhit's Genome-Wide SpliceArray platform. Under the terms, the two companies will jointly conduct a pilot study using Exonhit's Genome-Wide SpliceArray platform to gain insight on Alzheimer's disease molecular markers associated with clinical parameters. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.
Updates/Amendments	

Deal Date	10/05/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing
Deal Headline	Puma Biotechnology enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Puma Biotechnology Inc
Deal Value (USD mn)	
Region/Country	United States; Worldwide
Deal Details	Puma Biotechnology, Inc. has entered into an agreement with Pfizer Inc. to license the worldwide commercial rights to neratinib. Under the terms of the agreement, Puma will assume sole responsibility of global product development and commercialization of neratinib. Pfizer will be entitled to receive payments upon Puma's achievement of certain development milestones of neratinib, as well as royalty payments for any sales of neratinib.
Updates/Amendments	

Deal Date	08/31/2011
Deal Type	Partnership
Sub Category	Settlement
Deal Headline	Dr Reddy's enters into settlement with Pfizer
Deal Status	Completed
Acquirer/Partner	Dr Reddys Laboratories Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Dr Reddy's Laboratories has entered into a settlement agreement with Pfizer which will resolve litigation related to Lipitor Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets.
Updates/Amendments	Deal Updated date : 01/04/2011 Pfizer has filed patent infringement against Dr Reddy's Laboratories seeking a delay in launching the Indian drug maker's low-cost version of atorvastatin.

Deal Date	08/29/2011
Deal Type	Partnership
Sub Category	Development; License; Marketing
Deal Headline	Pfizer and Jennewein Biotechnologie enters into collaboration on human milk components
Deal Status	Completed
Acquirer/Partner	Jennewein Biotechnologie GmbH
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Nutrition has entered into licensing agreement with Jennewein Biotechnologie GmbH to develop and market two Human Milk Oligosaccharides. The partnership will focus on enabling the functional and immunological benefits of HMOs to become available to infants being fed with infant formulas.
Updates/Amendments	

Deal Date	08/22/2011
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into drug discovery partnership with University of California to speed delivery of promising therapies to patients
Deal Status	Completed
Acquirer/Partner	University of California
Source/Target	Centers for Therapeutic Innovation; Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer, Inc. and University of California San Diego Health Sciences have entered into an innovative, five-year research collaboration through Pfizer's Centers for Therapeutic Innovation. This research collaboration will allow medical researchers at University of California San Diego to join with Pfizer's scientists to speed translation of discoveries into medicine for patients. As part of the Pfizer's Centers for Therapeutic Innovation program, Pfizer will provide UC San Diego researchers access to resources such as antibody libraries and technologies, as well as funding to support the pre-clinical and clinical development of sponsored programs.</p> <p>Under the terms, the collaboration will utilize University of California San Diego's medical research strengths in key areas including neurosciences, cancer, inflammation, metabolism, clinical pharmacology, HIV and pain. Centers for Therapeutic Innovation partners receive intellectual property rights and are granted milestone payments and royalties tied to the advancement of mutually agreed upon drug candidates. The potential value to UC San Diego over the five-year agreement could exceed USD50 million.</p>
Updates/Amendments	

Deal Date	08/16/2011
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer collaborates with QIAGEN
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	QIAGEN
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into a global partnership with QIAGEN for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound, dacomitinib in global clinical development for treatment of non-small cell lung cancer. QIAGEN's proposed companion diagnostic will be based on its proprietary KRAS assay technology. QIAGEN and Pfizer will engage in collaborative efforts to develop the KRAS companion diagnostic for use with dacomitinib (PF-00299804). The global partnership covers clinical trials and submissions for a PMA application in the United States and the CE mark in Europe, as well as applicable regulatory approvals in other regions.
Updates/Amendments	

Deal Date	08/03/2011
Deal Type	Partnership
Sub Category	Award or Grant
Deal Headline	NCCN receives USD2 million educational grant from Pfizer to support tailored quality improvement plans at leading cancer centers
Deal Status	Completed
Acquirer/Partner	The National Comprehensive Cancer Network
Source/Target	Pfizer Inc
Deal Value (USD mn)	2
Region/Country	United States
Deal Details	The National Comprehensive Cancer Network (NCCN) has received a USD2 million grant from Pfizer Inc. to help support the first CME program to measure the impact on patient outcomes and clinician performance through data collected in the National Comprehensive Cancer Network Oncology Outcomes Database for Breast Cancer.
Updates/Amendments	

Deal Date	07/01/2011
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	Pfizer files sues against Aurobindo Pharma
Deal Status	Completed
Acquirer/Partner	Aurobindo Pharma Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has filed sued against Aurobindo Pharma Ltd alleging patent infringement pertaining to its cholesterol lowering drug Lipitor.
Updates/Amendments	

Deal Date	06/30/2011
Deal Type	Partnership
Sub Category	Development; License; Screening/Evaluation
Deal Headline	Pfizer enters into translational technology development agreement with BioPontis Alliance
Deal Status	Completed
Acquirer/Partner	BioPontis Alliance LLC
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. and BioPontis Alliance, LLC have entered into a translational technology development agreement which combines translational drug research with BioPontis asset based investment fund.</p> <p>Under the terms, Pfizer will provide guidance on the BioPontis Alliance product portfolio to help ensure that BioPontis Alliance's investment in particular development programs is in alignment with clinical need and market demand. Pfizer will have the opportunity to provide BioPontis Alliance with scientific and medical advice on the design of experiments and the product profile needed for a successful product development strategy. In addition, Pfizer will have an opportunity to evaluate and license early-stage therapeutic opportunities.</p>
Updates/Amendments	

Deal Date	06/28/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer and ChemRar High Tech Center plans to explore innovative medical research and development partnership in Russia
Deal Status	Completed
Acquirer/Partner	ChemRar High Tech Center; SatRx LLC
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into collaboration with ChemRar High Tech Center to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries. The companies will explore opportunities for accelerated development and commercialization of certain innovative compounds from Pfizer's pipeline, through technology transfer and out-licensing deals with venture funding. Through this arrangement, Pfizer and ChemRar plan to develop innovative compounds and vaccines to treat patients with cardiometabolic, infectious and oncology diseases.</p> <p>Under the terms, the two companies can further collaborate with other potential partners, including the Moscow Institute of Physics and Technology, the Skolkovo Foundation and other members of the Russian Biopharmaceutical Cluster Northern, created under the Federal Target Program of the Ministry of Industry and Trade of the Russian Federation. In addition, the companies can establish a shared-risk platform for several Pfizer R&D programs designed to achieve clinical candidates and proof of concept in the clinic.</p>
Updates/Amendments	<p>Deal Updated date : 06/22/2012</p> <p>Pfizer Inc. and ChemRar High Tech Center have entered into an agreement, under which Pfizer grants the ChemRar group company SatRx an exclusive rights to PF-00734200.</p> <p>Under the agreement, Pfizer has granted worldwide exclusive rights except China to SatRx for development, manufacturing, regulatory submission, and commercialization of the DPPIV molecule alone and in combination with certain classes of molecules. If approved and commercialized, Pfizer will</p>

	receive royalties and milestone payments from SatRx.
--	--

Deal Date	06/23/2011
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	BioMarin acquires assets from Pfizer
Deal Status	Completed
Acquirer/Partner	Biomarin Pharmaceutical Inc
Source/Target	
Deal Value (USD mn)	48.5 (Max)
Region/Country	Ireland
Deal Details	BioMarin Pharmaceutical Inc., has acquired a bulk biologics manufacturing plant from Pfizer, is built on ten acres occupying 133,000 square feet of floor space for USD48.5 million, approximately one-fifth of the expected cost to construct and validate a new facility.
Updates/Amendments	

Deal Date	06/08/2011
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into research partnerships
Deal Status	Completed
Acquirer/Partner	Beth Israel Deaconess Medical Center; Boston Childrens Hospital; Boston University School of Medicine; Harvard University; Partners HealthCare; The University of Massachusetts Medical School; Tufts Medical Center; Tufts University
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a research partnerships, called the Centers for Therapeutic Innovation, launched in Boston with Beth Israel Deaconess Medical Center, Boston University School of Medicine, Children's Hospital Boston, Harvard University, Partners HealthCare, Tufts Medical Center, Tufts University, as well as University of Massachusetts Medical School in Worcester. Pfizer anticipates investing approximately USD100 million in the Boston Centers for Therapeutic Innovation over the next five years. This sum is a total of the estimated support for research programs, potential milestone payments to partners for successful projects, and the cost to lease and operate the planned site in the Longwood Medical Area.
Updates/Amendments	

Deal Date	06/03/2011
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	Pfizer files suit against Impax Laboratories relating to generic Detrol
Deal Status	Completed
Acquirer/Partner	Impax laboratories Inc
Source/Target	Pfizer Health AB; Pfizer Inc; Pharmacia and Upjohn Company LLC
Deal Value (USD mn)	
Region/Country	North America; United States
Deal Details	Pfizer Inc., Pharmacia and Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax Laboratories, Inc for Detrol. Detrol is indicated for the treatment of overactive bladder and urinary incontinence.
Updates/Amendments	

Deal Date	06/02/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into worldwide licensing agreement with Clovis Oncology for PF-01367338
Deal Status	Completed
Acquirer/Partner	Clovis Oncology Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	255 (Max)
Region/Country	Worldwide
Deal Details	<p>Clovis Oncology, Inc. and Pfizer Inc. have entered into an agreement for the development and commercialization of PF-01367338. Clovis Oncology will take over responsibility for global product development and commercialization.</p> <p>Under the terms, Pfizer will receive an upfront license fee from Clovis, payable in equity in Clovis Oncology, and will be eligible to receive further payments totalling up to USD255 million upon Clovis Oncology's successful attainment of development, regulatory and sales milestones. Pfizer will also receive royalties on any product sales.</p>
Updates/Amendments	

Deal Date	06/01/2011
Deal Type	Partnership
Sub Category	Joint Venture
Deal Headline	Pfizer and Hisun sign memorandum of understanding to increase access to quality and low-cost medicines for patients in China
Deal Status	Completed
Acquirer/Partner	Pfizer Inc; Zhejiang Hisun Pharmaceutical Co Ltd
Source/Target	Hisun Pfizer Pharmaceuticals Co Ltd
Deal Value (USD mn)	
Region/Country	China
Deal Details	<p>Pfizer Inc. and Zhejiang Hisun Pharmaceuticals Co., Ltd have signed a memorandum of understanding to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena.</p> <p>Under the terms, the two companies will explore a potential business collaboration focused on manufacturing cooperation to deliver high-quality medicines, broader commercialization of medicines through a local and global sales and marketing infrastructure and research and development of off-patent medicines. Both parties could contribute select existing products and other relevant assets and capabilities to provide a solid platform for this potential joint venture.</p>
Updates/Amendments	<p>Deal Updated date : 09/12/2012</p> <p>Pfizer Inc. and Zhejiang Hisun Pharmaceuticals Co., Ltd have launched Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.</p>

Deal Date	05/26/2011
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	InSite Vision files joint patent infringement lawsuit with Merck against Sandoz
Deal Status	Completed
Acquirer/Partner	Insite Vision Inc; Sandoz Inc
Source/Target	Merck and Co Inc; Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	InSite Vision Incorporated will join Merck & Co., Inc. and Pfizer Inc. in filing a patent infringement lawsuit against Sandoz Inc. Merck will take the lead in prosecuting this lawsuit. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role.
Updates/Amendments	

Deal Date	05/25/2011
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into strategic partnerships with ICON and PAREXEL International
Deal Status	Completed
Acquirer/Partner	Icon Plc; Parexel International Corp
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a strategic partnerships with ICON plc and PAREXEL International Corporation, which will serve as strategic providers of clinical trial implementation services over a five-year period. Pfizer will retain scientific ownership of the clinical development process, and maintain strict oversight and quality standards relating to patient safety and regulatory compliance.
Updates/Amendments	

Deal Date	04/20/2011
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and Shanghai Pharmaceutical sign memorandum of understanding for potential strategic partnership
Deal Status	Announced
Acquirer/Partner	Shanghai Pharmaceutical Co Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China
Deal Details	<p>Pfizer Inc. has entered into collaboration with Shanghai Pharmaceutical Co. Ltd. to jointly pursue potential business opportunities in China. The potential partnership is intended to leverage both companies' strengths, matching Pfizer's global capabilities in developing innovative medicines with Shanghai Pharmaceutical's capabilities and reach in the China market. The companies are exploring a potential cooperation for the registration, commercialization and distribution in China of an innovative Pfizer product.</p> <p>In addition, the companies plan to explore future cooperation opportunities, including further distribution and commercialization, research and development activities, manufacturing and equity investment opportunities.</p>
Updates/Amendments	

Deal Date	04/07/2011
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into research and development collaboration with Zacharon to develop drugs for multiple rare disorders
Deal Status	Completed
Acquirer/Partner	Avalon Ventures; Pfizer Inc
Source/Target	Zacharon Pharmaceuticals Inc
Deal Value (USD mn)	210 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into strategic research collaboration with Zacharon Pharmaceuticals, Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.</p> <p>Under the terms, Zacharon's investor Avalon Ventures, will receive up-front payments and research and development funding under the collaboration to develop drugs against targets that impact lysosomal storage diseases. Zacharon is also eligible under the collaboration for payments for meeting development milestones, plus royalties and sales milestones upon commercialization.</p>
Updates/Amendments	

Deal Date	04/06/2011
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Pfizer enters agreement with Nuron Biotech
Deal Status	Completed
Acquirer/Partner	Nuron Biotech Inc
Source/Target	Pfizer Inc; Wyeth LLC
Deal Value (USD mn)	
Region/Country	Japan; South Korea; United States
Deal Details	Pfizer Inc. has entered into an agreement with Nuron Biotech Inc., under which Nuron has acquired assets relating to the vaccine HibTITER from Wyeth LLC, a wholly owned subsidiary of Pfizer for the U.S. and many other markets, including Japan and Korea.
Updates/Amendments	

Deal Date	04/04/2011
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Pfizer enters into co-promotion agreement with Daiichi Sankyo for olmesartan medoxomil
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Daiichi Sankyo China Holdings Co Ltd
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer Inc. has entered into an agreement with Daiichi Sankyo China Holdings Co Ltd to co-promote olmesartan medoxomil, known as Benicar in the United States and Olmetec in the Europe and Canada.
Updates/Amendments	

Deal Date	04/04/2011
Deal Type	Private Equity
Sub Category	100% Acquisition
Deal Headline	Pfizer to sell Capsugel business to Kohlberg Kravis Roberts
Deal Status	Completed
Acquirer/Partner	Kohlberg Kravis Roberts and Co LP
Source/Target	Capsugel
Deal Value (USD mn)	2375
Region/Country	United States
Deal Details	<p>Pfizer and Kohlberg Kravis Roberts and Co LP have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for USD2375 million in cash. Capsugel, is a manufacturer of hard capsules and an innovator in drug-delivery systems.</p> <p>Pfizer's financial advisors for the transaction were Morgan Stanley and Co. Inc and Guggenheim Securities, LLC. Cadwalader, Wickersham and Taft LLP and White and Case LLP acted as legal counsel for Pfizer. Simpson Thacher and Bartlett LLP acted as legal counsel for KKR.</p>
Updates/Amendments	<p>Deal Updated date : 08/01/2011</p> <p>Pfizer Inc. has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts and Co LP. Under the terms of the agreement, KKR acquired the Capsugel business for USD2375 million in cash.</p>

Deal Date	03/03/2011
Deal Type	Partnership
Sub Category	Distribution; Supply
Deal Headline	Charles River enters into supply agreement for Pfizer's genetically modified research models
Deal Status	Completed
Acquirer/Partner	Charles River Laboratories International Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a marketing and distribution agreement with Charles River Laboratories International, Inc. to provide certain Pfizer-developed genetically modified research models to the global biomedical research community. Under the terms, Charles River will supply a number of pre-competitive, transgenic research models developed by Pfizer across a broad range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.
Updates/Amendments	

Deal Date	02/06/2011
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Pfizer acquires consumer healthcare business of Ferrosan Holding
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ferrosan Consumer Health
Deal Value (USD mn)	
Region/Country	Denmark; Nordic; Russia
Deal Details	<p>Pfizer Inc., has acquired consumer healthcare business of Ferrosan Holding A/S, a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe from from Altor 2003 Fund GP Limited.</p> <p>Pfizer's financial advisors were Barclays Capital and Guggenheim Securities, LLC. Skadden, Arps, Slate, Meagher & Flom LLP acted as U.S. counsel for Pfizer with Gorrisen Federspiel advising Pfizer on Danish law</p>
Updates/Amendments	

Deal Date	01/25/2011
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into collaboration with seven universities
Deal Status	Completed
Acquirer/Partner	Albert Einstein College of Medicine of Yeshiva University; Columbia University Medical Center; Memorial Sloan Kettering Cancer Center; NYU Langone Medical Center; The Mount Sinai Medical Center; The Rockefeller University; Weill Cornell Medical College
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement, where major research-based medical centers with Rockefeller University, NYU Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College and have joined Pfizer's Centers for Therapeutic Innovation.
Updates/Amendments	

Deal Date	01/25/2011
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into collaboration with Alexandria Center
Deal Status	Completed
Acquirer/Partner	Alexandria Center for Life Science
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a lease agreement with the Alexandria Center for Life Science providing the Pfizer with research space to facilitate its New York City-based collaborations.
Updates/Amendments	

Deal Date	01/19/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Research and Discovery
Deal Headline	Pfizer and Theraclone Sciences enters into infectious disease and cancer antibody discovery collaboration
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Theraclone Sciences Inc
Deal Value (USD mn)	632 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide multi-year research and development collaboration with Theraclone Sciences, Inc. using Theraclone's I-STAR technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.</p> <p>Under the terms, Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration. Theraclone is eligible to receive undisclosed royalties on sales of any developed products and up to USD632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones. Pfizer will be responsible for preclinical and clinical development of the antibodies.</p>
Updates/Amendments	

Deal Date	01/19/2011
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Theracclone Sciences enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Theracclone Sciences Inc
Deal Value (USD mn)	632 (Max)
Region/Country	United States
Deal Details	Theracclone Sciences, Inc., has entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theracclone's I-STAR technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. Under the terms of the agreement, Theracclone and Pfizer will embark on a discovery program to identify broadly reactive antibodies directed against up to two infectious disease targets and up to two cancer targets. Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration. Theracclone is eligible to receive undisclosed royalties on sales of any developed products and up to USD632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones. Pfizer will be responsible for preclinical and clinical development of the antibodies.
Updates/Amendments	Deal Updated date : 08/29/2012 Theracclone Sciences, Inc., has entered into an agreement with Pfizer and in which Pfizer has selected a third target under its multi-year research and development collaboration with Theracclone. Pfizer receives an exclusive worldwide license to the therapeutic antibodies discovered under the collaboration. Theracclone will receive undisclosed funding as a result of the third target selection. Under the collaboration agreement, Theracclone is eligible to receive undisclosed royalties on sales of any developed products and up to USD632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones.

Deal Date	01/07/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer and Sutro Biopharma enters into agreement with for discovery, development and commercialization of novel peptide based therapeutics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Sutro Biopharma Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into multi-year collaboration with Sutro Biopharma Inc. for the research, development and commercialization of novel peptide-based therapeutics. Under the terms, Sutro Biopharma will receive an upfront payment of an undisclosed amount, and Pfizer will provide Sutro with ongoing research funding. Sutro is eligible to receive development milestone payments and royalties upon commercialization of any products that may result from the collaboration. Additional details of the partnership were not disclosed.
Updates/Amendments	

Deal Date	01/06/2011
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing; Research and Discovery
Deal Headline	Seattle Genetics collaborates with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Seattle Genetics Inc
Deal Value (USD mn)	208
Region/Country	Worldwide
Deal Details	Seattle Genetics, Inc. has entered into a collaboration agreement with Pfizer Inc. Pfizer is responsible for research, product development, manufacturing and commercialization of any ADC products under the collaboration. Under the terms, Pfizer will pay an upfront fee of USD8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target. Seattle Genetics is eligible to receive from Pfizer over USD200 million in progress-dependent milestones as well as royalties on worldwide net sales of any resulting ADC products. Seattle Genetics also will receive material supply and annual maintenance fees as well as research support payments for assistance provided to Pfizer under the collaboration.
Updates/Amendments	

Deal Date	12/29/2010
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Akorn sells Akorn-Strides joint venture product portfolio to Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Akorn Inc; Akorn Strides LLC
Deal Value (USD mn)	35
Region/Country	United States
Deal Details	Akorn-Strides LLC joint venture has entered into a purchase agreement with Pfizer Inc. to sell 16 abbreviated new drug approvals and 6 filed abbreviated new drug approvals. For its portion, Akorn, Inc. will receive USD35 million in cash. Akorn-Strides LLC will continue to manufacture and distribute the approved products until April 30, 2011.
Updates/Amendments	

Deal Date	12/20/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into license agreement with Phylogica
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Phylogica Ltd
Deal Value (USD mn)	134.5 (Max)
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into a collaboration and licensing agreement with Phylogica Ltd to discover novel peptide-based vaccines. Phylogica will employ its proprietary Phylomer drug discovery platform to identify Phylomer peptides suitable for further evaluation. Under the terms, Phylogica grants Pfizer certain rights, including an option to license any resulting Phylomers for further research, development and commercialisation of novel peptide-based vaccines derived from such Phylomers. Phylogica will receive an upfront payment of USD500,000. In addition, Phylogica is eligible to receive a commercial license payment and is also eligible to receive preclinical, clinical and other milestone payments of up to USD134 million, as well as royalties on worldwide sales.
Updates/Amendments	

Deal Date	12/20/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option
Deal Headline	Lpath grants Pfizer exclusive option for worldwide license for iSONEP
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Lpath Inc
Deal Value (USD mn)	511.5 (Max)
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an exclusive agreement with Lpath, Inc. providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEP. Under the terms, Pfizer will provide Lpath with an upfront option payment of USD14 million in addition to sharing the cost of the planned Phase Ib and Phase IIa trials. Following completion of the two studies, Pfizer has the right to exercise its option for worldwide rights to iSONEP for an undisclosed option fee and, if Pfizer exercises its option, Lpath will be eligible to receive development, regulatory and commercial milestone payments that could total up to USD497.5 million; in addition, Lpath will be entitled to receive tiered double-digit royalties based on sales of iSONEP. As part of the agreement, Lpath has granted to Pfizer a time-limited right of first refusal for ASONEP, Lpath's product candidate that is being evaluated for the treatment of cancer.
Updates/Amendments	

Deal Date	12/20/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into collaboration and licensing agreement with Phylogica
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Phylogica Ltd
Deal Value (USD mn)	134.5 (Max)
Region/Country	Worldwide
Deal Details	<p>Phylogica Ltd has entered into a collaboration and licensing agreement with Pfizer Inc. to discover novel peptide-based vaccines. Phylogica will employ its proprietary Phylomer drug discovery platform to identify Phylomer peptides suitable for further evaluation. Phylogica grants Pfizer certain rights, including an option to license any resulting Phylomers for further research, development and commercialisation of novel peptide-based vaccines derived from such Phylomers.</p> <p>Under the terms of the agreement, Phylogica will receive an upfront payment of USD500, 000. In addition, Phylogica is eligible to receive a commercial license payment and is also eligible to receive preclinical, clinical and other milestone payments of up to USD134 million, as well as royalties on worldwide sales.</p>
Updates/Amendments	<p>Deal Updated date : 12/12/2011</p> <p>Phylogica Ltd has successfully completed the first stage of its collaboration with Pfizer Inc. to discover novel peptide-based vaccines. Under the terms of the agreement, Phylogica will receive an undisclosed milestone payment.</p>

Deal Date	12/17/2010
Deal Type	Partnership
Sub Category	Development; License; Research and Discovery
Deal Headline	Pfizer and DiaGenic enters into collaboration on blood based biomarkers for early stages of Alzheimer's disease
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	DiaGenic ASA
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into a worldwide agreement for explorative research and development collaboration with DiaGenic ASA to identify biomarkers in early stages of Alzheimer's disease using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies. Under the terms, DiaGenic grants Pfizer a non-exclusive, world-wide license to use DiaGenic's mild cognitive impairment test and Alzheimer's disease tests in their research and drug development programs.
Updates/Amendments	

Deal Date	12/01/2010
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into collaboration with PeptiDream
Deal Status	Completed
Acquirer/Partner	PeptiDream Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a multi-year multi-target discovery with PeptiDream Inc.
Updates/Amendments	

Deal Date	11/16/2010
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into collaboration with University of California to improve drug discovery and development
Deal Status	Completed
Acquirer/Partner	University of California
Source/Target	Pfizer Inc
Deal Value (USD mn)	85 (Max)
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with University of California, San Francisco to accelerate the translation of biomedical research into effective new medications and therapies for patients. Under the terms, University of California will receive up to USD85 million in research support and milestone payments over the next five years if the partnership leads to the development of significant new therapies for diseases with high unmet medical need.
Updates/Amendments	

Deal Date	11/09/2010
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into drug repositioning collaboration with Biovista
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Biovista Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. and Biovista Inc. have entered into a pilot research collaboration agreement. The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista's Clinical Outcome Search Space technology.</p> <p>Under the terms, Biovista will collaborate with Pfizer's Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates. The terms of the agreement include an upfront payment and success-based milestones.</p>
Updates/Amendments	

Deal Date	10/31/2010
Deal Type	Partnership
Sub Category	Infringement; Settlement
Deal Headline	Mylan files patent infringement with Pfizer
Deal Status	Completed
Acquirer/Partner	Mylan Inc; Mylan Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc has filed a patent infringement suit against Mylan Pharmaceuticals Inc and Mylan Inc. regarding abbreviated new drug application with the FDA seeking approval to market sildenafil, generic versions of Viagra.
Updates/Amendments	<p>Deal Updated date : 04/30/2015</p> <p>Mylan Pharmaceuticals Inc. and Mylan Inc. have entered into a settlement agreement with Pfizer Inc. regarding sildenafil generic versions of Viagra.</p>

Deal Date	10/26/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Research and Discovery
Deal Headline	Pfizer enters global research collaboration and license agreement with MacroGenics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	MacroGenics Inc
Deal Value (USD mn)	
Region/Country	United States; Worldwide
Deal Details	Pfizer Inc. has entered into a global research collaboration and licensing agreement with MacroGenics, Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting products directed at two undisclosed cancer targets. Under the terms, MacroGenics will receive an upfront cash payment and research funding. In addition, MacroGenics will be eligible to receive escalating preclinical, clinical, regulatory and commercial milestone payments as well as tiered royalties on sales of products resulting from the collaboration.
Updates/Amendments	

Deal Date	10/26/2010
Deal Type	Partnership
Sub Category	License
Deal Headline	Ablexis enters into agreement with Pfizer and other pharma companies
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ablexis LLC
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Ablexis LLC has granted to its AlivaMab Mouse technology to a consortium of pharmaceutical companies on non-exclusive basis to each member. AlivaMab Mouse technology, an innovative next-generation platform for antibody drug discovery.</p> <p>Five of the top 15 global pharmaceutical companies, including Pfizer Inc., make up the membership of the Ablexis-Pharma consortium. Entry into the consortium required a non-refundable seven-figure payment by each consortium member. Upon delivery of the AlivaMab Mouse strains, Ablexis is entitled to receive an eight-figure payment from each consortium member in return for granting specified non-exclusive rights to utilize the technology in antibody discovery programs.</p>
Updates/Amendments	

Deal Date	10/20/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; Distribution
Deal Headline	Pfizer enters into collaboration with Laboratorio Teuto Brasileiro
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Laboratorio Teuto Brasileiro SA
Deal Value (USD mn)	
Region/Country	Brazil
Deal Details	Pfizer Inc. has entered into a partnership with Laboratorio Teuto Brasileiro S.A. to develop and commercialize generic medicines. Under the terms, Pfizer will make an upfront payment of BRL400 million and Teuto will be eligible to receive a performance-based milestone payment. Pfizer will have the opportunity to register and commercialize Teuto products in Brazil and various markets outside of the country under its own brands, including branded and unbranded generic medicines, covering a broad range of therapeutic areas, such as pain and inflammation, cardiovascular, anti-infectives, central nervous system and respiratory, among others. Teuto will gain access to select Pfizer products for distribution across its extensive distribution network and have the right to commercialize them under Teuto's own brand in Brazil.
Updates/Amendments	

Deal Date	10/20/2010
Deal Type	Mergers & Acquisitions
Sub Category	Minority Acquisition
Deal Headline	Pfizer acquires minority investment in Laboratorio Teuto Brasileiro
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Laboratorio Teuto Brasileiro SA
Deal Value (USD mn)	237 (Max)
Region/Country	Brazil
Deal Details	<p>Pfizer Inc. and Laboratorio Teuto Brasileiro S.A., a company in the Brazilian generics industry, to develop and commercialize generic medicines has entered into a definitive agreement in which Pfizer has acquired a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements. The partnership will enhance Pfizer's position in Brazil, a key emerging market, by providing access to Teuto's broad portfolio of approximately 250 products in more than 400 presentations.</p> <p>Under the terms of the agreement, Pfizer made an upfront payment of BRL400 million and Teuto will be eligible to receive a performance-based milestone payment. Pfizer has an option to acquire the remaining 60 percent of Teuto's shares beginning in 2014. Teuto's shareholders have an option to sell their 60 percent stake to Pfizer beginning in 2015.</p>
Updates/Amendments	

Deal Date	10/18/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing; Supply
Deal Headline	Pfizer enters into global commercialization agreement with Biocon
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Biocon Ltd
Deal Value (USD mn)	350 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive strategic global agreement with Biocon Limited for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargin, Aspart and Lispro. Pfizer will have exclusive rights to commercialize these products globally, with certain exceptions, including co-exclusive rights for all of the products with Biocon in Germany, India and Malaysia. Pfizer will also have co-exclusive rights with existing Biocon licensees with respect to some of the products, primarily in a number of developing markets. Biocon will be responsible for the clinical development, manufacture and supply of these biosimilar Insulin products, as well as for regulatory activities to secure approval for these products in various geographies.</p> <p>Under the terms, Pfizer will make upfront payments totalling USD200 million. Biocon is also eligible to receive additional development and regulatory milestone payments of up to USD150 million and will receive additional payments linked to Pfizer's sales of its four Insulin biosimilar products across global markets.</p>
Updates/Amendments	<p>Deal Updated date : 05/12/2012</p> <p>Pfizer Inc. and Biocon Limited have concluded their alliance to commercialize Biocon's biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses.</p>

	<p>Pfizer Inc. has entered into an exclusive strategic global agreement with Biocon Limited for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Pfizer will have exclusive rights to commercialize these products globally, with certain exceptions, including co-exclusive rights for all of the products with Biocon in Germany, India and Malaysia. Pfizer will also have co-exclusive rights with existing Biocon licensees with respect to some of the products, primarily in a number of developing markets. Biocon will be responsible for the clinical development, manufacture and supply of these biosimilar Insulin products, as well as for regulatory activities to secure approval for these products in various geographies.</p> <p>Under the terms, Pfizer will make upfront payments totalling USD200 million. Biocon is also eligible to receive additional development and regulatory milestone payments of up to USD150 million and will receive additional payments linked to Pfizer's sales of its four Insulin biosimilar products across global markets.</p>
--	--

Deal Date	10/12/2010
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires King Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	King Pharmaceuticals LLC
Deal Value (USD mn)	3600
Region/Country	United States
Deal Details	Pfizer Inc. has acquired King Pharmaceuticals, Inc. through the cash tender offer for the outstanding shares of common stock of King at a purchase price of USD14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, Pfizer acquired all of the remaining shares of King for USD14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately USD3600 million in cash.
Updates/Amendments	

Deal Date	10/11/2010
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; Development; Manufacturing
Deal Headline	Pfizer enters into agreement with MingSight Pharma
Deal Status	Completed
Acquirer/Partner	Mingsight Pharmaceuticals
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide agreement with MingSight Pharmaceuticals, where MingSight has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases. The lead compound licensed under the agreement has demonstrated efficacy in preclinical models of diabetic retinopathy.</p> <p>Under the terms, MingSight will pay Pfizer an upfront fee, paid in the form of cash and a convertible note, as well as development and sales related milestone payments, and royalties on future sales.</p>
Updates/Amendments	

Deal Date	10/06/2010
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires FoldRx Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	FoldRx Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc., has completed the acquisition of FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, The financial terms of the deal were not disclosed.</p> <p>Pfizer's financial advisor for the transaction was Jefferies & Company, Inc., while Ropes & Gray LLP was its legal advisor. Goldman Sachs & Co. served as FoldRx's financial advisor, while Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., served as its legal advisor.</p>
Updates/Amendments	

Deal Date	09/13/2010
Deal Type	Partnership
Sub Category	License; Patent-Non-exclusive
Deal Headline	Pfizer enters into patent licensing agreement with Asklepios
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Asklepios BioPharmaceutical Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into a patent licensing agreement with Asklepios BioPharmaceutical, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio.
Updates/Amendments	

Deal Date	08/03/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing; Research and Discovery
Deal Headline	Five Prime Therapeutics enters strategic alliance with GlaxoSmithKline to discover biologics for skeletal muscle disorders
Deal Status	Completed
Acquirer/Partner	GlaxoSmithKline Pharmaceuticals Ltd
Source/Target	Five Prime Therapeutics Inc
Deal Value (USD mn)	124 (Max)
Region/Country	Worldwide
Deal Details	<p>Five Prime Therapeutics, Inc. has entered into a strategic drug discovery alliance with GlaxoSmithKline Plc (GSK). The collaboration give GSK an exclusive access to FivePrime's drug discovery platforms and comprehensive proprietary collection of secreted proteins and transmembrane receptor proteins. FivePrime will conduct high-throughput in vitro and in vivo assays customized to identify potential drug targets and drug candidates for treating skeletal muscle diseases. GSK will have an option to exclusively license each drug target or drug candidate discovered by FivePrime from the collaboration and take on sole responsibility for additional preclinical studies, clinical development, manufacturing and worldwide commercialization.</p> <p>Under the terms, FivePrime will receive approximately USD15 million as an upfront fee, the purchase of FivePrime equity by GSK, and payments related to the research program. In addition, FivePrime is eligible for additional research program payments up to USD124 million in potential option exercise fees and milestone payments, as well as tiered royalties on global net sales for each product resulting from a selected drug target or drug candidate.</p>
Updates/Amendments	<p>Deal Updated date : 09/15/2014</p> <p>GlaxoSmithKline Plc has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities.</p> <p>Under the terms, GSK will receive exclusive rights to develop and commercialize products globally which are directed to the selected target.</p>

	<p>Five Prime will receive a payment of USD1.5 million in connection with the option exercise and is entitled to receive up to USD122.5 million in preclinical, development and commercial-related milestone payments and royalties in the low- to mid-single-digit range on net sales of products related to the target.</p> <p>Deal Updated date : 06/16/2011</p> <p>GlaxoSmithKline Plc and Five Prime Therapeutics, Inc. have expanded the scope of their discovery collaboration to include FivePrime's Rapid In vivo Protein Production System (RIPPPSM) technology for a large-scale in vivo screen for potential drug targets or drug candidates that modulate muscle wasting. As part of the expansion of the collaboration, FivePrime is eligible to receive from GSK additional research payments, milestone payments and potential option exercise fees, as well as royalties on global net sales for each product resulting from a selected drug target or drug candidate that results from the research program.</p>
--	--

Deal Date	07/30/2010
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Conatus acquires Idun Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Conatus Pharmaceuticals Inc
Source/Target	Idun Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Conatus Pharmaceuticals Inc., a privately-held drug development company focused on liver disease and oncology has completed the acquisition of Idun Pharmaceuticals, a subsidiary of Pfizer Inc. Financial terms were not disclosed.
Updates/Amendments	

Deal Date	07/29/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into licensing agreement with Katholieke Universiteit Leuven
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Katholieke Universiteit Leuven
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide licensing agreement with Katholieke Universiteit Leuven. The license agreement grants Pfizer exclusive and sub-licensable worldwide rights to further develop and commercialise Katholieke Universiteit Leuven's compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS. Under the terms, Katholieke Universiteit Leuven will provide Pfizer with exclusive access to the compounds developed in its LEDGF-integrase directed drug discovery programme and all related know-how. Pfizer seeks to advance several compound classes with this new mechanism of action.</p> <p>Under the terms, Pfizer will make an upfront and milestone payments to Katholieke Universiteit Leuven based upon the achievement of development, regulatory and sales goals. Katholieke Universiteit Leuven is also eligible to receive royalty payments on net sales of future products discovered or developed under the agreement.</p>
Updates/Amendments	

Deal Date	07/27/2010
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Pfizer enters into co-promotion agreement with Almirall for Conbriza in Spain
Deal Status	Completed
Acquirer/Partner	Almirall
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Spain
Deal Details	Pfizer Inc. has entered into a co-promotion agreement with Almirall S A to commercialize Pfizer's Conbriza in Spain.
Updates/Amendments	

Deal Date	07/13/2010
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into collaboration with Samsung Medical Center on liver cancer
Deal Status	Completed
Acquirer/Partner	Samsung Medical Center
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	South Korea
Deal Details	Pfizer Inc. has entered into a research partnership with Samsung Medical Center to identify genomic mechanisms responsible for clinical outcomes in Hepatocellular Carcinoma and jointly analyze tumors from Korean patients to generate gene expression profiles and that may direct therapies and enhance clinical outcomes in the patients with liver cancer.
Updates/Amendments	

Deal Date	06/30/2010
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	Pfizer files patent infringement against Mylan
Deal Status	Completed
Acquirer/Partner	Mylan Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc has filed a patent infringement suit against Mylan Pharmaceuticals Inc. after Mylan filed an abbreviated new drug application with the FDA seeking approval to market Sunitinib malate, a generic version of Sutent.
Updates/Amendments	

Deal Date	06/28/2010
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	McKesson Corporation enters into collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	McKesson Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	McKesson Patient Relationship Solutions and Pfizer Inc. have entered into an innovative program, the McKesson Pharmacy Intervention Program, which expands patient access to one-on-one behavioral coaching about the importance of taking medicines from retail pharmacists in the McKesson network.
Updates/Amendments	

Deal Date	06/20/2010
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Pfizer enters into agreement with Ergonex Pharma to acquire investigational treatment for pulmonary arterial hypertension
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ergonex Pharma GmbH
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with Ergonex Pharma GmbH, under which Pfizer will acquire terguride. Under the terms, Pfizer will support the completion of the ongoing Phase II trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize terguride for the treatment of PAH. Ergonex will be eligible to receive milestone payments and royalties on the sales of terguride for PAH.
Updates/Amendments	

Deal Date	05/17/2010
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into collaboration with Washington University
Deal Status	Completed
Acquirer/Partner	Washington University School of Medicine
Source/Target	Pfizer Inc
Deal Value (USD mn)	22.5
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into five-year collaboration agreement with Washington University School of Medicine. Pfizer will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.</p> <p>Under the terms, Pfizer will provide USD22.5 million to Washington University and give its scientists access to research data on a large array of Pfizer pharmaceutical candidates that are in clinical testing.</p>
Updates/Amendments	

Deal Date	05/07/2010
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Pfizer sells animal vaccine business in China to Harbin Pharmaceutical
Deal Status	Completed
Acquirer/Partner	Harbin BioVaccine
Source/Target	
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer Inc., a global pharmaceutical company, has sold its swine vaccine business in China to an animal health subsidiary of Harbin Pharmaceutical Group, Harbin Bio-Vaccine for an undisclosed amount. The assets sold comprised all those required to continue the manufacture and sale of Pfizer's RespiSure and RespiSure-One swine mycoplasma hyopneumoniae (MH) vaccines in China. The transaction financials are not disclosed.
Updates/Amendments	

Deal Date	04/15/2010
Deal Type	Partnership
Sub Category	License; Research and Discovery
Deal Headline	Pfizer enters into research agreement with Stemgent
Deal Status	Completed
Acquirer/Partner	Stemgent Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a collaboration and research licensing agreement with Stemgent, Inc. that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.</p> <p>Under the terms, Pfizer and Stemgent will form a joint research committee to review and evaluate the collaboration's progress, coordinate results publication, monitor information and materials exchange between the two parties, nominate compounds and provide guidance relating to research tools for use in stem cell research.</p>
Updates/Amendments	

Deal Date	04/06/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	MicuRx and Cumencor enters into discovery and development agreement with Pfizer for drug resistant tuberculosis in China
Deal Status	Completed
Acquirer/Partner	Cumencor Pharmaceuticals Inc; MicuRx Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China
Deal Details	<p>Pfizer Inc. has entered into a collaboration with MicuRx Pharmaceuticals, Inc. and Cumencor Pharmaceuticals, Inc. to discover therapeutic agents to treat multi-drug resistant tuberculosis.</p> <p>Under the terms, Pfizer will provide an upfront payment, funding for the discovery and preclinical development of antibiotics to treat multi-drug resistant tuberculosis, and payments linked to the development and commercialization including royalty payments on sales of any antibiotics developed through the collaboration. All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.</p>
Updates/Amendments	

Deal Date	04/01/2010
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into strategic alliance with Acacia to develop an innovative holistic technology solution
Deal Status	Completed
Acquirer/Partner	Acacia Living Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a strategic alliance with Acacia Living, Inc. to develop a technology solution to helping seniors age positively and independently.
Updates/Amendments	

Deal Date	03/23/2010
Deal Type	Partnership
Sub Category	Contract; Supply
Deal Headline	Pfizer and UNICEF enters into long-term agreement to supply Prevenar 13 to world's poorest countries
Deal Status	Completed
Acquirer/Partner	United Nations Childrens Fund
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an agreement with United Nations Children's Fund for the supply of Prevenar 13 in the world's poorest countries under the terms of the Advance Market Commitment pilot project against pneumococcal disease funded by GAVI.
Updates/Amendments	

Deal Date	03/22/2010
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into agreement with Hadassah Medical, Juvenile Diabetes Research Foundation and Hebrew University of Jerusalem
Deal Status	Completed
Acquirer/Partner	Hadassah Medical Center; Hebrew University of Jerusalem
Source/Target	Pfizer Inc; The Juvenile Diabetes Research Foundation
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into diabetes research collaboration with The Juvenile Diabetes Research Foundation, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.</p> <p>Under the terms, the program is jointly funded by Juvenile Diabetes Research Foundation and Pfizer. The research will focus on the preclinical evaluation of certain proprietary Pfizer compounds as candidates to promote beta cell replication and regeneration.</p>
Updates/Amendments	

Deal Date	03/16/2010
Deal Type	Partnership
Sub Category	Screening/Evaluation
Deal Headline	Pfizer collaborates with Tekmira to evaluate nucleic acid-lipid particle technology
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Arbutus Biopharma Corp
Deal Value (USD mn)	
Region/Country	Canada
Deal Details	Pfizer Inc. has entered into a research collaboration with Tekmira Pharmaceuticals Corporation. Tekmira and Pfizer will collaborate on evaluating Tekmira's stable nucleic acid-lipid particle technology to deliver small interfering RNA molecules provided by Pfizer. Tekmira will be responsible for preparing the stable nucleic acid-lipid particle formulations and Pfizer will evaluate the formulations in preclinical models. Financial terms of the collaboration were not disclosed.
Updates/Amendments	

Deal Date	03/15/2010
Deal Type	Partnership
Sub Category	Sales
Deal Headline	Sigma-Aldrich enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Sigma Aldrich Corp
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Sigma-Aldrich has entered into an agreement with Pfizer. Under the terms of the agreement, Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications.</p> <p>Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time.</p>
Updates/Amendments	

Deal Date	02/23/2010
Deal Type	Partnership
Sub Category	Joint Venture
Deal Headline	Pfizer, Lilly and Merck enters into collaboration to accelerate research and improve treatment of lung and gastric cancers in Asia
Deal Status	Completed
Acquirer/Partner	Eli Lilly and Company Ltd; Merck and Co Inc; Pfizer Inc
Source/Target	
Deal Value (USD mn)	
Region/Country	Asia-Pacific
Deal Details	<p>Pfizer Inc., Eli Lilly and Company and Merck and Co., Inc. have formed the Asian Cancer Research Group, Inc., an independent, not-for-profit company established to accelerate research and improve treatment for patients affected with the most commonly-diagnosed cancers in Asia. Initially, the Asian Cancer Research Group will focus on lung and gastric cancers, two of the most common forms of cancer in Asia.</p> <p>Lilly will be responsible for ultimately providing the data to the research public through an open-source concept managed by Lilly's Singapore research site. Lilly, Merck and Pfizer will each provide technical and intellectual expertise.</p>
Updates/Amendments	

Deal Date	02/07/2010
Deal Type	Partnership
Sub Category	Development; Distribution; Sales
Deal Headline	Pfizer and Keas enters into collaboration to help consumers take a more active role in health and wellness
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Keas
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an alliance to collaborate with Keas on the Keas' platform to enable health and wellness experts to author, sell and distribute personalized online care plans directly to patients. Under the terms, Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and care delivery.
Updates/Amendments	

Deal Date	02/04/2010
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer and DxS enters into agreement to develop a companion diagnostic for brain tumor patients
Deal Status	Completed
Acquirer/Partner	DxS Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and DxS Limited have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110) for the treatment of glioblastoma multiforme. Financial terms of the diagnostic agreement have not been disclosed.
Updates/Amendments	

Deal Date	01/31/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer enters into agreement with MDxHealth, Newcastle University and Cancer Research Technology Limited
Deal Status	Completed
Acquirer/Partner	Cancer Research Technology; MDxHealth SA; Newcastle University
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into an agreement with Newcastle University, Cancer Research Technology Limited and MDxHealth SA to collaborate on the identification and development of a biomarker predicting response to Pfizer, Cancer Research Technology and Newcastle University's drug candidate for PARP inhibition, PF-01367338.</p> <p>Under the terms, MDxHealth will provide biomarker discovery services, assay development services, clinical trial testing, and will retain rights to any methylation-based commercial companion diagnostic test that may result from this collaboration. Newcastle University will participate in biomarker discovery and validation activities. Cancer Research Technology will have rights to develop and commercialize new biomarkers in other fields. Pfizer will contribute experimental and intellectual input.</p>
Updates/Amendments	

Deal Date	01/29/2010
Deal Type	Venture Financing
Sub Category	Growth Capital/Expansion
Deal Headline	Merus completes EUR21.7 million Series B financing
Deal Status	Completed
Acquirer/Partner	Aglaia Oncology Fund; Bay City Capital LLC; Life Sciences Partners; Novartis Option Fund; Pfizer Inc
Source/Target	Merus Labs International Inc
Deal Value (USD mn)	30
Region/Country	Netherlands
Deal Details	Merus Labs International Inc. has completed EUR21.7 million (USD30.7 million) Series B financing led by Novartis Option Fund, Pfizer Inc., Bay City Capital, LSP (Life Sciences Partners) joined by existing investor Aglaia Oncology Fund. The Company plans to use the proceeds to further advance its product pipeline in oncology, inflammation and infectious disease.
Updates/Amendments	

Deal Date	01/26/2010
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into agreement with Tripos for benchware discovery 360
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Tripos International
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into a licensing agreement with Tripos International that allows Pfizer to deploy the capabilities of D360 to all scientists within its worldwide research sites. Under the terms, Pfizer will license to Tripos certain rights to its internally-developed discovery informatics system, RGate, and Tripos will extend capabilities within D360 to accommodate Pfizer's unique requirements. D360 will provide a leading technology to Pfizer scientists, while leveraging investment in their legacy system to reduce cost and create a modern, best-of-breed platform for drug discovery and development.
Updates/Amendments	

Deal Date	01/06/2010
Deal Type	Partnership
Sub Category	Clinical Trial Collaboration
Deal Headline	Pfizer and Debiopharm enters into collaboration to co-develop tremelimumab in advanced melanoma
Deal Status	Completed
Acquirer/Partner	Debiopharm
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a co-development agreement with Debiopharm Group to conduct a Phase III trial of tremelimumab. Under the terms, Debiopharm will be responsible for conducting the phase III trial of tremelimumab and Pfizer will retain responsibility for worldwide commercialization of the compound. Financial terms of the co-development agreement between Debiopharm and Pfizer have not been disclosed.
Updates/Amendments	

Deal Date	01/06/2010
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer enters into collaboration with Ensemble Discovery to develop novel drugs against protein-protein interaction targets
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ensemble Therapeutics Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a strategic alliance with Ensemble Discovery to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.</p> <p>Under the terms, the collaboration will deploy Ensemble's proprietary drug discovery platforms and Ensemblin compound libraries to discover and advance drug candidates. Pfizer will provide upfront and research payments to Ensemble and will have the right to develop and commercialize any products arising from the collaboration. In addition, Ensemble will receive development milestones plus royalties based on worldwide sales of any drugs emerging from the alliance and commercialized by Pfizer.</p>
Updates/Amendments	

Deal Date	01/05/2010
Deal Type	Partnership
Sub Category	Commercialization
Deal Headline	Pfizer and Strides Arcolab enters into collaboration on generic products
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Strides Shasun Ltd
Deal Value (USD mn)	
Region/Country	India
Deal Details	Pfizer Inc. and Strides Arcolab Limited have entered into collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its established products business unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest. The financial terms of the supply agreement were not disclosed.
Updates/Amendments	

Deal Date	01/05/2010
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer and TCG Lifesciences enters into collaboration to develop portfolio of preclinical candidate molecules
Deal Status	Completed
Acquirer/Partner	TCG Lifesciences Pvt Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a collaboration with TCG Lifesciences Limited to develop a portfolio of preclinical candidate molecules in a series of discovery target programs. Under the terms, TCG Lifesciences will develop the compounds up to the nomination of preclinical candidates. Pfizer will own the compounds, and TCG Lifesciences will receive research funding and will be eligible to receive research milestone payments as part of the partnership arrangement.
Updates/Amendments	

Deal Date	12/23/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into agreement with Compugen
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Compugen Ltd
Deal Value (USD mn)	
Region/Country	Israel
Deal Details	Pfizer Inc. has entered into collaboration agreement with Compugen Ltd. for the predictive discovery by Compugen of therapeutic peptide product candidates for three drug targets of interest to Pfizer. Under the terms, the discovery process will be based on various Compugen discovery platforms and funded by Pfizer following synthesis and delivered to Pfizer. Following an evaluation period, Pfizer will have the right to exercise options for worldwide exclusive milestone and royalty bearing licenses to develop and commercialize the selected product candidates or further optimize them to obtain final potent, selective product candidates with favorable pharmacokinetic properties.
Updates/Amendments	

Deal Date	12/22/2009
Deal Type	Partnership
Sub Category	License
Deal Headline	The Medicines Company enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	The Medicines Company
Source/Target	Pfizer Inc
Deal Value (USD mn)	420 (Max)
Region/Country	United States; Worldwide
Deal Details	The Medicines Company has entered into an exclusive worldwide licensing agreement with Pfizer for ApoA-I Milano. Under the terms of the agreement, Pfizer will receive an up-front payment of USD10 million for ApoA-I Milano and will receive additional payments upon the achievement of certain clinical, regulatory and sales milestones up to a total of USD410 million. Pfizer will also be eligible to receive single-digit royalty payments on worldwide net sales of ApoA-I Milano. The Medicines Company will also pay USD7.5 million to third parties.
Updates/Amendments	

Deal Date	12/20/2009
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into collaboration with Peking University for drug discovery
Deal Status	Completed
Acquirer/Partner	Peking University
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaboration with Peking University, Shenzhen Graduate School to develop novel technologies for drug discovery. Under the terms, Pfizer will provide funds to support projects and it will support a translational research and drug discovery center that Peking University intends to build.
Updates/Amendments	

Deal Date	12/18/2009
Deal Type	Partnership
Sub Category	Co-Development; Commercialization; Development; Manufacturing; Option
Deal Headline	Pfizer enters into agreement with Athersys for MultiStem
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Appian Labs LLC; Athersys Inc
Deal Value (USD mn)	111 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a worldwide collaboration agreement with Athersys, Inc. to develop and commercialize MultiStem for the treatment of inflammatory bowel disease for the worldwide market.</p> <p>Under the terms, Athersys received an up-front cash payment of USD6 million from Pfizer and will receive research funding and support during the initial phase of the collaboration. In addition, Athersys is also eligible to receive milestone payments of up to USD105 million upon the successful achievement of certain development, regulatory and commercial milestones. Athersys will be responsible for manufacturing and Pfizer will pay for manufacturing product for clinical development and commercialization purposes. Pfizer will have responsibility for development, regulatory and commercialization and will pay Athersys tiered royalties on worldwide commercial sales of MultiStem IBD products. Alternatively, in lieu of royalties and certain commercialization milestones, Athersys may elect to co-develop with Pfizer and the parties will share development and commercialization expenses and profits/losses on an agreed basis beginning at phase III clinical development.</p>
Updates/Amendments	

Deal Date	12/17/2009
Deal Type	Partnership
Sub Category	Commercialization; Research and Discovery
Deal Headline	Pfizer enters into antibody discovery collaboration with Adimab
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Adimab Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer, Inc. has entered into research collaboration with Adimab, Inc. where, Adimab will use its proprietary discovery platform to identify fully human antibodies against one central nervous system/pain target selected by Pfizer. The agreement gives Pfizer rights to commercialize antibodies generated from the collaboration.</p> <p>Under the terms, Adimab will receive upfront payments. In addition, Adimab is eligible to receive preclinical milestones, clinical development milestones, commercial milestones, licensing fees and royalties on therapeutic and diagnostic product sales.</p>
Updates/Amendments	

Deal Date	12/14/2009
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Pfizer and Takeda enters into agreement to co-promote Actos in China
Deal Status	Completed
Acquirer/Partner	Pfizer China Research and Development Co Ltd; Pfizer Inc; Tianjin Takeda Pharmaceuticals Co Ltd
Source/Target	Takeda Pharmaceutical Company Ltd
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer Inc. and Takeda Pharmaceutical Company Limited have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos with Tianjin Takeda Pharmaceuticals Co Ltd in China. Pfizer's Chinese affiliate will receive a fixed ratio of Actos net sales.
Updates/Amendments	

Deal Date	12/13/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Hospira and ChemGenex enters into agreement for Leukemia drug in Europe
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Chemgenex Pharmaceuticals Ltd
Deal Value (USD mn)	124.48 (Max)
Region/Country	Albania; Algeria; Andorra; Angola; Austria; Bahrain; Belgium; Benin; Bosnia and Herzegovina; Botswana; Bulgaria; Burkina Faso; Burundi; Cameroon; Cape Verde; Chad; Channel Islands; Comoros; Cote d'Ivoire (Ivory Coast); Croatia; Cyprus; Czech Republic; Democratic Republic of the Congo; Denmark; Djibouti; Egypt; Equatorial Guinea; Eritrea; Estonia; Ethiopia; Faroe Islands; Finland; France; Gabon; Gaza Strip; Germany; Ghana; Gibraltar; Greece; Guernsey; Guinea; Guinea-Bissau; Hungary; Iceland; Iraq; Ireland; Isle of Man; Israel; Italy; Jersey; Jordan; Kenya; Kuwait; Latvia; Lebanon; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; Luxembourg; Macedonia; Madagascar; Malawi; Mali; Malta; Mauritania; Mauritius; Mayotte; Moldova; Monaco; Morocco; Mozambique; Namibia; Netherlands; Niger; Nigeria; Norway; Oman; Poland; Portugal; Qatar; Reunion; Romania; Rwanda; Saint Helena; San Marino; Sao Tome and Principe; Saudi Arabia; Scotland; Seborga; Senegal; Serbia; Seychelles; Sierra Leone; Slovakia; Slovenia; Somalia; South Africa; Spain; Sudan; Swaziland; Sweden; Switzerland; Syria; Tanzania; The Central African Republic; The Gambia; The Republic of the Congo; Togo; Tunisia; Turkey; Uganda; United Arab Emirates; United Kingdom; West Bank; Western Sahara; Yemen; Zambia; Zimbabwe
Deal Details	<p>Hospira, Inc., a subsidiary of Pfizer Inc. has entered into an exclusive agreement with ChemGenex Pharmaceuticals Limited to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate in Europe, the Middle East and parts of Africa.</p> <p>Under the terms, Hospira will make an initial payment of EUR11.1 million, with the potential for up to an additional EUR74.1 million, in performance milestone payments based on the successful development and commercialization of omacetaxine. In addition, following successful commercialization, Hospira will pay ChemGenex a royalty on product sales in the Territory.</p>
Updates/Amendments	

Deal Date	12/08/2009
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into agreement with Crown Bioscience to research and develop new treatments for Asian Cancers
Deal Status	Completed
Acquirer/Partner	Crown Bioscience Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer Inc. has entered into a collaboration with Crown Bioscience, Inc. to research and develop therapeutics for Asian cancers. Under the terms, Crown will receive an upfront payment and research funding, as well as milestone payments based on the achievement of preclinical and clinical goals. The companies will work together to discover and advance multiple candidates for clinical development. The work will take place at Crown's research facility located in Taicang, China.
Updates/Amendments	

Deal Date	12/03/2009
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre
Deal Status	Completed
Acquirer/Partner	BC Cancer Agency; Vancouver Prostate Centre
Source/Target	Pfizer Inc
Deal Value (USD mn)	9
Region/Country	United States
Deal Details	<p>Pfizer, Inc. has entered into a USD9 million, three-year research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia and Vancouver General Hospital Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer.</p> <p>The research collaboration project focuses on identifying new biomarkers and treatment targets for breast and ovarian cancer, and will help Pfizer to more efficiently test new agents to delay the progression and improve survival in prostate cancer patients. The collaboration aims to identify new therapeutic targets and new biomarkers of disease and treatment. In addition, as part of the breast cancer research program, ovarian cancer will also be decoded to identify new and much needed biomarkers and therapeutic targets for more personalized approaches in ovarian cancer treatment.</p>
Updates/Amendments	

Deal Date	11/30/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer and Protalix enter into agreement to develop and commercialize Gaucher's Disease treatment
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Protalix BioTherapeutics Inc
Deal Value (USD mn)	115 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide agreement with Protalix BioTcs to develop and commercialize taliglucerase alfa. Under the terms, Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercialization rights in Israel.</p> <p>Under the terms, Pfizer will make an upfront payment of USD60 million to Protalix. In addition, Protalix is eligible to receive additional regulatory milestone payments of up to USD55 million. Pfizer and Protalix will share future revenues and expenses for the development and commercialization of taliglucerase alfa on a 60 percent/40 percent basis respectively.</p>
Updates/Amendments	

Deal Date	11/19/2009
Deal Type	Partnership
Sub Category	License; Marketing
Deal Headline	Pfizer enters into licensing agreement with FAES Farma to market Bilastina in Mexico
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Faes Farma SA
Deal Value (USD mn)	
Region/Country	Chile; Colombia; Costa Rica; Mexico; Venezuela
Deal Details	Pfizer, Inc. has entered into a licensing agreement with Faes Farma SA. Under the terms, Pfizer obtains the rights to market Bilastina in Mexico, while Faes Farma retains the right to commercialise the product directly in Mexico, on co-marketing conditions.
Updates/Amendments	Deal Updated date : 11/19/2009 Pfizer, Inc. has extended its licensing agreement with Faes Farma SA. Under the terms, Pfizer and Faes Farma extend the territory of collaboration with bilastine to 21 additional countries: Venezuela, Colombia, Chile, Costa Rica and another 17 Central American and Caribbean countries.

Deal Date	11/17/2009
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into collaboration with Drugs for Neglected Diseases initiative for neglected tropical diseases
Deal Status	Completed
Acquirer/Partner	Drugs for Neglected Diseases initiative
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. and Drugs for Neglected Diseases initiative (DNDI) have entered an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis, visceral leishmaniasis and Chagas disease. DNDI will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.</p> <p>Under the terms, scientists in institutes affiliated with DNDI will test at least 150,000 compounds in the Pfizer library against <i>Trypanosoma brucei</i>, <i>Leishmania donovani</i> and <i>Trypanosoma cruzi</i>, the parasites that cause human African trypanosomiasis, visceral leishmaniasis and Chagas Disease, respectively.</p>
Updates/Amendments	

Deal Date	11/10/2009
Deal Type	Partnership
Sub Category	Commercialization; Distribution; Supply
Deal Headline	Pfizer enters into collaboration with BMP Sunstone on Women's Healthcare Product
Deal Status	Completed
Acquirer/Partner	BMP Sunstone Corp
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer China Inc. and BMP Sunstone Corp have entered into an exclusive agreement to exclusively import, distribute and promote Depo-Provera in China.
Updates/Amendments	

Deal Date	10/28/2009
Deal Type	Partnership
Sub Category	Commercialization; Distribution; Sales
Deal Headline	Pfizer enters into promotion agreement with Genepharm
Deal Status	Completed
Acquirer/Partner	Genepharm Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Australia
Deal Details	Pfizer Australia's Established Products Business Unit has entered into a distribution and services agreement with Genepharm Limited to promote and sell Pfizer's established off-patent medicines to Australian pharmacies. Under the terms, Genepharm will promote and distribute Pfizer's off-patent branded medicines to pharmacies via Genepharm's direct distribution and promote and sell a number of branded generics of Pfizer medicines.
Updates/Amendments	

Deal Date	09/27/2009
Deal Type	Venture Financing
Sub Category	Growth Capital/Expansion
Deal Headline	NovoCure completes financing
Deal Status	Completed
Acquirer/Partner	Index Ventures; Johnson and Johnson Development Corp; Pfizer Inc
Source/Target	Novocure Ltd
Deal Value (USD mn)	
Region/Country	United States
Deal Details	NovoCure Ltd has completed financing round from Pfizer Inc, Johnson and Johnson Development Corporation and Index Ventures. The proceeds from their investment will be used to fund NovoCure's newly-diagnosed GBM pivotal clinical trial.
Updates/Amendments	

Deal Date	09/25/2009
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Pfizer enters into strategic alliance with Eisai for pregabalin
Deal Status	Completed
Acquirer/Partner	Eisai Co Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Pfizer Inc. has entered into a co-promotion agreement for pregabalin with Eisai Co., Ltd. in Japan.
Updates/Amendments	

Deal Date	09/21/2009
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Pfizer and Wyeth to divest certain animal health assets to Boehringer Ingelheim
Deal Status	Completed
Acquirer/Partner	Boehringer Ingelheim GmbH
Source/Target	
Deal Value (USD mn)	
Region/Country	Australia; Canada; Europe; United States
Deal Details	Pfizer Inc. and Wyeth have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer's pending acquisition of Wyeth. Under the terms of the agreement, Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and intellectual property, primarily from Wyeth's Fort Dodge Animal Health portfolio in the U.S. and Canada. Products primarily include cattle and small animal vaccines and some animal health pharmaceuticals. Boehringer Ingelheim also intends to acquire certain animal health assets in other jurisdictions, including companion animal vaccines in Australia, and cattle vaccines in the European Union and South Africa.
Updates/Amendments	Deal Updated date : 10/26/2009 Pfizer Inc. and Wyeth, have closed the agreement with Boehringer Ingelheim to divest certain animal health assets. The acquisition, which includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens the company's position as a leading vaccine supplier. Terms of the deal were not disclosed.

Deal Date	09/18/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Wyeth and Ambrx enter into multitarget alliance to develop protein drugs
Deal Status	Completed
Acquirer/Partner	Ambrx Inc
Source/Target	Wyeth
Deal Value (USD mn)	
Region/Country	Canada; United States
Deal Details	Wyeth, a company of Pfizer Inc. has entered into collaboration with Ambrx Inc. to discover, develop, and commercialize protein drug candidates against three targets in multiple disease areas. Under the terms, Ambrx will receive up-front payments and research funding as well as development and regulatory milestones and tiered royalties.
Updates/Amendments	

Deal Date	08/27/2009
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer and Abbott enters into collaboration on companion diagnostic test
Deal Status	Completed
Acquirer/Partner	Abbott Molecular Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with Abbott Molecular to develop a molecular diagnostic test intended to screen non-small cell lung cancer tumors for the presence of gene rearrangements. Under the terms, Abbott will develop a companion diagnostic test that will determine a patient's genetic status and will be used in patient selection for future clinical trials of PF-02341066.
Updates/Amendments	

Deal Date	08/26/2009
Deal Type	Partnership
Sub Category	License; Marketing; Sales
Deal Headline	Pfizer and Mylan Specialty enters into licensing agreement for EpiPen in Japan
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Mylan Specialty LP
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Pfizer Inc. has entered into an exclusive licensing agreement with Mylan Specialty L.P., a subsidiary of Mylan Inc., under which Pfizer will obtain the exclusive rights to market and sell EpiPen Injection 0.3/0.15mg in Japan. Under the terms, the exclusive rights to market and sell the next-generation EpiPen Injection in Japan will be transferred to Pfizer from Mylan Seiyaku.
Updates/Amendments	

Deal Date	08/26/2009
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Pfizer and Astellas enters into co-promotion agreement for Caduet combination tablets
Deal Status	Completed
Acquirer/Partner	Astellas Pharma Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Pfizer Japan Inc. has entered into a co-promotion agreement with Astellas Pharma Inc. for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet Combination Tablets in Japan.
Updates/Amendments	<p>Deal Updated date : 07/08/2011</p> <p>Pfizer Japan Inc. has amended the co-promotion agreement for the transfer of distribution rights for Caduet with Astellas Pharma Inc. for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet Combination Tablets for which Pfizer holds the marketing approval rights in Japan.</p>

Deal Date	08/19/2009
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and Private Access enters into collaboration to develop online community to accelerate clinical research
Deal Status	Completed
Acquirer/Partner	Private Access
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a collaboration with Private Access to create a new online community aimed at increasing clinical trial awareness and participation. The site will be the first to focus on patient privacy rights to connect patients, physicians and researchers with tailored information, tools and technology that will lead to more informed decisions about patient care, including clinical trial participation industry-wide.</p> <p>Pfizer's collaboration with Private Access will help address patients' and physicians' top concerns regarding research and clinical trials. The companies will work toward reducing the time needed to develop new and improved treatments by making it possible for researchers and investigators based on express private access rights granted by the patient to conduct more focused searches for clinical trial candidates.</p>
Updates/Amendments	

Deal Date	07/01/2009
Deal Type	Partnership
Sub Category	Development; Supply
Deal Headline	Pfizer enters into master services and supply agreement with Graceway
Deal Status	Completed
Acquirer/Partner	Graceway Pharmaceuticals
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into a master services and supply agreement with Graceway Pharmaceuticals, LLC, under which Pfizer has agreed to perform developmental and clinical services for two early stage Stearoyl CoA Desaturase 1 inhibitor and a Cholesterol-Acyltransferase inhibitor and an Activin-Like Kinase 5 inhibitor.
Updates/Amendments	

Deal Date	07/01/2009
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; License
Deal Headline	Pfizer enters into acquisition and licensing agreement with Graceway
Deal Status	Completed
Acquirer/Partner	Graceway Pharmaceuticals
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an acquisition and licensing agreement with Graceway Pharmaceuticals, LLC, under which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules, Stearoyl CoA Desaturase 1 inhibitor, Activin-Like Kinase 5 inhibitor and a Cholesterol-Acyltransferase inhibitor from Pfizer and the related transferred or licensed intellectual properties.
Updates/Amendments	

Deal Date	06/30/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; Manufacturing; Research and Discovery
Deal Headline	Wyeth Pharmaceuticals and Catalyst Biosciences enters into agreement to develop and commercialize Factor VIIa products
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Catalyst Biosciences Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Wyeth Pharmaceuticals has entered into an exclusive worldwide collaboration with Catalyst Biosciences, Inc. for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments under the collaboration, including an upfront payment of USD21 million, research funding and milestone payments, could exceed USD500 million, exclusive of royalty payments.</p> <p>Under the terms, Wyeth will support the discovery, research and preclinical development by Catalyst of Factor VIIa products, including CB 813. The term of the exclusive research portion of the collaboration is two years, and may be extended by Wyeth for up to three additional years. Wyeth will be responsible for the development, manufacturing and worldwide commercialization of products resulting from the collaboration. Catalyst anticipates it would earn payments of up to USD40 million or more over the next two years, including the upfront payment, committed research funding and preclinical and clinical milestone payments. In addition, Catalyst will be eligible to receive escalating clinical development and commercialization milestones, plus tiered double-digit royalties on sales of products resulting from the collaboration.</p>
Updates/Amendments	<p>Deal Updated date : 04/08/2015</p> <p>As per the merger plans between Targacept, Inc. and Catalyst Biosciences, Inc. the agreement between Pfizer and Catalyst Biosciences has been terminated.</p>

Deal Date	06/08/2009
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Sanofi-aventis acquires Diabel manufacturing facility from Pfizer
Deal Status	Completed
Acquirer/Partner	sanofi aventis Deutschland GmbH
Source/Target	
Deal Value (USD mn)	41.88
Region/Country	Germany
Deal Details	Sanofi-Aventis Deutschland GmbH has purchased Diabel manufacturing plant in Frankfurt-Hochst, Germany from Pfizer Inc. The scope of the acquisition includes buildings, equipment, machinery and some existing contracts. This acquisition is valued at EUR30 million. The acquisition of this production facility will contribute to the objectives of Lantus sales growth.
Updates/Amendments	

Deal Date	06/03/2009
Deal Type	Private Placement
Sub Category	None
Deal Headline	Pfizer completes USD10500 million in private placement financing
Deal Status	Completed
Acquirer/Partner	Undisclosed
Source/Target	Pfizer Inc
Deal Value (USD mn)	10500 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. has completed offerings of EUR5850 million and GBP1500 million of senior unsecured notes (totaling approximately USD10500 million) to undisclosed investors. The notes consist of EUR1850 million of 3.625 percent notes due 2013, EUR2000 million of 4.75 percent notes due 2016, EUR2000 million of 5.75 percent notes due 2021 and GBP1500 million of 6.50 percent notes due 2038.</p> <p>The notes were offered in a private placement pursuant to Regulation S under the Securities Act of 1933, as amended. Pfizer intends to use the net offering proceeds for general corporate purposes, including funding a portion of the purchase price of the pending Wyeth acquisition and the refinancing of existing debt.</p>
Updates/Amendments	

Deal Date	05/19/2009
Deal Type	Partnership
Sub Category	Acquisition of Rights; Commercialization; Supply
Deal Headline	Pfizer enters into licensing agreement with Claris Lifesciences
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Claris Lifesciences Ltd
Deal Value (USD mn)	
Region/Country	Albania; Andorra; Australia; Austria; Belgium; Bermuda; Bosnia and Herzegovina; Bulgaria; Canada; Channel Islands; Croatia; Czech Republic; Denmark; Estonia; Europe; Faroe Islands; Finland; France; Germany; Gibraltar; Greece; Greenland; Guernsey; Hungary; Iceland; Ireland; Isle of Man; Italy; Jersey; Latvia; Liechtenstein; Lithuania; Luxembourg; Macedonia; Malta; Moldova; Monaco; Netherlands; New Zealand; North America; Norway; Poland; Portugal; Romania; San Marino; Scotland; Seborga; Serbia; Slovakia; Slovenia; Spain; St Pierre and Miquelon; Sweden; Switzerland; United Kingdom; United States
Deal Details	Pfizer has entered into an agreements with Claris Lifesciences Ltd. to commercialize sterile injectable medicines after the products are no longer patent protected, and have lost market exclusivity in North America, Europe, Australia and New Zealand. Under the terms of the agreements, Pfizer has acquired rights to 15 injectable products covering a broad range of therapeutic areas including anti-infectives and pain
Updates/Amendments	Deal Updated date : 08/24/2012 Pfizer Inc. has terminated its supply agreement with Claris Lifesciences Ltd.

Deal Date	05/18/2009
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Almac enters collaboration with Pfizer and The Petacc3 Translational Research Working Party
Deal Status	Completed
Acquirer/Partner	Petacc3 Translational Research Working Party; Pfizer Inc
Source/Target	Almac Diagnostics
Deal Value (USD mn)	
Region/Country	United Kingdom
Deal Details	Almac Diagnostics Ltd, Pfizer Inc. and the PETACC3 Translational Research Working Party have entered into collaboration for the study involving gene expression profiling of formalin-fixed paraffin-embedded samples from the Pan-European Trials in Adjuvant Colon Cancer (PETACC 3) trial using Almac Diagnostic's unique Colorectal Cancer DSA research tool to identify molecular subtypes, biomarkers and drug targets.
Updates/Amendments	

Deal Date	05/05/2009
Deal Type	Partnership
Sub Category	Development; License; Patent-Non-exclusive; Research and Discovery
Deal Headline	Pfizer enters into agreement with Wisconsin Alumni Research Foundation
Deal Status	Completed
Acquirer/Partner	Wisconsin Alumni Research Foundation
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into a licensing agreement with the Wisconsin Alumni Research Foundation for human embryonic stem cell patents for the development of new drug therapies. Under the terms, Pfizer will be provided with the rights to work with hES cells for drug research and discovery.
Updates/Amendments	

Deal Date	05/01/2009
Deal Type	Partnership
Sub Category	Infringement; Settlement
Deal Headline	Mylan file infringement against Pfizer
Deal Status	Completed
Acquirer/Partner	Mylan Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Matrix Laboratories Limited, a subsidiary of Mylan Inc. notified Pfizer Inc. that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Lipitor. Matrix asserts the non-infringement of our patent covering the crystalline form of atorvastatin, which (including the six-month pediatric exclusivity period) expires in 2017, and the non-infringement of two formulation patents. In June 2009, we filed actions against Matrix, Mylan and another Mylan subsidiary in the U.S. District Court for the District of Delaware and the U.S. District Court for the Northern District of West Virginia asserting the infringement of the crystalline patent and two process patents that expire in 2016.
Updates/Amendments	<p>Deal Updated date : 01/25/2011</p> <p>Mylan Inc. has entered into a settlement agreement with Pfizer Inc. which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg and 80 mg, known generically as Atorvastatin Calcium Tablets. The terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.</p>

Deal Date	04/24/2009
Deal Type	Partnership
Sub Category	Development
Deal Headline	Pfizer enters into collaboration with University College London to develop pioneering stem cell sight therapies
Deal Status	Completed
Acquirer/Partner	University College London
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a collaboration with University College London to advance development of stem cell-based therapies for age-related macular degeneration. The collaboration will accelerate the research process by bringing together the pioneering work of University College London's researchers in the field of cell-based therapies and Pfizer's expertise in design and delivery of therapeutics.</p> <p>Under the terms, Pfizer will provide funding to University College London to enable research into the development of stem cell-based therapies for age related macular degeneration as well as other retinal diseases. Pfizer will also contribute expertise in the design and execution of clinical studies, interaction with global regulators, and in product manufacturing techniques.</p>
Updates/Amendments	

Deal Date	04/23/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option
Deal Headline	Pfizer and University College London enters into collaboration to advance development of stem cell-based therapies
Deal Status	Completed
Acquirer/Partner	University College London
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Regenerative Medicine has entered into a collaboration and licensing agreement with University College London focused on gaining better understanding into how to develop stem cell-based therapies for certain ophthalmic conditions. The collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer's expertise in the design and delivery of therapeutics. Pfizer's contributions will include expertise in the design and execution of clinical studies and interaction with global regulators as well as in product manufacturing techniques. The collaboration will examine how human embryonic stem cells differentiate into retinal pigment epithelium with the goal of developing stem cell-based therapies primarily for wet and dry macular degeneration.</p> <p>Under the terms, Pfizer will provide funding to University College London to enable research into the development of stem cell-based therapies for wet and dry macular degeneration as well as other retinal diseases. Pfizer is granted exclusive worldwide rights to develop and commercialize a retinal pigment epithelium stem cell-based therapeutic in the ophthalmology field. After the completion of preclinical safety studies, Pfizer will have the option to conduct clinical trials to determine efficacy of treatment and commercialize any resulting product.</p>
Updates/Amendments	

Deal Date	04/22/2009
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into agreement with Medicines for Malaria Venture
Deal Status	Completed
Acquirer/Partner	MMV Medicines for Malaria Venture
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Australia
Deal Details	Pfizer Inc. has entered into an agreement with Medicines for Malaria Venture that is designed to facilitate advancements against malaria. Under the terms, Medicines for Malaria Venture will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments for malaria. The screening will be undertaken at the Eskitis Institute for Cell and Molecular Therapies at Griffith University in Brisbane, Australia.
Updates/Amendments	

Deal Date	04/16/2009
Deal Type	Partnership
Sub Category	Commercialization; Development; Joint Venture; Research and Discovery
Deal Headline	GlaxoSmithKline forms joint venture with Pfizer
Deal Status	Completed
Acquirer/Partner	GlaxoSmithKline Plc; Pfizer Inc
Source/Target	
Deal Value (USD mn)	
Region/Country	United Kingdom
Deal Details	<p>GlaxoSmithKline plc and Pfizer Inc have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialization of HIV medicines. The new HIV business will be more sustainable and broader in scope than either company's individually, and will hold a 19% share of the growing market and have an industry-leading pipeline. GSK will initially hold an 85% equity interest in the new company and Pfizer will hold 15%. The new company will have a broad product portfolio of 11 marketed products including market-leading therapies such as Combivir, Kivexa and Selzentry/Celsentri. The clear focus of the new business is to invest in research and development of innovative HIV treatments and formulations that improve adherence and overcome resistance to the virus.</p> <p>If all milestones were to be achieved, GSK's equity interest in the new company would be 75.5% and Pfizer's would be 24.5%. In the event that the only milestones achieved are in respect of the pipeline assets originally contributed by GSK, GSK's equity interest in the new company would be 91% and Pfizer's would be 9%. In the event that the only milestones achieved are in respect of the products and pipeline assets originally contributed by Pfizer, GSK's equity interest in the new company would be 69.5% and Pfizer's would be 30.5%.</p>
Updates/Amendments	

Deal Date	04/01/2009
Deal Type	Partnership
Sub Category	Joint Venture
Deal Headline	Pfizer and GlaxoSmithKline forms ViiV Healthcare Limited
Deal Status	Completed
Acquirer/Partner	GlaxoSmithKline Plc; Pfizer Inc
Source/Target	ViiV Healthcare Ltd
Deal Value (USD mn)	
Region/Country	United Kingdom
Deal Details	<p>Pfizer Inc. has entered into an agreement with GlaxoSmithKline plc to create ViiV Healthcare Limited, company focused solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines. Pfizer and GlaxoSmithKline have contributed certain HIV-related product and pipeline assets to the new company.</p> <p>Pfizer's equity interest in ViiV could vary from 9% to 30.5%, and GlaxoSmithKline's equity interest could vary from 69.5% to 91%, depending upon the milestones achieved with respect to the original pipeline assets contributed by Pfizer and by GlaxoSmithKline to ViiV.</p>
Updates/Amendments	<p>Deal Updated date : 10/01/2013</p> <p>Pfizer Inc. and GlaxoSmithKline Plc has triggered reduction in interest in ViiV Healthcare Limited on the Food and Drug Administration approval of Tivicay. This approval triggered a reduction in Pfizer's interest in ViiV from 13.5% to 12.6% and an increase in GlaxoSmithKline's equity interest in ViiV from 76.5% to 77.4%.</p>

Deal Date	03/20/2009
Deal Type	Partnership
Sub Category	Infringement; Settlement
Deal Headline	Mylan enters into infringement with OSI Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Mylan Pharmaceuticals Inc
Source/Target	Genentech Inc; OSI Pharmaceuticals Inc; Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	OSI Pharmaceuticals Inc. has filed lawsuit against Mylan Pharmaceuticals Inc. for infringement of US Patent for Tarceva (erlotinib). The lawsuit is based on Abbreviated New Drug Applications filed by Mylan seeking permission to manufacture and market a generic version of Tarceva before the expiration of the patents.
Updates/Amendments	Deal Updated date : 07/24/2013 Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI Pharmaceuticals Inc., Pfizer Inc. and Genentech Inc. that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg. This product is the generic version of TARCEVA. All other terms and conditions of the settlement are confidential.

Deal Date	03/19/2009
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and PlaNet Finance enters into collaboration to study options for expanding access to healthcare in China
Deal Status	Completed
Acquirer/Partner	PlaNet Finance
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer Inc. has entered into a collaboration with PlaNet Finance to conduct an in-depth research project on the healthcare needs of the working poor in China. The study will examine the availability and existing sources of medicines, patient purchasing patterns, and the level of access to medical services.
Updates/Amendments	

Deal Date	03/09/2009
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	MannKind acquires assets from Pfizer
Deal Status	Completed
Acquirer/Partner	Mallinckrodt Plc
Source/Target	
Deal Value (USD mn)	33
Region/Country	Germany
Deal Details	MannKind Corporation has purchased Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery. The aggregate purchase price is USD33 million, subject to certain adjustments.
Updates/Amendments	

Deal Date	03/09/2009
Deal Type	Partnership
Sub Category	Commercialization; Marketing
Deal Headline	Pfizer enters into agreement with Aurobindo Pharma
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Aurobindo Pharma Ltd
Deal Value (USD mn)	
Region/Country	Albania; Andorra; Austria; Belgium; Bosnia and Herzegovina; Bulgaria; Channel Islands; Croatia; Czech Republic; Denmark; Estonia; Faroe Islands; Finland; France; Germany; Gibraltar; Greece; Guernsey; Hungary; Iceland; Ireland; Isle of Man; Italy; Jersey; Latvia; Liechtenstein; Lithuania; Luxembourg; Macedonia; Malta; Moldova; Monaco; Netherlands; Norway; Poland; Portugal; Romania; San Marino; Scotland; Seborga; Serbia; Slovakia; Slovenia; Spain; Sweden; Switzerland; United Kingdom; United States
Deal Details	Pfizer Inc has entered into agreements with Aurobindo Pharma Ltd to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the United States and Europe, further progressing its Established Products Business Unit strategy. Under the terms of the agreements, Pfizer has acquired rights to 39 generic solid oral dose products in the United States and 20 in Europe, plus an additional 11 in France. These medicines cover a broad range of therapeutic areas including cardiovascular disease and Central Nervous System disorders, and will be commercialized in the U.S. through Pfizer's Greenstone subsidiary.
Updates/Amendments	

Deal Date	03/04/2009
Deal Type	Partnership
Sub Category	License; Supply
Deal Headline	Pfizer enters into marketing agreement with Aurobindo for finished dosage products
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Aurobindo Pharma Ltd
Deal Value (USD mn)	
Region/Country	India
Deal Details	Pfizer Inc. has entered into a licensing and supply agreements with Aurobindo Pharma Ltd. for several solid dosage and sterile products. Under the terms, Pfizer will take on license, an array of generic pills and injectable medicines, as it look to off-patent medicines.
Updates/Amendments	Deal Updated date : 05/19/2009 Pfizer Inc. has expanded its agreement with Aurobindo Pharma Ltd. Under the terms, Pfizer has acquired rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging market countries. These medicines include antibiotics and anti-infectives, and cover a broad range of disease areas like cardiovascular and central nervous system disorders. Pfizer will commercialize the 60 products in phases tailoring its approach for different regions.

Deal Date	03/02/2009
Deal Type	Partnership
Sub Category	License; Screening/Evaluation
Deal Headline	Pfizer and Xencor enter into antibody technology licensing agreement
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Xencor Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a technology licensing and evaluation agreement with Xencor, Inc. to optimize the performance of therapeutic monoclonal antibodies. Pfizer will apply Xencor's proprietary Xtend antibody half-life prolongation technology and XmAb ADCC enhancing technology to its antibody drug candidates.</p> <p>Under the terms, Pfizer will have access to Xencor's antibody optimization technology during a non-exclusive research period for evaluation of the technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor's technology for one program. Xencor will receive an upfront payment from Pfizer and is eligible to receive additional consideration based on Pfizer's successful commercialization of products that incorporate the Xencor technology.</p>
Updates/Amendments	

Deal Date	03/02/2009
Deal Type	Partnership
Sub Category	Co-Promotion; Commercialization
Deal Headline	Pfizer and Bausch and Lomb to co-promote products for the treatment of ophthalmic conditions
Deal Status	Completed
Acquirer/Partner	Bausch and Lomb Inc; Pfizer Inc
Source/Target	
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. and Bausch and Lomb have entered into a co-promotion agreement involving both companies' prescription ophthalmic pharmaceuticals in the United States. The five-year agreement includes Pfizer's Xalatan and Bausch and Lomb's Alrex, Lotemax and Zylet. The co-promotion agreement also will apply to Bausch and Lomb's besifloxacin ophthalmic suspension, 0.6%. Under the terms, both the Pfizer and Bausch and Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin.
Updates/Amendments	

Deal Date	01/25/2009
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer completes acquisition of Wyeth
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Wyeth
Deal Value (USD mn)	68000 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc., has completed the acquisition of Wyeth for approximately USD68000 million. Under the terms of the transaction, each outstanding share of Wyeth common stock has been converted into the right to receive USD33 in cash and 0.985 of a share of Pfizer common stock and it provides immediate value to Wyeth shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 16 percent of Pfizer's shares. The transaction is financed through a combination of cash, debt and stock.</p>
Updates/Amendments	<p>Pfizer and Wyeth have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at USD50.19 per share, or a total of approximately USD68000 million.</p> <p>Under the terms of the transaction, each outstanding share of Wyeth common stock will be converted into the right to receive USD33 in cash and 0.985 of a share of Pfizer common stock, subject to the terms of the merger agreement. Based on the closing price of Pfizer stock as of January 23, 2009, the stock component is valued at USD17.19 per share.</p> <p>The transaction will be financed through a combination of cash, debt and stock. A consortium of banks has provided commitments for a total of USD22.5 billion in debt.</p> <p>Pfizer's lead financial advisors are Bank of America Merrill Lynch, Goldman Sachs and J.P. Morgan. Barclays and Citigroup are acting as financial advisors. Its legal advisor is Cadwalader, Wickersham & Taft LLP. Wyeth's financial advisors are Morgan Stanley and Evercore Partners and its legal</p>

	advisor is Simpson Thacher & Bartlett LLP. In addition, Wachtell, Lipton, Rosen & Katz served as counsel to Wyeth's Board of Directors.
--	---

Deal Date	12/22/2008
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into agreement with Sangamo
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Sangamo Biosciences Inc
Deal Value (USD mn)	3
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with Sangamo BioSciences, Inc. to provide Pfizer with a worldwide, non-exclusive license for the use of Zinc Finger Nuclease reagents to permanently eliminate the Glutamine Synthetase gene in Chinese Hamster Ovary cell lines and for the use of these ZFN-modified cells for clinical and commercial production of therapeutic proteins.</p> <p>Under the terms, Sangamo will receive an upfront payment of USD3 million from Pfizer for a fully paid license. Sangamo will provide a worldwide, fully paid, perpetual, royalty free, non-exclusive, license for the use of certain ZFN reagents to Pfizer. The license may not be sublicensed although Pfizer may transfer any GS ZFN-modified CHO cell line to a contract manufacturer solely for such contract manufacturer to manufacture Pfizer's therapeutic proteins for Pfizer.</p>
Updates/Amendments	

Deal Date	12/19/2008
Deal Type	Partnership
Sub Category	Option; Research and Discovery
Deal Headline	Pfizer enters into non-exclusive drug discovery collaboration with Novocell
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Novocell Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Novocell, Inc. has entered into a non-exclusive drug discovery collaboration with Pfizer Inc., granting Pfizer access to Novocell's proprietary pancreatic progenitor cells derived from human embryonic stem cells.</p> <p>Under the terms, Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding. In addition, Novocell will receive payments relating to the sale by Pfizer of any exclusive therapeutic discovered as a result of the collaboration. The duration of the research collaboration will be 2 years with the option by Pfizer to extend.</p>
Updates/Amendments	

Deal Date	12/17/2008
Deal Type	Partnership
Sub Category	Commercialization; Development; Supply
Deal Headline	Pfizer enters into exclusive strategic alliance with Auxilium for Xiaflex
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Auxilium Pharmaceuticals Inc
Deal Value (USD mn)	485 (Max)
Region/Country	Europe
Deal Details	<p>Pfizer Inc. has entered into an exclusive strategic alliance with Auxilium Pharmaceuticals, Inc. for the development, commercialization and supply of Xiaflex. Pfizer will receive exclusive rights to commercialize Xiaflex in the 27 member countries of the European Union and 19 other European and Eurasian countries. In addition, Pfizer will be primarily responsible for regulatory activities for Xiaflex in these countries.</p> <p>Under the terms, Pfizer will make an up-front payment of USD75 million to Auxilium and up to USD410 million in potential milestone payments, with USD150 million tied to regulatory milestones and USD260 million based on sales milestones. Auxilium will receive increasing tiered royalties based on sales of Xiaflex in Pfizer's territories.</p>
Updates/Amendments	

Deal Date	12/08/2008
Deal Type	Partnership
Sub Category	License; Marketing; Supply
Deal Headline	Pfizer and Sigma-Tau enters into agreement to market a potential new treatment for malaria in Africa
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Sigma tau Industrie Farmaceutiche Riunite SpA
Deal Value (USD mn)	
Region/Country	Middle East and Africa
Deal Details	<p>Pfizer Inc. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A have entered into a licensing and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim in Africa.</p> <p>Under the agreement, Pfizer and Sigma-Tau will ensure access to this novel medicine in Africa in collaboration with the various local stakeholders. Following applicable regulatory submissions and approvals, Pfizer will market the drug in the public and private sectors locally in Africa, and Sigma-Tau will be responsible for the institutional sector. Financial details are undisclosed.</p>
Updates/Amendments	

Deal Date	12/05/2008
Deal Type	Partnership
Sub Category	Technology Divestment
Deal Headline	Emergent Biosolutions enters into agreement with Pfizer Inc
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Emergent Biosolutions Inc
Deal Value (USD mn)	2.55 (Max)
Region/Country	United States
Deal Details	Emergent BioSolutions Inc. has entered into an agreement with Pfizer Inc., where Pfizer acquired technology, materials and related documentation pertaining to Pertussis or whooping cough from Emergent. Under the terms, Pfizer paid USD1.8 million for Pertussis technology, product material, data, technical and scientific information, intellectual property, trade secrets, standard operating procedures, batch records, historical manufacturing records and regulatory documentation relating to the technology. In addition, Pfizer will pay Emergent a future milestone payment of up to USD750,000 based on the results.
Updates/Amendments	

Deal Date	10/19/2008
Deal Type	Partnership
Sub Category	Joint Venture
Deal Headline	Pfizer and UCB forms Cyclofluidic to accelerate drug discovery process
Deal Status	Completed
Acquirer/Partner	Cyclofluidic; Pfizer Inc; UCB SA
Source/Target	
Deal Value (USD mn)	
Region/Country	United Kingdom
Deal Details	<p>Pfizer Ltd and UCB SA have formed Cyclofluidic, a technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time. Pfizer and UCB will continue to support Cyclofluidic by co-funding its research and development.</p> <p>The aim of Cyclofluidic is to develop technologies that automate and integrate processes known as flow chemistry and flow biology to help pharmaceutical companies shorten timelines within the drug development process. Cyclofluidic will be jointly owned by Pfizer and UCB, with each company having both a seat and scientific observer rights on the board.</p>
Updates/Amendments	

Deal Date	09/23/2008
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and Grameen Health enters into partnership to explore sustainable healthcare delivery models for the developing world
Deal Status	Completed
Acquirer/Partner	Grameen Health
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaboration with Graméen Health Care Services Ltd. an affiliate of Grameen Bank to identify sustainable models for healthcare delivery in the developing world. The partners will jointly evaluate ways to improve Grameen Health's existing healthcare delivery systems and primary care clinics in rural Bangladesh. As part of its commitment to the collaboration, Pfizer is dedicating key employees to provide technical and advisory support.
Updates/Amendments	

Deal Date	09/22/2008
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Durect enters into agreement with Alpharma for Eladur
Deal Status	Terminated
Acquirer/Partner	Alpharma Inc
Source/Target	Durect Corp; Pfizer Inc
Deal Value (USD mn)	263 (Max)
Region/Country	Worldwide
Deal Details	<p>DURECT Corporation has entered into a development and licensing agreement with Alpharma Inc. granting the exclusive worldwide rights to develop and commercialize DURECT's ELADUR.</p> <p>Under the terms, Alpharma will pay DURECT an upfront license fee of USD20 million, with possible additional payments of up to USD93 million upon the achievement of predefined development and regulatory milestones spread over multiple clinical indications and geographical territories as well as possible additional payments of up to USD150 million in sales based milestones. If ELADUR is commercialized, Durect would also receive a royalty on product sales. Alpharma will control and fund the development program.</p>
Updates/Amendments	<p>Deal Updated date : 02/28/2012</p> <p>Pfizer Inc. and DURECT Corporation have terminated the development and licensing agreement between Alpharma and DURECT relating to the worldwide development and commercialization of ELADUR.</p>

Deal Date	09/03/2008
Deal Type	Partnership
Sub Category	Co-Promotion; Commercialization; Development
Deal Headline	Pfizer and Medivation enter into global agreement to co-develop and market Dimebon
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Medivation Inc
Deal Value (USD mn)	725 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. and Medivation, Inc. have entered into an agreement to develop and commercialize Dimebon. In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S. Pfizer will have responsibility for development, regulatory and commercialization outside the U.S.</p> <p>Under the terms, Medivation will receive an up-front cash payment of USD225 million. Medivation also is eligible to receive payments of up to USD500 million upon the attainment of development and regulatory milestones plus additional undisclosed commercial milestone payments. Medivation and Pfizer will collaborate on the Phase III program in Alzheimer's disease, Huntington's disease development and regulatory filings in the United States. The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses on a 60 percent/40 percent basis, with Pfizer assuming the larger share of both expenses and profit/losses and will pay Medivation tiered royalties on commercial sales outside of the U.S.</p> <p>The agreement is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. J.P. Morgan served as financial advisor, and Cooley Godward Kronish LLP served as legal advisor, to Medivation on this transaction.</p>
Updates/Amendments	<p>Deal Updated date : 01/18/2012</p> <p>Pfizer Inc. and Medivation Inc. have terminated the development of an experimental Alzheimer's drug.</p>

Deal Date	07/03/2008
Deal Type	Partnership
Sub Category	Commercialization; Distribution
Deal Headline	Pfizer enters into exclusive distributional and promotional agreement with NovaMed
Deal Status	Completed
Acquirer/Partner	Novamed Pharmaceuticals Pvt Ltd
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	China
Deal Details	Pfizer China Inc. has entered into an exclusive agreement with NovaMed Pharmaceuticals Inc. to facilitate Chinese patient access to established oncology products. The agreement provides NovaMed with exclusive distributional and promotional rights for six established Pfizer China's oncology products. The agreement will allow Pfizer China to continue its focus on the growth of its new innovative oncology products in China. The six established oncology products include Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal.
Updates/Amendments	

Deal Date	06/24/2008
Deal Type	Partnership
Sub Category	License; Option
Deal Headline	Melior signs option agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Melior Discovery Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Melior Discovery, Inc. has entered into an option agreement that provides Pfizer Inc. the exclusive right to negotiate a license to MLR-1023. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior agreed to utilize its in-vivo theratRACE indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer.
Updates/Amendments	

Deal Date	06/12/2008
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer and the University of Pennsylvania enter into USD15 million partnership
Deal Status	Completed
Acquirer/Partner	University Of Pennsylvania School Of Medicine
Source/Target	Pfizer Inc
Deal Value (USD mn)	15
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into USD15million collaboration with the University Of Pennsylvania School Of Medicine. The partnership will include collaborations between Pfizer and the University in the areas of scientific research, clinical development and clinical care and policy. Pfizer and the University Of Pennsylvania School Of Medicine will develop an initiative to improve the management of cardiovascular risk and patient adherence to treatments, among patients currently served by the University of Pennsylvania's Health System.</p> <p>Under the terms, Pfizer will pay University Of Pennsylvania USD15 million over a three-year period, during which time scientists from Pfizer and University Of Pennsylvania's School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas.</p>
Updates/Amendments	

Deal Date	06/10/2008
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer and University of California San Francisco form alliance to advance a broad range of research
Deal Status	Completed
Acquirer/Partner	University of California
Source/Target	Pfizer Inc
Deal Value (USD mn)	9.5 (Max)
Region/Country	United States
Deal Details	Pfizer, Inc. and University of California San Francisco have entered into a collaboration that spans many disciplines, several University of California campuses and multiple Pfizer research units. The three year agreement, with research and other support from Pfizer of up to USD9.5 million, establishes a UCSF team to help identify promising areas of mutual interest and facilitate project management. Pfizer has first rights of negotiation for intellectual property generated by the sponsored research.
Updates/Amendments	

Deal Date	06/10/2008
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and University of California, San Francisco form alliance to advance a broad range of research
Deal Status	Completed
Acquirer/Partner	University of California
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer, Inc. and University of California, San Francisco have entered into a collaboration that spans many disciplines, several University of California campuses and multiple Pfizer research units. The three year agreement, with research and other support up to USD9.5 million, establishes a university team to help identify promising areas of mutual interest and facilitate project management.</p> <p>The Pfizer- University of California, San Francisco agreement will encourage collaborations between the company and University of California, San Francisco's unit of QB3, the multi-campus California Institute for Quantitative Biosciences, headquartered at University of California, San Francisco.</p>
Updates/Amendments	

Deal Date	06/06/2008
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer licenses Pathway Studio Enterprise from Ariadne Genomics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ariadne Genomics Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into a licensing agreement with Ariadne Genomics Inc. where, Pfizer has purchased a multi-site license for Pathway Studio Enterprise. Pfizer is going to use it to assemble reference networks of biological interactions from internal and public data sources for interpretation of experimental results throughout its research facilities.
Updates/Amendments	

Deal Date	05/20/2008
Deal Type	Partnership
Sub Category	License; Research and Discovery
Deal Headline	Five Prime enters into oncology and diabetes collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Five Prime Therapeutics Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Five Prime Therapeutics Inc. and Pfizer Inc. have entered into a worldwide collaborative research and licensing agreement for the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes.</p> <p>Under the terms, FivePrime will screen its comprehensive protein library in both cell-based assays and primary in vivo screens directed toward finding potential therapeutic protein products and antibody targets. Upon the collaboration, FivePrime will receive an up-front payment and an equity investment from Pfizer and three years of committed research funding. Pfizer will have exclusive worldwide rights to develop and commercialize certain products and targets discovered during the research term, in exchange for future milestones and royalties.</p>
Updates/Amendments	<p>Deal Updated date : 03/26/2013</p> <p>As per the 10-K , dated on 03/26/2013 of Five Prime Therapeutics Inc., collaboration between Pfizer and Five Prime has ended.</p>

Deal Date	04/25/2008
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into research consortium
Deal Status	Completed
Acquirer/Partner	Entelos Inc; Massachusetts Institute of Technology Center; University of California; University of Massachusetts
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer has entered into a collaboration agreement with four research universities, University of California, Santa Barbara, the Massachusetts Institute of Technology, University of Massachusetts and Entelos. Under the terms, Pfizer is funding the three-year and USD14 million Insulin Resistance Pathway Project to look at insulin signalling in adipose cells to increase understanding of diabetes and obesity.
Updates/Amendments	

Deal Date	04/23/2008
Deal Type	Partnership
Sub Category	Product Divestment
Deal Headline	Pfizer Animal Health enters into agreement to acquire animal health products from Schering-Plough
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Animal Health has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation. Under the terms, Pfizer Animal Health will acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering Swine E. coli Vaccines, Equine Influenza and Tetanus Vaccines, Ruminant Neonatal and Clostridia Vaccines, Rabies Vaccines, Companion Animal Veterinary Specialty Products and Parasiticides & Anti-inflammatories.
Updates/Amendments	

Deal Date	04/16/2008
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Celldex and Pfizer enter into a licensing and development agreement
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Celldex Therapeutics INC
Deal Value (USD mn)	440 (Max)
Region/Country	Worldwide
Deal Details	Celldex Therapeutics Inc. and Pfizer Inc. have entered into a license and development agreement, under which Pfizer was granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in Phase 2 development for the treatment of glioblastoma multiforme. The agreement also gives Pfizer exclusive rights to the use of EGFRvIII vaccines in other potential indications. As per the agreement, Pfizer made an upfront payment of USD40 million and made a USD10 million equity investment in Celldex. Pfizer will fund all development costs for these programs and Celldex is also eligible to receive potential milestone payments exceeding USD390 million for the successful development and commercialization of CDX-110 and additional EGFRvIII vaccine products, as well as royalties on any product sales.
Updates/Amendments	Deal Updated date : 11/01/2010 Celldex Therapeutics Inc. and Pfizer Inc. have terminated the license and development agreement which they entered on April 16, 2008

Deal Date	04/15/2008
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and Ingenuity Systems enter into strategic partnership for pathway analysis
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Ingenuity Systems
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Pharmaceuticals, Inc. and Ingenuity Systems have entered into a multi-year strategic partnership which promotes enterprise-wide deployment of IPA, enabling more researchers to use IPA for the exploration, interpretation, and analysis of life science information. In addition, Pfizer will integrate IPA and content from the Ingenuity knowledge base with other informatics solutions used throughout the Pfizer organization.
Updates/Amendments	

Deal Date	03/02/2008
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer to acquire Serenex
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Serenex Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement to acquire Serenex, Inc. Under the terms, Pfizer will acquire the rights to SNX-5422 and Serenex's proprietary drug discovery technology and extensive small molecule Hsp90 inhibitor compound library. The transaction is expected to close in the second quarter of 2008. Financial terms of the deal were not disclosed.
Updates/Amendments	Deal Updated date : 06/01/2008 Pfizer Inc. has completed the acquisition of Serenex, Inc. Other terms of the deal are not disclosed.

Deal Date	03/01/2008
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	Mylan file infringement agreement against Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Health AB; Pfizer Inc; Pharmacia and Upjohn Company LLC
Source/Target	Mylan Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Mylan Pharmaceuticals Inc. and Sandoz B.V. has notified Pfizer Inc. and filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Detrol LA. They assert the invalidity and/or non-infringement of three formulation patents for Detrol LA.
Updates/Amendments	<p>Deal Updated date : 06/01/2010 Pfizer Inc. filed actions against Sandoz and Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of New Jersey asserting the infringement of two of the formulation patents.</p> <p>Deal Updated date : 09/07/2012 Mylan Inc. and its subsidiary, Mylan Pharmaceuticals Inc., has entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.</p>

Deal Date	02/20/2008
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Pfizer enters into agreement with Genstruct in drug safety
Deal Status	Completed
Acquirer/Partner	Genstruct Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into a research agreement with Genstruct Inc. to cover current and future collaborations. The collaboration under this agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury. Although financial terms were not disclosed, the master research agreement allows Genstruct to retain valuable biomarker intellectual property rights.
Updates/Amendments	

Deal Date	02/19/2008
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Encysive Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Encysive Pharmaceuticals Inc
Deal Value (USD mn)	195 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc., has completed the acquisition of Encysive Pharmaceuticals Inc., a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension is commercially available in much of the European Union and is approved in other markets. Under the terms of the agreement, Pfizer made a cash tender offer for all issued and outstanding shares of Encysive for USD2.35 per share, representing an equity value of approximately USD195 million.</p> <p>Lazard Frères and Co. LLC and Weil, Gotshal & Manges LLP advised Pfizer on this transaction. Morgan Stanley and Covington & Burling LLP advised Encysive.</p>
Updates/Amendments	

Deal Date	02/01/2008
Deal Type	Partnership
Sub Category	Marketing; Sales
Deal Headline	Pfizer enters into agreement with moksha8
Deal Status	Completed
Acquirer/Partner	moksha8 Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Afghanistan; Albania; American Samoa; Andorra; Armenia; Australia; Austria; Azerbaijan; Bangladesh; Belarus; Belgium; Bhutan; Bosnia and Herzegovina; Brunei; Bulgaria; Cambodia; Channel Islands; China; Cook Islands; Croatia; Czech Republic; Denmark; East Timor; Estonia; Europe; Faroe Islands; Federated States of Micronesia; Fiji; Finland; France; French Polynesia; Georgia; Germany; Gibraltar; Greece; Guam; Guernsey; Hong Kong; Hungary; Iceland; India; Indonesia; Iran; Ireland; Isle of Man; Italy; Japan; Jersey; Kazakhstan; Kiribati; Kyrgyzstan; Lao Peoples Democratic Republic; Latin America; Latvia; Liechtenstein; Lithuania; Luxembourg; Macau; Macedonia; Malaysia; Maldives; Malta; Marshall Islands; Moldova; Monaco; Mongolia; Myanmar; Nauru; Nepal; Netherlands; New Caledonia; New Zealand; North Korea; Northern Mariana Islands; Norway; Pakistan; Palau; Papua New Guinea; Philippines; Poland; Portugal; Romania; Russia; San Marino; Scotland; Seborga; Serbia; Singapore; Slovakia; Slovenia; Solomon Islands; South Korea; Spain; Sri Lanka; Sweden; Switzerland; Taiwan; Tajikistan; Thailand; Tonga; Turkmenistan; Tuvalu; Ukraine; United Kingdom; Uzbekistan; Vanuatu; Vietnam; Wallis and Futuna
Deal Details	Pfizer, Inc. has entered into a strategic alliance with moksha8, Inc. for the launch of over twenty products in four therapeutic areas, CNS disease, anti-infectives, cardiovascular disease and pain management to the fastest growing markets of the world, with an initial focus on Asia, Latin America and Eastern Europe.
Updates/Amendments	

Deal Date	01/30/2008
Deal Type	Partnership
Sub Category	Development; Distribution; License; Manufacturing
Deal Headline	Pfizer enters into agreement with International Partnership for Microbicides for Maraviroc
Deal Status	Completed
Acquirer/Partner	International Partnership for Microbicides
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with the International Partnership for Microbicides where, Pfizer gave International Partnership for Microbicides a royalty-free license to maraviroc. Under the terms, International Partnership for Microbicides would work to develop maraviroc as a vaginal microbicide with the right to develop, manufacture and distribute the microbicide in developing countries. Pfizer has granted these rights to International Partnership for Microbicides without a royalty.
Updates/Amendments	

Deal Date	01/22/2008
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer and Aureon Laboratories enters into collaboration to establish quantitative biometrics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Aureon Laboratories Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into a research collaboration with Aureon Laboratories, Inc. to establish quantitative biometrics for assessing therapeutic response of prostate cancer patients treated with hormone therapy. The collaboration will utilize Aureon's integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.
Updates/Amendments	

Deal Date	01/16/2008
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer and Scil Technology enters into agreement for novel cartilage growth factor
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Scil Technology GmbH
Deal Value (USD mn)	250 (Max)
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into an exclusive licensing agreement for worldwide collaboration with Scil Technology GmbH on Scil's cartilage specific growth factor CD-RAP. Under the terms, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for upfront and milestone payments of approximately USD250 million depending on the achievement of various development and regulatory milestones.
Updates/Amendments	

Deal Date	01/07/2008
Deal Type	Partnership
Sub Category	Development
Deal Headline	Genomic Health enters into collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Genomic Health Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Genomic Health Inc. has entered into collaboration with Pfizer Inc. for the development of a genomic test to estimate the risk of recurrence following surgery for patients with Stage I-III renal carcinoma, clear cell type that has not spread to other parts of the body. As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX breast cancer test.
Updates/Amendments	

Deal Date	01/07/2008
Deal Type	Partnership
Sub Category	Contract; Manufacturing; Supply
Deal Headline	Hikal enters into manufacturing agreement with Pfizer for supply of active pharmaceutical ingredients
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Hikal Ltd
Deal Value (USD mn)	
Region/Country	India
Deal Details	Hikal Ltd. has entered into a contract manufacturing agreement for supply of active pharmaceutical ingredients with Pfizer Inc. Terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	01/01/2008
Deal Type	Partnership
Sub Category	Supply
Deal Headline	Sobi enters into collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Swedish Orphan Biovitrum AB
Deal Value (USD mn)	
Region/Country	Albania; Andorra; Austria; Belgium; Bosnia and Herzegovina; Bulgaria; Channel Islands; Croatia; Czech Republic; Denmark; Estonia; Europe; Faroe Islands; Finland; France; Germany; Gibraltar; Greece; Guernsey; Hungary; Iceland; Ireland; Isle of Man; Italy; Jersey; Latvia; Liechtenstein; Lithuania; Luxembourg; Macedonia; Malta; Moldova; Monaco; Netherlands; Norway; Poland; Portugal; Romania; San Marino; Scotland; Seborga; Serbia; Slovakia; Slovenia; Spain; Sweden; Switzerland; United Kingdom
Deal Details	Swedish Orphan Biovitrum AB has entered into a supply agreement with Pfizer, Inc. for ReFacto AF/XYNTHA.
Updates/Amendments	Deal Updated date : 02/15/2012 Swedish Orphan Biovitrum AB and Pfizer, Inc. have extended their agreement for ReFacto AF/XYNTHA until 31 December 2020, with an option to be further renewed. Sobi will continue to be the global supplier of the drug substance for ReFacto AF/XYNTHA.

Deal Date	12/27/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into translational molecular medicine collaboration with Source MDx
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Source MDx
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer, Inc. has entered into a multi-year translational molecular medicine collaboration with Source MDx, Inc. to develop and validate RNA-based pharmacodynamic and predictive biomarkers within Pfizer's cancer and inflammation therapeutic development programs. This molecular diagnostics collaboration will combine Pfizer's expertise in genomic profiling with Source MDx's expertise in RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells.</p> <p>Under the terms, Source MDx and Pfizer will collaborate on a series of clinical studies in oncology and inflammation. Source MDx will receive an equity investment and technology license payment, plus research and development funding over the term of the alliance. Source MDx will retain commercial rights to diagnostic biomarkers discovered and validated from the collaboration. The agreement includes provisions under which Pfizer and Source MDx can commercialize any companion diagnostics that may be developed as part of the collaboration.</p>
Updates/Amendments	

Deal Date	12/17/2007
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires COVX
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	CovX Research LLC
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc., has completed the acquisition of CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer's biologic portfolio. Financial terms of the transaction were not disclosed.
Updates/Amendments	

Deal Date	12/04/2007
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer enters into exclusive worldwide collaboration with Adolor to develop and commercialize novel pain compounds
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Adolor Corp
Deal Value (USD mn)	264.4 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide collaboration with Adolor Corporation to develop and commercialize ADL5859 and ADL5747. Pfizer will be responsible for securing regulatory approvals and commercialization on a worldwide basis.</p> <p>Under the terms, Pfizer and Adolor will share revenues and expenses 60/40 percent in the United States. Outside the U.S., Pfizer will fund development activities and, on commercialization, Adolor will receive royalties on Pfizer net sales. Adolor will receive an upfront, non-refundable payment of USD30 million, plus USD1.9 million reimbursement for prior Phase II development costs. Adolor may also receive payments of up to USD232.5 million upon the achievement of development and regulatory milestones for its Delta compounds. More than 50 percent of these milestones may be earned prior to regulatory approval of the compounds, with the first milestone payment available to be earned on commencement of Phase IIb clinical studies.</p>
Updates/Amendments	<p>Deal Updated date : 12/21/2010</p> <p>Adolor Corp. and Pfizer Inc. have decided to discontinue further development of two compounds Adolor discovered that were being developed as potential pain treatments.</p>

Deal Date	11/29/2007
Deal Type	Partnership
Sub Category	License; Research and Discovery
Deal Headline	Pfizer enters into multi-target drug discovery research collaboration with Graffinity Pharma
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Graffinity Pharmaceuticals GmbH
Deal Value (USD mn)	
Region/Country	Germany
Deal Details	<p>Pfizer, Inc. has entered into drug discovery collaboration with Graffinity Pharmaceuticals GmbH where, Graffinity will provide Pfizer with access to its proprietary, fragment-based screening technology for use in screening Pfizer drug targets.</p> <p>Under the terms, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of novel small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.</p>
Updates/Amendments	

Deal Date	11/16/2007
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Coley
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Coley Pharmaceutical Group Inc
Deal Value (USD mn)	164
Region/Country	United States
Deal Details	<p>Pfizer Inc. has completed the acquisition of Coley Pharmaceutical Group, Inc., a publicly-held biopharmaceutical company. Under the terms of the agreement, Pfizer made a cash tender offer for all of the outstanding common stock of Coley for USD8.00 per share, representing an enterprise value of USD164 million.</p> <p>Lazard Frères and Co, LLC, and Covington & Burling, LLP advised Pfizer on this transaction. JPMorgan and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised Coley Pharmaceutical Group.</p>
Updates/Amendments	

Deal Date	11/13/2007
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer enters into agreement with Nektar
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Nektar Therapeutics
Deal Value (USD mn)	135
Region/Country	United States
Deal Details	Pfizer and Nektar Therapeutics have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin product currently in Phase 1 clinical development. Under the terms of the agreement, Nektar will receive a one-time payment of USD135 million from Pfizer in satisfaction of all remaining obligations under existing agreements relating to Exubera and NGI. Pfizer has agreed to transfer its remaining rights and all economic benefits for Exubera and NGI. This transfer of Pfizer's interests would include the transfer of the Exubera New Drug Application and Investigational New Drug Applications and all ex-U.S. regulatory filings and applications, continuation of ongoing Exubera clinical trials and certain supply chain transition activities.
Updates/Amendments	

Deal Date	11/12/2007
Deal Type	Partnership
Sub Category	Development; Marketing; Research and Discovery
Deal Headline	Pfizer enters into collaboration with DIREVO Biotech on therapeutic proteases
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	DIREVO Biotech AG
Deal Value (USD mn)	
Region/Country	Germany
Deal Details	Pfizer, Inc. has entered into collaboration agreement with DIREVO Biotech AG to develop therapeutic proteases for different targets as potential treatments for various diseases. Under the terms, Direvo will use its protein engineering expertise to discover and optimize preclinical candidates. Pfizer will then be responsible for the development and marketing of the respective compounds. Direvo will receive payments upon reaching certain research and development milestones as well as royalties for any resulting product that reaches the market.
Updates/Amendments	

Deal Date	10/30/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer and Taisho signs letter of intent for Taisho's schizophrenia drug candidate
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Taisho Pharmaceutical Co Ltd
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. and Taisho Pharmaceutical Co., Ltd. have concluded a letter of intent for the licensing agreement rights for development and commercialization with regard to TS-032 in Japan.</p> <p>Under the terms, Taisho would grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. If the license agreement is signed, Taisho will receive from Pfizer an initial payment of USD22 million. Taisho will also receive milestone payments tied to progress of development, as well as royalties and milestone payments tied to sales if TS-032 is approved by regulatory authorities and launched.</p>
Updates/Amendments	<p>Deal Updated date : 01/07/2008</p> <p>Pfizer Inc. and Taisho Pharmaceutical Co., Ltd. have entered into a definitive agreement, which replaces the letter of intent for worldwide, excluding Japan collaboration to research, develop and commercialize TS-032.</p> <p>Under the terms, Taisho will grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. Taisho will receive from Pfizer an initial payment of USD22 million. Taisho will also receive milestone payments tied to progress of development, as well as royalties and milestone payments tied to sales if TS-032 is approved by regulatory authorities and launched.</p>

Deal Date	10/14/2007
Deal Type	Partnership
Sub Category	Miscellaneous
Deal Headline	Pfizer collaborates with Sermo
Deal Status	Completed
Acquirer/Partner	Sermo
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into collaboration with Sermo to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Through this collaboration, Sermo's community of physicians will have access to Pfizer's clinical content in tangible ways that allow for the transparent and efficient exchange of knowledge.
Updates/Amendments	

Deal Date	09/27/2007
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into license agreement with SupplyScape
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	SupplyScape Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into an agreement with SupplyScape Corporation where, Pfizer gained license for SupplyScape's E-Pedigree data management software to enhance patient safety, secure the drug supply channel and meet regulatory compliance requirements.
Updates/Amendments	

Deal Date	08/28/2007
Deal Type	Partnership
Sub Category	Development; License; Manufacturing; Research and Discovery
Deal Headline	Pfizer enters into licensing agreement with XOMA for bacterial cell expression technology
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Xoma Corp
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a licensing agreement with XOMA Ltd. where, XOMA licensed non-exclusive, worldwide rights to its patented bacterial cell expression technology for phage display and other research, development and manufacturing of antibody products.</p> <p>Under the terms, XOMA will receive an upfront, non-dilutive cash payment of USD30 million and milestone, royalty and other fees on future sales of all products subject to this license, including products in late-stage clinical development.</p>
Updates/Amendments	

Deal Date	08/14/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into agreement with Icagen in ion channel-focused therapeutics for pain and related disorders
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Icagen Inc
Deal Value (USD mn)	397 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide collaboration and licensing agreement with Icagen, Inc. for the discovery, development and commercialization of compounds which modulate three specific sodium ion channels as new potential treatments for pain and related disorders. Under the terms of the agreement, Icagen and Pfizer will combine resources to identify compounds that target these three ion channels in a global research and development collaboration. Pfizer will fund all aspects of the collaboration including the research and preclinical development efforts at Icagen and will have exclusive worldwide rights to commercialize products that result from the collaboration.</p> <p>Under the terms, Pfizer will provide USD38.0 million in committed funding to Icagen over the first two years of the collaboration, including an initial upfront license fee of USD12.0 million, up to USD15.0 million through an equity commitment, and research and development funding. The equity commitment is comprised of an initial investment in Icagen common stock in the amount of USD5.0 million at fair market value on the effective date of the agreement and an equity put option, exercisable by Icagen, to sell to Pfizer at fair market value up to USD10.0 million of common stock, subject to certain terms and conditions, at any time during the first eighteen months following the signing of the agreement. Additionally, Icagen is eligible to receive USD359 million in research, development, regulatory and commercialization milestones for each product. Icagen is also eligible to receive tiered royalties, against which the commercialization milestones are creditable, depending upon sales achieved.</p>
Updates/Amendments	<p>Deal Updated date : 09/21/2009</p> <p>Pfizer Inc. has extended its collaboration and licensing agreement with</p>

	Icagen, Inc. for one year.
--	----------------------------

Deal Date	08/13/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	FoldR collaborates with Cystic Fibrosis Foundation Therapeutics
Deal Status	Completed
Acquirer/Partner	Cystic Fibrosis Foundation Therapeutics Inc; Pfizer Inc
Source/Target	FoldRx Pharmaceuticals Inc
Deal Value (USD mn)	58 (Max)
Region/Country	Worldwide
Deal Details	FoldRx Pharmaceuticals, Inc. has entered into collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. where FoldRx will receive up to USD22 million over five years to discover and develop new compounds aimed at treating a core defect in cystic fibrosis. FoldRx will use its novel yeast-based, high throughput screening platform to detect new compounds that could improve the function of a misfolded protein associated with cystic fibrosis, thus helping treat the disease. Under the terms, FoldRx will retain full worldwide commercialization rights and receive CFFT payments upon successful completion of specific research and development milestones, including development of two clinical candidates to the point of Phase I clinical trials. CFFT will be eligible to receive royalties from FoldRx on net sales of any approved products.
Updates/Amendments	<p>Deal Updated date : 11/19/2012 Pfizer Inc. has expanded its research collaboration with Cystic Fibrosis Foundation Therapeutics Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508. Under the terms, CFFT will invest up to USD58 million to speed the discovery and development of potential therapies that target the underlying cause of cystic fibrosis.</p> <p>Deal Updated date : 10/07/2010 The agreement between FoldRx and Cystic Fibrosis Foundation Therapeutics Inc. was transferred to Pfizer Inc. as part of the acquisition of FoldRx by Pfizer.</p>

Deal Date	07/30/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into global development agreement with Hydra Biosciences to develop TRPV3-antagonist products for pain
Deal Status	Completed
Acquirer/Partner	
Source/Target	Hydra Biosciences Inc
Deal Value (USD mn)	195
Region/Country	Worldwide
Deal Details	Pfizer Global Research Development has entered into a collaboration agreement with Hydra Biosciences Inc. to develop TRPV3-antagonist product candidates for pain. Under the terms, Hydra will receive upfront and success-based development milestone payments of USD195 million for the first developed product launched and more for additional approved indications. Pfizer will fund all R&D under the agreement and will receive exclusive access to Hydra's TRPV3 patents as well as an exclusive license to commercialise any compound from the collaboration. Once the products are on the market, Pfizer will pay worldwide royalties to Hydra.
Updates/Amendments	

Deal Date	07/26/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Hydra Biosciences enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Hydra Biosciences Inc
Deal Value (USD mn)	195
Region/Country	United States
Deal Details	Hydra Biosciences has entered into an agreement with Pfizer Global Research & Development. The collaboration will be focused on TRPV3 antagonist product candidates for pain. Under the terms of the agreement, Hydra will receive upfront and success-based development milestone payments totaling USD195 million for the first developed product launched, with upside potential for additional approved indications. Pfizer will fund all research and development under the agreement and will receive exclusive access to Hydra's TRPV3 patents as well as an exclusive license to commercialize any compound from the collaboration. Once the products are on the market, Pfizer will pay worldwide royalties to Hydra.
Updates/Amendments	

Deal Date	04/26/2007
Deal Type	Partnership
Sub Category	Commercialization; Research and Discovery
Deal Headline	Bristol-Myers Squibb enters into collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Bristol Myers Squibb Company
Deal Value (USD mn)	1000 (Max)
Region/Country	Worldwide
Deal Details	Bristol- Myers Squibb Company entered into a worldwide collaboration with Pfizer Inc. to develop and commercialize Apixaban. Under the terms, an upfront payment of USD250 million will be paid by Pfizer to Bristol-Myers Squibb. Pfizer will fund 60percent of all planned development costs and Bristol-Myers Squibb will fund 40percent. Bristol-Myers Squibb may also receive additional payments of up to USD750 million based on development and regulatory milestones. The companies will jointly develop the clinical and marketing strategy of apixaban, and will share commercialization expenses and profits/losses equally on a global basis.
Updates/Amendments	

Deal Date	04/26/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Bristol-Myers Squibb enters into collaboration with Pfizer
Deal Status	Completed
Acquirer/Partner	Bristol Myers Squibb Company
Source/Target	Pfizer Inc
Deal Value (USD mn)	50
Region/Country	Worldwide
Deal Details	Bristol- Myers Squibb Company has entered into a worldwide collaboration with Pfizer Inc. for research, development and commercialization of a Pfizer discovery program which includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes.Under the terms, Pfizer will be responsible for all research and early-stage development activities for the metabolic disorders program, and the companies will jointly conduct Phase III development and commercialization activities. Bristol-Myers Squibb will make an upfront payment of USD50 million to Pfizer as part of this agreement. The companies will share all development and commercialization expenses along with profits/losses on a 60percent-40percent basis, with Pfizer assuming the larger share of both expenses and profit/losses.
Updates/Amendments	

Deal Date	04/20/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Patent-Exclusive
Deal Headline	Osi pharmaceuticals enters into licensing agreement with Pfizer for Macugen
Deal Status	Completed
Acquirer/Partner	OSI Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Rest of the World; Worldwide
Deal Details	Osi pharmaceuticals Inc. has entered into an exclusive licensing agreement with Pfizer Inc. to develop and commercialize Macugen in the rest of the world. Osi pharmaceuticals and Pfizer have also agreed to provide each other with certain transitional services related to Macugen.
Updates/Amendments	

Deal Date	04/09/2007
Deal Type	Partnership
Sub Category	Contract
Deal Headline	Pfizer enters agreement with Caliper for in vivo profiling experiments
Deal Status	Completed
Acquirer/Partner	Caliper Life Sciences Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with Caliper Life Sciences, Inc. Under the terms of agreement Caliper's Discovery Alliances & Services division will conduct certain in vivo profiling experiments for Pfizer. Under the one-year contract, Caliper will utilize its in vivo compound profiling platform to study the effects of acute or chronic drug dosing in mice to try and uncover new uses for compounds already in development.
Updates/Amendments	

Deal Date	04/04/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Research and Discovery
Deal Headline	Pfizer enters into agreement with pSivida
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Psivida Corp
Deal Value (USD mn)	168.8 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide collaborative research and licensing agreement with pSivida for pSivida's controlled drug delivery technologies in ophthalmic applications. Under the terms, pSivida will receive up to approximately AUD182 million in development and sales related milestones. The two companies will work together on a joint research program aimed at developing ophthalmic products using pSivida's sustained drug delivery technology. In addition to the milestone payments, Pfizer will fund the cost of the joint research program.</p>
Updates/Amendments	<p>Deal Updated date : 06/14/2011</p> <p>Pfizer Inc. and pSivida Corp have amended and restated its research and development agreement to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.</p> <p>Under this revised agreement, Pfizer will make an initial payment of USD2.3 million. pSivida will, with technical assistance from Pfizer, have the right to develop the glaucoma product candidate through Phase II clinical trials. At that point, Pfizer may exercise its option for an exclusive, worldwide license to develop and commercialize the product candidate in return for a USD20 million payment, double-digit royalty payments on any sales of the product and additional development, regulatory and sales performance milestone payments of up to USD146.5 million.</p> <p>If Pfizer does not exercise its option, pSivida will retain the right to develop and commercialize the glaucoma product on its own or with a partner. As part of the amended agreement, pSivida regains all rights to its intellectual property in ophthalmic applications previously included in the original research and collaboration agreement other than that required for the</p>

	Iatanoprost implant.
--	----------------------

Deal Date	04/02/2007
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into non-exclusive licensing agreement with Genencor
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Genencor International
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement with Genencor, where Pfizer was granted a non-exclusive license to technology that enhances the level of expression of secreted polypeptides in microorganisms for use in the development of protein therapeutics.
Updates/Amendments	

Deal Date	04/01/2007
Deal Type	Partnership
Sub Category	License
Deal Headline	Sigma-Aldrich enters into license agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Sigma Aldrich Corp
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Sigma-Aldrich has entered into agreement with Pfizer for a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.
Updates/Amendments	

Deal Date	02/22/2007
Deal Type	Partnership
Sub Category	Research and Discovery
Deal Headline	Entelos enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Entelos Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Entelos, Inc. and Pfizer have entered into research agreement. Entelos to continue research using the Entelos Cardiovascular PhysioLab platform.
Updates/Amendments	

Deal Date	02/15/2007
Deal Type	Partnership
Sub Category	License; Patent-Exclusive
Deal Headline	Pfizer enters into patent agreement with InSite Vision
Deal Status	Completed
Acquirer/Partner	Insite Vision Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a worldwide, exclusive royalty bearing licensing agreement with InSite Vision Incorporated under Pfizer's Patent family titled Method of Treating Eye Infections with Azithromycin. Pfizer's granting of this license will enhance the position and marketability of InSite's AzaSite franchise.</p> <p>Under the terms, Pfizer will grant InSite a worldwide, exclusive license, including the right to sublicense, to U.S. and all foreign counterparts patents on the parent case titled Method of Treating Eye Infections with Azithromycin and patent applications together with any reissues, extensions, or supplementary protection certificates of any of the foregoing for use in connection with InSite's AzaSite franchise products.</p>
Updates/Amendments	

Deal Date	02/05/2007
Deal Type	Venture Financing
Sub Category	Growth Capital/Expansion
Deal Headline	Genizon BioSciences completes CAD10 million Series D equity financing
Deal Status	Completed
Acquirer/Partner	BTF Pty Ltd; Pfizer Inc
Source/Target	Genizon BioSciences
Deal Value (USD mn)	8.44
Region/Country	Canada
Deal Details	Genizon BioSciences has completed CAD10 million Series D equity financing from Pfizer Inc. and existing investor BTF BV of Haarlem. Genizon will use the funds to conduct genome-wide association studies in the Quebec Founder Population and to enhance and commercialize discoveries already generated from previous studies.
Updates/Amendments	

Deal Date	02/01/2007
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer to acquire BioRexis Pharmaceutical Corp
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	BioRexis Pharmaceutical Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has entered into an agreement to acquire BioRexis Pharmaceutical Corp, a privately-held biopharmaceutical company with a number of diabetes candidates and a novel technology platform for developing new protein drug candidates. Financial terms of the agreement were not disclosed. The acquisition is a further step in Pfizer strategy to accelerate business development and licensing activity.
Updates/Amendments	<p>Deal Updated date : 03/31/2007</p> <p>Pfizer Inc. has acquired BioRexis Pharmaceutical Corp, a privately held biopharmaceutical company with a number of diabetes candidates and a novel technology platform for developing new protein drug candidates.</p> <p>Pfizer Inc. has entered into an agreement to acquire BioRexis Pharmaceutical Corp, a privately-held biopharmaceutical company with a number of diabetes candidates and a novel technology platform for developing new protein drug candidates. Financial terms of the agreement were not disclosed. The acquisition is a further step in Pfizer strategy to accelerate business development and licensing activity.</p>

Deal Date	01/29/2007
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into cardiac safety alliance with iCardiac Technologies
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	iCardiac Technologies Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into a multi-year research alliance with iCardiac Technologies, Inc. to develop and validate advanced ECG-based cardiac safety biomarkers utilizing the COMPAS technology platform. Under the terms, iCardiac and Pfizer will collaborate on a research program comprised of a series of studies, including retrospective and prospective ECG data analyses.</p> <p>Under the terms, iCardiac will receive an equity investment and technology license payment, plus research and development funding over the term of the alliance. iCardiac will retain commercial rights to the validated technology platform and new biomarkers for future application in cardiac safety clinical trials and technologies.</p>
Updates/Amendments	

Deal Date	01/24/2007
Deal Type	Partnership
Sub Category	Development; Research and Discovery
Deal Headline	Pfizer enters into agreement with MediVas
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	MediVas LLC
Deal Value (USD mn)	
Region/Country	Germany; United States
Deal Details	Pfizer Inc. has entered into a collaborative research agreement with MediVas, LLC. The agreement is focused on the research and development of advanced delivery methods for proprietary Pfizer compounds to treat diseases of the eye. By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, MediVas and Pfizer hope to create a product that can change the paradigm of how ophthalmic treatments are administered.
Updates/Amendments	

Deal Date	01/09/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; Research and Discovery
Deal Headline	Pfizer enters into collaboration with Archemix to discover aptamer therapeutics
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Archemix Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into an agreement with Archemix Corp. for the discovery of aptamers for the development and commercialization as therapeutics. As part of the collaboration, Archemix will use its proprietary SELEX technology to discover and generate product candidates to three disease-associated targets identified by Pfizer. Pfizer will be responsible for developing and commercializing the resulting product candidates.</p> <p>Under the terms of the agreement, Archemix will receive an upfront cash payment as well as research funding and development milestones. Archemix is also entitled to receive a royalty on any marketed products developed under the collaboration.</p>
Updates/Amendments	

Deal Date	01/09/2007
Deal Type	Partnership
Sub Category	License
Deal Headline	BaroFold Grants Protein Technology Research License to Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	BaroFold Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer, Inc. has entered into an agreement with BaroFold, Inc. where, Pfizer was granted a multi-site research license for BaroFold's proprietary PreEMT high pressure technology for solubilizing, disaggregating and refolding proteins. Pfizer joins several other biotechnology firms and pharmaceutical corporations who have licensed BaroFold's technology to refold and produce proteins.
Updates/Amendments	

Deal Date	01/08/2007
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into strategic drug discovery collaboration with PTC Therapeutics utilizing GEMS technology platform
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	PTC Therapeutics Inc
Deal Value (USD mn)	141 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide research collaboration and licensing agreement with PTC Therapeutics, Inc. for the development of pharmaceuticals through the application of PTC's GEMS, Gene Expression Modulation by Small-Molecules technology.</p> <p>Under the terms, Pfizer has made an initial upfront payment of USD10 million, will purchase an equity stake of USD10 million subject to certain closing conditions, and provide supportive funding for PTC's research efforts. At Pfizer's option, the collaboration may include up to 10 targets and PTC could earn up to USD121 million in milestones per target based on the achievement of certain development, regulatory, and commercial goals. Pfizer will receive exclusive worldwide rights and pay PTC royalties on worldwide net sales of any products resulting from this collaboration.</p>
Updates/Amendments	

Deal Date	01/04/2007
Deal Type	Partnership
Sub Category	Acquisition of Rights; Development; License; Option; Research and Discovery
Deal Headline	Pfizer enters into collaborative research and licensing agreement with Elusys
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Elusys Therapeutics Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. has entered into an exclusive collaborative research and licensing agreement with Elusys Therapeutics, Inc. to develop new therapeutics for diseases select infectious using Elusys' HP Antibody technology. The research collaboration will include ETI-211 in addition to research into other indications.</p> <p>Under the terms, Elusys and Pfizer will collaborate on determining the full product profile of ETI-211 and perform research on other indications of the HP Antibody technology. Elusys will receive an upfront equity investment, research and development funding plus near-term research milestones. Elusys has also granted Pfizer an option to acquire an exclusive worldwide license to products developed under the agreement, and upon exercise, the company will receive significant clinical and sales milestones, as well as royalties on future sales of products resulting from the collaboration.</p>
Updates/Amendments	

Deal Date	12/20/2006
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into licensing agreement with Kosan for motilin agonist program
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Kosan Biosciences Inc
Deal Value (USD mn)	262.5 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a worldwide licensing agreement with Kosan Biosciences Incorporated for Kosan's motilin agonist program. The agreement includes Kosan's clinical candidate, KOS-2187 and related compounds. Kosan and Pfizer will collaborate on filing of regulatory documents and initiation of a Phase 1 clinical trial of KOS-2187. Pfizer will be responsible for all development, regulatory and commercial activities related to the motilin agonist program.</p> <p>Under the terms, Kosan will receive an upfront payment of USD12.5 million and will be eligible to receive up to USD250 million for the successful development and commercialization of KOS-2187 for one indication, as well as royalties on worldwide sales. This total value of up to USD250 million includes development milestone payments of up to USD72.5 million. Should Pfizer elect to develop KOS-2187 for a second indication or to develop other Kosan compounds within the licensed rights, additional development and commercial milestones may be payable to Kosan as well as royalties on worldwide sales of any licensed Kosan product.</p>
Updates/Amendments	<p>Deal Updated date : 12/31/2008</p> <p>The agreement between Pfizer, Inc. and Kosan Biosciences Incorporated is assumed to be terminated as a result of the discontinuing the development of KOS-2187.</p>

Deal Date	11/06/2006
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Research and Discovery
Deal Headline	Wyeth enters into research and licensing agreement with Ablynx
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc; Wyeth Pharmaceutical Co Ltd
Source/Target	Ablynx nv
Deal Value (USD mn)	212.5 (Max)
Region/Country	Worldwide
Deal Details	<p>Wyeth and Ablynx NV have entered into an exclusive research collaboration and license agreement to discover, develop and commercialise Nanobodies directed at the tumour necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas. Ablynx has granted Wyeth exclusive worldwide rights to Nanobodies targeting the clinically validated target tumour necrosis factor alpha. Ablynx and Wyeth will collaborate to advance these novel biologics through preclinical development.</p> <p>Under the terms, Ablynx will receive an initial payment, research support and milestone payments. Potential payments to Ablynx could total up to USD212.5 million for the successful development and commercialisation of multiple products. In addition Ablynx will receive royalties on product sales.</p>
Updates/Amendments	<p>Deal Updated date : 11/04/2011</p> <p>Ablynx nv has regained worldwide rights from Pfizer Inc. to develop and commercialize Nanobodies targeting TNF-alpha. Under the terms, Pfizer returned all licensed rights including intellectual property. In return for these rights and assets, if an anti-TNF-alpha Nanobody is approved, Ablynx will share milestone payments it receives from any third party licensee with Pfizer, up to a capped amount of USD50 million, as well as pay a royalty on sales of such products.</p>

Deal Date	10/06/2006
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires PowderMed
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	PowderMed Inc
Deal Value (USD mn)	
Region/Country	United Kingdom
Deal Details	Pfizer Inc., has completed the acquisition of PowderMed Ltd., a privately held U.K. Company specializing in the emerging science of DNA-based vaccines. Financial terms of the deal were not disclosed.
Updates/Amendments	

Deal Date	10/06/2006
Deal Type	Partnership
Sub Category	Cross-License
Deal Headline	Aegerion Pharmaceuticals enters into collaboration with Pfizer and the University of Pennsylvania
Deal Status	Completed
Acquirer/Partner	University of Pennsylvania
Source/Target	Aegerion Pharmaceuticals Inc; Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Aegerion Pharmaceuticals Inc. has entered into collaboration with Pfizer Inc. and the University of Pennsylvania for a cross-licensing relationship covering a range of patents related to the use of microsomal triglyceride transfer protein inhibitors. Under the terms of the agreement, Aegerion can independently pursue product development opportunities involving MTP-based therapies as potential treatments to reduce LDL cholesterol. MTP inhibitors have been proven effective in reducing LDL.
Updates/Amendments	

Deal Date	09/18/2006
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Pfizer enters into agreement with TransTech
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	TransTech Pharma Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive worldwide licensing agreement with TransTech Pharma Inc. for the development and commercialization of small and large molecule compounds under development by TransTech. Pfizer gains exclusive worldwide rights to develop and commercialize TransTech's portfolio of RAGE modulators, TTP488 and TTP4000.</p> <p>Under the terms, TransTech will receive upfront and near-term milestone payments of USD155 million and the potential for significant additional milestone payments for the successful development and commercialization of multiple RAGE antagonists in several indications. TransTech will also receive royalties on worldwide sales of products. Pfizer will provide TransTech additional funding during the research term to support continued expansion of the RAGE portfolio.</p>
Updates/Amendments	

Deal Date	09/18/2006
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	vTv Therapeutics enters into agreement with Pfizer
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	vTv Therapeutics Inc
Deal Value (USD mn)	169.2
Region/Country	United States
Deal Details	<p>vTv Therapeutics, Inc., formerly TransTech Pharma, Inc. and Pfizer Inc. have entered into a licensing agreement for the development and commercialization of small and large molecule compounds under development by TransTech. These compounds target the receptor for advanced glycation end products and have potential use in the treatment of Alzheimer's disease. As per the terms, Pfizer gains exclusive worldwide rights to develop and commercialize TransTech's portfolio of receptor for advanced glycation end products modulators. The most advanced molecules are: x, an orally available small-molecule compound that has completed a Phase 2a study in Alzheimer's patients and is currently in a Phase 2 study in patients with diabetic nephropathy; and TTP4000, a large-molecule compound that is expected to enter Phase 1 clinical trials before the end of 2006.</p> <p>Under the terms, TransTech will receive USD169.2 million of upfront, milestone and research fees during 2006 to 2010 for the successful development and commercialization of multiple receptor for advanced glycation end products antagonists in several indications. TransTech will also receive royalties on worldwide sales of products.</p>
Updates/Amendments	<p>Deal Updated date : 12/01/2011</p> <p>vTv Therapeutics, Inc., formerly TransTech Pharma, Inc. and Pfizer Inc. have terminated agreement and TransTech Pharma reacquired azeliragon in 2011.</p>

Deal Date	09/01/2006
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into agreement with Quark Biotech for the treatment of neovascular wet age-related macular degeneration
Deal Status	Completed
Acquirer/Partner	Quark Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Inc. has entered into a licensing agreement with Quark Biotech Inc. for exclusive worldwide rights to a compound for the treatment of neovascular wet age-related macular degeneration.
Updates/Amendments	

Deal Date	09/01/2006
Deal Type	Partnership
Sub Category	Commercialization; Development; License
Deal Headline	Quark Pharmaceuticals enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Quark Pharmaceuticals Inc
Deal Value (USD mn)	608 (Max)
Region/Country	Worldwide
Deal Details	<p>Quark Pharmaceuticals Inc. and Pfizer have an exclusive worldwide license to develop and commercialize drug candidates that inhibit proprietary target gene RTP801 through RNAi. Under the agreement, Pfizer has the exclusive right to develop and commercialize drugs for both ophthalmic and non-ophthalmic indications.</p> <p>Under the terms of the agreement, Pfizer is responsible for all future preclinical and clinical development costs of the licensed drug candidates, as well as all regulatory filings and approvals. Pfizer had paid to Quark an aggregate of USD51.8 million in up-front fees, cost reimbursements and milestone payments. The agreement provides for up to USD299 million in additional development and product approval milestone payments. Pfizer is required to pay to Quark royalties on any sales of licensed products and up to an additional USD309 million of sales-based milestone payments.</p>
Updates/Amendments	

Deal Date	08/02/2006
Deal Type	Partnership
Sub Category	Infringement
Deal Headline	Novo Nordisk files patent infringement against Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Novo Nordisk AS
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Novo Nordisk Company has filed a lawsuit against Pfizer, Inc. claiming that Pfizer's product Exubera infringes patents owned by Novo Nordisk. The patents cover inhaled insulin treatment for diabetes. The lawsuit, filed in United States Federal Court in the Southern District of New York, alleges that Pfizer willfully infringed the patents and seeks compensatory damages. Novo Nordisk also announced it intends to file a motion for preliminary injunction seeking a court order that would prohibit Pfizer from continuing its unlawful conduct while the lawsuit is in progress.
Updates/Amendments	Deal Updated date : 12/10/2007 Novo Nordisk Inc. has settled a lawsuit against Pfizer claiming that Pfizer's product Exubera infringed patents owned by Novo Nordisk. The patents cover inhaled insulin treatment for diabetes.

Deal Date	06/14/2006
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into agreement with Bayer to license compounds for potential treatment of obesity, diabetes and related disorders
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Bayer Healthcare Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an agreement with Bayer Pharmaceuticals Corporation, subsidiary of Bayer HealthCare. Pursuant the terms, Pfizer was granted an exclusive worldwide rights to Bayer's DGAT-1 inhibitors, BAY 74-4113.</p> <p>Under the terms, Bayer will receive an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized.</p>
Updates/Amendments	

Deal Date	04/06/2006
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Rinat Neurosciences Corp
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Rinat Neuroscience Corp
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc., has completed the acquisition of Rinat Neuroscience Corp., a privately held biotechnology company that is developing therapeutic proteins for the treatment of diseases and disorders of the central nervous system. The financial terms of the transaction were not disclosed.</p> <p>Lazard and Covington and Burling advised Pfizer on this transaction. Lehman Brothers and Wilson, Sonsini, Goodrich and Rosati advised Rinat Neuroscience.</p>
Updates/Amendments	

Deal Date	03/23/2006
Deal Type	Partnership
Sub Category	Commercialization; License; Option; Research and Discovery
Deal Headline	NOXXON Pharma enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	NOXXON Pharma AG
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	NOXXON Pharma AG has entered into global collaboration with Pfizer Inc. regarding the discovery and development of Spiegelmer products. In addition, the two companies entered into an exclusive worldwide license agreement relating to NOXXON's preclinical lead Spiegelmer for treating obesity. Under the agreements, Pfizer will make upfront cash payments as well as R & D milestone payments. In addition, NOXXON is eligible to receive royalties on the sale of products commercialized under these agreements. Pfizer will also make an equity investment in NOXXON. Under the terms of the collaboration, NOXXON will use its Spiegelmer technology to create product candidates to disease-associated targets identified by Pfizer. Pfizer will have the option to select up to three targets per year to collaborate on with NOXXON. Under the license agreement, NOXXON granted to Pfizer an exclusive worldwide license to NOX-B11.
Updates/Amendments	

Deal Date	02/12/2006
Deal Type	Partnership
Sub Category	Commercialization; License
Deal Headline	King collaborates with Arrow
Deal Status	Completed
Acquirer/Partner	King Pharmaceuticals Holdings LLC
Source/Target	Arrow International Inc
Deal Value (USD mn)	110 (Max)
Region/Country	New Zealand
Deal Details	<p>King Pharmaceuticals, Inc. has entered into a collaboration with Arrow International Limited to commercialize one or more novel formulations of ramipril, the active ingredient in King's Altace product. Under a series of agreements, Arrow granted King rights to certain current and future new drug applications regarding novel formulations of ramipril and intellectual property, including patent rights and technology licenses relating to these novel formulations. Arrow will have responsibility for the manufacture and supply of the new formulations of ramipril for King.</p> <p>Upon execution of the agreements, King made an initial payment to Arrow of USD35 million. King made an additional payment of USD25 million to Arrow. Arrow will also receive future payments from King of USD50 million. Additionally, Arrow will earn fees for the manufacture and supply of the new formulations of ramipril.</p>
Updates/Amendments	

Deal Date	12/19/2005
Deal Type	Partnership
Sub Category	Commercialization; Development; Option
Deal Headline	Trubion Pharmaceuticals enters into collaboration agreement with Wyeth Pharmaceuticals
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc; Wyeth Pharmaceuticals Inc
Source/Target	Emergent Biosolutions Inc; Trubion PharmaceuticalsLtd Inc
Deal Value (USD mn)	452.5 (Max)
Region/Country	Worldwide
Deal Details	<p>Trubion Pharmaceuticals Inc has entered into collaboration agreement with Wyeth Pharmaceuticals, wholly-owned subsidiary of Pfizer Inc for the development and worldwide commercialization of CD20-directed therapeutics and non-CD20 targets.Under the agreement, Trubion provided research services for an initial three-year period ended December 22, 2008 with the option for Pfizer to extend the service period for two additional one-year periods.</p> <p>Pfizer will pay to Emergent upto USD250 million and up to USD200 million based on the achievement of specified regulatory and sales milestones for CD20-directed therapies and non-CD20 targets respectively. In addition, Emergent will receive royalty payments based on net sales.</p> <p>Note: Trubion Pharmaceuticals was acquired by Emergent Biosolutions Inc.</p>
Updates/Amendments	<p>Deal Updated date : 06/30/2008 Pfizer Inc exercised the first option under the terms of the agreement to extend the research period for an additional one-year period through December 22, 2009.</p> <p>Deal Updated date : 06/30/2009 Pfizer Inc exercised the second option under the terms of the agreement to extend the research period for an additional one-year period through December 22, 2010. Pfizer has retained a subset of the non-CD20 targets licensed from the Emergent and released the remaining targets.</p>

	<p>Deal Updated date : 05/31/2011</p> <p>Emergent BioSolutions Inc and Pfizer Inc have entered into a third amendment to the collaboration agreement ("Biosimilar Amendment") in which Emergent released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of the amendment, Emergent received USD2.5 million non-refundable payment upon execution of the agreement along with sales milestones.</p>
	<p>Deal Updated date : 09/30/2012</p> <p>Emergent BioSolutions Inc. has terminated agreement (Pfizer Agreement) with Pfizer. Emergent right to receive royalty payments under the Biosimilar amendment survives termination of the Pfizer agreement.</p>

Deal Date	11/21/2005
Deal Type	Partnership
Sub Category	Manufacturing; Marketing; Research and Discovery
Deal Headline	Incyte enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Incyte Corp
Deal Value (USD mn)	783 (Max)
Region/Country	Worldwide
Deal Details	Pfizer has entered into an agreement with Incyte Corporation to research, manufacture and market Incyte's anti-inflammatory CCR2 antagonist drugs. Under the agreement, Incyte will receive an upfront payment of USD40 million and will be eligible to receive additional milestone payments of up to USD743 million for the successful development and commercialization of CCR2 antagonists in multiple indications, as well as royalties on worldwide sales. Pfizer will gain exclusive worldwide development and commercialization rights to Incyte's portfolio of CCR2 antagonist compounds, the most advanced of which is currently in Phase IIa studies in rheumatoid arthritis and insulin-resistant obese patients. Pfizer will also provide research funding to Incyte to support the continued expansion of the CCR2 compound portfolio.
Updates/Amendments	

Deal Date	11/10/2005
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	King Pharmaceuticals enters into strategic alliance with Pain Therapeutics to develop and commercialize Remoxy
Deal Status	Terminated
Acquirer/Partner	King Pharmaceuticals Inc
Source/Target	Pain Therapeutics Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>King Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc. has entered into an exclusive worldwide strategic alliance with Pain Therapeutics, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. The companies will jointly manage Phase III and New Drug Application submissions in the U.S. King will have this responsibility outside the U.S. Upon regulatory approval, King will assume sole control and worldwide responsibility to exclusively commercialize Remoxy and other abuse-resistant opioid drugs. Pain Therapeutics retains all development and commercial rights in Australia and New Zealand.</p> <p>Under the terms of the agreement, King will make an upfront payment of USD150 million in cash to Pain Therapeutics. Pain Therapeutics could also receive additional milestone payments of up to USD150 million in cash based on the successful clinical and regulatory development of Remoxy and other abuse-resistant opioid products. This amount includes a USD15 million cash payment upon acceptance of a regulatory filing for Remoxy and an additional USD15 million upon its approval. King is responsible for all R&D expenses related to this alliance, which could total USD100 million. King will record net sales of all products and pay Pain Therapeutics a 20% royalty, except as to the first USD1 billion net in cumulative sales, which royalty is set at 15%. King is also responsible for the payment of third-party royalty obligations of Pain Therapeutics related to this alliance.</p>
Updates/Amendments	<p>Deal Updated date : 10/27/2014</p> <p>Pfizer Inc. has discontinued its collaboration agreement with Pain Therapeutics, Inc. to develop and commercialize REMOXY. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.</p>

Deal Date	09/28/2005
Deal Type	Partnership
Sub Category	Commercialization; License
Deal Headline	Eisai enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Eisai Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Eisai Inc., subsidiary of Eisai Co Ltd and Pfizer Inc. have entered into an in-license agreement for exclusive U.S. rights to promote FRAGMIN (dalteparin sodium injection), an anti-coagulant. Eisai also will assume responsibility for post-marketing studies and product distribution, as well as book all U.S. sales. According to this agreement, Pfizer will transfer the New Drug Application for FRAGMIN to Eisai for the duration of the deal.</p> <p>Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. With this agreement, Eisai aims to strengthen its position in critical care in the United States and help improve the quality of life for patients.</p>
Updates/Amendments	

Deal Date	08/15/2005
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Bioren
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Bioren Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc. has completed its acquisition of Bioren Inc. Under which Pfizer purchased all outstanding stock of Bioren for an undisclosed amount. Other terms of the deal are not disclosed.
Updates/Amendments	

Deal Date	08/04/2005
Deal Type	Venture Financing
Sub Category	Growth Capital/Expansion
Deal Headline	Aureon Laboratories completes USD20 million Series B financing
Deal Status	Completed
Acquirer/Partner	Atlas Venture; Pfizer Inc; Sprout Group; Undisclosed
Source/Target	Aureon Laboratories Inc
Deal Value (USD mn)	20
Region/Country	United States
Deal Details	Aureon Laboratories has completed USD20 million Series B financing from Atlas Venture, Sprout Group, Pfizer, and a consortium of European investors with expertise in the medical diagnostics industry. Proceeds from this financing Aureon will move aggressively toward concluding its clinical validation work and prepare for the commercial launch of its initial Prostate Px.
Updates/Amendments	

Deal Date	06/22/2005
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Rinat Vicuron
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Vicuron Pharmaceuticals Inc
Deal Value (USD mn)	1900 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc., has completed the acquisition of Vicuron Pharmaceuticals, Pennsylvania-based drug developer with two products under FDA review for USD1900 million or USD29.10 per share which is a 74 percent premium over Vicuron's 90-day average stock price, which closed at USD15.80 and shot up 77 percent in premarket trading.</p> <p>Lazard and Cadwalader, Wickersham & Taft LLP advised Pfizer in the transaction. Morgan Stanley and O'Melveny & Myers LLP advised Vicuron.</p>
Updates/Amendments	

Deal Date	03/24/2005
Deal Type	Partnership
Sub Category	Commercialization; Development; License; Manufacturing
Deal Headline	Pfizer enters into license agreement with Coley ProMune
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Coley Pharmaceutical Group Inc
Deal Value (USD mn)	505 (Max)
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive global licensing agreement with Coley Pharmaceutical Group to develop, manufacture and commercialize Coley's ProMune.</p> <p>Under the terms, Pfizer will make an initial payment of USD50 million to Coley, with the potential for up to USD455 million in additional milestone payments, plus royalties based on the successful development and commercialization of ProMune. Pfizer will fund future development of ProMune, including planned Phase III trials for the treatment of non-small cell lung cancer.</p>
Updates/Amendments	

Deal Date	02/24/2005
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Idun Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Idun Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Pfizer Inc has completed the acquisition of Idun Pharmaceuticals Inc., a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases. Financial terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	01/20/2005
Deal Type	Partnership
Sub Category	Development; License; Research and Discovery
Deal Headline	Pfizer and Rigel enters into collaborative agreement for the treatment of allergic asthma and other respiratory diseases
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Rigel Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into a worldwide collaborative research and licensing agreement with Rigel Pharmaceuticals, Inc. for the development of inhaled products for the treatment of allergic asthma and other respiratory diseases such as chronic obstructive pulmonary disease. The collaboration is focused on Rigel's preclinical small molecule compounds.</p> <p>Under the terms of the agreement, Rigel will receive an upfront cash payment, as well as milestone payments and royalties on any future product sales. Pfizer will make an equity investment in Rigel and will be responsible for the worldwide development and commercialization of any resulting products. Financial terms of the agreement were not announced.</p>
Updates/Amendments	<p>Deal Updated date : 05/06/2011</p> <p>Pfizer Inc. has terminated the agreement and returned rights to an early-stage asthma drug, R343 to Rigel Pharmaceuticals Inc.</p>

Deal Date	01/20/2005
Deal Type	Partnership
Sub Category	Development; License; Research and Discovery
Deal Headline	Rigel Pharmaceuticals enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Rigel Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Rigel Pharmaceuticals Inc. and Pfizer Inc. have entered into a research collaborative and licensing agreement for the development of inhaled products for the treatment of allergic asthma and other respiratory diseases, such as chronic obstructive pulmonary disease. The collaboration is focused on Rigel's preclinical small molecule compounds, which inhibit IgE receptor signaling in respiratory tract mast cells by blocking the signaling enzyme Syk kinase. Under the terms of the agreement, Rigel will receive an upfront cash payment, as well as milestone payments and royalties on any future product sales. Pfizer will make an equity investment in Rigel and will be responsible for the worldwide development and commercialization of any resulting products.
Updates/Amendments	

Deal Date	01/20/2005
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Angiosyn
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Angiosyn Inc
Deal Value (USD mn)	527 (Max)
Region/Country	United States
Deal Details	<p>Pfizer Inc. has acquired Angiosyn Inc., a privately held biopharmaceutical company. The acquisition extends Pfizer's research commitment in ophthalmology and allows the company to further develop Angiosyn's novel angiostatic agent.</p> <p>Under the agreement, Angiosyn would be merged into a wholly-owned subsidiary of Pfizer, and Angiosyn's stockholders would receive an upfront payment and other compensation, which together total up to USD527 million, plus royalties on future sales. Full payment is contingent on successful completion of commercial development for an ophthalmic indication and a second therapeutic area.</p>
Updates/Amendments	

Deal Date	12/21/2004
Deal Type	Partnership
Sub Category	Development; License; Manufacturing; Marketing; Sales
Deal Headline	Pfizer Animal Health enters into license agreement with Immucell
Deal Status	Terminated
Acquirer/Partner	Pfizer Animal Health MA EEIG
Source/Target	Immucell Corp
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	Pfizer Animal Health, a division of Pfizer, Inc. has entered into an exclusive worldwide product development and marketing agreement with Immucell Corporation for Mast Out. Immucell granted Pfizer a worldwide, exclusive, long-term license to sell the product. Under the terms, IMMUCELL received an upfront payment of USD1.5 million from Pfizer and are eligible to receive contingent milestone payments and royalties on sales. Pfizer will be responsible for clinical, regulatory and commercial manufacturing development.
Updates/Amendments	Deal Updated date : 07/19/2007 Pfizer Animal Health, a division of Pfizer, Inc. has terminated its exclusive worldwide product development and marketing agreement with Immucell Corporation for Mast Out.

Deal Date	05/31/2004
Deal Type	Partnership
Sub Category	Co-Development; Co-Promotion
Deal Headline	Yamanouchi enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Yamanouchi Pharmaceutical Co Ltd
Deal Value (USD mn)	
Region/Country	Japan
Deal Details	Yamanouchi Pharmaceutical Co Ltd has entered into agreement with Pfizer Inc. in order to restructure the existing partnership between the two companies in Japan. Under the terms of agreement, Yamanouchi and Pfizer reaffirm that they will co-develop and co-promote the COX-2 inhibitor compounds valdecoxib* and parecoxib* in Japan.
Updates/Amendments	

Deal Date	12/01/2003
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Esperion
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Esperion Therapeutics Inc
Deal Value (USD mn)	1300
Region/Country	United States
Deal Details	Pfizer Inc. has completed the acquisition of Esperion Therapeutics, Inc., a biopharmaceutical company. Pursuant to this agreement, Pfizer made a cash tender offer to acquire the shares of Esperion stock for USD1300 million at a price of USD35 per share, subject to certain conditions. This price represents a 54 percent premium over Esperion's average closing share price during the last 20 trading days.
Updates/Amendments	

Deal Date	05/30/2003
Deal Type	Partnership
Sub Category	Marketing
Deal Headline	Novo Nordisk A/S enters into agreement with Pfizer
Deal Status	Terminated
Acquirer/Partner	Pfizer Inc
Source/Target	Novo Nordisk AS
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Novo Nordisk A/S has entered into agreement with Pfizer (originally Pharmacia & Upjohn) has attempted to terminate the license agreement under which Pfizer markets Novo Nordisk's portfolio of hormone replacement therapy (HRT) products in the United States. Novo Nordisk disputes Pfizer's ability to terminate the agreement, which covers the currently marketed products Activella and Vagifem.
Updates/Amendments	

Deal Date	12/19/2002
Deal Type	Partnership
Sub Category	Commercialization; Development
Deal Headline	Pfizer enters into agreement with Neurocrine Biosciences to develop, promote Insomnia treatment
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Neurocrine Biosciences Inc
Deal Value (USD mn)	400
Region/Country	Worldwide
Deal Details	<p>Pfizer Inc. has entered into an exclusive global agreement with Neurocrine Biosciences Inc. for the development and commercialization of indiplon, Neurocrine's Phase III compound for the treatment of insomnia.</p> <p>Under terms of the collaboration, Neurocrine will receive an initial payment of USD100 million and up to USD300 million in milestone payments. Pfizer will fund the ongoing development of indiplon and pay royalties on worldwide sales and co-promotion fees in the United States.</p>
Updates/Amendments	

Deal Date	12/01/2002
Deal Type	Partnership
Sub Category	Co-Development; Co-Promotion; Commercialization
Deal Headline	Osi pharmaceuticals enters into development and commercialization agreement with Pfizer for Macugen
Deal Status	Terminated
Acquirer/Partner	OSI Pharmaceuticals Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	Worldwide
Deal Details	<p>Osi pharmaceuticals Inc. has entered into an agreement with Pfizer to jointly develop and commercialize Macugen for the prevention and treatment of diseases of the eye and related conditions.</p> <p>Under the terms, the parties' will share profits and losses from the commercialization of Macugen in the United States. The payment of royalties to Osi pharmaceuticals by Pfizer based on net sales of Macugen outside the United States extends, on a country-by-country basis, until the later of 15 years after commercial launch and the expiration of the patent rights licensed to Pfizer in each particular country. The royalty rate on net sales of Macugen outside the United States is reduced on a country-by-country basis to the extent that the patent rights in a particular country expire or a generic form of Macugen is marketed in that country.</p>
Updates/Amendments	<p>Deal Updated date : 04/20/2007</p> <p>Osi pharmaceuticals Inc. has terminated an agreement with Pfizer with respect to the co-promotion of Macugen in the United States.</p>

Deal Date	07/25/2002
Deal Type	Partnership
Sub Category	Distribution; Manufacturing; Marketing; Sales
Deal Headline	Eisai enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Eisai Inc
Source/Target	Pfizer Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. has entered into a collaborative agreement with Pfizer Inc. in which Eisai has exclusive U.S. rights to promote Pfizer's anti-seizure product, Cerebyx (fosphenytoin sodium injection). Under this agreement, Eisai will be responsible for sales and marketing, while Pfizer will be responsible for manufacturing and distribution in the U.S.
Updates/Amendments	

Deal Date	07/15/2002
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Pharmacia
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Pharmacia Corp
Deal Value (USD mn)	60000
Region/Country	Sweden
Deal Details	<p>Pfizer Inc., has completed the acquisition of Pharmacia Corporation in a stock-for-stock transaction valued at USD60000 million, expanding the company's core strengths in pharmaceuticals and health care.</p> <p>Under the transaction, Board of Directors of Pharmacia intends to proceed with its previously announced spin-off of its remaining 84% ownership of Monsanto to its current shareholders. After the Monsanto spin-off, Pfizer exchange 1.4 shares of Pfizer common stock for each outstanding share of Pharmacia stock in a tax-free transaction valued at USD45.08 per Pharmacia share, based on Pfizer's July 12 closing stock price of USD32.20. This transaction represents a 44% premium based on the average closing prices of the two stocks over the last 30 days, adjusted for the Monsanto spin-off. Pfizer's shareholders own approximately 77% of the combined company, and Pharmacia's shareholders own approximately 23%.</p> <p>Pfizer was advised by Lazard and Bear Stearns & Co. Inc. Pharmacia was advised by Goldman, Sachs & Co. Cadwalader, Wickersham and Taft provided legal counsel to Pfizer and Sullivan & Cromwell provided legal counsel to Pharmacia.</p>
Updates/Amendments	

Deal Date	12/12/2001
Deal Type	Partnership
Sub Category	License
Deal Headline	Pfizer enters into asthma collaboration with Entelos
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Entelos Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	<p>Pfizer Inc. and Entelos, Inc. have entered into a science and technology collaboration agreement. Pfizer will provide research funding and license fees to Entelos, as well as success fees for achieving specific research objectives. Entelos will also receive milestone payments for certain novel biological insights and biomarkers accepted by Pfizer.</p> <p>Under the terms, Entelos scientists will prioritize specific Pfizer asthma drug candidates based on their predicted clinical efficacy using Entelos Asthma PhysioLab technology. Entelos will also analyze phenotypic response patterns, as simulated in normal and asthmatic patients, to recommend appropriate treatment for each phenotype. As part of the research effort, Entelos aims to identify novel insights related to the therapeutic efficacy of certain respiratory pathways as well as novel biomarkers of drug response.</p>
Updates/Amendments	<p>Deal Updated date : 06/23/2010</p> <p>Entelos, Inc. has expanded the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and it's PhysioLab Simulation Server.</p>

Deal Date	10/10/2001
Deal Type	Partnership
Sub Category	Development; Research and Discovery; Sub-License
Deal Headline	Lexicon enters an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Lexicon Pharmaceuticals Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Lexicon Genetics Incorporated has signed an agreement with Pfizer Inc a non-exclusive, internal research use of Lexicon's isogenic DNA technology in gene targeting under the patent covering. Pfizer already holds a non-exclusive license from Lexicon for internal research use of Lexicon's patented positive-negative selection technology. Financial details were not disclosed.
Updates/Amendments	

Deal Date	09/26/2001
Deal Type	Partnership
Sub Category	Acquisition of Rights
Deal Headline	Lexicon enters into an agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Lexicon Genetics Inc
Deal Value (USD mn)	
Region/Country	United States
Deal Details	Lexicon Genetics Incorporated has signed an agreement with Pfizer Inc for sale of chemical compounds to Pfizer Inc for non-exclusive use in Pfizer's internal drug discovery programs. Financial terms of the agreement were not disclosed.
Updates/Amendments	

Deal Date	04/11/2001
Deal Type	Partnership
Sub Category	Marketing
Deal Headline	Boehringer Ingelheim enters into agreement with Pfizer
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Boehringer Ingelheim GmbH
Deal Value (USD mn)	
Region/Country	Germany; Worldwide
Deal Details	Boehringer Ingelheim and Pfizer Inc have entered into a long-term worldwide agreement to jointly market Spiriva (tiotropium), a novel once-a-day inhaled treatment for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema. Under terms of the agreement, Boehringer Ingelheim and Pfizer will conduct additional clinical trials and further develop Spiriva.
Updates/Amendments	

Deal Date	02/07/2000
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Warner Lambert
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Warner Lambert Company LLC
Deal Value (USD mn)	90000
Region/Country	United States
Deal Details	Pfizer Inc. has completed the acquisition of Warner-Lambert Company. Under the terms, Pfizer exchanged 2.75 shares of common stock for each outstanding share of Warner-Lambert common stock in a tax-free transaction valued at USD98.31 per Warner-Lambert share, or an equity value of USD90000 million.
Updates/Amendments	

Deal Date	01/31/1995
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires SmithKline Beecham Animal Health
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	SmithKline Beecham Plc
Deal Value (USD mn)	1500
Region/Country	United Kingdom
Deal Details	Pfizer Inc. has acquired SmithKline Beecham Animal Health business for approximately USD1500 million. The acquired business has been fully integrated into the Pfizer's animal health business.
Updates/Amendments	

Deal Date	11/01/1994
Deal Type	Partnership
Sub Category	Co-Promotion
Deal Headline	Pfizer enters into agreement with Eisai
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Eisai Co Ltd
Deal Value (USD mn)	
Region/Country	Albania; Andorra; Austria; Belgium; Bosnia and Herzegovina; Bulgaria; Channel Islands; Croatia; Czech Republic; Denmark; Estonia; Faroe Islands; Finland; France; Germany; Gibraltar; Greece; Guernsey; Hungary; Iceland; Ireland; Isle of Man; Italy; Japan; Jersey; Latvia; Liechtenstein; Lithuania; Luxembourg; Macedonia; Malta; Moldova; Monaco; Netherlands; Norway; Poland; Portugal; Romania; San Marino; Scotland; Seborga; Serbia; Slovakia; Slovenia; Spain; Sweden; Switzerland; United Kingdom; United States
Deal Details	Pfizer Inc. has entered into an agreement with Eisai Co. Ltd. for the promotion of ARICEPT and development of new treatments for Alzheimer's disease and other cognitive disorders. Under the terms, Eisai will book all United States sales of ARICEPT.
Updates/Amendments	Deal Updated date : 03/25/2009 Pfizer Inc. will continue to co-promote Aricept in the United States, Japan and key markets in Europe.

Deal Date	12/31/1993
Deal Type	Mergers & Acquisitions
Sub Category	100% Acquisition
Deal Headline	Pfizer acquires Charwell Pharmaceuticals
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Chartwell Pharmaceuticals
Deal Value (USD mn)	41.5 (Max)
Region/Country	United Kingdom
Deal Details	Pfizer Inc. has acquired Charwell Pharmaceuticals Ltd, a distributor of over-the-counter consumer health care products located in the United Kingdom, for approximately USD41.5 million.
Updates/Amendments	

Deal Date	12/31/1992
Deal Type	Mergers & Acquisitions
Sub Category	Asset Acquisition
Deal Headline	Pfizer acquires assets from Koshin Medical
Deal Status	Completed
Acquirer/Partner	Pfizer Inc
Source/Target	Undisclosed assets
Deal Value (USD mn)	16.4 (Max)
Region/Country	Japan
Deal Details	Pfizer Inc. has acquired certain assets and liabilities of Koshin Medical Corp., a distributor of hospital products in Japan, for approximately USD16.4 million. Other terms of the deal are not disclosed.
Updates/Amendments	

Sales

Sales by Product (USD mn)

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Aricept	Rest of the World	Annual	USD	454	450	326	235			
Aricept	Rest of the World	Q1	USD	107	99	94	62			
Aricept	Rest of the World	Q2	USD	103	106	84	59			
Aricept	Rest of the World	Q3	USD	106	117	71	52			
Aricept	Rest of the World	Q4	USD	117	115	77	62			
Aromasin	Rest of the World	Annual	USD	323	303	196	173			
Aromasin	Rest of the World	Q1	USD	86	76	52	48			
Aromasin	Rest of the World	Q2	USD	81	88	52				
Aromasin	Rest of the World	Q3	USD	72	77	48				
Aromasin	Rest of the World	Q4	USD	84	62	45	47			
Aromasin	United States	Annual	USD	160	58	14	12			
Aromasin	United States	Q1	USD	42	38	4	3			
Aromasin	United States	Q2	USD	41	7	3				
Aromasin	United States	Q3	USD	39	8	3				
Aromasin	United States	Q4	USD	38	5	3	3			
Aromasin	Worldwide	Annual	USD	483	361	210	185			
Aromasin	Worldwide	Q1	USD	128	114	56	51			
Aromasin	Worldwide	Q2	USD	122	95	55				
Aromasin	Worldwide	Q3	USD	111	85	51				
Aromasin	Worldwide	Q4	USD	122	67	48	50			
BeneFIX	Rest of the	Annual	USD	357	392	417	437	457	427	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
	World									
BeneFIX	Rest of the World	Q1	USD	87	93	98	101	109	104	104
BeneFIX	Rest of the World	Q2	USD	87	100	102	108	112	106	104
BeneFIX	Rest of the World	Q3	USD	89	102	105	112	122	114	104
BeneFIX	Rest of the World	Q4	USD	94	97	112	116	114	104	
BeneFIX	United States	Annual	USD	286	301	358	395	399	325	
BeneFIX	United States	Q1	USD	67	71	85	88	92	70	80
BeneFIX	United States	Q2	USD	77	76	91	109	115	87	79
BeneFIX	United States	Q3	USD	67	76	96	101	91	81	71
BeneFIX	United States	Q4	USD	75	78	86	97	102	87	
BeneFIX	Worldwide	Annual	USD	643	693	775	832	856	752	
BeneFIX	Worldwide	Q1	USD	154	164	183	189	201	173	184
BeneFIX	Worldwide	Q2	USD	164	176	193	217	227	193	183
BeneFIX	Worldwide	Q3	USD	156	178	201	213	212	194	176
BeneFIX	Worldwide	Q4	USD	169	175	198	213	216	191	
Caduet	Rest of the World	Annual	USD	188	266	225	200	181		
Caduet	Rest of the World	Q1	USD	49	61	56	51	45		
Caduet	Rest of the World	Q2	USD	42	69	54	50			
Caduet	Rest of the World	Q3	USD	41	70	55	47			
Caduet	Rest of the World	Q4	USD	56	66	60	52	50		
Caduet	United States	Annual	USD	339	272	33	23			
Caduet	United States	Q1	USD	86	81	9	5	5		
Caduet	United States	Q2	USD	84	74	4	6			
Caduet	United States	Q3	USD	86	80	13	5			

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Caduet	United States	Q4	USD	83	37	7	7	5		
Caduet	Worldwide	Annual	USD	527	538	258	223	180		
Caduet	Worldwide	Q1	USD	135	142	65	56	50		
Caduet	Worldwide	Q2	USD	126	143	58	56			
Caduet	Worldwide	Q3	USD	127	150	68	52			
Caduet	Worldwide	Q4	USD	139	103	67	59	54		
Cardura	Rest of the World	Annual	USD	401	375	333	292	260	207	
Cardura	Rest of the World	Q1	USD	99	94	83	75	65	51	44
Cardura	Rest of the World	Q2	USD	108	100	90	74	67	54	47
Cardura	Rest of the World	Q3	USD	94	91	77	69	63	51	48
Cardura	Rest of the World	Q4	USD	100	90	83	74	64	51	
Cardura	United States	Annual	USD	12	5	5	4	4	4	
Cardura	United States	Q1	USD	8	2	1	1	1	1	1
Cardura	United States	Q2	USD	2	1	1	1	1	1	1
Cardura	United States	Q3	USD	1	1	2	1	1	1	1
Cardura	United States	Q4	USD	1	1	1	1	1	1	
Cardura	Worldwide	Annual	USD	413	380	338	296	263	211	
Cardura	Worldwide	Q1	USD	107	96	84	76	66	52	45
Cardura	Worldwide	Q2	USD	110	101	91	75	68	55	48
Cardura	Worldwide	Q3	USD	95	92	79	70	64	52	49
Cardura	Worldwide	Q4	USD	101	91	84	75	64	52	
Celebrex	Rest of the World	Annual	USD	794	926	974	985	964	686	
Celebrex	Rest of the World	Q1	USD	182	208	227	229	222	183	146
Celebrex	Rest of the World	Q2	USD	206	231	238	238	242	166	153

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Celebrex	Rest of the World	Q3	USD	188	238	238	244	246	161	162
Celebrex	Rest of the World	Q4	USD	218	249	271	274	254	176	
Celebrex	United States	Annual	USD	1580	1597	1745	1933	1735	144	
Celebrex	United States	Q1	USD	388	383	407	424	402	22	26
Celebrex	United States	Q2	USD	398	391	421	477	520	58	30
Celebrex	United States	Q3	USD	390	405	438	508	517	51	33
Celebrex	United States	Q4	USD	404	418	479	524	295	14	
Celebrex	Worldwide	Annual	USD	2374	2523	2719	2918	2699	830	
Celebrex	Worldwide	Q1	USD	570	591	634	653	624	205	172
Celebrex	Worldwide	Q2	USD	604	622	659	715	762	224	183
Celebrex	Worldwide	Q3	USD	578	643	676	752	764	212	194
Celebrex	Worldwide	Q4	USD	622	667	750	798	550	190	
Chantix / Champix	Rest of the World	Annual	USD	425	394	357	305	269	245	
Chantix / Champix	Rest of the World	Q1	USD	83	105	86	79	61	61	61
Chantix / Champix	Rest of the World	Q2	USD	98	104	92	82	71	68	65
Chantix / Champix	Rest of the World	Q3	USD	89	88	84	72	65	56	56
Chantix / Champix	Rest of the World	Q4	USD	155	97	95	72	72	60	
Chantix / Champix	United States	Annual	USD	330	326	313	343	377	426	
Chantix / Champix	United States	Q1	USD	106	94	92	87	86	97	159
Chantix / Champix	United States	Q2	USD	72	86	80	84	99	106	148
Chantix / Champix	United States	Q3	USD	74	68	62	82	93	103	142
Chantix / Champix	United States	Q4	USD	78	78	79	90	100	120	
Chantix / Champix	Worldwide	Annual	USD	755	720	670	648	647	671	
Chantix / Champix	Worldwide	Q1	USD	189	199	178	166	147	158	220
Chantix /	Worldwide	Q2	USD	170	190	172	166	170	173	213

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Champix	Global									
Chantix / Champix	Worldwide	Q3	USD	163	156	146	154	158	159	198
Chantix / Champix	Worldwide	Q4	USD	233	175	174	162	172	180	
Dalacin/Cleocin	Rest of the World	Annual	USD	149	143	142	143	147		
Dalacin/Cleocin	Rest of the World	Q1	USD			34	33			
Dalacin/Cleocin	Rest of the World	Q2	USD		35	36				
Dalacin/Cleocin	Rest of the World	Q3	USD	37	36	34	35	39		
Dalacin/Cleocin	Rest of the World	Q4	USD	39	39	38	39	39		
Dalacin/Cleocin	United States	Annual	USD	65	59	90	56	37		
Dalacin/Cleocin	United States	Q1	USD			15	17			
Dalacin/Cleocin	United States	Q2	USD		17	17				
Dalacin/Cleocin	United States	Q3	USD	17	15	40	15	11		
Dalacin/Cleocin	United States	Q4	USD	10	14	18	11	8		
Dalacin/Cleocin	Worldwide	Annual	USD	214	192	232	199	184		
Dalacin/Cleocin	Worldwide	Q1	USD			49	50			
Dalacin/Cleocin	Worldwide	Q2	USD		52	53				
Dalacin/Cleocin	Worldwide	Q3	USD	54	51	74	50	50		
Dalacin/Cleocin	Worldwide	Q4	USD	53	53	56	50	46		
Depo Provera	Rest of the World	Annual	USD				134	141	113	
Depo Provera	Rest of the World	Q1	USD				28	33		
Depo Provera	Rest of the World	Q2	USD				35	33	34	21
Depo Provera	Rest of the World	Q3	USD				30	34	28	17
Depo Provera	Rest of the World	Q4	USD				41	41	27	
Depo	United	Annual	USD				57	60	57	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Provera	States									
Depo Provera	United States	Q1	USD				9	20		
Depo Provera	United States	Q2	USD				18	7	17	13
Depo Provera	United States	Q3	USD				20	20	17	18
Depo Provera	United States	Q4	USD				11	13	10	
Depo Provera	Worldwide	Annual	USD				191	201	170	
Depo Provera	Worldwide	Q1	USD				37	53		
Depo Provera	Worldwide	Q2	USD				53	40	51	34
Depo Provera	Worldwide	Q3	USD				50	54	45	36
Depo Provera	Worldwide	Q4	USD				52	54	37	
Detrol / Detrol LA	Rest of the World	Annual	USD	324	326	275	187	146		
Detrol / Detrol LA	Rest of the World	Q1	USD	85	84	72	48			
Detrol / Detrol LA	Rest of the World	Q2	USD	84	85	78	50	41		
Detrol / Detrol LA	Rest of the World	Q3	USD	74	77	64	42	34		
Detrol / Detrol LA	Rest of the World	Q4	USD	81	80	61	47	36		
Detrol / Detrol LA	United States	Annual	USD	689	557	486	375	54		
Detrol / Detrol LA	United States	Q1	USD	176	141	123	103			
Detrol / Detrol LA	United States	Q2	USD	176	145	127	105	16		
Detrol / Detrol LA	United States	Q3	USD	163	136	112	89	21		
Detrol / Detrol LA	United States	Q4	USD	174	135	124	78	16		
Detrol / Detrol LA	Worldwide	Annual	USD	1013	883	761	562	201		
Detrol / Detrol LA	Worldwide	Q1	USD	261	225	195	151			
Detrol / Detrol	Worldwide	Q2	USD	260	230	205	155	57		

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
LA										
Detrol / Detrol LA	Worldwide	Q3	USD	237	213	176	131	54		
Detrol / Detrol LA	Worldwide	Q4	USD	255	215	185	125	52		
Diflucan	Rest of the World	Annual	USD	272	260	255	239	213		
Diflucan	Rest of the World	Q1	USD				45	50		
Diflucan	Rest of the World	Q2	USD			64	59	45		
Diflucan	Rest of the World	Q3	USD	72	72	60	58	40		
Diflucan	Rest of the World	Q4	USD	72	62	74	77	78		
Diflucan	United States	Annual	USD	6	5	4	3	7		
Diflucan	United States	Q1	USD					2		
Diflucan	United States	Q2	USD			3	1	1		
Diflucan	United States	Q3	USD	2		1	1	2		
Diflucan	United States	Q4	USD	1	2		1	2		
Diflucan	Worldwide	Annual	USD	278	265	259	242	220		
Diflucan	Worldwide	Q1	USD				45	52		
Diflucan	Worldwide	Q2	USD			67	60	46		
Diflucan	Worldwide	Q3	USD	74	72	61	59	42		
Diflucan	Worldwide	Q4	USD	73	64	74	78	80		
Effexor	Rest of the World	Annual	USD	492	436	316	267	234	193	
Effexor	Rest of the World	Q1	USD	124	104	88	69	56	51	45
Effexor	Rest of the World	Q2	USD	129	113	82	69	60	47	47
Effexor	Rest of the World	Q3	USD	117	113	70	60	60	46	48
Effexor	Rest of the World	Q4	USD	122	106	76	69	58	50	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Effexor	United States	Annual	USD	1226	242	109	173	110	95	
Effexor	United States	Q1	USD	592	100	41	36	26	23	25
Effexor	United States	Q2	USD	492	55	24	56	36	27	20
Effexor	United States	Q3	USD	58	52	37	36	26	20	22
Effexor	United States	Q4	USD	84	35	7	45	22	25	
Effexor	Worldwide	Annual	USD	1718	678	425	440	344	288	
Effexor	Worldwide	Q1	USD	716	204	129	105	82	73	70
Effexor	Worldwide	Q2	USD	621	168	106	125	96	74	67
Effexor	Worldwide	Q3	USD	175	165	107	96	86	66	70
Effexor	Worldwide	Q4	USD	206	141	83	114	80	74	
Enbrel	Rest of the World	Annual	USD	3274	3666	3737	3774	3850	3333	
Enbrel	Rest of the World	Q1	USD	802	870	899	877	914	759	733
Enbrel	Rest of the World	Q2	USD	808	914	988	960	977	822	766
Enbrel	Rest of the World	Q3	USD	799	957	893	932	955	844	701
Enbrel	Rest of the World	Q4	USD	865	925	957	1005	1004	907	
EpiPen	Rest of the World	Annual	USD				60	54	66	
EpiPen	Rest of the World	Q1	USD			7	10	8	8	7
EpiPen	Rest of the World	Q2	USD			13	19	13	15	14
EpiPen	Rest of the World	Q3	USD		12	15	18	19	15	18
EpiPen	Rest of the World	Q4	USD				14	14	28	
EpiPen	United States	Annual	USD				213	240	273	
EpiPen	United States	Q1	USD			51	62	55	68	90
EpiPen	United States	Q2	USD			79	54	76	70	79

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
EpiPen	United States	Q3	USD		47	52	67	60	91	91
EpiPen	United States	Q4	USD				30	50	43	
EpiPen	Worldwide	Annual	USD				273	294	339	
EpiPen	Worldwide	Q1	USD			58	72	63	76	97
EpiPen	Worldwide	Q2	USD			92	73	89	85	93
EpiPen	Worldwide	Q3	USD		59	67	85	79	107	110
EpiPen	Worldwide	Q4	USD				44	64	71	
Fragmin	Rest of the World	Annual	USD	301	339	339	336	358	312	
Fragmin	Rest of the World	Q1	USD	72	77	79	76	81	73	70
Fragmin	Rest of the World	Q2	USD	75	88	88	85	92	80	74
Fragmin	Rest of the World	Q3	USD	71	86	80	81	88	77	73
Fragmin	Rest of the World	Q4	USD	83	88	92	94	97	82	
Fragmin	United States	Annual	USD	40	43	42	23	6	24	
Fragmin	United States	Q1	USD	18	14	12	10		1	8
Fragmin	United States	Q2	USD	9	9	13	9	3	8	8
Fragmin	United States	Q3	USD	13	9	11	2	1	8	7
Fragmin	United States	Q4	USD		11	6	2	1	8	
Fragmin	Worldwide	Annual	USD	341	382	381	359	364	335	
Fragmin	Worldwide	Q1	USD	90	91	91	86	81	74	78
Fragmin	Worldwide	Q2	USD	84	97	101	94	95	88	82
Fragmin	Worldwide	Q3	USD	84	95	91	83	90	84	80
Fragmin	Worldwide	Q4	USD	83	99	98	96	98	89	
Genotropin	Rest of the World	Annual	USD	676	684	628	573	539	454	
Genotropin	Rest of the World	Q1	USD	161	163	154	142	129	107	100
Genotropin	Rest of	Q2	USD	173	178	162	145	138	117	115

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
pin	the World									
Genotropin	Rest of the World	Q3	USD	160	169	153	138	136	109	113
Genotropin	Rest of the World	Q4	USD	182	174	159	148	136	121	
Genotropin	United States	Annual	USD	209	205	204	199	184	162	
Genotropin	United States	Q1	USD	45	46	41	47	37	32	25
Genotropin	United States	Q2	USD	60	52	50	53	56	50	37
Genotropin	United States	Q3	USD	51	46	59	45	37	32	34
Genotropin	United States	Q4	USD	53	61	54	54	54	48	
Genotropin	Worldwide	Annual	USD	885	889	832	772	723	617	
Genotropin	Worldwide	Q1	USD	206	209	195	189	166	138	125
Genotropin	Worldwide	Q2	USD	233	230	212	198	194	167	152
Genotropin	Worldwide	Q3	USD	211	215	212	183	173	142	147
Genotropin	Worldwide	Q4	USD	235	235	213	202	190	169	
Geodon / Zeldox	Rest of the World	Annual	USD	163	163					
Geodon / Zeldox	Rest of the World	Q1	USD	41	38					
Geodon / Zeldox	Rest of the World	Q2	USD	42	42					
Geodon / Zeldox	Rest of the World	Q3	USD	38	46					
Geodon / Zeldox	Rest of the World	Q4	USD	42	37					
Geodon / Zeldox	United States	Annual	USD	864	859					
Geodon / Zeldox	United States	Q1	USD	213	194					
Geodon / Zeldox	United States	Q2	USD	205	216					
Geodon / Zeldox	United States	Q3	USD	224	217					
Geodon / Zeldox	United States	Q4	USD	222	232					
Geodon / Zeldox	Worldwide	Annual	USD	1027	1022					
Geodon /	Worldwide	Q1	USD	254	232					

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Zeldox	e									
Geodon / Zeldox	Worldwide	Q2	USD	247	258					
Geodon / Zeldox	Worldwide	Q3	USD	262	263					
Geodon / Zeldox	Worldwide	Q4	USD	264	269					
Ibrance	Rest of the World	Q1	USD							7
Ibrance	Rest of the World	Q2	USD							12
Ibrance	Rest of the World	Q3	USD							19
Ibrance	United States	Q1	USD							422
Ibrance	United States	Q2	USD							502
Ibrance	United States	Q3	USD							531
Ibrance	Worldwide	Q1	USD							429
Ibrance	Worldwide	Q2	USD							514
Ibrance	Worldwide	Q3	USD							550
Inlyta	Rest of the World	Annual	USD			18	164	222	225	
Inlyta	Rest of the World	Q1	USD				28	48	52	57
Inlyta	Rest of the World	Q2	USD				36	56	57	63
Inlyta	Rest of the World	Q3	USD			1	41	56	56	59
Inlyta	Rest of the World	Q4	USD			17	59	62	60	
Inlyta	United States	Annual	USD			82	155	188	205	
Inlyta	United States	Q1	USD			7	35	40	44	44
Inlyta	United States	Q2	USD			17	35	45	54	45
Inlyta	United States	Q3	USD			28	42	46	48	36
Inlyta	United States	Q4	USD			30	43	58	59	
Inlyta	Worldwide	Annual	USD			100	319	410	430	
Inlyta	Worldwide	Q1	USD			7	63	88	95	101

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Inlyta	Worldwide	Q2	USD			17	71	101	111	108
Inlyta	Worldwide	Q3	USD			29	83	102	105	95
Inlyta	Worldwide	Q4	USD			47	102	119	119	
Inspra	Rest of the World	Annual	USD	152	191	209	227	230		
Inspra	Rest of the World	Q1	USD			48	51	60		
Inspra	Rest of the World	Q2	USD			54	57	61		
Inspra	Rest of the World	Q3	USD	36	50	50	52	56		
Inspra	Rest of the World	Q4	USD	43	52	57	67	54		
Inspra	United States	Annual	USD	5	4	5	6	3		
Inspra	United States	Q1	USD			1	1	1		
Inspra	United States	Q2	USD			2	2	1		
Inspra	United States	Q3	USD	1	1	1	1	1		
Inspra	United States	Q4	USD	1	1	1	2			
Inspra	Worldwide	Annual	USD	157	195	214	233	233		
Inspra	Worldwide	Q1	USD			49	52	61		
Inspra	Worldwide	Q2	USD			56	59	62		
Inspra	Worldwide	Q3	USD	37	51	51	53	57		
Inspra	Worldwide	Q4	USD	44	53	58	69	54		
Lipitor	Rest of the World	Annual	USD	5404	4574	3016	1883	1820	1699	
Lipitor	Rest of the World	Q1	USD	1447	1080	1012	455	407	402	369
Lipitor	Rest of the World	Q2	USD	1500	1179	924	459	447	469	417
Lipitor	Rest of the World	Q3	USD	1236	1132	557	455	452	413	394
Lipitor	Rest of the	Q4	USD	1221	1183	523	514	514	416	

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
	World									
Lipitor	United States	Annual	USD	5329	5003	932	432	242	161	
Lipitor	United States	Q1	USD	1310	1305	383	171	50	39	42
Lipitor	United States	Q2	USD	1313	1412	296	86	96	40	44
Lipitor	United States	Q3	USD	1298	1470	192	78	38	41	27
Lipitor	United States	Q4	USD	1408	816	61	97	58	41	
Lipitor	Worldwide	Annual	USD	10733	9577	3948	2315	2061	1860	
Lipitor	Worldwide	Q1	USD	2757	2385	1395	626	457	441	411
Lipitor	Worldwide	Q2	USD	2813	2591	1220	545	543	509	461
Lipitor	Worldwide	Q3	USD	2534	2602	749	533	490	454	422
Lipitor	Worldwide	Q4	USD	2629	1999	584	611	572	456	
Lyrica	Rest of the World	Annual	USD	1639	2179	2486	2632	2853	993	
Lyrica	Rest of the World	Q1	USD	371	462	560	628	636	565	446
Lyrica	Rest of the World	Q2	USD	397	535	631	643	714	568	473
Lyrica	Rest of the World	Q3	USD	401	582	606	626	732	244	454
Lyrica	Rest of the World	Q4	USD	470	600	689	735	771	267	
Lyrica	United States	Annual	USD	1424	1514	1672	1963	2315	2662	
Lyrica	United States	Q1	USD	352	364	395	438	514	621	782
Lyrica	United States	Q2	USD	365	373	404	491	601	651	788
Lyrica	United States	Q3	USD	356	379	430	509	585	703	786
Lyrica	United States	Q4	USD	351	398	443	525	614	687	
Lyrica	Worldwide	Annual	USD	3063	3693	4158	4595	5168	3655	
Lyrica	Worldwide	Q1	USD	723	826	955	1066	1150	1187	1229
Lyrica	Worldwide	Q2	USD	762	908	1035	1134	1315	1219	1261
Lyrica	Worldwide	Q3	USD	757	961	1036	1135	1317	947	1240
Lyrica	Worldwide	Q4	USD	821	998	1132	1260	1385	955	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Medrol	Rest of the World	Annual	USD	342	358	383	316	269	182	
Medrol	Rest of the World	Q1	USD	84	87	96	73	63	56	38
Medrol	Rest of the World	Q2	USD	83	86	98	84	72	59	44
Medrol	Rest of the World	Q3	USD	86	94	89	76	66	58	42
Medrol	Rest of the World	Q4	USD	89	91	100	83	68	50	
Medrol	United States	Annual	USD	113	152	140	148	174	220	
Medrol	United States	Q1	USD	25	34	38	40	43	45	76
Medrol	United States	Q2	USD	30	49	43	39	43	54	71
Medrol	United States	Q3	USD	33	33	24	31	35	54	61
Medrol	United States	Q4	USD	25	36	35	38	53	68	
Medrol	Worldwide	Annual	USD	455	510	523	464	443	402	
Medrol	Worldwide	Q1	USD	109	121	134	113	106	101	114
Medrol	Worldwide	Q2	USD	113	135	141	123	115	113	115
Medrol	Worldwide	Q3	USD	119	127	113	107	101	112	102
Medrol	Worldwide	Q4	USD	114	127	135	121	121	118	
Neurontin	Rest of the World	Annual	USD	244	226	187	171	164	149	
Neurontin	Rest of the World	Q1	USD			45	42	37	42	32
Neurontin	Rest of the World	Q2	USD			50	45	47	36	35
Neurontin	Rest of the World	Q3	USD	59	53	40	38	39	35	34
Neurontin	Rest of the World	Q4	USD	63	21	52	46	40	36	
Neurontin	United States	Annual	USD	78	63	48	45	47	47	
Neurontin	United States	Q1	USD			13	10	12	13	12
Neurontin	United	Q2	USD			12	11	11	12	12

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Neurontin	United States	Q3	USD	21	14	12	12	12	10	11
Neurontin	United States	Q4	USD	21	12	11	12	12	12	
Neurontin	Worldwide	Annual	USD	322	289	235	216	210	196	
Neurontin	Worldwide	Q1	USD			58	52	49	55	44
Neurontin	Worldwide	Q2	USD			62	56	58	48	47
Neurontin	Worldwide	Q3	USD	80	67	52	50	51	45	45
Neurontin	Worldwide	Q4	USD	84	55	63	58	52	48	
Norvasc	Rest of the World	Annual	USD	1473	1422	1301	1190	1073	955	
Norvasc	Rest of the World	Q1	USD	355	347	320	291	267	243	227
Norvasc	Rest of the World	Q2	USD	411	366	337	303	272	242	230
Norvasc	Rest of the World	Q3	USD	330	345	306	292	262	232	228
Norvasc	Rest of the World	Q4	USD	377	364	338	304	272	239	
Norvasc	United States	Annual	USD	33	23	48	39	39	36	
Norvasc	United States	Q1	USD	13	9	14	10	11	9	9
Norvasc	United States	Q2	USD	11	9	11	10	10	9	10
Norvasc	United States	Q3	USD		5	13	11	8	9	10
Norvasc	United States	Q4	USD	9		10	8	10	9	
Norvasc	Worldwide	Annual	USD	1506	1445	1349	1229	1112	991	
Norvasc	Worldwide	Q1	USD	368	356	334	301	278	252	236
Norvasc	Worldwide	Q2	USD	422	375	348	313	282	251	240
Norvasc	Worldwide	Q3	USD	330	350	319	303	270	241	238
Norvasc	Worldwide	Q4	USD	386	364	348	312	282	248	
Premarin Family	Rest of the World	Annual	USD	91	98	96	91	83	67	
Premarin Family	Rest of the World	Q1	USD	22	22	24	24	20	16	14

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Premarin Family	Rest of the World	Q2	USD	22	26	24	21	22	17	15
Premarin Family	Rest of the World	Q3	USD	22	26	25	22	20	17	15
Premarin Family	Rest of the World	Q4	USD	25	24	23	24	22	17	
Premarin Family	United States	Annual	USD	949	915	977	1001	992	951	
Premarin Family	United States	Q1	USD	234	213	237	220	228	215	243
Premarin Family	United States	Q2	USD	238	229	250	252	252	242	236
Premarin Family	United States	Q3	USD	241	241	237	254	244	246	229
Premarin Family	United States	Q4	USD	236	232	253	275	268	248	
Premarin Family	Worldwide	Annual	USD	1040	1013	1073	1092	1076	1018	
Premarin Family	Worldwide	Q1	USD	256	235	261	244	248	232	257
Premarin Family	Worldwide	Q2	USD	260	255	274	273	274	259	251
Premarin Family	Worldwide	Q3	USD	263	267	262	276	264	263	244
Premarin Family	Worldwide	Q4	USD	261	256	276	299	290	264	
Prevnar / Prevenar (70valent)	Rest of the World	Annual	USD	1039	488	399				
Prevnar / Prevenar (70valent)	Rest of the World	Q1	USD	339	153	138				
Prevnar / Prevenar (70valent)	Rest of the World	Q2	USD	298	155	84				
Prevnar / Prevenar (70valent)	Rest of the World	Q3	USD	179	98	81				
Prevnar / Prevenar (70valent)	Rest of the World	Q4	USD	223	82	96				
Prevnar / Prevenar (70valent)	United States	Annual	USD	214						
Prevnar / Prevenar (70valent)	United States	Q1	USD	181						

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Prevnar / Prevenar (70valent)	United States	Q2	USD	33						
Prevnar / Prevenar (70valent)	Worldwide	Annual	USD	1253	488	399				
Prevnar / Prevenar (70valent)	Worldwide	Q1	USD	520	153	138				
Prevnar / Prevenar (70valent)	Worldwide	Q2	USD	331	155	84				
Prevnar / Prevenar (70valent)	Worldwide	Q3	USD	179	98	84				
Prevnar / Prevenar (70valent)	Worldwide	Q4	USD	223	82	96				
Prevnar / Prevenar 13	Rest of the World	Annual	USD	655	1729	1831				
Prevnar / Prevenar 13	Rest of the World	Q1	USD	78	345	387				478
Prevnar / Prevenar 13	Rest of the World	Q2	USD	86	393	487				490
Prevnar / Prevenar 13	Rest of the World	Q3	USD	195	552	428				525
Prevnar / Prevenar 13	Rest of the World	Q4	USD	296	439	529				
Prevnar / Prevenar 13	United States	Annual	USD	1761	1928	1887				
Prevnar / Prevenar 13	United States	Q1	USD	208	651	554				1031
Prevnar / Prevenar 13	United States	Q2	USD	483	428	429				768
Prevnar / Prevenar 13	United States	Q3	USD	540	454	440				1011
Prevnar / Prevenar 13	United States	Q4	USD	530	395	464				
Prevnar / Prevenar 13	Worldwide	Annual	USD	2416	3657	3781				
Prevnar / Prevenar 13	Worldwide	Q1	USD	286	996	941				1509

Product Name	Region/ Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
13										
Prevnar / Prevenar 13	Worldwide	Q2	USD	569	821	916				1258
Prevnar / Prevenar 13	Worldwide	Q3	USD	735	1006	868				1536
Prevnar / Prevenar 13	Worldwide	Q4	USD	826	834	993				
Prevnar family (Prevenar 13 + Prevenar 70valent)	Rest of the World	Annual	USD				2170	2310	2220	
Prevnar family (Prevenar 13 + Prevenar 70valent)	Rest of the World	Q1	USD				477	456	459	
Prevnar family (Prevenar 13 + Prevenar 70valent)	Rest of the World	Q2	USD				552	628	622	
Prevnar family (Prevenar 13 + Prevenar 70valent)	Rest of the World	Q3	USD				490	546	530	
Prevnar family (Prevenar 13 + Prevenar 70valent)	Rest of the World	Q4	USD				651	680	609	
Prevnar family (Prevenar 13 + Prevenar 70valent)	United States	Annual	USD				1804	2154	4026	
Prevnar family (Prevenar 13 + Prevenar 70valent)	United States	Q1	USD				450	471	846	
Prevnar family (Prevenar 13 + Prevenar 70valent)	United States	Q2	USD				417	469	880	
Prevnar family (Prevenar 13 + Prevenar 70valent)	United States	Q3	USD				469	592	1046	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Prevnar 13 + Prevenar 70valent)										
Prevnar family (Prevnar 13 + Prevenar 70valent)	United States	Q4	USD				468	621	1253	
Prevnar family (Prevnar 13 + Prevenar 70valent)	Worldwide	Annual	USD				3974	4464	6245	
Prevnar family (Prevnar 13 + Prevenar 70valent)	Worldwide	Q1	USD				927	927	1306	
Prevnar family (Prevnar 13 + Prevenar 70valent)	Worldwide	Q2	USD				969	1097	1503	
Prevnar family (Prevnar 13 + Prevenar 70valent)	Worldwide	Q3	USD				959	1139	1576	
Prevnar family (Prevnar 13 + Prevenar 70valent)	Worldwide	Q4	USD				1119	1301	1862	
Pristiq	Rest of the World	Annual	USD	61	103	137	158	184	163	
Pristiq	Rest of the World	Q1	USD	10	21	30	35	38	43	36
Pristiq	Rest of the World	Q2	USD	14	26	34	40	49	40	37
Pristiq	Rest of the World	Q3	USD	16	27	32	39	47	41	36
Pristiq	Rest of the World	Q4	USD	21	29	41	44	50	39	
Pristiq	United States	Annual	USD	405	474	493	540	553	553	
Pristiq	United States	Q1	USD	100	108	121	131	134	118	143
Pristiq	United States	Q2	USD	99	121	124	137	149	137	157

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Pristiq	United States	Q3	USD	102	119	120	134	131	144	138
Pristiq	United States	Q4	USD	104	126	128	138	139	154	
Pristiq	Worldwide	Annual	USD	466	577	630	698	737	715	
Pristiq	Worldwide	Q1	USD	110	129	151	166	172	161	179
Pristiq	Worldwide	Q2	USD	113	147	158	177	198	177	194
Pristiq	Worldwide	Q3	USD	118	146	152	173	178	185	174
Pristiq	Worldwide	Q4	USD	125	155	169	182	189	193	
Protonix	United States	Annual	USD				185	198		
Protonix	United States	Q1	USD	158	59					
Protonix	United States	Q2	USD	171	44		48	50		
Protonix	United States	Q3	USD	203	65		42	55		
Protonix	United States	Q4	USD				48	46		
Rapamune	Rest of the World	Annual	USD	191	184	161	149	137	112	
Rapamune	Rest of the World	Q1	USD	47	43	37	35	34	27	24
Rapamune	Rest of the World	Q2	USD	46	54	39	38	31	26	26
Rapamune	Rest of the World	Q3	USD	49	49	43	36	36	24	21
Rapamune	Rest of the World	Q4	USD	49	38	42	40	38	35	
Rapamune	United States	Annual	USD	197	188	185	201	202	85	
Rapamune	United States	Q1	USD	44	46	45	49	54	26	21
Rapamune	United States	Q2	USD	51	46	46	48	56	27	21
Rapamune	United States	Q3	USD	55	47	49	55	61	9	17
Rapamune	United States	Q4	USD	47	49	45	49	32	24	
Rapamune	Worldwide	Annual	USD	388	372	346	350	339	197	
Rapamune	Worldwide	Q1	USD	91	89	82	84	88	53	45
Rapamune	Worldwide	Q2	USD	97	100	85	86	87	53	47

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Rapamune	Worldwide	Q3	USD	104	96	92	91	96	32	38
Rapamune	Worldwide	Q4	USD	96	87	87	89	69	59	
Refacto AF/Xynthia	Rest of the World	Annual	USD	324	409	478	479	494	416	
Refacto AF/Xynthia	Rest of the World	Q1	USD	69	91	107	110	115	93	97
Refacto AF/Xynthia	Rest of the World	Q2	USD	80	106	112	115	134	106	107
Refacto AF/Xynthia	Rest of the World	Q3	USD	80	108	122	119	125	107	112
Refacto AF/Xynthia	Rest of the World	Q4	USD	95	104	137	135	120	109	
Refacto AF/Xynthia	United States	Annual	USD	80	97	106	123	137	117	
Refacto AF/Xynthia	United States	Q1	USD	21	26	25	29	30	28	32
Refacto AF/Xynthia	United States	Q2	USD	18	17	26	31	37	35	32
Refacto AF/Xynthia	United States	Q3	USD	22	32	28	29	35	23	28
Refacto AF/Xynthia	United States	Q4	USD	19	22	27	34	34	32	
Refacto AF/Xynthia	Worldwide	Annual	USD	404	506	584	602	631	533	
Refacto AF/Xynthia	Worldwide	Q1	USD	90	117	132	139	145	120	129
Refacto AF/Xynthia	Worldwide	Q2	USD	98	123	138	146	171	142	139
Refacto AF/Xynthia	Worldwide	Q3	USD	102	140	150	148	160	130	140
Refacto AF/Xynthia	Worldwide	Q4	USD	114	126	164	169	154	141	
Relpax	Rest of the World	Annual	USD	134	148	149	141	137	119	
Relpax	Rest of the World	Q1	USD			34	34	34	28	24
Relpax	Rest of the World	Q2	USD			36	34	32	25	24

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Relpax	Rest of the World	Q3	USD	33	39	36	34	35	34	24
Relpax	Rest of the World	Q4	USD	36	40	43	39	36	31	
Relpax	United States	Annual	USD	189	193	219	218	244	233	
Relpax	United States	Q1	USD			51	52	53	52	54
Relpax	United States	Q2	USD			53	60	66	57	63
Relpax	United States	Q3	USD	42	47	56	49	57	57	59
Relpax	United States	Q4	USD	48	51	59	57	69	67	
Relpax	Worldwide	Annual	USD	323	341	368	359	382	352	
Relpax	Worldwide	Q1	USD			85	86	87	80	78
Relpax	Worldwide	Q2	USD			89	94	98	82	87
Relpax	Worldwide	Q3	USD	75	86	92	83	92	91	83
Relpax	Worldwide	Q4	USD	84	91	102	96	105	98	
Revatio	Rest of the World	Annual	USD	188	223	222	240	225	195	
Revatio	Rest of the World	Q1	USD	45	48	51	58	61	48	45
Revatio	Rest of the World	Q2	USD	47	56	56	58	55	46	49
Revatio	Rest of the World	Q3	USD	44	60	57	57	52	45	48
Revatio	Rest of the World	Q4	USD	52	59	58	67	57	57	
Revatio	United States	Annual	USD	293	312	312	67	51	65	
Revatio	United States	Q1	USD	69	75	85	14	15	15	21
Revatio	United States	Q2	USD	75	74	87	20	13	19	25
Revatio	United States	Q3	USD	72	80	78	18	12	9	25
Revatio	United States	Q4	USD	77	83	62	15	11	22	
Revatio	Worldwide	Annual	USD	481	535	534	307	276	260	
Revatio	Worldwide	Q1	USD	114	123	136	72	76	63	66
Revatio	Worldwide	Q2	USD	122	130	143	78	68	65	74

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
	e									
Revatio	Worldwide	Q3	USD	116	140	135	75	64	53	73
Revatio	Worldwide	Q4	USD	129	142	120	82	67	79	
Somavert	Rest of the World	Annual	USD	125	144	151	165	172	150	
Somavert	Rest of the World	Q1	USD				37	39		36
Somavert	Rest of the World	Q2	USD			37	41	45	38	39
Somavert	Rest of the World	Q3	USD			37	43	44	37	40
Somavert	Rest of the World	Q4	USD	33	38	42	44	45	40	
Somavert	United States	Annual	USD	32	39	46	52	57	68	
Somavert	United States	Q1	USD				11	11		19
Somavert	United States	Q2	USD			12	14	14	17	20
Somavert	United States	Q3	USD			12	13	15	17	19
Somavert	United States	Q4	USD	9	12	13	14	17	20	
Somavert	Worldwide	Annual	USD	157	183	197	217	229	218	
Somavert	Worldwide	Q1	USD				48	50		55
Somavert	Worldwide	Q2	USD			49	55	59	55	59
Somavert	Worldwide	Q3	USD			49	56	59	54	59
Somavert	Worldwide	Q4	USD	42	50	55	58	61	60	
Sulperazon	Rest of the World	Annual	USD	213	218	262	309	354	339	
Sulperazon	Rest of the World	Q1	USD			58	71	88	98	96
Sulperazon	Rest of the World	Q2	USD			71	73	92	80	105
Sulperazon	Rest of the World	Q3	USD	49	51	62	78	90	72	102
Sulperazon	Rest of the World	Q4	USD	60	63	71	87	85	89	
Sutent	Rest of	Annual	USD	796	880	899	853	821	752	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
	the World									
Sutent	Rest of the World	Q1	USD	190	207	214	218	190	169	176
Sutent	Rest of the World	Q2	USD	193	225	232	220	217	195	178
Sutent	Rest of the World	Q3	USD	190	220	212	193	200	186	177
Sutent	Rest of the World	Q4	USD	223	228	241	222	214	201	
Sutent	United States	Annual	USD	270	307	337	351	354	368	
Sutent	United States	Q1	USD	69	69	86	84	78	73	102
Sutent	United States	Q2	USD	62	71	87	92	93	98	107
Sutent	United States	Q3	USD	67	78	82	85	87	93	83
Sutent	United States	Q4	USD	72	89	82	90	95	103	
Sutent	Worldwide	Annual	USD	1066	1187	1236	1204	1174	1120	
Sutent	Worldwide	Q1	USD	259	276	300	302	268	242	278
Sutent	Worldwide	Q2	USD	255	296	319	312	310	294	285
Sutent	Worldwide	Q3	USD	257	298	294	278	287	279	260
Sutent	Worldwide	Q4	USD	295	317	323	312	310	305	
Tikosyn	United States	Annual	USD						179	
Tikosyn	United States	Q1	USD						37	61
Tikosyn	United States	Q2	USD						42	55
Tikosyn	United States	Q3	USD						44	20
Tikosyn	United States	Q4	USD						56	
Toviaz	Rest of the World	Annual	USD	67	88	94	116	154	151	
Toviaz	Rest of the World	Q1	USD			21	25	32	35	38
Toviaz	Rest of the World	Q2	USD			24	34	43	38	43
Toviaz	Rest of the World	Q3	USD			23	26	39	36	38

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Toviaz	Rest of the World	Q4	USD	20	24	26	31	41	42	
Toviaz	United States	Annual	USD	70	99	113	120	134	116	
Toviaz	United States	Q1	USD			25	27	31	29	26
Toviaz	United States	Q2	USD			28	31	36	33	24
Toviaz	United States	Q3	USD			29	31	30	23	22
Toviaz	United States	Q4	USD	23	26	31	31	36	31	
Toviaz	Worldwide	Annual	USD	137	187	207	236	288	267	
Toviaz	Worldwide	Q1	USD			46	52	63	63	64
Toviaz	Worldwide	Q2	USD			52	65	79	71	67
Toviaz	Worldwide	Q3	USD			52	57	69	59	60
Toviaz	Worldwide	Q4	USD	43	50	57	62	77	73	
Tygacil	Rest of the World	Annual	USD	160	150	183	208	211	194	
Tygacil	Rest of the World	Q1	USD	38	37	41	44	44	44	46
Tygacil	Rest of the World	Q2	USD	41	37	48	51	54	49	48
Tygacil	Rest of the World	Q3	USD	38	38	45	54	58	51	45
Tygacil	Rest of the World	Q4	USD	43	38	49	59	55	50	
Tygacil	United States	Annual	USD	164	148	152	150	112	110	
Tygacil	United States	Q1	USD	46	36	40	43	30	29	30
Tygacil	United States	Q2	USD	47	38	38	41	28	28	11
Tygacil	United States	Q3	USD	40	38	37	38	27	30	24
Tygacil	United States	Q4	USD	31	36	37	28	27	23	
Tygacil	Worldwide	Annual	USD	324	298	335	358	323	304	
Tygacil	Worldwide	Q1	USD	84	73	81	87	74	74	76
Tygacil	Worldwide	Q2	USD	88	75	86	92	82	77	59
Tygacil	Worldwide	Q3	USD	78	76	82	92	85	81	69

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Tygacil	Worldwide	Q4	USD	74	74	86	87	82	73	
Unasyn	Rest of the World	Annual	USD	238	255	226	211	206	118	
Unasyn	Rest of the World	Q1	USD			54	55	46	53	
Unasyn	Rest of the World	Q2	USD			55	53	54	48	
Unasyn	Rest of the World	Q3	USD	58	55			52	49	
Unasyn	Rest of the World	Q4	USD	62	57	63	54	55	42	
Unasyn	United States	Annual	USD	6	6	2	1	1		
Unasyn	United States	Q1	USD				1		2	
Unasyn	United States	Q2	USD			2			3	
Unasyn	United States	Q3	USD	3	3			1	1	
Unasyn	United States	Q4	USD		2					
Unasyn	Worldwide	Annual	USD	244	231	228	212	207	118	
Unasyn	Worldwide	Q1	USD			54	56	46	55	
Unasyn	Worldwide	Q2	USD			57	53	54	50	
Unasyn	Worldwide	Q3	USD	61	58			52	50	
Unasyn	Worldwide	Q4	USD	62	59	63	54	55	42	
Vfend	Rest of the World	Annual	USD	565	661	665	714	719	643	
Vfend	Rest of the World	Q1	USD	128	149	153	170	165	169	146
Vfend	Rest of the World	Q2	USD	144	174	160	163	210	156	151
Vfend	Rest of the World	Q3	USD	136	171	166	175	167	155	134
Vfend	Rest of the World	Q4	USD	157	167	186	206	177	163	
Vfend	United States	Annual	USD	260	86	89	61	36	39	
Vfend	United States	Q1	USD	60	46	25	17	12	13	10

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Vfend	United States	Q2	USD	63	18	18	14	11	7	12
Vfend	United States	Q3	USD	64		21	18	7	10	6
Vfend	United States	Q4	USD	73	22	25	12	6	9	
Vfend	Worldwide	Annual	USD	825	747	754	775	756	682	
Vfend	Worldwide	Q1	USD	188	195	178	187	177	182	156
Vfend	Worldwide	Q2	USD	207	192	178	177	221	162	162
Vfend	Worldwide	Q3	USD	200	171	187	193	174	165	140
Vfend	Worldwide	Q4	USD	230	189	211	218	183	172	
Viagra	Rest of the World	Annual	USD	936	978	916	749	545	36	
Viagra	Rest of the World	Q1	USD	226	232	228	216	133	117	104
Viagra	Rest of the World	Q2	USD	257	245	218	204	140	122	109
Viagra	Rest of the World	Q3	USD	217	249	230	166	139	9	98
Viagra	Rest of the World	Q4	USD	236	252	240	163	133	10	
Viagra	United States	Annual	USD	992	1003	1135	1132	1140	1261	
Viagra	United States	Q1	USD	253	238	268	245	241	279	292
Viagra	United States	Q2	USD	234	250	267	280	287	326	292
Viagra	United States	Q3	USD	242	244	287	294	288	324	289
Viagra	United States	Q4	USD	263	271	313	313	324	332	
Viagra	Worldwide	Annual	USD	1928	1981	2051	1881	1685	1297	
Viagra	Worldwide	Q1	USD	479	470	496	461	374	396	396
Viagra	Worldwide	Q2	USD	491	495	485	484	427	448	401
Viagra	Worldwide	Q3	USD	459	493	517	460	427	333	387
Viagra	Worldwide	Q4	USD	499	523	553	476	457	342	
Xalatan/Xalacom	Rest of the World	Annual	USD	1123	1074	768	559	473	377	
Xalatan/Xalacom	Rest of the	Q1	USD	277	256	216	139	113	94	83

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
	World									
Xalatan/Xalacom	Rest of the World	Q2	USD	298	277	199	140	123	94	88
Xalatan/Xalacom	Rest of the World	Q3	USD	259	268	172	132	119	94	86
Xalatan/Xalacom	Rest of the World	Q4	USD	289	273	181	148	95	95	
Xalatan/Xalacom	United States	Annual	USD	626	176	38	30	23	22	
Xalatan/Xalacom	United States	Q1	USD	145	136	11	8	6	8	6
Xalatan/Xalacom	United States	Q2	USD	151	14	10	7	5	5	6
Xalatan/Xalacom	United States	Q3	USD	157	9	9	8	5	5	5
Xalatan/Xalacom	United States	Q4	USD	173	17	8	7	6	4	
Xalatan/Xalacom	Worldwide	Annual	USD	1749	1250	806	589	495	399	
Xalatan/Xalacom	Worldwide	Q1	USD	422	392	227	147	119	102	89
Xalatan/Xalacom	Worldwide	Q2	USD	449	291	209	147	128	99	94
Xalatan/Xalacom	Worldwide	Q3	USD	416	277	181	140	124	98	91
Xalatan/Xalacom	Worldwide	Q4	USD	462	290	189	155	100	100	
Xalkori	Rest of the World	Q1	USD							77
Xalkori	Rest of the World	Q2	USD							75
Xalkori	Rest of the World	Q3	USD							80
Xalkori	United States	Q1	USD							62
Xalkori	United States	Q2	USD							62
Xalkori	United States	Q3	USD							60
Xalkori	Worldwide	Q1	USD							139
Xalkori	Worldwide	Q2	USD							137
Xalkori	Worldwide	Q3	USD							140
Xanax XR	Rest of the World	Annual	USD	256	254	224	227	211	181	
Xanax XR	Rest of the	Q1	USD			54	58	49	45	40

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
	World									
Xanax XR	Rest of the World	Q2	USD			58	54	57	44	44
Xanax XR	Rest of the World	Q3	USD	58	64	53	56	52	44	43
Xanax XR	Rest of the World	Q4	USD	70	63	59	59	52	48	
Xanax XR	United States	Annual	USD	51	52	50	49	42	44	
Xanax XR	United States	Q1	USD			14	12	10	10	13
Xanax XR	United States	Q2	USD			11	11	11	11	12
Xanax XR	United States	Q3	USD	14	13	13	13	10	12	12
Xanax XR	United States	Q4	USD	13	11	12	13	11	12	
Xanax XR	Worldwide	Annual	USD	307	306	274	276	253	224	
Xanax XR	Worldwide	Q1	USD			68	70	59	54	53
Xanax XR	Worldwide	Q2	USD			69	65	68	54	56
Xanax XR	Worldwide	Q3	USD	72	77	66	69	63	55	55
Xanax XR	Worldwide	Q4	USD	83	74	71	72	63	60	
Xeljanz	Rest of the World	Annual	USD				2	20	53	
Xeljanz	Rest of the World	Q1	USD					2	8	22
Xeljanz	Rest of the World	Q2	USD					3	12	28
Xeljanz	Rest of the World	Q3	USD				1	6	14	32
Xeljanz	Rest of the World	Q4	USD				1	9	19	
Xeljanz	United States	Annual	USD				112	289	470	
Xeljanz	United States	Q1	USD				11	50	89	175
Xeljanz	United States	Q2	USD				22	65	116	189
Xeljanz	United States	Q3	USD				34	79	113	202
Xeljanz	United States	Q4	USD				45	95	153	
Xeljanz	Worldwide	Annual	USD				114	308	523	

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Xeljanz	Worldwide	Q1	USD				11	52	96	197
Xeljanz	Worldwide	Q2	USD				22	68	128	217
Xeljanz	Worldwide	Q3	USD				35	85	127	235
Xeljanz	Worldwide	Q4	USD				46	104	172	
Zithromax / Zmax	Rest of the World	Annual	USD	401	433	423	380	302	269	
Zithromax / Zmax	Rest of the World	Q1	USD	99	121	118	112	90	82	78
Zithromax / Zmax	Rest of the World	Q2	USD	108	108	105	85	72	69	66
Zithromax / Zmax	Rest of the World	Q3	USD	86	89	86	81	65	65	53
Zithromax / Zmax	Rest of the World	Q4	USD	108	115	114	102	76	70	
Zithromax / Zmax	United States	Annual	USD	14	20	12	7	12	7	
Zithromax / Zmax	United States	Q1	USD	4	7	5	4	2	4	2
Zithromax / Zmax	United States	Q2	USD	2	6	1		4		1
Zithromax / Zmax	United States	Q3	USD	4	4	3	3	3	4	3
Zithromax / Zmax	United States	Q4	USD	4	3	3	2	3	2	
Zithromax / Zmax	Worldwide	Annual	USD	415	453	435	387	314	275	
Zithromax / Zmax	Worldwide	Q1	USD	103	128	123	116	92	86	80
Zithromax / Zmax	Worldwide	Q2	USD	110	114	106	83	76	68	67
Zithromax / Zmax	Worldwide	Q3	USD	90	93	89	84	67	68	56
Zithromax / Zmax	Worldwide	Q4	USD	112	118	117	104	79	73	
Zoloft	Rest of the World	Annual	USD	461	510	473	425	368	315	
Zoloft	Rest of the World	Q1	USD	103	120	113	102	88	75	63
Zoloft	Rest of the World	Q2	USD	125	130	124	107	91	76	104
Zoloft	Rest of the World	Q3	USD	108	124	112	102	91	79	58

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Zoloft	Rest of the World	Q4	USD	125	136	124	114	99	86	
Zoloft	United States	Annual	USD	71	63	68	44	55	58	
Zoloft	United States	Q1	USD	17	15	17	14	13	11	16
Zoloft	United States	Q2	USD	19	16	15	2	13	17	79
Zoloft	United States	Q3	USD	18	15	17	14	14	16	14
Zoloft	United States	Q4	USD	17	17	19	14	15	14	
Zoloft	Worldwide	Annual	USD	532	573	541	469	423	374	
Zoloft	Worldwide	Q1	USD	120	135	130	116	101	86	79
Zoloft	Worldwide	Q2	USD	144	146	139	109	104	93	183
Zoloft	Worldwide	Q3	USD	126	139	129	116	104	95	72
Zoloft	Worldwide	Q4	USD	142	153	143	128	113	100	
Zosyn/Tazocin	Rest of the World	Annual	USD	325	292	267	223	148		
Zosyn/Tazocin	Rest of the World	Q1	USD	86	72	64	51	38		
Zosyn/Tazocin	Rest of the World	Q2	USD	80	77	69	58	38		
Zosyn/Tazocin	Rest of the World	Q3	USD	78	74	70	57	36		
Zosyn/Tazocin	Rest of the World	Q4	USD	81	69	64	57	36		
Zosyn/Tazocin	United States	Annual	USD	627	344	217	172	155		
Zosyn/Tazocin	United States	Q1	USD	178	107	64	36	36		
Zosyn/Tazocin	United States	Q2	USD	150	85	72	44	37		
Zosyn/Tazocin	United States	Q3	USD	177	75	39	47	44		
Zosyn/Tazocin	United States	Q4	USD	122	77	42	45	38		
Zosyn/Tazocin	Worldwide	Annual	USD	952	636	484	395	303		
Zosyn/Tazocin	Worldwide	Q1	USD	264	179	128	87	74		
Zosyn/Tazocin	Worldwide	Q2	USD	230	162	141	102	75		
Zosyn/Tazocin	Worldwide	Q3	USD	255	149	109	104	80		

Product Name	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015	2016
Zosyn/Tazocin	Worldwide	Q4	USD	203	146	106	102	74		
Zyvox	Rest of the World	Annual	USD	563	643	680	665	671	620	
Zyvox	Rest of the World	Q1	USD	131	147	154	166	156	152	104
Zyvox	Rest of the World	Q2	USD	145	165	182	176	176	172	95
Zyvox	Rest of the World	Q3	USD	137	167	170	154	168	138	76
Zyvox	Rest of the World	Q4	USD	150	164	174	169	172	157	
Zyvox	United States	Annual	USD	613	640	665	688	680	264	
Zyvox	United States	Q1	USD	161	172	171	176	165	119	23
Zyvox	United States	Q2	USD	154	160	161	170	172	87	19
Zyvox	United States	Q3	USD	148	154	158	165	171	27	18
Zyvox	United States	Q4	USD	150	154	175	177	172	30	
Zyvox	Worldwide	Annual	USD	1176	1283	1345	1353	1352	883	
Zyvox	Worldwide	Q1	USD	292	319	325	342	321	271	127
Zyvox	Worldwide	Q2	USD	299	325	343	346	348	259	114
Zyvox	Worldwide	Q3	USD	285	321	328	319	339	165	94
Zyvox	Worldwide	Q4	USD	300	318	349	346	343	187	

Sales by Segment/Therapy Area

Therapy Area	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015
Animal Health	Worldwide	Annual	USD	3575	4184	4299			
Animal Health	Worldwide	Q1	USD	846	982	1026			
Animal Health	Worldwide	Q2	USD	893	1055	1085			
Animal Health	Worldwide	Q3	USD	860	1041	1017			
Animal Health	Worldwide	Q4	USD	976	1106	1171			
BMP (Bone)	Worldwide	Annual	USD	400	340			228	232

Therapy Area	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015
Morphogenetic Protein)									
BMP (Bone Morphogenetic Protein)	Worldwide	Q1	USD	98	93			40	37
BMP (Bone Morphogenetic Protein)	Worldwide	Q2	USD	99	101			51	75
BMP (Bone Morphogenetic Protein)	Worldwide	Q3	USD	101	83			56	57
BMP (Bone Morphogenetic Protein)	Worldwide	Q4	USD	102	63			81	63
Consumer Healthcare	Worldwide	Annual	USD	2772	3057	3212	3342	3446	3395
Consumer Healthcare	Worldwide	Q1	USD	663	745	727	811	761	808
Consumer Healthcare	Worldwide	Q2	USD	678	721	769	800	912	840
Consumer Healthcare	Worldwide	Q3	USD	673	774	780	788	821	817
Consumer Healthcare	Worldwide	Q4	USD	758	817	936	943	953	930
Emerging Markets	Worldwide	Annual	USD	8662	9295	9960	10215		
Emerging Markets	Worldwide	Q1	USD	1972	2178	2299	2420		
Emerging Markets	Worldwide	Q2	USD	2250	2415	2620	2615		
Emerging Markets	Worldwide	Q3	USD	2072	2438	2389	2431		
Emerging Markets	Worldwide	Q4	USD	2368	2264	2652	2749		
Established Products	Worldwide	Annual	USD	10098	9214	10235	9457	25149	21587
Established Products	Worldwide	Q1	USD	2786	2367	2801	2352	5990	5014

Therapy Area	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015
Established Products	Worldwide	Q2	USD	2730	2317	2681	2385	6513	5090
Established Products	Worldwide	Q3	USD	2168	2230	2383	2296	6239	5219
Established Products	Worldwide	Q4	USD	2414	2300	2370	2424	6407	6264
Global Established Pharmaceutical (GEP)	Worldwide	Annual	USD				27619	25149	20075
Global Established Pharmaceutical (GEP)	Worldwide	Q1	USD				6861	5990	5014
Global Established Pharmaceutical (GEP)	Worldwide	Q2	USD				6921	6513	5090
Global Established Pharmaceutical (GEP)	Worldwide	Q3	USD				6675	6239	4889
Global Established Pharmaceutical (GEP)	Worldwide	Q4	USD				7160	6407	5082
Global Innovative Pharmaceutical (GIP)	Worldwide	Annual	USD				14317	13861	13954
Global Innovative Pharmaceutical (GIP)	Worldwide	Q1	USD				3306	3076	3075
Global Innovative Pharmaceutical (GIP)	Worldwide	Q2	USD				3726	3547	3497
Global Innovative Pharmaceutical (GIP)	Worldwide	Q3	USD				3640	3490	3521
Global Innovative Pharmaceutical (GIP)	Worldwide	Q4	USD				3645	3748	3862

Therapy Area	Region/Country	Period	Currency	2010	2011	2012	2013	2014	2015
Pharmaceutical (GIP)									
Global Vaccines	Worldwide	Annual	USD				3965	4480	6454
Global Vaccines	Worldwide	Q1	USD				923	925	1328
Global Vaccines	Worldwide	Q2	USD				970	1097	1580
Global Vaccines	Worldwide	Q3	USD				954	1140	1629
Global Vaccines	Worldwide	Q4	USD				1118	1318	1917
Nutrition	Worldwide	Annual	USD	1867	2138				
Nutrition	Worldwide	Q1	USD	458	470				
Nutrition	Worldwide	Q2	USD	476	493				
Nutrition	Worldwide	Q3	USD	441	577				
Nutrition	Worldwide	Q4	USD	492	598				
Oncology	Worldwide	Annual	USD	1414	1323	1310	1646	2218	2954
Oncology	Worldwide	Q1	USD	361	311	288	372	488	528
Oncology	Worldwide	Q2	USD	349	339	323	399	570	713
Oncology	Worldwide	Q3	USD	335	332	329	407	551	786
Oncology	Worldwide	Q4	USD	369	341	370	468	609	928
Primary Care	Worldwide	Annual	USD	23328	22670	15558	13272		
Primary Care	Worldwide	Q1	USD	5866	5441	4097	3238		
Primary Care	Worldwide	Q2	USD	5923	5870	4018	3333		
Primary Care	Worldwide	Q3	USD	5653	5948	3610	3259		
Primary Care	Worldwide	Q4	USD	5886	5411	3833	3442		
Specialty Care	Worldwide	Annual	USD	15021	15245	14151	13288		
Specialty Care	Worldwide	Q1	USD	3521	3927	3580	3164		
Specialty Care	Worldwide	Q2	USD	3769	3699	3497	3378		
Specialty Care	Worldwide	Q3	USD	3717	3799	3406	3349		
Specialty Care	Worldwide	Q4	USD	4014	3820	3668	3397		

Financial Statements

Statement type : Balance Sheet (USD mn)

View : Annual

Period :3

	2015	2014	2013
Cash, Cash Equivalents	3641	3343	2183
Short Term Investments	19649	32779	30225
Accounts & Notes Receivable, Net	8176	8401	9357
Accounts Receivable, Net	8176	8401	9357
Notes Receivable, Net	0	0	0
Inventories	7513	5663	6166
Other Current Assets	4825	5409	8313
Total Current Assets	43804	55595	56244
Property, Plant & Equipment, Net	13766	11760	12397
Property, Plant & Equipment	27268	24986	25678
Accumulated Depreciation	13502	13226	13281
Long Term Investments & Receivables	15999	17518	16406
Long Term Investments	15999	17518	16406
Other Long Term Assets	93891	82692	87054
Total Intangible Assets	88598	77236	81904
Goodwill	48242	42069	42519
Other Intangible Assets	40356	35167	39385
Misc. Long Term Assets	2555	2632	2371
Total Long Terms Assets	123656	111970	115857
Total Assets	167460	167566	172101
Accounts Payable	3620	3210	3234
Accrued Taxes	418	531	678
Other Payables & Accruals	2359	1841	1792
Short Term Debt	10160	5141	6027
Short Term Borrowings	0	0	3967
Current Portion of Long Term Debt	10160	5141	2060
Other Short Term Liabilities	10990	9153	9972
Deferred Revenue	0	0	0
Misc Short Term Liabilities	10345	9061	9648
Total Current Liabilities	29399	21587	23366
Long Term Debt	28818	31541	30462
Long Term Borrowings	28818	31541	30462

	2015	2014	2013
Other Long Term Liabilities	44245	42817	41653
Accrued Liabilities	0	0	0
Pension Liabilities	8119	10264	7303
Deferred Revenue	0	0	0
Misc Long Term Liabilities	8186	8639	8433
Total Long Term Liabilities	73063	74358	72115
Total Liabilities	102462	95945	95481
Preferred Equity	26	29	33
Share Capital & Additional Paid In Capital	81475	79432	77736
Total Common Stock	459	455	453
Treasury Stock	79252	73021	67923
Retained Earnings	71993	72176	69732
Other Equity, Net	-9522	-7316	-3271
Equity Before Minority Interest	64720	71300	76307
Minority Interest	278	321	313
Total Equity	64998	71621	76620
Shares Outstanding	6175	6291	6399
Number of Treasury Shares	3003	2819	2652
Net Debt	15688	560	4081
Net Debt to Equity	24.14	0.78	5.33
Tangible Common Equity Ratio	-30.31	-6.6	-6.24
Current Ratio	1.49	2.58	2.41
Cash Conversion Cycle	202.76	161.14	187.85
Number of Employees	97900	78300	77700

Statement type : Income Statement (USD mn)

View : Annual

Period :3

	2015	2014	2013
Total Revenue	48851	49407	51452
Cost of Revenue, Total	9433	9033	9250
Gross Profit	39418	40374	42202
Other Operating Income	0	0	0
Operating Expenses	23869	24909	25314
Other Operating Expenses	-1830	0	0
Operating Income (Loss)	15549	15465	16888
Interest Expense, Net	728	935	1011
Interest Expense	1199	1360	1414
Interest Income	471	425	403
Foreign Exch (Gain) Loss	806	0	0

	2015	2014	2013
(Income) Loss from Affiliates	0	0	0
Other Non-Op (Income) Loss	-518	-1642	-945
Income (Loss) Before Tax, Adjusted	8965	12240	15716
Abnormal Losses (Gains)	5568	3932	1106
Merger/Acquisition Expense	895	183	376
Disposal of Assets	-232	0	0
Asset Write-Down	818	0	0
Legal Settlement	1257	0	0
Other Abnormal Items	2830	3749	730
Income (Loss) Before Tax	8965	12240	15716
Income Tax Expense (Benefit)	1990	3121	4306
Current Income Tax	2010	2799	2580
Deferred Income Tax	-20	322	1726
Tax Allowance/Credit	0	0	0
Income (Loss) from Continuing Operations	6975	9119	11410
Net Extraordinary Losses (Gains)	-11	-48	-10662
Discontinued Operations	-11	-48	-10662
Income (Loss) Including Minority Interest	6986	9167	22072
Minority Interest	26	32	69
Net Income	6960	9135	22003
Preferred Dividends	2	2	2
Other Adjustments	0	0	0
Net Income Available to Common Shareholders	12108	11972	12101
Net Income Avail to Common Shareholders, Adjusted	12108	11972	12101
Net Abnormal Losses (Gains)	5161	2887	762
Net Extraordinary Losses (Gains)	-11	-48	-10662
Basic Weighted Avg Shares	6176	6346	6813
Basic EPS	1	1	3
Basic EPS from Continued Operations	1	1	2
Basic EPS from Continued Operations, Adjusted	2	2	2
Diluted Weighted Average Shares	6257	6424	6895
Diluted EPS	1	1	3
Diluted EPS from Continued Operations	1	1	2

	2015	2014	2013
Diluted EPS from Continued Operations, Adjusted	2	2	2
EBITDA	20706	21002	23298
EBITDA Margin (T12M)	42	43	45
EBIT	15549	15465	16888
Gross Margin	81	82	82
Operating Margin	32	31	33
Profit Margin	25	24	24
Sales per Employee	498989	630996	662188
Dividends per Share	1	1	1
Total Cash Common Dividends	7141	6690	6540

Statement type : Cash Flow (USD mn)**View : Annual****Period :3**

	2015	2014	2013
Net Income	6960	9135	22003
Depreciation & Amortization	5157	5537	6410
Non-Cash Items	2548	1151	-897
Stock-Based Compensation	669	586	523
Deferred Income Taxes	-18	317	1703
Other Non-Cash Adjustments	1897	248	-3123
Change in Non-Cash Work Cap	-159	1111	614
(Inc) Dec in Accounts Receivables	21	148	940
Inc (Dec) in Accounts Payable	254	297	382
(Inc) Dec in Inventories	-199	175	-538
Inc (Dec) in Other	-235	491	-170
Net Cash From Discontinued Operations	6	-51	-10446
Cash from Operating Activities	14512	16883	17684
Disposal of Intangible Assets	0	0	0
Acquisition of Fixed Prod Assets	-1397	-1199	-1206
Acquisition of Intangible Assets	-99	0	0
Net Change in Long Term Investment	-2613	-4573	-3465
Decrease in Long Term Investment	6929	6145	7555

	2015	2014	2013
Increase in Long Term Investment	-9542	-10718	-11020
Net Cash From Acquisitions & Divestitures	-16466	-579	-274
Cash from Divestitures	0	0	0
Cash for Acquisition of Subsidiaries	-16466	-579	-274
Cash for Joint Ventures	0	0	0
Other Investing Activities	17595	697	-5599
Cash from Investing Activities	-2980	-5654	-10544
Dividends Paid	-6940	-6609	-6580
Cash From (Repayment) Debt	1306	549	6036
Cash (Repurchase) of Equity	-4897	-3998	-14540
Increase in Capital Stock	1263	1002	1750
Decrease in Capital Stock	-6160	-5000	-16290
Other Financing Activities	298	72	109
Cash from Financing Activities	-10233	-9986	-14975
Net Changes in Cash	299	1160	-7898
Cash Paid for Taxes	2383	2100	2874
Cash Paid for Interest	1302	1550	1729
EBITDA	16981	18786	21594
Trailing 12M EBITDA Margin	35	38	42
Net Cash Paid for Acquisitions	16466	579	274
Free Cash Flow	13115	15684	16478
Free Cash Flow to Firm	14048	16697	17505
Free Cash Flow to Equity	14416	16227	22506
Free Cash Flow per Basic Share	2	2	2
Price to Free Cash Flow	15	13	13
Cash Flow to Net Income	2	2	1

SEC Filings

Date	Form_Name	Form_Description
11/01/2016	8-K	pfe-10022016x8k.htm
11/01/2016	EX-99	pfe-10022016xex99.htm
11/01/2016	8-K	pfe-10022016x8k.htm
11/01/2016	EX-99	pfe-10022016xex99.htm
10/27/2016	8-K	n8k102716.htm
10/27/2016	8-K	n8k102716.htm
08/22/2016	8-K	d57934d8k.htm
08/22/2016	8-K	d57934d8k.htm
08/11/2016	10-Q	pfe-7032016x10q.htm
08/11/2016	EX-10.1	pfe-07032016x10qexhibit101.htm

Date	Form_Name	Form_Description
08/11/2016	10-Q	pfe-7032016x10q.htm
08/11/2016	EX-10.1	pfe-07032016x10qexhibit101.htm
08/02/2016	8-K	pfe-07032016x8k.htm
08/02/2016	EX-99	pfe-07032016xex99.htm
08/02/2016	8-K	pfe-07032016x8k.htm
08/02/2016	EX-99	pfe-07032016xex99.htm
06/03/2016	8-K	d193755d8k.htm
06/03/2016	8-K	d193755d8k.htm
05/16/2016	EX-99.1	d178752dex991.htm
05/16/2016	EX-99.1	d178752dex991.htm
05/16/2016	8-K	d178752d8k.htm
05/16/2016	8-K	d178752d8k.htm
05/12/2016	10-Q	pfe-4032016x10q.htm
05/12/2016	EX-10.1	pfe-4032016x10qexhibit101.htm
05/12/2016	10-Q	pfe-4032016x10q.htm
05/12/2016	EX-10.1	pfe-4032016x10qexhibit101.htm
05/03/2016	8-K	pfe-04032016x8k.htm
05/03/2016	EX-99	pfe-04032016xex99.htm
05/03/2016	8-K	pfe-04032016x8k.htm
05/03/2016	EX-99	pfe-04032016xex99.htm
05/02/2016	8-K	pfe8k428.htm
05/02/2016	8-K	pfe8k428.htm
04/06/2016	8-K	d175229d8k.htm
04/06/2016	EX-10.1	d175229dex101.htm
04/06/2016	EX-99.1	d175229dex991.htm
04/06/2016	8-K	d175229d8k.htm
04/06/2016	EX-10.1	d175229dex101.htm
04/06/2016	EX-99.1	d175229dex991.htm
03/09/2016	8-K	n8k9316.htm
03/09/2016	EX-99.1	x993916.htm
03/09/2016	8-K	n8k9316.htm
03/09/2016	EX-99.1	x993916.htm
02/29/2016	10-K	pfe-12312015x10kshell.htm
02/29/2016	10-K	pfe-12312015x10kshell.htm
02/16/2016	8-K	pfe-12312015x8ka.htm
02/16/2016	EX-99.1	pfe-12312015xex99.htm
02/16/2016	8-K	pfe-12312015x8ka.htm
02/16/2016	EX-99.1	pfe-12312015xex99.htm
02/08/2016	8-K	n8k2516.htm
02/08/2016	EX-99.1	x992816.htm
02/08/2016	8-K	n8k2516.htm
02/08/2016	EX-99.1	x992816.htm
02/02/2016	8-K	pfe-12312015x8k.htm
02/02/2016	EX-99	pfe-12312015xex99.htm
02/02/2016	8-K	pfe-12312015x8k.htm
02/02/2016	EX-99	pfe-12312015xex99.htm

News

News Date	02/11/2016
Category	Device approval
Headline	Pfizer's Prevenar 13 Received Approval For Use In Infants And Children In China
Summary	Pfizer China announced that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its pneumococcal 13-valent conjugate vaccine, Prevenar 13, in China for active immunization for the prevention of invasive diseases (including bacteremic pneumonia, meningitis, septicemia, and bacteraemia) caused by Streptococcus pneumoniae (S. Pneumoniae) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in infants and children aged 6 weeks to 15 months. S. pneumoniae is the most common cause of invasive disease as well as pneumonia and upper respiratory tract infections.

News Date	01/11/2016
Category	Product Discontinuation
Headline	Pfizer Discontinued Global Development Of Bococizumab, Its Investigational PCSK9 Inhibitor
Summary	Pfizer Inc announced the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders. As a result, Pfizer has decided to discontinue the development program, including the two ongoing cardiovascular outcome studies.

News Date	31/10/2016
Category	MAA
Headline	European Medicines Agency Validated The Marketing Authorization Application For Avelumab For The Treatment Of Metastatic Merkel Cell Carcinoma

Summary	Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) announced that the European Medicines Agency (EMA) has validated for review Merck KGaA, Darmstadt, Germany's Marketing Authorization Application (MAA) for avelumab, for the proposed indication of metastatic Merkel cell carcinoma (MCC), a rare and aggressive skin cancer, which impacts approximately 2,500 Europeans a year. Validation of the MAA confirms that submission is complete and begins the EMA's centralized review process. If approved, avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, could be the first approved treatment indicated for metastatic MCC in the EU. Patients with metastatic MCC face a very poor prognosis, with less than 20 percent surviving beyond five years.
---------	---

News Date	21/10/2016
Category	sNDA
Headline	FDA Approved Supplemental New Drug Application For Xtandi In Advanced Prostate Cancer
Summary	Astellas Pharma Inc (TSE: 4503) and Pfizer Inc (NYSE:PFE) announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for Xtandi (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.

News Date	20/10/2016
Category	Partnership / Strategic Alliance
Headline	Debiopharm International SA Announced Clinical Collaboration With The Merck-Pfizer Alliance In Cancer Immunotherapy
Summary	Debiopharm International announced that it had entered into a collaboration agreement with Merck and Pfizer (NYSE:PFE) to evaluate Debio 1143, an oral, small molecule inhibitor of IAPs (Inhibitor of Apoptosis Proteins), in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Debio 1143 is currently in Phase II development for Head and Neck and Ovarian Cancer. Avelumab is under clinical investigation across a broad range of tumor types by the Merck-Pfizer Alliance. Under the terms of the agreement, Debiopharm will be responsible for conducting the Phase I/Ib clinical trial in NSCLC.

News Date	19/10/2016
Category	Awards/Grants/Funds

Headline	Pfizer Awarded Grant To Evaluate Vaccine To Protect Newborns Against Group B Streptococcus Infection
Summary	Pfizer Inc (NYSE:PFE) announced an award of a grant from the Bill & Melinda Gates Foundation to conduct a Phase 1/2 clinical trial of Pfizer's vaccine candidate against group B Streptococcus(group B strep or GBS) infection, a leading cause of neonatal sepsis, a serious life-threatening blood infection. The investigational vaccine is designed to protect newborns via maternal immunization.

News Date	19/10/2016
Category	Regulatory-Others
Headline	CDC Advisory Committee On Immunization Practices Votes To Recommend New Dosing Schedule For Vaccination With Trumenba (Meningococcal Group B Vaccine)
Summary	Pfizer Inc (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that: For persons at increased risk for meningococcal disease and for use during serogroup B outbreaks, 3 doses of Trumenba should be administered at 0, 1-2, and 6 months.

News Date	17/10/2016
Category	Product Update-Others
Headline	Pfizer Announced The U.S. Availability Of Biosimilar Inflectra (Infliximab-Dyyb)
Summary	Pfizer Inc (NYSE:PFE) announced that the company will begin shipment of Inflectra (infliximab-dyyb)for injection, a biosimilar of Remicade (infliximab) to wholesalers in the United States (U.S.) in late November 2016.

News Date	15/10/2016
Category	Presentations
Headline	Pfizer To Present New Data On Xeljanz (Tofacitinib Citrate) For Ulcerative Colitis At UEG Week 2016

Summary	Pfizer Inc (NYSE:PFE) announced that three abstracts for Xeljanz (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis (UC), will be presented at the upcoming United European Gastroenterology Week (UEG Week 2016), October 15-19 in Vienna, Austria. The tofacitinib presentations will highlight new research results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Induction trials, including one oral presentation looking at the effect of prior treatment with tumor necrosis factor inhibitors (TNFi) on efficacy endpoints. In addition, two abstracts have been accepted as poster presentations, highlighting results by endoscopic response, and onset of action, respectively.
---------	---

News Date	11/10/2016
Category	Partnership / Strategic Alliance
Headline	Transgene Announced Collaboration With Merck KGaA, Darmstadt, Germany, And Pfizer To Evaluate The Combination Of Tg4001 With Avelumab In HPV-Positive Head And Neck Cancer In A Phase 1/2 Study
Summary	Transgene announced that it had entered a collaboration agreement with the science and technology company Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) under which Transgene will sponsor a Phase 1/2 study evaluating the potential of the therapeutic vaccine candidate TG4001 in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, for the treatment of human papilloma virus- (HPV-) positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy.

News Date	10/10/2016
Category	Trial Results
Headline	First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Showed Sutent (sunitinib) Extended Disease Free Survival After Surgical Removal
Summary	Pfizer Inc (NYSE:PFE) announced results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating Sutent (sunitinib) as adjuvant therapy. The trial showed Sutent extended disease-free survival (DFS) by more than one year versus placebo in patients who were at high risk for recurrence after surgical resection of renal cell carcinoma (RCC) (HR 0.761; P=0.030 [95% CI: 0.594-0.975]). These results will be presented today during a Presidential Symposium (Abstract No LBA11_PR) at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology being held in Copenhagen, Denmark. The results have also been published online by The New England Journal of Medicine.

News Date	09/10/2016
Category	Trial Results

Headline	Pfizer Presented Promising New Immunotherapy Combination Data With Inlyta (Axitinib) In Advanced Renal Cell Carcinoma (RCC) Pfizer Presents Promising New Immunotherapy Combination Data With Inlyta (Axitinib) In Advanced Renal Cell Carcinoma (RCC)
Summary	Pfizer Inc (NYSE:PFE) announced data from an ongoing, investigational Phase 1b study of Inlyta (axitinib) combined with the checkpoint inhibitor pembrolizumab (A4061079, NCT02133742), a PD-1 inhibitor known as Keytruda and marketed by Merck, known as MSD outside the United States and Canada, in treatment-naïve patients with advanced renal cell carcinoma (RCC). The study was designed to establish dosing and evaluate the safety and anti-tumor activity of Inlyta when combined with pembrolizumab in first-line treatment of advanced RCC.

News Date	06/10/2016
Category	Partnership / Strategic Alliance
Headline	ICU Medical Inc Acquired The Hospira Infusion Systems Business From Pfizer Inc For USD 1 Billion In Cash And Stock
Summary	ICU Medical Inc (NASDAQ:ICUI) and Pfizer Inc (NYSE:PFE) announced that they have entered into a definitive agreement under which ICU Medical will acquire all of Pfizer's global infusion therapy business, Hospira Infusion Systems (HIS), for USD 1 billion in cash and stock. The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with ICU Medical's existing businesses, will create a leading pure-play infusion therapy company, with estimated pro forma combined revenues of approximately USD 1.45 billion based on trailing twelve month results as of June 2016.

News Date	06/10/2016
Category	Partnership / Strategic Alliance
Headline	ICU Medical Inc. To Acquire The Hospira Infusion Systems Business From Pfizer Inc. For USD 1 Billion In Cash And Stock
Summary	ICU Medical Inc. announced that they have entered into a definitive agreement under which ICU Medical will acquire all of Pfizer's global infusion therapy business, Hospira Infusion Systems, for USD 1 billion in cash and stock. The Hospira Infusion Systems business includes 4 pumps, solutions, and devices that, when combined with ICU Medical's existing businesses, will create a leading pure-play infusion therapy company, with estimated pro forma combined revenues of approximately USD 1.45 billion based on trailing tTheylve month results as of June 2016.

News Date	28/09/2016
Category	Trial Results

Headline	Pfizer Showcased Progress Of Broad-Based Oncology Portfolio At European Society For Medical Oncology (ESMO) 2016 Congress
Summary	Pfizer Inc (NYSE:PFE) announced that it has presented data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. The presentations demonstrate progress addressing cancer's complex challenges through our work across 11 tumor types and eight distinct mechanisms of action, including two immuno-oncology/targeted therapy combination studies in renal cell carcinoma (RCC).

News Date	28/09/2016
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition Of Medivation
Summary	Pfizer Inc (NYSE: PFE) announced the successful completion of its acquisition of Medivation, Inc.(NASDAQ: MDVN). As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for USD 81.50 per share in cash, without interest, subject to any required withholding of taxes. In addition, notices of guaranteed delivery have been delivered for 17,659,861 shares of Medivation common stock, representing approximately 10.6% of the shares outstanding. Following its acceptance of the tendered shares, Pfizer completed its acquisition of Medivation through a second-step merger. Pfizer and its wholly-owned subsidiary accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.

News Date	26/09/2016
Category	Company Announcements-Others
Headline	Pfizer Decided Remaining One Company Best Positions Company To Maximize Future Value Creation
Summary	Pfizer Inc. announced that, after an extensive evaluation, the company's Board of Directors and Executive Leadership Team had determined the company was best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two, separate publicly traded companies at this time.

News Date	23/09/2016
Category	Company Announcements-Others
Headline	Pfizer Announced Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation

Summary	Pfizer Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended had expired with respect to Pfizer's pending acquisition of Medivation, Inc. (NASDAQ: MDVN).
---------	---

News Date	22/09/2016
Category	Financial Performance-Others
Headline	Pfizer Declared 30-Cent Fourth-Quarter 2016 Dividend
Summary	Pfizer Inc declared a 30-cent fourth-quarter 2016 dividend on the company's common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016. The fourth-quarter 2016 cash dividend the 312th consecutive quarterly dividend paid by Pfizer.

News Date	16/09/2016
Category	CHMP opinion
Headline	Pfizer Received Positive CHMP Opinion For Ibrance (Palbociclib) In Combination With Endocrine Therapy For The Treatment Of Hr+/Her2- Metastatic Breast Cancer In Europe
Summary	Pfizer Inc (NYSE:PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Ibrance (palbociclib) be granted marketing authorization in the European Union (EU) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The CHMP's positive opinion is for Ibrance to be used in combination with an aromatase inhibitor, as well as in combination with fulvestrant in women who have received prior endocrine therapy. The CHMP's opinion will now be reviewed by the European Commission (EC).

News Date	16/09/2016
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results From Reflections B537-02 Study For Pf-06438179 (Infliximab-Pfizer) A Potential Biosimilar To Remicade (Infliximab)
Summary	Pfizer Inc (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade (infliximab) met its primary endpoint. The trial demonstrated equivalent efficacy of the proposed biosimilar PF-06438179 to the originator product as measured by the American College of Rheumatology 20 (ACR20) response at Week 14. PF-06438179 being developed as a potential biosimilar to Remicade.

News Date	15/09/2016
Category	Trial Results
Headline	Merck And Pfizer Announced Investigational Ertugliflozin Met Primary Endpoint Of A1C Reduction When Added To Sitagliptin And Metformin In People With Type 2 Diabetes
Summary	Merck (NYSE: MRK) in partnership with Pfizer Inc (NYSE: PFE) announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. Both 5 mg and 15 mg daily doses of ertugliflozin showed significantly greater reductions in A1C of 0.69 percent and 0.76 percent, respectively, compared with placebo ($p<0.001$, for both comparisons), when added to patients on a background of sitagliptin (100 mg/day) and stable metformin (1500 mg/day). These study results were presented for the first time during an oral session at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany.

News Date	15/09/2016
Category	Trial Results
Headline	Merck And Pfizer Announced Investigational Ertugliflozin Met Primary Endpoint Of A1c Reduction When Added To Sitagliptin And Metformin In People With Type 2 Diabetes
Summary	Merck (NYSE: MRK) announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. Both 5 mg and 15 mg daily doses of ertugliflozin showed significantly greater reductions in A1C of 0.69 percent and 0.76 percent, respectively, compared with placebo ($p<0.001$, for both comparisons), when added to patients on a background of sitagliptin (100 mg/day) and stable metformin (=1500 mg/day). These study results were presented for the first time during an oral session at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany.

News Date	14/09/2016
Category	Regulatory-Others
Headline	FDA Advisory Committees Recommend To Remove Boxed Warning In Labeling For Pfizer's Smoking Cessation Therapy, Chantix (Varenicline)

Summary	U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee reviewed data from EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) evaluating the neuropsychiatric safety of CHANTIX (varenicline). The Committees recommended by a majority vote to remove the boxed warning regarding serious neuropsychiatric adverse events from the CHANTIX labeling. The role of the Advisory Committees is to provide recommendations to the FDA; however, the FDA makes the final labeling decisions.
---------	--

News Date	13/09/2016
Category	Company Announcements-Others
Headline	Pfizer Launched New "Moodivator" App To Help Support, Encourage And Motivate People With Depression
Summary	Pfizer Inc announced that it had launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7 percent) experience at least one major depressive episode in any given year.

News Date	07/09/2016
Category	Management Changes
Headline	Pfizer Appointed Chief Scientific Officer For Neuroscience Research
Summary	Pfizer Inc announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.

News Date	01/09/2016
Category	Conferences
Headline	Pfizer Invited Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Summary	Pfizer Inc announced that it has invited investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 at 12:15 p.m. Eastern Daylight Time.

News Date	31/08/2016
Category	Drug approvals
Headline	Xalkori (Crizotinib) Received Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Summary	Pfizer Inc. announced that the European Commission had approved XALKORI (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). In the European Union (EU), XALKORI is also indicated for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC. In March of this year, XALKORI was approved by the United States (U.S.) Food and Drug Administration for patients with metastatic NSCLC whose tumors are ROS1-positive. With this approval, XALKORI becomes the only biomarker-driven therapy approved for patients with either ALK positive or ROS1-positive advanced NSCLC in the EU and U.S.

News Date	29/08/2016
Category	Partnership / Strategic Alliance
Headline	Pfizer And Adolor Entered Into Exclusive Worldwide Collaboration To Develop And Commercialize Novel Pain Compounds
Summary	Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced an exclusive worldwide collaboration to develop and commercialize novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both compounds are proprietary Delta opioid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions.

News Date	24/08/2016
Category	Partnership / Strategic Alliance
Headline	Pfizer Acquired Small Molecule Anti-Infective Business From AstraZeneca
Summary	Pfizer Inc. (NYSE:PFE) announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States. The agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam), the marketed agents Merrem/Meronem(meropenem) and Zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL. Zavicefta specifically addresses multi-drug resistant Gram-negative infections, including those resistant to carbapenem antibiotics, one of the most significant unmet medical needs in bacterial infections treated with hospital anti-infectives.

News Date	24/08/2016
Category	Mergers & Acquisitions
Headline	Astrazeneca Sold Small Molecule Antibiotics Business To Pfizer
Summary	<p>AstraZeneca announced that it has entered into an agreement with Pfizer Inc (Pfizer) to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US. The agreement reinforces AstraZeneca's focus on developing transformational medicines in its three main therapy areas, while realising value from the strong portfolio of established and late-stage small molecule antibiotics through Pfizer's dedicated commercialisation and development capabilities in anti-infectives. The portfolio comprises the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.</p>

News Date	23/08/2016
Category	Presentations
Headline	Bristol-Myers Squibb And Pfizer Presented New Eliquis (Apixaban) Analyses At ESC Congress 2016
Summary	<p>Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.(NYSE: PFE) announced that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy. These new data from post-hoc analyses from ARISTOTLE (Apixaban for Reduction In STroke and Other Thromboembolic Events in Atrial Fibrillation) and retrospective real-world data analyses continue to underscore the Alliance's commitment to the evaluation of Eliquis for patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Of note, several of the real-world data analyses are part of Acropolis (Apixaban ExperienCe Through Real-WORLD POpuLation Studies), a global real-world data research program designed to further evaluate the effectiveness and safety of apixaban in routine clinical practice.</p>

News Date	23/08/2016
Category	Presentations
Headline	Bristol-Myers Squibb And Pfizer Presented New Eliquis (Apixaban) Analyses At ESC Congress 2016

Summary	Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) announced that 19 abstracts presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy. These new data from post-hoc analyses from ARISTOTLE (Apixaban for Reduction In STroke and Other Thromboembolic Events in Atrial Fibrillation) and retrospective real-world data analyses continue to underscore the Alliance's commitment to the evaluation of Eliquis for patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Of note, several of the real-world data analyses are part of Acropolis (Apixaban ExperienCe Through Real-WORld POpuLation Studies), a global real-world data research program designed to further evaluate the effectiveness and safety of apixaban in routine clinical practice.
---------	--

News Date	22/08/2016
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Medivation
Summary	Pfizer Inc (NYSE:PFE) and Medivation Inc (NASDAQ:MDVN) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for USD 81.50 a share in cash for a total enterprise value of approximately USD 14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately USD 0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.

News Date	22/08/2016
Category	Mergers & Acquisitions
Headline	Pfizer To Acquired Medivation
Summary	Pfizer Inc. and Medivation, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for USD 81.50 a share in cash for a total enterprise value of approximately USD 14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately USD 0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.

News Date	19/08/2016
-----------	------------

Category	Drug approvals
Headline	FDA Approved Troxyca ER (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-Release Capsules CII With Abuse-Deterrent Properties For The Management Of Pain
Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TROXYCA ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes. However, abuse of TROXYCA ER by these routes is still possible. It is the only oxycodone with oral abuse-deterrent features described in the labeling.

News Date	08/08/2016
Category	Product Update-Others
Headline	Pfizer Announced Publication Of New Analysis Showing Long-Term Therapy With Vyndaqel (Tafamidis) Slowed Progression Of Rare Neurodegenerative Disease
Summary	Pfizer Inc (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of Vyndaqel in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5.5 years, showed that treatment with Vyndaqel initiated during the early stage of the disease resulted in minimal neurological disease progression and in preservation of body weight, which often declines as the disease progresses. Vyndaqel was well tolerated with no new safety signals observed. The new findings were published online in Amyloid: The Journal of Protein Folding Disorders.

News Date	01/08/2016
Category	Mergers & Acquisitions
Headline	Pfizer Aimed To Become Industry Leader In Gene Therapy With Aquisition Of Bamboo Therapeutics Inc
Summary	Pfizer Inc announced that it had acquired Bamboo Therapeutics, Inc. This acquisition significantly expanded Pfizer's expertise in gene therapy by providing Pfizer with a clinical and several pre-clinical assets that complement the company's rare disease portfolio, an advanced recombinant Adeno-Associated Virus (rAAV) vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility that Bamboo acquired from the University of North Carolina earlier this year.

News Date	28/07/2016
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Pfizer And Western Oncolytics Announced Immuno-Oncology Research Collaboration To Investigate Novel Oncolytic Virus Technology
Summary	Pfizer Inc and Western Oncolytics announced that they had entered into a development collaboration, license and option agreement to advance Western Oncolytics' novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel technology platform to Pfizer's cancer vaccine efforts and provides an additional tool to bolster its immuno-oncology portfolio.

News Date	28/07/2016
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results From Pivotal Phase 3 Maintenance Trial Of Oral Xeljanz (Tofacitinib Citrate) In Ulcerative Colitis
Summary	Pfizer Inc announced top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Sustain, the third Phase 3 study of XELJANZ (tofacitinib citrate) being investigated in patients with moderately to severely active ulcerative colitis (UC). OCTAVE Sustain is a 52 week study that evaluated oral tofacitinib 5 mg and 10 mg twice daily (BID) as a maintenance treatment in adult patients with moderately to severely active UC who previously completed and achieved clinical response in either the OCTAVE Induction 1 or OCTAVE Induction 2 studies.

News Date	25/07/2016
Category	Trial Results
Headline	Spark Therapeutics And Pfizer Announced Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity
Summary	Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced updated results of the first cohort from the ongoing Phase 1/2 clinical trial of SPK-9001, the lead investigational candidate in the companies' SPK-FIX program, in development for the treatment of hemophilia B as a potential one-time therapy. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, was developed using Spark's proprietary technology platform for selecting, designing, manufacturing and formulating highly optimized gene therapies. SPK-9001 has received breakthrough therapy designation from the U.S. Food and Drug Administration.

News Date	21/07/2016
-----------	------------

Category	Breakthrough
Headline	Spark Therapeutics And Pfizer Announced Receipt Of Food And Drug Administration Breakthrough Therapy Designation For SPK-9001 For The Treatment Of Hemophilia B
Summary	Spark Therapeutics and Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies' SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, is being investigated in an ongoing Phase 1/2 trial as a potential one-time therapy.

News Date	21/07/2016
Category	Breakthrough
Headline	Spark Therapeutics And Pfizer Announced Receipt Of FDA Breakthrough Therapy Designation For SPK-9001 For The Treatment Of Hemophilia B
Summary	Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies' SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, is being investigated in an ongoing Phase 1/2 trial as a potential one-time therapy.

News Date	19/07/2016
Category	Product Update-Others
Headline	Pfizer Received World Health Organization Prequalification For Multi-Dose Vial Presentation Of Prevenar 13
Summary	Pfizer Inc announced that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). WHO prequalification allows for the global use of Prevenar 13 MDV by United Nations agencies and countries worldwide that require WHO prequalification

News Date	13/07/2016
Category	Trial Results
Headline	Pfizer Announced The Publication Of Final Results From Two Pivotal Phase 3 Studies Of Crisaborole Topical Ointment In Patients With Mild To Moderate Atopic Dermatitis

Summary	Pfizer Inc announced the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology
---------	--

News Date	13/07/2016
Category	Partnership / Strategic Alliance
Headline	Pfizer and NovaMedica Announced a Strategic Partnership in Russia
Summary	Pfizer, Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines.

News Date	12/07/2016
Category	Drug approvals
Headline	Pfizer Received Food And Drug Administration Approval For Prevnar 13 In Adults Age 18 Through 49
Summary	Pfizer Inc announced that Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13 is the only pneumococcal vaccine approved across the lifespan.

News Date	08/07/2016
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results From Phase 3 S-TRAC Trial Of Sutent (sunitinib) As Adjuvant Therapy In Patients At High Risk Of Recurrent Renal Cell Carcinoma
Summary	Pfizer Inc announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery. The S-TRAC trial is the first RCC trial of a tyrosine kinase inhibitor (TKI) to prolong DFS in the adjuvant setting. The concept of adjuvant therapy is to help lower the risk of cancer recurrence in patients with early-stage cancer.

News Date	06/07/2016
Category	Trial Initiations
Headline	Merck KGaA And Pfizer Initiated Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer
Summary	Merck and Pfizer announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first Phase III study evaluating the addition of an immune checkpoint inhibitor to standard-of-care in first-line treatment for this aggressive disease.

News Date	06/07/2016
Category	Trial Initiations
Headline	Merck And Pfizer Initiated Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer
Summary	Merck and Pfizer announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first Phase III study evaluating the addition of an immune checkpoint inhibitor to standard-of-care in first-line treatment for this aggressive disease.

News Date	28/06/2016
Category	Trial Results
Headline	Pfizer Announced Two Additional Phase 3 Lipid-Lowering Studies Of Bococizumab Delivered Positive Topline Results
Summary	Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among adults at high and very high risk for cardiovascular events who were receiving a maximally tolerated dose of a highly effective statin.

News Date	27/06/2016
-----------	------------

Category	Financial Performance-Others
Headline	Pfizer Advances Biosimilars Leadership With Investment In A New World-Class Global Biotechnology Center In China
Summary	Pfizer Inc announced that it will invest approximately USD 350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China.

News Date	24/06/2016
Category	Partnership / Strategic Alliance
Headline	Hikma Acquired Six Injectable Products In Europe
Summary	Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) announced that it has agreed to acquire a portfolio of six injectable products and their related customer contracts from Pfizer Inc. (NYSE: PFE).

News Date	24/06/2016
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition Of Anacor
Summary	Pfizer Inc announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive USD 99.25 net in cash (without interest but subject to required withholding of taxes).

News Date	24/06/2016
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition Of Anacor
Summary	Pfizer Inc. announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive USD 99.25 net in cash.

News Date	23/06/2016
Category	Financial Performance-Others
Headline	Pfizer Declared 30-Cent Third-Quarter 2016 Dividend

Summary	The board of directors of Pfizer Inc declared a 30-cent third-quarter 2016 dividend on the company's common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer.
---------	---

News Date	21/06/2016
Category	Company Announcements-Others
Headline	Pfizer Invited Public To View And Listen To Webcast Of Conference Call With Analysts
Summary	Pfizer Inc. invited investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on August 2, 2016. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2016 Performance Report, to be issued that morning.

News Date	16/06/2016
Category	Geography expansion
Headline	Pfizer Broke Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts
Summary	Pfizer Inc broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company's presence in the state, Pfizer will invest more than USD 200 million in development of the 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines. The new 5-story building is expected to be operational by January 2019. Approximately 75 new employees will be hired to support clinical manufacturing. In addition to the Andover campus, Massachusetts is home to Pfizer's Research and Development hub in Cambridge. Pfizer has approximately 2,000 employees based in Massachusetts.

News Date	16/06/2016
Category	Company Announcements-Others
Headline	Help Pfizer Change The Future Of Healthy Aging
Summary	Pfizer Inc announced that it is challenging people across the United States (U.S.) to develop the next big idea in healthy aging through a unique partnership with crowdfunding platform Indiegogo (link is external). As the first pharmaceutical company to partner with Indiegogo, Pfizer will tap into the 400,000-strong Pfizer Get Old community and Indiegogo's vast pool of entrepreneurs to submit and vote on innovative products or services that support healthy living as we age. The best idea will receive U.S. USD 50,000 in funding and an opportunity to meet with a team of Pfizer experts to help bring it from concept to reality.

News Date	14/06/2016
Category	Product Update-Others
Headline	Shire To License PF-00547659 From Pfizer, Adding To Established And Leading Gastrointestinal Portfolio
Summary	Shire plc (LSE: SHP, NASDAQ: SHPG) announced it has agreed to license global rights to all indications for PF-00547659 from Pfizer Inc. (NYSE: PFE). PF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD). PF-00547659 has been evaluated in more than 700 patients in Phase 1 and 2 trials, and Phase 3 trials are expected to begin after consultation with global health authorities. Closing of the transaction is subject to HSR approval.

News Date	12/06/2016
Category	Trial Results
Headline	Pfizer Announced Final Results From Inotuzumab Ozogamicin Pivotal Phase 3 Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia
Summary	Pfizer Inc announced the publication of findings from the Phase 3 INO-VATE ALL study in the online issue of The New England Journal of Medicine. The study, also known as Study 1022, is an open-label, randomized, Phase 3 study evaluating the safety and efficacy of inotuzumab ozogamicin as compared with investigator-choice chemotherapy in 326 adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). Results showed improvement over chemotherapy on a number of measures including complete hematologic remission and progression-free survival (PFS). Updated results and newly available overall survival (OS) data were also presented as a late-breaking oral presentation (no-LB2233) today at the 21st Congress of the European Hematology Association (EHA) 2016 Annual Meeting in Copenhagen, Denmark.

News Date	11/06/2016
Category	Trial Results
Headline	Merck And Pfizer Announced Two Pivotal Phase 3 Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes

Summary	Merck in partnership with Pfizer Inc announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). These results from the VERTIS clinical development program of ertugliflozin will be presented for the first time at the 76th Scientific Sessions of the American Diabetes Association, which are being held in New Orleans from June 10-14, 2016.
---------	--

News Date	11/06/2016
Category	Trial Results
Headline	Merck And Pfizer Announced Two Pivotal Phase 3 Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1c Reductions In Patients With Type 2 Diabetes
Summary	Merck (NYSE:MRK) in partnership with Pfizer Inc. (NYSE:PFE) announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). These results from the VERTIS clinical development program of ertugliflozin will be presented for the first time at the 76th Scientific Sessions of the American Diabetes Association, which are being held in New Orleans from June 10-14, 2016.

News Date	10/06/2016
Category	Partnership / Strategic Alliance
Headline	Icon Announced Service Agreement With Pfizer
Summary	ICON plc, (NASDAQ: ICLR) announced it has signed a three-year agreement with Pfizer Inc. (NYSE:PFE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.

News Date	10/06/2016
Category	Partnership / Strategic Alliance
Headline	Parexel Announced Master Services Agreement With Pfizer

Summary	Parexel International Corporation (NASDAQ: PRXL) announced that it has signed a services agreement with Pfizer Inc. Under the terms of this agreement, Parexel continued to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.
---------	--

News Date	09/06/2016
Category	Company Announcements-Others
Headline	Pro Golfer Jim Furyk Teamed With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination
Summary	Pfizer announced that this Father's Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On Father's Day 2003, Furyk won a Major with his coach and father, Mike, by his side. This year, Jim will be one of 156 golfers to gather in Oakmont, PA, to play in one of professional golf's major championship tournaments.

News Date	08/06/2016
Category	Product Update-Others
Headline	Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (Xeljanz) Provided Clinicians With Additional Information For The Treatment Of Moderate To Severe Rheumatoid Arthritis
Summary	Pfizer Inc announced that 23 abstracts, including research and analyses for tofacitinib citrate (XELJANZ), will be featured at the upcoming European League Against Rheumatism (EULAR) Congress (June 8-11, London). The research being shared at the meeting provides new and additional information on the efficacy and safety profile of tofacitinib citrate, including its use as a single agent without methotrexate.

News Date	08/06/2016
Category	Regulatory Opinion
Headline	Pfizer Announced Food And Drug Administration Advisory Committees' Recommended ALO-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-Release Capsules For Approval

Summary	Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, "management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate."
---------	--

News Date	08/06/2016
Category	:Partnership / Strategic Alliance
Headline	DKSH And Pfizer Expanded Collaboration In Thailand
Summary	DKSH announced that its provided marketing and promotional services for certain Pfizer antibiotic and cardiovascular products in hospitals, clinics and pharmacies across Thailand.

News Date	07/06/2016
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results From Second Phase 3 Trial Of Oral Xeljanz(Tofacitinib Citrate) In Adults With Psoriatic Arthritis
Summary	Pfizer Inc announced top-line results from Oral Psoriatic Arthritis triAL (OPAL) Beyond, the second Phase 3 study of XELJANZ (tofacitinib citrate) being investigated in patients with active psoriatic arthritis (PsA). This study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adult patients with active PsA who had an inadequate response to at least one tumor necrosis factor inhibitor (TNFi), making it the first PsA study to focus exclusively on TNFi-IR patients. ¹ OPAL Beyond met its primary efficacy endpoints demonstrating a statistically significant ($p<0.0001$) improvement with tofacitinib 5 mg BID and 10 mg BID compared to placebo treatment as measured by American College of Rheumatology 20 (ACR20) response and Health Assessment Questionnaire Disability Index (HAQ-DI) score at 3 months.

News Date	07/06/2016
Category	Company Announcements-Others
Headline	Pfizer Announced A Mother's Mission To Help Prevent Another Life Lost To MenB

Summary	The Kimberly Coffey Foundation had teamed up with Pfizer Inc on a national survey to better understand parents' knowledge of meningococcal disease and available vaccines. One moment Patti Wukovits was preparing for her daughter's high school graduation, and the next moment she was watching her fight for her life for 9 days in the intensive care unit. In 2012, Patti lost her 17-year-old daughter, Kimberly Coffey, to group B meningococcal disease, also known as MenB, just days before Kim's senior prom and high school graduation. Following this tragedy, Patti established The Kimberly Coffey Foundation to help educate parents and healthcare professionals specifically about MenB and to help prevent another family from enduring a loss due to this vaccine-preventable disease.
---------	---

News Date	06/06/2016
Category	Trial Results
Headline	Merck Announced Pivotal Avelumab Study Shows Positive Results In Metastatic Merkel Cell Carcinoma In American Society Of Clinical Oncology (ASCO) Annual Meeting 2016
Summary	Merck and Pfizer announced results from the first pivotal, international, multicenter, open-label, Phase II study of avelumab*, which showed a 31.8% objective response rate (ORR) (28 of 88 patients; 95.9% CI: 21.9–43.1%†), in the pre-planned primary analysis of the study, and a manageable safety profile in patients with metastatic Merkel cell carcinoma (MCC) who were treated with avelumab in second or subsequent lines of therapy. Tumor responses were rapid, with 78.6% of patients (22 of 28) responding within 7 weeks of starting treatment, and durable, with 82.1% of patients (23 of 28) still responding at the time of analysis. No unexpected safety signals were reported. These data will be reported today during an oral presentation at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.

News Date	06/06/2016
Category	Trial Results
Headline	Pfizer Presented Promising Data From Next Generation ALK/ROS1 Inhibitor In Advanced Non-Small Cell Lung Cancer
Summary	Pfizer Inc announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. These data were presented in an oral presentation at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

News Date	06/06/2016
-----------	------------

Category	Trial Results
Headline	Pfizer Pivotal Avelumab Study Showed Positive Results In Metastatic Merkel Cell Carcinoma Presented At American Society Of Clinical Oncology (ASCO) Annual Meeting 2016
Summary	Merck KGaA and Pfizer announced results from the first pivotal, international, multicenter, open-label, Phase II study of avelumab, which showed a 31.8% objective response rate (ORR) (28 of 88 patients; 95.9% CI: 21.9–43.1%†), in the pre-planned primary analysis of the study, and a manageable safety profile in patients with metastatic Merkel cell carcinoma (MCC) who were treated with avelumab in second or subsequent lines of therapy. Tumor responses were rapid, with 78.6% of patients (22 of 28) responding within 7 weeks of starting treatment, and durable, with 82.1% of patients (23 of 28) still responding at the time of analysis. No unexpected safety signals were reported. These data will be reported during an oral presentation at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

News Date	04/06/2016
Category	Trial Results
Headline	Pfizer Presented Data From Phase 1b Trial Investigating Utomilumab (A 4-1BB Agonist) In Combination With A Checkpoint Inhibitor
Summary	Pfizer Inc announced results from a Phase 1b trial of Pfizer's investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1 inhibitor, in patients with advanced solid tumors. This is the first reported study of a 4-1BB agonist combined with a checkpoint inhibitor. Encouraging safety data from the study were shared today as an oral presentation at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

News Date	03/06/2016
Category	Partnership / Strategic Alliance
Headline	ViiV Healthcare Announced Public Tender Agreement With Botswana Ministry Of Health For Dolutegravir
Summary	ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders confirmed a public tender agreement with the Ministry of Health in Botswana to support the implementation of a new national 'Treat All' programme which aims to ensure people living with HIV in the country get tested and receive treatment. This is the first time dolutegravir will be made available as part of a national health programme in sub-Saharan Africa since the WHO recommended dolutegravir as alternative first line treatment in HIV patients in late 2015

News Date	01/06/2016
Category	Product Launch
Headline	Greenstone Llc Introduced Dofetilide Capsules
Summary	Greenstone LLC, a US-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Dofetilide Capsules to its ever-expanding generic pharmaceutical product line. The product is offered and available in dosage strengths of 125 mcg (0.125 mg) x 60 capsules per bottle, 250 mcg (0.250 mg) x 60 capsules per bottle and 500 mcg (0.5 mg) x 60 capsules per bottle.

News Date	24/05/2016
Category	Partnership / Strategic Alliance
Headline	Vifor Pharma To License Commercialisation Rights To Pfizer's Proposed Biosimilar, Retacrit, In The Field Of Nephrology In The US
Summary	Vifor Pharma announced that it has further expanded its Erythropoiesis Stimulating Agent (ESA) portfolio with the licensing of commercialisation rights in the US dialysis market to Pfizer's Retacrit, a proposed biosimilar epoetin, in the field of nephrology.

News Date	24/05/2016
Category	Partnership / Strategic Alliance
Headline	Vifor Pharma Expanded ESA Product Portfolio With Rights To Commercialise Pfizer's Proposed Epoetin Alfa Biosimilar, Retacrit, In The US Dialysis Market
Summary	Vifor Pharma announced that it has further expanded its Erythropoiesis Stimulating Agent (ESA) portfolio with the licensing of commercialisation rights in the US dialysis market to Pfizer's Retacrit, a proposed biosimilar epoetin, in the field of nephrology.

News Date	23/05/2016
Category	Product Update-Others
Headline	Pfizer Announced CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP

Summary	Pfizer Inc. announced that the European Summary of Product Characteristics (SmPC) and Package Leaflet for CHAMPIX (varenicline) have been updated to include safety and efficacy data from the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial. As part of the update, the black triangle symbol, which indicated that additional safety monitoring for CHAMPIX in the EU was required, has been removed. EAGLES is a post-authorization safety study/post-marketing requirement study, which was conducted in 16 countries and designed to evaluate the neuropsychiatric safety of CHANTIX/CHAMPIX and bupropion versus placebo and nicotine replacement therapy patch (NRT) in patients with and without a history of psychiatric disorder. The outcomes of the EAGLES trial were recently published in <i>The Lancet</i> . ² The CHAMPIX EU label update was implemented following the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
---------	---

News Date	20/05/2016
Category	Priority Review
Headline	Pfizer Announced European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)
Summary	Pfizer Inc. announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA (Meningococcal Group B Vaccine) for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused by <i>Neisseria meningitidis</i> serogroup B (Mb) in individuals aged 10 years and older. The acceptance marks the beginning of the regulatory review process for this vaccine in the EU.

News Date	19/05/2016
Category	Trial Results
Headline	Spark Therapeutics And Pfizer Announced Data From Initial Subjects In Hemophilia B Trial Demonstrating Consistent Therapeutic Levels Of Factor IX Expression
Summary	Spark Therapeutics (ONCE) and Pfizer Inc. (PFE) announced that new data will be presented on June 11 at the European Hematology Association's (EHA) 21st Congress. These data will show encouraging initial observations for the first subjects dosed in the Phase 1/2 clinical trial of SPK-9001, the lead investigational compound in the SPK-FIX program, which is being studied for the treatment of Hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized high-activity human Factor IX variant, was developed using Spark's proprietary technology platform for selecting, designing, manufacturing and formulating highly optimized gene therapies. The conference abstract, including a figure demonstrating Factor IX activity levels (as % of normal) expressed by subject over time, was made available

News Date	19/05/2016
Category	Presentations
Headline	Spark Therapeutics And Pfizer Announce Data From Initial Subjects IN Hemophilia B Trial Demonstrating Consistent Therapeutic Levels Of Factor IX Expression
Summary	Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced that new data will be presented on June 11 at the European Hematology Association's (EHA) 21st Congress. These data will show encouraging initial observations for the first subjects dosed in the Phase 1/2 clinical trial of SPK-9001, the lead investigational compound in the SPK-FIX program, which is being studied for the treatment of Hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized high-activity human Factor IX variant, was developed using Spark's proprietary technology platform for selecting, designing, manufacturing and formulating highly optimized gene therapies.

News Date	19/05/2016
Category	Product Launch
Headline	Hospira Launched Lifecare Pca 7.0 Infusion System, First Pca Pump That Integrates With The Electronic Medical Record
Summary	Hospira, a Pfizer (NYSE: PFE) company and a leading provider of infusion technologies, announced the launch of the LifeCare PCA 7.0 Infusion System.

News Date	18/05/2016
Category	Product Update-Others
Headline	Merck KGaA And Pfizer Presented Avelumab Data In Seven Different Cancers At ASCO Annual Meeting
Summary	Merck KGaA and Pfizer announced that avelumab presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3–7, 2016, in Chicago, IL. The avelumab presentations, from the rapidly accelerating JAVELIN clinical development program, include new study results from a number of difficult-to-treat cancers, including data from the pivotal Phase II trial of avelumab being investigated as second-line treatment for metastatic Merkel cell carcinoma (MCC). Additional data include highlights from mesothelioma, adrenocortical carcinoma, non-small cell lung cancer, and urothelial bladder, gastric and ovarian cancers, as well as updated safety data.

News Date	18/05/2016
-----------	------------

Category	Meeting schedules
Headline	Pfizer Showcased Diverse And Growing Oncology Portfolio At The American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
Summary	<p>Pfizer Inc. announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action. Presentations include eight oral presentations and five poster discussions that span Pfizer's internal and collaborative scientific advances. Highlights include the first presentation of a novel immunotherapy combination study involving a 4-1BB agonist and checkpoint inhibitor as a potential new immunotherapy strategy and new clinical data featuring breakthrough treatments IBRANCE (palbociclib) and XALKORI (crizotinib), as well as investigational assets avelumab, an anti-PD-L1 IgG1 monoclonal antibody that is being developed in collaboration with Merck KGaA, Darmstadt, Germany, and lorlatinib, a next-generation ALK/ROS1 tyrosine kinase inhibitor.</p>

News Date	18/05/2016
Category	Meeting schedules
Headline	Merck And Pfizer Presented Avelumab Data In Seven Different Cancers At ASCO Annual Meeting
Summary	<p>Merck and Pfizer announced that avelumab presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3–7, 2016, in Chicago, IL. The avelumab presentations, from the rapidly accelerating JAVELIN clinical development program, include new study results from a number of difficult-to-treat cancers, including data from the pivotal Phase II trial of avelumab being investigated as second-line treatment for metastatic Merkel cell carcinoma (MCC). Additional data include highlights from mesothelioma, adrenocortical carcinoma, non-small cell lung cancer, and urothelial bladder, gastric and ovarian cancers, as well as updated safety data.</p>

News Date	17/05/2016
Category	Trial Results
Headline	Pfizer Announced Global Survey Finds Disconnects Between Physicians And People Living With Rheumatoid Arthritis (RA)

Summary	Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management. The findings from more than 1,700 rheumatologists in 15 countries builds upon results from the global patient survey findings, released in 2015, involving 3,900 adults living with RA. The combined survey data demonstrate disconnects between patients and physicians across multiple aspects of RA disease management. Most strikingly, new data from the physician survey revealed that two in three physicians stated that their patients living with RA say they feel "good enough" even though clinical assessments indicated active disease.
---------	---

News Date	16/05/2016
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Anacor
Summary	Pfizer Inc. and Anacor Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for USD 99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately USD 5.2 billion, which assumes the conversion of Anacor's outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor's flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.

News Date	16/05/2016
Category	Company Announcements-Others
Headline	Icon And Pfizer Honoured As Clinical Research Team Of The Year At The Clinical And Research Excellence Awards
Summary	ICON plc, (NASDAQ: ICLR) announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards which took place in Boston on the 27th April.

News Date	16/05/2016
Category	Mergers & Acquisitions
Headline	Pfizer To Acquire Anacor

Summary	Pfizer Inc. and Anacor Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for USD 99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately USD 5.2 billion, which assumes the conversion of Anacor's outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor's flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
---------	---

News Date	13/05/2016
Category	Trial Results
Headline	Pfizer Presented Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting
Summary	Pfizer Inc. announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responses against ten additional MnB strains, in both adolescents and young adults. The data, which continue to support the vaccine's current safety and tolerability profile, were presented at the 34th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2016).

News Date	11/05/2016
Category	Awards/Grants/Funds
Headline	Pfizer Awarded More Than USD 1 Million In Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative
Summary	Pfizer Inc. announced that it has awarded a total of more than USD 1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer's Breast Cancer: A Story Half Told initiative, aimed at uncovering gaps in the public's knowledge of MBC and bringing greater attention to the unique needs and experiences of people living with this disease. The need for greater research funding is among the most pressing the MBC community faces, with only about 7 percent of the total breast cancer investment focused on MBC.

News Date	10/05/2016
Category	Trial Initiations

Headline	First Dosing Of Pfizer DART Candidate In Phase 1 Study Triggers Milestone Payment To MacroGenics
Summary	MacroGenics, Inc. announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART, platform. Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported in various tumors, including breast, ovarian, endometrial, colorectal and pancreatic cancers, and is correlated with poor survival of patients. The commencement of the Phase 1 study triggers a Dollar 2 million milestone payment to MacroGenics under the companies' October 2010 agreement.

News Date	05/05/2016
Category	Partnership / Strategic Alliance
Headline	Wave Life Sciences Entered Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
Summary	Wave Life Sciences Ltd. (NASDAQ: WVE) announced that it has entered into a research, license and option agreement with Pfizer Inc. (NYSE: PFE) for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together Wave's proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer's hepatic targeting technology for enhanced delivery to the liver.

News Date	05/05/2016
Category	Partnership / Strategic Alliance
Headline	Wave Life Sciences Enters Collaboration With Pfizer To Develop Genetically Targeted Therapies For The Treatment Of Metabolic Diseases
Summary	Wave Life Sciences Ltd. (NASDAQ:WVE) announced that it has entered into a research, license and option agreement with Pfizer Inc. (NYSE: PFE) for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together Wave's proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer's hepatic targeting technology for enhanced delivery to the liver.

News Date	28/04/2016
Category	Financial Performance-Others

Headline	Pfizer Hosted Annual Meeting Of Shareholders
Summary	The board of directors of Pfizer Inc. declared a 30-cent second-quarter 2016 dividend on the company's common stock, payable June 1, 2016, to shareholders of record at the close of business on May 13, 2016. The second-quarter 2016 cash dividend will be the 310th consecutive quarterly dividend paid by Pfizer

News Date	26/04/2016
Category	Enrollment Update (Trial participants)
Headline	Pfizer Announced Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled
Summary	Pfizer Inc. announced patient enrollment completion in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab. SPIRE-2 is evaluating the efficacy and safety of bococizumab compared to placebo in reducing the risk of major cardiovascular events among approximately 10,600 patients at high risk for cardiovascular disease - including those without a prior history of cardiovascular events – who are on highly-effective statins or with documented statin intolerance.

News Date	25/04/2016
Category	Partnership / Strategic Alliance
Headline	ViiV Healthcare Extended Medicines Patent Pool Licence Agreement For Dolutegravir To Cover All Lower Middle-Income Countries
Summary	ViiV Healthcare owned by GSK, with Pfizer Inc. announced an extension of overall country coverage of its existing licence agreement for adults formulation of dolutegravir to the Medicines Patent Pool (MPP) to cover all lower middle income countries (LMICs).

News Date	22/04/2016
Category	Trial Results
Headline	Pfizer Announced CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet

Summary	Pfizer Inc. announced results published in <i>The Lancet</i> from the largest clinical trial of approved smoking cessation medicines, called EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study). This smoking cessation trial included 8,144 adult smokers and was designed to compare the neuropsychiatric safety of CHANTIX/CHAMPIX (varenicline) and bupropion with placebo and nicotine patch in adult smokers with and without a history of psychiatric disorders. The authors concluded that the trial did not show a significant increase in the incidence of the composite primary safety endpoint of serious neuropsychiatric adverse events with CHANTIX/CHAMPIX or bupropion compared to placebo and nicotine patch. Differences between incidence rates were considered significant if their associated 95% confidence intervals (CIs) were entirely above or below zero. Approximately half of the trial participants had a history of psychiatric disorders, either past and in remission or present and clinically stable. The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.
---------	--

News Date	19/04/2016
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib)
Summary	Pfizer Inc. announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. The study met its primary endpoint by demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus letrozole compared with letrozole plus placebo in post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer who had not received previous systemic treatment for their advanced disease. The PALOMA-2 trial provides confirmatory evidence for IBRANCE in combination with letrozole in the first-line setting, which was first studied in the Phase 2 PALOMA-1 trial. These data will support additional planned global regulatory submissions and a request for conversion of the accelerated approval for IBRANCE to regular approval in the U.S. Detailed efficacy and safety results from PALOMA-2 will be submitted for presentation at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

News Date	07/04/2016
Category	Partnership / Strategic Alliance
Headline	Pfizer Tapped IBM For Research Collaboration To Transform Parkinson's Disease Care

Summary	Pfizer Inc. announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson's disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient's disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options
---------	---

News Date	06/04/2016
Category	Drug approvals
Headline	Pfizer Received European Approval For New Multi-Dose Vial Presentation Of Prevenar 13
Summary	Pfizer Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.

News Date	06/04/2016
Category	Mergers & Acquisitions
Headline	Pfizer Announced Termination Of Proposed Combination With Allergan
Summary	Pfizer Inc. announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an "Adverse Tax Law Change" under the merger agreement.

News Date	06/04/2016
Category	Mergers & Acquisitions
Headline	Allergan Reiterated Strong Standalone Growth Profile And Strategy Following Termination Of Pfizer Transaction
Summary	Allergan plc announced that its merger agreement with Pfizer has been terminated by mutual agreement. In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan USD 150 million for reimbursement of expenses associated with the transaction.

News Date	06/04/2016
Category	Mergers & Acquisitions
Headline	Allergan Reiterated Strong Standalone Growth Profile And Strategy Following Termination Of Pfizer Transaction
Summary	Allergan plc announced that its merger agreement with Pfizer has been terminated by mutual agreement, effective . In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan USD 150 million for reimbursement of expenses associated with the transaction.

News Date	05/04/2016
Category	Drug approvals
Headline	Pfizer Announced Food And Drug Administartion Approved INFLECTRA(Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications
Summary	Pfizer announced that the United States (U.S.) Food and Drug Administration (FDA) approved Celltrion's INFLECTRA (biosimilar infliximab) across all eligible indications of the reference product, Remicade (infliximab).1INFLECTRA is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U.S

News Date	05/04/2016
Category	Trial Initiations
Headline	Merck And Pfizer Announced First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma
Summary	Merck and Pfizer announced the treatment of the first patient in a Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in an advanced renal cell carcinoma (RCC) setting. The study, JAVELIN Renal 101, is the first pivotal trial investigating avelumab in combination with INLYTA (axitinib), a tyrosine kinase inhibitor (TKI), in patients with previously untreated advanced RCC, and the only Phase III trial currently evaluating an anti-PD-L1 immunotherapy in combination with a vascular endothelial growth factor (VEGF)-receptor TKI in this setting. The 5-year survival rate for patients with distant metastatic RCC is approximately 12 percent.

News Date	05/04/2016
Category	Trial Results

Headline	Pfizer Announced Positive Top-Line Results From The First Phase 3 Trial Of Investigational Tofacitinib In Adults With Psoriatic Arthritis
Summary	Pfizer Inc. announced top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis trial (OPAL) Broaden. This study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adult patients with active psoriatic arthritis (PsA) who had an inadequate response to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and who were tumor necrosis factor inhibitor (TNFi)-naïve. OPAL Broaden met its primary efficacy endpoints demonstrating that both tofacitinib 5 mg BID and 10 mg BID were superior to treatment with placebo at 3 months as measured by American College of Rheumatology 20 (ACR20) response and Health Assessment Questionnaire Disability Index (HAQ-DI) score.

News Date	05/04/2016
Category	Product Update-Others
Headline	Merck And Pfizer Announced First Patient Treated In Phase III Combination Study With Avelumab And Inlyta In Renal Cell Carcinoma
Summary	Merck and Pfizer announced the treatment of the first patient in a Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in an advanced renal cell carcinoma (RCC) setting. The study, JAVELIN Renal 101, is the first pivotal trial investigating avelumab in combination with INLYTA (axitinib), a tyrosine kinase inhibitor (TKI), in patients with previously untreated advanced RCC, and the only Phase III trial currently evaluating an anti-PD-L1 immunotherapy in combination with a vascular endothelial growth factor (VEGF)-receptor TKI in this setting. The 5-year survival rate for patients with distant metastatic RCC is approximately 12 percent

News Date	04/04/2016
Category	Company Announcements-Others
Headline	Pfizer And Allergan Issued Statement
Summary	Pfizer Inc. and Allergan plc issued the following statement regarding the recently issued Department of Treasury Notice:

News Date	01/04/2016
Category	Trial Results
Headline	Pfizer Announced Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

Summary	Pfizer Inc. announced that the Phase 3 SPIRE-AI (AutoInjector) trial of the investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i) bococizumab administered with a pre-filled pen met its co-primary endpoints: percent change from baseline in low-density lipoprotein cholesterol (LDL-C) reduction at 12 weeks compared to placebo and proportion of patients successfully operating the pre-filled pen. The SPIRE-AI trial is the second study completed of the six SPIRE Phase 3 lipid-lowering studies, and they expect it will be part of the potential regulatory filing for bococizumab
---------	--

News Date	31/03/2016
Category	Company Announcements-Others
Headline	Pfizer Inc. Issued Statement
Summary	Pfizer Inc. (NYSE: PFE) Issued The Following Statement.

News Date	30/03/2016
Category	Conferences
Headline	Bristol-Myers Squibb And Pfizer Announced Global Real-World Data Program And Presented New Analyses Of Eliquis (apixaban) At The American College Of Cardiology's 65th Annual Scientific Session
Summary	Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL. The new analyses contribute to the Bristol-Myers Squibb and Pfizer Alliance's body of evidence on the use of Eliquis to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of patients with venous thromboembolism (VTE). Abstracts include new analyses from Phase 3 ARISTOTLE and AMPLIFY clinical studies, as well as a number of retrospective analyses of real-world data. The Alliance is pleased to present new analyses from both Phase 3 clinical trials and real-world databases at this important cardiology conference, said Douglas Manion, M.D., head of specialty development, Bristol-Myers Squibb. Clinical trial data help to evaluate the safety and efficacy of Eliquis under well-controlled circumstances, while real-world data can offer additional insight into the use of Eliquis for its approved indications in routine clinical practice.

News Date	30/03/2016
Category	Company Announcements-Others
Headline	Pfizer And Allergan Received Request For Additional Information From Federal Trade Commission Regarding Proposed Combination

Summary	Pfizer Inc. and Allergan plc announced that the companies have received a request for additional information from the U.S. Federal Trade Commission ("FTC") with respect to their previously announced pending combination. The request for information from the FTC, often referred to as a "second request," was fully anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act").
---------	--

News Date	30/03/2016
Category	Presentations
Headline	Bristol-Myers Squibb And Pfizer Announced Global Real-World Data Program And Present New Analyses Of Eliquis (Apixaban) At The American College Of Cardiology's 65th Annual Scientific Session
Summary	Bristol-Myers Squibb Company and Pfizer Inc announced that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL. The new analyses contribute to the Bristol-Myers Squibb and Pfizer Alliance's body of evidence on the use of Eliquis to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of patients with venous thromboembolism (VTE). Abstracts include new analyses from Phase 3 ARISTOTLE and AMPLIFY clinical studies, as well as a number of retrospective analyses of real-world data. The Alliance is pleased to present new analyses from both Phase 3 clinical trials and real-world databases at this important cardiology conference, said Douglas Manion, M.D., head of specialty development, Bristol-Myers Squibb. Clinical trial data help to evaluate the safety and efficacy of Eliquis under well-controlled circumstances, while real-world data can offer additional insight into the use of Eliquis for its approved indications in routine clinical practice.

News Date	30/03/2016
Category	Company Announcements-Others
Headline	Pfizer And Allergan Received Request For Additional Information From Federal Trade Commission Regarding Proposed Combination
Summary	Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) announced that they have received a request for additional information from the U.S. Federal Trade Commission ("FTC") with respect to their previously announced pending combination. The request for information from the FTC, often referred to as a "second request," was fully anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act")

News Date	23/03/2016
-----------	------------

Category	Priority Review
Headline	Pfizer Announced European Medicines Agency Accepted For Review Its Marketing Authorization Application For XELJANZ (Tofacitinib Citrate) For The Treatment Of Moderate To Severe Rheumatoid Arthritis
Summary	Pfizer Inc. announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA.

News Date	22/03/2016
Category	Company Announcements-Others
Headline	Pfizer Joined The Human Vaccines Project To Help Decode The Immune System
Summary	Pfizer Inc. announced that it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer.

News Date	18/03/2016
Category	Trial Results
Headline	Pfizer Announced Oral Tofacitinib, An Investigational JAK Inhibitor, Meets Primary And Key Secondary Endpoints In Two Pivotal Phase 3 Ulcerative Colitis Trials
Summary	Pfizer Inc announced the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulcerative colitis (OCTAVE) program at the 11th Congress of ECCO. Results from OCTAVE Induction 1 and OCTAVE Induction 2, evaluating the efficacy and safety of oral tofacitinib 10 mg twice daily (BID) in inducing remission in adult patients with moderately to severely active ulcerative colitis (UC), were presented during the Scientific Session 7: ECCO Fellowships & Grants (abstract no A-1213, Oral presentation no 19).

News Date	16/03/2016
Category	Conferences
Headline	Pfizer Presented New Data On Investigational Tofacitinib In Inflammatory Bowel Disease At The 11th Congress Of ECCO

Summary	Pfizer Inc. announced that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn's disease will be presented at the 11th Congress of ECCO, which will be held March 16-19 in Amsterdam, The Netherlands. Among the abstracts are detailed results from two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program. Tofacitinib is being studied as an investigational treatment for adult patients with moderate to severe active UC.
---------	--

News Date	15/03/2016
Category	Company Announcements-Others
Headline	Pfizer Celebrated A Year Of Achievements In 2015 Annual Review
Summary	Pfizer Inc. released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, our scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improve patient health.

News Date	11/03/2016
Category	Drug approvals
Headline	XALKORI (Crizotinib) Approved By U.S. Food and Drug Administration For The Treatment Of Patients With ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XALKORI (crizotinib) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In 2015, the FDA granted Breakthrough Therapy and Priority Review designations for this indication. XALKORI also is indicated for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

News Date	09/03/2016
Category	Product Update-Others
Headline	Pfizer New Survey Revealed Many Living With Symptoms Of Diabetic Nerve Pain Are Undiagnosed Despite Severe And Constant Pain

Summary	Pfizer Inc. in collaboration with the American Diabetes Association announced results of a joint multicultural survey, Community Health Perspectives, which found significant gaps in awareness, diagnosis and management of a serious diabetes-related complication known as painful diabetic peripheral neuropathy or diabetic nerve pain. The findings were particularly pronounced among African American and Hispanic American communities that experience symptoms of diabetic nerve pain, including burning, shooting pain in the feet or hands. Community Health Perspectives was conducted to support Step On Up, an educational program about diabetic nerve pain that encourages people to speak with a health care provider.
---------	--

News Date	09/03/2016
Category	Financial Deals-Others
Headline	Pfizer Commenced USD 5 Billion Accelerated Share Repurchase
Summary	Pfizer Inc. announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase USD 5 billion of Pfizer's common stock. This agreement is part of Pfizer's existing share repurchase authorization.

News Date	08/03/2016
Category	Trial Results
Headline	Pfizer Announced Publication Of Study Results Of BeneFIX Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis For Hemophilia B
Summary	Pfizer Inc. announced the publication of the Phase 3 study results of a once-weekly regimen of BeneFIX Coagulation Factor IX (recombinant) 100 IU/kg prophylaxis versus on-demand treatment in people with moderately severe or severe hemophilia B. The findings were published in Haemophilia, the official journal of the World Federation of Hemophilia.

News Date	03/03/2016
Category	Partnership / Strategic Alliance
Headline	Merck, Pfizer And Verastem Announced Combination Trial Of Avelumab And VS-6063 In Ovarian Cancer

Summary	Merck, Pfizer and Verastem announced that they have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
---------	--

News Date	03/03/2016
Category	Partnership / Strategic Alliance
Headline	Merck, Pfizer And Verastem Announced Combination Trial Of Avelumab And VS-6063 In Ovarian Cancer
Summary	Merck, Pfizer and Verastem announced that they have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.

News Date	29/02/2016
Category	Product line expansion
Headline	MacroGenics Provided Update On Corporate Progress And 2015 Financial Results
Summary	MacroGenics, Inc. announced a corporate progress update and reported financial results for the year ended December 31, 2015.

News Date	24/02/2016
Category	Trial Results
Headline	ViiV Healthcare Announced First Phase II HIV Prevention Study Results For Investigational Long-Acting Injectable Cabotegravir
Summary	ViiV Healthcare owned by GSK, with Pfizer Inc. and Shionogi Limited presented positive results from the 41 week phase IIa ECLAIR study, which evaluated the safety, tolerability, dosing and satisfaction with the investigational, long-acting, injectable cabotegravir as monotherapy for pre-exposure prophylaxis (PrEP) in HIV-uninfected healthy adult males not at high risk of acquiring HIV.1 Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

News Date	24/02/2016
-----------	------------

Category	Drug approvals
Headline	Pfizer Announced Food and Drug Administration Approval Of XELJANZ XR (Tofacitinib Citrate) Extended-Release Tablets, The First And Only Once-Daily Oral JAK Inhibitor Treatment For Rheumatoid Arthritis
Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved XELJANZ XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). XELJANZ XR is the first and only once-daily oral RA treatment in its class, known as Janus kinase (JAK) inhibitors.

News Date	23/02/2016
Category	Trial Results
Headline	ViiV Healthcare Announced Phase II Study Results For First Two Drug, Long-Acting Injectable Regimen For HIV-1 Treatment
Summary	ViiV Healthcare owned by GSK, with Pfizer Inc. and Shionogi Limited presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015.

News Date	22/02/2016
Category	Mergers & Acquisitions
Headline	GSK's Global HIV Business ViiV Healthcare Completed Transactions To Acquire Bristol-Myers Squibb's Research And Development HIV Assets
Summary	GlaxoSmithKline plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has completed two previously announced transactions with Bristol-Myers Squibb to acquire its late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets. The completion of both transactions follows antitrust approval by the relevant regulatory authorities in the US, with the integration process beginning immediately.

News Date	19/02/2016
Category	Drug approvals
Headline	Pfizer Received Expanded FDA Approval For IBRANCE (Palbociclib) In HR+, HER2-Metastatic Breast Cancer

Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer's metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy. Pfizer's supplemental New Drug Application (sNDA) for IBRANCE was reviewed and approved under the FDA's Breakthrough Therapy designation and Priority Review programs based on results from the Phase 3 PALOMA-3 trial in pre-, peri- and post-menopausal women with HR+, HER2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the adjuvant or metastatic setting.
---------	--

News Date	16/02/2016
Category	Patent Infringements/ Lawsuits
Headline	Pfizer, Wyeth Reached Agreement In Principle To Resolve Medicaid Drug Rebate Claims For 2001-2006 Period For Protonix
Summary	Pfizer Inc. reported that its Wyeth subsidiary has reached an agreement in principle to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug Protonix (pantoprazole sodium) between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. When finalized, the agreement in principle is expected to fully resolve cases pending in Federal District Court for the District of Massachusetts before the Honorable Douglas P. Woodlock.

News Date	12/02/2016
Category	Partnership / Strategic Alliance
Headline	Sandoz Strengthens Its Biosimilars Portfolio With Acquisition Of Pfizer's Biosimilar Infliximab In Eea
Summary	Sandoz, a Novartis company announced that it has acquired from Pfizer the rights for the development and commercialization of PF-06438179 (biosimilar infliximab) in the 28 countries that form the European Economic Area (EEA). Infliximab is a tumor necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis (RA) and psoriasis.

News Date	09/02/2016
Category	Regulatory Opinion
Headline	Pfizer Commended The Food and Drug Administration Advisory Committee's Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications

Summary	Pfizer Inc. commended recommendation by the United States (U.S.) Food and Drug Administration's (FDA) Arthritis Advisory Committee to approve the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion's proposed biosimilar infliximab, to which Pfizer holds exclusive U.S. commercialization rights, is the first biosimilar monoclonal antibody (mAb) therapy to be reviewed by the FDA for licensure in the U.S., and is only the second biosimilar to be recommended for approval by a U.S. FDA Advisory Committee.
---------	---

News Date	08/02/2016
Category	Company Announcements-Others
Headline	Pfizer Named Executive Leadership Team For Combined Organization Upon Close Of Proposed Allergan Transaction
Summary	Pfizer Inc. announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction.

News Date	01/02/2016
Category	Partnership / Strategic Alliance
Headline	Portola Pharmaceuticals Entered Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To USD 120 Million
Summary	Portola Pharmaceuticals (NASDAQ:PTLA) announced that it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to Bristol-Myers Squibb Company and Pfizer Inc. to be developed as an antidote for apixaban and other Factor Xa inhibitors. Separately, Portola has entered into a clinical collaboration agreement with Bayer HealthCare to include its Factor Xa inhibitor rivaroxaban in this clinical development program in Japan.

News Date	01/02/2016
Category	Partnership / Strategic Alliance
Headline	Bristol-Myers Squibb And Pfizer Signed Collaboration With Portola Pharmaceuticals To Develop And Commercialize Investigational Andexanet Alfa In Japan
Summary	Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

News Date	01/02/2016
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Bristol-Myers Squibb And Pfizer Signed Collaboration With Portola Pharmaceuticals To Develop And Commercialize Investigational Andexanet Alfa In Japan
Summary	Bristol-Myers Squibb Company (and Pfizer Inc. announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

News Date	13/01/2016
Category	Partnership / Strategic Alliance
Headline	California Institute for Biomedical Research (Calibr) Enters Worldwide Strategic Collaboration with Pfizer Inc.
Summary	The California Institute for Biomedical Research (Calibr), a nonprofit translational research institute, announced that it has entered into a global strategic collaboration with Pfizer Inc.(NYSE: PFE) to develop novel antibody-based therapeutic agents for the treatment of heart failure. Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists.

News Date	11/01/2016
Category	Partnership / Strategic Alliance
Headline	Schrodinger Announced Research Collaboration with Pfizer Inc
Summary	Schrodinger, Inc. announced that it has entered into a research collaboration agreement with Pfizer Inc. (NYSE: PFE), in which the two companies will work together to develop a computational model for predicting key properties relevant to biotherapeutic candidates.

News Date	09/01/2016
Category	Awards/Grants/Funds
Headline	Pfizer Awarded USD 46M In Financing To Four Early-Stage Companies
Summary	Pfizer announced that the company has awarded a total of USD 46 million in financing to four early-stage companies whose specialties align with the pharma giant's core areas of R&D interest.

News Date	08/01/2016
Category	Financial Deals-Others
Headline	Pfizer Expands Research And Development Equity Investment Strategy To Access Early-Stage Scientific Innovations
Summary	Pfizer Inc. announced an expansion of its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer's core interests. The first four investments of the newly focused initiative include USD 46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy. Additional opportunities will continue to be identified by Pfizer's scientific leadership through their active involvement, and Pfizer will help recipient companies fully explore their platforms in the hopes of advancing new therapeutic pathways.

News Date	08/01/2016
Category	Partnership / Strategic Alliance
Headline	Pfizer Entered Into Translational Research Collaboration With Adaptive Biotechnologies To Help Advance Novel Immuno-Oncology Solutions
Summary	Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer's growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit from immunotherapy.

News Date	07/01/2016
Category	Partnership / Strategic Alliance
Headline	4D Molecular Therapeutics Announced Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development
Summary	4D Molecular Therapeutics (4DMT) announced both an investment by and a collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to discover and develop targeted and proprietary next-generation AAV vectors for cardiac disease indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to potentially identify and optimize novel gene delivery vectors for use in potential cardiac gene therapy products.

News Date	05/01/2016
-----------	------------

Category	Venture Financing
Headline	Cortexyme Raised USD 15 Million Series A
Summary	Cortexyme, Inc. raised USD 15 million in Series A financing led by Pfizer Inc. along with new investment from Takeda Pharmaceutical Company Ltd., through its venture arm, and other private investors. Existing investors such as Dolby Family Ventures also participated.

News Date	04/01/2016
Category	Partnership / Strategic Alliance
Headline	Merck KGaA, Pfizer And Syndax Announced Collaboration To Evaluate Combination Of Avelumab And Entinostat In Ovarian Cancer
Summary	Merck KGaA, Pfizer and Syndax Pharmaceuticals, Inc. announced that they have entered into a collaboration agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax's entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated, recurrent ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types by the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer. This is an exclusive agreement between the alliance and Syndax to study the combination of these two investigational agents in ovarian cancer. Syndax will be responsible for conducting the Phase Ib/II clinical trial in ovarian cancer.

News Date	04/01/2016
Category	Partnership / Strategic Alliance
Headline	Merck Pfizer And Syndax Announced Collaboration To Evaluate Combination Of Avelumab And Entinostat In Ovarian Cancer
Summary	Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax's entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated, recurrent ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types by the Merck-Pfizer Alliance. This is an exclusive agreement between the alliance and Syndax to study the combination of these two investigational agents in ovarian cancer. Syndax will be responsible for conducting the Phase Ib/II clinical trial in ovarian cancer

News Date	04/01/2016
Category	Partnership / Strategic Alliance
Headline	Kinemed Entered Into Strategic Proteomic Biomarker Discovery Collaboration With Pfizer Inc.
Summary	KineMed Inc. announced that it has entered into a strategic collaboration with Pfizer Inc. (NYSE:PFE) to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed's platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.

News Date	01/01/2016
Category	Product Launch
Headline	Greenstone Llc Introduced Tolterodine Tartrate Extended Release Capsules
Summary	Greenstone LLC, a US-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of tolterodine tartrate extended release capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 2 mg x 30 capsules per bottle, 2 mg x 90 capsules per bottle, 4 mg x 30 capsules per bottle, and 4 mg x 90 capsules per bottle.

News Date	22/12/2015
Category	Trial Initiations
Headline	Merck KGaA And Pfizer Advanced Clinical Development Program With Two Additional Phase III Trials Of Avelumab
Summary	Merck KGaA announced the opening of trial sites for an international Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer. The JAVELIN Ovarian 200 trial is the first Phase III study of a PD-L1 inhibitor investigated as a treatment for platinum-resistant/refractory ovarian cancer. The alliance also announced that the US Food and Drug Administration has provided approval to move forward with a Phase III study of avelumab as a maintenance treatment, in the first-line setting, in patients with locally advanced or metastatic urothelial cancer. The first trial sites are expected to open shortly

News Date	22/12/2015
Category	Product Update-Others

Headline	Merck And Pfizer Advanced Clinical Development Program With Two Additional Phase III Trials Of Avelumab
Summary	Merck and Pfizer announced the opening of trial sites for an international Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer. The JAVELIN Ovarian 200 trial is the first Phase III study of a PD-L1 inhibitor investigated as a treatment for platinum-resistant/refractory ovarian cancer. The alliance also announced that the US Food and Drug Administration has provided approval to move forward with a Phase III study of avelumab as a maintenance treatment, in the first-line setting, in patients with locally advanced or metastatic urothelial cancer. The first trial sites are expected to open shortly.

News Date	10/12/2015
Category	Trial Results
Headline	Pfizer AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death And Major Bleeding In Deep Vein Thrombosis And Pulmonary Embolism Patients Treated With Eliquis (Apixaban) Or Conventional Therapy
Summary	Bristol-Myers Squibb Company and Pfizer Inc. announced results from a post-hoc early time course subanalysis of the Phase 3 AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy) trial. The subanalysis demonstrated Eliquis (apixaban) was comparable to conventional therapy (subcutaneous enoxaparin overlapped and followed by oral warfarin dose-adjusted to an international normalized ratio of 2.0 to 3.0) in recurrent VTE and VTE-related death with significantly less major bleeding during the first 7, 21 and 90 days after starting treatment. These data were published in <i>Thrombosis and Haemostasis</i> .

News Date	10/12/2015
Category	Priority Review
Headline	Pfizer Announced Food and Drug Administration Acceptance Of IBRANCE (Palbociclib) Supplemental New Drug Application With Priority Review In HR+, HER2-Metastatic Breast Cancer

Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for a supplemental New Drug Application (sNDA) for Pfizer's breast cancer medication, IBRANCE (palbociclib). If approved, the sNDA would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus fulvestrant plus placebo in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer, regardless of menopausal status, whose disease progressed after endocrine therapy, including those with and without prior treatment for their metastatic disease. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 2016
---------	--

News Date	09/12/2015
Category	Trial Initiations
Headline	Merck KGaA And Pfizer Initiated Two Phase III Studies Of Investigational Immunotherapy Avelumab In Advanced Gastric And Gastro-Esophageal Junction Cancers
Summary	Merck KGaA and Pfizer initiated the initiation of two Phase III studies of avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab in the first-line and third-line settings, with overall survival (OS) as the primary endpoint in both trials.

News Date	09/12/2015
Category	Partnership / Strategic Alliance
Headline	Spark Therapeutics Announces USD 15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program
Summary	Spark Therapeutics, Inc. (NASDAQ:ONCE) announced that it has earned a USD 15 million milestone payment from Pfizer Inc.(NYSE:PFE) under the companies' global collaboration for the potential development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. This is the first milestone achieved under the agreement that was entered into in December 2014.

News Date	09/12/2015
Category	Trial Initiations
Headline	Merck And Pfizer Initiated Two Phase III Studies Of Investigational Immunotherapy Avelumab In Advanced Gastric And Gastro-Esophageal Junction Cancers

Summary	Merck and Pfizer announced the initiation of two Phase III studies of avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab in the first-line and third-line settings, with overall survival (OS) as the primary endpoint in both trials.
---------	--

News Date	08/12/2015
Category	Priority Review
Headline	Pfizer Announced U.S. Food and Drug Administration Acceptance And Priority Review Of Supplemental New Drug Application For XALKORI(Crizotinib) For The Treatment Of Patients With ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for XALKORI (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In April 2015, XALKORI received Breakthrough Therapy designation by the FDA for this potential indication. If approved, XALKORI would be the first FDA-approved biomarker-driven therapy for the treatment of ROS1-positive metastatic NSCLC. XALKORI is currently indicated for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The projected FDA action date is April 2016.

News Date	08/12/2015
Category	Awards/Grants/Funds
Headline	Pfizer Awarded More Than USD 4 Million In Grants To Further Clinical Research In Advanced Breast Cancer For 2015
Summary	Pfizer Inc announced the first-ever recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Five grants totaling more than USD 4 million in funding were awarded to support clinical research projects investigating IBRANCE (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, in advanced breast cancer for 2015. Simultaneously, the company announced that it will award up to USD 4 million in new grants through the ASPIRE Breast Cancer Research Awards Program in 2016

News Date	07/12/2015
Category	Drug approvals
Headline	Pfizer Received U.S. Food and Drug Administration Approval Of New QuilliChew ER (Methylphenidate Hydrochloride) Extended-Release Chewable Tablets CII

Summary	Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the treatment of ADHD in patients ages 6 years old and above – liquid Quillivant XR (methylphenidate HCl) CII and new QuilliChew ER chewable tablets
---------	--

News Date	07/12/2015
Category	Drug approvals
Headline	Pfizer Received US Food And Drug Administration Approval Of New Quillichew ER (Methylphenidate Hydrochloride) Extended-Release Chewable Tablets CII
Summary	Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the treatment of ADHD in patients ages 6 years old and above – liquid Quillivant XR (methylphenidate HCl) CII and new QuilliChew ER chewable tablets

News Date	03/12/2015
Category	Conferences
Headline	Collectis Announced Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier
Summary	Collectis announced that it hosted a conference call with Pfizer Inc. (PFE) and Servier on December 7, 2015 at 8:00 a.m. Eastern Time to discuss their previously announced UCART19 development collaboration.

News Date	01/12/2015
Category	Product Launch
Headline	Greenstone Llc Introduced Linezolid Tablets
Summary	Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of linezolid tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 600 mg x 20 tablets per bottle and 600 mg x unit dose packages of 20 tablets.

News Date	25/11/2015
Category	Trial Results
Headline	Pfizer Reported Top-Line Results From A Phase 3 Study Of LYRICA (Pregabalin) Capsules CV In Adults With Post-Traumatic Peripheral Neuropathic Pain

Summary	Pfizer Inc. announced top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. The study did not meet its primary efficacy endpoint.
---------	--

News Date	25/11/2015
Category	Regulatory Opinion
Headline	Merck KGaA And Pfizer Received Positive Opinion For Orphan Drug Designation For Avelumab In Merkel Cell Carcinoma From European Medicines Agency Committee For Orphan Medicinal Products
Summary	Merck KGaA and Pfizer announced that the European Medicines Agency (EMA)'s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug designation (ODD) for avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by the European Commission (EC), expected in December. The COMP positive opinion is for the cancer immunotherapy avelumab, for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer. Each year, there are approximately 2,500 new cases of MCC diagnosed in the European Union (EU). There is currently no therapy approved specifically for the treatment of metastatic MCC.

News Date	25/11/2015
Category	Label revisions
Headline	Pfizer Received European Approval To Expand Use Of XALKORI (Crizotinib) To First-Line Treatment Of Adults With ALK-Positive Advanced Non-Small Cell Lung Cancer
Summary	Pfizer Inc. announced that the European Commission has approved a label update to expand use of XALKORI (crizotinib) to first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The Summary of Product Characteristics also has been updated to include efficacy data from PROFILE 1014, which demonstrated that XALKORI significantly prolonged progression-free survival (PFS) in previously untreated patients with ALK-positive advanced nonsquamous NSCLC when compared to standard platinum-based chemotherapy regimens

News Date	25/11/2015
Category	Regulatory Opinion
Headline	Merck And Pfizer Received Positive Opinion For Orphan Drug Designation For Avelumab In Merkel Cell Carcinoma From European Medicines Agency Committee For Orphan Medicinal Products

Summary	Merck and Pfizer announced that the European Medicines Agency (EMA)'s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug designation (ODD) for avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by the European Commission (EC), expected in December. The COMP positive opinion is for the cancer immunotherapy avelumab, for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer. Each year, there are approximately 2,500 new cases of MCC diagnosed in the European Union (EU). ⁽³⁾ There is currently no therapy approved specifically for the treatment of metastatic MCC.
---------	---

News Date	23/11/2015
Category	Mergers & Acquisitions
Headline	Pfizer And Allergan Combined
Summary	Pfizer Inc. and Allergan plc announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer, a global innovative biopharmaceutical company, will combine with Allergan, a global pharmaceutical company and a leader in a new industry model – Growth Pharma, in a stock transaction currently valued at USD 363.63 per Allergan share, for a total enterprise value of approximately USD 160 billion, based on the closing price of Pfizer common stock of USD 32.18 on November 20, 2015. The transaction represents more than a 30 percent premium based on Pfizer's and Allergan's unaffected share prices as of October 28, 2015. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares, and Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares.

News Date	23/11/2015
Category	Mergers & Acquisitions
Headline	Pfizer And Allergan Announced To Combine

Summary	Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer, a global innovative biopharmaceutical company, will combine with Allergan, a global pharmaceutical company and a leader in a new industry model – Growth Pharma, in a stock transaction currently valued at USD 363.63 per Allergan share, for a total enterprise value of approximately USD 160 billion, based on the closing price of Pfizer common stock of USD 32.18 on November 20, 2015. The transaction represents more than a 30 percent premium based on Pfizer's and Allergan's unaffected share prices as of October 28, 2015. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares, and Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares.
---------	---

News Date	19/11/2015
Category	Partnership / Strategic Alliance
Headline	Servier Exercised Exclusive Worldwide Licensing Option With Cellectis For UCART19, An Allogeneic CAR-T Cell Therapy For Hematological Malignancies
Summary	Cellectis announced that they signed an amendment to their existing collaboration agreement from February 2014 especially for UCART19, a TALEN gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy.

News Date	18/11/2015
Category	Trial Results
Headline	Pfizer Reported Positive Topline Results From Phase 3 Trial Comparing XALKORI (Crizotinib) To Chemotherapy In Previously Untreated East Asian Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Summary	Pfizer Inc. announced that PROFILE 1029, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated East Asian patients with ALK-positive advanced non-small cell lung cancer (NSCLC) when compared to a standard chemotherapy doublet. In this study, XALKORI was used as the first systemic therapy for patients with advanced ALK-positive NSCLC, and patients could have received therapy and/or surgery for early stage disease before they were diagnosed with metastatic disease.

News Date	18/11/2015
Category	Breakthrough
Headline	Merck KGaA And Pfizer Received Food and Drug Administration Breakthrough Therapy Designation For Avelumab In Metastatic Merkel Cell Carcinoma

Summary	Merck KGaA and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen. Breakthrough Therapy designation is designed to accelerate the development and review of medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the therapy may demonstrate a substantial improvement over current available therapies. MCC is a rare and aggressive type of skin cancer. Each year, there are approximately 1,500 new cases of MCC diagnosed in the US. There is currently no therapy approved specifically for the treatment of metastatic MCC
---------	--

News Date	18/11/2015
Category	Breakthrough
Headline	Merck And Pfizer Received Food And Drug Administration Breakthrough Therapy Designation For Avelumab In Metastatic Merkel Cell Carcinoma
Summary	Merck and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen. Breakthrough Therapy designation is designed to accelerate the development and review of medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the therapy may demonstrate a substantial improvement over current available therapies. MCC is a rare and aggressive type of skin cancer. Each year, there are approximately 1,500 new cases of MCC diagnosed in the US. There is currently no therapy approved specifically for the treatment of metastatic MCC

News Date	18/11/2015
Category	Partnership / Strategic Alliance
Headline	Thermo Fisher Scientific Signed Development Agreement For Next-Generation Sequencing-Based Companion Diagnostic
Summary	Thermo Fisher Scientific entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal next-generation sequencing oncology test that will serve as a companion diagnostic for non-small cell lung cancer across multiple drug development programs.

News Date	16/11/2015
Category	Company Announcements-Others

Headline	Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma
Summary	The International Trachoma Initiative (ITI), Pfizer Inc. and International Coalition for Trachoma Control (ICTC) (link is external) partners announced Pfizer's donation of the 500 millionth dose of Zithromax (azithromycin) Tablets, an antibiotic used to treat trachoma in certain countries. The milestone marks significant achievement in global efforts to help eliminate this infectious and preventable eye disease that can lead to permanent blindness, as a public health threat by the year 2020.

News Date	06/11/2015
Category	Conferences
Headline	Bristol-Myers Squibb And Pfizer To Present New Data On Eliquis (apixaban) At The American Heart Association (AHA) Scientific Sessions 2015
Summary	Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the American Heart Association (AHA) Scientific Sessions 2015, to be held November 7-11 in Orlando, Florida. The new data, including four oral presentations, contribute to the Bristol-Myers Squibb and Pfizer Alliance's research in nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) in patients treated with Eliquis. Abstracts include new data analyses from the pivotal Phase 3 study, ARISTOTLE, as well as a number of real-world data analyses.

News Date	06/11/2015
Category	Conferences
Headline	Bristol-Myers Squibb And Pfizer Presented New Data On Eliquis (Apixaban) At The American Heart Association (AHA) Scientific Sessions 2015
Summary	Bristol-Myers Squibb Company and Pfizer Inc. announced that 22 abstracts will be presented at the American Heart Association (AHA) Scientific Sessions 2015, to be held November 7-11 in Orlando, Florida. The new data, including four oral presentations, contribute to the Bristol-Myers Squibb and Pfizer Alliance's research in nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) in patients treated with Eliquis. Abstracts include new data analyses from the pivotal Phase 3 study, ARISTOTLE, as well as a number of real-world data analyses.

News Date	05/11/2015
Category	Company Announcements-Others
Headline	Pfizer Expanded Its Patient Assistance Program, Doubling The Income Eligibility Limit To Benefit Even More Patients Taking Pfizer Medicines

Summary	Pfizer announced that in response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced that it will immediately double the allowable income level for its patient assistance program, so that even more patients in need could be eligible to receive their Pfizer medicines for free. With this change, more than 40 medicines offered for free through the program will now be available to eligible patients earning up to 4 times the Federal Poverty Level (FPL) adjusted for family size (USD 47,080 for a single person; USD 97,000 for a family of four).
---------	---

News Date	05/11/2015
Category	Company Announcements-Others
Headline	Global Analysis Of Metastatic Breast Cancer Landscape Revealed Gaps In Patient Care And Support
Summary	Pfizer Inc., working collaboratively with the European School of Oncology (ESO) released the Global Status of Metastatic Breast Cancer (MBC): A 2005 – 2015 Decade Report, which revealed both areas of improvement and substantial gaps in care, access to resources and support, and treatment outcomes for women with MBC

News Date	04/11/2015
Category	Trial Initiations
Headline	Merck KGaA And Pfizer Announced Initiation Of Phase III First-Line Trial Of Avelumab In Patients With Recurrent Or Stage IV Non-Small Cell Lung Cancer
Summary	Merck KGaA and Pfizer announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab in a treatment naive advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who have not previously received any treatment for their systemic lung cancer. Avelumab (previously known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body's own immune system to fight cancer.

News Date	04/11/2015
Category	Trial Initiations
Headline	Merck And Pfizer Announced Initiation Of Phase III First-Line Trial Of Avelumab In Patients With Recurrent Or Stage IV Non-Small Cell Lung Cancer

Summary	Merck and Pfizer announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naive advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab, compared with platinum-based doublet chemotherapy in patients with late-stage NSCLC who have not previously received any treatment for their systemic lung cancer. Avelumab (previously known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body's own immune system to fight cancer.
---------	--

News Date	03/11/2015
Category	Trial Results
Headline	ViiV Healthcare Announced Positive Headline Results From A Study Of Two Drug Injectable Regimen For HIV Maintenance Therapy
Summary	ViiV Healthcare, with GSK, Pfizer Inc. and Shionogi Limited announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). The 32 week results of LATTE 2 will be presented at a forthcoming scientific conference. ViiV Healthcare and Janssen Sciences Ireland UC (Janssen) are collaborating to conduct LATTE 2.

News Date	02/11/2015
Category	Meeting schedules
Headline	Pfizer Announced New Data ContinuedTo Characterize The Safety And Efficacy Of XELJANZ (Tofacitinib Citrate) In The Treatment Of Rheumatoid Arthritis
Summary	Pfizer Inc. announced that 26 new scientific abstracts, including 20 presentations for XELJANZ (tofacitinib citrate) in rheumatoid arthritis (RA) will be presented on behalf of Pfizer at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2015 Annual Meeting (November 7-11, San Francisco, CA).

News Date	01/11/2015
Category	Product Launch
Headline	Greenstone Llc Introduced Linezolid For Oral Suspension

Summary	Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of linezolid for oral suspension to its ever-expanding generic pharmaceutical product line. The product is offered in powder form in dosage strengths of 100 mg / 5 mL x 150 mL as reconstituted suspension.
---------	---

News Date	29/10/2015
Category	Trial Initiations
Headline	Halozyme Announced First Clinical Dosing Of Pfizer's Rivipansel Using Enhance Technology
Summary	Halozyme Therapeutics, Inc. announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.

News Date	29/10/2015
Category	Company Announcements-Others
Headline	Pfizer Announcement Regarding Allergan Plc
Summary	Pfizer noted the announcement by Allergan that was released earlier regarding a potential transaction between the companies. Pfizer confirms that it is in preliminary friendly discussions with Allergan in relation to a potential transaction.

News Date	29/10/2015
Category	Partnership / Strategic Alliance
Headline	Pfizer Announced Collaboration With GSK On Next-Generation Design Of Portable, Continuous, Miniature And Modular (PCMM) Oral Solid Dose Development And Manufacturing Units
Summary	Pfizer Inc. announced that a multi-year collaboration with GSK on the development of a next-generation equipment design, building upon Pfizer's existing portable, continuous, miniature and modular (PCMM) prototype for oral solid dose (OSD) pharmaceutical development and manufacturing.

News Date	29/10/2015
Category	Partnership / Strategic Alliance
Headline	Allergan plc Confirmed Discussions Regarding Potential Business Combination Transaction With Pfizer Inc.

Summary	Allergan plc confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction. Allergan stated that no agreement has been reached and there can be no certainty that these discussions will lead to a transaction, or as to the terms on which a transaction, if any, might be agreed. The company will not comment on speculation regarding the terms of a potential transaction.
---------	--

News Date	19/10/2015
Category	Breakthrough
Headline	Pfizer's Inotuzumab Ozogamicin Received Food and Drug Administration Breakthrough Therapy Designation For Acute Lymphoblastic Leukemia (ALL)
Summary	Pfizer Inc. announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL).

News Date	14/10/2015
Category	Regulatory-Others
Headline	Pfizer Received Complete Response Letter From Food and Drug Administration For Oral XELJANZ (Tofacitinib Citrate) Supplemental New Drug Application For Moderate To Severe Chronic Plaque Psoriasis
Summary	Pfizer Inc. announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for XELJANZ(tofacitinib citrate) for the treatment of adult patients with moderate to severe chronic plaque psoriasis. The Agency provided recommendations specific to the moderate to severe chronic plaque psoriasis sNDA. Pfizer will work with the Agency to determine an appropriate path forward to address their comments, including providing additional safety analyses of XELJANZ for the proposed indication.

News Date	13/10/2015
Category	Awards/Grants/Funds
Headline	Pfizer And The Union For International Cancer Control Awarded 20 Grants Totaling USD 760,000 To Address The Needs Of Metastatic Breast Cancer Patients Worldwide
Summary	Pfizer Inc. and the Union for International Cancer Control (UICC) announced the recipients from the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC MBC Challenge), a first-of-its-kind initiative to address the unique challenges facing women with metastatic breast cancer worldwide. In total, 20 organizations from 18 countries have been selected to receive grants amounting to USD 760,000 (USD) in funding provided by Pfizer.

News Date	13/10/2015
Category	Partnership / Strategic Alliance
Headline	Protalix Biotherapeutics Sold Its Share In Collaboration Agreement For Elelyso And A 6 Percent Equity Stake In Protalix To Pfizer For A Total Of USD 46 Million
Summary	Protalix BioTherapeutics, Inc. announced that the Company sold its share in the collaboration agreement for Elelyso to its commercialization partner, Pfizer Inc. Under the initial collaboration agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a 60 percent/40 percent basis globally, excluding Israel and Brazil. As amended, Pfizer is responsible for 100 percent of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company will be responsible for all expenses and retain all revenues.

News Date	09/10/2015
Category	Trial Results
Headline	Pfizer's Phase 2 Study Demonstrated Safety, Tolerability And Immunogenicity Of TRUMENBA When Coadministered With Meningococcal A, C, Y And W-135 Polysaccharide Conjugate (MCV4) And Tetanus, Diphtheria And Pertussis (Tdap) Vaccines In Adolescents
Summary	Pfizer Inc. announced that researchers presented for the first time data from a randomized, controlled Phase 2 study of its meningococcal serogroup B vaccine, TRUMENBA®, coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines in adolescents. The data, which were released in an oral presentation at IDWeek 2015 in San Diego, are based on a study conducted in more than 2,600 healthy individuals 10 through 12 years of age that evaluated the safety, tolerability and immunogenicity of TRUMENBA when coadministered with MCV4 and Tdap. Data demonstrated that immune responses following TRUMENBA, MCV4 and Tdap vaccines given concomitantly were noninferior to immune responses to MCV4 and Tdap alone or TRUMENBA alone.

News Date	07/10/2015
Category	Fast Track
Headline	Merck KGaA And Pfizer Announced Investigational Immunotherapy Avelumab Receives Food and Drug Administration Fast Track Designation For Metastatic Merkel Cell Carcinoma

Summary	Merck KGaA and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer. ^{1,2} This announcement builds on the recent FDA Orphan Drug designation that was granted for avelumab on September 21, 2015 for the treatment of MCC. The Fast Track designation is designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and address an unmet medical need.
---------	--

News Date	07/10/2015
Category	Fast Track
Headline	Merck And Pfizer Announced Investigational Immunotherapy Avelumab Received Food and Drug Administration Fast Track Designation For Metastatic Merkel Cell Carcinoma
Summary	Merck and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer. This announcement builds on the recent FDA Orphan Drug designation that was granted for avelumab on September 21, 2015 for the treatment of MCC. The Fast Track designation is designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and address an unmet medical need.

News Date	01/10/2015
Category	Partnership / Strategic Alliance
Headline	Pfizer Completed Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline
Summary	Pfizer Inc. announced that it has completed the acquisition of GlaxoSmithKline's quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.

News Date	01/10/2015
Category	Product Launch
Headline	Greenstone Llc Introduced Ethosuximide Capsules, Usp
Summary	Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of ethosuximide capsules and ethosuximide oral solution to its ever-expanding generic pharmaceutical product line. The capsules are offered in dosage strength of 250 mg in bottles of 100 counts, and the oral solution in a dosage strength of 250 mg/5 mL as oral solution.

News Date	30/09/2015
Category	Company Announcements-Others
Headline	Pfizer Partners With Breast Cancer Leaders To Chronicle The Lives Of Women With Metastatic Breast Cancer Through The Lenses Of Prominent Photographers
Summary	Pfizer Inc., in partnership with five leading breast cancer advocacy organizations announced the next chapter of the Breast Cancer: A Story Half Told initiative, launched in 2014 to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer (MBC), the most advanced form of breast cancer. Research conducted as part of this initiative revealed that the majority of Americans (60%) reported they know little to nothing about MBC. ¹ The new chapter aims to address this lack of understanding through the perspectives of women living with MBC, as chronicled by prominent photographers.

News Date	30/09/2015
Category	Company Announcements-Others
Headline	AM-Pharma And Pfizer Inc. Shortlisted For "Best Partnership Alliance" In Scrip Awards
Summary	AMPharma B.V., and Pfizer Inc. have been nominated for the prestigious category of "Best Partnership Alliance" for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the global pharmaceutical industry.

News Date	25/09/2015
Category	Orphan Drug
Headline	Merck And Pfizer Announced Food And Drug Administration Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma
Summary	Merck and Pfizer announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer. Each year, there are approximately 1,500 new cases of MCC diagnosed in the US

News Date	24/09/2015
Category	Product Launch
Headline	Pfizer's Sayana Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection

Summary	Pfizer Inc. announced that the company's injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection. This follows the recent approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of an update to the Sayana Press label, adding the option for self-injection by women when considered appropriate by a healthcare professional (HCP)
---------	--

News Date	24/09/2015
Category	Partnership / Strategic Alliance
Headline	Merck And Pfizer Collaborated With Dako, An Agilent Technologies Company, On Development Of Companion Diagnostic For Investigational Anti-PD-L1 Antibody, Avelumab
Summary	Merck and Pfizer announced that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx)

News Date	22/09/2015
Category	Product Launch
Headline	Pfizer New Centrum VitaMints Offered A Refreshingly New Way To Take A Multivitamin
Summary	Pfizer Consumer Healthcare announced the launch of Centrum VitaMints, a great-tasting and easy-to-take multivitamin that offers consumers the essential nutrients they can enjoy like a mint, from Centrum, a brand they know and trust.

News Date	21/09/2015
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results From Two Phase 3 Trials Of Oral Tofacitinib In Adults With Moderate-To-Severe Ulcerative Colitis
Summary	Pfizer Inc. announced top-line results from two Phase 3 induction trials of tofacitinib 10 mg twice daily (BID) tablets in the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) global clinical development program for the treatment of adults with moderate to severe ulcerative colitis (UC): OCTAVE Induction 1 (A3921094) and OCTAVE Induction 2 (A3921095). Both studies met their primary endpoints as measured by the proportion of patients receiving tofacitinib in remission at Week 8 compared to patients receiving placebo

News Date	18/09/2015
-----------	------------

Category	Company Announcements-Others
Headline	Pfizer Inc. Announced Results Of Early Tenders And Consents In Exchange Offers
Summary	<p>Pfizer Inc. announced that, as of 5:00 p.m., New York City time, on September 17, 2015 (the "Early Consent Date"), the aggregate principal amounts of each series of notes listed in the table below (collectively, the "Hospira Notes") issued by Hospira, Inc., a recently acquired subsidiary of Pfizer, had been validly tendered and not validly withdrawn in connection with Pfizer's previously announced offers to exchange any and all validly tendered and accepted Hospira Notes for new notes to be issued by Pfizer (collectively, the "Pfizer Notes"), and the related solicitations of consents to amend the indenture governing the Hospira Notes and the Hospira Notes (together, the "Exchange Offers"). A Registration Statement on Form S-4 (File No. 333-206758) (the "Registration Statement") relating to the issuance of the Pfizer Notes was filed with the Securities and Exchange Commission ("SEC") on September 3, 2015, as amended by Amendment No. 1 to the Registration Statement, filed with the SEC on September 16, 2015, but has not yet been declared effective.</p>

News Date	11/09/2015
Category	Conferences
Headline	Merck KGaA And Pfizer Presented Updates For Avelumab At The European Cancer Congress 2015
Summary	Merck KGaA and Pfizer announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab will be presented at this year's ECC in Vienna, Austria, September 25–29, 2015

News Date	11/09/2015
Category	Conferences
Headline	Merck And Pfizer Presented Updates For Avelumab At The European Cancer Congress 2015
Summary	Merck and Pfizer announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab will be presented at this year's ECC in Vienna, Austria, September 25–29, 2015

News Date	09/09/2015
Category	Partnership / Strategic Alliance

Headline	Evotec Enters Into Licence And Collaboration Agreement With Pfizer Inc In Tissue Fibrosis
Summary	Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.

News Date	09/09/2015
Category	Trial Initiations
Headline	Bristol-Myers Squibb And Pfizer Enrolled First Patient In Phase 4 AUGUSTUS Trial To Evaluate Safety Of Eliquis (apixaban) In Nonvalvular Atrial Fibrillation Patients With A Recent Acute Coronary Syndrome Or Undergoing Percutaneous Coronary Intervention
Summary	Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into the Phase 4 clinical trial, AUGUSTUS. This two-by-two factorial, randomized controlled trial evaluates the safety of Eliquis versus warfarin or other vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation (NVAF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), also known as a stent. In addition, patients are also randomized to aspirin or placebo. All patients received a P2Y12 inhibitor (such as clopidogrel) in combination with either Eliquis or a VKA. Eliquis is approved to reduce the risk of stroke and systemic embolism in patients with NVAF.

News Date	09/09/2015
Category	Trial Initiations
Headline	Bristol-Myers Squibb And Pfizer Enrolled First Patient In Phase 4 AUGUSTUS Trial To Evaluate Safety Of Eliquis (Apixaban) In Nonvalvular Atrial Fibrillation Patients With A Recent Acute Coronary Syndrome Or Undergoing Percutaneous Coronary Intervention
Summary	Bristol-Myers Squibb Company and Pfizer Inc announced that the first patient has been enrolled into the Phase 4 clinical trial, AUGUSTUS. This two-by-two factorial, randomized controlled trial will evaluate the safety of Eliquis versus warfarin or other vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation (NVAF) and a recent acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), also known as a stent. In addition, patients will also be randomized to aspirin or placebo. All patients will receive a P2Y12 inhibitor (such as clopidogrel) in combination with either Eliquis or a VKA. Eliquis is approved to reduce the risk of stroke and systemic embolism in patients with NVAF

News Date	03/09/2015
Category	Company Announcements-Others

Headline	Pfizer Inc. Commenced Exchange Offers For Hospira Notes
Summary	Pfizer Inc. announced that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, Inc. ("Hospira"), our recently acquired subsidiary, for new notes to be issued by Pfizer as described in the table below. A Registration Statement on Form S-4 (the "Registration Statement") relating to the issuance of the Pfizer Notes (as defined below) was filed with the U.S. Securities and Exchange Commission (the "SEC") on September 3, 2015 but has not yet been declared effective.

News Date	03/09/2015
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition Of Hospira
Summary	Pfizer Inc. announced that it has completed its acquisition of Hospira, Inc.

News Date	27/08/2015
Category	Product Launch
Headline	Hospira Announced First Installation Of Plum 360 Infusion System With Hospira Mednet
Summary	Hospira Inc (NYSE: HSP) announced the first installation of the Plum 360™ infusion system with Hospira MedNet, at Shannon Medical Center in San Angelo, Texas. The Plum 360 infusion system, supported by the new Hospira MedNet version 6.1 safety software, is the latest addition to Hospira's innovative portfolio of next-generation smart pumps.

News Date	26/08/2015
Category	Product Update-Others
Headline	Alliance Foundation Trials And Austrian Breast And Colorectal Cancer Study Group Open Largest Global Phase 3 Trial Of Targeted Therapy, IBRANCE (Palbociclib), For Patients With Hormone Receptor-Positive Early Breast Cancer

Summary	The Alliance Foundation Trials, LLC the Austrian Breast & Colorectal Cancer Study Group (ABCSCG) and Pfizer Inc. announced the launch of the Palbociclib Collaborative AdjuvantStudy, or PALLAS. This global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (NSABP) and PrECOG, LLC (PrECOG). The PALLAS trial will evaluate whether the addition of IBRANCE® (palbociclib), developed by Pfizer, to standard therapy will improve disease-free survival and prevent the disease from recurring. Patients treated in this study will have cancers that are hormone receptor-positive (HR+), meaning their growth is fueled by the hormone estrogen, but are negative for human epidermal growth factor receptor 2 (HER2-), a different tumor-associated protein. About 60 to 65 percent of breast cancers in the United States fall into this category.
---------	---

News Date	25/08/2015
Category	Partnership / Strategic Alliance
Headline	Alvogen To Acquire Product Portfolio From Pfizer For The U.S. Market
Summary	Alvogen has entered into a definitive agreement with Pfizer Inc. (NYSE: PFE), under which it will acquire a portfolio of four pharmaceutical products, in the U.S

News Date	25/08/2015
Category	Partnership / Strategic Alliance
Headline	Hospira And Cerner Expanded Agreement To Advance Integration Of I.V.-Emr Technology
Summary	Hospira Inc (NYSE: HSP) announced a commitment to advance the integration of I.V.-EMR technology. The expanded agreement strengthens both companies' ability to continue to bring innovative technologies to market, designed to enhance interoperability between Hospira's smart intravenous (I.V.) infusion devices and Cerner's CareAware solutions to meet the evolving needs of healthcare organizations.

News Date	24/08/2015
Category	Conferences
Headline	Bristol-Myers Squibb And Pfizer To Present New Data On Eliquis (apixaban) At The ESC Congress 2015

Summary	Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced that 22 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) patient populations. In addition, data from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
---------	--

News Date	24/08/2015
Category	Conferences
Headline	Bristol-Myers Squibb And Pfizer Presented New Data On Eliquis (Apixaban) At The ESC Congress 2015
Summary	Bristol-Myers Squibb Company (and Pfizer Inc.(NYSE:PFE) announced that 22 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) patient populations. In addition, data from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care

News Date	24/08/2015
Category	Regulatory-Others
Headline	Pfizer Received Clearance From U.S. Federal Trade Commission For Hospira Acquisition
Summary	Pfizer Inc announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Hospira (NYSE:HSP). The FTC's clearance is contingent upon Pfizer's commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan

News Date	21/08/2015
Category	Trial Results
Headline	Pfizer Announced Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)

Summary	Pfizer Inc. announced the positive topline results of two Phase 3 studies of TRUMENBA (Meningococcal Group B Vaccine). One study included approximately 3,600 healthy individuals 10 through 18 years of age, and the other study included approximately 3,300 healthy individuals 18 through 25 years of age. Both studies met all primary immunogenicity endpoints, demonstrating robust immune responses against certain invasive meningococcal B strains after the vaccine dose series. Safety and tolerability data from both studies were also consistent with data from previous studies
---------	---

News Date	20/08/2015
Category	MAA
Headline	Pfizer Announced European Medicines Agency Validates Marketing Authorization Application For IBRANCE (Palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer
Summary	Pfizer Inc. announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for IBRANCE(palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. With this validation, the Pfizer application is complete and the EMA will now begin the review procedure.

News Date	20/08/2015
Category	Company Announcements-Others
Headline	Charleston Area Medical Center Integrated Smart Pump Technology To Advance Patient Safety
Summary	Hospira announced the successful implementation of interoperability between the company's Plum A+ intravenous (I.V.) infusion devices with Hospira MedNet safety software and the electronic medical record at all four hospitals in the Charleston Area Medical Center Health System, Inc. (CAMC) in Charleston, W. Va. With this successful implementation, Hospira becomes the first smart pump manufacturer to integrate infusion systems with a third major EMR platform. This advanced technology is also known as I.V.-EMR interoperability.

News Date	18/08/2015
Category	Patent Grants
Headline	Pfizer, Provectus Biopharmaceuticals Awarded US Patent Protecting Use Of PV-10 As Part Of Combination Therapy For Cancer

Summary	Provectus Biopharmaceuticals Inc. (NYSE MKT: PVCT) announced that it has received a patent from the US Patent and Trademark Office, U.S. Patent number 9,107,887. The patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.
---------	--

News Date	14/08/2015
Category	Company Announcements-Others
Headline	Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition
Summary	Pfizer Inc. announced that it was granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (NYSE: HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada.

News Date	13/08/2015
Category	Mergers & Acquisitions
Headline	Pfizer Received Approval From The Australian Competition And Consumer Commission For Pending Acquisition Of Hospira
Summary	Pfizer Inc. announced that the Australian Competition and Consumer Commission (ACCC) has approved the company's pending acquisition of Hospira, Inc. (NYSE:HSP) and found no need for remedies.

News Date	10/08/2015
Category	Orphan Drug
Headline	Gliknik licensee Pfizer Received Orphan Drug Designation From U.S. Food And Drug Administration For Drug Candidate Directed Towards Rare Neurological Disorder
Summary	Gliknik Inc., announced that its licensee Pfizer Inc. (NYSE: PFE) received notification from the U.S. Food and Drug Administration (FDA) that its autoimmune candidate drug GL-2045, a recombinant Intravenous Immune Globulin (IVIG)-mimetic, has been granted orphan drug designation for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

News Date	04/08/2015
Category	Mergers & Acquisitions
Headline	Pfizer Received Approval From European Commission For Pending Acquisition Of Hospira

Summary	Pfizer Inc. announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company's pending acquisition of Hospira, Inc. (NYSE: HSP). The Commission's decision includes Pfizer's commitment to divest certain assets.
---------	---

News Date	03/08/2015
Category	Partnership / Strategic Alliance
Headline	Pfizer And Synthon Entered Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis
Summary	Pfizer Inc. and Synthon, an international pharmaceutical company announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS).

News Date	03/08/2015
Category	Partnership / Strategic Alliance
Headline	Pfizer And Synthon Entered Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis
Summary	Pfizer Inc. and Synthon announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS).

News Date	22/07/2015
Category	Company Announcements-Others
Headline	Pfizer Announced Expansion Of Lease Agreement With Massachusetts Institute Of Technology Subsidiary For Kendall Square Research Facility
Summary	Pfizer announced the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ). With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main Street in Kendall Square. This space will continue to house the R&D activities that relocated to 610 Main Street in 2014, and will enable the consolidation of Pfizer's three other leased spaces in Cambridge into the one campus.

News Date	08/07/2015
Category	Partnership / Strategic Alliance

Headline	Pfizer's Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announced Collaboration To Help Advance Immunological Research
Summary	Pfizer's Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced a collaboration agreement to conduct research in the field of immunological diseases. CTI and JMF will identify and co-fund translational research projects with leading academic medical centers within the CTI network. The goal of each research project will be to identify and validate a potential drug candidate for an immunological disease that can be moved into further clinical testing.

News Date	07/07/2015
Category	Trial Initiations
Headline	Pfizer Began Phase 2b Study Of Its Investigational Multi-Antigen Staphylococcus Aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery
Summary	Pfizer Inc. announced enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery. The purpose of the study, named STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy), is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery.

News Date	02/07/2015
Category	Priority Review
Headline	Pfizer Announced Food and Drug Administration Acceptance For Review Of New Drug Application For A Once-Daily Formulation Of XELJANZ (Tofacitinib Citrate) Modified Release Tablets
Summary	Pfizer Inc. announced that the United States Food and Drug Administration (FDA) accepted for review Pfizer's new drug application (NDA) for XELJANZ (tofacitinib citrate) 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in February 2016 for the NDA.

News Date	02/07/2015
Category	Partnership / Strategic Alliance
Headline	Technology For Ion Channel And Transporter Drug R&D

Summary	XRpro Sciences Inc announced its acquisition of assets related to the ion channel biology platform from Pfizer Inc. (NYSE: PFE) that had previously been obtained as part of Pfizer's 2011 acquisition of Icagen, Inc. XRPro Sciences also acquired all of Pfizer's rights to the "Icagen" name and trademark. XRPro Sciences is re-launching the Icagen brand and will provide comprehensive services for ion channel and transporter drug discovery, combining Icagen's industry-leading scientific expertise and extensive portfolio of assays and cell lines with XRpro Sciences' proprietary, label-free X-ray fluorescence technology. The new Icagen will continue to operate out of the existing facility in Research Triangle Park, North Carolina in addition to the current XRpro Sciences Inc. site in Cambridge, Massachusetts. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen, ensuring continuity of their extensive scientific expertise.
---------	---

News Date	25/06/2015
Category	Management Changes
Headline	Joseph J. Echevarria Elected To Pfizer's Board Of Directors
Summary	Pfizer Inc. announced the election of Joseph J. Echevarria to its Board of Directors, effective immediately. Mr. Echevarria also was appointed to the Audit, Regulatory and Compliance and Science and Technology Committees of Pfizer's Board.

News Date	24/06/2015
Category	Regulatory-Others
Headline	U.S. Centers for Disease Control and Prevention Advisory Committee On Immunization Practices Votes To Recommend Serogroup B Meningococcal Disease Vaccination Including TRUMENBA For Adolescents And Young Adults 16 Through 23 Years Of Age
Summary	Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. Specifically, the ACIP voted that a serogroup B meningococcal (MenB) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age.

News Date	23/06/2015
Category	Partnership / Strategic Alliance

Headline	Glycomimetics Received USD 20 Million Payment From Pfizer Following Initiation Of Phase 3 Trial With Rivipansel
Summary	GlycoMimetics, Inc. announced that Pfizer Inc. has dosed the first patient in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study - a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis (VOC) in patients hospitalized with sickle cell disease who are six years of age or older. The start of this trial triggered the second of two milestone payments from Pfizer to GlycoMimetics totaling USD35 million for Phase 3 initiation. GlycoMimetics received a USD15 million milestone payment from Pfizer in May 2014.

News Date	23/06/2015
Category	Trial Initiations
Headline	Pfizer Announced Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease
Summary	Pfizer Inc. announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older.

News Date	23/06/2015
Category	Company Announcements-Others
Headline	Pfizer Announced New Online Community, Quitter's Circle, Helps Smokers Trade Cigarettes For Real-Time Support
Summary	The American Lung Association and Pfizer announced the launch of Quitter's Circle, a mobile app (link is external) and online community designed to help smokers face common obstacles associated with quitting through educational, social and financial support. Within a few clicks, smokers can start a quit team with friends and family, find resources to connect with a healthcare provider and crowdsource funds to support the cost of a quit attempt

News Date	22/06/2015
Category	Partnership / Strategic Alliance
Headline	GSK Announced Regulatory Update On Divestment Of Nimenrix And Mencevax
Summary	GlaxoSmithKline plc announced that it is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc)

News Date	22/06/2015
-----------	------------

Category	Trial Results
Headline	Portola, Bristol-Myers Squibb And Pfizer Announced Full Results Of Second Part Of Phase 3 ANNEXA-A Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal Of Anticoagulant Effect Of Factor Xa Inhibitor Eliquis (apixaban)
Summary	Portola Pharmaceuticals (NASDAQ: PTLA), Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced full results from the second part of the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote and U.S. Food and Drug Administration designated breakthrough therapy, administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity of the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers ages 50-75 years.

News Date	22/06/2015
Category	Partnership / Strategic Alliance
Headline	Pfizer Entered Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline
Summary	Pfizer Inc. announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately USD 130 million (EUR 115 million). This transaction will add two high-quality and complementary vaccines to Pfizer's portfolio, allowing the company to reach a broader global population

News Date	18/06/2015
Category	Trial Results
Headline	Spark Therapeutics To Present With Pfizer Inc. Preclinical Data On Their Lead SPK-FIX Product Candidate For Hemophilia B At The 2015 International Society Of Thrombosis And Haemostasis Congress In June
Summary	Spark Therapeutics (Nasdaq:ONCE) announced that it, along with collaboration partner, Pfizer Inc., will present the results of preclinical testing that supports the safety and efficacy of the lead compound in their SPK-FIX hemophilia B program at the International Society on Thrombosis and Haemostasis (ISTH) during the ISTH 2015 Congress taking place in Toronto, Ontario, Canada from June 20th through June 25th. ISTH is a global, not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders and their Congress is the largest global event in the field.

News Date	11/06/2015
-----------	------------

Category	Trial Results
Headline	Pfizer Reported Top Line Results From A Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation In Pediatric Patients With Major Depressive Disorder
Summary	Pfizer Inc announced the top line results from a Phase 3 study which evaluated the efficacy, safety, and tolerability of Pristiq (desvenlafaxine succinate sustained-release formulation) in pediatric patients ages 7 to 17 with Major Depressive Disorder (MDD).

News Date	10/06/2015
Category	Product Update-Others
Headline	Pfizer Built Upon Robust Body Of Knowledge For XELJANZ (Tofacitinib Citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)
Summary	Pfizer Inc. announced that more than 20 abstracts including new rheumatoid arthritis (RA) research for XELJANZ (tofacitinib citrate) will be presented at the European League Against Rheumatism Annual Congress (EULAR 2015) June 10-15, Rome, Italy. Highlights include over six-years of safety and efficacy data from two long-term extension studies, real-world experience analyses, and clinical, patient-reported and radiographic efficacy outcomes with XELJANZ monotherapy, as well as health economics outcomes research that include patient-preference data for XELJANZ in patients with RA. Notably, new results from the XELJANZ 11 mg once daily clinical pharmacology program will be presented during the Congress, demonstrating equivalence in key pharmacokinetic parameters to XELJANZ 5 mg twice daily.

News Date	08/06/2015
Category	Conferences
Headline	Pfizer Announced Twelve Presentations Including New Research Data On Tofacitinib For Chronic Plaque Psoriasis And Atopic Dermatitis At World Congress Of Dermatology
Summary	Pfizer Inc. announced that it has twelve presentations, including new research data on tofacitinib for chronic plaque psoriasis and atopic dermatitis, at the upcoming 23rd World Congress of Dermatology (WCD) meeting to be held on June 8-13 in Vancouver, Canada. Among the highlights are three late-breaking research presentations, including 52-week pooled results from the Oral treatment Psoriasis Trials (OPT) Pivotal studies, an integrated safety summary across the OPT development program for oral tofacitinib, and the first presentation of two year results from OPT Extend, the ongoing long-term extension study of tofacitinib in moderate to severe chronic plaque psoriasis. In addition, new Phase 2a data for topical tofacitinib in the treatment of atopic dermatitis will be presented for the first time.

News Date	04/06/2015
Category	Company Announcements-Others
Headline	Pfizer Challenged Conventional Views Of Aging Through New Campaign
Summary	Pfizer announced that it is challenging Americans to embrace aging as not an end, but a beginning—a time to fulfill old dreams and make new ones a reality. For graduation season 2015, “Get Ready. Get Set. Get Old.” releases its “Commencement Day” video and new Get Old branding that serve as reminders of the inspiration, hopes and dreams that begin the next phase of every journey.

News Date	30/05/2015
Category	Trial Results
Headline	Pfizer Announced Palbociclib More Than Doubled Progression-Free Survival In Phase 3 Trial For Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy
Summary	Pfizer Inc. announced study results demonstrating palbociclib in combination with fulvestrant was superior to treatment with a standard of care, fulvestrant, by significantly extending progression-free survival (PFS) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed during or after endocrine therapy (HR 0.42, median PFS, 9.2 vs. 3.8 months, in their respective arms, p<0.000001). Results from the Phase 3 PALOMA-3 study will be featured today in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) and will be presented as a late-breaker on Monday, June 1 at 8:00 a.m. CDT (Abstract #LBA502). The results will also be simultaneously published online by The New England Journal of Medicine. The Principal Investigator for the study, Nicholas C. Turner, MD, PhD, consultant medical oncologist at The Royal Marsden and Institute of Cancer Research in London, United Kingdom, will present these data

News Date	29/05/2015
Category	Drug approvals
Headline	Pfizer's RAPAMUNE (Sirolimus) Became First Food and Drug Administration Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system. This is the first approved treatment that helps stabilize lung function in patients with LAM.

News Date	28/05/2015
Category	Awards/Grants/Funds
Headline	Pfizer Announced USD 3 Million Grants Program To Further Clinical Research In Advanced Breast Cancer
Summary	Pfizer Inc. announced the launch of a competitive, peer-reviewed grants program to support clinical research projects investigating IBRANCE (palbociclib) in advanced breast cancer. The multi-year program, which will award a total of up to USD 3 million in grants to investigators in the United States, is an extension of Pfizer's Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) initiative. It is the first ASPIRE program to focus on breast cancer research

News Date	28/05/2015
Category	Company Announcements-Others
Headline	Pfizer Global Survey Found Adults With Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have A More Positive View Of Their Health
Summary	Pfizer announced initial results of its global survey of more than 3,600 adults with rheumatoid arthritis (RA) in 13 countries. The RA NarRAtive patient survey is the first of its kind to simultaneously evaluate the patient and healthcare professional (HCP) relationship and communication, as well as the patient's experience and satisfaction with treatment and disease management. The data show that a patient's perception of their RA and its treatment, as well as their relationship with their HCP, can impact the management of their disease

News Date	14/05/2015
Category	Company Announcements-Others
Headline	Pfizer Received Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira
Summary	Pfizer Inc. announced that it has received a request for additional information from the U.S. Federal Trade Commission ("FTC") with respect to its previously announced proposed acquisition of Hospira. The request for information from the FTC, often referred to as a "second request," was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act").

News Date	14/05/2015
Category	Management Changes
Headline	Marc Tessier-Lavigne, Ph.D. Leaved Pfizer Board Of Directors

Summary	Pfizer Inc. announced that Director Marc Tessier-Lavigne, Ph.D. has decided to step down from its Board of Directors on May 14, 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr. Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company.
---------	--

News Date	13/05/2015
Category	Meeting schedules
Headline	Merck KGaA, And Pfizer Presened Data At ASCO For Avelumab, An Investigational Anti-PD-L1 Antibody
Summary	Merck KGaA and Pfizer announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.

News Date	13/05/2015
Category	Meeting schedules
Headline	Merck And Pfizer Presented Data At American Society Of Clinical Oncology For Avelumab, An Investigational Anti-PD-L1 Antibody
Summary	Merck and Pfizer announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.

News Date	11/05/2015
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Minority Interest In AM-Pharma; Secures Option To Acquire Company
Summary	AMPharma B.V. and Pfizer Inc. announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury (AKI) related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of USD 87.5 million for the minority equity interest and exclusive option, with additional potential payments of up to USD 512.5 million upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed.

News Date	11/05/2015
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Pfizer Acquired Minority Interest In AM-Pharma; Secured Option To Acquire Company
Summary	AMPharma B.V., and Pfizer Inc. announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury (AKI) related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016.

News Date	06/05/2015
Category	Management Changes
Headline	Pfizer Appointed New Leaders For BioTherapeutics Research And Development And Rinat
Summary	Pfizer Inc. announced two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Pfizer's Cambridge and Boston, Massachusetts locations. Dr. Ehlers will report directly to Mikael Dolsten, M.D., Ph.D., President of Worldwide Research & Development. In addition, John Lin, M.D., Ph.D., has been selected as Senior Vice President and Chief Scientific Officer of Rinat. Dr. Lin will report directly to Robert T. Abraham, Ph.D., Group Senior Vice President for Oncology-Rinat Research & Development.

News Date	23/04/2015
Category	Financial Performance-Others
Headline	Pfizer Hosted Annual Meeting Of Shareholders
Summary	The board of directors of Pfizer Inc. declared a 28-cent second-quarter 2015 dividend on the company's common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer.

News Date	21/04/2015
Category	Breakthrough

Headline	Pfizer Receives U.S Food and Drug Administration Breakthrough Therapy Designation For XALKORI (Crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer
Summary	Pfizer Inc. announced that XALKORI (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Occurring in approximately one percent of NSCLC cases, ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC. XALKORI currently is approved in the U.S. for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

News Date	21/04/2015
Category	Trial Results
Headline	Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Met Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Summary	Pfizer announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) compared to that achieved with standard of care chemotherapy

News Date	21/04/2015
Category	Partnership / Strategic Alliance
Headline	Pain Therapeutics Resumed Responsibility For Remoxy
Summary	Pain Therapeutics, Inc. reported it had recently resumed responsibility for Remoxy under the terms of a letter agreement with Pfizer. The letter agreement was entered into within the scope of the previously disclosed provisions of the Collaboration Agreement between the two companies relating to the return of Remoxy.

News Date	20/04/2015
Category	Presentations
Headline	MacroGenics Presented Pre-Clinical Data On Its Multivalent DR5 DART At The AACR Annual Meeting
Summary	MacroGenics, Inc. announced the presentation of pre-clinical data for Dual-Affinity Re-Targeting (DART) molecules that target DR5 at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. In addition, MacroGenics' collaboration partner, Pfizer Inc., presented pre-clinical data on a DART molecule that simultaneously targets P-cadherin and CD3.

News Date	20/04/2015
Category	Patent Grants
Headline	Pfizer And Provectus Biopharmaceuticals Receive Patent Allowance For Use Of PV-10 In Combination With Systemic Immunotherapy Agents In Treatment Of Cancer
Summary	Provectus Biopharmaceuticals Inc. (NYSE MKT: PVCT) announced that it has received from the US Patent and Trademark Office a Notice of Allowance for a joint patent application made with Pfizer Inc. The patent will protect use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.

News Date	20/04/2015
Category	Trial Initiations
Headline	Global Strategic Partners Merck KGaA And Pfizer Initiated Phase III Study With Avelumab In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer
Summary	Merck KGaA and Pfizer Inc announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy.

News Date	20/04/2015
Category	Trial Initiations
Headline	Global Strategic Partners Merck And Pfizer Initiated Phase III Study With Avelumab In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer
Summary	Merck and Pfizer announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab* (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy

News Date	16/04/2015
Category	Presentations
Headline	MacroGenics Announced Presentations at AACR Annual Meeting 2015

Summary	MacroGenics, Inc. announced that pre-clinical data from programs based on its Dual-Affinity Re-Targeting (DART) bi-specific technology will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA by the Company and Pfizer, Inc., one of MacroGenics' collaboration partners.
---------	--

News Date	16/04/2015
Category	Company Announcements-Others
Headline	Pfizer Launched 2014 Integrated Annual Review
Summary	Pfizer Inc. addressed some challenging questions often posed by shareholders and the public in its latest integrated annual review for 2014. In a series of video Q&As, Pfizer colleagues respond to questions such as: "Why do people say medicines are so expensive?" and "Why is it so difficult to find a cure for cancer?"

News Date	15/04/2015
Category	Trial Results
Headline	Pfizer Announced PALOMA-3 Trial For IBRANCE (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy
Summary	Pfizer Inc announced that the Phase 3 PALOMA-3 trial for IBRANCE (palbociclib) met its primary endpoint of demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus fulvestrant compared with fulvestrant plus placebo in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer following disease progression during or after endocrine therapy. The study was stopped early due to efficacy based on an assessment by an independent Data Monitoring Committee (DMC). These are the first randomized Phase 3 trial results for IBRANCE, a new anti-cancer medicine with the novel mechanism of cyclin-dependent kinase 4/6 (CDK 4/6) inhibition.

News Date	15/04/2015
Category	Partnership / Strategic Alliance
Headline	Regimmune Announced Collaboration With JDRF And Pfizer Inc For Type 1 Diabetes Prevention And Treatment Promoting Regulatory T-Cells

Summary	REGiMMUNE Corporation and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI's proprietary GalCer/liposome platform for immunological tolerance for the treatment of type 1 diabetes (T1D). Under the terms of the collaboration, REGiMMUNE will develop an antigen-specific therapeutic liposome that potentially prevents or delays the onset of T1D and induces immunologic tolerance.
---------	---

News Date	13/04/2015
Category	Intellectual Property-Others
Headline	Mylan Settled Patent Litigation Related To Viagra
Summary	Mylan N.V. (NASDAQ: MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals Inc have entered into a settlement and license agreement with Pfizer Inc., Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S.FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction.

News Date	09/04/2015
Category	Company Announcements-Others
Headline	Pfizer Launched First Annual PCSK9 Competitive Grants Program To Advance Cardiovascular Disease Research
Summary	Pfizer Inc. announced the launch of a new competitive grants program the company is funding to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease. Pfizer currently is studying bococizumab, an investigational PCSK9 inhibitor, in a Phase 3 clinical trial program, known as SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events), for its potential to lower low density lipoprotein cholesterol (LDL-C) and improve cardiovascular outcomes.

News Date	07/04/2015
Category	Partnership / Strategic Alliance
Headline	Global Strategic Partners Merck KGaA And Pfizer Finalized Agreement To Co-Promote XALKORI (Crizotinib)

Summary	Merck KGaA and Pfizer Inc. announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI(crizotinib). This agreement showcases the alliance's commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.
---------	--

News Date	07/04/2015
Category	Partnership / Strategic Alliance
Headline	Global Strategic Partners Merck And Pfizer Finalized Agreement To Co-Promote Xalkori (crizotinib)
Summary	Merck and Pfizer announced the finalization of the co-promotion agreement allowing the companies to jointly co-promote Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib). This agreement showcases the alliance's commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab-based treatment regimens in the future.

News Date	06/04/2015
Category	Management Changes
Headline	Kathrin U. Jansen, Ph.D., To Lead Pfizer's Vaccine Research And Development Unit
Summary	Pfizer Inc. announced that Kathrin U. Jansen, Ph.D., has been appointed Senior Vice President, Vaccine Research & Development, and will be responsible for leading all Pfizer vaccine research and development programs, effective June 1st, 2015. Dr. Jansen will report directly to Mikael Dolsten, M.D., Ph.D., President of Worldwide Research and Development at Pfizer, and will be based in Pfizer's Pearl River, New York research site.

News Date	02/04/2015
Category	Partnership / Strategic Alliance
Headline	BIND Therapeutics Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins
Summary	BIND Therapeutics, Inc. announced that BIND Therapeutics have extended of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline. The collaboration was originally established in April 2013 and the timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016.

News Date	30/03/2015
Category	Management Changes
Headline	Dr. Charles Reay Mackay Joined Pfizer As Chief Scientific Officer, Inflammation And Immunology Research Unit
Summary	Pfizer Inc. announced that Charles Reay Mackay, Ph.D., will join the company as Chief Scientific Officer for Pfizer's Inflammation and Immunology Research Unit. Professor Mackay will report directly to Jose-Carlos Gutierrez-Ramos, Ph.D., group vice president of BioTherapeutics Research & Development, and will be based in Pfizer's R&D hub in Cambridge, MA.

News Date	23/03/2015
Category	Product Recalls/ Holds
Headline	Pfizer And Lilly Prepared To Resume Phase 3 Chronic Pain Program For Tanezumab
Summary	Pfizer Inc. and Eli Lilly and Company (NYSE:LLY) announced that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a USD 200 million upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. Food and Drug Administration (FDA) to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February 2015

News Date	23/03/2015
Category	Partnership / Strategic Alliance
Headline	Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
Summary	Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) announced that they have preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a USD 200 million upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. Food and Drug Administration (FDA) to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February 2015.

News Date	20/03/2015
Category	Trial Results

Headline	Pfizer Announced Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials
Summary	Pfizer Inc. announced the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program at the 73rd American Academy of Dermatology (AAD) Annual Meeting. These results, evaluating the efficacy and safety of tofacitinib citrate for the treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, have been selected for oral presentation during the Pearls from the Posters New and Noteworthy Research Finds [abstract 2020]. Additionally, an integrated analysis of safety data from the OPT global clinical development program for tofacitinib was presented during the Late-Breaking Research in Dermatology Forums [abstract 2587].

News Date	18/03/2015
Category	Trial Results
Headline	Results Of Pfizer's Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Published In The New England Journal Of Medicine
Summary	Pfizer Inc announced the publication of findings from its Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) in the March 19 issue of The New England Journal of Medicine. The study, conducted in collaboration with Julius Clinical and the University Medical Centre Utrecht in the Netherlands, investigated the efficacy of immunization with Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) to prevent a first episode of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-bacteremic/non-invasive CAP, and vaccine-type invasive pneumococcal disease (IPD) in adults aged 65 years and older. The study achieved its primary and secondary objectives

News Date	12/03/2015
Category	Trial Results
Headline	Pfizer Reported Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia

Summary	Pfizer Inc. announced top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM). The primary endpoint of the study was not achieved as there was not a statistically significant difference between pregabalin and placebo in mean pain score. The treatment difference was 0.66 points, which reflects an improvement of 1.60 points from baseline for pregabalin-treated patients and 0.94 points for placebo ($p=0.121$). This study was conducted to fulfill a post-marketing commitment required by the U.S. Food and Drug Administration (FDA) when Lyrica was approved for the management of fibromyalgia. The safety and efficacy of pregabalin in pediatric patients have not been established
---------	---

News Date	03/03/2015
Category	Drug approvals
Headline	Pfizer Received European Approval For New Indication For Prevenar 13 For Prevention Of Vaccine-Type Pneumococcal Pneumonia In Adults
Summary	Pfizer Inc. announced that the European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from Pfizer's landmark Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease (IPD) in adults aged 65 and older.

News Date	26/02/2015
Category	Product Update-Others
Headline	Centers for Disease Control and Prevention Advisory Committee On Immunization Practices Voted To Recommend Serogroup B Meningococcal Disease Vaccination For Persons At Increased Risk

<p>Summary</p> <p>Pfizer Inc. announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend serogroup B meningococcal vaccination to help protect individuals at increased risk. Specifically, the ACIP voted to recommend serogroup B meningococcal vaccination for persons aged 10 years and older at increased risk for meningococcal disease, including:</p> <ul style="list-style-type: none"> Persons with persistent complement component deficiencies Persons with anatomic or functional asplenia Microbiologists routinely exposed to isolates of <i>Neisseria meningitidis</i> Persons identified to be at increased risk because of a serogroup B meningococcal disease outbreak
--

News Date	24/02/2015
Category	Trial Results
Headline	Pfizer Announced Positive Top-Line Results Of A Phase 2 Study Of TRUMENBA(Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, And W) And Tetanus, Diphtheria And Pertussis (Tdap) Vaccines In Adolescents
Summary	Pfizer Inc announced positive top-line results of a Phase 2 study of TRUMENBA(Meningococcal Group B Vaccine) co-administered with FDA-approved, routine meningococcal (groups A, C, Y and W) (MCV4) and single-dose tetanus, diphtheria and pertussis (Tdap) vaccines in more than 2,600 healthy individuals 10 through 12 years of age. The study met its co-primary immunogenicity objectives regarding co-administration of TRUMENBA with MCV4 and Tdap vaccines.

News Date	18/02/2015
Category	Partnership / Strategic Alliance
Headline	Pharmacosmos Entered Into Agreement With Pfizer For Rights In Canada To Monofer
Summary	Pharmacosmos A/S announced that it has entered into an agreement with Pfizer Inc. under which Pfizer would acquire the exclusive commercialization rights to Monofer in Canada. Monofer, under development by Pharmacosmos in Canada, is an innovative intravenous iron replacement therapy for the treatment of iron deficiency anaemia (IDA).

News Date	13/02/2015
Category	Priority Review
Headline	Pfizer Announced Food and Drug Administration (Acceptance For Review Of A New Drug Application For ALO-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride

Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride), extended-release capsules, an abuse-deterrent formulation (ADF) opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ALO-02 is an extended-release oxycodone specifically designed to reduce abuse via the oral, intranasal (i.e., snorting) and intravenous (IV) routes when crushed.
---------	---

News Date	12/02/2015
Category	Trial Results
Headline	Safety And Efficacy Of ELELYSO (Taliglucerase Alfa) For Injection In Pediatric Patients With Type 1 Gaucher Disease In Long-Term Outcome Study Presented At The World Symposium 2015
Summary	Pfizer Inc. announced that researchers presented new data which expand on the existing body of data for ELELYSO (taliglucerase alfa) for injection in pediatric patients with Type 1 Gaucher disease. These data, which were released today in an oral presentation at the 11th Annual WORLDSymposium in Orlando, include results from a Phase 3, multi-center, extension trial evaluating the long-term efficacy and safety of ELELYSO in pediatric patients with Type 1 Gaucher disease who were treatment-naive or previously treated with imiglucerase

News Date	09/02/2015
Category	Financial Performance-Others
Headline	Pfizer Commenced USD 5 Billion Accelerated Share Repurchase
Summary	Pfizer Inc. announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase USD 5 billion of Pfizer's common stock. This agreement is part of Pfizer's existing share repurchase authorization under which an additional USD 11 billion of authority was announced in October 2014.

News Date	05/02/2015
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Hospira

Summary	Pfizer Inc. and Hospira, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world's leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for USD 90 a share in cash for a total enterprise value of approximately USD 17 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive upon closing, accretive by USD 0.10 - USD 0.12 per share for the first full year following the close of the transaction with additional accretion anticipated thereafter
---------	---

News Date	04/02/2015
Category	Priority Review
Headline	Pfizer Announced Food and Drug Administration Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ (Tofacitinib Citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis
Summary	Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate) 5 mg and 10 mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in October 2015 for the sNDA

News Date	04/02/2015
Category	Awards/Grants/Funds
Headline	Pfizer Marked World Cancer Day With Grant To Union For International Cancer Control To Address The Needs Of Metastatic Breast Cancer Patients
Summary	Pfizer Inc. announced a grant to the Union for International Cancer Control (UICC) for a first-of-its-kind initiative to address the unique challenges facing metastatic breast cancer (MBC) patients. While great progress has been made in the management of breast cancer, it remains a significant and growing global health issue and patients are commonly diagnosed in the advanced stages of the disease. The Seeding Progress and Resources for the Cancer Community (SPARC): Metastatic Breast Cancer Challenge will provide grants to support initiatives worldwide that encourage sustainable change in addressing the specific needs of people living with metastatic breast cancer

News Date	03/02/2015
Category	Accelerated approval

Headline	Pfizer Received U.S. Food and Drug Administration Accelerated Approval Of IBRANCE (Palbociclib)
Summary	Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of IBRANCE (palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease. ¹ This indication is approved under accelerated approval based on progression-free survival (PFS). ¹ Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The confirmatory Phase 3 trial, PALOMA-2, is fully enrolled

News Date	01/02/2015
Category	Product Launch
Headline	Greenstone Llc Introduced Trandolapril / Verapamil Hydrochloride Er Tablets
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announce the introduction of Trandolapril/Verapamil Hydrochloride Extended Release (ER) tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 1mg/240mg x 100; 2mg/180mg x100; 2mg/240mg x 100; 4mg/240mg x 100.

News Date	29/01/2015
Category	Partnership / Strategic Alliance
Headline	OPKO And Pfizer Received Regulatory Clearance For Global Agreement
Summary	OPKO Health Inc (NYSE:OPK) and Pfizer Inc. (NYSE: PFE) announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows termination of the waiting period under the Hart-Scott Rodino Act

News Date	26/01/2015
Category	Conferences
Headline	Pfizer Committed To Further Reduce Price For Prevenar 13 In The World's Poorest Countries Through 2025

Summary	Pfizer Inc. announced new commitments aimed at ensuring the world's most resource-limited countries have access to Prevenar 13 (pneumococcal polysaccharide conjugate vaccine (PCV), 13 – valent, adsorbed) through Gavi, the Vaccine Alliance. Pfizer's commitments were announced during Gavi's pledging conference being held in Berlin, Germany, in support of Gavi's 2016 – 2020 strategy
---------	--

News Date	22/01/2015
Category	Regulatory Opinion
Headline	Prevenar 13 Received European Medicines Agency's Committee for Medicinal Products for Human Use Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia In Adults
Summary	Pfizer Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the indication for Prevenar 13(pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) be expanded to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older. Prevenar 13 is currently approved in Europe for the prevention of invasive pneumococcal disease (IPD) in the same population. The CHMP's positive opinion will now be reviewed by the European Commission (EC). The decision on whether to approve Prevenar 13 for this indication will be made by the EC and will be applicable to all European Union member states plus Iceland, Lichtenstein and Norway.

News Date	21/01/2015
Category	Awards/Grants/Funds
Headline	Pfizer And The Avon Foundation For Women Award 23 Grants Totalled USD 1 Million In Funding To Support Patients Living With Metastatic Breast Cancer
Summary	Pfizer Inc. and the Avon Foundation for Women announced the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify. In total, 23 non-profit organizations will receive grants totaling USD 1 million in funding to support and educate more than 5,000 metastatic breast cancer patients, their caregivers, and their communities. The Avon-Pfizer Metastatic Breast Cancer Grants Program was created in June 2014 to support advocacy, academic and other nonprofit organizations that provide information and services to help people with metastatic breast cancer navigate the medical and emotional challenges associated with their disease

News Date	20/01/2015
Category	Device approval

Headline	Hospira Received FDA Clearance For Plum 360 Infusion System
Summary	Hospira Inc (NYSE: HSP) announced that the company has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum 360 infusion system with Hospira MedNet safety software. The newest in Hospira's portfolio of infusion devices, the Plum 360 system builds on the unique air management and secondary delivery features of Plum A+, while expanding its drug library and wireless capability to enable streamlined electronic medical record (EMR) integration.

News Date	08/01/2015
Category	Partnership / Strategic Alliance
Headline	Repligen Receives Milestone Payment From Pfizer
Summary	Repligen Corporation (Nasdaq:RGEN) announced that it received a USD 1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement, Repligen has received USD 7 million in upfront and milestone payments. Repligen remains eligible to receive up to USD 63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement.

News Date	08/01/2015
Category	Regulatory-Others
Headline	Pfizer Provided Update On IBRANCE (Palbociclib)
Summary	The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc. that at this time there is no plan for an Oncologic Drugs Advisory Committee meeting for IBRANCE (palbociclib). Pfizer continues to have an open and productive dialogue with the FDA as the application for IBRANCE advances. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 13, 2015. The Company reports that it has entered label discussions with the FDA and hopes to be able to bring IBRANCE to patients who need it as soon as possible.

News Date	05/01/2015
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Redvax GmbH

Summary	Pfizer Inc. announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.
---------	--

News Date	05/01/2015
Category	Product Update-Others
Headline	Protalix Biotherapeutics Announced New Strategy For Accelerated Growth
Summary	Protalix BioTherapeutics, Inc. announced the Company's newly implemented strategy for accelerated growth. The strategy centers around prioritizing existing and new pipeline candidates to focus on bio-better products with potentially clinically superior profiles that offer a clear competitive advantage. The following highlights the details of the strategic plan.

News Date	15/12/2014
Category	Partnership / Strategic Alliance
Headline	Genable Welcomed The Announcement By Its Development Partner Spark Therapeutics Of A Collaboration With Pfizer In Developing Treatments For Haemophilia B
Summary	Spark Therapeutics announced that it has entered into a global collaboration with Pfizer Inc. for the development and potential exploitation of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus(AAV) vectors for the potential treatment of haemophilia B. The companies will work together on a worldwide basis with the aim of bringing an important investigational gene therapy to patients.

News Date	15/12/2014
Category	Partnership / Strategic Alliance
Headline	Opko And Pfizer Entered Into Global Agreement For Opko's Long-Acting Human Growth Hormone (hGH-CTP)

Summary	OPKO Health, Inc and Pfizer Inc announced that they have entered into a worldwide agreement for the development and commercialization of OPKO's long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. hGH-CTP is currently in a global phase 3 trial in adults and a global phase 2 trial in children and has orphan drug designation in the U.S. and Europe for both adults and children with GHD.
---------	---

News Date	08/12/2014
Category	Partnership / Strategic Alliance
Headline	Pfizer Expanded Rare Disease Research With Establishment Of Gene Therapy Platform
Summary	Pfizer Inc. (NYSE:PFE) announced two strategic decisions to expand the company's rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. First is an agreement with Spark Therapeutics to develop SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential treatment of Hemophilia B expected to enter Phase 1/2 clinical trials in the first half of 2015. Additionally, Pfizer has appointed Michael Linden, Ph.D., Professor at King's College London and Director of the University College London Gene Therapy Consortium, who will be with the company for a two-year secondment to lead gene therapy research in the rare disease area.

News Date	08/12/2014
Category	Partnership / Strategic Alliance
Headline	iTeos Therapeutics Announced License And Collaboration With Pfizer Inc. For Discovery And Development Of Cancer Immunosuppression Targets
Summary	iTeos Therapeutics SA announced a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase and Tryptophan 2,3-dioxygenase . Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. Additionally, the parties will collaborate to discover and validate new targets that play key roles in the ability of tumors to evade immune responses. These new targets will be shared by iTeos and Pfizer for further independent or collaborative development.

News Date	01/12/2014
Category	Mergers & Acquisitions

Headline	Pfizer Completed Acquisition Of Baxter's Marketed Vaccines
Summary	<p>Pfizer Inc. (NYSE:PFE) announced that it has completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.</p> <p>"NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines," said Susan Silbermann, president and general manager, Pfizer Vaccines. "These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases."</p>

News Date	01/12/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Celecoxib Capsules
Summary	<p>Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc. (NYSE: PFE) announced the introduction of Celecoxib to its ever-expanding generic pharmaceutical product line. The product is offered in capsule form in dosage strengths of 50 mg x 60 capsules per bottle; 100 mg x 100 capsules per bottle; 100 mg x 500 capsules per bottle; 200 mg x 100 capsules per bottle; 200 mg x 500 capsules per bottle; and 400 mg x 60 capsules per bottle.</p>

News Date	17/11/2014
Category	Partnership / Strategic Alliance
Headline	Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Summary	<p>Pfizer Inc. (NYSE:PFE) announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer. Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's broad portfolio of approved and investigational oncology therapies.</p>

News Date	13/11/2014
Category	Partnership / Strategic Alliance

Headline	Novel Agreement Expanded Access to Pfizer's Contraceptive, Sayana Press, for Women Most in Need in the World's Poorest Countries
Summary	Pfizer Inc., the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) announced an agreement that will expand access to Pfizer's injectable contraceptive, Sayana Press (medroxyprogesterone acetate), for women most in need in 69 of the world's poorest countries. Through this collaboration of organizations from the public and private sectors, Sayana Press will be sold for USD1 per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.

News Date	01/11/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Sirolimus Tablets
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced, on October 27, 2014, the introduction of Sirolimus tablets to its ever-expanding generic pharmaceutical product line. The product is offered as 1 mg and 2 mg tablets in bottles of 100 tablets each.

News Date	27/10/2014
Category	Partnership / Strategic Alliance
Headline	Pain Therapeutics Regained Full Rights To Remoxy
Summary	Pain Therapeutics, Inc. reported it believes it will regain full development and commercial rights to Remoxy from Pfizer, Inc. On October 24th, Pfizer hosted a conference call with us during aftermarket hours to inform us of their intention to terminate development of Remoxy. Actual termination will become effective six months from today, pursuant to the terms of a Collaboration Agreement.

News Date	27/10/2014
Category	Partnership / Strategic Alliance
Headline	Pfizer to Discontinued Agreement on REMOXY (oxycodone) Extended-Release Capsules CII
Summary	Pfizer Inc. (NYSE:PFE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.

News Date	25/09/2014
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition Of InnoPharma
Summary	Pfizer Inc. (NYSE:PFE) announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.

News Date	25/09/2014
Category	Partnership / Strategic Alliance
Headline	Thermo Fisher Scientific Announced Agreement With Glaxosmithkline And Pfizer To Develop Oncology Companion Diagnostics Using Next-Generation Sequencing (NGS)
Summary	Thermo Fisher Scientific and pharmaceutical companies GlaxoSmithKline and Pfizer have entered into an agreement to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs. Thermo Fisher intends to submit this test for premarket approval to the Food and Drug Administration (FDA) and other global regulatory authorities, following successful development and validation of the test. The test will be developed using Thermo Fisher Scientific's Ion Personal Genome Machine (PGM) Dx Platform, Ion AmpliSeq technology, and content from the Oncomine Cancer Research Panel.

News Date	16/09/2014
Category	Partnership / Strategic Alliance
Headline	MedGenesis Entered Into Agreement With Pfizer Inc. For Potential Treatments For Parkinson's Disease
Summary	MedGenesis Therapeutics Inc. announced that it has entered into an agreement with Pfizer Inc. granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor protein and convection enhanced delivery technology to be used in research for potential treatments for Parkinson's disease.

News Date	16/09/2014
Category	Partnership / Strategic Alliance
Headline	Medgenesis Entered Into Agreement With Pfizer Inc For Potential Treatments For Parkinson's Disease

Summary	MedGenesis Therapeutix Inc announced that it has entered into an agreement with Pfizer Inc granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.
---------	--

News Date	01/09/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Cabergoline Tablets
Summary	Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of cabergoline tablets to its ever-expanding generic pharmaceutical product line. The product is offered in tablet form in dosage strengths of 0.5 mg x eight tablets per bottle.

News Date	28/08/2014
Category	Conferences
Headline	Protalix Announced Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs
Summary	Protalix BioTherapeutics, Inc. announced that it will host a conference call on September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly announced with Pfizer on August 28, 2014. In addition, the Company's management will also provide an update on the additional ongoing clinical programs, PRX-112 and PRX-102, and hold a Q&A session.

News Date	28/08/2014
Category	Drug approvals
Headline	Pfizer And Protalix Biotherapeutics Announced FDA Approval Of Pediatric Indication For Elelyso (Taliglucerase Alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease
Summary	Pfizer Inc. and Protalix BioTherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Elelyso (taliglucerase alfa) for injection for pediatric patients. Elelyso is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.

News Date	26/08/2014
Category	Partnership / Strategic Alliance

Headline	Pfizer And Merck Collaborated On Study Evaluating Novel Anti-Cancer Combination Regimen
Summary	Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (Xalkori) with Merck's investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). The financial terms of the agreement were not disclosed.

News Date	22/07/2014
Category	;Partnership / Strategic Alliance
Headline	Puma Biotechnology Announced Amendment To Neratinib Licensing Agreement With Pfizer
Summary	Puma Biotechnology Inc (NYSE: PBYI) announced an amendment to its licensing agreement with Pfizer for Puma's investigational drug PB272 (neratinib). Puma was currently developing PB272 for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.

News Date	01/07/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Doxazosin Mesylate Tablets
Summary	Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Doxazosin Mesylate tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 1 mg x 100; 2 mg x 100; 4 mg x 100 and 8 mg x 100.

News Date	27/06/2014
Category	Trial Results
Headline	Protalix Announced New Data On Elelyso (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
Summary	Protalix BioTherapeutics, Inc. announced that new clinical data on Elelyso (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. Elelyso, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease.

News Date	23/06/2014
Category	Meeting schedules
Headline	Protalix Biotherapeutics Announced New Data On Elelyso (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
Summary	Protalix BioTherapeutics, Inc. announced that new clinical data on Elelyso and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel.

News Date	18/06/2014
Category	Partnership / Strategic Alliance
Headline	MRC Technology Sells Its Melanocortin Receptors Programme To Pfizer Inc
Summary	MRC Technology announced that it has sold to Pfizer Inc. its melanocortin receptors (MCRs) programme, which includes a set of small molecules. Targets for these small molecules came to the attention of MRC Technology from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London (QMUL), and MRC Technology ran a screening programme in collaboration with QMUL. MCRs have a wide and varied distribution throughout the body, being found in the central nervous system, periphery and immune cells.

News Date	18/06/2014
Category	Partnership / Strategic Alliance
Headline	Pfizer And Cellectis Have Entered Into Global Strategic Cancer Immunotherapy Collaboration
Summary	Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).

News Date	04/06/2014
Category	Partnership / Strategic Alliance

Headline	Kinemed Collaboration With Pfizer Inc. In Diabetes Was Extended
Summary	KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed's novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

News Date	01/06/2014
Category	Partnership / Strategic Alliance
Headline	MD Anderson teamed up with Pfizer to advance cancer immunotherapy
Summary	The University of Texas MD Anderson Cancer Center announced that it will collaborate with Pfizer in the development of immune-based approaches to cancer treatment, the first such agreement made through MD Anderson's Moon Shots Program immunotherapy platform.

News Date	30/05/2014
Category	Drug approvals
Headline	Protalix Announced Elelyso (Taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
Summary	Protalix BioTherapeutics, Inc. announced that Health Canada has granted regulatory approval to Elelyso (taliglucerase alfa for injection) for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. Elelyso may also be used for the hematological manifestations in pediatric patients with a confirmed diagnosis of Type 3 Gaucher disease. Elelyso will be marketed in Canada by Pfizer Inc., the Company's commercialization partner.

News Date	22/05/2014
Category	Drug approvals
Headline	Protalix Announced Elelyso (Taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
Summary	Protalix BioTherapeutics, Inc. announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia. Elelyso will be marketed in Australia by Pfizer Inc., the Company's commercialization partner.

News Date	14/05/2014
Category	Partnership / Strategic Alliance
Headline	American College Of Physicians ,Cecity And Pfizer Collaborated To Increase Adult Immunization Rat
Summary	The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE:PFE) announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three organizations made the announcement during the annual National Adult Influenza and Immunization Summit meeting being held May 13-15 in Atlanta.

News Date	02/05/2014
Category	Partnership / Strategic Alliance
Headline	Second Genome Entered Into Agreement With Pfizer Inc. On Microbiome Research Initiative In Obesity
Summary	Second Genome Inc announced that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.

News Date	01/04/2014
Category	Partnership / Strategic Alliance
Headline	EMD Serono Entered into Research Agreement with Pfizer and Broad Institute
Summary	EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The research project will be jointly funded by EMD Serono and Pfizer.

News Date	01/04/2014
Category	Product Launch

Headline	Greenstone Llc Introduced Rifabutin Capsules
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Rifabutin Capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 150mg x 100.

News Date	01/03/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Piroxicam Capsules
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Piroxicam Capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 10mg x 100 and 20mg x 100.

News Date	26/02/2014
Category	Partnership / Strategic Alliance
Headline	Saniona Announced Collaboration With Pfizer To Research And Develop Small Molecule Treatments For Neurological Disorders
Summary	Saniona announced a drug discovery and development collaboration with Pfizer. The collaboration focused on research of medicines to treat neurological disorders, using Saniona's expertise in ion channels and related technology platforms. Under the terms of the agreement, Pfizer received exclusive worldwide rights to research, develop, manufacture and commercialize medicines identified through the collaboration.

News Date	12/02/2014
Category	Trial Results
Headline	Protalix Biotherapeutics Announced Oral GCD Data To Be Presented At WORLD Symposium 2014
Summary	Protalix BioTherapeutics, Inc. announced that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor Ari Zimran at the 10th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2014 being held February 10-13 in San Diego, CA. Oral GCD is the Company's orally-delivered proprietary formulation of the plant cell-expressed enzyme, glucocerebrosidase (GCD), and contains the same active substance as taliglucerase alfa (Elelyso), the Company's approved enzyme replacement therapy.

News Date	06/02/2014
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Protalix Biotherapeutics' Technology Transfer Agreement For UPLYSO (Alfatriglycerase) With Brazil's Ministry Of Health Approved By The Brazilian National Institute Of Industrial Property
Summary	Protalix BioTherapeutics, Inc. announced that the Brazilian National Institute of Industrial Property (INPI) has approved the Company's previously-announced supply and technology transfer agreement with Fundação Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO (alfatriglycerase). The Company announced the execution of the supply and technology transfer agreement on June 19, 2013, and receipt of the approval results in the final effectiveness of the agreement as of January 23, 2014. The Company has already completed the first shipment of the drug to Brazil under the agreement.

News Date	05/02/2014
Category	Partnership / Strategic Alliance
Headline	Pfizer And Merck Collaborated On Innovative Anti-Cancer Combination Studies
Summary	Pfizer Inc. (NYSE:PFE) announced that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer's axitinib (INLYTA) in renal cell carcinoma (RCC). A separate Phase I study will evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566), Pfizer's investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation and survival.

News Date	05/02/2014
Category	Partnership / Strategic Alliance
Headline	Ichor Entered Into An Agreement With Pfizer To Develop Electroporation Devices For Use In Therapeutic Cancer Vaccine Regimens
Summary	Ichor Medical Systems Inc announced that it has entered into a Collaboration and License Agreement with Pfizer. Ichor's TriGrid intramuscular electroporation technology will be used to facilitate clinical administration of DNA-based vaccines as part of Pfizer's preclinical cancer vaccine-based immunotherapy research program. Electroporation is a method that uses electrical pulses to create temporary pores in cell membranes, potentially allowing efficient uptake of a DNA-based vaccine or other substance.

News Date	05/02/2014
Category	Partnership / Strategic Alliance
Headline	Merck Entered Strategic Collaborations With Amgen, Incyte And Pfizer To Evaluate Novel Combination Anti-Cancer Regimens With MK-3475
Summary	Merck announced it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck's investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed.

News Date	23/01/2014
Category	Product Update-Others
Headline	Protalix Announced Successful Manufacturing Facility Evaluation By Health Canada
Summary	Protalix BioTherapeutics, Inc. announced that Health Canada has completed a successful on-site evaluation of the Company's manufacturing facility in Carmiel, Israel, as part of its ongoing review of the new drug submission (NDS) for taliglucerase alfa for the treatment of Gaucher disease. The purpose of the on-site evaluation was to verify the facility's compliance with certain Canadian food and drug regulations and, upon completion of the evaluation, Health Canada recommended approval from a facility perspective. A decision on final marketing approval of taliglucerase alfa in Canada is expected during 2014.

News Date	13/01/2014
Category	Conferences
Headline	Protalix Biotherapeutics Provided Full-Year 2014 Strategic Outlook
Summary	Protalix BioTherapeutics, Inc. announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will discuss the Company's corporate objectives and key milestones in a presentation at the 32nd Annual J.P. Morgan Healthcare Conference on January 16, 2014 at 12:00 PM, Pacific Time. Dr. Aviezer's presentation will include a discussion of the Company's 2014 strategic outlook and clinical highlights.

News Date	13/01/2014
Category	Partnership / Strategic Alliance

Headline	Portola Pharmaceuticals Has Entered Into Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Summary	Portola Pharmaceuticals (Nasdaq:PTLA) announced that it has entered into a second clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) to study Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa (PRT4445), with the oral Factor Xa inhibitor Eliquis (apixaban). The original agreement, announced in November 2012, covered the conduct of a Phase 2 proof-of-concept study. Results of the Phase 2 study were presented at the 2013 Congress of the International Society on Thrombosis and Haemostasis (ISTH) and demonstrated andexanet alfa's ability to produce an immediate and either temporary or sustained reversal of the anticoagulation activity of Eliquis. The new clinical collaboration agreement will be in effect through Phase 3 studies with Eliquis and any potential U.S. and EU regulatory approval of andexanet alfa. The Phase 3 studies are expected to start in the first half of 2014.

News Date	09/01/2014
Category	Partnership / Strategic Alliance
Headline	Avillion Group Partnered With Pfizer To Co-Develop Bosulif (Bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia
Summary	The Avillion Group (Avillion) announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's Bosulif (bosutinib).

News Date	01/01/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Tolterodine Tartrate Tablets
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announce the introduction of Tolterodine Tartrate Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 1mg x 60; 1mg x500; 2mg x 60 and 2mg x500.

News Date	01/01/2014
Category	Product Launch
Headline	Greenstone Llc Introduced Sirolimus

Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Sirolimus to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100.
---------	--

News Date	24/12/2013
Category	Partnership / Strategic Alliance
Headline	Kissei Announces Licensing Agreement With Pfizer Inc. For KUX-1151, A Novel Investigational Therapy For Gout And Hyperuricemia
Summary	Kissei Pharmaceutical Co., Ltd. announced that it concluded an agreement with Pfizer Inc. granting exclusive rights to Pfizer to develop and commercialize the investigational therapy KUX-1151 for gout and hyperuricemia. KUX-1151 was discovered by Kissei.

News Date	19/12/2013
Category	Trial Initiations
Headline	Athersys Confirms Completion Of Patient Enrollment Of Pfizer's Phase II Study Of Multistem(R) Cell Therapy For Ulcerative Colitis
Summary	Athersys, Inc. (Nasdaq:ATHX) announced that Pfizer Inc. has completed patient enrollment of a Phase II clinical study involving administration of Athersys' MultiStem cell therapy to ulcerative colitis patients as part of a 2009 collaboration agreement between Athersys and Pfizer. The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects with moderate to severe ulcerative colitis. Athersys expects initial results from the study to be disclosed in the second quarter of 2014.

News Date	18/12/2013
Category	Partnership / Strategic Alliance
Headline	Mylan Announced Acquisition Of Rights To Novel LAMA Respiratory Compound From Pfizer
Summary	Mylan Inc. (Nasdaq: MYL) announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications.

News Date	11/12/2013
Category	Partnership / Strategic Alliance

Headline	Octapharma AG Entered Into Agreement With Pfizer For The Future Commercialization And Marketing In The U.S. Of An Investigational Intravenous Therapy For The Urgent Reversal Of An Oral Anticoagulant
Summary	Octapharma AG announced it has entered into an agreement with Pfizer Inc. for the future marketing and commercialization of human prothrombin complex concentrate (PCC), an investigational agent under FDA review for the urgent reversal of Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients who require urgent surgery or invasive procedures. Under the terms of the agreement, Octapharma AG has exclusive rights to commercialize this product globally, with the exception of the U.S. where Pfizer was exclusively responsible for marketing and commercialization.

News Date	06/12/2013
Category	Partnership / Strategic Alliance
Headline	Abcam Signed Licence Agreement With Pfizer To Supply Compounds To Researchers
Summary	Abcam Plc., announced that it has entered into a licence agreement with Pfizer. Under the terms of the agreement, Abcam's Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.

News Date	02/12/2013
Category	Partnership / Strategic Alliance
Headline	Pfizer Acquires Polocard, Poland's Leading Over-The-Counter Heart Attack Prevention Brand
Summary	Pfizer Inc. (NYSE: PFE) announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicicum), and the leading over-the-counter (OTC) brand for heart attack prevention in Poland, from ZF Polpharma SA.

News Date	01/12/2013
Category	Product Launch
Headline	Greenstone Llc Introduced Voriconazole For Oral Suspension
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Voriconazole for Oral Suspension to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 40mg/mL bottle.

News Date	14/10/2013
Category	Trial Results
Headline	Protalix Biotherapeutics Announced Positive Phase I Clinical Trial Results For Oral GCD In Gaucher Disease Patients
Summary	Protalix BioTherapeutics, Inc. announced initial positive results from its phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. In the trial, Oral GCD was well-tolerated, and active enzyme was detected in patients' blood circulation. Oral GCD is an orally available form of the plant cell-expressed enzyme, glucocerebrosidase or GCD, which is the same active substance as the Company's approved enzyme replacement therapy, Elelyso. Oral GCD is an active form of human glucocerebrosidase which is naturally encapsulated within the carrot cells in which it is produced.

News Date	30/09/2013
Category	Partnership / Strategic Alliance
Headline	Gliknik Entered Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
Summary	Gliknik Inc., announced that it entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

News Date	30/07/2013
Category	Partnership / Strategic Alliance
Headline	Lonza And Biowa Signed License Agreements With Pfizer, Inc. Allowing Use Of Their Potelligent CHOK1SV Cell Line For Therapeutic Antibody Research And Development
Summary	BioWa Inc. and Lonza announced that they have entered into research agreements with Pfizer Inc. allowing the use of the Potelligent CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer's pipeline.

News Date	01/07/2013
Category	Partnership / Strategic Alliance
Headline	Bioventus Acquires Exclusive Rights To Pfizer's BMP Portfolio

Summary	Bioventus, a leader in active orthopaedic healing, announced agreement with Pfizer Inc. for an exclusive, worldwide license to Pfizer's bone morphogenetic protein (BMP) portfolio of development programs and associated intellectual property. The portfolio includes a next-generation BMP in development, designed to offer additional options to currently-marketed BMP products, and the rights to rhBMP-2 in indications and fields previously reserved to Pfizer. Bioventus has also acquired an exclusive option to a BMP program for soft tissue indications.
---------	---

News Date	26/06/2013
Category	Partnership / Strategic Alliance
Headline	Karo Bio Announced Extension Of Existing Collaboration With Pfizer To Discover And Develop Drugs For Autoimmune Diseases
Summary	Karo Bio AB (publ) announced the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.

News Date	12/06/2013
Category	Conferences
Headline	Protalix Biotherapeutics Hosted Analyst Event In New York City
Summary	Protalix BioTherapeutics, Inc. announced that it will be hosting an analyst event on June 20, 2013 at 8:00 AM EDT in New York City. The meeting will feature presentations on Elelyso, PRX-102 for the treatment of Fabry disease and Oral GCD for the treatment of Gaucher disease, as well as presentations on previously undisclosed product candidates.

News Date	06/06/2013
Category	Partnership / Strategic Alliance
Headline	CytomX Announced Global Strategic Collaboration With Pfizer To Develop And Commercialize Multiple Probody Drug Conjugates In Oncology
Summary	CytomX Therapeutics, Inc. announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop and commercialize multiple Probody Drug Conjugates (PDCs). CytomX's novel Probody Platform brings to the collaboration a proprietary, highly differentiated approach to developing safer and more effective antibody-drug conjugates (ADCs). PDCs are engineered to combine cytotoxic agents with masked Probodies that remain inert in healthy tissue but are activated specifically in the tumor microenvironment, opening up new target space for this emerging therapeutic class.

News Date	29/04/2013
Category	Drug approvals
Headline	UPLYSO (Alfatadaliglycerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease
Summary	Protalix BioTherapeutics, Inc. announced that the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) and the Public Health Institute of Chile have both granted regulatory approval to UPLYSO (alfataliglycerase) for the long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. UPLYSO will be marketed in Mexico and Chile by Pfizer Inc., the Company's commercialization partner.

News Date	29/04/2013
Category	Partnership / Strategic Alliance
Headline	Hospira And Novaquest Co-Investment I, L.P. Entered Into Collaborative Arrangement
Summary	Hospira and NovaQuest Co-Investment Fund I, L.P. entered into a collaborative arrangement for the following biosimilar products: Hospira's erythropoietin (in the U.S. and Canada), filgrastim (in the U.S.) and pegylated filgrastim (globally).

News Date	28/04/2013
Category	Partnership / Strategic Alliance
Headline	Merck And Co Inc And Pfizer Entered Worldwide Collaboration Agreement To Develop And Commercialize Ertugliflozin, An Investigational Medicine For Type 2 Diabetes
Summary	Merck & Co Inc and Pfizer Inc announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Ertugliflozin is Phase III ready, with trials expected to begin later in 2013.

News Date	18/04/2013
Category	Partnership / Strategic Alliance
Headline	Aspen Invested More Than R1,9 Billion In Infant Nutritional Deal With Pfizer

Summary	Aspen Group companies have concluded agreements with Nestlé S.A. in respect of the acquisition of certain rights to intellectual property licenses, net assets and shares in the IN businesses presently conducted by Pfizer which distribute a portfolio of IN products in Australia (the "Australian IN business") and certain Southern African territories (South Africa, Botswana, Namibia, Lesotho, Swaziland and Zambia)(the "Southern African IN business") for a total purchase consideration of USD 215 million. The IN portfolio covers all age stages (infants, toddlers and early childhood) and consists of premium, specialty and standard ranges supported by strong umbrella brands including S26 Gold, S26 and SMA. The revenue for the Australian and Southern African IN businesses amounted to AUD 83 million and ZAR 180 million respectively in 2012.
---------	---

News Date	03/04/2013
Category	Partnership / Strategic Alliance
Headline	BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins
Summary	BIND Therapeutics announced that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies. The collaboration aims to employ BIND's Medicinal Nanoengineering platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs.

News Date	03/04/2013
Category	Partnership / Strategic Alliance
Headline	Chop Collaborated With Pfizer's Centers For Therapeutic Innovation To Speed Pediatric Research & Development
Summary	Pfizer Inc announced that The Children's Hospital of Philadelphia (CHOP) and Pfizer Inc were joining forces with the goal of translating biomedical discoveries into novel treatments. CHOP is announcing its participation in the Centers for Therapeutic Innovation (CTI) network, a novel collaboration model built by Pfizer that brings academic researchers together with Pfizer scientists to expedite the pace of innovation.

News Date	27/03/2013
Category	Partnership / Strategic Alliance
Headline	Pfizer-Kinemed Collaboration Extended To Target Novel Diabetes Pathways

Summary	KineMed Inc announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed's unique dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
---------	--

News Date	18/03/2013
Category	Drug approvals
Headline	UPLYSO (Alfatagalidase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease
Summary	Protalix BioTherapeutics, Inc. announced that the Brazilian National Health Surveillance Agency (ANVISA, Agencia Nacional de Vigilancia Sanitaria) has granted regulatory approval to UPLYSO (alfataliglicerase) for the long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. Gaucher disease is a rare lysosomal storage disorder that affects approximately 10,000 people worldwide.

News Date	01/03/2013
Category	Partnership / Strategic Alliance
Headline	Repligen Announced Licensing Agreement With Pfizer For Spinal Muscular Atrophy Program
Summary	Repligen Corporation (NASDAQ:RGEN) announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Under the terms of the agreement, Repligen is entitled to receive up to USD 70 million from Pfizer, commencing with an upfront payment of USD 5 million and total potential future milestone payments of up to USD 65 million as well as royalties on any future sales of SMA compounds developed under the agreement. SMA is an orphan neurodegenerative genetic disease that presents early in life.

News Date	13/02/2013
Category	Trial Results
Headline	Protalix Announced New Clinical Data On Elelyso To Be Presented At The WORLD Symposium 2013

Summary	Protalix BioTherapeutics, Inc. announced that new clinical data on Elelyso (taliglucerase alfa) will be presented at the 9th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2013 being held February 13-15 in Orlando, Florida. Elelyso, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease.
---------	---

News Date	14/01/2013
Category	Product Launch
Headline	Pfizer Announced Availability Of Quillivant XR (Methylphenidate Hydrochloride) CII For Extended-Release Oral Suspension In The United States
Summary	Pfizer Inc announced that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD). Quillivant XR is the first once-daily, extended-release liquid methylphenidate for ADHD and is now available by prescription.

News Date	03/01/2013
Category	Partnership / Strategic Alliance
Headline	Philogen S.p.A. Announced Worldwide Licensing Agreement With Pfizer Inc For Dekavil, An Investigational Immunoregulatory Therapy For Autoimmune Diseases
Summary	Philogen S.p.A. announced that it has entered into a strategic worldwide license agreement with Pfizer for Dekavil, a novel investigational therapy for autoimmune diseases. Philogen will receive an upfront payment and will be eligible to receive milestone and royalty payments. Pfizer retains exclusive rights to market any products that may be developed as a result of the collaboration.

News Date	01/01/2013
Category	Product Launch
Headline	Greenstone Llc Introduced Atorvastatin Calcium Tablets
Summary	Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Atorvastatin Calcium Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 10mg x 90; 10mg x 1,000; 20mg x 90; 20mg x 1,000; 40mg x 90; 40mg x 500; 80mg x 90; 80mg x 500.

News Date	21/12/2012
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase
Summary	Halozyme Therapeutics, Inc. (HALO) announced that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (PFE) for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze technology. Enhanze is Halozyme's proprietary drug delivery platform and is based on the Company's patented recombinant human hyaluronidase enzyme (rHuPH20).

News Date	06/12/2012
Category	Partnership / Strategic Alliance
Headline	Protalix Biotherapeutics Signed Clinical Development Agreement With Pfizer For ELELYSO (Taliglucerase Alfa)
Summary	Protalix BioTherapeutics, Inc. announced that it has entered into a Clinical Development Agreement with Pfizer Inc. under which Protalix will continue to manage, administer and sponsor current, ongoing clinical trials relating to ELELYSO (taliglucerase alfa). Protalix is currently sponsoring adult and pediatric extension studies of ELELYSO. New clinical trials for ELELYSO will be conducted and sponsored by Pfizer.

News Date	01/12/2012
Category	Product Launch
Headline	Greenstone Llc Introduced Phenytoin Tablets
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Phenytoin Tablets, USP to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 50mg.

News Date	30/11/2012
Category	Mergers & Acquisitions
Headline	Pfizer Completed Sale of Nutrition Business to Nestle

Summary	Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestle for USD11.85 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.
---------	---

News Date	19/11/2012
Category	Partnership / Strategic Alliance
Headline	Cystic Fibrosis Foundation Therapeutics Announced USD 58 Million CF Drug Discovery Agreement With Pfizer
Summary	Cystic Fibrosis Foundation Therapeutics Inc announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

News Date	01/11/2012
Category	MAA
Headline	European Commission Issued Decision On Taliglucerase Alfa Marketing Authorization Application
Summary	Protalix BioTherapeutics, Inc. announced that the European Commission (EC) has issued a Commission Decision refusing the Marketing Authorization for taliglucerase alfa, an enzyme replacement therapy (ERT) for the treatment of Gaucher disease. The EC has endorsed the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) recommendation not to issue a Marketing Authorization for taliglucerase alfa in the European Union. The CHMP recommendation was not related to the safety, quality or efficacy of taliglucerase alfa, but solely to the specific requirements of the European Union (EU) Orphan Drug Regulation.

News Date	01/11/2012
Category	Partnership / Strategic Alliance
Headline	Portola, Bristol-Myers Squibb And Pfizer Signed Clinical Collaboration Agreement to Study ELIQUIS and Portola's Universal Factor Xa Inhibitor Antidote PRT4445
Summary	Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban). PRT4445 is a universal Factor Xa inhibitor antidote in clinical development designed to reverse the anticoagulant activity of any Factor Xa inhibitor. No agents are approved to reverse the activity of Factor Xa inhibitors.

News Date	01/11/2012
Category	Partnership / Strategic Alliance
Headline	Portola, Bristol-Myers Squibb And Pfizer Signed Clinical Collaboration Agreement To Study ELIQUIS And Portola's Universal Factor Xa Inhibitor Antidote PRT4445
Summary	Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban). PRT4445 is a universal Factor Xa inhibitor antidote in clinical development designed to reverse the anticoagulant activity of any Factor Xa inhibitor. No agents are approved to reverse the activity of Factor Xa inhibitors.

News Date	01/11/2012
Category	Product Launch
Headline	Greenstone Llc Introduced Sildenafil Tablets
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Sildenafil Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 20mg.

News Date	01/11/2012
Category	Product Launch
Headline	Greenstone Llc Introduced Diclofenac Sodium/Misoprostol Tablets
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Diclofenac Sodium/Misoprostol tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 50 mg and 75 mg.

News Date	30/10/2012
Category	Partnership / Strategic Alliance
Headline	Cyprotex Announced A Collaborative Research Agreement With Pfizer

Summary	Cyprotex PLC (AIM:CRX) announced a collaborative research agreement between Apredica LLC (a wholly owned subsidiary of Cyprotex PLC) and Pfizer Inc. The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved. The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology.
---------	--

News Date	22/10/2012
Category	Mergers & Acquisitions
Headline	Pfizer Acquired NextWave Pharmaceuticals, Inc.
Summary	Pfizer Inc announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

News Date	01/10/2012
Category	Product Launch
Headline	Greenstone Llc Introduced Phenytoin Oral Suspension, Usp
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Phenytoin Oral Suspension, USP to its ever-expanding generic pharmaceutical product line.

News Date	12/09/2012
Category	Partnership / Strategic Alliance
Headline	Pfizer And Hisun Announced Launch Of Hisun-Pfizer Pharmaceuticals Co., Ltd.
Summary	Pfizer Inc. (NYSE: PFE), and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267) announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd. (hereafter referred to as Hisun-Pfizer), a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. The creation of the joint venture marks an important milestone in strengthening the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena.

News Date	11/09/2012
Category	Partnership / Strategic Alliance

Headline	Visterra Signed Antibody Discovery Collaboration Deal With Pfizer
Summary	Visterra Inc announced that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.

News Date	01/09/2012
Category	Product Launch
Headline	Greenstone Llc Introduced Trifluridine Ophthalmic Solution, 1 Percent Sterile
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Trifluridine Ophthalmic Solution to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 7.5 mL.

News Date	13/08/2012
Category	Partnership / Strategic Alliance
Headline	Pfizer And AstraZeneca Entered Into Agreement For Over-The-Counter Nexium
Summary	Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for Nexium (esomeprazole magnesium), a leading prescription drug approved to treat the symptoms of gastroesophageal reflux disease (GERD). Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market Nexium for the approved over-the-counter indications in the United States, Europe and the rest of the world. Under the agreement, Pfizer will make an upfront payment of USD 250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.

News Date	09/08/2012
Category	Partnership / Strategic Alliance
Headline	Nodality Entered Into A Multi-Year Strategic Collaboration With Pfizer In Autoimmune Disease

Summary	Nodality Inc announced a strategic collaboration with Pfizer Inc. for the use of Nodality's proprietary Single Cell Network Profiling (SCNP) technology as a tool for the development of Pfizer compounds. The agreement establishes a multi-year, collaborative effort that will initially focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling. The agreement also provides Pfizer the option to engage Nodality in companion diagnostics development. The terms of the agreement include an upfront payment, R&D funding, and success-based milestone payments.
---------	---

News Date	07/08/2012
Category	Partnership / Strategic Alliance
Headline	Mylan Specialty And Pfizer Announced Licensing Agreement For EpiPen Injection 0.3/0.15mg In Japan
Summary	Mylan Specialty L.P., a subsidiary of Mylan Inc and Pfizer Inc announced a license agreement, under which Pfizer will obtain the exclusive rights to market and sell EpiPen Injection 0.3/0.15mg in Japan. These products, known in the U.S. as EpiPen (epinephrine) 0.3mg and EpiPen Jr (epinephrine) 0.15mg Auto-Injectors, are for self-administration for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise or unknown triggers. EpiPen Injection is the only approved epinephrine auto-injector in Japan.

News Date	01/08/2012
Category	Product Launch
Headline	Greenstone LLC Introduced MONTELUKAST Sodium Tablets and Chewable Tablets
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Montelukast Sodium Tablets and Chewable Tablets to its ever-expanding generic pharmaceutical product line. The tablets are offered in dosage strengths of 10 mg and the chewable tablets are offered in dosage strengths of 4 mg and 5 mg.

News Date	27/06/2012
Category	Patent Infringements/ Lawsuits
Headline	Breckenridge And Alembic Announced Paragraph IV ANDA Litigation With Pfizer On Desvenlafaxine Tablets (Pristiq)

Summary	Breckenridge Pharmaceutical, Inc. announced that Breckenridge and Alembic Pharmaceuticals Limited were named codefendants in a Paragraph IV lawsuit filed by Pfizer Inc. concerning their ANDA desvenlafaxine succinate extended-release tablets 50mg and 100mg, a generic version of Pristiq by Pfizer Inc. Breckenridge and Alembic filed their Paragraph IV ANDA on the first-possible submission date and expects to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge.
---------	---

News Date	22/06/2012
Category	Regulatory-Others
Headline	EMA Adopted Opinion On Taliglucerase Alfa Marketing Authorization Application
Summary	Pfizer Inc and Protalix BioTherapeutics, Inc. announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted an Opinion recommending against the Marketing Authorization of taliglucerase alfa, an enzyme replacement therapy (ERT) for the treatment of Gaucher disease. As part of its Opinion, the CHMP gave a positive risk-benefit assessment for taliglucerase alfa concluding that the benefits of the medicine outweighed its risks in the treatment of Type 1 Gaucher disease.

News Date	22/06/2012
Category	Partnership / Strategic Alliance
Headline	Pfizer Granted ChemRar High Tech Center Group Company A Worldwide Exclusive License For Molecule DPP-IV For Diabetes Treatment
Summary	Pfizer Inc. and ChemRar High Tech Center (ChemRar) announced an agreement under which Pfizer grants the ChemRar group company SatRx an exclusive rights to PF-00734200, a DPP -IVi compound. The DPP-IVi compound is being developed for treatment of Type 2 Diabetes, one of the most burdensome chronic non-communicable diseases, which is fast gaining epidemic proportions throughout the world.

News Date	13/06/2012
Category	Partnership / Strategic Alliance
Headline	CSHL announced collaboration to speed development of new cancer therapies
Summary	Cold Spring Harbor Laboratory (CSHL) has announced a research collaboration with Pfizer Inc. to develop a next-generation human short hairpin RNA (shRNA) library which could be used to silence gene expression via the process of RNA interference (RNAi) and identify new therapeutic targets in cancer.

News Date	11/06/2012
Category	Partnership / Strategic Alliance
Headline	Protalix Received USD 25 Million Milestone Payment For U.S. Approval Of Elelyso
Summary	<p>Protalix BioTherapeutics, Inc. announced that it has received a USD 25 million milestone payment from Pfizer Inc. as part of the companies' global commercial agreement for Elelyso (taliglucerase alfa). This payment was triggered by the U.S. Food and Drug Administration's (FDA) approval of Elelyso for the treatment of type 1 Gaucher disease on May 1, 2012. On November 30, 2009, Pfizer and Protalix entered into an exclusive license and supply agreement relating to the development and commercialization of Elelyso. Under the terms of the agreement, Protalix granted Pfizer an exclusive, worldwide license to Elelyso except in Israel. Except with respect to Protalix's commercialization efforts in Israel, Pfizer and Protalix share the revenues and expenses related to the worldwide commercialization of ELEYSO on a 60 percent/40 percent basis, respectively, with certain agreed upon limits on the amounts of shared expenses. Protalix retained exclusive commercialization rights to the Israeli market for Elelyso, including all revenues and expenses. Upon signing the license and supply agreement in November 2009, Pfizer made an upfront payment of USD 60 million to Protalix and subsequently made a USD 5 million payment to Protalix upon Protalix's achievement of a performance milestone. On March 31, 2012, Protalix had cash and cash equivalents USD 45.6 million. On a proforma basis, including the receipt of the USD 25 million milestone payment for the approval of Elelyso in the United States, cash and cash equivalents on March 31, 2012 would have been USD 70.6 million.</p>

News Date	01/05/2012
Category	Drug approvals
Headline	Pfizer And Protalix Biotherapeutics Announced FDA Approval Of Elelyso (Taliglucerase Alfa) For The Treatment Of Gaucher Disease
Summary	<p>Pfizer Inc. and Protalix BioTherapeutics, Inc announced that the United States (U.S.) Food and Drug Administration (FDA) approved Elelyso (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.</p>

News Date	01/05/2012
Category	Product Launch
Headline	Greenstone LLC Introduced OLANZAPINE Tablets

Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Olanzapine Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg tablets.
---------	--

News Date	01/04/2012
Category	Product Launch
Headline	Greenstone LLC Introduced Ziprasidone HCL Capsule Authorized Generic of GEODON
Summary	Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc (NYSE: PFE) announced the introduction of Ziprasidone HCl Capsules to its everexpanding generic pharmaceutical product line. The product is offered in dosage strengths of 20 mg, 40 mg, 60 mg, and 80 mg capsules.

News Date	12/03/2012
Category	Partnership / Strategic Alliance
Headline	Biocon And Pfizer Concluded Commercialization Agreement
Summary	Biocon and Pfizer announced the conclusion of their alliance to commercialize Biocon's biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently.

News Date	27/02/2012
Category	Mergers & Acquisitions
Headline	Pfizer Acquires Alacer Corp., a Leading Vitamin Supplements Company
Summary	Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.

News Date	22/02/2012
Category	Partnership / Strategic Alliance
Headline	LG Life Sciences And Pfizer Team Up For Branded Generics Franchise In Korea
Summary	LG Life Science announced that it has agreed to produce the generic version of Pfizer's anticoagulant Cilostazol and prokinetic agent Itopride, entered the local generic drug market. Pfizer was responsible for sales.

News Date	16/02/2012
Category	Partnership / Strategic Alliance
Headline	TCG Lifesciences Announced Nomination of Pre-clinical Development Candidate
Summary	TCGLifesciences Limited announced the nomination of a pre-clinical development candidate under a R&D collaboration entered into in 2009 with Pfizer Inc. As per the agreement, Pfizer will own the Candidate and other back up candidates while TCGLS will receive a milestone payment for its success in moving these molecules to the candidate stage.

News Date	07/02/2012
Category	Partnership / Strategic Alliance
Headline	Faes Farma And Pfizer Signed A New Agreement To Extend Bilastine's Licence To Another 21 Latin American Markets
Summary	Faes Farma and Pfizer signed an agreement to licence bilastine in Mexico, where launching is planned for the beginning of 2013, once the product is approved by the country's sanitary authorities.

News Date	09/01/2012
Category	Partnership / Strategic Alliance
Headline	SFJ Pharma Ltd II Announced Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
Summary	SFJ Pharma Ltd. II (President & CEO: Robert F. DeBenedetto, "SFJ") announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

News Date	01/12/2011
Category	Partnership / Strategic Alliance
Headline	Karo Bio Entered Into Collaboration With Pfizer To Discover And Develop Innovative Drugs For Autoimmune Diseases
Summary	Karo Bio AB (publ) has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

News Date	01/12/2011
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition of Excaliard
Summary	Pfizer Inc. (NYSE: PFE) announced that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.

News Date	30/11/2011
Category	Mergers & Acquisitions
Headline	Pfizer Completes Acquisition of Ferrosan Consumer Health's Business
Summary	Pfizer Inc. (NYSE:PFE) announced that it has completed its previously announced acquisition of Ferrosan Consumer Health's business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

News Date	21/11/2011
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Excaliard Pharmaceuticals
Summary	Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.

News Date	09/11/2011
Category	Mergers & Acquisitions
Headline	Mylan to acquired Pfizer Respiratory Delivery Platform
Summary	Mylan Inc. (Nasdaq: MYL) announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform. Advair Diskus and Seretide Diskus are inhaled fixed-dose combinations of Fluticasone Propionate and Salmeterol delivered via a dry powder inhaler and are used to treat asthma and COPD (chronic obstructive pulmonary disorder).

News Date	27/10/2011
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition Of Icagen
Summary	Pfizer Inc. (NYSE: PFE) announced that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive USD6.00 in cash, without interest thereon, and less any applicable withholding and transfer taxes.

News Date	26/10/2011
Category	Partnership / Strategic Alliance
Headline	Pfizer Establishes Precision Medicine Research Collaboration With Medco
Summary	Pfizer Inc. (NYSE: PFE) announced that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes.

News Date	13/10/2011
Category	Partnership / Strategic Alliance
Headline	Humana and Pfizer Has Formed Research Partnership to Improve Health Care Delivery for Seniors
Summary	Humana Inc. (NYSE: HUM) and Pfizer Inc. (NYSE: PFE) announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations.

News Date	12/10/2011
Category	Partnership / Strategic Alliance
Headline	deCODE Announces Agreement with Pfizer to Search for Variants in the Human Genome that Confer Risk of Systemic Lupus Erythematosis
Summary	deCODE genetics announced that it has entered into a research collaboration with Pfizer Inc., the objective of which is to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis by utilizing deCODE's expertise in gene discovery.

News Date	10/10/2011
Category	Partnership / Strategic Alliance
Headline	Exonhit Entered Into Research Agreement With Pfizer To Identify Alzheimer's Disease Biomarkers
Summary	Exonhit (Alternext: ALEHT) announced that it has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer's disease (AD) biomarkers using Exonhit's Genome-Wide SpliceArray (GWSA) platform

News Date	05/10/2011
Category	Partnership / Strategic Alliance
Headline	Puma Biotechnology Announced Licensing Agreement With Pfizer For The Development And Commercialization Of Neratinib, An Investigational PanHER Inhibitor; Closed USD 55 Million Private Placement And Completed Merger
Summary	Puma Biotechnology Inc. announced an agreement with Pfizer to license the worldwide commercial rights to neratinib, a potent, irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases. Neratinib is being studied in the neoadjuvant, adjuvant and metastatic settings in patients with HER2/ErbB2 positive breast cancer.

News Date	16/08/2011
Category	Partnership / Strategic Alliance
Headline	Qiagen And Pfizer Partnered To Develop Companion Diagnostic For Novel Compound In Global Clinical Trials For Lung Cancer
Summary	Qiagen (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced it has entered into a partnership with Pfizer Inc. (NYSE: PFE) for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer (NSCLC). Financial terms of the agreement were not disclosed.

News Date	03/08/2011
Category	Awards/Grants/Funds
Headline	NCCN Receives USD2 Million Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer Centers

Summary	The National Comprehensive Cancer Network (NCCN) announced the development of the first continuing medical education (CME) program to leverage data in the NCCN Oncology Outcomes Database (NCCN Database) to objectively measure the impact of comprehensive performance improvement on patient outcomes. The NCCN Opportunities for Improvement initiative is supported by a three- year, USD2 million educational grant from Pfizer.
---------	---

News Date	01/08/2011
Category	Mergers & Acquisitions
Headline	Capsugel Now A Standalone Business
Summary	Pfizer Inc. announced that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, "KKR"), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously announced agreement, KKR acquired the Capsugel business for USD 2.375 billion in cash.

News Date	08/07/2011
Category	Partnership / Strategic Alliance
Headline	Pfizer And Astellas Announced The Transfer Of Distribution Rights for Caduet Combination Tablets To Astellas
Summary	Pfizer Japan Inc. (hereafter: Pfizer, Headquarters: Tokyo, President: Ichiro Umeda) and Astellas Pharma Inc. (hereafter: Astellas, Headquarters: Tokyo, President: Yoshihiko Hatanaka) announced that the companies have reached the change of the co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet Combination Tablets (generic name: amlodipine besylate and atorvastatin calcium), for which Pfizer holds the marketing approval rights in Japan, effective on October 1st, 2011.

News Date	05/07/2011
Category	Awards/Grants/Funds
Headline	Cell Signaling Technology Inc Granted A Patent License To Pfizer

Summary	Cell Signaling Technology Inc (CST) announced that it has entered into an agreement with Pfizer Inc. (NYSE: PFE) that provides Pfizer with a worldwide non-exclusive license under the patent estates pooled by CST and Astellas Pharma, Inc. (Patent Estates) relating to EML4 anaplastic lymphoma kinase (ALK). The fusion kinase EML4-ALK has been found to be present in a subset of patients with non-small cell lung cancer (NSCLC). Pfizer and Abbott entered into a separate agreement in 2009 to develop and commercialize a diagnostic test designed to screen NSCLC tumors for the presence of rearrangements in the ALK gene. Pfizer will grant a sublicense to Abbott under the Patent Estates for Abbott to commercialize diagnostic products based on fluorescence in situ hybridization (FISH) technology for ALK detection. Detection of ALK-positive NSCLC is necessary for selection of patients for treatment with Pfizer's crizotinib, an investigational oral first-in-class agent that inhibits ALK.
---------	---

News Date	28/06/2011
Category	Partnership / Strategic Alliance
Headline	Pfizer and ChemRar High Tech Center Announced Plans to Explore Innovative Medical Research and Development Partnership in Russia
Summary	Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) announced that they have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries. The announcement was made during the BIO International Convention.

News Date	23/06/2011
Category	Mergers & Acquisitions
Headline	Biomarin Agrees To Acquire Biologics Manufacturing Plant In Ireland From Pfizer
Summary	BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has entered into a definitive agreement to acquire a bulk biologics manufacturing plant from Pfizer, located in Shanbally, Cork, Ireland. The plant, which was completed and validated in 2009, is built on ten acres occupying 133,000 square feet of floor space. It was approved by the Irish Medicines Board in 2010. The purchase price is USD 48.5 million, approximately one-fifth of the expected cost to construct and validate a new facility. The purchase is expected to close in the third quarter of 2011 following the wind down of current operations and the transfer of the Irish EPA license.

News Date	16/06/2011
Category	Partnership / Strategic Alliance

Headline	Five Prime Therapeutics Provided An Update On Its Strategic Discovery Collaborations With Pfizer And Glaxosmithkline
Summary	<p>Five Prime Therapeutics, Inc. (FivePrime) announced the completion of the three-year funded research program with Pfizer Inc. (NYSE: PFE), that began in 2008 and focused on the discovery of antibody targets and novel therapeutic protein products to treat multiple cancer indications and diabetes. During the three-year research program, FivePrime designed and conducted cell-based and primary <i>in vivo</i> screens against FivePrime's comprehensive library of extracellular proteins and successfully identified numerous targets that may lead to future protein or antibody candidates. FivePrime screened more than 1,000 extra-cellular domains of receptor proteins <i>in vivo</i> in animal models of disease as part of the research program. FivePrime also conducted target validation work and advanced studies of leads and targets identified in the research program.</p>

News Date	08/06/2011
Category	Partnership / Strategic Alliance
Headline	Boston's Top Academic Medical Centers Joined Pfizer's Centers For Therapeutic Innovation
Summary	<p>Pfizer Inc announced its network of translational research partnerships, called the Centers for Therapeutic Innovation, has launched in Boston with Beth Israel Deaconess Medical Center, Boston University School of Medicine, Children's Hospital Boston, Harvard University, Partners HealthCare, Tufts Medical Center, Tufts University, as well as University of Massachusetts Medical School in Worcester. These organizations follow on previously announced partnerships with academic medical institutions in California and New York City.</p>

News Date	02/06/2011
Category	Partnership / Strategic Alliance
Headline	Clovis Oncology, Inc. Received License For Worldwide Development And Commercialization Rights To Pfizer's Oral And IV Parp Inhibitor Pf-01367338
Summary	<p>Clovis Oncology, Inc. announced an agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of Pfizer's oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338, currently in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small molecule inhibitor of PARP and will be developed by Clovis as both a monotherapy and in combination with chemotherapeutic agents for the potential treatment of selected cancer patients.</p>

News Date	01/06/2011
Category	Partnership / Strategic Alliance

Headline	Pfizer And Hisun Signed MOU To Increase Access To Quality And Low-Cost Medicines For Patients In China
Summary	Pfizer Inc (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267) jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture. This potential partnership aimed to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena.

News Date	26/05/2011
Category	Patent Infringements/ Lawsuits
Headline	Insite Vision Announced Joint Patent Infringement Lawsuit With Merck Against Sandoz
Summary	InSite Vision Incorporated (OTCBB:INSV) announced that it will join Merck (NYSE:MRK), known as MSD outside the United States (U.S.) and Canada, and Pfizer Inc. (NYSE:PFE) in filing a patent infringement lawsuit against Sandoz Inc.

News Date	25/05/2011
Category	Partnership / Strategic Alliance
Headline	Pfizer Announced New Strategic Partnerships With Icon And Parexel International Corporation
Summary	Pfizer Inc announced strategic partnerships with Icon plc and Parexel International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011. The new partnerships will be fully implemented over an 18-to-24 month period.

News Date	10/05/2011
Category	Trial Results
Headline	Biocrea And Pfizer Jointly Presented Details On Novel PDE10 Inhibitors At The 241st ACS National Meeting & Exposition
Summary	BioCrea GmbH reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

News Date	01/05/2011
Category	Product Launch

Headline	Greenstone LLC Announced Introduction of EXEMESTANE Tablets — Its Latest Generic Pharmaceutical Product
Summary	Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc announced the introduction of EXEMESTANE tablets to its ever-expanding generic pharmaceutical product line.

News Date	01/05/2011
Category	Product Launch
Headline	Greenstone LLC Announced Introduction of LATANOPROST Ophthalmic Solution — Its Latest Generic Pharmaceutical Product
Summary	Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc announced the introduction of LATANOPROST to its ever-expanding generic pharmaceutical product line.

News Date	20/04/2011
Category	Partnership / Strategic Alliance
Headline	Pfizer And Shanghai Pharmaceutical Sign Memorandum Of Understanding For Potential Strategic Partnership
Summary	Shanghai Pharmaceutical Co. Ltd. (SHSE: 601607) and Pfizer Inc. (NYSE: PFE) announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China.

News Date	04/04/2011
Category	Mergers & Acquisitions
Headline	Pfizer Sold Capsugel To KKR
Summary	Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, "KKR") announced they have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for USD 2.375 billion in cash. Capsugel, the world leader in hard capsules and an innovator in drug-delivery systems, generated approximately USD 750 million in revenue and manufactured more than 180 billion hard capsules in 2010.

News Date	03/04/2011
Category	Mergers & Acquisitions
Headline	Pfizer Selled Capsugel to KKR

Summary	Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, "KKR") announced they have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for USD2.375 billion in cash. Capsugel, the world leader in hard capsules and an innovator in drug-delivery systems, generated approximately USD750 million in revenue and manufactured more than 180 billion hard capsules in 2010.
---------	---

News Date	26/03/2011
Category	Product Update-Others
Headline	Greenstone Announced Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling
Summary	Greenstone LLC announced that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg Tablets [100-count bottle] and Finasteride 5mg Tablets [90-count bottle], both distributed in the U.S. market. The recall is due to the possibility that incorrect labels have been placed on the bottles by a third-party manufacturer. This is the only lot number being recalled and no other lots or markets are believed to be impacted.

News Date	03/03/2011
Category	Partnership / Strategic Alliance
Headline	Charles River Announces Agreement To Supply Pfizer's Genetically Modified Research Models
Summary	Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has entered into a marketing and distribution agreement with Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, to provide certain Pfizer-developed genetically modified research models to the global biomedical research community. Under this agreement, Charles River will supply a number of pre-competitive, transgenic research models developed by Pfizer across a broad range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.

News Date	01/03/2011
Category	Mergers & Acquisitions
Headline	Pfizer Completes Acquisition Of King Pharmaceuticals, Inc

Summary	Pfizer Inc. (NYSE: PFE) announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary of Pfizer. Under the terms of the transaction, each outstanding share of King common stock has been converted into the right to receive USD14.25, net in cash (without interest and less any required holding taxes). Prior to the merger, Parker Tennessee Corp. acquired approximately 92.5% of the outstanding King shares through a tender offer. Effective as of the close of trading yesterday, King common stock ceased trading on the New York Stock Exchange.
---------	--

News Date	06/02/2011
Category	Mergers & Acquisitions
Headline	Pfizer To Acquire Ferrosan's Consumer Healthcare Business
Summary	Pfizer Inc. (NYSE:PFE) announced that it has entered into a definitive agreement to purchase Ferrosan's consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

News Date	07/01/2011
Category	Partnership / Strategic Alliance
Headline	Sutro Biopharma Forged Partnership With Pfizer For Discovery, Development And Commercialization Of Novel Peptide-Based Therapeutics. Company's First Major Collaboration Validates Potential Of Biochemical Protein Synthesis Technology Platform
Summary	Sutro Biopharma announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

News Date	05/01/2011
Category	Partnership / Strategic Alliance
Headline	Pfizer Announced Seven Of New York City's Top Research Hospitals Join Global Centers For Therapeutic Innovation

Summary	Pfizer Inc. announced that seven major research-based medical centers in New York City, including Rockefeller University, NYU Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College, have joined Pfizer's Centers for Therapeutic Innovation, a network of partnerships that aims to speed the translation of biomedical research into life-saving medicines. The first Center was established in November of last year at the University of California, San Francisco.
---------	---

News Date	29/12/2010
Category	Partnership / Strategic Alliance
Headline	Akorn Announced The Sale Of The Akorn-Strides Joint Venture Product Portfolio To Pfizer Inc
Summary	Akorn Inc (NASDAQ: AKRX) reported that its Akorn-Strides LLC joint venture has entered into a purchase agreement with Pfizer Inc. to sell 16 Abbreviated New Drug Approvals (ANDAs) and 6 filed ANDAs. For its portion, Akorn Inc received USD 35 million in cash. Akorn-Strides LLC continued to manufacture and distribute the approved products until April 30, 2011.

News Date	20/12/2010
Category	Partnership / Strategic Alliance
Headline	Phylogica Signed Collaboration And Licensing Deal With Pfizer
Summary	Phylogica Ltd (ASX: PYC) announced that it has entered into a collaboration and licensing agreement with Pfizer to discover novel peptide-based vaccines. Phylogica will employ its proprietary Phylomer drug discovery platform to identify Phylomer peptides suitable for further evaluation.

News Date	17/12/2010
Category	Partnership / Strategic Alliance
Headline	DiaGenic and Pfizer collaborated on blood based biomarkers for early stages of Alzheimer's disease
Summary	DiaGenic ASA [OSL:DIAG] and Pfizer Inc [NYSE: PFE] signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

News Date	16/11/2010
-----------	------------

Category	Partnership / Strategic Alliance
Headline	University Of California San Francisco Partnered With Pfizer To Improve Drug Discovery, Development
Summary	UCSF and Pfizer, Inc. announced that they have formed a new partnership to accelerate the translation of biomedical research into effective new medications and therapies for patients

News Date	09/11/2010
Category	Partnership / Strategic Alliance
Headline	Biovista Announces A Drug Repositioning Collaboration With Pfizer
Summary	Biovista announced that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista's Clinical Outcome Search Space (COSS) technology.

News Date	26/10/2010
Category	Partnership / Strategic Alliance
Headline	MacroGenics Entered Global Research Collaboration And License Agreement With Pfizer
Summary	MacroGenics Inc announced that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets. MacroGenics' DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. These DART proteins are amenable to several applications and can potentially be used to redirect the body's cell-destroying, immune effector cells against tumor cells.

News Date	20/10/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil

Summary	Pfizer Inc. (NYSE: PFE) announced that it has entered into a partnership with Laboratorio Teuto Brasileiro S.A. Pfizer will acquire a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements. The partnership will enhance Pfizer's position in Brazil, a key emerging market, by providing access to Teuto's broad portfolio of approximately 250 products in more than 400 presentations. Through this partnership, Pfizer will have access to significant distribution networks in rural and suburban areas in Brazil and the opportunity to register and commercialize Teuto's products in various markets outside Brazil. In addition, Pfizer will have two representatives on Teuto's board of directors.
---------	---

News Date	12/10/2010
Category	Mergers & Acquisitions
Headline	Pfizer To Acquire King Pharmaceuticals, Inc
Summary	Pfizer Inc. (NYSE: PFE) and King Pharmaceuticals, Inc. (NYSE: KG) announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for USD3600 million in cash, or USD14.25 per share, which represents a premium of approximately 40% to King's closing price as of October 11, 2010, and 46% percent to the one-month average closing price as of the same date. The transaction was approved by the boards of both companies and is expected to be accretive to Pfizer's adjusted diluted earnings per share (1) by approximately USD0.02 annually in 2011 and 2012, and approximately USD0.03 - USD0.04 annually from 2013 through 2015.

News Date	27/09/2010
Category	Partnership / Strategic Alliance
Headline	Progenics Extended Agreement With Pfizer For Relistor Commercialization
Summary	Progenics Pharmaceuticals, Inc (Nasdaq: PGNX) announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth's commercialization of RELISTOR(R) (methylnaltrexone bromide) Subcutaneous Injection in the United States through at least December 31, 2010.

News Date	14/09/2010
Category	Partnership / Strategic Alliance
Headline	KU Leuven Entered Into License Agreement With Pfizer

Summary	Katholieke Universiteit Leuven announced that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise KU Leuven's compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS. The compounds, named ledgins, have been shown to inhibit the interaction between the viral integrase and the cellular protein LEDGF/p75 and form the basis for a new class of drugs that block HIV without cross-resistance with existing anti-HIV drugs.
---------	---

News Date	13/07/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer And SMC Collaborated On Liver Cancer
Summary	Samsung Medical Center and Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.

News Date	20/06/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer Entered Into Agreement With Ergonex Pharma To Acquire Investigational Treatment For Pulmonary Arterial Hypertension
Summary	Pfizer Inc. (NYSE: PFE) and Ergonex Pharma GmbH announced that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension (PAH). Under the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize terguride for the treatment of PAH. Ergonex will be eligible to receive milestone payments and royalties on the sales of terguride for PAH.

News Date	10/06/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer and UCSF formed alliance to advance a broad range of research
Summary	Pfizer, Inc. and UCSF have launched a collaboration that spans many disciplines, several UC campuses and multiple Pfizer research units.

News Date	17/05/2010
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Pfizer, Washington University Announce Groundbreaking Collaboration
Summary	Pfizer Inc. and Washington University have entered into an agreement, under which Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

News Date	07/05/2010
Category	Partnership / Strategic Alliance
Headline	BDA Advised Pfizer On Divestment Of Animal Vaccine Business In China To Harbin Pharmaceutical
Summary	Business Development Asia LLC announced that its client, Pfizer Inc ("Pfizer", NYSE: PFE), the global pharmaceutical company, has sold its market-leading swine vaccine business in China to an animal health subsidiary of Harbin Pharmaceutical Group ("Hayao"), Harbin Bio-Vaccine.

News Date	15/04/2010
Category	Partnership / Strategic Alliance
Headline	Stemgent And Pfizer Announced Collaboration
Summary	Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.

News Date	06/04/2010
Category	Partnership / Strategic Alliance
Headline	Micurx Pharmaceuticals And Cumencor Pharmaceuticals Partner With Pfizer To Discover And Develop Antibiotics For Drug-Resistant Tuberculosis In China
Summary	MicuRx Pharmaceuticals Inc and Cumencor Pharmaceuticals Inc announced that the companies have entered a collaboration with Pfizer (NYSE: PFE) to discover novel therapeutic agents to treat multi-drug resistant tuberculosis (MDR-TB). Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx's proprietary technology platform to discover and develop novel antibiotics for MDR-TB.

News Date	01/04/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer And Acacia Living Partner Supported Seniors In Living Independently
Summary	Pfizer Inc and Acacia Living Inc (Acacia) announced they have entered into a strategic alliance to develop an innovative holistic technology solution dedicated to helping seniors age positively and independently.

News Date	23/03/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer Signed Long-Term Agreement To Supply Prevenar 13 To The World's Poorest Countries
Summary	Pfizer Inc. (NYSE:PFE) announced it has signed a 10-year Provisional Supply Agreement to supply Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine the company's 13-valent pneumococcal conjugate vaccine, for infants and young children in the world's poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease. The AMC is a novel public-private approach to public health funding designed to create a sustainable marketplace, ensure a stable supply of pneumococcal vaccines and stimulate the development and expansion of manufacturing capacity of vaccines specifically for the world's poorest countries.

News Date	22/03/2010
Category	Partnership / Strategic Alliance
Headline	JDRF Announced Diabetes Research Collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem
Summary	The Juvenile Diabetes Research Foundation announced that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.

News Date	16/03/2010
Category	Partnership / Strategic Alliance
Headline	Tekmira And Pfizer Initiated New Research Collaboration
Summary	Tekmira Pharmaceuticals Corporation (TSX: TKM) announced the initiation of a new research collaboration with Pfizer (NYSE: PFE).

News Date	23/02/2010
Category	Partnership / Strategic Alliance
Headline	Lilly, Merck, And Pfizer Join Forces To Accelerated Research And Improve Treatment Of Lung And Gastric Cancers In Asia
Summary	Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. announced the formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.

News Date	07/02/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer and Keas Have Partnered to Help Consumers Take a More Active Role in Their Health and Wellness
Summary	Pfizer and Keas announced they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and care delivery.

News Date	04/02/2010
Category	Partnership / Strategic Alliance
Headline	Qiagen Unit And Pfizer Entered Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
Summary	Pfizer Inc. (NYSE: PFE) and DxS (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed.

News Date	31/01/2010
Category	Partnership / Strategic Alliance
Headline	MDxHealth Closed Agreement With Pfizer, Newcastle University And CRT To Identify A Predictive Biomarker For PARP Inhibitor Therapies

Summary	MDxHealth SA (NYSE Euronext: MDXH) announced that it has signed an agreement with Newcastle University (UK), Cancer Research Technology Limited (CRT) and Pfizer Inc. to collaborate on the identification and development of a biomarker predicting response to Pfizer, CRT and Newcastle University's drug candidate for PARP inhibition, PF-01367338. The partners believe identification of a successful predictive biomarker could potentially lead to the development of a companion diagnostic to guide treatment decisions in ovarian and breast cancers.
---------	---

News Date	06/01/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer And Debiopharm Collaborated To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma
Summary	Pfizer Inc. (Pfizer) and Debiopharm Group (Debiopharm) announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab.

News Date	05/01/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer and Strides Arcolab Collaborated on Generic Products
Summary	Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest. The financial terms of the supply agreement were not disclosed.

News Date	05/01/2010
Category	Partnership / Strategic Alliance
Headline	Pfizer And TCG Lifesciences Announced A Collaboration To Develop Portfolio Of Preclinical Candidate Molecules
Summary	TCG Lifesciences Limited and Pfizer Inc announced that they have entered into a collaboration to develop a portfolio of preclinical candidate molecules in a series of discovery target programs.

News Date	17/12/2009
-----------	------------

Category	Partnership / Strategic Alliance
Headline	Adimab Announced New Antibody Discovery Collaborations And Achievement Of Milestones In Two Existing Partnerships
Summary	Adimab Inc announced the initiation of research collaborations with Pfizer and an undisclosed second company. Adimab also announced the receipt of milestone payments from two announced discovery collaborations with Merck and Roche.

News Date	14/12/2009
Category	Partnership / Strategic Alliance
Headline	Takeda And Pfizer Co-Promoted Takeda's Actos (Pioglitazone Hcl) For The Treatment Of Type 2 Diabetes In China
Summary	Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China. The exclusive co-promotion agreement will build on the current sales capability for Actos in China by increasing the number of medical representatives supporting the sales and marketing of the product and expanding the product reach utilizing the territory coverage of Pfizer in China, the largest multinational pharmaceutical company in China. Pfizer's Chinese affiliate will receive a fixed ratio of Actos net sales.

News Date	08/12/2009
Category	Partnership / Strategic Alliance
Headline	Correcting And Replacing Pfizer And Crown Bioscience Announced A Collaboration To Research And Develop New Treatments For Asian Cancers
Summary	Pfizer and Crown Bioscience Inc. announced that they had entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers represent an important unmet medical need as well as a significant market opportunity.

News Date	03/12/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer and B.C. Launched USD9 Million Collaboration To Tackle Cancer

Summary	Pfizer entered into a three-year, USD9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
---------	--

News Date	30/11/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer And Protalix Entered Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
Summary	Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher's disease. Under the terms of the agreement, Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercialization rights in Israel. Taliglucerase alfa is the first enzyme replacement therapy derived from a proprietary plant cell-based expression platform using genetically engineered carrot cells.

News Date	17/11/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer and DNDI Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases
Summary	Pfizer Inc and Drugs for Neglected Diseases initiative (DNDI) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDI will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.

News Date	28/10/2009
Category	Partnership / Strategic Alliance
Headline	New Relationship To Service Retail Pharmacy

Summary	Pfizer Australia's Established Products Business Unit (EPBU) announced that it has entered into a distribution and services agreement (Agreement) with Genepharm (Australia) Limited (Genepharm) to promote and sell the full range of Pfizer's established off-patent medicines to Australian pharmacies. The Agreement represented a significant market initiative for the sale of Pfizer's off-patent medicines via Genepharm's marketing and sales force Australia wide.
---------	--

News Date	25/09/2009
Category	Partnership / Strategic Alliance
Headline	Eisai Announced Agreement With Pfizer On Strategic Alliance For Alzheimers Disease Treatment Aricept
Summary	Eisai Co Ltd (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced that it has reached a comprehensive agreement with Pfizer Inc. (Headquarters: New York, CEO and Chairman of the Board: Jeffrey Kindler, "Pfizer") regarding the strategic alliance for the Alzheimers Disease treatment, Aricept (donepezil hydrochloride). Eisai and Pfizer have been in discussions to resolve their dispute concerning the strategic alliance and development agreement which was signed in October 1994.

News Date	19/08/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer And Private Access Announced Plans To Develop Online Community To Accelerate Clinical Research
Summary	Pfizer Inc announced that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation. The site will be the first to focus on patient privacy rights to connect patients, physicians and researchers with tailored information, tools and technology that will lead to more informed decisions about patient care, including clinical trial participation industry-wide.

News Date	01/07/2009
Category	Mergers & Acquisitions
Headline	Graceway Pharmaceuticals Acquired Early-Stage Dermatological Molecules From Pfizer

Summary	Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.
---------	--

News Date	01/07/2009
Category	Partnership / Strategic Alliance
Headline	Graceway Pharmaceuticals Acquired Early-Stage Dermatological Molecules From Pfizer
Summary	Graceway Pharmaceuticals, LLC announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.

News Date	19/05/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer Expanded Its Generics Portfolio Through Innovative Licensing Deals, Increasing Access To Medicines For Billions Worldwide
Summary	Pfizer Inc announced that it has entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and significantly expanding its portfolio of medicines in its Established Products Business Unit.

News Date	18/05/2009
Category	Partnership / Strategic Alliance
Headline	Almac Announced Collaboration With Pfizer And The PETACC3 Translational Research Working Party
Summary	Almac Diagnostics announced a collaborative study between Almac, Pfizer and the PETACC3 Translational Research Working Party (PTRW). The study involves gene expression profiling of formalin-fixed paraffin-embedded (FFPE) samples from the Pan-European Trials in Adjuvant Colon Cancer (PETACC 3) trial using Almac Diagnostic's unique Colorectal Cancer DSA research tool to identify molecular subtypes, biomarkers and drug targets.

News Date	11/05/2009
Category	Meeting schedules

Headline	Pfizer And Quark
Summary	Quark Pharmaceuticals Inc announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation," at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 3-7, 2009, in Fort Lauderdale, Florida. PF-04523655 is currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD).

News Date	05/05/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer And Wisconsin Alumni Research Foundation (Warf) Signed License Agreement For Human Embryonic Stem Cells
Summary	Pfizer Inc and the Wisconsin Alumni Research Foundation (WARF) announced that they had signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.

News Date	24/04/2009
Category	Partnership / Strategic Alliance
Headline	UCL–Pfizer Developed Pioneering Stem Cell Sight Therapies
Summary	UCL has entered into a collaboration with the biopharmaceutical group Pfizer, negotiated by UCL Business, to advance development of stem cell-based therapies for age-related macular degeneration (AMD).

News Date	23/04/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer And University College London Announced Collaboration To Advance Development Of Stem Cell-Based Therapies
Summary	Pfizer Regenerative Medicine announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding into how to develop stem cell-based therapies for certain ophthalmic conditions.

News Date	22/04/2009
Category	Partnership / Strategic Alliance

Headline	Pfizer And Medicines For Malaria Venture Advancing International Research Efforts In The Fight Against Malaria
Summary	Pfizer Inc and Medicines for Malaria Venture (MVV) had signed an agreement that is designed to facilitate advancements in the battle against malaria, a disease that afflicts vulnerable populations in the developing world each year. Under the agreement, MMV will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments for malaria.

News Date	16/04/2009
Category	Partnership / Strategic Alliance
Headline	Glaxosmithkline And Pfizer Announced Innovative Agreement To Create A New World-Leading, Specialist HIV Company
Summary	GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines. The new HIV business will be more sustainable and broader in scope than either company's individually, and will hold a 19% share of the growing market and have an industry-leading pipeline. GSK will initially hold an 85% equity interest in the new company and Pfizer will hold 15%.

News Date	07/04/2009
Category	Partnership / Strategic Alliance
Headline	Aurobindo Pharma Inked Marketing Deal With Pfizer For Finished Dosage Products
Summary	Aurobindo Pharma Ltd has inked licensing and supply agreements for several solid dosage and sterile products with Pfizer Inc., a global leader in pharmaceuticals. Pfizer's deal with Aurobindo is its first in-licensing deal, where the US-based pharma giant takes on license, products from Aurobindo.

News Date	19/03/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer, PlaNet Finance Partner Has Studied Options for Expanding Access to Healthcare in China
Summary	Pfizer Inc and PlaNet Finance announced that they will team up to conduct an in-depth research project on the healthcare needs of the working poor in China. The study will examine the availability and existing sources of medicines, patient purchasing patterns, and the level of access to medical services. The study ultimately aims to help both organizations identify models that may enhance and expand access to medicines and healthcare services for the working poor in China.

News Date	19/03/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer Expanded Its Generics Portfolio Through Innovative Licensing Deals, Increasing Access To Medicines For Billions Worldwide
Summary	Pfizer Inc announced that it has entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and significantly expanding its portfolio of medicines in its Established Products Business Unit.

News Date	09/03/2009
Category	Partnership / Strategic Alliance
Headline	Mannkind Agreed With Pfizer On The Purchase Of Frankfurt Insulin Manufacturing Plant
Summary	MannKind Corporation (Nasdaq: MNKD) announced that it has entered into agreements with Pfizer Inc. (NYSE: PFE) to purchase Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery. The aggregate purchase price is USD33 million, subject to certain adjustments. At MannKind's option, up to USD30 million worth of the company's common stock may be issued to Pfizer at closing and applied toward the full purchase price. The transfer of certain real property rights pursuant to this transaction will require the consent of third parties.

News Date	02/03/2009
Category	Partnership / Strategic Alliance
Headline	Xencor and Pfizer have entered into Antibody Technology Licensing Agreement
Summary	Xencor, Inc., announced that it has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies. Pfizer will apply Xencor's proprietary Xtend antibody half-life prolongation technology and XmAb ADCC enhancing technology to its antibody drug candidates.

News Date	02/03/2009
Category	Partnership / Strategic Alliance
Headline	Pfizer And Bausch And Lomb Co-Promoted Products For The Treatment Of Ophthalmic Conditions

Summary	Pfizer Inc and Bausch and Lomb announced a co-promotion agreement involving both companies' prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.
---------	--

News Date	02/02/2009
Category	Partnership / Strategic Alliance
Headline	TCG Lifesciences strengthened its relationship with Pfizer
Summary	TCG Lifesciences, a research services and informatics company has extended its master services agreement with Pfizer.

News Date	22/12/2008
Category	Partnership / Strategic Alliance
Headline	Sangamo BioSciences Announced License Agreement With Pfizer for Zinc Finger Nucleases for Protein Production
Summary	Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced an agreement to provide Pfizer Inc (NYSE: PFE) with a worldwide, non-exclusive license for the use of certain ZFP Nuclease (ZFNs) reagents to permanently eliminate the Glutamine Synthetase (GS) gene in Chinese Hamster Ovary (CHO) cell lines and for the use of these ZFN-modified cells for clinical and commercial production of therapeutic proteins. Under the terms of the agreement Sangamo will receive an upfront payment of USD3.0 million from Pfizer for a fully paid license.

News Date	11/12/2008
Category	Partnership / Strategic Alliance
Headline	Hovione Bought Pfizer's Loughbeg Api Facility
Summary	Hovione announced that it has agreed with Pfizer to acquire their Loughbeg Active Pharmaceutical Ingredients site in Ireland. This site manufactures intermediates for Lipitor active pharmaceutical ingredient.

News Date	08/12/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer and Sigma-Tau Announced an Agreement to Market a Potential New Treatment for Malaria in Africa

Summary	Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), announced that they have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.
---------	--

News Date	19/10/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer and UCB Announced Formation of New Company 'Cyclofluidic' to Accelerate Drug Discovery Process
Summary	Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time. The UK Government's Technology Strategy Board has helped facilitate this innovative arrangement between Pfizer and UCB and will continue to support Cyclofluidic by co-funding its R&D.

News Date	23/09/2008
Category	Partnership / Strategic Alliance
Headline	Grameen Health and Pfizer Announced Novel Partnership to Explore Sustainable Healthcare Delivery Models for the Developing World
Summary	Pfizer Inc and Grameen Health, announced that they will work together to identify sustainable models for healthcare delivery in the developing world.

News Date	03/09/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer and Medivation Enter Into Global Agreement To Co-Develop And Market Dimebon For The Treatment Of Alzheimer's And Huntington's Diseases
Summary	Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease.

News Date	03/09/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer and Medivation Entered into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases

Summary	Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease.
---------	---

News Date	24/06/2008
Category	Partnership / Strategic Alliance
Headline	Melior Signed Option Agreement with Pfizer
Summary	Melior Discovery, Inc. announced that it has signed an option agreement that provides Pfizer Inc the exclusive right to negotiate a license to MLR-1023, Melior's drug candidate for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior agreed to utilize its in-vivo theratRACE indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer.

News Date	12/06/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer Inc And The University Of Pennsylvania Announced USD 15 Million Partnership
Summary	Pfizer Inc (NYSE:PFE) announced that it has entered into a USD 15-million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership included collaborations between Pfizer and the University in the areas of scientific research, clinical development and clinical care and policy.

News Date	09/06/2008
Category	Mergers & Acquisitions
Headline	Pfizer Completed Acquisition of Encysive Pharmaceuticals
Summary	Pfizer Inc (NYSE:PFE) announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) through a merger of Pfizer's wholly-owned subsidiary, Explorer Acquisition Corp., with and into Encysive. Encysive is now a wholly-owned subsidiary of Pfizer.

News Date	20/05/2008
Category	Partnership / Strategic Alliance

Headline	FivePrime And Pfizer Entered Oncology And Diabetes Collaboration
Summary	Five Prime Therapeutics Inc. and Pfizer Inc announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes. Under the collaboration, FivePrime will screen its comprehensive protein library in both cell-based assays and primary in vivo screens directed toward finding potential therapeutic protein products and antibody targets.

News Date	25/04/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer Entered into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology
Summary	Pfizer has entered into a collaboration agreement with four major research universities – University of California, Santa Barbara (UCSB); Caltech; the Massachusetts Institute of Technology; and University of Massachusetts – and Entelos, a physiological modeling company, to re-examine the regulatory mechanisms of human energy metabolism. Pfizer is funding the three-year and USD 14 million Insulin Resistance Pathway (IRP) Project to look at insulin signaling in adipose (fat) cells to increase understanding of diabetes and obesity, inextricably linked conditions that affect 7 percent of the U.S. population.

News Date	16/04/2008
Category	Partnership / Strategic Alliance
Headline	Moksha8 Launched Broad Product Portfolio In Key Emerging Markets
Summary	moksha8, Inc. announced strategic partnerships with Roche and Pfizer, the launch of over twenty products and establishment of its Latin America headquarters in Sao Paulo, Brazil. moksha8 is committed to providing the highest quality medicine to the fastest growing markets of the world, with an initial focus on Asia, Latin America and Eastern Europe.

News Date	18/03/2008
Category	Mergers & Acquisitions
Headline	Pfizer Animal Health Acquired Catapult Genetics and Bovigen

<p>Summary</p> <p>Pfizer Animal Health announced it will acquire two market-leading livestock genomics companies:</p> <p>Catapult Genetics, Pty., Ltd., focused on developing and commercializing innovative livestock DNA tests and gene markers to assist global food producers, processors and retailers in improving profitability and quality in the global food chain; and</p> <p>Bovigen, LLC, which markets DNA technology, including Catapult's products in the U.S. and throughout Canada, Central America and South America.</p>
--

<p>News Date</p> <p>02/03/2008</p>
<p>Category</p> <p>Partnership / Strategic Alliance</p>
<p>Headline</p> <p>Pfizer Acquired Serenex To Extend Oncology Pipeline And Access Novel Technology Platform</p>
<p>Summary</p> <p>Pfizer Inc announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate and an extensive compound library that targets Heat Shock Protein 90 (Hsp90), an exciting target in the fight against cancer.</p>

<p>News Date</p> <p>19/02/2008</p>
<p>Category</p> <p>Mergers & Acquisitions</p>
<p>Headline</p> <p>Pfizer Acquired Encysive Pharmaceuticals</p>
<p>Summary</p> <p>Pfizer Inc announced that it has entered into an agreement to acquire Encysive Pharmaceuticals Inc. (NASDAQ: ENCY), a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) is commercially available in much of the European Union and is approved in other markets.</p>

<p>News Date</p> <p>30/01/2008</p>
<p>Category</p> <p>Partnership / Strategic Alliance</p>
<p>Headline</p> <p>IPM Reached Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide</p>

Summary	Expanding the pipeline of HIV prevention tools in development, the International Partnership for Microbicides (IPM) announced that Pfizer Inc has agreed to give IPM a royalty-free license to maraviroc, its newly-approved HIV treatment, as a microbicide for the prevention of HIV infection. Maraviroc, sold under the trade name Selzentry/Celsentri, is one of a new class of antiretroviral drugs known as CCR5 blockers, which works to prevent HIV infection by preventing the virus from gaining entry into target cells.
---------	--

News Date	16/01/2008
Category	Partnership / Strategic Alliance
Headline	Pfizer and Scil Finalized Agreement for Novel Cartilage Growth Factor
Summary	Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil's cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for upfront and milestone payments of approximately US USD250 million depending on the achievement of various development and regulatory milestones.

News Date	07/01/2008
Category	Partnership / Strategic Alliance
Headline	Hikal Ltd. Announced Manufacturing Agreement With Pfizer For Supply Of API's
Summary	Hikal Limited announced that it has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients with Pfizer Inc., a global leader in Pharmaceuticals.

News Date	07/01/2008
Category	Partnership / Strategic Alliance
Headline	Taisho and Pfizer Finalized Agreement for Novel Schizophrenia Drug Candidate
Summary	Taisho Pharmaceutical Co., Ltd. and Pfizer Inc, have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop and commercialize TS-032, a new schizophrenia drug candidate discovered by Taisho, currently in pre-clinical development.

News Date	17/12/2007
-----------	------------

Category	Mergers & Acquisitions
Headline	Pfizer Acquired Covx To Extend Biotherapeutics Investment
Summary	Pfizer Inc announced it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer's biologic portfolio.

News Date	16/11/2007
Category	Mergers & Acquisitions
Headline	Pfizer Acquired Coley Pharmaceutical Group
Summary	Pfizer Inc (NYSE: PFE) announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

News Date	13/11/2007
Category	Partnership / Strategic Alliance
Headline	Pfizer And Nektar Reached Agreement On Exubera
Summary	Pfizer and Nektar Therapeutics announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin product currently in Phase 1 clinical development.

News Date	30/10/2007
Category	Partnership / Strategic Alliance
Headline	Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate
Summary	Taisho Pharmaceutical Co., Ltd. and Pfizer Inc have concluded a letter of intent with regard to TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in the pre-clinical stage. The letter of intent relates to a proposed license agreement regarding rights for development and commercialization of the substance outside Japan.

News Date	14/10/2007
Category	Partnership / Strategic Alliance

Headline	Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care
Summary	Pfizer Inc and Sermo announced a strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Sermo is a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide new insights into medications, devices and treatments.

News Date	28/08/2007
Category	Partnership / Strategic Alliance
Headline	Xoma Licensed Antibody Technology to Pfizer
Summary	Xoma Ltd. (Nasdaq:Xoma) announced that it has licensed to Pfizer Inc., non-exclusive, worldwide rights to Xoma's patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products.

News Date	26/04/2007
Category	Partnership / Strategic Alliance
Headline	Bristol-Myers Squibb And Pfizer Announced Worldwide Collaboration To Develop And Commercialize Anticoagulant And Metabolic Compounds
Summary	Bristol- Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) announced a worldwide collaboration to develop and commercialize apixaban, an anticoagulant discovered by Bristol-Myers Squibb being studied for the prevention and treatment of a broad range of venous and arterial thrombotic conditions. In a separate agreement, the companies will also collaborate on the research, development and commercialization of a Pfizer discovery program which includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes.

News Date	02/04/2007
Category	Partnership / Strategic Alliance
Headline	Genector International Inc Licensed Technology For Production Of Secreted Polypeptides Licensed By pfizer inc

Summary	Genencor announced that it has granted Pfizer a non-exclusive license to technology that enhances the level of expression of secreted polypeptides (proteins) in microorganisms for use in the development of protein therapeutics. The technology described in United States Patents 6,544,792 and 6,642,027 improves processes for protein production in microorganisms which in turn may reduce the cost of developing protein-based drugs. The terms of the agreement were not disclosed.
---------	---

News Date	19/01/2007
Category	Mergers & Acquisitions
Headline	Pfizer Animal Health Completed Acquisition of Embrex
Summary	Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) announced the completion of its acquisition of Embrex, Inc. (Nasdaq: EMBX), an international agricultural biotechnology company known for its Inovoject vaccine-delivery systems. Completion followed the Embrex shareholder meeting at which Embrex shareholders approved the merger. The transaction has an aggregate equity purchase price of approximately USD155 million.

News Date	15/11/2006
Category	Mergers & Acquisitions
Headline	Pfizer Animal Health Agreed to Acquire Embrex, Inc., the Leader in 'In Ovo' Poultry Vaccine-Delivery Technology
Summary	Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) has agreed to acquire Embrex, Inc. (NASDAQ: EMBX), an international agricultural biotechnology company known for its Inovoject vaccine-delivery systems.

News Date	23/03/2006
Category	Partnership / Strategic Alliance
Headline	NOXXON Pharma AG Announced Global Strategic Alliance With Pfizer NOX-B11 Spiegelmer For Obesity Treatment Licensed
Summary	NOXXON Pharma AG announced a multi-year global collaboration with Pfizer Inc. (NYSE: PFE) regarding the discovery and development of Spiegelmerproducts. In addition, the two companies entered into an exclusive worldwide license agreement relating to NOXXON's preclinical lead Spiegelmerfor treating obesity. Under both agreements, Pfizer will make upfront cash payments as well as R & D milestone payments. In addition, NOXXON is eligible to receive royalties on the sale of products commercialized under these agreements. Pfizer will also make an equity investment in NOXXON.

News Date	28/10/2005
Category	Geography expansion
Headline	The World's Most Advanced Capsule Plant Opened In China
Summary	Capsugel announced that the new plant of Suzhou Capsugel Ltd., a division of Pfizer Inc, officially opened on October 28th 2005, marking it the most advanced capsule production plant based in China.

News Date	22/06/2005
Category	Mergers & Acquisitions
Headline	Pfizer to Acquired Vicuron Pharmaceuticals to Extend Its Research Commitment in Anti-Infectives
Summary	Pfizer Inc and Vicuron Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement whereby Pfizer will acquire Vicuron, a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections.

News Date	30/05/2003
Category	Partnership / Strategic Alliance
Headline	Novo Nordisk Disputed Pfizer's Attempted Termination Of Us Hormone Replacement Therapy Agreement
Summary	Novo Nordisk A/S announced that Pfizer has attempted to terminate the license agreement under which Pfizer markets Novo Nordisk's portfolio of hormone replacement therapy products in the United States. Novo Nordisk disputes Pfizer's ability to terminate the agreement, which covers the currently marketed products Activella and Vagifem.

News Date	10/10/2001
Category	Partnership / Strategic Alliance
Headline	Lexicon Genetics Licensed Patented Gene Targeting Technology To Pfizer Inc
Summary	Lexicon Genetics Incorporated announced that it has granted a non-exclusive, internal research use license to Pfizer Inc. (NYSE: PFE) under the patent covering the use of Lexicon's isogenic DNA technology in gene targeting. Pfizer already holds a non-exclusive license from Lexicon for internal research use of Lexicon's patented positive-negative selection technology. Financial details were not disclosed.

myPHARMA thinktank's modules cover the biotech and pharma industry from end to end. Our databases provide:



Company Specs: company names, country, stock exchange details, industry class, revenue, R&D spending, and market capitalization



Industry Deals: deal status, source target, acquirer, partner, deal type, and deal value



Products: name, phase name, phase status, ingredients, therapeutic indication, clinical trials, regulatory filings, partners, actions and targets, ATC, and Chemical and Biological classes



Industry News: press releases, news and clippings



Key Events: presented by product, date, country, category, application, phase, and therapeutic indication



Regulatory Framework: we show records by product name, active ingredient, approval date, approval type, company name, and application type



Patent Landscape: patent families, expiry dates, extensions, legal status, and patent documents

